Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient

ABSTRACT

A carboxylic acid derivative of formula (I):  
                 
 
wherein R 1  is —COOH, —COOR 6 , etc.; A is a single bond, alkylene, etc.; R 2  is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R 3  is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE 2  receptor, especially subtypes EP 3  and/or EP 4  and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer&#39;s disease, cancer, dysmenorrhea, endometriosis, etc.

TECHNICAL FIELD

The present invention relates to carboxylic acid derivatives. Morespecifically, the present invention relates to a carboxylic acidderivative of formula (I)

wherein all symbols have the same meanings as described below;a non-toxic salt thereof and a pharmaceutical agent comprising the sameas an active ingredient.

BACKGROUND ART

Prostaglandin E₂ (PGE₂) has been known as a metabolite in thearachidonic acid cascade. It has been known that PGE₂ possessescyto-protective activity, uterine contractile activity, a pain-inducingeffect, a promoting effect on digestive peristalsis, an awaking effect,a suppressive effect on gastric acid secretion, hypotensive activity,and diuretic activity.

In the recent study, it was found that PGE₂ receptor was divided intosome subtypes, which possesses different physical roles from each other.At present, four receptor subtypes are known and they are called EP₁,EP₂, EP₃ and EP₄ respectively [J. Lipid Mediators Cell Signaling, 12,379-391 (1995)].

Among these subtypes, EP₃ receptor was believed to be involved in signaltransduction of peripheral nerve, control of exothermal reaction incentral nerve, formation of memory by expressing in cerebral neuron,vascularization, reabsorption of urine by expressing in renal tubular,uterine contraction, production of ACTH, platelet aggregation. Besides,it was expressed in vascular smooth muscle, heart and gastrointestinaltract also. EP₄ receptor was believed to be involved in suppression ofTNF-α production and induction of IL-10 production.

So the compounds which can bind to EP₃ receptor and/or EP₄ receptorstrongly and show the antagonizing activity, are useful for theprevention and/or treatment of diseases induced by excess activation ofEP₃ receptor and/or EP₄ receptor, for example, pain such as cancerouspain, fractural pain, pain following surgical and dental procedures;allodynia, hyperalgesia, pruritus, urticaria, atopic dermatitis, contactdermatitis, rhus dermatitis, allergic conjunctivitis, various symptomsby treating with dialysis, asthma, rhinitis, sneeze, urinary frequencysuch as neurogenic bladder, neurogenic bladder, irritant bladder,unstable bladder, urinary frequency that originate with prostate-glandenlargement; urinary disturbance, ejaculatory failure, fever, systemicinflammatory response syndrome, learning disturbance, Alzheimer'sdisease, angiogenesis, cancer such as formulation of cancer, growth ofcancer and metastasis of cancer; retinopathy, patch of red, erythematouspatches, achromoderma, pigmented spot, scald, burn, burn by steroid,renal failure, nephropathy, acute nephritis, chronic nephritis, abnormalblood levels of electrolytes, threatened premature delivery, abortionthreatened, hypermenorrhea, dysmenorrhea, uterine fibroids, premenstrualsyndrome, reproductive disorder, stress, anxiety disorders, depression,psychosomatic disorder, mental disorder, thrombosis, embolism, transientischemia attack, cerebral infarction, atheroma, organ transplant,myocardial infarction, cardiac failure, hypertension, arteriosclerosis,circulatory failure and circulatory failure induced ulcer, neuropathies,vascular dementia, edema, various arthritis, rheumatism, diarrhea,constipation, disorder of bilious excretion, ulcerative colitis, Crohn'sdisease, irritable bowel syndrome, alleviation of rebound phenomenonafter steroid, dose reduction of steroid and adjunct for steroidwithdrawal and/or bone diseases such as osteoporosis, rheumatoidarthritis, osteoarthritis, abnormal bone formation; cancer such asformation of cancer, proliferation of cancer, metastasis of cancer toorgans and to bones and hypercalcemia induced metastasis to bones ofcancer; systemic granuloma, immunological diseases such as ALS, multiplesclerosis, Sjoegren's syndrome, systemic lupus erythematosus, AIDS;allergy such as allergic conjunctivitis, allergic rhinitis, contactdermatitis, psoriasis; atopy such as atopic dermatitis; asthma,pyorrhea, gingivitis, periodontitis, neuronal cell death, Alzheimer'sdisease, pulmonary injury, hepatopathy, acute hepatopathy, nephritis,renal failure, myocardial ischemia, Kawasaki disease, scald, ulcerativecolitis, Crohn's disease, multiple organ failure, chronic headache suchas migraine headache, tension-type headache or mixed headache thereof,cluster headache; pain, angiogenesis, angiitis, venous insufficiency,varicose veins, anal fistula, diabetes insipidus, stress, endometriosis,adenomyosis of the uterus, neonatal patent ductus arteriosus,cholelithiasis etc. Moreover, it relates to sleeping disorder andplatelet aggregation, so the compounds are considered to be useful forthem.

As a compound useful for a treatment of a disease related prostaglandinE receptor, for example, (A) in a specification of WO 99/47497, acompound of formula (A):

wherein HET^(a) is a 5- to 12-membered mono- or bi-aromatic ring; A^(a)is a group of one or two atoms; X^(a) is 5- to 10-membered mono- orbi-aryl, heteroaryl, and the rings may be substituted with R^(14a) andR^(15a); B^(a) is —(C(R^(18a))₂)_(pa)—Y^(a)—C(R^(18a))_(qa)—; R^(1a),R^(2a) and R^(3a) are hydrogen, halogen, lower alkyl, lower alkenyl,lower alkynyl, etc.; and (B) in a specification of WO 00/20371, acompound of formula (B)

wherein Ar^(1b) is aryl or heteroaryl; W^(b) is a 3- to 6-memberedlinking chain containing 0-2 of a hetero atom(s); Ar^(2b) is aryl orheteroaryl which may be substituted with R^(3b); R^(3b) is hydrogen,lower alkyl, lower alkenyl, lower alkynyl, CHF₂, CF₃, halogen,halo(C1-6) alkyl, N(R^(5b))₂, cyano, nitro, C(R^(6b))₃; X^(b) is alinking chain; Q^(b) is COOH, tetrazole, SO₃H, hydroxamic acid,CONHSO₂R^(12b), SO₂NHCOR_(12b); were described

DISCLOSURE OF THE INVENTION

The present inventors have energetically studied to find the compoundwhich bind to PGE₂ receptor, EP₃ and/or EP₄ receptor specifically andshow an inhibitory activity against it, to find out that the carboxylicacid derivatives of formula (I) achieve the purpose and completed thepresent invention.

The present invention is relates to(1) a carboxylic acid derivative of formula (I):

wherein R¹ is —COOH, —COOR⁴, —CH₂OH, —CONR⁵SO₂R⁶, —CONR⁷R⁸,—CH₂NR⁵SO₂R⁶, —CH₂NR⁹COR¹⁰, —CH₂NR⁹CONR⁵SO₂R⁶, —CH₂SO₂NR⁹COR¹⁰,—CH₂OCONR⁵SO₂R⁶, tetrazole, 1,2,4-oxadiazol-5-one,1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one,1,3-thiazolidin-2,4-dione or 1,2,3,5-oxathiadiazol-2-one,

R⁴ is C1-6 alkyl or —(C1-4 alkylene)-R¹¹,

R¹¹ is hydroxy, C1-4 alkoxy, —COOH, C1-4 alkoxycarbonyl or —CONR⁷R⁸,

R⁵ is hydrogen or C1-6 alkyl,

R⁶ is

(i) C1-6 alkyl,

(ii) a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to 15-memberedmono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R¹²or unsubstituted,

(iii) C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl substituted with a C3-15mono-, bi- or tri-carbocyclic ring or a 3- to 15-membered mono-, bi- ortri-heterocyclic ring which is substituted with 1-5 of R¹² orsubstituted,

R⁷ and R⁸ each independently, is

(i) hydrogen,

(ii) C1-6 alkyl,

(iii) hydroxy,

(iv) —COR¹⁷,

(v) a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to 15-memberedmono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R¹²or unsubstituted, or

(vi) C1-4 alkyl substituted with a C3-15 mono-, bi- or tri-carbocyclicring or a 3- to 15-membered mono-, bi- or tri-heterocyclic ring which issubstituted with 1-5 of R¹² or unsubstituted,

R⁹ is hydrogen or C1-6 alkyl,

R¹⁰ is

(i) hydrogen

(ii) C1-6 alkyl,

(iii) a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to 15-memberedmono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R¹²or unsubstituted, or

(iv) C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl substituted with a C3-15mono-, bi- or tri-carbocyclic ring or a 3- to 15-membered mono-, bi- ortri-heterocyclic ring which is substituted with 1-5 of R¹² orunsubstituted,

R¹² is (a) C1-16 alkyl, (b) C1-6 alkoxy, (c) C1-6 alkylthio, (d)halogen, (e) CF₃, (f) cyano, (g) nitro, (h) hydroxy, (i) —COOR¹³, (j)—NHCOR¹³, (k) —SO₂R¹⁴, (l) —NR¹⁵R¹⁶, (m) a C3-7 mono-carbocyclic ringwhich is sub d with C1-4 alkyl or oxo or unsubstituted, (n) a 3- to7-membered mono-heterocyclic ring which is substituted with C1-4 alkylor oxo or unsubstituted, or (o) C1-4 alkyl substituted with hydroxy,—COOR¹³, —NHCOR¹³, —SO₂R¹⁴ or —NR¹⁵R¹⁶,

R¹³ is hydrogen, C1-4 alkyl, phenyl, or phenyl-(C1-4) alkyl,

R¹⁴ is C1-4 alkyl,

R¹⁵ and R¹⁶ each independently, is hydrogen, C1-4 alkyl, phenyl orphenyl-(C1-4) alkyl,

R¹⁷ is C1-4 alkyl or phenyl,

A is

(i) a single bond,

(ii) C1-6 alkylene,

(iii) C2-6 alkenylene,

(iv) C2-6 alkynylene,

(v) —O—(C1-3 alkylene),

(vi) —S—(C1-3 alkylene),

(vii) —NR²⁰—(C1-3 alkylene),

(viii) —CONR²¹—(C1-3 alkylene),

(ix) —(C1-3 alkylene)-O—(C1-3 alkylene),

(x) —(C1-3 alkylene)-S—(C1-3 alkylene),

(xi) —(C1-3 alkylene)-NR²⁰—(C1-3 alkylene),

(xii) —(C1-3 alkylene)-CONR²¹—(C1-3 alkylene),

(xiii) -Cyc1,

(xiv) —(C1-4 alkylene)-Cyc1 or

(xv) -Cyc1-(C1-4 alkylene),

the alkylene, alkenylene and alkylene in A may be substituted with 1-6of the following substituents of (a)-(i):

(a) C1-6 alkyl, (b) C1-6 alkoxy, (c) halogen, (d) CHF₂, (e) CF₃, (f)OCHF₂, (g) OCF₃, (h) hydroxy, (i) hydroxy-(C1-4) alkyl,

R²⁰ is hydrogen, C1-4 alkyl, —SO₂—(C1-4) alkyl or C2-5 acyl,

R²¹ is hydrogen or C1-4 alkyl,

Cyc1 is a C3-7 mono-carbocylic ring or a 3- to 7-memberedmono-heterocyclic ring which is substituted with 1-4 of C1-6 alkyl, C1-4alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkyl, halogen, CHF₂, CF₃,nitro or cyano, or unsubstituted,

B ring is a C3-12 mono- or bi-carbocyclic ring or a 3- to 12-memberedmono- or bi-heterocyclic ring,

R² is C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6alkynyl, halogen, CHF₂, CF₃, nitro, cyano, phenyl or oxo,

m is 0, 1 or 2,

n is 1 or 2 when -D-R³ binds to B ring at the ortho position based on-A-R¹,

n is 0, 1 or 2 when -D-R³ binds to B ring at the non-ortho positionbased on -A-R¹,

Q is

(1)(i) —(C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene)-Cyc2,

(ii) —(C1-4 alkylene)-Z-Cyc3,

(iii) C1-4 alkyl substituted with a substituent(s) selected from—NR²⁴R²⁵, —S(O)_(p)R²⁶, cyano, —NR²³COR²⁷, —NR²³SO₂R²⁸ and—NR²³CONR²⁴CONR²⁵,

(iv) C1-4 alkoxy(C1-4) alkoxy, —NR²³COR²⁷, —COR²⁸, —OSO₂R²⁸, —NR²³SO₂R²⁸or —NR²³CONR²⁴R²⁵,

(v) a C3-7 mono-carbocyclic ring or a 3- to 6-membered mono-heterocyclicring which is substituted with 1-5 of R³⁰, wherein one R³⁰ of themalways binds to the ring at the non 1-position,

(vi) a C8-15 mono-, bi- or tri carbocyclic ring or a 7- to 15-memberedmono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R³⁰or unsubstituted,

(vii) -T-Cyc5,

(viii) -L-Cyc⁶⁻¹, -L-(C3-6 cycloalkyl), -L-CH₂—(C3-6 cycloalkyl),-L-(C2-4 alkylene)-Cyc⁶⁻² or -L-(C1-4 alkylene)_(q)-Cyc⁶⁻³, wherein thecycloalkyl is substituted with 1-5 of R³⁰ or unsubstituted,

(2)(i) phenoxy,

(ii) benzyloxy,

(iii) hydroxy(C1-4) alkyl,

(iv) C1-4 alkoxy(C1-4) alkyl, or,

(v) —(C1-4 alkylene)-O-benzyl, or

(3)(i) C2-6 alkenyl,

(ii) C2-6 alkynyl,

(iii) C1-6 alkyl substituted with 1-3 halogen(s),

(iv) cyano,

(v) nitro,

(vi) —NR³³R³⁴,

(vii) —CONR³³R³⁴,

(viii) —S(O)_(p)—(C1-4) alkynyl,

(ix) —S(O)_(p)—CHF₂,

(x) —S(O)_(p)—NR³³R³⁴,

(xi) —O—(C3-6) alkynyl

(xii) —O—CHF₂, or

(xiii) C3-7 cycloalkyl,

R²² is hydrogen, C1-4 alkyl, —SO₂—(C1-4) or C2-5 acyl

R²³ is hydrogen, C1-4 alkyl, phenyl or phenyl(C1-4) alkyl,

R²⁴ and R²⁵ each independently, is hydrogen, C1-4 alkyl, Cyc4 or (C1-4alkylene)-Cyc4,

R²⁶ is C1-4 alkyl or Cyc4,

R²⁷ is hydrogen, C1-4 alkyl, —OR²⁹ or Cyc4,

R²⁸ is C1-4 alkyl, Cyc4 or —(C1-4 alkylene)-Cyc4,

R²⁹ is hydrogen, C1-4 alkyl Cyc4 or (C1-4 alkylene)-Cyc4,

R³⁰ is C1-8 alkyl, C1-8 alkoxy, C1-8 alkylthio, halogen, CF₃, OCF₃,SCF₃, CHF₂, SCHF₂, hydroxy, cyano, nitro, —NR³¹R³², —CONR³¹R³², formyl,C2-5 acyl, hydroxy(C1-4) alkyl, C1-4 alkoxy(C1-4) alkyl, C1-4alkylthio(C1-4) alkyl, —(C1-4 alkylene)-CONR³¹R³², —SO₂(C1-4) alkyl,—NR²³CO—(C1-4) alkyl, —NR₂₃SO₂ (C1-4) alkyl, benzoyl, oxo, a C3-7mono-carbocyclic ring, a 3- to 7-membered mono-heterocyclic ring, —(C1-4alkylene)-NR³¹R³², -M-(C3-7 mono-carbocyclic ring), or -M-(3- to7-membered mono-heterocyclic ring),

the C3-7 mono-carbocyclic ring and 3- to 7-membered mono-heterocyclicring in R³⁰ may be substituted with 1-5 of the following substituents(a)-(l):

(a) C1-6 alkyl, (b) C2-6 alkenyl, (c) C2-6 alkynyl, (d) c1-6 alkoxy, (e)C1-6 alkylthio, (f) halogen, (g) CHF₂, (h) CF₃, (I) nitro, (j) cyano,(k) hydroxy, (l) amino;

M is —O—, —S—, C1-4 alkylene, —O—(C1-4 alkylene)-, —S—(C1-4 alkylene)-,—(C1-4 alkylene)-O— or —(C1-4 alkylene)-S—,

R³¹ and R³² each independently, is hydrogen or C1-4 alkyl,

Cyc2 is a C3-15 mono-, bi- tri-carbocyclic ring or a 3- to 15-memberedmono-, bi- tri-heterocyclic ring which is substituted with 1-5 of R³⁰ orunsubstituted,

Z is —O—, —S(O)_(p)—, —NR²²—, —NR²³CO—, —NR²³SO₂—, —NR²²—(C1-4alkylene)-, —S(O)_(p)—(C1-4 alkylene)-, —O—(C2-4 alkylene)-,—NR²³CO—(C1-4 alkylene) or —NR²³SO₂—(C1-4 alkylene),

p is 0, 1 or 2,

Cyc3 is a C3-15 mono-, bi- tri-carbocyclic ring or a 3- to 15-memberedmono-, bi- tri-heterocyclic ring which is substituted with 1-5 of R³⁰ orunsubstituted,

Cyc4 is a C3-12 mono-, bi-carbocyclic ring or a 3- to 12-membered mono-,bi-heterocyclic ring which is substituted with 1-5 of R³⁰ orunsubstituted,

T is —O—, —NR²²—, —O—(C1-4 alkylene)-, —S(O)_(p)—(C1-4 alkylene)- or—NR²²—(C1-4 alkylene)-,

Cyc5 is a 3- to 15-membered mono-, bi- tri-heterocyclic ring which issubstituted with 1-5 of R³⁰ or unsubstituted,

q is 0 or 1,

L is —O— or —NR²³—,

Cyc⁶⁻¹ is phenyl or benzyl which is substituted with one or more R³⁰,

Cyc⁶⁻² is a C3-6 mono-carbocyclic ring which is substituted with 1-5 ofR³⁰ or unsubstituted,

Cyc⁶⁻³ is a C7-15 mono-, bi- or tri-carbocyclic ring which issubstituted with 1-5 of R³⁰ or unsubstituted,

R³³ and R³⁴ each independently, is hydrogen, C1-4 alkyl, phenyl orbenzyl, or

NR³³R³⁴ is a 3- to 6-membered mono-heterocyclic ring containing onenitrogen and optionally containing one hetero atom selected fromnitrogen, oxygen and sulfur,

D is

(1) a 1- or 2-membered linking chain comprising an atom(s) selected fromcarbon, nitrogen, oxygen and sulfur, which may contain a double bond ora triple bond in the chain and may be substituted with 1-4 of R⁴⁰,

(2) a 3- to 6-membered linking chain comprising atoms selected fromcarbon, nitrogen, oxygen and sulfur, which may contain a double bond ora triple bond in the chain and may be substituted with 1-12 of R⁴⁰,wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is asubstituent of R³, taken together may form —(CH₂)_(y)—, in which y is1-4, or

(3) a 7- to 10-membered linking chain comprising atoms selected fromcarbon, nitrogen, oxygen and sulfur, which may contain a double bond ora triple bond and may be substituted with 1-20 of R⁴⁰, wherein R⁴⁰substituted on the atom bound to R³, and R⁴² which is a substituent ofR³, taken together may form —(CH₂)_(y)—,

R⁴⁰ is (a) C1-8 alkyl, (b) C2-8 alkenyl, (c) C2-8 alkynyl, (d) oxo, (e)halogen, (f) CF₃, (g) hydroxy, (h) C1-6 alkoxy, (i) C2-6 alkenyloxy, (j)C2-6 alkynyloxy, (k) OCF₃, (l) —S(O)_(p)—(C1-6) alkyl,(m)—S(O)_(p)—(C2-6) alkenyl, (n) —S(O)_(p)—(C2-6) alkynyl, (o) C2-5acyl, (p) Cyc9, (q) C1-4 alkoxy(C1-4) alkoxy, or (r) C1-8 alkyl, C2-8alkenyl or C2-8 alkynyl substituted with 1 or 2 of substituents selectedfrom halogen, CF₃, OCF₃, hydroxy, cyano, C1-4 alkoxy, —S(O)_(p)—(C1-6)alkyl, Cyc9 and C1-4 alkoxy(C1-4) alkoxy or

two R⁴⁰'s taken together with the atom of a linking chain to which theybind, may form a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to15-membered mono-, bi- or tri-heterocyclic ring containing 1-2 heteroatom(s) selected from O, S, SO₂ and N, wherein the carbocyclic ring andthe heterocyclic ring may be substituted with 1-3 substituent(s)selected from C1-4 alkyl, C1-4 alkoxy, C2-5 acyl, SO₂(C1-4 alkyl),phenyl and phenyl(C1-4) alkyl,

Cyc9 is a C3-6 mono-carbocyclic ring or a 3- to 6-memberedmono-heterocyclic ring, which is substituted with 1-5 of R⁴¹ orunsubstituted,

R⁴¹ is C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkoxy(C1-4) alkyl,halogen, CF₃, OCF₃, SCF₃, hydroxy, cyano, formyl, C2-5 acyl, —SO₂—(C1-4)alkyl, —NR²³CO—(C1-4) alkyl, benzoyl or oxo,

R³ is

(1) C1-6 or

(2) a C3-15 mono, bi- or tri carbocyclic ring or a 3- to 15-memberedmono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R⁴²or unsubstituted,

R⁴² is (a) C1-6 alkyl, (b) C1-6 alkoxy, (c) C1-6 alkylthio, (d) halogen,(e) cyano, (f) CF₂, (g) CHF₂, (h) OCF₃, (i) OCHF₂, (j) SCF₃, (k)—NR⁴³R⁴⁴, (l) —SO₂R⁴⁵, (m) —NR⁴⁶COR⁴⁷, (n) hydroxy, (o) oxo, (p) C1-4alkoxy(C1-4) alkyl, (q) Cyc10, (r) C1-6 alkylene-Cyc10, (s) —CO-Cyc10,(t) —W-Cyc10, (u) —(C1-6 alkylene)-W-Cyc10, (v) —W—(C1-6 alkylene)-Cyc10or (w) —(C1-6 alkylene)-W—(C1-6 alkylene)-Cyc10,

R⁴³ and R⁴⁴ each independently, is hydrogen or C1-4 alkyl,

R⁴⁵ is C1-4 alkyl,

R⁴⁶ is hydrogen or C1-4 alkyl,

R⁴⁷ is hydrogen or C1-4 alkyl,

Cyc10 is a C3-12 mono- or bi-carbocyclic ring or a 3- to 12-memberedmono- or bi-heterocyclic ring which is substituted with 1-5 ofsubstitutes of the following (a)-(j) or unsubstituted,

(a) C1-4 alkyl, (b) C2-5 acyl, (c) 1-4 alkoxy, (d) halogen, (e) hydroxy,(f) nitro, (g) cyano, (h) amine, (i) CF₃, (j) OCF₃,

W is —O—, —S(O)_(p)— or —NR⁴⁸—,

R⁴⁸ is hydrogen or C1-4 alkyl;

or a non-toxic salt thereof,

(2) a process of the preparation thereof, and

(3) a pharmaceutical agent comprising the same as an active ingredient.

DETAILED DESCRIPTION OF THE INVENTION

In the present invention, the C1-4 alkyl includes methyl, ethyl, propyl,butyl and isomers thereof.

In the present invention, the C1-6 alkyl includes methyl, ethyl, propyl,butyl, pentyl, hexyl and isomers thereof.

In the present invention, the C1-8 alkyl includes methyl, ethyl, propyl,butyl, pentyl, hexyl, heptyl, octyl and isomers thereof.

In the present invention, the C2-6 alkenyl includes ethenyl, propenyl,butenyl, pentenyl, hexenyl and isomers thereof.

In the present invention, the C2-8 alkenyl includes ethenyl, propenyl,butenyl, pentenyl, hexenyl, heptenyl, octenyl and isomers thereof.

In the present invention, the C2-6 alkynyl includes ethynyl, propynyl,butynyl, pentynyl, hexynyl and isomers thereof.

In the present invention, the C2-8 alkynyl includes ethynyl, propynyl,butynyl, pentynyl, hexynyl, heptynyl, octynyl and isomers thereof.

In the present invention, the C3-6 alkynyl includes propynyl, butynyl,pentynyl, hexynyl and isomers thereof.

In the present invention, the C1-4 alkoxy includes methoxy, ethoxy,propoxy, butoxy and isomers thereof.

In the present invention, the C1-6 alkoxy includes methoxy, ethoxy,propoxy, butoxy, pentyloxy, hexyloxy and isomers thereof.

In the present invention, the C1-8 alkoxy includes methoxy, ethoxy,propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy and isomersthereof.

In the present invention, the C1-4 alkylthio includes methythio,ethylthio, propylthio, butylthio and isomers thereof.

In the present invention, the C1-6 alkylthio includes methythio,ethylthio, propylthio, butylthio, pentylthio, hexylthio and isomersthereof.

In the present invention, the C1-6 alkylthio includes methythio,ethylthio, propylthio, butylthio, pentylthio, hexylthio, hepthylthio,octylthio and isomers thereof.

In the present invention, the phenyl(C1-4) alkyl includes phenylmethyl,phenylethyl, phenylpropyl, phenylbutyl and isomers thereof.

In the present invention, the hydroxy(C1-4) alkyl includeshydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and isomersthereof.

In the present invention, the C1-4 alkoxy(C1-4) alkyl includesmethoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl,ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, butoxymethyl andisomers thereof.

In the present invention, the C1-4 alkylthio(C1-4) alkyl includesmethylthiomethyl, methylthiothyl, methylthiopropyl, methylthiobutyl,ethylthiomethyl, ethylthioethyl, ethylthiopropyl, ethylthiobutyl,propylthiomethyl, butylthiomethyl and isomers thereof.

In the present invention, the C1-4 alkoxy(C1-4) alkoxy includesmethoxymethoxy, methoxyethoxy, methoxypropoxy, methoxybutoxy,ethoxymethoxy, ethoxyethoxy, ethoxypropoxy, ethoxybutoxy and isomersthereof.

In the present invention, the C1-4 alkoxycarbonyl includesmethoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl andisomers thereof.

In the present invention, the C1-3 alkylene includes methylene,ethylene, trimethylene and isomers thereof.

In the present invention, the C1-4 alkylene includes methylene,ethylene, trimethylene, tetramethylene and isomers thereof.

In the present invention, the C1-6 alkylene includes methylene,ethylene, trimethylene, tetramethylene, pentamethylene, hexamethyleneand isomers thereof.

In the present invention, the C2-6 alkylenylene includes ethylene,trimethylene, tetramethylene, pentamethylene and hexamethylene havingone or two double bond(s) and isomers thereof.

In the present invention, the C2-6 alkynylene is ethylene, trimethylene,tetramethylene, pentamethylene and hexamethylene having one or twotriple bond(s) and isomers thereof.

In the present invention, the halogen includes fluoride, chloride,bromide and iodide.

In the present invention, the C2-5 acyl includes acetyl, propionyl,butyryl, valeryl and isomers thereof.

In the present invention, the C3-6 mono-carbocyclic ring includes a C3-6unsaturated or partially or fully saturated mono-carbocyclic ring, forexample, cyclopropane, cyclobutane, cyclopentane, cyclohexane,cyclopentene, cyclohexene, and benzene.

In the present invention, the C3-7 saturated mono-carbocyclic ringincludes cyclopropane, cyclobutane, cyclopentane, cyclohexane,cyclopentene, cyclohexene, and cycloheptene.

In the present invention, the 3- to 6-membered mono-heterocyclic ringincludes a 3- to 6-membered unsaturated or partially or fully saturatedmono-heterocyclic ring containing 1-4 nitrogen(s), one oxygen and/or onesulfur, for example, aziridine, oxirane, thiirane, azetidine, oxetane,thietane, pyrrolidine, pyrroline, imidazoline, imidazolidine,pyrazoline, pyrazolidine, furan, thiophene, pyrrole, oxazole, isoxazole,thiazole, isothiazole, imidazole, pyrazole, triazole, tetrazole,pyridine, pyrimidine, pyrazine, piperidine, piperazine, morpholine,thiomorpholine, pyran, and thiopyran ring.

In the present invention, the 3- to 7-membered saturatedmono-heterocyclic ring containing 1 or 2 hetero atom(s) selected from O,S, SO₂ and N or benzene fused thereof, for example, aziridine,azetidine, pyrrolidine, imidazolidine, pyrazolidine, piperidine,piperazine, perhydropyridazine, perhydroazepine, perhydrodiazepine,oxirane, oxetane, tetrahydrofuran, tetrahydropyran, perhydrooxepine,thiirane, thiiran-1,1-dione, thietane, thietan-1,1-dione,tetrahydrothiophene, tetrahydrothiophen-1,1-dione, tetrahydrothiopyran,tetrahydrothiopyran-1,1-dione, perhydrothiepine,perhydrothiepin-1,1-dione, oxazolidine, isoxazolidine, thiazolidine,isothiazolidine, tetrahydrooxazine, perhydrooxazepine,tetrahydrothiazine, perhydrothiazepine, morpholine, thiomorpholine,indoline, isoindoline, dihydrobenzofuran, dihydroisobenzofuran,dihydrobenzothiophene, dihydroisobenzothiophene, dihydroindazole,tetrahydroquinoline, tetrahydroisoquinoline, and chroman ring.

In the present invention, the 3- to 6-membered mono-heterocyclic ringcontaining one nitrogen and optionally containing one hetero atomselected from nitrogen, oxygen and sulfur includes 3- to 6-memberedunsaturated or partially or fully saturated mono-heterocyclic ringcontaining 1-2 nitrogen(s), one nitrogen and one oxygen, or one nitrogenand one sulfur, for example, aziridine, oxirane, thiirane, azetidine,oxetane, thietane, pyrrolidine, pyrroline, imidazoline, imidazolidine,pyrazoline, pyrazolidine, pyrrole, oxazole, isoxazole, thiazole,isothiazole, imidazole, pyrazole, pyridine, pyrimidine, pyrazine,piperidine, piperazine, morpholine, and thiomorpholine ring.

In the present invention, the C3-7 mono-carbocyclic ring includes a C3-7unsaturated or partially or fully saturated mono-carbocyclic ring, forexample, cyclopropane, cyclobutane, cyclopentane, cyclohexane,cycloheptane, cyclopentene, cyclohexene, and benzene.

In the present invention, the 3- to 7-membered mono-heterocyclic ringincludes a 3- to 7-membered mono-heterocyclic ring containing 1-4nitrogen(s), one oxygen and/or one sulfur, for example, aziridine,oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline,imidazoline, imidazolidine, pyrazoline, pyrazolidine, furan, thiophene,pyrrole, oxazole, isothiazole, thiazole, isothiazole, imidazole,pyrazole, triazole, tetrazole, pyridine, pyrimidine, pyrazine,piperidine, piperazine, morpholine, thiomorpholine, pyran, thiopyran,azepine, and diazepine ring.

In the present invention, the C7-15 mono-, bi- or tri-carbocyclic ringincludes an unsaturated or partially or fully saturated C7-15 mono-, bi-or tri-carbocyclic ring, for example, cycloheptane, cycloheptene,indene, naphthalene, indan, tetrahydronaphthaldene, azulene, fluorene,phenanthrene, anthracene, and biphenylene ring.

In the present invention, the 7- to 15-membered mono-, bi- ortri-heterocyclic ring includes an unsaturated or partially or fullysaturated 7- to 15-membered mono-, bi- or tri-heterocyclic ringcontaining 1-4 nitrogen(s), 1-2 oxygen(s), one sulfur, one nitrogen andone oxygen, or one nitrogen and one sulfur, for example, azepine,diazepine, perhydroazepine, benzofuran, benzothiophene, benzothiazole,indole, benzoxazole, benzimidazole, benzopyrazole, benzotriazole,benzodioxane, thienopyridine, indoline, isoindoline, 1,3-dioxaindan,chroman, isochroman, quinoline, isoquinoline, quinazoline, quinoxaline,tetrahydroquinoline, tetrahydroisoquinoline, carbazole, acridine,phenanthridine, xanthene, phenazine, phenothiazine, phenoxathiin,phenoxazine, and thianthrene ring.

In the present invention, the C3-12 mono- or bi-carbocyclic ring is anunsaturated or partially or fully saturated C3-12 mono- orbi-carbocyclic ring, for example, cyclopropane, cyclobutane,cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene,cycloheptene, benzene, indene, naphthalene, indan,tetrahydronaphthalene, and azulene.

In the present invention, the 3- to 12-membered mono- or bi-heterocyclicring includes an unsaturated or partially or fully saturated 3- to12-membered mono- or bi-heterocyclic ring containing 1-4 nitrogen(s),1-2 oxygen(s) and/or one sulfur, for example, aziridine, oxirane,thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline,imidazoline, imidazolidine, pyrazoline, pyrazolidine, furan, thiophene,pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole,triazole, tetrazole, pyridine, pyrimidine, pyrazine, piperidine,piperazine, morpholine, thiomorpholine, pyran, thiopyran, azepine,benzofuran, benzothiophene, benzothiazole, indole, isoindole,benzoxazole, benzimidazole, benzopyrazole, benzotriazole, benzodioxane,thienopyridine, indoline, isoindoline, 1,3-dioxaindan, chroman,isochroman, quinoline, isoquinoline, quinazoline, quinoxaline,tetrahydroquinoline, and tetrahydroisoquinoline ring.

In the present invention, the C3-15 mono-, bi- or tri-carbocyclic ringincludes an unsaturated or partially or fully saturated C3-15 mono-, bi-or tri-carbocyclic ring, for example, cyclopropane, cyclobutane,cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene,cycloheptene, benzene, indene, naphthalene, indan,tetrahydronaphthalene, azulene, fluorene, phenanthrene, anthracene, andbiphenylene.

In the present invention, the 3- to 15-membered mono-, bi- ortri-heterocyclic ring includes an unsaturated or partially or fullysaturated 3- to 15-membered mono-, bi- or tri-heterocyclic ringcontaining 1-4 nitrogen(s), 1-2 oxygen(s) and/or one sulfur, forexample, aziridine, oxirane, thiirane, azetidine, oxetane, thietane,pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline,pyrazolidine, furan, thiophene, pyrrole, oxazole, isoxazole, thiazole,isothiazole, imidazole, pyrazole, triazole, tetrazole, pyridine,pyrimidine, pyrazine, piperidine, piperazine, morpholine,thiomorpholine, pyran, thiopyran, azepine, diazepine, perhydroazepine,benzofuran, benzothiophene, benzothiazole, indole, isoindole,benzoxazole, benzimidazole, benzopyrazole, benzotriazole, benzodioxane,thienopyridine, indoline, isoindoline, 1,3-dioxaindan, chroman,isochroman, quinoline, isoquinoline, quinazoline, quinoxaline,tetrahydroquinoline, tetrahydroisoquinoline, carbazole, acridine,phenanthridine, xanthene, phenazine, phenothiazine, phenoxathiin,phenoxazine, and thianthrene ring.

In the present invention, the 1- or 2-membered linking chain comprisingan atom(s) selected from carbon, nitrogen, oxygen and sulfur, which maycontain a double bond or a triple bond in the chain and may besubstituted with 1-4 of R⁴⁰, includes —C(R⁴⁰)u-, -G-, —C(R⁴⁰)u-C(R⁴⁰)u-,—CH═CH—, —C≡C—, -G-C(R⁴⁰)u-, —C(R⁴⁰)u-G-, —NHCO—, —NR⁴⁰⁻¹—CO—, —NHSO₂—,—NR⁴⁰⁻¹—SO₂—, —CONH—, —CONR⁴⁰⁻¹—, —SO₂—NH—, or —SO₂—NR⁴⁰⁻¹—, wherein uis 0, 1 or 2; G is —O—, —S—, —SO—, —SO₂—, —NH—, —NR⁴⁰⁻¹—, or —CO—; R⁴⁰⁻¹is C1-8 alkyl, C2-8 alkynyl, —S(O)p-C1-6 alkyl, —S(O)p-C2-6 alkenyl,—S(O)p-C2-6 alkynyl, C2-5 acyl, Cyc9, or C1-8 alkyl, C2-8 alkenyl orC2-8 alkynyl substituted with 1-2 substituent(s) selected from halogen,CF₃, OCF₃, hydroxy, C1-4 alkoxy, —S(O)p-(C1-6) alkyl, Cyc9 and C1-4alkoxy(C1-4) alkoxy.

In the present invention, the 3- to 6-membered linking chain comprisingatoms selected from carbon, nitrogen, oxygen and sulfur, which maycontain a double bond or a triple bond in the chain and may besubstituted with 1-12 of R⁴⁰, includes —[C(R¹⁴)u]₃—, —[C(R⁴⁰)u]₄—,—[C(R⁴⁰)u]₅—, —[C(R⁴⁰)u]₆—, —CH═CH—C(R⁴⁰)u-, —CH═CH—[C(R¹⁴)u]₂—,—C(R⁴⁰)u-CH═CH—C(R⁴⁰)u-, —C(R⁴⁰)u-CH═CH—, —[C(R⁴⁰)u]₂—CH═CH—,—C≡C—C(R⁴⁰)u-, —C≡C—[C(R⁴⁰)u]₂—, —C(R⁴⁰)u-C≡C—C(R⁴⁰)u-, —C(R⁴⁰)u-C≡C—,—[C(R⁴⁰)u]₂—C≡C—, —[C(R⁴⁰)u]₂-G-, —[C(R⁴⁰)_(u)]₃-G-, —[C(R⁴⁰)_(u)]₄-G-,—[C(R⁴⁰)_(u)]-G-, -G-[C(R⁴⁰)_(u)]₂—, -G-[C(R⁴⁰)_(u)]₃—,-G-[C(R⁴⁰)_(u)]₄—, -G-[C(R⁴⁰)_(u)]₅—, -E-C(R⁴⁰)_(u)—, -E-[C(R⁴⁰)_(u)]₂—,-E-[C(R⁴⁰)_(u)]₃—, -E-[C(R⁴⁰)_(u)]₄—, —C(R⁴⁰)_(u)-G-C(R⁴⁰)_(u)—,—C(R⁴⁰)_(u)-E-C(R⁴⁰)_(u)—, -G-C(R⁴⁰)_(u)-G-, -G-[C(R⁴⁰)_(u)]₂-G-,-G-[C(R⁴⁰)_(u)]₃-G-, -G-[C(R⁴⁰)_(u)]₄-G-, -G-C(R⁴⁰)_(u)-E-,-G-[C(R⁴⁰)_(u)]₂-E-, -G-[C(R⁴⁰)_(u)]₃-E-, -G-C(R⁴⁰)_(u)-E-C(R⁴⁰)—,-G-[C(R⁴⁰)_(u)]₂-E-C(R⁴⁰)—, -G-C(R⁴⁰)_(u)—CH═CH—,-G-[C(R⁴⁰)_(u)]₂—CH═CH—,

wherein E is —NHCO—, NR⁴⁰⁻¹CO—, NHSO₂—, NR⁴⁰⁻¹SO²—, —CONH—, —CONR⁴⁰⁻¹—,—SO₂NH—, or —SO₂NR⁴⁰⁻¹—, wherein the group containing a ring is bound atthe position where the number is described, and the other symbols havethe same meanings as described above.

In the present invention, the 7- to 10-membered linking chain comprisingatoms selected from carbon, nitrogen, oxygen and sulfur, which maycontain a double bond or a triple bond in the chain and may besubstituted with 1-20 of R⁴⁰, includes —[C(R⁴⁰)_(u)]₇—, —[C(R⁴⁰)_(u)]₈—,—[C(R⁴⁰)_(u)]₉—, —[C(R⁴⁰)_(u)]₁₀—, —CH═CH—[C(R⁴⁰)_(u)]₅—,—[C(R⁴⁰)_(u)]₅—CH═CH—, —C≡C—[C(R⁴⁰)_(u)]₅—, —[C(R⁴⁰)_(u)]₅—C≡C—,—[C(R⁴⁰)_(u)]₆-G-, —[C(R⁴⁰)_(u)]₇-G-, —[C(R⁴⁰)_(u)]₈-G-,—[C(R⁴⁰)_(u)]₉-G-, -G-[C(R⁴⁰)_(u)]₆, -G-[C(R⁴⁰)_(u)]₇,-G-[C(R⁴⁰)_(u)]₈-, -G-[C(R⁴⁰)_(u)]₉—, -E-[C(R⁴⁰)_(u)]₅—,-E-[C(R⁴⁰)_(u)]₆—, -E-[C(R⁴⁰)_(u)]₇—, -E-[C(R⁴⁰)_(u)]₈—,—C(R⁴⁰)_(u)-G-[C(R⁴⁰)_(u)]₅—, —[C(R⁴⁰)_(u)]₅-G-C(R⁴⁰)_(u)—,—C(R⁴⁰)_(u)-E-[C(R⁴⁰)_(u)]₄—, —[C(R⁴⁰)_(u)]₄-E-C(R⁴⁰)_(u)—,-G-[C(R⁴⁰)_(u)]₅-G-, -G-[C(R⁴⁰)_(u)]₆-G-, -G-[C(R⁴⁰)_(u)]₇-G-,-G-[C(R⁴⁰)_(u)]₈-G-, -G-[C(R⁴⁰)_(u)]₄-E-, -G-[C(R⁴⁰)_(u)]₅-E-,-G-[C(R⁴⁰)_(u)]₆-E-, G-[C(R⁴⁰)_(u)]₇-E-, -G-[C(R⁴⁰)_(u)]₃-E-C(R⁴⁰)—,-G-[C(R⁴⁰)_(u)]₄-E-C(R⁴⁰)—,

wherein all symbols have the same meanings as described above.

Unless otherwise specified, all isomers are included in the presentinvention. For example, alkyl, alkenyl, alkynyl and alkylene groupsinclude straight-chain and also branched-chain ones. In addition,isomers in double bond, ring, fused ring (E-, Z-, cis-, trans-isomer),isomers generated from asymmetric carbon atom(s) (R-, S-, α-, β-isomer,enantiomer, diastereomer), optically active isomers having opticalrotation (D-, L-, d-, l-isomer), polar compounds separated bychromatography (more polar compound, less polar compound), equilibriumcompounds, mixtures thereof at arbitrary ratios and racemic mixtures areincluded in the present invention.

A preferably compound of formula (I) is the compound which is

[I] n is 1 or 2,

Q is

(1)(i) —(C1-4 alkylene, C2-4 alkenylene or C2-4 alkenylene)-Cyc2,

(ii) C1-4 alkylene)-Z-Cyc3,

(iii) C1-4 alkyl substituted with —NR²⁴R²⁵, —S(O)_(p)R²⁶, cyano,—NR²³COR²⁷, —NR²³SO₂R²⁸ or —NR²³CONR²⁴R²⁵,

(iv) C1-4 alkoxy(C1-4) alkoxy —NR²³COR²⁷, —COR²⁸, —OSO₂R²⁸, —NR²³SO₂R²⁸or —NR²³CONR²⁴R²⁵,

(v) a C3-7 mono-carbocyclic ring or 3- to 6-membered mono-heterocyclicring which is substituted with 1-5 of R³⁰, wherein one R³⁰ is alwayssubstituted on the ring at the non 1-position,

(vi) a C8-15 mono-, bi- or tri-carbocyclic ring or 7- to 15-memberedmono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R³⁰or unsubstituted,

(vii) -T-Cyc5,

(viii) -L-Cyc⁶⁻¹, -L-(C2-4 alkylene)-Cyc⁶⁻² or -L-(C1-4alkylene)_(q)-Cyc⁶⁻³,

D is

(1) a 1- or 2-membered linking chain comprising an atom(s) selected fromcarbon, nitrogen, oxygen and sulfur, which may contain a double bond ora triple bond in the chain and may be substituted with 1-4 of R⁴⁰,

(2) a 3- to 6-membered linking chain comprising atoms selected fromcarbon, nitrogen, oxygen and r, which may contain a double bond or atriple bond in the chain and may be substituted with 1-12 of R⁴⁰,wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is asubstituent of R³, taken together may form —(CH₂)_(y), in which y is1-4;

[II] n is 1 or 2,

Q is

(2)(i) phenoxy,

(ii) benzyloxy,

(iii) hydroxy(C1-4) alkyl,

(iv) C1-4 alkoxy(C1-4) alkyl, or

(v) —(C1-4 alkylene)-O—(C1-4 alkylene)-Cyc7,

D is

(2) a 3- to 6-membered linking chain comprising atoms selected fromcarbon, nitrogen, oxygen and sulfur, which may contain a double bond ora triple bond in the chain and may be substituted with 1-12 of R⁴⁰,wherein R⁴ substituted on the atom bound to R³, and R⁴² which is asubstituent of R³, taken together may form —(CH₂)_(y)—, in which y is1-4;

[III] n is 1 or 2,

Q is

(3) C2-6 alkenyl,

(ii) C2-6 alkynyl,

(iii) C1-6 alkyl substituted with 1-3 halogen(s),

(iv) cyano,

(v) nitro,

(vi) —NR³³R³⁴,

(vii) —CONR³³R³⁴,

(viii) —S(O)_(p)—(C2-4) alkynyl,

(ix) —S(O)_(p)—CHF₂,

(x) —S(O)_(p)—NR³³R³⁴,

(xi) —O—(C3-6) alkynyl,

(xii) —O—CHF₂, or

(xiii) C3-7 cycloalkyl

D is

(1) a 1- or 2-membered linking chain comprising an atom(s) selected fromcarbon, nitrogen oxygen and sulfur, which may contain a double bond or atriple bond in the chain and may be substituted with 1-4 of R⁴⁰;

[IV] n is 0,

D is

(1) a 1- or 2-membered linking chain comprising an atom(s) selected fromcarbon, nitrogen, oxygen and sulfur, which may contain a double bond ora triple bond in the chain and may be substituted with 1-4 of R⁴⁰,

(2) a 3- to 6-membered lining chain comprising atoms selected fromcarbon, nitrogen, oxygen and sulfur, which may contain a double bond ora triple bond in the chain and may be substituted with 1-12 of R⁴⁰,wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is asubstituent of R³, taken together may form —(CH₂)_(y), in which y is1-4;

[V] n is 0, 1 or 2,

Q is

(1)(i) —(C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene)-Cyc2,

(ii) —(C1-4 alkylene)-Z-Cyc3,

(iii) C1-4 alkyl substituted with —NR²⁴R²⁵, —S(O)_(p)R²⁶, cyano,—NR²³COR²⁷, —NR²³SO₂R²⁸ or —NR²³CONR²⁴R²⁵,

(iv) C1-4 alkoxy(C1-4) alkoxy, —NR²³COR²⁷, —COR²⁸, —OSO₂R²⁸, —NR²³SO₂R²⁸or —NR²³CONR²⁴R²⁵,

(v) a C3-7 mono-carbocyclic ring or 3- to 6-membered mono-heterocyclicring which is substituted with 1-5 of R³⁰, wherein one R³⁰ is alwayssubstitute on the rings at the non 1-position,

(vi) a C8-15 mono-, bi- or tri-carbocyclic ring or 7- to 15-memberedmono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R³⁰or unsubstituted,

(vii) -T-Cyc5,

(viii) -L-Cyc⁶⁻¹, -L-(C2-4 alkylene)-Cyc⁶⁻² or -L-(C1-4alkylene)_(q)-Cyc⁶⁻³,

(2)(i) phenoxy,

(ii) benzyloxy,

(iii) hydroxy(C1-4) alkyl,

(iv) C1-4 alkoxy(C1-4) alkyl, or

(v) —(C1-4 alkylene)-O—(C1-4 alkylene)-Cyc7, or

(3)(i) C2-6 alkenyl,

(ii) C2-6 alkynyl,

(iii) C1-6 alkyl substituted with 1-3 halogen(s),

(iv) cyano,

(v) nitro,

(vi) —NR³³R³⁴,

(vii) —CONR³³R³⁴,

(viii) —S(O)_(p)—(C1-4) alkynyl,

(ix) —S(O)_(p)—CHF₂,

(x) —S(O)_(p)—NR³³R³⁴,

(xi) —O—(C3-6) alkynyl,

(xii) —O—CHF₂, or

(xiii) C3-7 cycloalkyl,

D is

(3) a 7- to 10-membered linking chain comprising atoms selected fromcarbon, nitrogen, oxygen and sulfur, which may contain a double bond ora triple bond in the chain and may be substituted with 1-20 of R⁴⁰,wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is asubstituent of R³, taken together may form —(CH₂)_(y)—.

In the compound specified in [III], when D is —NR⁴⁰⁻²CO— or —NR⁴⁰⁻²CS—,wherein R⁴⁰⁻² is hydrogen or C1-8 alkyl, and Q is C1-6 alkyl substitutedwith 1-3 halogen(s), cyano or nitro, A is (i) a single bond, (ii) C1-6alkylene, (iii) C2-6 alkenylene, (iv) C2-6 alkynylene, (v) —O—(C1-3alkylene), (vi) —S—(C1-3 alkylene), (vii) —NR²⁰—(C1-3 alkylene), (viii)—CONR²¹—(C1-3 alkylene), (ix) —(C1-3 alkylene)-O—(C1-3 alkylene), (x)—(C1-3 alkylene)-S-(C1-3 alkylene), (xi) —(C1-3 alkylene)-NR²⁰—(C1-3alkylene), (xii) —(C1-3 alkylene)-CONR²¹—(C1-3 alkylene), (xiii) -Cyc1or (xv) -Cyc1-(C1-4 alkylene).

In the compound specified in [V], when D is —NR⁴⁰⁻²CO—(C5-6 alkylene) or—NR⁴⁰⁻²CS—(C5-6 alkylene), in which the carbon atoms of the C5-6alkylene are unsubstituted or substituted with C1-6 alkoxy, and Q isC1-6 alkyl substituted with 1-3 halogen(s), cyano or nitro, A is (i) asingle bond, (ii) C1-6 alkylene, (iii) C2-6 alkenylene, (iv) C2-6alkynylene, (v) —O—(C1-3 alkylene), (vi) —S—(C1-3 alkylene), (vii)—NR²⁰—(C1-3 alkylene), (viii) —CONR²¹—(C1-3 alkylene), (ix) —(C1-3alkylene)-O—(C1-3 alkylene), (x) —(C1-3 alkylene)-S—(C1-3 alkylene),(xi) —(C1-3 alkylene)-NR²⁰—(C1-3 alkylene), (xii) —(C1-3alkylene)-CONR²¹—(C1-3 alkylene), (xiii) -Cyc1 or (xv) -Cyc1-(C1-4alkylene).

Among the compounds specified in [I], preferred is a compound wherein

[I-1] n is 1 or 2,

Q is

(1)(i) —(C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene)-Cyc2,

(ii) —(C1-4 alkylene)-Z-Cyc3,

(iii) C1-4 alkyl substituted with —NR²⁴R²⁵, —S(O)_(p)R²⁶, cyano,—NR²³COR²⁷, —NR²³SO₂R²⁸ or —NR²³CONR²⁴R²⁵,

(iv) C1-4 alkoxy(C1-4) alkoxy, —NR²³COR²⁷, —COR²⁸, —OSO₂R²⁸, —NR²³SO₂R²⁸or —NR²³CONR²⁴R²⁵,

(v) a C3-7 mono-carbocyclic ring or 3- to 6-membered mono-heterocyclicring which is substituted with 1-5 of R³⁰ wherein one R³⁰ is alwayssubstituted on the ring at the non 1-position,

(vi) a C8-15 mono-, bi- or tri-carbocyclic ring or 7- to 15-memberedmono, bi- or tri-heterocyclic ring which is substituted with 1-5 of R³⁰or unsubstituted,

(vii) -T-Cyc5,

(viii) -L-Cyc⁶⁻¹, -L-(C2-4 alkylene)-Cyc⁶⁻² or -L-(C1-4alkylene)_(q)-Cyc⁶⁻³,

D is

(1) a 1- or 2-membered linking chain comprising an atom(s) selected fromcarbon, nitrogen, oxygen and sulfur, which may contain a double bond ora triple bond in the chain and may be substituted with 1-4 of R⁴⁰, and

[I-2] n is 1 or 2,

Q is

(1)(i) —(C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene)-Cyc2,

(ii) —(C1-4 alkylene)-Z-Cyc3,

(iii) C1-4 alkyl substituted with —NR²⁴R²⁵, —S(O)_(p)R²⁶, cyano,—NR²³COR²⁷, —NR²³SO₂R²⁸ or —NR²³CONR²⁴R²⁵,

(iv) C1-4 alkoxy(C1-4) alkoxy, —NR²³COR²⁷, —COR²⁸, —OSO₂R²⁸, —NR²³SO₂R²⁸or —NR²³CONR²⁴R²⁵,

(v) a C3-7 mono-carbocyclic ring or 3- to 6-membered mono-heterocyclicring which is substituted with 1-5 of R³⁰, wherein R³⁰ is alwayssubstituted on the above ring at the non 1-position,

(vi) a C8-15 mono-, bi- or tri-carbocyclic ring or 7- to 15-memberedmono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R³⁰or unsubstituted,

(vii) -T-Cyc5,

(vii) -L-Cyc⁶⁻¹, -L-(C2-4 alkylene)-Cyc⁶⁻² or -L-(C1-4alkylene)_(q)-Cyc⁶⁻³,

D is

(2) a 3- to 6-membered linking chain comprising atoms selected fromcarbon, nitrogen, oxygen and sulfur, which may contain a double bond ora triple bond in the chain and may be substituted with 1-12 of R⁴⁰,wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is asubstituent of R³, taken together may form —(CH₂)_(y)—, in which y is1-4.

More preferably A in the present compound of formula (I) is

(i) a single bond,

(ii) C1-4 alkylene,

(iii) C2-4 alkenylene,

(iv) C2-4 alkynylene,

(v) —O—(C1-2 alkylene),

(vi) —S—(C1-2 alkylene),

(vii) —NR²⁰—(C1-2 alkylene),

(viii) —CONR²¹—(C1-2 alkylene),

(ix) —CH₂—O—(C1-2 alkylene),

(x) —CH₂—S—(C1-2 alkylene),

(xi) —CH₂—NR²⁰—(C1-2 alkylene),

(xii) —CH₂—CONR²¹—(C1-2 alkylene),

(xiii) -Cyc1,

(xiv) —(C1-2 alkylene)-Cyc1 or

(xv) -Cyc1-(C1-2 alkylene).

Especially preferable A is a single bond, methylene, ethylene,trimethylene, tetramethylene, vinylene, 1-propenylene, ethynylene,1-propynilene, —O—CH₂—, —O—(CH₂)₂—, —CH₂—O—CH₂—, —S—CH₂—, —S—(CH₂)₂—,—CH₂—S—CH₂—, —NR²⁰—CH₂—, —NR²⁰—(CH₂)₂—, —CH₂—NR²⁰—CH₂—, —CH₂-phenyl, or—CONH—CH₂.

Preferable B ring in the present compound of formula (I) is a C3-12mono- or bi-carbocyclic ring or 3- to 12-membered mono- orbi-heterocyclic ring containing 1-4 nitrogen(s), 1-2 oxygen(s) and/orone sulfur.

Concrete B ring includes cyclopropane, cyclobutane, cyclopentane,cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene,benzene, indene, naphthalene, indan, tetrahydronaphthalene, azulene,aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine,pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, furan,thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole,imidazole, pyrazole, triazole, pyridine, pyrimidine, pyrazine,piperidine, piperazine, morpholine, thiomorpholine, pyran, thiopyran,azepine, diazepine, perhydroazepine, benzofuran, benzothiophene,benzothiazole, indole, isoindole, benzoxazole, benzimidazole,benzopyrazole, benzotriazole, benzodioxane, thienopyridine, indoline,isoindoline, 1,3-dioxaindan, chroman, isochroman, quinoline,isoquinoline, quinazoline, quinoxaline, tetrahydroquinoline, andtetrahydroisoquinoline ring.

Preferable B ring is cyclopentane, cyclohexane, cycloheptane,cyclopentene, cyclohexene, benzene, indene, naphthalene, indan,tetrahydronaphthalene, furan, thiophene, pyrrole, oxazole, isoxazole,thiazole, isothiazole, imidazole, pyrazole, pyridine, pyrimidine,pyrazine, azepine, benzofuran, benzothiophene, benzothiazole, indole,isoindole, benzoxazole, benzimidazole, benzopyrazole, indoline,isoindoline, quinoline, and tetrahydroquinoline ring. Especiallypreferable B ring is cyclohexane, benzene, indene, naphthalene, indan,tetrahydronaphthalene, furan, thiophene, pyrrole, pyridine, benzofuran,benzothiophene, indole, isoindole, indoline, isoindoline, quinoline, ortetrahydroquinoline ring.

Preferable Q in the present compound of formula (I) is

(1)(i) —(C1-4 alkylene or C2-4 alkenylene)-Cyc2,

(ii) —(C1-4 alkylene)-Z-Cyc3,

(iii) C1-4 alkyl substituted with —NR²⁴R²⁵, —S(O)_(p)R²⁶, cyano,—NR²³COR²⁷,

(iv) C1-4 alkoxy(C1-4) alkoxy, —NR²³COR²⁷, —COR²⁸, —OSO₂R²⁸, —NR²³SO₂R²⁸or —NR²³CONR²⁴R²⁵,

(vi) a C7-12 mono or bi-carbocyclic ring or 7- or 12-membered mono- orbi-heterocyclic ring which is substituted with 1-5 of R³⁰ orunsubstituted,

(vii) -T-Cyc5,

(viii) -L-Cyc⁶⁻¹, -L-(C3-6 cycloalkyl), -L-CH₂—(C3-6 cycloalkyl),-L-(C2-4 alkylene)-Cyc⁶⁻² or -L-(C1-4 alkylene)_(q)-Cyc⁶⁻³,

(2)(i) phenoxy,

(ii) benzyloxy,

(iii) hydroxy(C1-4) alkyl,

(iv) C1-4 alkoxy(C1-4) alkyl, or

(v) —(C1-1 alkylene)-O-benzyl, or

(3)(i) C2-6 alkenyl,

(ii) C2-6 alkynyl,

(iii) C1-6 alkyl substituted with 1-3 halogen(s),

(iv) cyano,

(v) nitro,

(vi) —NR³³R³⁴,

(vii) —CONR³³R³⁴,

(viii) -Cyc8.

In preferable Q preferable Cyc2 is a C3-12 mono- or bi-carbocyclic ringor 3- to 12-membered mono- or bi-heterocyclic ring containing 1-4nitrogen(s), 1-2 oxygen(s) and/or one sulfur, which is substituted with1-5 of R³⁰ or unsubstituted. Concrete Cyc2 includes cyclopropane,cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene,cyclohexene, cycloheptene, benzene, indene, naphthalene, indan,tetrahydronaphthalene, azulene, aziridine, oxirane, thiirane, azetidine,oxetane, thietane, pyrrolidine, pyrroline, imidazoline, imidazolidine,pyrazoline, pyrazolidine, furan, thiophene, pyrrole, oxazole, isoxazole,thiazole, isothiazole, imidazole, pyrazole, triazole, tetrazole,pyridine, pyrimidine, pyrazine, piperidine, piperazine, morpholine,thiomorpholine, pyran, thiopyran, azepine, diazepine, perhydroazepine,benzofuran, benzothiophene, benzothiazole, indole, benzoxazole,benzimidazole, benzopyrazole, benzotriazole, benzodioxane,thienopyridine, indoline, isoindoline, 1,3-dioxaindan, chroman,isochroman, quinoline, isoquinoline, quinazoline, and quinoxaline ring.

More preferable Q is cyclopropane, cyclohexane, benzene, naphthalene,tetrahydronaphthalene, pyrrolidine, imidazoline, furan, thiophene,pyrrole, oxazole, thiazole, imidazole, pyrazole, triazole, pyridine,pyrimidine, pyrazine, piperazine, morpholine, indole, benzimidazole, orbenzothiazole.

All groups of Z is preferable.

Preferable Cyc3 is a C3-12 mono- or bi-carbocyclic ring or 3- to12-membered mono- or bi-heterocyclic ring containing 1-4 nitrogen(s),1-2 oxygen(s) and/or one sulfur, which is substituted with 1-5 of R³⁰ orunsubstituted. Concrete Cyc3 includes cyclopropane, cyclobutane,cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene,cycloheptene, benzene, indene, naphthalene, indan,tetrahydronaphthalene, azulene, aziridine, oxirane, thiirane, azetidine,oxetane, thietane, pyrrolidine, pyrroline, imidazoline, imidazolidine,pyrazoline, pyrazolidine, furan, thiophene, pyrrole, oxazole, isoxazole,thiazole, isothiazole, imidazole, pyrazole, triazole, tetrazole,pyridine, pyrimidine, pyrazine, piperidine, piperazine, morpholine,thiomorpholine, pyran, thiopyran, azepine, diazepine, perhydroazepine,benzofuran, benzothiophene, benzothiazole, indole, benzoxazole,benzimidazole, benzopyrazole, benzotriazole, benzodioxane,thienopyridine, indoline, isoindoline, 1,3-dioxaindan, chroman,isochroman, quinoline, isoquinoline, quinazoline, and quinoxaline ring.

More preferable Cyc3 is cyclopropane, cyclohexane, benzene, naphthalene,tetrahydronaphthalene, pyrrolidine, furan, thiophene, pyrrole, oxazole,thiazole, imidazole, pyrazole, triazole, pyridine, pyrimidine, pyrazine,piperazine, morpholine, indole, benzimidazole, or benzothiazole.

All groups of T is preferable.

Preferable Cyc5 is 3- to 12-membered mono- or bi-heterocyclic ringcontaining 1-4 nitrogen(s), 1-2 oxygen(s) and/or one sulfur that theyare substituted with 1-5 of R³⁰ or unsubstituted. Concrete Cyc5 includesaziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine,pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, furan,thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole,imidazole, pyrazole, triazole, tetrazole, pyridine, pyrimidine,pyrazine, piperidine, piperazine, morpholine, thiomorpholine, pyran,thiopyran, azepine, diazepine, perhydroazepine, benzofuran,benzothiophene, benzothiazole, indole, benzoxazole, benzimidazole,benzopyrazole, benzotriazole, benzodioxane, thienopyridine, indoline,isoindoline, 1,3-dioxaindan, chroman, isochroman, quinoline,isoquinoline, quinazoline, or quinoxaline ring.

More preferable Cyc5 is pyrrolidine, furan, thiophene, pyrrole, oxazole,thiazole, imidazole, pyrazole, triazole, pyridine, pyrimidine, pyrazine,piperazine, morpholine, indole, benzimidazole, benzothiazole,benzodioxane, or 1,3-dioxaindan.

In the compound of formula (I) of the present invention,

(1) preferable D as the 1- or 2-membered linking chain comprising anatom(s) selected from carbon, nitrogen, oxygen and sulfur is —CH₂—,—(CH₂)₂—, —CH═CH—, —C≡C—, —O—, —NH—, —CO—, —O—CH₂—, —CH₂—O—, —CONH—,—NHCO—, —NHSO₂—, —N(CH₃)—SO₂—, or —SO₂NH—,

(2) preferable D as the 3- to 6-membered linking chain comprising atomsselected from carbon, nitrogen, oxygen and sulfur is —(CH₂)₃—, —(CH₂)₄—,—(CH₂)₅—, —(CH₂)₆—, —CH═CH—CH₂—, —CH═CH—(CH₂)₂—, —CH═CH—(CH₂)₃—,—C≡C—CH₂—, —C≡C—(CH₂)₂—, —C≡C—(CH₂)₃—, —(CH₂)₂—O—, —(CH₂)₃—O—,—(CH₂)₄—O—, —O—(CH₂)₅—, —O—CH₂—CH(R⁴⁰)—, —O—CH₂—CH(R⁴⁰)—CH₂—,—O—CH₂—CH₂—CH(R⁴⁰)—, —O—CH₂—CH═CH—, —O—(CH₂)₂—CH═CH—, —NR⁴⁰⁻¹—(CH₂)₂—,—NR⁴⁰⁻¹—(CH₂)₃—, —S—(CH₂)₂—, —S—(CH₂)₃—, —SO₂—(CH₂)₂—, —SO₂—(CH₂)₃—,—CH₂—NHCO—, —NHCO—CH₂—, —NR⁴⁰⁻¹CO—CH₂—, —NHCO—CHR⁴⁰—, —NHCO—C(R⁴⁰)₂—,—NHCO—(CH₂)₂—, —NHCO—CHR⁴⁰—CH₂—, —NHCO—CH₂—CHR⁴⁰—, —NHCO—CHR⁴⁰—CHR⁴⁰—,—CONH—CH₂—, —CONR⁴⁰⁻¹—CH₂—, —CONH—CHR⁴⁰—, —CONH—C(R⁴⁰)₂—, —CONH—(CH₂)₂—,—CONH—CHR⁴⁰—CH₂—, —CONH—CHR⁴⁰—(CH₂)₂—, —CONH—CH₂—CHR⁴⁰—,—CONH—CH(R⁴⁰)—CH(R⁴⁰)—, —NHSO₂—CH₂—, —NR⁴⁰⁻¹SO₂—CH₂—, —NHSO₂—CHR⁴⁰—,—NHSO₂—C(R⁴⁰)₂—, —NHSO₂—(CH₂)₂—, —NHSO₂—CHR⁴⁰—CH₂—, —NHSO₂—CH₂—CHR⁴⁰—,—NHSO₂—CH(R⁴⁰)—CH(R⁴⁰)—, —SO₂NH—CH₂—, —SO₂NR⁴⁰⁻¹—CH₂—, —SO₂NH—CHR⁴⁰—,—SO₂NH—C(R⁴⁰)₂—, —SO₂NH—(CH₂)₂—, —SONH₂—CHR⁴⁰—CH₂—, —SO₂NH—CH₂—CHR⁴⁰—,—SO₂NH—CH(R⁴⁰)—CH(R⁴⁰)—, —CH₂—O—CH₂—, —CH₂—O—(CH₂)₂—, —(CH₂)₂—O—CH₂—,—(CH₂)₂—O—(CH₂)₂—, —O—(CH₂)₂—O—, —O—(CH₂)₃—O—, —O—(CH₂)₄—O—,—O—CH₂—CH(R⁴⁰)—CH₂—O—, —O—CH₂—CO—, —O—CH₂—NR⁴⁰⁻¹—, —O—(CH₂)₂—NR⁴⁰⁻¹—,—O—(CH₂)₂—NR⁴⁰⁻¹—CH₂—, —O—(CH₂)₃—NR⁴⁰⁻¹, —O—CH₂—CH₂—NHCO—,—O—CH₂—CH₂—NR⁴⁰⁻¹—CO—, —O—CH₂—CH(R⁴⁰)—NHCO—, —O—CH₂—CH(R⁴⁰)—NR⁴⁰⁻¹CO—,—O—CH₂—CH₂—NHSO₂—, —O—CH₂—CH₂—NR⁴⁰⁻¹SO₂—, —O—CH₂—CH(R⁴⁰)—NHSO₂—,—O—CH₂—CH(R⁴⁰)—NR⁴⁰⁻¹SO₂—, —O—CH₂—CONH—, —O—CH₂—CONR⁴⁰⁻¹—,—O—CH₂—CONH—CH₂—, —O—(CH₂)₂—CONH—CH₂—, —O—CH₂—CONR⁴⁰⁻¹—CHR⁴⁰—,—O—CH₂—NHCO—CH₂—, —O—(CH₂)₂—NHCO—CH₂—, —O—CH₂—NR⁴⁰⁻¹CO—CHR⁴⁰—,

(3) preferable D as, the 7- to 10-membered linking chain comprisingatoms selected from carbon, nitrogen, oxygen and sulfur is —(CH₂)₇—,—(CH₂)₈—, —(CH₂)₉—, —(CH₂)₁₀—, —O—(CH₂)₆—, —O—(CH₂)₇—, —O—(CH₂)₈—,—O—(CH₂)₉—, —NR⁴⁰⁻¹—(CH₂)₆—, —NR⁴⁰⁻¹—(CH₂)₇—, —S—(CH₂)₆—, —S—(CH₂)₇—,—SO₂—(CH₂)₆—, —SO₂—(CH₂)₇—, —NHCO—(CH₂)₅—, —NR⁴⁰⁻¹CO—(CH₂)₅—,—CONH—(CH₂)₅—, CO—NR⁴⁰⁻¹—(CH₂)₅—, —NHSO₂—(CH₂)₅—, —NR⁴⁰⁻¹SO₂—(CH₂)₅—,—SO₂NH—(CH₂)₅—, —SO₂NR⁴⁰⁻¹—(CH₂)₅—, —O—(CH₂)₅—O—, —O—(CH₂)₆—O—,—O—(CH₂)₅—NR⁴⁰⁻¹—, —O—(CH₂)₅—NR⁴⁰⁻¹—, —O—(CH₂)₄—NHCO—,—O—(CH₂)₄—NR⁴⁰⁻¹CO—, —O—(CH₂)₄—CONH—, —O—(CH₂)₄—CONR⁴⁰⁻¹—, —(CH₂)₆—O—,—(CH₂)₇—O—, —(CH₂)₈—O—, —(CH₂)₉—O—,

Preferable R⁴⁰ is methyl, ethyl, propyl, isopropyl, butyl, isobutyl,methoxy, ethoxy, propoxy, butoxy, methoxymethyl, methoxyethyl, hydroxy,hydroxymethyl, hydroxyethyl, cyclopropyl, cyclohexyl, benzene,cyclopropylmethyl, cyclohexylmethyl, benzyl, or acetyl.

Preferable R⁴⁰ is methyl, ethyl, propyl, isopropyl, butyl, isobutyl,methoxymethyl, methoxyethyl, hydroxymethyl, hydroxyethyl, cyano methyl,cyano ethyl, methylsulfonyl, cyclopropyl, cyclohexyl, benzene,cyclopropylmethyl, cyclohexylmethyl, benzyl, or acetyl.

In the compound of the present invention, in the linking of D, astructure wherein R⁴⁰ which binds to the atom bound to R³, and R⁴² whichis a substituent of R³, taken together forms —(CH₂)_(y)—, is a ring offormula:

Concretely, it is

and especially, it is preferable that R³ is benzene ring.

In the compound of the present invention, preferable R³ is (1) C1-6alkyl, or (2) a C3-12 mono- or bi-carbocyclic ring or 3- to 12-memberedmono-, bi- or tri-heterocyclic ring containing 1-4 nitrogen(s), 1-2oxygen(s) and/or one sulfur. Concretely, examples include (1) methyl,ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl,and (2) substituted with 1-5 of R⁴² or unsubstituted, cyclopropane,cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene,cyclohexene, cycloheptene, benzene, indene, naphthalene, indan,tetrahydronaphthalene, azulene, aziridine, oxirane, thiirane, azetidine,oxetane, thietane, pyrrolidine, pyrroline, imidazoline, imidazolidine,pyrazoline, pyrazolidine, furan, thiophene, pyrrole, oxazole, isoxazole,thiazole, isothiazole, imidazole, pyrazole, triazole, tetrazole,pyridine, pyrimidine, pyrazine, piperidine, piperazine,tetrahydropyridine, morpholine, thiomorpholine, pyran, thiopyran,azepine, diazepine, perhydroazepine, benzofuran, benzothiophene,benzothiazole, indole, benzoxazole, benzimidazole, benzopyrazole,benzotriazole, benzodioxane, thienopyridine, indoline, isoindoline,1,3-dioxaindan, chroman, isochroman, quinoline, isoquinoline,quinazoline, quinoxaline, tetrahydroquinoline, tetrahydroisoquinoline,carbazole, phenoxazine, acridine, and 9,10-dihydroacridine.

More preferable R³ is (1) propyl, isopropyl, butyl, isobutyl, pentyl orhexyl, or (2) cyclohexane, benzene, naphthalene, tetrahydronaphthalene,furan, thiophene, pyrrole, imidazole, pyrazole, triazole, pyridine,piperidine, piperazine, tetrahydropyridine, morpholine, benzofuran,benzothiophene, indole, benzimidazole, benzopyrazole, benzotriazole,benzodioxane, 1,3-dioxaindan, chroman, quinoline, isoquinoline,tetrahydroquinoline, tetrahydroisoquinoline, carbazole, phenoxazine, or9,10-dihydroacridine which is substituted with 1-5 of R⁴² orunsubstituted.

In the compounds of the present invention of formula (I), for example,concrete compounds are the compounds described in examples.

Salt:

The compound of the present invention of formula (I) may be convertedinto a corresponding salt by known methods. Non-toxic and water-solublesalts are preferable. In the present invention, salts are salts ofalkali metals, such as potassium, sodium, etc.; salts of alkaline-earthmetals, such as calcium, magnesium, etc.; ammonium salts,pharmaceutically acceptable organic amines, such as tetramethylammonium,triethylamine, methylamine, dimethylamine, cyclopentylamine,benzylamine, phenethylamine, piperidine, monoethanolamine,diethanolamine, tris(hydroxymethyl)methylamine, lysine, arginine,N-methyl-D-glucamine, etc.

In the present invention, preferable acid addition salts are non-toxicand water-soluble salts. In the present invention, acid addition saltsare salts of inorganic acids such as hydrochloride, hydrobromide,sulfate, phosphate, nitrate; salts of organic acids e.g. acetate,lactate, tartrate, oxalate, fumarate, maleate, citrate, benzoate,methanesulphonate, ethanesulphonate, benzenesulphonate,toluenesulphonate, isethionate, glucuronate, gluconate.

The compound of formulae (I) and a salt thereof may be converted intothe corresponding hydrates by conventional means.

Preparation of the Compound of the Present Invention

The present compound of formula (I) may be prepared, for example, by thefollowing method.(1) In the compound of formula (I), wherein R¹ is COOH, that is, thecompound of formula (Ia):

wherein all symbols have the same meanings as described above;may be prepared by subjecting to deprotection the compound of formula(Ib)

wherein R⁴⁻¹ is C1-6 alkyl and the other symbols have the same meaningsas described above.

The method of deprotection is known, for example, it includes the methodof

(1) deprotection under alkaline conditions,

(2) deprotection under acidic conditions,

(3) hydrogenolysis.

Deprotection under alkaline conditions is known, for example it may becarried out in water-miscible organic solvent (e.g. methanol, ethanol,tetrahydrofuran, dioxane or a mixture thereof), using an aqueoussolution of alkali (e.g. sodium hydroxide, potassium hydroxide orpotassium carbonate), or a mixture thereof at −10-90° C.

Deprotection under acidic conditions may be carried out, for example, ina organic solvent (e.g. dichloromethane, chloroform, dioxane, ethylacetate, anisole), using an organic acid (e.g. acetic acid,trifluoroacetic acid, methanesulfonic acid, p-tosylic acid), or aninorganic acid (e.g. hydrogen chloride or sulfuric acid) or a mixturethereof (e.g. hydrogen bromide/acetic acid) at 0-100° C.

Hydrogenolysis may be carried out, for example, in a solvent (ether,e.g. tetrahydrofuran, dioxane, dimethoxyethane, diethyl ether; alcohol,e.g. methanol, ethanol; benzene, e.g. benzene, toluene; ketone, e.g.acetone, methyl ethyl ketone; nitrile, e.g. acetonitrile; amide, e.g.dimethylformamide; water, ethyl acetate, acetic acid or two more mixturethereof), in the presence of a catalyst (e.g. palladium on carbon,palladium black, palladium hydroxide, platinum dioxide or Raney-nickel),at ordinary or elevated pressure of hydrogen gas or in the presence ofammonium formate at 0-200° C.

(2) The compound of formula (Ib) may be prepared by reacting

(i) the compound of formula (II-1)

wherein X is halogen and the other symbols have the same meanings asdescribed above;and the compound of formula (III-1)H-A-COOR⁴⁻¹  (III-1)wherein all symbols have the same meanings as described above; or(ii) the compound of formula (II-1) and the compound of formula (III-2)XZn-A-COOR⁴⁻¹  (III-2)wherein all symbols have the same meanings as described above.

Besides, (iii) the compound of formula (Ib) may be also prepared byreacting the compound of formula (II-2)

wherein all symbols have the same meanings as described above;and a Wittig reagent or a malonic acid.

The above reactions (i) and (ii) are known, for example, it may becarried out in an organic solvent (e.g. dimethylsulfoxide,tetrahydrofuran, dimethylformamide), in the presence or absence of atertiary amine (e.g. dimethylaminopyridine, pyridine, triethylamine),using a ligand (e.g. 1,1′-bis(diphenylphosphino)ferrocene) and apalladium complex (e.g. bisacetoxy palladium) at 60-120° C.

The above reaction (iii) is known, for example, the reaction with aWittig reagent may be carried out in an organic solvent (e.g.tetrahydrofuran, dimethylsulfoxide), in the presence of an base (sodiumhydroxide, potassium t-butoxide), using a Wittig reagent (e.g. triethylphosphonoacetate, 4-triphenyl phosphinobutyrate), at 0-50° C., and thereaction with a malonic acid may be carried out in an organic solvent(e.g. pyridine), using piperidine at 100-120° C.

Besides, (iv) in the compound of formula (Ib), the compound wherein oneof Q is —(C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene)-Cyc2,—(C1-4 alkylene)-O-Cyc3, —O-Cyc⁶⁻¹, —O—CH₂-Cyc⁶⁻¹, —O—(C2-4alkylene)-Cyc⁶⁻² or —O—(C1-4 alkylene)_(q)-Cyc⁶⁻³, that is, the compoundof formula (Ib-1)

wherein Q¹ is —(C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene)-Cyc2,—(C1-4 alkylene)-O-Cyc3, —O-Cyc⁶⁻¹, —O—CH₂-Cyc⁶⁻¹, —O—(C2-4alkylene)-Cyc⁶⁻² or —O—(C1-4 alkylene)_(q)-Cyc⁶⁻³, and the other symbolshave the same meanings as described above;may be also prepared by reacting the compound of formula (Ib-2)

wherein G is a single bond, C1-4 alkylene, C2-4 alkenylene or C2-4alkynylene and the other symbols have the same meanings as describedabove;with (a) mesyl chloride, subsequently, by reacting the compound offormula (IV-1)Cyc2  (IV-1)wherein all symbols have the same meanings as described above;or (b) the compound of formula (IV-2)Cyc3-OH  (IV-2),the compound of formula (IV-3)Cyc⁶⁻¹-OH  (IV-3),the compound of formula (IV-4)Cyc⁶⁻¹-CH₂—OH  (IV-4),the compound of formula (IV-5)Cyc⁶⁻²-(C2-4 alkylene)-OH  (IV-5)or the compound of formula (IV-6)Cyc⁶⁻³-(C1-4 alkylene)-OH  (IV-6)wherein all symbols have the same meanings as described above.

The above reactions are known, for example, the reaction (a) is carriedout in an organic solvent (e.g. tetrahydrofuran, dimethylformamide), inthe presence of a tertiary amine (e.g. dimethylaminopyridine, pyridine,triethylamine), with mesyl chloride, and then a obtained compound wasadded to a mixture of the compound of formula (IV-1) and sodium hydride,in an organic solvent (e.g. tetrahydrofuran, dimethylformamide).

The reaction (b) is carried out in an organic solvent (e.g.tetrahydrofuran), using triphenyl phosphine and diethyl azodicarbonate,at 0-50° C.

Besides, in the compound of formula (Ib), the compound in which A is thegroup including alkylene may be also prepared by subjecting to reductionthe compound in which A is the group including alkenylene.

Reduction reaction is known, for example, it is carried out in organicsolvent (e.g. tetrahydrofuran, ethanol or a mixture thereof), using anickel salt (e.g. nickel dichloride or a hydrate thereof) or a cobaltsalt, and sodium borohydride, at 0-50° C. or in organic solvent (e.g.tetrahydrofuran, dimethoxyethane, diethyl ether, methanol, ethanol,benzene, toluene, dimethylformamide, water, ethyl acetate, acetic acidor a mixture of two or more thereof), in the presence of a catalyticagent (palladium-carbon, palladium black, palladium hydroxide, platinumdioxide or Raney-nickel), in the presence or absence of an inorganicacid such as hydrochloric acid, sulfuric acid, hypochlorous acid, boricacid, tetrafluoroboric acid) or an organic acids (e.g. acetic acid,p-toluenesulfonic acid, oxalic acid, trifluoroacetic acid, formic acid),under atmosphere of hydrogen gas, under atmospheric or reduced pressure,at 0-200° C.

(3) The compound of formula (Ib) may be also prepared by methods of(i)-(ix).

(i) In the compound of formula (Ib), wherein D is —CONR⁴⁰-D^(a)-, thatis, the compound of formula (Ib-3)

wherein D^(a) is, as —CONR⁴⁰-D^(a)-, (1) a 2-membered linking chain, (2)a 3- to 6-membered linking chain or (3) a 7- to 10-membered linkingchain, and the other symbols have the same meanings as described above;may be prepared by subjecting to amidation reaction the compound offormula (V-1)

wherein all symbols have the same meanings as described above;and the compound of formula (VI)R⁴⁰HN-D^(a)-R³  (VI)wherein all symbols have the same meanings as described above.

Amidation reaction is known, for example, it is carried out in anorganic solvent (e.g. tetrahydrofuran, methylene chloride, chloroform,benzene, toluene, acetone, acetonitrile, diethyl ether,dimethylformamide or a mixture thereof), in the presence or absence of atertiary amines (e.g. dimethylaminopyridine, pyridine, triethylamine),using a condensing agent (e.g. 1,3-dicyclohexylcarbodiimide (DCC),1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC),2-chloro-1-methylpyridium iodide), or in the presence or absence of acatalytic amount of dimethylformamide, using acyl halide (e.g. oxalylchloride, thionyl chloride, phosphorus oxychloride) at 0-50° C.(ii) In the compound of formula (Ib), wherein D is —NR⁴⁰CO-D^(a)-, thatis, the compound of formula (Ib-4):

wherein D^(a) represents, as —NR⁴⁰CO-D^(a)-, (1) a 2-membered linkingchain, (2) a 3- to 6-membered linking chain, or (3) a 7- to 10-memberedlinking chain; and other symbols have the same meanings as describedbelow;may be prepared by subjecting to amidation reaction the compound offormula (V-2):

wherein all symbols have the same meanings as described below;with the compound of formula (VII-1):HOOC-D^(a)-R³  (VII-1)wherein all symbols have the same meanings as described below.

The amidation reaction is publicly known and carried out by, forexample, the method as described above.(iii) In the compound of formula (Ib), wherein D is —CO-D^(b)-, that is,the compound of formula (Ib-5):

wherein D^(b) represents, as —CO-D^(b), (1) a 1- or 2-membered linkingchain, (2) a 3- to 6-membered linking chain, or (3) a 7- to 10-memberedlinking chain; and other symbols have the same meanings as describedbelow;may be prepared by reacting the compound of formula (V-3):

wherein all symbols have the same meanings as described below;with the compound of formula (VIII):XMg-D^(b)-R³  (VIII)wherein all symbols have the same meanings as described below;followed by oxidation reaction.

The reaction is publicly known and carried out in, for example, anorganic solvent (tetrahydrofuran, etc.) by using a Grignard reagent (X)(4-methyl-2-phenylpentylmagnesium bromide, etc.) at −78° C.

The oxidation reaction is publicly known and carried out in, forexample, an organic solvent (dimethyl sulfoxide, etc.) in the presenceof a tertiary amine (dimethylaminopyridine, pyridine, triethylamine,etc.) by using an oxidizing agent (a sulfur trioxide-pyridine complex,etc.) at 0 to 50° C.(iv) In the compound of formula (Ib), wherein D is —O-D^(b)-, that is,the compound of formula (Ib-6):

wherein D^(b) represents, as —O-D^(b), (1) a 1- or 2-membered linkingchain, (2) a 3- to 6-membered linking chain, or (3) a 7- to 10-memberedlinking chain; and other symbols have the same meanings as describedbelow;may be prepared by reacting the compound of formula (V-4):

wherein all symbols have the same meanings as described below;with the compound of formula (IX):HO-D^(b)-R³  (IX)wherein all symbols have the same meanings as described below.

The reaction is publicly known and carried out in, for example, anorganic solvent (tetrahydrofuran, methylene chloride, diethyl ether,acetone, etc.) in the presence of an azo compound (diethylazodicarboxylate, diisopropyl azodicarboxylate,1,1′-(azodicarbonyl)dipiperidine, 1,1′-azobis(N,N-dimethylformamide),etc.) and a phosphine compound (triphenylphosphine, tributylphosphine,trimethylmethylphosphine, etc.) at 0 to 60° C.(v) In the compound of formula (Ib), wherein D is —SO₂-D^(b), that is,the compound of formula (Ib-7):

wherein D^(b) represents, as —SO₂-D^(b)-, (1) a 1- or 2-membered linkingchain, (2) a 3- to 6-membered linking chain, or (3) a 7- to 10-memberedlinking chain; and other symbols have the same meanings as describedbelow;may be prepared by subjecting to oxidation reaction the compound offormula (Ib-8):

wherein all symbols have the same meanings as described below;with the compound of formula (VIII).

The oxidation reaction is publicly known and carried out in, forexample, an organic solvent (methylene chloride, etc.) in the presenceof disodium hydrogen phosphate by using a peracid (3-chloroperbenzoicacid, etc.) at −30 to 50° C.

The compound of formula (Ib-8) may be prepared by reacting the compoundof formula (V-5):

wherein all symbols have the same meanings as described below;with the compound of formula (X):HS-D^(b)-R³  (X)wherein all symbols have the same meanings as described below.

The reaction is publicly known and carried out in, for example, anorganic solvent (dimethylformamide, etc.) by using sodium hydride at 0to 50° C.(vi) In the compound of formula (Ib), wherein D is (1) a 2-carbon atommembered linking chain, (2) a 3- to 6-carbon atom membered linkingchain, or a 7- to 10-carbon atom membered linking chain, that is, thecompound of formula (Ib-9):

wherein D^(c) represents (1) a 2-carbon atom membered linking chain, (2)a 3- to 6-carbon atom membered linking chain, or a 7- to 10-carbon atommembered linking chain; and other symbols have the same meanings asdescribed below;may be prepared by reacting the compound of formula (V-6):

wherein Tf represents trifluoromethylsulfoxy; and other symbols have thesame meanings as described below;with the compound of formula (XI-1):

wherein D^(c-1) represents (1) a single bond, (2) a 1- to 4-carbon atommembered linking chain, or (3) a 5- to 8-carbon atom membered linkingchain; and other symbols have the same meanings as described below;or the compound of formula (XI-2):

wherein all symbols have the same meanings as described below;or subjecting the reaction product obtained by the reaction to reductionreaction.

The reaction between the compound of formula (V-6) and the compound offormula (XI-1) is publicly known and carried out in, for example, anorganic solvent (dimethylformamide, etc.) by usingdi(triphenylphosphine)palladium chloride, copper iodide,tetrabutylammonium iodide and a base (triethylamine, etc.) at 0 to 50°C.

The reaction between the compound of formula (V-6) and the compound offormula (XI-1) is publicly known and carried out in, for example, anorganic solvent (dimethylformamide, etc.) by usingtetrakis(triphenylphosphine)palladium and potassium phosphate at 20 to100° C.

The reduction reaction is carried out by the same method as describedabove.(vii) In the compound of formula (Ib), wherein D is —CH₂—NR⁴⁰CO-D^(d)-,that is, the compound of formula (Ib-10):

wherein Dd represents, as —CH₂NR⁴⁰CO-D^(d)-, (1) a 3- to 6-memberedlinking chain, or (2) a 7- to 10-membered linking chain; and othersymbols have the same meanings as described below;may be prepared by subjecting to amidation reaction the compound offormula (V-7):

wherein all symbols have the same meanings as described below;with the compound of formula (VII-2):HOOC-D^(d)-R³  (VII-2)wherein all symbols have the same meanings as described below.

The amidation reaction is carried out by the same method as describedabove.(viii) In the compound of formula (Ib), wherein D is:

wherein D^(e) represents, as

(1) a 5- or 6-membered linking chain, or (2) a 7- to 10-membered linkingchain;that is, the compound of formula (Ib-11):

wherein all symbols have the same meanings as described below;may be prepared by reacting the compound of formula (V-5):

wherein all symbols have the same meanings as described below;with piperazine and then subjecting to amidation reaction with thecompound of formula (VII-3):HOOC-D^(e)-R³  (VII-3)wherein all symbols have the same meanings as described below.

The reaction between the compound of formula (V-5) with piperazine ispublicly known and carried out in, for example, an organic solvent(dioxane, t-butanol, methylene chloride or a solvent mixture thereof) byusing tris(dibenzylideneacetone)dipallarium(0),2-dicylohexylphosphino-2′-(N,N-dimethylamino)biphenyl and cesiumcarbonate at 80 to 120° C.

The amidation reaction is carried out by the same method as describedabove.(ix) In the compound of formula (Ib), the compound of formula (Ib-12):

wherein

represents a bicyclic heterocycle represented by

and other symbols have the same meanings as described below;may be prepared by subjecting to cyclization reaction the compound offormula (Ib-3) wherein R⁴⁰ is a hydrogen atom, that is, the compound offormula (Ib-3-1):

wherein all symbols have the same meanings as described below.

The cyclization reaction is publicly known and carried out in, forexample, an organic solvent (methanol, etc.) by using potassiumcarbonate at 0 to 50° C. and then by using trimethylsilyldiazomethane at0 to 50° C.(4) In the compound of formula (I), wherein R¹ is COOR⁴⁻² (wherein R⁴⁻²represents —(C1 to 4 alkylene)-R¹¹ group), that is, the compound offormula (Ic):

wherein all symbols have the same meanings as described below;may be prepared by reacting the compound of formula (Ia) with thecompound of formula (XII):

X—(C1-4 alkylene)-R¹¹  (XII)

wherein all symbols have the same meanings as described below.

The reaction is publicly known and carried out in, for example, anorganic solvent (dimethylformamide, tetrahydrofuran, acetone,acetonitrile, etc.) by using potassium carbonate, sodium carbonate,sodium hydride, etc. at 0 to 50° C.(5) In the compound of formula (I), wherein R¹ is CONR⁷R⁸ or CONR⁵SO₂R⁶,that is, the compound of formula (Id-1):

wherein all symbols have the same meanings as described below;or the compound of formula (Id-2):

wherein all symbols have the same meanings as described below;may be prepared by subjecting the compound of formula (Ia) to amidationreaction with the compound of formula (XIII-1):NHR⁷R⁸  (XIII-1)wherein all symbols have the same meanings as described below;or the compound of formula (XIII-2):NHR⁵SO₂R⁶  (XIII-2)wherein all symbols have the same meanings as described below.

The amidation reaction is publicly known and carried out by theabove-described method or, alternatively, by reacting in, for example,an organic solvent (tetrahydrofuran, etc.) in the presence/absence of acatalytic amount of dimethylformamide by using an acid halide (ethylchloroformate, oxalyl chloride, thionyl chloride, phosphorusoxychloride, etc.) and aqueous ammonia at 0 to 50° C.(6) In the compound of formula (I), wherein R¹ is tetrazole, that is,the compound of formula (Ie):

wherein all symbols have the same meanings as described below;may be prepared by reacting the compound of formula (XIV):

with trimethyltin azide.

The reaction is publicly known and carried out in, for example, anorganic solvent (methanol, toluene, etc.) at 100 to 130° C.(7) In the compound of formula (I), wherein R¹ is 1,2,4-oxadiazol-5-one,1,2,4-oxadiazole-5-thione, 1,2,4-thiadiazol-5-one or1,2,3,5-oxathiadiazol-2-one, that is, the compound of formula (If):

wherein R^(1f) represents 1,2,4-oxadiazol-5-one,1,2,4-oxadiazole-5-thione, 1,2,4-thiadiazol-5-one or1,2,3,5-oxathiadiazol-2-one; and other symbols have the same meanings asdescribed below;may be prepared by reacting the compound of formula (XV):

with, (i) a compound (XVI-1):

or a compound (XVI-2):

or(ii) a compound (XVI-3):SOCl₂  (XVI-3)or(iii) after reacting with a compound (XV-2), further reacting with aboron trifluoride ether complex salt.

The reaction (i) is publicly known and carried out in, for example, anorganic solvent (acetonitrile, tetrahydrofuran, etc.) in the presence of1,8-diazabicyclo[5.4.0]undec-7-ene at 0 to 50° C.

The reaction (ii) is publicly known and carried out in, for example, anorganic solvent (acetonitrile, tetrahydrofuran, etc.) in thepresence/absence of a tertiary amine (dimethylaminopyridine, pyridine,triethylamine, etc.) at 0 to 50° C.

The reaction (iii) is publicly known and carried out by, for example,reacting with the compound (XV-2) in an organic solvent (acetonitrile,tetrahydrofuran, etc.) and then using a boron trifluoride ether complexsalt at 0 to 50° C.(8) In the compound of formula (I), wherein R¹ is CH₂—OH, that is, thecompound of formula (Ig):

wherein all symbols have the same meanings as described below;may be prepared by subjecting the compound of formula (Ia) to reductionreaction.

The reduction reaction is publicly known and carried out in, forexample, an organic solvent (tetrahydrofuran, diglyme, etc.) by using aborane complex at 0 to 50° C.(9) In the compound of formula (I), wherein R¹ is —CH₂—NR⁹SO₂R⁶,—CH₂—NR⁹COR¹⁰ or —CH₂—NR⁹CO—NR⁵SO₂R⁶, that is, the compound of formula(Ih-1):

wherein all symbols have the same meanings as described below;the compound of formula (Ih-2):

wherein all symbols have the same meanings as described below; orthe compound of formula (Ih-3):

wherein all symbols have the same meanings as described below;may be prepared by subjecting to amidation reaction the compound offormula (XVII):

wherein all symbols have the same meanings as described below;with the compound of formula (XVIII-1):R⁶SO₂Cl  (XVIII-1)wherein all symbols have the same meanings as described below; orthe compound of formula (XVIII-2):R¹⁰COCl  (XVIII-2)wherein all symbols have the same meanings as described below; orreacting the compound of formula (XVI) with the compound of formula(XVIII-3):R⁶SO₂N═C═O  (XVIII-3)wherein all symbols have the same meanings as described below.

The amidation reaction is publicly known and carried out by, forexample, the above-described method.

The reaction between the compound of formula (XVI) and the compound offormula (XVII-3) is publicly known and carried out in, for example, anorganic solvent (acetonitrile, toluene, benzene, methylene chloride,tetrahydrofuran, dimethylformamide, pyridine, etc.) at 0° C. to 50° C.(10) In the compound of formula (I), wherein R¹ is —CH₂—OCONR⁵SO₂R⁶,that is, the compound of formula (Ii):

wherein all symbols have the same meanings as described below;may be prepared by reacting the compound of formula (Ig):

wherein all symbols have the same meanings as described below;with the compound of formula (XVIII-3):R⁶SO₂N═C═O  (XVIII-3)wherein all symbols have the same meanings as described below.

The reaction is publicly known and carried out in the same manner as thereaction between the compound of formula (XVI) and the compound offormula (XVII-3) as described above.(11) In the compound of formula (I), wherein R¹ is —SO₂NR⁷COR¹⁰, thatis, the compound of formula (Ij):

wherein all symbols have the same meanings as described below;may be prepared by subjecting to amidation reaction a compound whereinR⁸ is a hydrogen atom in the compounds represented by formula (XIX):

wherein all symbols have the same meanings as described below;with the compound of formula (XX):R¹⁰COOH  (XX)wherein all symbols have the same meanings as described below.

The amidation reaction is publicly known and carried out by, forexample, the above-described method.

In the compound of formula (Ij), wherein -A-SO₂NR⁷COR¹⁰ is-A^(j-i)-CH₂—SO₂NR⁷COR¹⁰, that is, the compound of formula (IJ-1):

wherein A^(j-1) represents a group lacking one carbon atom in analkylene group A in (ii), (v) to (xii) and (xv), (iii) C2-5 alkenyleneor (iv) C2-5 alkynylene, wherein all symbols have the same meanings asdescribed below;may be prepared by subjecting to amidation reaction the compound offormula (XXI):

with the compound of formula (XXII):NHR⁷COR¹⁰  (XXII)wherein all symbols have the same meanings as described below.

The amidation reaction is publicly known and carried out by, forexample, the above-described method.

The compounds represented by formulae (II-1) and (II-2) may be preparedby a method in accordance with the following reaction scheme 1.

The compounds represented by formulae (V-1), (V-2), (V-3), (V-4), (V-5),(V-6) and (V-7) may be prepared by a method in accordance with thefollowing reaction schemes 2-1 and 2-2.

The compound of formula (Ib-2) may be prepared by a method in accordancewith the following reaction scheme 3-1 or 3-2.

In the compound of formula (Ib-2), wherein -A- is ethylene may beprepared by a method in accordance with the following reaction scheme 4too.

The compounds represented by formulae (XIX) and (XXI) may be prepared bya method in accordance with the following reaction scheme 5.

The compounds represented by formulae (XIV), (XV) and (XVII) may beprepared by a method in accordance with the following reaction scheme 6.

In the Reaction schemes 1 to 4,

Y¹ represents formyl or X (wherein X has the same meaning as definedabove);

Y² represents a group in the stage before the introduction of (O)_(n),i.e., blocked (C1 to 4) alkyl-OH, an ester group, etc.;

Y³ represents:

(i) COOT¹ (wherein T¹ represents a carboxyl-protective group (forexample, methyl, ethyl, t-butyl, benzyl, etc.));

(ii) NR⁴⁰T² (wherein T² represents an amino-protective group (forexample, t-butoxycarbonyl, etc.));

(iii) T³ (wherein T³ represents a protected aldehyde group (for example,dimethylacetal, etc.));

(iv) OT⁴ (wherein T⁴ represents a hydroxy-protective group (for example,methoxymethyl, tetrahydropyranyl, etc.)); or

(v) fluorine;

G′ represents a single bond, C1-3 alkylene, a C2-3 alkenylene or C2-3alkynylene;

s is 1 to 5; and t is 1 to 4.

The compounds of formula (V-A) are either publicly known or may beprepared by a publicly known method.

Among other starting compounds, the compounds represented by formulae(III-1), (III-2), (IV-1), (IV-2), (IV-3), (IV-4), (IV-5), (IV-6), (VI),(VII-1), (VII-2), (VII-3), (VIII), (IX), (X), (XI-1), (XI-2), (XII),(XIII-1), (XIII-2), (XVI-1), (XVI-2), (XVI-3), (XVIII-1), (XVIII-2),(XVIII-3), (XX) and (XXII) are either publicly known or may be preparedby a publicly known method.

The reagents are each either publicly known per se or may be prepared bya publicly known method.

In the case of the compound of the present invention having hydroxyl andamino, the target compound of the present invention can be easilyproduced by using a compound having respectively adequate protectivegroups preliminarily introduced thereinto, subjecting the compound tovarious reactions and then performing deprotection by appropriatelyselecting deprotection reactions suiting them, i.e., an alkalihydrolysis, a deprotection reaction under acidic conditions or adeprotection reaction by hydrogenolysis.

It can be easily understood by a person skilled in the art that examplesof the hydroxy-protective group include methoxymethyl,tetrahydropyranyl, t-butyldimethylsilyl, acetyl and benzyl. However,other protective groups may be used without particular restriction, solong as they can be easily and selectively removed.

Examples of the amino include benzyloxycarbonyl, t-butoxycarbonyl andtrifluoroacetyl. However, other protective groups may be used withoutparticular restriction, so long as they can be easily and selectivelyremoved. For example, those reported by T. W. Greene, Protective Groupsin Organic Synthesis, Wiley, New York (1991) can be used.

In each reaction described herein, a reaction product can be purified bya purification procedure commonly employed, for example, distillationunder atmospheric or reduced pressure, high-performance liquidchromatography by using silica gel or magnesium silicate, thin layerchromatography, column chromatography, washing, recrystallization andthe like. Purification may be carried out either after the completion ofeach reaction or after the completion of several successive reactions.

Pharmacological Activity of the Compound of the Present Invention:

The compound of the present invention of formula (I) strongly binds toPGE₂ receptors, in particular, EP₃ and/or EP₄ receptors which aresubtypes thereof and antagonize the same.

The pharmacological activity is confirmed by the followingreceptor-binding experiment by using cells expressing prostanoidreceptor subtypes.

(i) Receptor-Binding Experiment by Using Cells Expressing ProstanoidReceptor Subtypes

In accordance with the method of Sugimoto et al. [J. Biol. Chem., 267,6463-6466 (1992)], CHO cells respectively expressing prostanoid receptorsubtypes (mouse EP₁, EP₂, EP_(3α) and EP₄) were prepared to givemembrane preparations.

Each membrane fraction (50 μl) thus prepared and a reaction solution(150 μl) containing ³H-PGE₂ were incubated at room temperature for 1hour. After ceasing the reaction with an ice-cooled buffer (3 ml), thebound ³H-PGE₂ was trapped in a glass filter (GF/B) by filtering withsuction under reduced pressure. Then the bound radioactivity wasmeasured with a liquid scintillator.

Kd value and Bmax value were determined by Scatchard plots [Ann. N.Y.Acad. Sci., 51, 660 (1949)]. Nonspecific bond was determined as bond inthe presence of unlabeled PGE₂ in excess (2.5 μM). The ³H-PGE₂-bindinginhibitory effects of the invention compounds were measured by adding³H-PGE₂ (2.5 nM) and the invention compounds at various concentrations.In every reaction, the following buffer was employed.

Buffer: potassium phosphate (10 mM, pH 6.0), EDTA (1 mM), MgCl₂ (10 mM),NaCl (0.1 M).

The dissociation constant Ki (μM) of each compound was determined inaccordance with the following formula. Table 1 shows the results.Ki=IC ₅₀/(1+([C]/Kd)) TABLE 1 Ki (μM) Ex. compound EP₁ receptor EP₂receptor EP₃ receptor EP₄ receptor 8(13) >10 >10 0.27 0.038(ii) EP₃ Antagonistic Activity Measurement Experiment by Using CellsExpressing Prostanoid Receptor Subtype

In accordance with the method of Sugimoto et al. [J. Biol. Chem., 267,6463-6466 (1992)], CHO cells expressing a mouse EP₃ receptor subtype.These cells were sowed in a 96-well microplate at a density of 10⁴cells/well and incubated for 2 days before using in the experiment.After washing each well with PBS (100 μl), the cells were allowed tointake Fura-2AM for 60 minutes. After washing with an HEPES solution, atest compound and PGE₂ (10 nM) were added at 37° C. and a change in theintracellular calcium concentration was measured. Namely, after excitingat 340/380 nm in wavelength, the fluorescences at 510 nm were measuredand thus the fluorescence intensity ratio was determined.

The antagonistic action of the test compound was calculated as theinhibitory ratio to the reaction using PGE₂ (10 nM) alone and IC₅₀ wasdetermined.

(iii) EP₄ Antagonistic Activity Measurement Experiment by Using CellsExpressing Prostanoid Receptor Subtype

In accordance with the method of Nishigaki et al. [FEBS Lett., 364,339-341 (1995)], CHO cells respectively expressing mouse EP₄ receptorsubtypes were prepared. After sowing on a 24-well microplate at adensity of 10⁵ cells/well, the cells were incubated for 2 days beforeuse in the experiment. After washing each cell with MEM (minimumessential medium) (500 μl), an assay medium (MEM containing 1 mmol/LIBMX, 1% BSA) (450 μl) was added and the cells were incubated at 37° C.for 10 minutes. Next, PGE₂ was added alone or together with a solution(50 μl) containing a test compound and the reaction was initiated. Afterreacting at 37° C. for 10 min, ice-cooled TCA (10% w/v) (500 μl) wasadded to thereby cease the reaction. The liquid reaction mixture wasonce frozen (−80° C.) and thawed. Next, the cells were peeled with ascraper and centrifuged at 13,000 rpm for 3 minutes. Using thesupernatant thus obtained, the cAMP concentration was measured with acAMP assay kit. Namely, a buffer of a [¹²⁵I]cAMP assay kit (manufacturedby Amersham) was added to 125 μl of the supernatant to give a totalvolume of 500 μl. Then this mixture was mixed with a 0.5 mol/L of asolution (1 ml) of tri-n-octylamine in chloroform. After removing TCA inthe chloroform layer, the aqueous layer was employed as a sample and thecAMP in the sample was quantified in accordance with the methoddescribed in the [¹²⁵I]cAMP assay kit.

The antagonistic effect (IC₅₀) of the test compound was calculated asthe inhibitory ratio to the reaction at 100 nM, i.e., the concentrationat which PGE₂ alone shows a submaximal cAMP producing effect, and IC₅₀was determined.

As the results of the above experiments, it was clarified that theinvention compounds have a potent EP₃ and/or EP₄ receptor antagonisticactivity.

Toxicity:

It has been confirmed that the compounds of the present invention offormula (I) have sufficiently low toxicity and thus are safe enough inusing as drugs.

INDUSTRIAL APPLICABILITY

Application to Drugs:

The compounds of the present invention of formula (I) bind to a PGE₂receptor and show an antagonism, which makes them useful. In particular,these compounds bind to the subtypes EP₃ and/or EP₄ and antagonize thereceptors. Therefore, they are expected as useful in preventing and/ortreating diseases such as pain (cancerous pain, pain accompanying bonefracture, postoperative pain, post-extraction toothache, etc.),allodynia, hyperalgesia, itch, urticaria, atopic dermatitis, contactdermatitis, poison ivy dermatitis, allergic conjunctivitis, varioussymptoms in dialysis, asthma, rhinitis, allergic rhinitis, nasalobstruction, sneeze, psoriasis, urinary frequency (neurogenic bladder,nervous bladder, irritative bladder, unstable bladder, urinary frequencyaccompanying prostate-gland enlargement, etc.), urinary disturbance,dysspermia, fever, systemic inflammatory response syndrome, learningdisability, Alzheimer's disease, angiogenesis, cancer (canceration,cancer proliferation, cancer metastasis into organ, cancer metastasisinto bone, hypercalcemia accompanying cancer metastasis into bone,etc.), retinosis, red spot, erythema, leukoma, skin spot, burn,ambustion, steroid burn, renal insufficiency, nephropathy, acutenephritis, chronic nephritis, blood electrolyte imbalance, threatenedpremature delivery, threatened abortion, epimenorrhagia, dysmenorrhea,endometriosis, premenstrual syndrome, adenomyosis uteri, reproductivedisturbance, stress, anxiety, depression, psychosomatic disorder, mentaldiseases, thrombosis, embolism, transient ischemic attack, braininfraction, atheroma, organ transplantation, myocardial infarction,heart failure, hypertension, arteriosclerosis, circulatory disturbanceand ulcer accompanying the same, nerve disorder, vascular dementia,edema, diarrhea, constipation, biliary discharge disorder, ulcerativecolitis, Crohn's disease, irritable colitis, relieving rebound phenomenaafter using steroids, accelerating reduction and elimination ofsteroids, bone diseases (osteoporosis, rheumatoid arthritis, arthritisdeformans, osteodysplasty, etc.), systemic granuloma, immune diseases(amyotrophic lateral sclerosis (ALS), multiple sclerosis, Sjoegren'ssyndrome, systemic lupus erythematosus, AIDS, etc.), pyorrheaalveolaris, gingivitis, periodontal disease, nerve cell death, lunginjury, liver injury, acute hepatitis, myocardial ischemia, Kawasaki'sdisease, multiple organ failure, chronic headache (hemicrania, tensionheadache, mixed headache thereof or cluster headache), angiitis, venousinsufficiency, varicose vein, anal fistula, diabetes insipidus, newbornpatent ductus arteriosus, cholelithiasis, sleep disturbance and plateletaggregation.

The compounds of the present invention of formula (I) or nontoxic saltsthereof may be combined with other drugs and administered as combinationdrugs for:

(1) complementing and/or enhancing the preventive and/or therapeuticeffects of the compounds;

(2) improving the dynamics and absorption of the compounds and reducingthe administration dose thereof; and/or

(3) relieving the side effects of the compounds.

A combination drug of the compound of formula (I) with other drug may beadministered in the form of a blend containing both of the components ina single preparation. Alternatively, the components may be processedinto separate preparations and administered. The separate preparationsmay be administered either at the same time or at a definite timeinterval. In the case of administering at a definite time interval, thecompound of formula (I) may be administered first followed by theadministration of the other drug. Alternatively, the other drug may beadministered first followed by the administration of the compound offormula (I). The administration methods may be either the same ordifferent.

Diseases on which the preventive and/or therapeutic effects are exertedby the combination drug are not particularly restricted. That is, theymay be any diseases so long as the preventive and/or therapeutic effectsof the compounds of formula (I) thereon can be complemented and/orenhanced.

Examples of other drugs for complementing and/or enhancing thepreventive and/or therapeutic effect of the compounds of formula (I) onpain include nonsteroid antiinflammatory agents, N-type calcium channelinhibitors, nitrogen monoxide synthase inhibitors, cannabinoid-2receptor stimulating agents and the like.

Examples of other drugs for complementing and/or enhancing thepreventive and/or therapeutic effect of the compounds of formula (I) onitch, urticaria, atopic dermatitis, contact dermatitis, allergicconjunctivitis and various symptoms in dialysis include steroids,nonsteroid antiinflammatory agents, immune suppressants, antiallergicagents, mediator release inhibitors, leukotriene receptor antagonists,antihistamines, forskolin preparations, phosphodiesterase inhibitors,nitrogen monoxide synthase inhibitors, cannabinoide-2 receptorstimulating agents and the like.

Examples of other drugs for complementing and/or enhancing thepreventive and/or therapeutic effect of the compounds of formula (I) oncancer (canceration, cancer proliferation, cancer metastasis into organ,cancer metastasis into bone, hypercalcemia accompanying cancermetastasis into bone, etc.) include anticancer agents, analgesics,bisphosphonate preparations, calcitonin preparations, metalloproteinaseinhibitors and the like.

Examples of other drugs for complementing and/or enhancing thepreventive and/or therapeutic effect of the compounds of formula (I) onchronic headache include nonsteroid antiinflammatory agents, ergotaminepreparations, calcium antagonists, serotonin agonists, EDG-5 agonistsand the like.

Examples of the nonsteroid antiinflammatory agents include salsalate,sodium salicylate, aspirin, aspirin dialuminate blend, diflunisal,indomethacin, sprofen, ufenamate, dimethylisopropylazulene, bufexamac,felbinac, diclofenac, tolmetin sodium, clinoril, fenbufen, nabumetone,proglumetacin, indometacin farncecil, acemetacin, proglumetacin maleate,amfenac sodium, mofezolac, etodolac, ibuprofen, ibuprofen piconol,naproxen, flurbiprofen, flurbiprofen axetil, ketoprofen, fenoprofencalcium, tiaprofen, oxaprozin, pyranoprofen, loxoprofen sodium,alminoprofen, zaltoprofen, mefenamic acid, aluminum mefenamate,tolfenamic acid, floctafenine, ketophenylbutazone, oxyfenbutazone,piroxicam, tenoxicam, ampiroxicam, napageln ointment, epirizol,tiaramide hydrochloride, tinoridine hydrochloride, emorfazone, sulpirin,migrenin, saridon, sedes G, amipylo N, sorbon, pyrazolone-based remediesfor cold, acetoaminophen, fenacetine, dimethothiazine mesylate,meloxicam, celecoxib, rofecoxib, valdecoxib, simetride-containingagents, pyrazolone-free remedies for cold and the like.

Examples of the steroids include, e.g., as drugs for external use,clobetasol propionate, diflorasone acetate, fluocinonide, mometazonefurancarboxylate, betametazone dipropionate, betametazone butyratepropionate, betametazone valerate, difluprednate, budesonide,diflucortolone valerate, amicinonide, halcinonide, dexamethasone,dexamethasone propionate, dexamethasone valerate, dexamethasone acetate,hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone butyratepropionate, deprodone propionate, prednisolone valerate acetate,fluocinolone acetonide, beclometasone propionate, triamcinoloneacetonide, flumetasone pivalate, alclometasone propionate, clobetasonebutyrate, prednisolone, beclomethasone propionate, fludroxycortide andthe like.

Examples of drugs for internal use and injections include cortisoneacetate, hydrocortisone, hydrocortisone sodium phosphate, hydrocortisonesodium succinate, fludrocortisone acetate, prednisolone, prednisoloneacetate, prednisolone sodium succinate, prednisolone butyl acetate,prednisolone sodium phosphate, halopredone acetate, methylprednisolone,methylprednisolone acetate, methylprednisolone sodium succinate,triamcinolone, triamcinolone acetate, triamcinolone acetonide,dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate,dexamethasone palmitate, paramethasone acetate, betamethasone and thelike.

Examples of inhalations include beclometasone propionate, fluticasonepropionate, budesonide, flunisolide, triamcinolone, ST-126P,ciclesonide, dexamethasone palomithionate, monometasonefurancarboxylate, prasterone sulfonate, deflazacort, methylprednisolonsleptanate, methylprednisolon sodium succinate and the like.

Examples of the immune suppressants include protopic (FK-506),methotrexate, cyclosporin, ascomycin, leflunomide, bucillamine,salazosulfapyridine and the like.

Examples of the mediator release inhibitors include tranilast, sodiumcromoglycate, amlexanox, repirinast, ibudilast, tazanolast, pemirolastpotassium and the like.

Examples of the leukotriene receptor antagonists include pranlukasthydrate, montelukast, zafirlukast, MCC-847, KCA-757, CS-615, YM-158,L-740515, CP-195494, LM-1484, RS-635, A-93178, S-36496, BIIL-284,ONO-4057 and the like.

Examples of the antihistamines include ketotifen fumarate, mequitazine,azelastine hydrochloride, oxatomide, terfenadine, emedastine fumarate,epinastine hydrochloride, astemizole, ebastine, cetirizinehydrochloride, bepotastine, fexofenadine, loratadine, desloratadine,olopatadine hydrochloride, TAK-427, ZCR-2060, NIP-530, mometasonefuroate, mizolastine, BP-294, andolast, auranofin, acrivastine, etc.

Examples of the anticancer agents include alkylating agents (nitrogenmustard-N-oxide hydrochloride, cyclophosphamide, ifosfamide, melphalan,thiotepa, carboquaone, buslufan, etc.), nitrosourea derivatives(nimustine hydrochloride, ranimustine, etc.), metabolic antagonists(methotrexate, mercaptopurine, 6-mercaptopurine riboside, fluorouracil,tegafur, UFT, carmofur, doxyfluridine, cytarabine, enocitabine, etc.),anticancer antibiotics (actinomycin D, mitomycin C, daunorubicinhydrochloride, doxorubicin hydrochloride, aclarubicin hydrochloride,neocarzinostatin, pirarubicin, epirubicin, idarubicin, chromomycin A3,bleomycin, heplomycin sulfate, etc.), plant alkaloids (vinblastinesulfate, vincristine sulfate, vindensine sulfate, etc.), hormone drugs(estramustine phosphate sodium, mepitiostane, epitiostanol, tamoxifencitrate, diesthylstilbestrol phosphate, medroxyprogesterone acetate,anastrozole, fadrozole, leuprolide, etc.), immunopotentiators (lentinan,picibanil, krestin, sizofuran, ubenimex, interferon, etc.) and others(L-asparaginase, procarbazine hydrochloride, mitoxantrone hydrochloride,cisplatin, carboplatin, etc.).

Examples of the phosphodiesterase inhibitors include PDE4 inhibitorssuch as roliplam, cilomilast (trade name: Ariflo), Bay 19-8004, NIK-616,roflumilast (BY-217), cipamfylline (BRL-61063), atizoram (CP-80633),SCH-351591, YM-976, V-11294A, PD-168787, D-4396, IC-485 and the like.

Examples of the ergotamine preparations include dihydroergotaminemesylate, ergotamine tartarate and the like.

Examples of the calcium antagonists include nifedipine, benidipinehydrochloride, diltiazem hydrochloride, verapamil hydrochloride,nisoldipine, nitrendipine, bepridil hydrochloride, amlodipine besylate,lomerizine hydrochloride and the like.

Examples of the serotonin agonists include sumatriptan, zolmitriptan,naratriptan, rizatriptan, eletriptan, almotriptan, frovatriptan and thelike.

The ratio by mass of the compounds of formula (I) to other drugs is notparticularly limited.

Two or more of other drugs optionally selected can be used incombination.

Other drugs to be used for complementing and/or enhancing the preventiveand/or therapeutic effects of the compounds of formula (I) involve notonly those which have been found out hitherto based on theabove-described mechanism but also those which will found out in future.

To employ the compounds of formula (I) or combination drugs of thecompounds of formula (I) with other drugs for the above-describedpurposes, they are usually administered systemically or topically, andorally or parenterally.

Although the administration dose varies depending on the age, bodyweight and conditions of a patient, therapeutic effect, administrationroute, treatment time, etc., the single administration dose to an adultusually ranges from 1 ng to 100 mg and the administration is made onceto several times per day in the case of oral administration.Alternatively, the single administration dose ranges from 0.1 ng to 10mg and the administration is made once to several times per day in thecase of parenteral administration. Alternatively, intravenousadministration is continuously made for 1 hour to 24 hours per day.

Needless to say, the administration dose varies depending on variousfactors as discussed above. Thus, an administration dose smaller thanthe lower limit as defined above is enough in some cases, while anadministration dose exceeding the upper limit is needed in other cases.

To administrate the compounds of formula (I) or combination drugs of thecompounds of formula (I) with other drugs, use is made of solidpreparations for internal use and liquid preparations for internal usefor oral administration as well as injections, preparations for externaluse, suppositories, eye drops, inhalations and the like for parenteraladministration.

Examples of the solid preparations for internal use include tablets,pills, capsules, dusts, granules and the like. The capsules include hardcapsules and soft capsules.

Such a solid preparation for internal use is prepared by a formulationmethod commonly employed by using one or more active substances eitheras such or as a mixture with an excipient (lactose, mannitol, glucose,microcrystalline cellulose, starch, etc.), a binder(hydroxypropylcellulose, polyvinylpyrrolidone, magnesium metasilicatealuminate, etc.) a disintegrating agent (calcium cellulose glycolate,etc.), a lubricant (magnesium stearate, etc.), a stabilizer, and adissolution aid (glutamic acid, aspartic acid, etc.). If necessary, itmay be coated with a coating agent (sucrose, gelatin,hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, etc.).It may be coated with two or more layers. Moreover, capsules made of anabsorbable material such as gelatin are involved in the scope thereof.

The liquid preparations for internal use involve pharmaceuticallyacceptable solutions, suspensions, emulsions, syrups, elixirs and thelike. Such a liquid preparation is prepared by dissolving, suspending oremulsifying one or more active substances in a diluent commonly employed(purified water, ethanol, a mixture thereof, etc.). The liquidpreparation may further contain a moistening agent, a suspending agent,an emulsifier, a sweetener, a flavor, a perfume, a preservative, abuffer and the like.

The dosage forms of the parenteral administration preparations forexternal use involve ointments, gels, creams, fomentations, patches,liniments, atomized agents, inhalations, sprays, aerosols, nasal dropsand the like. Such a preparation contains one or more active substancesand is prepared by a publicly known method or in accordance with aformulation commonly employed.

Ointments are prepared in accordance with a publicly known formulationor a formulation commonly employed. For example, they are prepared bylevigating or melting one or more active substances in a base. Theointment base is selected from among publicly known ones or thosecommonly employed. For example, use may be made of one base or a mixtureof two or more thereof selected from higher fatty acids or higher fattyacid esters (adipic acid, myristic acid, palmitic acid, stearic acid,oleic acid, adipic acid esters, myristic acid esters, palmitic acidesters, stearic acid esters, oleic acid esters, etc.), waxes (beeswax,whale wax, ceresin, etc.), surfactants (polyoxyethylene alkyl etherphosphoric acid esters, etc.), higher alcohols (cetanol, stearylalcohol, cetostaryl alcohol, etc.), silicone oils (dimethylpolysiloxane,etc.), hydrocarbons (hydrophilic vaseline, white vaseline, refinedlanolin, liquid paraffin, etc.), glycols (ethylene glycol, diethyleneglycol, propylene glycol, polyethylene glycol, macrogol, etc.),vegetable oils (castor oil, olive oil, sesame oil, turpentine oil,etc.), animal oils (mink oil, yolk oil, squalane, squalene, etc.),water, absorption promoters and skin irritation inhibitors. Theointments may further contain a humectant, a preservative, a stabilizer,an antioxidant, a flavor, etc.

Gels are prepared in accordance with a publicly known formulation or aformulation commonly employed. For example, they are prepared by meltingone or more active substances in a base. The gel base is selected fromamong publicly known ones or those commonly employed. For example, usemay be made of one base or a mixture of two or more thereof selectedfrom among lower alcohols (ethanol, isopropyl alcohol, etc.), gellingagents (carboxymethylcellulose, hydroxyethylcellulose,hydroxypropylcellulose, ethylcellulose, etc.), neutralizing agents(triethanolamine, diisopropanolamine, etc.), surfactants (polyethyleneglycol monostearate, etc.), gums, water, absorption promoters and skinirritation inhibitors. The gels may further contain a preservative, anantioxidant, a flavor, etc.

Creams are prepared in accordance with a publicly known formulation or aformulation commonly employed. For example, they are prepared by meltingor emulsifying one or more active substances in a base. The cream baseis selected from among publicly known ones or those commonly employed.For example, use may be made of one base or a mixture of two or morethereof selected from among higher fatty acid esters, lower alcohols,hydrocarbons, polyhydric alcohols (propylene glycol, 1,3-butyleneglycol, etc.), higher alcohols (2-hexyldecanol, cetanol, etc.),emulsifiers (polyoxyethylene alkyl ethers, fatty acid esters, etc.),water, absorption promoters and skin irritation inhibitors. The creamsmay further contain a preservative, an antioxidant, a flavor, etc.

Fomentations are prepared in accordance with a publicly knownformulation or a formulation commonly employed. For example, they areprepared by melting one or more active substances in a base, kneadingand then applying and spreading the kneaded matter on a substrate. Thefomentation base is selected from among publicly known ones or thosecommonly employed. For example, use may be made of one base or a mixtureof two or more thereof selected from among thickeners (polyacrylic acid,polyvinylpyrrolidone, acacia, starch, gelatin, methylcellulose, etc.),moistening agents (urea, glycerol, propylene glycol, etc.), fillers(kaolin, zinc oxide, talc, calcium, magnesium, etc.), water, dissolutionaids, tackifiers and skin irritation inhibitors. The fomentations mayfurther contain a preservative, an antioxidant, a flavor, etc.

Patches are prepared in accordance with a publicly known formulation ora formulation commonly employed. For example, they are prepared bymelting one or more active substances in a base and then applying andspreading on a substrate. The patch base is selected from among publiclyknown ones or those commonly employed. For example, use may be made ofone base or a mixture of two or more thereof selected from among polymerbases, fats and oils, higher fatty acids, tackifiers and skin irritationinhibitors. The patches may further contain a preservative, anantioxidant, a flavor, etc.

Liniments are prepared in accordance with a publicly known formulationor a formulation commonly employed. For example, they are prepared bydissolving, suspending or emulsifying one or more active substances inone or more media selected from among water, alcohols (ethanol,polyethylene glycol, etc.), higher fatty acids, glycerol, soap,emulsifiers, suspending agents and the like. The liniments may furthercontain a preservative, an antioxidant, a flavor, etc.

Atomized agents, inhalations and sprays may contain, in addition to adiluent commonly employed, a stabilizer such as sodium hydrogen sulfite,a buffer for imparting isotonicity, for example, an isotonic agent suchas sodium chloride, sodium citrate or citric acid. Methods for producinga spray are described in detail in, for example, U.S. Pat. No. 2,868,691and U.S. Pat. No. 3,095,355.

The injections for parenteral administration involve solutions,suspensions, emulsions and solid injections to be dissolved or suspendedbefore use. Such an injection is used by dissolving, suspending oremulsifying one or more active substances in a solvent. As the solvent,use is made of, for example, distilled water for injection,physiological saline, vegetable oils, alcohols such as propylene glycol,polyethylene glycol or ethanol and mixtures thereof. The injection mayfurther contain a dissolution aid (glutamic acid, aspartic acid,polysorbate 80 (registered trade name), etc.), a suspending agent, anemulsifier, a soothing agent, a buffer, a preservative, etc. Such aninjection is produced by sterilizing at the final step or employingaseptic conditions. Alternatively, it is also possible that an asepticsolid product such as a freeze-dried product is produced and sterilizedor dissolved in aseptic distilled water for injection or another solventbefore use.

The inhalations for parenteral administration involve aerosols, powdersto be inhaled and liquids to be inhaled. Such inhalations may be in theform to be dissolved or suspended in water or another adequate mediumbefore use.

The inhalations may be produced in accordance with a publicly knownmethod.

For example, liquid preparations for inhalation are prepared byappropriately selecting a preservative (benzalkonium chloride, paraben,etc.), a colorant, a buffer (sodium phosphate, sodium acetate, etc.), anisotonic agent (sodium chloride, concentrated glycerol, etc.), athickener (carboxyvinyl polymer, etc.), an absorption promoter and thelike.

Powdery preparations for inhalation are prepared by appropriatelyselecting a lubricant (stearic acid, its salt, etc.), a binder (starch,dextrin, etc.), an excipient (lactose, cellulose, etc.), a coloringagent, a preservative (benzalkonium chloride, paraben, etc.), anabsorption promoter, etc.

To administrate liquid preparation for inhalation, a spraying device(atomizer, nebulizer, etc.) are usually employed. To administer powderypreparations for inhalation, a device of administering a powdery drugfor inhalation is usually employed.

Examples of other compositions for parenteral administration includesuppositories for rectal administration and pessaries for vaginaladministration which contain one or more active substances and areprepared in accordance with common formulations.

BEST MODE FOR CARRYING OUT THE INVENTION

Now, the present invention is described in greater detail by referenceto the following Referential Examples and Examples, although the presentinvention is not construed as being restricted thereto.

Solvents given in parentheses concerning chromatographic separation andTLC indicate each the elution solvent or the developing solvent employedand the ratio is expressed in ratio by volume.

Solvents given in parentheses concerning NMR indicate each the solventemployed in measurement.

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention is explained below in detail based on ReferenceExamples and Examples, however, the present invention is not limitedthereto.

The solvents in the parentheses show the developing or eluting solventsand the ratios of the solvents used are by volume in chromatographicseparations or TLC. The solvents in the parentheses in NMR show thesolvents for measurement.

REFERENCE EXAMPLE 1 4-amino-3-hydroxybenzoic acid methyl esterhydrochloride

To an anhydrous methanol (100 ml) was added thionyl chloride (14.0 ml)at −10° C. during 20 minutes. After stirring the mixture for 15 minutes,3-hydroxy-4-aminobenzoic acid (10.0 g) was added at the sametemperature. The appeared suspension was stirred at room temperatureovernight. The mixture was concentrated and then azeotroped withmethanol (50 ml, twice). To the residue was added diethyl ether, and theresidue was collected by suction filtration in washing with diethylether to give the title compound (12.8 g) having the following physicaldata.

TLC: Rf 0.49 (n-hexane:ethyl acetate=1:1).

REFERENCE EXAMPLE 2 3-hydroxy-4-iodobenzoic acid methyl ester

To a solution of the compound prepared in Reference Example 1 (4.90 g)in concentrated hydrochloric acid (20 ml) was added a solution of sodiumnitrite (1.83 g) in water (15 ml) during 15 minutes. The mixture wasstirred for 20 minutes. To the mixture was added a solution of potassiumiodide (8.00 g) in water (30 ml) during 10 minutes. The mixture wasstirred at room temperature for 20 minutes and then stirred at 60° C.for 1 hour. The reaction mixture was extracted with ethyl acetate, andthen the organic layer was washed with a saturated aqueous solution ofsodium thiosulfate, water and a saturated aqueous solution of sodiumchloride subsequently, dried over anhydrous magnesium sulfate and thenconcentrated. The residue was purified by column chromatography(n-hexane:ethyl acetate=4:1˜2:1) to give the title compound (4.57 g)having the following physical data.

TLC: Rf 0.33 (hexane:ethyl acetate=4:1).

REFERENCE EXAMPLE 3 4-iodo-3-[2-(naphthalen-2-yl)ethyloxy]benzoic acidmethyl ester

A solution of the compound prepared in Reference Example 2 (3.00 g),2-(2-naphthyl)ethanol (2.23 g), triphenylphosphine (4.25 g) and1,1′-(azodicarbonyl)dipiperidine (4.09 g) in anhydrous tetrahydrofuran(50 ml) was stirred at room temperature for 12 hours under an atmosphereof argon. The mixture was diluted with diethyl ether and filtered. Thefiltrate was concentrated. The residue was purified by columnchromatography (n-hexane:ethyl acetate=20:1˜10:1˜5:1) to give the titlecompound (4.64 g) having the following physical data.

TLC: Rf 0.54 (n-hexane:ethyl acetate=4:1).

REFERENCE EXAMPLE 44-hydroxymethyl-2-[2-(naphthalen-2-yl)ethyloxy]phenyl iodide

To a solution of the compound prepared in Reference Example 2 (4.61 g)in anhydrous methylene chloride (40 ml) was added Diisobutyl aluminumhydride (0.95M hexane solution, 28 ml) during 10 minutes at −78° C.under an atmosphere of argon. The temperature of the mixture was arisedto −40° C. during 1 hour. To the reaction mixture were added methanoland a saturated aqueous solution of sodium sulfate. The appeared solidwas filitered off and then the filtrate was concentrated.

The residue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=4:1˜3:1) to give the title compound (4.21 g)having the following physical data.

TLC: Rf 0.55 (n-hexane:ethyl acetate=1:1).

EXAMPLE 1 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethyloxy]cinnamic acidethyl ester

The mixture of the compound prepared in Reference Example 4 (2.54 g),ethyl acrylate (1.36 ml), triethylamine (4.38 ml),1,1′-bis(diphenylphosphino)ferrocene (348 mg) and palladium(II) acetate(141 mg) in anhydrous dimethylsulfoxide (25 ml) was stirred at 100° C.for 30 minutes under an atmosphere of argon. To the reaction mixturewere added water and ethyl acetate and the mixture was filtered. Thefiltrate was extracted with ethyl acetate and the organic layer waswashed with water and a saturated aqueous solution of sodium chloride,subsequently, dried over anhydrous sodium sulfate and then concentrated.The residue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1˜1:1) to give the title compound (2.07 g)having the following physical data.

TLC: Rf 0.47 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃):δ 7.99(d, J=16 Hz, 1H), 7.86-7.76(m, 4H),7.50-7.40(m, 4H), 6.94(s, 1H), 6.90(d, J=2.1 Hz, 1H), 6.52(d, J=16 Hz,1H), 4.67(d, J=5.4 Hz, 2H), 4.34(t, J=6.6 Hz, 2H), 4.27(q, J=7.2 Hz,2H), 3.33(t, J=6.6 Hz, 2H), 1.34(t, J=7.2 Hz, 3H).

EXAMPLE 2 2-[2-(naphthalen-2-yl)ethyloxy]-4-(1-pyrazolylmethyl)cinnamicacid ethyl ester

To a solution of the compound prepared in Example 1 (1.74 g) andtriethylamine (1.29 ml) in anhydrous tetrahydrofuran (20 ml) was addedmesyl chloride (537 μl) under an atmosphere of argon and the mixture wasstirred for 15 minutes. The reaction mixture was extracted with ethylacetate, and the organic layer was washed with water and a saturatedaqueous solution of sodium chloride subsequently, dried over anhydroussodium sulfate and concentrated. To a solution of pyrazole (346 mg) inanhydrous N,N-dimethylformamide (8 ml) was added sodium hydride (63.1%in oil) (193 mg) at 0° C. under an atmosphere of argon and the mixturewas stirred for 10 minutes. To the mixture was added the solution of theabove-mentioned crude product in anhydrous N,N-dimethylformamide (8 ml)and the mixture was stirred at room temperature for 1 hour. To thereaction mixture was added water at 0° C. and the mixture was extractedwith diethyl ether. The organic layer was washed with water and asaturated aqueous solution of sodium chloride subsequently, dried overanhydrous sodium sulfate and concentrated to give the title compound(crude, 1.17 g). The compound was used to the next step without furtherpurification.

TLC: Rf 0.36 (n-hexane:ethyl acetate=2:1).

EXAMPLE 2(1)˜2(12)

Using corresponding compounds, the following compounds were obtained bythe same procedure of Example 2.

EXAMPLE 2(1)(2E)-3-(2-(2-(chroman-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenicacid ethyl ester

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 2(2)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenicacid ethyl ester

TLC: Rf 0.67 (chloroform:methanol=9:1).

EXAMPLE 2(3)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid ethyl ester

TLC: Rf 0.45 (n-hexane:ethyl acetate=2:1).

EXAMPLE 2(4)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(thiophen-2-ylmethyl)phenyl)-2-propenicacid ethyl ester

TLC: Rf 0.31 (n-hexane:ethyl acetate=3:1).

EXAMPLE 2(5)(2E)-3-(2-(2-(naphthalen-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenicacid ethyl ester

TLC: Rf 0.62 (n-hexane:ethyl acetate=3:1).

EXAMPLE 2(6)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxymethylphenyl)-2-propenicacid ethyl ester

TLC: Rf 0.46 (n-hexane:ethyl acetate=4:1).

EXAMPLE 2(7)(2E)-3-(2-(2-(benzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenicacid ethyl ester

TLC: Rf 0.46 (chloroform:methanol=10:1).

EXAMPLE 2(8)(2E)-3-(2-(2-methoxy-2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenicacid ethyl ester

TLC: Rf 0.46 (n-hexane:ethyl acetate=1:1).

EXAMPLE 2(9)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-methylpyridin-3-yloxymethyl)phenyl)propanoicacid ethyl ester

TLC: Rf 0.48 (n-hexane:ethyl acetate=1:1).

EXAMPLE 2(10)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-2-yloxy)phenyl)propanoicacid methyl ester

TLC: Rf 0.55 (n-hexane:ethyl acetate=2:1).

EXAMPLE 2(11)3-(2-(4-methyl-2-(4-fluoro-3-methylphenyl)pentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.50 (n-hexane:ethyl acetate=2:1).

EXAMPLE 2(12)3-(2-(2-(9,10-dihydroacridin-9-one-10-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.32 (n-hexane:ethyl acetate=1:2).

EXAMPLE 3(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

To a mixture of the compound prepared in Example 2 (253 mg) intetrahydrofuran (2 ml)-methanol (1.5 ml) was added 2N aqueous solutionof sodium hydroxide (1.5 ml) and the mixture was stirred at 50° C. for 1hour. The reaction mixture was neutralized with 1N hydrochloric acid andthen extracted with ethyl acetate. The organic layer was washed withwater and a saturated aqueous solution of sodium chloride subsequently,dried over anhydrous magnesium sulfate and concentrated. The residue waspurified by column chromatography on silica gel (n-hexane:ethylacetate=3:2˜2:3) to give the title compound (186 mg) having thefollowing physical data.

TLC: Rf 0.28 (n-hexane:ethyl acetate=1:1);

NMR (200 MHz, CDCl₃): δ 8.07 (d, J=16.0 Hz, 1H), 7.88-7.72 (m, 4H), 7.57(d, J=2.0 Hz, 1H), 7.51-7.35 (m, 5H), 6.77 (brd, J−7.8 Hz, 1H), 6.72(brs, 1H), 6.51 (d, J=16.0 Hz, 1H), 6.29 (t, J=2.0 Hz, 1H), 5.30 (s,2H), 4.25 (t, J=6.6 Hz, 2H), 3.28 (t, J=6.6 Hz, 2H).

EXAMPLE 3(1)˜EXAMPLE 3(202)

Using the compounds prepared in Example 2(1)˜2(12) or correspondingcompounds, the following compounds were obtained by the same procedureof Example 3 or continued conversion to known salts.

EXAMPLE 3(1)(2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-hydroxymethylphenyl)-2-propenoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.05 (d, J=16 Hz, 1H), 7.50 (d, J=8.1 Hz, 1H),6.97-6.88 (m, 2H), 6.50 (d, J=16 Hz, 1H), 4.68 (s, 2H), 4.37-4.19 (m,2H), 2.68 (t, J=6.6 Hz, 2H), 2.37-2.07 (m, 2H), 2.16 (s, 3H), 2.12 (s,6H), 2.00-1.81 (m, 2H), 1.37 (s, 3H).

EXAMPLE 3(2)(2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-methoxychroman-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoicacid hydrochloride

TLC: Rf 0.55 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.29 (s, 1H), 7.90-7.65 (m, 4H), 7.26 (s, 1H),6.98 (d, J=7.5 Hz, 1H), 6.53 (d, J=16.2 Hz, 1H), 5.42 (s, 2H), 4.40-4.10(m, 2H), 3.52 (s, 3H), 2.66-2.56 (m, 2H), 2.20-1.76 (m, 4H), 2.09 (s,3H), 2.07 (s, 3H), 2.00 (s, 3H), 1.32 (s, 3H).

EXAMPLE 3(3)(2E)-3-(2-(2-(2,5,7,8-tetramethylchroman-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoicacid hydrochloride

TLC: Rf 0.52 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₄): δ 9.28 (s, 1H), 7.85-7.65 (m, 4H), 7.26 (s, 1H),6.68 (d, J=7.8 Hz, 1H), 6.60-6.46 (m, 2H), 5.42 (s, 2H), 4.40-4.15 (m,2H), 2.64-2.54 (m, 2H), 2.24-1.76 (m, 4H), 2.12 (s, 3H), 2.11 (s, 3H),1.98 (s, 3H), 1.33 (s, 3H).

EXAMPLE 3(4)(2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-(pyrazol1-ylmethyl)phenyl)-2-propenoic acid

TLC: Rf 0.38 (chloroform:methanol=19:1);

NMR (300 MHz, DMSO-d₆): δ 12.28 (bs, 1H), 7.82 (d, J=1.8 Hz, 1H), 7.77(d, J=16 Hz, 1H), 7.61 (d, J=8.0 Hz, 1H), 7.46 (d, J=1.8 Hz, 1H), 7.41(bs, 1H), 6.92 (s, 1H), 6.71 (d, J=8.0 Hz, 1H), 6.46 (d, J=16 Hz, 1H),6.27 (t, J=1.8 Hz, 1H), 5.32 (s, 2H), 4.27-4.03 (m, 2H), 2.56 (m, 2H),2.17-1.71 (m, 4H), 2.04 (s, 3H), 2.01 (s, 3H), 1.98 (s, 3H), 1.27 (s,3H).

EXAMPLE 3(5)(2E)-3-(2-(3-phenoxypropoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoicacid hydrochloride

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.29 (m, 1H), 7.80 (d, J=16 Hz, 1H), 7.79 (m,1H), 7.71 (d, J=7.8 Hz, 1H), 7.67 (m, 1H), 7.32-7.22 (m, 3H), 7.04-6.88(m, 4H), 6.55 (d, J=16 Hz, 1H), 5.41 (s, 2H), 4.24 (t, J=6.2 Hz, 2H),4.15 (t, J=6.1 Hz, 2H), 2.24 (m, 2H).

EXAMPLE 3(6)(2E)-3-(2-(4-phenoxybutoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoicacid hydrochloride

TLC: Rf 0.56 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.29 (m, 1H), 7.81 (m, 1H), 7.80 (d, J=16 Hz,1H), 7.71 (d, J=7.8 Hz, 1H), 7.67 (m, 1H), 7.32-7.21 (m, 3H), 7.04-6.86(m, 4H), 6.57 (d, J=16 Hz, 1H), 5.41 (s, 2H), 4.15 (t, J=5.7 Hz, 2H),4.03 (t, J=6.0 Hz, 2H), 2.02-1.81 (m, 4H).

EXAMPLE 3(7)(2E)-3-(2-(2-(chroman-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoicacid hydrochloride

TLC: Rf 0.62 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.26 (s, 1H), 7.81 (m, 1H), 7.79 (d, J=16 Hz,1H), 7.71 (d, J=8.1 Hz, 1H), 7.67 (m, 1H), 7.30 (s, 1H), 7.08-6.96 (m,3H), 6.83-6.70 (m, 2H), 6.56 (d, J=16 Hz, 1H), 5.42 (s, 2H), 4.35-4.17(m, 3H), 2.90-2.66 (m, 2H), 2.29-2.02 (m, 3H), 1.82-1.65 (m, 1H).

EXAMPLE 3(8)(2E)-3-(2-(6-phenoxyhexyloxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoicacid hydrochloride

TLC: Rf 0.56 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.22 (s, 1H), 7.78 (s, 1H), 7.77 (d, J=16 Hz,1H), 7.69 (d, J=8.1 Hz, 1H), 7.64 (s, 1H), 7.31-7.20 (m, 3H), 7.01-6.85(m, 4H), 6.55 (d, J=16 Hz, 1H), 5.40 (s, 2H), 4.08 (t, J=6.3 Hz, 2H),3.95 (t, J=6.5 Hz, 2H), 1.89-1.66 (m, 4H), 1.60-1.40 (m, 4H).

EXAMPLE 3(9)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoicacid hydrochloride

TLC: Rf 0.36 (chloroform:methanol=19:1);

NMR (300 MHz, DMSO-d₆): δ 9.28 (m, 1H), 7.92-7.77 (m, 6H), 7.72-7.64 (m,2H), 7.56-7.42 (m, 3H), 7.27 (s, 1H), 6.98 (d, J=7.8 Hz, 1H), 6.55 (d,J=16 Hz, 1H), 5.39 (s, 2H), 4.35 (t, J=6.6 Hz, 2H), 3.27 (t, J=6.6 Hz,2H).

EXAMPLE 3(10)(2E)-3-(2-(2-(benzofuran-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoicacid hydrochloride

TLC: Rf 0.52 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.28 (s, 1H), 7.84-7.65 (m, 4H), 7.58-7.47 (m,2H), 7.31 (s, 1H), 7.27-7.15 (m, 2H), 7.00 (d, J=8.1 Hz, 1H), 6.73 (s,1H), 6.57 (d, J=16 Hz, 1H), 5.41 (s, 2H), 4.41 (t, J=6.3 Hz, 2H), 3.34(t, J=6.3 Hz, 2H).

EXAMPLE 3(11)(2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-(2-methylimidazol1-ylmethyl)phenyl)-2-propenoic acid hydrochloride

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CD₃OD): δ 7.93 (d, J=16 Hz, 1H), 7.61 (d, J=8.1 Hz, 1H),7.45 (s, 2H), 6.93 (s, 1H), 6.81 (d, J=8.1 Hz, 1H), 6.52 (d, J=16 Hz,1H), 5.32 (d, J=15 Hz, 1H), 5.28 (d, J=15 Hz, 1H), 4.41-4.21 (m, 2H),2.65 (t, J=7.1 Hz, 2H), 2.61 (s, 3H), 2.29-1.80 (m, 4H), 2.11 (s, 3H),2.08 (s, 3H), 2.05 (s, 3H), 1.35 (s, 3H).

EXAMPLE 3(12)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

[Salt-Free]

TLC: Rf 0.33 (hexane:ethyl acetate=1:1);

NMR (200 MHz, CDCl₃): δ 7.84-7.68 (m, 4H), 7.54 (d, J=1.8 Hz, 1H),7.48-7.35 (m, 3H), 7.33 (d, J=2.2 Hz, 1H), 7.08 (d, J=7.4 Hz, 1H),6.74-6.65 (m, 2H), 6.28-6.23 (m, 1H), 5.24 (s, 2H), 4.19 (t, J=6.4 Hz,2H), 3.22 (t, J=6.4 Hz, 2H), 2.93-2.82 (m, 2H), 2.56-2.45 (m, 2H).

Sodium Salt:

TLC: Rf 0.33 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, DMSO-d₆): δ7.94-7.82 (m, 4H), 7.77 (d, J=2.1 Hz, 1H),7.56-7.40 (m, 4H), 7.07 (d, J=7.8 Hz, 1H), 6.83 (s, 1H), 6.64 (d, J=8.1Hz, 1H), 6.24 (t, J=2.1 Hz, 1H), 5.23 (s, 2H), 4.17 (t, J=6.6 Hz, 2H),3.19 (t, J=6.6 Hz, 2H), 2.70 (t, J=7.8 Hz, 2H), 2.18 (t, J=7.8 Hz, 2H).

EXAMPLE 3(13)(2E)-3-(2-(naphthalen-2-ylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.57 (hexane:ethyl acetate=1:3);

NMR (500 MHz, DMSO-d₆): δ 8.01-7.87 (m, 4H), 7.78 (d, J=2.0 Hz, 1H),7.69 (d, J=16 Hz, 1H), 7.63-7.48 (m, 4H), 7.43 (d, J=2.0 Hz, 1H), 7.08(s, 1H), 6.73 (d, J=8.0 Hz, 1H), 6.47 (d, J=16 Hz, 1H), 6.23 (t, J=2.0Hz, 1H), 5.30 (s, 2H), 5.29 (s, 2H).

EXAMPLE 3(14)(2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-(2H-1,2,3-triazol-2-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (200 MHz, CD₃OD): δ 7.92 (d, J=16.2 Hz, 1H), 7.71 (s, 2H), 7.52 (d,J=7.6 Hz, 1H), 6.85 (s, 1H), 6.80 (d, J=8.4 Hz, 1H), 6.47 (d, J=16.2 Hz,1H), 5.56 (s, 2H), 4.36-4.08 (m, 2H), 2.64 (t, J=6.6 Hz, 2H), 2.20-2.00(m, 2H), 2.12 (s, 3H), 2.08 (s, 3H), 2.05 (s,3H), 1.96-1.80 (m, 2H),1.33 (s, 3H).

EXAMPLE 3(15)(2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-(1H-1,2,3-triazol-1-ylmethyl)phenyl)-2-propenoicacid hydrochloride

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (200 MHz, CD₃OD): δ 8.37 (d, J=1.2 Hz, 1H), 8.24 (d, J=1.2 Hz, 1H),7.93 (d, J=16.4 Hz, 1H), 7.59 (d, J=8.2 Hz, 1H), 7.01 (brs, 1H), 6.93(brd, J=8.2 Hz, 1H), 6.50 (d, J=16.4 Hz, 1H), 5.70 (s, 2H), 4.90 (s,2H), 4.45-4.15 (m, 2H), 2.72-2.58 (m, 2H), 2.26-1.80 (m, 4H), 2.11 (s,3H), 2.08 (s, 3H), 2.05 (s, 3H), 1.34 (s, 3H).

EXAMPLE 3(16)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-benzylphenyl)-2-propenoic acid

TLC: Rf 0.37 (hexane:ethyl acetate=2:1);

NMR (200 MHz, CDCl₃): δ 8.12 (d, J=16.4 Hz, 1H), 7.88-7.74 (m, 4H),7.52-7.10 (m, 9H), 6.79 (brd, J=8.0 Hz, 1H), 6.72 (brs, 1H), 6.52 (d,J=16.4 Hz, 1H), 4.26 (t, J=6.6 Hz, 2H), 3.95 (s, 2H), 3.29 (t, J=6.6 Hz,2H).

EXAMPLE 3(17)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(thiophen-2-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.31 (hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 8.12 (d, J=16.2 Hz, 1H), 7.86-7.74 (m, 4H),7.50-7.38 (m, 4H), 7.15 (dd, J=5.1, 1.2 Hz, 1H), 6.92 (dd, J=5.1, 3.6Hz, 1H), 6.84 (d, J=7.5 Hz, 1H), 6.82-6.76 (m, 2H), 6.53 (d, J=16.2 Hz,1H), 4.29 (t, J=6.8 Hz, 2H), 4.12 (s, 2H), 3.31 (t, J=6.8 Hz, 2H).

EXAMPLE 3(18)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(thiophen-3-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.31 (hexane:ethyl acetate=2:1);

NMR (200 MHz, CDCl₃): δ 8.13 (d, J=16.0 Hz, 1H), 7.88-7.74 (m, 4H),7.52-7.36 (m, 4H), 7.25 (dd, J=4.6, 3.2 Hz, 1H), 6.96-6.85 (m, 2H), 6.80(brd, J=8.0 Hz, 1H), 6.73 (brs, 1H), 6.53 (d, J=16.0 Hz, 1H), 4.27 (t,J=6.6 Hz, 2H), 3.95 (s, 2H), 3.30 (t, J=6.6 Hz, 2H).

EXAMPLE 3(19)4-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)butanoicacid

TLC: Rf 0.35 (hexane:ethyl acetate=1:1);

NMR (200 MHz, CDCl₃): δ 7.84-7.73 (m, 3H), 7.69 (brs, 1H), 7.54 (d,J=1.6 Hz, 1H), 7.50-7.32 (m, 4H), 7.02 (d, J=7.6 Hz, 1H), 6.74-6.64 (m,2H), 6.25 (t, J=2.1 Hz, 1H), 5.24 (s, 2H), 4.18 (t, J=6.6 Hz, 2H), 3.21(t, J=6.6 Hz, 2H), 2.57 (t, J=7.5 Hz, 2H), 2.20 (t, J=7.4 Hz, 2H),1.88-1.68 (m, 2H).

EXAMPLE 3(20)(2E)-3-(2-(2-(naphthalen-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.26 (hexane:ethyl acetate=1:1);

NMR (200 MHz, CDCl₃): δ 8.14-8.02 (m, 2H), 7.90-7.72 (m, 2H), 7.60-7.34(m, 7H), 6.76 (brd, J=8.0 Hz, 1H), 6.70 (brs, 1H), 6.53 (d, J=16.2 Hz,1H), 6.27 (t, J=2.1 Hz, 1H), 5.26 (s, 2H), 4.32 (t, J=7.0 Hz, 2H), 3.62(t, J=7.0 Hz, 2H).

EXAMPLE 3(21)(2E)-3-(2-(3-(naphthalen-2-yl)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.26 (hexane:ethyl acetate=1:1);

NMR (200 MHz, CDCl₃): δ 8.09 (d, J=16.2 Hz, 1H), 7.84-7.72 (m, 3H),7.66-7.30 (m, 7H), 6.77 (brd, J=8.0 Hz, 1H), 6.66 (brs, 1H), 6.59 (d,J=16.2 Hz, 1H), 6.27 (t, J=2.1 Hz, 1H), 5.28 (s, 2H), 4.00 (t, J=6.3 Hz,2H), 2.97 (t, J=7.5 Hz, 2H), 2.32-2.14 (m, 2H).

EXAMPLE 3(22)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxymethylphenyl)-2-propenoicacid

TLC: Rf 0.52 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.13 (d, J=16 Hz, 1H), 7.87-7.76 (m, 4H),7.57-7.39 (m, 4H), 7.34-7.24 (m, 2H), 7.06-6.92 (m, 5H), 6.56 (d, J=16Hz, 1H), 5.05 (s, 2H), 4.35 (t, J=6.8 Hz, 2H), 3.33 (t, J=6.8 Hz, 2H).

EXAMPLE 3(23)2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)aceticacid

TLC: Rf 0.48 (hexane:ethyl acetate=1:4);

NMR (300 MHz, CDCl₃): δ 7.83-7.73 (m, 3H), 7.68 (s, 1H), 7.54 (d, J=1.8Hz, 1H), 7.49-7.32 (m, 4H), 7.11 (d, J=7.5 Hz, 1H), 6.74 (dd, J=7.8, 1.5Hz, 1H), 6.69 (d, J=1.5 Hz, 1H), 6.26 (t, J=2.1 Hz, 1H), 5.26 (s, 2H),4.17 (t, J=6.6 Hz, 2H), 3.58 (s, 2H), 3.17 (t, J=6.6 Hz, 2H).

EXAMPLE 3(24)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-oxopyrrolidin-1-yl)phenyl)-2-propenoicacid

TLC: Rf 0.36 (chloroform:methanol=10:1);

NMR (200 MHz, CDCl₃): δ 8.10 (d, J=16.0 Hz, 1H), 7.90-7.76 (m, 4H),7.52-7.36 (m, 4H), 6.86-6.76 (m, 2H), 6.54 (d, J=16.0 Hz, 1H), 4.41 (s,2H), 4.31 (t, J=6.5 Hz, 2H), 3.32 (t, J=6.5 Hz, 2H), 3.24 (t, J=7.0 Hz,2H), 2.45 (t, J=8.0 Hz, 2H), 2.10-1.88 (m, 2H).

EXAMPLE 3(25)2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenoxy)aceticacid

TLC: Rf 0.68 (chloroform:methanol:acetic acid=20:1:1);

NMR (300 MHz, CDCl₃): δ 7.83-7.75 (m, 3H), 7.70 (s, 1H), 7.55 (dd,J=1.8, 0.6 Hz, 1H), 7.49-7.32 (m, 4H), 6.84 (d, J=7.8 Hz, 1H), 6.78-6.71(m, 2H), 6.26 (t, J=2.1 Hz, 1H), 5.22 (s, 2H), 4.59 (s, 2H), 4.25 (t,J=7.1 Hz, 2H), 3.25 (t, J=7.1 Hz, 2H).

EXAMPLE 3(26)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-benzyloxyphenyl)-2-propenoicacid

TLC: Rf 0.46 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.06 (d, J=16 Hz, 1H), 7.87-7.76 (m, 4H),7.50-7.29 (m, 9H), 6.60-6.51 (m, 2H), 6.46 (d, J=16 Hz, 1H), 5.05 (s,2H), 4.29 (t, J=6.8 Hz, 2H), 3.33 (t, J=6.8 Hz, 2H).

EXAMPLE 3(27)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-dimethylaminomethylphenyl)-2-propenoicacid

TLC: Rf 0.48 (chloroform:methanol=5:1);

NMR (200 MHz, DMSO-d₆): δ 7.92-7.80 (m, 5H), 7.62-7.40 (m, 4H), 7.01(brs, 1H), 6.88 (d, J=7.6 Hz, 1H), 6.50 (d, J=16.0 Hz, 1H), 4.33 (t,J=6.4 Hz, 2H), 3.37 (s, 2H), 3.26 (t, J=6.4 Hz, 2H), 2.13 (s, 6H).

EXAMPLE 3(28)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylcarbamoylphenyl)-2-propenoicacid

TLC: Rf 0.40 (chloroform:methanol=10:1);

NMR (200 MHz, DMSO-d₆): δ 10.26 (s, 1H), 7.98-7.70 (m, 8H), 7.65-7.30(m, 7H), 7.12 (t, J=7.3 Hz, 1H), 6.67 (d, J=16.2 Hz, 1H), 4.49 (t, J=6.4Hz, 2H), 3.42-3.24 (m, 2H).

EXAMPLE 3(29)(2E)-3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.57 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.03 (d, J=16 Hz, 1H), 7.57 (d, J=2.1 Hz, 1H),7.46 (d, J=8.0 Hz, 1H), 7.40 (d, J=2.1 Hz, 1H), 7.37-7.20 (m, 5H), 6.78(d, J=8.0 Hz, 1H), 6.71 (s, 1H), 6.50 (d, J=16 Hz, 1H), 6.30 (t, J=2.1Hz, 1H), 5.31 (s, 2H), 4.18 (t, J=6.9 Hz, 2H), 3.13 (t, J=6.9 Hz, 2H).

EXAMPLE 3(30)(2E)-3-(2-(naphthalen-2-ylmethoxymethyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.38 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 8.12 (d, J=16 Hz, 1H), 7.88-7.78 (m, 4H), 7.61(d, J=8.1 Hz, 1H), 7.57 (d, J=2.2 Hz, 1H), 7.53-7.39 (m, 4H), 7.27 (m,1H), 7.17 (d, J=8.1 Hz, 1H), 6.40 (d, J=16 Hz, 1H), 6.30 (t, J=2.2 Hz,1H), 5.35 (s, 2H), 4.75 (s, 2H), 4.65 (s, 2H).

EXAMPLE 3(31)(2E)-3-(2-((3E)-4-phenyl-3-butenyloxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.23 (hexane:ethyl acetate=1:1);

NMR (200 MHz, CDCl₃): δ 8.03 (d, J=16.0 Hz, 1H), 7.58-7.18 (m, 8H),6.81-6.74 (m, 2H), 6.56 (d, J=16.0 Hz, 2H), 6.34-6.19 (m, 2H), 5.33 (s,2H), 4.10 (t, J=6.5 Hz, 2H), 2.74 (q, J=6.5 Hz, 2H).

EXAMPLE 3(32)(2E)-3-(2-(2-hydroxy-3-phenoxypropoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.47 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.28 (bs, 1H), 7.86-7.77 (m, 2H), 7.62 (d,J=8.0 Hz, 1H), 7.46 (dd, J=2.0, 0.8 Hz, 1H), 7.32-7.23 (m, 2H),7.03-6.88 (m, 4H), 6.73 (d, J=8.0 Hz, 1H), 6.52 (d, J=16 Hz, 1H), 6.27(t, J=2.0 Hz, 1H), 5.47 (bs, 1H), 5.33 (s, 2H), 4.26-3.99 (m, 5H).

EXAMPLE 3(33)(2E)-3-(2-(2-(1,4-benzodioxan-6-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.44 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.01 (d, J=16.0 Hz, 1H), 7.57 (d, J=2.0 Hz, 1H),7.46 (d, J=8.0 Hz, 1H), 7.40 (d, J=2.0 Hz, 1H), 6.83-6.73 (m, 4H), 6.70(s, 1H), 6.48 (d, J=16.0 Hz, 1H), 6.30 (t, J=2.0 Hz, 1H), 5.30 (s, 2H),4.23 (br, 4H), 4.13 (t, J=7.0 Hz, 2H), 3.01 (t, J=7.0 Hz, 2H).

EXAMPLE 3(34)(2E)-3-(2-(2-(1,4-benzodioxan-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.44 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.02 (d, J=16.0 Hz, 1H), 7.58 (dd, J=2.0, 0.5Hz, 1H), 7.50 (d, J=8.0 Hz, 1H), 7.43 (dd, J=2.0, 0.5 Hz, 1H), 6.88-6.76(m, 6H), 6.48 (d, J=16.0 Hz, 1H), 6.32 (t, J=2.0 Hz, 1H), 5.33 (s, 2H),4.42 (dq, J=2.0, 7.0 Hz, 1H), 4.32 (dd, J=11.0, 2.0 Hz, 1H), 4.29-4.15(m, 2H), 4.00 (dd, J=11.0, 7.0 Hz, 1H), 2.18 (q, J=7.0 Hz, 2H).

EXAMPLE 3(35)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-cyanomethylphenyl)-2-propenoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 7.94-7.78 (m, 5H), 7.69 (d, J=7.8 Hz, 1H),7.60-7.42 (m, 3H), 7.12 (s, 1H), 6.96 (d, J=7.8 Hz, 1H), 6.54 (d, J=15.9Hz, 1H), 4.37 (t, J=6.6 Hz, 2H), 4.04 (s, 2H), 3.40-3.20 (m, 2H).

EXAMPLE 3(36)(2E)-3-(2-(2-(naphthalen-2-yloxy)ethyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.35 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 8.20 (d, J=16 Hz, 1H), 7.75-7.66 (m, 3H),7.63-7.56 (m, 2H), 7.45-7.37 (m, 2H), 7.35-7.27 (m, 1H), 7.20-7.04 (m,4H), 6.41 (d, J=16 Hz, 1H), 6.30 (t, J=2.1 Hz, 1H), 5.35 (s, 2H), 4.23(t, J=6.7 Hz, 2H), 3.28 (t, J=6.7 Hz, 2H).

EXAMPLE 3(37)(2E)-3-(2-(2-(N-benzoyl-N-methylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.30 (chloroform:methanol=10:1);

NMR (500 MHz, DMSO-d₆ at 100 degrees): δ 7.80 (d, J=16.0 Hz, 1H), 7.73(d, J=2.0 Hz, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.46 (d, J=2.0 Hz, 1H),7.41-7.36 (m, 5H), 6.98 (s, 1H), 6.80 (d, J=8.0 Hz, 1H), 6.44 (d, J=16.0Hz, 1H), 6.26 (t, J=2.0 Hz, 1H), 5.32 (s, 2H), 4.25 (brt, 2H), 3.78(brt, 2H), 3.02 (s, 3H).

EXAMPLE 3(38)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylthiomethylphenyl)-2-propenoicacid

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.30 (brs, 1H), 7.92-7.75 (m, 5H), 7.60-7.42(m, 4H), 7.37-7.12 (m, 5H), 7.05 (s, 1H), 6.94 (d, J=7.8 Hz, 1H), 6.48(d, J=16.2 Hz, 1H), 4.26 (t, J=6.6 Hz, 2H), 4.23 (s, 2H), 3.24 (t, J=6.6Hz, 2H).

EXAMPLE 3(39)(2E)-3-(2-(2-(benzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.31 (chloroform:methanol 10:1);

NMR (300 MHz, CDCl₃): δ 7.92 (d, J=15.5 Hz, 1H), 7.77 (d, J=7.0 Hz, 2H),7.56 (s, 1H), 7.50-7.36 (br, 5H), 6.81-6.64 (m, 4H), 6.30 (br, 1H), 5.30(br, 2H), 4.15 (br, 2H), 3.92 (br, 2H).

EXAMPLE 3(40)(2E)-3-(2-(2-methoxy-3-phenoxypropoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.42 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.29 (brs, 1H), 7.83 (d, J=2.1 Hz, 1H), 7.79(d, J=16.2 Hz, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.50-7.44 (m, 1H), 7.34-7.23(m, 2H), 7.06-6.88 (m, 4H), 6.74 (d, J=8.1 Hz, 1H), 6.53 (d, J=16.2 Hz,1H), 6.28 (t, J=2.1 Hz, 1H), 5.33 (s, 2H), 4.30-4.08(m, 4H), 4.00-3.88(m, 1H), 3.44 (s, 3H).

EXAMPLE 3(41)(2E)-3-(2-(2-methoxy-2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.59 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.03 (d, J=16 Hz, 1H), 7.92-7.81 (m, 4H),7.57-7.42 (m, 5H), 7.37 (d, J=2.1 Hz, 1H), 6.78 (dd, J=8.0, 1.2 Hz, 1H),6.70 (d, J=1.2 Hz, 1H), 6.60 (d, J=16 Hz, 1H), 6.28 (t, J=2.1 Hz, 1H),5.28 (s, 2H), 4.78 (dd, J=7.2, 4.5 Hz, 1H), 4.27 (dd, J=9.9, 7.2 Hz,1H), 4.12 (dd, J=9.9, 4.5 Hz, 1H), 3.41 (s, 3H).

EXAMPLE 3(42)(2E)-3-(2-(pyrazol-1-ylmethyl)-3-(2-(naphthalen-2-yl)ethoxy)thiophen-4-yl)-2-propenoicacid

TLC: Rf 0.59 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.85-7.72 (m, 4H), 7.60 (d, J=16 Hz, 1H),7.52-7.38 (m, 5H), 7.12 (d, J=2.0 Hz, 1H), 6.45 (d, J=16 Hz, 1H), 6.17(t, J=2.0 Hz, 1H), 5.16(s, 2H), 4.21 (t, J=6.8 Hz, 2H), 3.27 (t, J=6.8Hz, 2H).

EXAMPLE 3(43)(2E)-3-(3-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)thiophen-2-yl)-2-propenoicacid

TLC: Rf 0.59 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.87 (d, J=16 Hz, 1H), 7.84-7.76 (m, 3H), 7.72(s, 1H), 7.53-7.36 (m, 4H), 7.11 (d, J=2.0 Hz, 1H), 7.08 (s, 1H), 6.17(t, J=2.0 Hz, 1H), 6.12 (d, J=16 Hz, 1H), 4.97 (s, 2H), 4.26 (t, J=6.8Hz, 2H), 3.24 (t, J=6.8 Hz, 2H).

EXAMPLE 3(44)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-mesyl-N-phenylaminomethyl)phenyl)-2-propenoicacid

TLC: Rf 0.51 (chloroform:methanol=19:1);

NMR (300 MHz, DMSO-d₆): δ 7.89-7.81 (m, 4H), 7.75 (d, J=16 Hz, 1H),7.56-7.18 (m, 9H), 6.96 (s, 1H), 6.85 (d, J=8.1 Hz, 1H), 6.45 (d, J=16Hz, 1H), 4.85 (s, 2H), 4.26 (t, J=6.3 Hz, 2H), 3.21 (t, J=6.3 Hz, 2H),3.08 (s, 3H).

EXAMPLE 3(45)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-acetyl-N-phenylaminomethyl)phenyl)-2-propenoicacid

TLC: Rf 0.67 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.09 (d, J=16 Hz, 1H), 7.88-7.75 (m, 4H),7.50-7.27 (m, 7H), 7.02-6.94 (m, 2H), 6.82 (s, 1H), 6.73 (d, J=7.8 Hz,1H), 6.53 (d, J=16 Hz, 1H), 4.85 (s, 2H), 4.25 (t, J=6.6 Hz, 2H), 3.29(t, J=6.6 Hz, 2H), 1.88 (s, 3H).

EXAMPLE 3(46)(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-benzoyl-N-methylaminomethyl)phenyl)-2-propenoicacid

TLC: Rf 0.58 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.11 (d, J=16 Hz, 1H), 7.89-7.75 (m, 4H),7.55-7.30 (m, 9H), 7.02-6.61 (m, 2H), 6.55 (d, J=16 Hz, 1H), 4.80-4.22(m, 4H), 3.34 (t, J=6.6 Hz, 2H), 3.12-2.78 (m, 3H).

EXAMPLE 3(47)(2E)-3-(2-(2-(naphthalen-2-yl)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.64 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.02 (d, J=16 Hz, 1H), 7.88-7.74 (m, 4H), 7.57(d, J=1.8 Hz, 1H), 7.50-7.36 (m, 5H), 6.76 (d, J=8.1 Hz, 1H), 6.72 (s,1H), 6.49 (d, J=16 Hz, 1H), 6.29 (t, J=2.3 Hz, 1H), 5.29 (s, 2H),4.20-4.06 (m, 2H), 3.47 (m, 1H), 1.54 (d, J=6.9 Hz, 3H).

EXAMPLE 3(48)3-(2-((naphthalen-2-yl)carbonylmethoxy)-4-(pyrazole-1-methyl)phenyl)propanoicacid

TLC: Rf 0.57 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 12.08 (brs, 1H), 8.76 (s, 1H), 8.20-7.95 (m,4H), 7.75-7.60 (m, 3H), 7.36 (d, J=0.9 Hz, 1H), 7.14 (d, J=7.8 Hz, 1H),6.91 (s, 1H), 6.67 (d, J=7.8 Hz, 1H), 6.18 (t, J=2.0 Hz, 1H), 5.72 (s,2H), 5.23 (s, 2H), 2.86 (t, J=7.7 Hz, 2H), 2.57 (t, J=7.7 Hz, 2H).

EXAMPLE 3(49)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrrol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.76 (m, 3H), 7.72 (s, 1H), 7.47-7.37 (m,3H), 7.07 (d, J=7.5 Hz, 1H), 6.66 (t, J=2.1 Hz, 2H), 6.63 (d, J=7.5 Hz,1H), 6.55 (d, J=1.5 Hz, 1H), 6.18 (t, J=2.1 Hz, 2H), 4.98 (s, 2H), 4.19(t, J=6.6 Hz, 2H), 3.23 (t, J=6.6 Hz, 2H), 2.87 (t, J=7.8 Hz, 2H), 2.50(t, J=7.8 Hz, 2H).

EXAMPLE 3(50)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-methylpyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.83-7.75 (m, 3H), 7.72 (s, 1H), 7.46-7.37 (m,3H), 7.32 (s, 1H), 7.12-7.06 (m, 2H), 6.72-6.68 (m, 2H), 5.15 (s, 2H),4.21 (t, J=6.6 Hz, 2H), 3.23 (t, J=6.6 Hz, 2H), 2.87 (t, J=7.8 Hz, 2H),2.50 (t, J=7.8 Hz, 2H), 2.03 (s, 3H).

EXAMPLE 3(51)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3,5-dimethylpyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.83-7.75 (m, 3H), 7.71 (s, 1H), 7.46-7.37 (m,3H), 7.04 (d, J=7.8 Hz, 1H), 6.59 (s, 1H), 6.55 (d, J=7.8 Hz, 1H), 5.82(s, 1H), 5.13 (s, 2H), 4.19 (t, J=6.6 Hz, 2H), 3.21 (t, J=6.6 Hz, 2H),2.85 (t, J=7.8 Hz, 2H), 2.49 (t, J=7.8 Hz, 2H), 2.23 (s, 3H), 2.12 (s,3H).

EXAMPLE 3(52)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylsulfonylmethylphenyl)propanoicacid

TLC: Rf 0.46 (acetone:toluene=1:1);

NMR (300 MHz, CDCl₃): δ 7.85-7.77 (m, 3H), 7.72 (s, 1H), 7.66-7.37 (m,8H), 6.99 (d, J=7.2 Hz, 1H), 6.58 (d, J=1.8 Hz, 1H), 6.41 (dd, J=7.2,1.8 Hz, 1H), 4.23 (s, 2H), 4.12 (t, J=6.6 Hz, 2H), 3.22 (t, J=6.6 Hz,2H), 2.86 (t, J=7.8 Hz, 2H), 2.49 (t, J=7.8 Hz, 2H).

EXAMPLE 3(53)3-(2-(2-(1,1′-biphenyl-4-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.067 (chloroform);

NMR (300 MHz, CDCl₃): δ 7.60-7.50 (m, 5H), 7.45-7.38 (m, 2H), 7.36-7.30(m, 4H), 7.09 (d, J=7.2 Hz, 1H), 6.70 (d, J=7.2 Hz, 1H), 6.68 (s, 1H),6.26 (t, J=2.1 Hz, 1H), 5.25 (s, 2H), 4.15 (t, J=6.6 Hz, 2H), 3.10 (t,J=6.6 Hz, 2H), 2.88 (t, J=8.1 Hz, 2H), 2.53 (t, J=8.1 Hz, 2H).

EXAMPLE 3(54)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-benzoylaminophenyl)propanoic acid

TLC: Rf 0.57 (chloroform:methanol 10:1);

NMR (300 MHz, CDCl₃): δ 12.0 (s, 1H), 10.1(s, 1H), 7.95-7.81 (m, 6H),7.59-7.41 (m 7H), 7.26 (dd, J=8.1, 1.8 Hz, 1H), 7.05 (d, J=8.1 Hz, 1H),4.23 (t, J=6.3 Hz, 2H), 3.24 (t, J=6.3 Hz, 2H), 2.70 (t, J=7.5 Hz, 2H),2.34 (t, J=7.5 Hz, 2H).

EXAMPLE 3(55)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-benzoyl-N-methylamino)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.86-7.75 (m, 3H), 7.65 (s, 1H), 7.50-7.40 (m,2H), 7.37-7.12 (m, 6H), 6.97 (d, J=7.8 Hz, 1H), 6.58 (dd, J=7.8, 1.8 Hz,1H), 6.43 (d, J=1.8 Hz, 1H), 4.01 (t, J=6.6 Hz, 2H), 3.45 (s, 3H), 3.11(t, J=6.6 Hz, 2H), 2.79 (t, J=8.1 Hz, 2H), 2.44 (t, J=8.1 Hz, 2H).

EXAMPLE 3(56)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-mesyl-N-methylamino)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.85-7.76 (m, 3H), 7.75(s, 1H), 7.48-7.39 (m,3H), 7.12 (d, J=8.1 Hz, 1H), 6.91 (d, J=2.1 Hz, 1H), 6.79 (dd, J=8.1,2.1 Hz, 1H), 4.28 (t, J=6.6 Hz, 2H), 3.28 (t, J=6.6 Hz, 2H), 3.26 (s,3H), 2.89 (t, J=8.1 Hz, 2H), 2.89 (s, 3H), 2.52 (t, J=8.1 Hz, 2H).

EXAMPLE 3(57)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-mesylaminophenyl)propanoic acid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 12.1 (s, 1H), 9.55(s, 1H), 7.92-7.80 (m, 4H),7.53-7.42 (m 3H), 7.04 (d, J=8.1 Hz, 1H), 6.81 (d, J=2.4 Hz, 1H), 6.67(dd, J=8.1, 2.4 Hz, 1H), 4.20 (t, J=6.3 Hz, 2H), 3.21 (t, J=6.3 Hz, 2H),2.92 (s, 3H), 2.68 (t, J=7.8 Hz, 2H), 2.35 (t, J=7.8 Hz, 2H).

EXAMPLE 3(58)3-(2-(2-(1,1′-biphenyl-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.16 (hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 7.53 (d, J=3.0 Hz, 1H), 7.45-7.21 (m, 10H), 7.07(d, J=7.8 Hz, 1H), 6.67 (dd, J=7.5, 1.2 Hz, 1H), 6.51 (s, 1H), 6.26 (t,J=2.1 Hz, 1H), 5.21 (s, 2H), 3.94 (t, J=7.2 Hz, 2H), 3.08 (t, J=7.2 Hz,2H), 2.82 (t, J=7.5 Hz, 2H), 2.47 (t, J=7.5 Hz, 2H).

EXAMPLE 3(59)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(benzimidazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.72 (s, 1H), 7.89-7.82 (m, 3H), 7.80 (s, 1H),7.71-7.61 (m, 2H), 7.52-7.42 (m, 3H), 7.30-7.23 (m, 2H), 7.07 (s, 1H),7.06 (d, J=7.5 Hz, 1H), 6.78 (d, J=7.8 Hz, 1H), 5.46 (s, 2H), 4.22 (t,J=6.6 Hz, 2H), 3.18 (t, J=6.6 Hz, 2H), 2.69 (t, J=8.1 Hz, 2H), 2.34 (t,J=8.1 Hz, 2H).

EXAMPLE 3(60)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-methyl-2-oxoimidazolidin-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.76 (m, 3H), 7.75 (s, 1H), 7.49-7.38 (m,3H), 7.06 (d, J=6.9 Hz, 1H), 6.78-6.70 (m, 2H), 4.29 (s, 2H), 4.26 (t,J=6.3 Hz, 2H), 3.36-3.22 (m, 2H), 3.26 (t, J=6.3 Hz, 2H), 3.19-3.09 (m,2H), 2.88 (t, J=7.8 Hz, 2H), 2.82 (s, 3H), 2.52 (t, J=7.8 Hz, 2H).

EXAMPLE 3(61)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-oxopyridin-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.73 (m, 3H), 7.72 (s, 1H), 7.47-7.35 (m,3H), 7.29 (m, 1H), 7.21 (dd, J=6.9, 2.1 Hz, 1H), 7.08 (d, J=7.8 Hz, 1H),6.81 (s, 1H), 6.75 (d, J=7.2 Hz, 1H), 6.63 (d, J=9.0 Hz, 1H), 6.12 (dd,J=6.6, 1.2 Hz, 1H), 5.06 (s, 2H), 4.23 (t, J=6.6 Hz, 2H), 3.23 (t, J=6.6Hz, 2H), 2.87 (t, J=7.8 Hz, 2H), 2.50 (t, J=7.8 Hz, 2H).

EXAMPLE 3(62)3-(2-(2-(1,1′-biphenyl-3-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.39 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.59-7.24 (m, 11H), 7.09 (d, J=7.2 Hz, 1H), 6.72(d, J=7.5 Hz, 1H), 6.67 (s, 1H), 6.25 (t, J=2.1 Hz, 1H), 5.24 (s, 2H),4.15 (t, J=6.6 Hz, 2H), 3.14 (t, J=6.6 Hz, 2H), 2.87 (t, J=7.5 Hz, 2H),2.50 (t, J=7.5 Hz, 2H).

EXAMPLE 3(63)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylsulfonylaminophenyl)propanoicacid

TLC: Rf 0.69 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.68 (m, 6H), 7.53-7.36 (m, 6H), 6.93 (d,J=8.1 Hz, 1H), 6.68 (d, J=1.8 Hz, 1H), 6.58 (s, 1H), 6.38 (dd, J=8.1,1.8 Hz, 1H), 4.16 (t, J=6.6 Hz, 2H, 3.22 (t, J=6.6 Hz, 2H), 2.80 (t,J=7.5 Hz, 2H), 2.46 (t, J=7.5 Hz, 2H).

EXAMPLE 3(64)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-acetylaminophenyl)propanoic acid

TLC: Rf 0.41 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ7.84-7.72 (m, 4H), 7.48-7.38 (m, 4H), 7.10 (d,J=1.8 Hz, 1H), 7.03 (d, J=8.1 Hz, 1H), 6.69 (dd, J=8.1, 1.8 Hz, 1H),4.29 (t, J=6.6 Hz, 2H), 3.27 (t, J=6.6 Hz, 2H), 2.84 (t, J=7.5 Hz, 2H),2.48 (t, J=7.5 Hz, 2H), 2.15 (s, 3H).

EXAMPLE 3(65)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-methylpyridin-3-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 7.98 (dd, J=4.8, 1.2 Hz, 1H), 7.89-7.80 (m,4H), 7.53-7.41 (m, 3H), 7.35 (dd, J=8.3, 1.1 Hz, 1H), 7.18-7.05 (m, 3H),6.92 (dd, J=7.7, 1.4 Hz, 1H), 5.07 (s, 2H), 4.28 (t, J=6.4 Hz, 2H), 3.21(t, J=6.4 Hz, 2H), 2.73 (t, J=7.8 Hz, 2H), 2.38 (t, J=7.8 Hz, 2H), 2.37(s, 3H).

EXAMPLE 3(66)3-(2-(4-methyl-2-(naphthalen-1-yl)pentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.59 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.23 (d, J=8.4 Hz, 1H), 7.91 (m, 1H),7.84-7.68 (m, 2H), 7.62-7.34 (m, 5H), 6.98 (d, J=7.2 Hz, 1H), 6.81 (s,1H), 6.60 (d, J=7.2 Hz, 1H), 6.20 (t, J=2.1 Hz, 1H), 5.18 (s, 2H),4.18-3.99 (m, 3H), 2.54 (t, J=7.5 Hz, 2H), 2.16 (t, J=7.5 Hz, 2H),1.99-1.78 (m, 2H), 1.44 (m, 1H), 0.87 (d, J=6.6 Hz, 3H), 0.082 (d, J=6.6Hz, 3H).

EXAMPLE 3(67)3-(2-(2-(benzothiophen-3-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 7.97 (dd, J=6.6, 1.2 Hz, 1H), 7.90 (dd, J=6.6,1.5 Hz, 1H), 7.76 (d, J=1.5 Hz, 1H), 7.54 (s, 1H), 7.45-7.33 (m, 3H),7.04 (d, J=7.8 Hz, 1H), 6.88 (s, 1H), 6.64 (d, J=7.8 Hz, 1H), 6.23 (t,J=2.1 Hz, 1H), 5.23 (s, 2H), 4.22 (t, J=6.6 Hz, 2H), 3.31 (t, J=6.6 Hz,2H), 2.68 (t, J=7.5 Hz, 2H), 2.33 (t, J=7.5 Hz, 2H).

EXAMPLE 3(68)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-3-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 8.32 (d, J=2.7 Hz, 1H), 8.14 (dd, J=4.7, 1.4Hz, 1H), 7.89-7.80 (m, 4H), 7.54-7.38 (m, 4H), 7.30 (m, 1H), 7.11 (d,J=7.8 Hz, 1H), 7.06 (d, J=1.5 Hz, 1H), 6.92 (dd, J=7.8, 1.5 Hz, 1H),5.09 (s, 2H), 4.27 (t, J=6.4 Hz, 2H), 3.21 (t, J=6.4 Hz, 2H), 2.73 (t,J=7.6 Hz, 2H), 2.38 (t, J=7.6 Hz, 2H).

EXAMPLE 3(69)3-(2-(2-(indol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.48 (hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.61 (d, J=8.1 Hz, 1H), 7.53 (dd, J=2.1, 0.6 Hz,1H), 7.37 (dd, J=8.1, 0.8 Hz, 1H), 7.31 (dd, J=2.1, 0.6 Hz, 1H),7.25-7.17 (m, 2H), 7.13-7.05 (m, 2H), 6.71 (dd, J=7.7, 1.7 Hz, 1H), 6.56(d, J=1.2 Hz, 1H), 6.50 (dd, J=3.3, 0.9 Hz, 1H), 6.25 (t, J=2.1 Hz, 1H),5.20 (s, 2H), 4.51 (t, J=5.3 Hz, 2H), 4.20 (t, J=5.3 Hz, 2H), 2.82 (t,J=7.7 Hz, 2H), 2.44 (t, J=7.7 Hz, 2H).

EXAMPLE 3(70)3-(2-(2-(1-methylindol-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.60 (d, J=7.8 Hz, 1H), 7.53 (d, J=1.8 Hz, 1H),7.33 (d, J=1.8 Hz, 1H), 7.32-7.05 (m, 4H), 6.95 (s, 1H), 6.73-6.65 (m,2H), 6.25 (t, J=1.8 Hz, 1H), 5.23 (s, 2H), 4.16 (t, J=6.6 Hz, 2H), 3.72(s, 3H), 3.22 (t, J=6.6 Hz, 2H), 2.90 (t, J=7.8 Hz, 2H), 2.55 (t, J=7.8Hz, 2H).

EXAMPLE 3(71)3-(2-(2-(benzothiophen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=10:1);

NMR (300 Hz, DMSO-d₆): δ 7.86 (m, 1H), 7.78 (d, J=1.8 Hz, 1H), 7.73 (m,1H), 7.43 (d, J=1.8 Hz, 1H), 7.35-7.23 (m, 3H), 7.07 (d, J=7.5 Hz, 1H),6.88 (s, 1H), 6.66 (d, J=7.5 Hz, 1H), 6.24 (t, J=1.8 Hz, 1H), 5.25 (s,2H), 4.20 (t, J=6.0 Hz, 2H), 3.36 (t, J=6.0 Hz, 2H), 2.76 (t, J=7.8 Hz,2H), 2.39 (t, J=7.8 Hz, 2H).

EXAMPLE 3(72)3-(2-(2-(benzofuran-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.45 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 7.78 (d, J=1.8 Hz, 1H), 7.55-7.46 (m, 2H),7.43 (d, J=1.8 Hz, 1H), 7.26-7.14 (m, 2H), 7.05 (d, J=7.8 Hz, 1H), 6.91(s, 1H), 6.70-6.62 (m, 2H), 6.24 (t, J=1.8 Hz, 1H), 5.25 (s, 2H), 4.26(t, J=6.3 Hz, 2H), 3.25 (t, J=6.3 Hz, 2H), 2.68 (t, J=7.8 Hz, 2H), 2.35(t, J=7.8 Hz, 2H).

EXAMPLE 3(73)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-methylpyridin-5-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.39 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.24 (d, J=3.0 Hz, 1H), 7.85-7.72 (m, 4H),7.50-7.38 (m, 3H), 7.20-7.12 (m, 2H), 7.04 (d, J=8.4 Hz, 1H), 6.95-6.85(m, 2H), 4.99 (s, 2H), 4.29 (t, J=6.6 Hz, 2H), 3.28 (t, J=6.6 Hz, 2H),2.91 (t, J=8.1 Hz, 2H), 2.54 (t, J=8.1 Hz, 2H), 2.48 (s, 3H).

EXAMPLE 3(74)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-2-yloxy)phenyl)propanoicacid

TLC: Rf 0.41 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.20 (m, 1H), 7.84-7.61 (m, 5H), 7.48-7.37 (m,3H), 7.13 (d, J=8.1 Hz, 1H), 6.97 (m, 1H), 6.86 (dt, J=8.4, 1.1 Hz, 1H),6.68-6.59 (m, 2H), 4.22 (t, J=6.7 Hz, 2H), 3.26 (t, J=6.7 Hz, 2H), 2.90(t, J=7.9 Hz, 2H), 2.55 (t, J=7.9 Hz, 2H).

EXAMPLE 3(75)3-(2-(2-(naphthalen-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.30 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.07 (d, J=8.1 Hz, 1H), 7.87 (d, J=7.5 Hz, 1H),7.76 (dd, J=6.3, 3.3 Hz, 1H), 7.57-7.42 (m, 5H), 7.33 (d, J=2.4 Hz, 1H),7.08 (d, J=7.5 Hz, 1H), 6.69 (d, J=7.5 Hz, 1H), 6.66 (s, 1H), 6.24 (t,J=2.4 Hz, 1H), 5.21 (s, 2H), 4.27 (t, J=6.6 Hz, 2H), 3.56 (t, J=6.6 Hz,2H), 2.85 (t, J=7.2 Hz, 2H), 2.49 (t, J=7.2 Hz, 2H).

EXAMPLE 3(76)3-(2-(2-(chroman-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.31 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.55 (d, J=1.2 Hz, 1H), 7.39 (d, J=1.8 Hz, 1H),7.13 (d, J=8.4 Hz, 1H), 7.09-7.02 (m, 2H), 6.87-6.70 (m, 4H), 6.28 (t,J=1.8 Hz, 1H), 5.28 (s, 2H), 4.35-4.09 (m, 3H), 2.92 (t, J=7.2 Hz, 2H),2.90-2.70 (m, 2H), 2.61 (t, J=7.2 Hz, 2H), 2.20-2.00 (m, 3H), 1.88-1.75(m, 1H).

EXAMPLE 3(77) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.60 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.70 (m, 4H), 7.50-7.25 (m, 5H), 7.14-6.94(m, 4H), 6.56 (d, J=2.4 Hz, 1H), 6.47(dd, J=8.1, 2.4 Hz, 1H), 4.19 (t,J=6.5 Hz, 2H), 3.25 (t, J=6.5 Hz, 2H), 2.88 (t, J=7.8 Hz, 2H), 2.53 (t,J=7.8 Hz, 2H).

EXAMPLE 3(78)3-(2-(2-(1-methylindol-3-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.38 (chloroform:methanol=15:1);

NMR (300 MHz, CDCl₃): δ 7.61 (m, 1H), 7.53 (d, J=1.8 Hz, 1H), 7.34 (d,J=1.8 Hz, 1H), 7.33-7.19 (m, 3H), 7.16-7.08 (m, 2H), 6.96 (s, 1H),6.74-6.66 (m, 2H), 6.25 (t, J=1.8 Hz, 1H), 5.23 (s, 2H), 4.17 (t, J=6.6Hz, 2H), 3.75 (s, 3H), 3.22 (t, J=6.6 Hz, 2H), 2.91 (t, J=8.1 Hz, 2H),2.56 (t, J=8.1 Hz, 2H).

EXAMPLE 3(79)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-methylimidazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.45 (chloroform:methanol=7:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.58 (m, 5H), 7.47-7.36 (m, 3H), 7.14-7.07(m, 1H), 6.88-6.44 (m, 3H), 4.93 and 4.91 (s, 2H), 4.22-4.08 (m, 2H),3.27-3.17 (m, 2H), 2.95-2.85 (m, 2H), 2.60-2.49 (m, 2H), 2.20 and 2.08(s, 3H).

EXAMPLE 3(80)3-(2-(4-methyl-2-(naphthalen-2-yl)pentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.83-7.76 (m, 3H), 7.70 (s, 1H), 7.53 (d, J=1.8Hz, 1H), 7.47-7.37 (m, 3H), 7.34 (d, J=1.8 Hz, 1H), 7.05 (d, J=7.5 Hz,1H), 6.71-6.64 (m, 2H), 6.26 (t, J=1.8 Hz, 1H), 5.23 (s, 2H), 4.14-3.99(m, 2H), 3.33 (m, 1H), 2.89-2.66 (m, 2H), 2.35 (t, J=7.5 Hz, 2H),1.88-1.42 (m, 3H), 0.91 (d, J=6.3 Hz, 3H), 0.89 (d, J=6.3 Hz, 3H).

EXAMPLE 3(81)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-cyanopyridin-3-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.27 (dd, J=4.5, 1.2 Hz, 1H), 7.84-7.70 (m, 4H),7.50-7.27 (m, 5H), 7.13 (d, J=7.8 Hz, 1H), 6.96 (s, 1H), 6.87 (d, J=7.5Hz, 1H), 5.17 (s, 2H), 4.31 (t, J=6.3 Hz, 2H), 3.28 (t, J=6.3 Hz, 2H),2.89 (t, J=8.1 Hz, 2H), 2.52 (t, J=8.1 Hz, 2H).

EXAMPLE 3(82)3-(2-(2-methoxy-2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.31 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.90-7.80 (m, 4H), 7.55-7.45 (m, 4H), 7.33 (d,J=2.1 Hz, 1H), 7.08 (d, J=7.8 Hz, 1H), 6.71 (dd, J=7.8, 1.5 Hz, 1H),6.64 (s, 1H), 6.25 (t, J=2.1 Hz, 1H), 5.23 (s, 2H), 4.73 (dd, J=6.9, 4.8Hz, 1H), 4.22 (dd, J=9.9, 6.9 Hz, 1H), 4.07 (dd, J=9.9, 4.8 Hz, 1H),3.37 (s, 3H), 2.87 (t, J=7.5 Hz, 2H), 2.53 (dt, 7.5, 7.5 Hz, 2H).

EXAMPLE 3(83)3-(2-(4-methyl-2-phenylpentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.44 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.54 (m, 1H), 7.38-7.17 (m, 6H), 7.07 (d, J=7.5Hz, 1H), 6.69 (dd, J=7.5, 1.5 Hz, 1H), 6.65 (s, 1H), 6.26 (t, J=2.4 Hz,1H), 5.24 (s, 2H), 4.06-3.91 (m, 2H), 3.15 (m, 1H), 2.90-2.68 (m, 2H),2.40 (t, J=7.8 Hz, 2H), 1.78-1.40 (m, 3H), 0.89 (d, J=6.6 Hz, 3H), 0.87(d, J=6.6 Hz, 3H).

EXAMPLE 3(84)3-(2-(4-methyl-2-phenylpentyloxy)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.35 (hexane:ethyl acetate=2:1).

EXAMPLE 3(85)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.21 (hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 7.82-7.78 (m, 3H), 7.74 (brs, 1H), 7.48-7.39 (m,3H), 7.30-7.25 (m, 2H), 7.13 (d, J=7.8 Hz, 1H), 6.97-6.90 (m, 5H), 4.99(s, 2H), 4.29 (t, J=6.6 Hz, 2H), 3.27 (t, J=6.6 Hz, 2H), 2.93-2.88 (m,2H), 2.56-2.51 (m, 2H).

EXAMPLE 3(86)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylaminomethylphenyl)propanoicacid

TLC: Rf 0.45 (chloroform:methanol=9:1).

EXAMPLE 3(87)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-phenyl-N-methylaminomethyl)phenyl)propanoicacid

TLC: Rf 0.45 (chloroform:methanol=9:1).

EXAMPLE 3(88)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-ethyl-N-phenylaminomethyl)phenyl)propanoicacid

TLC: Rf 0.45 (chloroform:methanol=9:1).

EXAMPLE 3(89)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-(pyrazol-1-yl)propyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.76 (m, 3H), 7.75 (s, 1H), 7.51 (d, J=2.1Hz, 1H), 7.49-7.38 (m, 3H), 7.33 (d, J=2.1 Hz, 1H), 7.03 (d, J=7.5 Hz,1H), 6.69-6.61 (m, 2H), 6.23 (t, J=2.1 Hz, 1H), 4.25 (t, J=6.6 Hz, 2H),4.11 (t, J=7.2 Hz, 2H), 3.27 (t, J=6.6 Hz, 2H), 2.87 (t, J=7.2 Hz, 2H),2.58-2.47 (m, 4H), 2.22-2.10 (m, 2H).

EXAMPLE 3(90)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.72 (m, 4H), 7.49-7.38 (m, 3H), 7.24 (d,J=8.1 Hz, 1H), 7.13 (d, J=7.5 Hz, 1H), 7.03 (s, 1H), 6.95-6.89 (m, 1H),6.77 (s, 1H), 6.74-6.68 (m, 1H), 5.06 (s, 2H), 4.31 (t, J=6.6 Hz, 2H),3.28 (t, J=6.6 Hz, 2H), 2.90 (t, J=8.1 Hz, 2H), 2.53 (t, J=8.1 Hz, 2H),2.29 (s, 3H).

EXAMPLE 3(91)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.72 (m, 4H), 7.50-7.31 (m, 4H), 7.28-7.12(m, 4H), 6.92-6.86 (m, 2H), 4.99 (s, 2H), 4.29 (t, J=6.6 Hz, 2H), 3.28(t, J=6.6 Hz, 2H), 2.91 (t, J=8.1 Hz, 2H), 2.54 (t, J=8.1 Hz, 2H).

EXAMPLE 3(92)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-methoxyphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.54 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.70 (m, 4H), 7.50-7.38 (m, 3H), 7.11 (d,J=7.5 Hz, 1H), 7.00-6.80 (m, 6H), 5.09 (s, 2H), 4.28 (t, J=6.3 Hz, 2H),3.86 (s, 3H), 3.26 (t, J=6.3 Hz, 2H), 2.89 (t, J=7.8 Hz, 2H), 2.51 (t,J=7.8 Hz, 2H).

EXAMPLE 3(93)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.54 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.72 (m, 4H), 7.50-7.38 (m, 3H), 7.20-7.10(m, 3H), 6.98-6.82 (m, 4H), 5.01 (s, 2H), 4.30 (t, J=6.6 Hz, 2H), 3.28(t, J=6.6 Hz, 2H), 2.91 (t, J=7.8 Hz, 2H), 2.53 (t, J=7.8 Hz, 2H), 2.27(s, 3H).

EXAMPLE 3(94) 3-(2-(2-phenylethoxy)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.65 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.34-7.19 (m, 7H), 7.13 (m, 1H), 6.99-6.90 (m,5H), 4.99 (s, 2H), 4.20 (t, J=6.6 Hz, 2H), 3.11 (t, J=6.6 Hz, 2H),2.93-2.87 (m, 2H), 2.57-2.52 (m, 2H).

EXAMPLE 3(95)3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.58 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.54 (d, J=1.5 Hz, 1H), 7.36-7.20 (m, 6H), 7.09(d, J=7.2 Hz, 1H), 6.71 (d, J=7.5 Hz, 1H), 6.66 (s, 1H), 6.26 (t, J=1.8Hz, 1H), 5.22 (s, 2H), 4.12 (t, J=6.6 Hz, 2H), 3.07 (t, J=6.6 Hz, 2H),2.86 (t, J=7.8 Hz, 2H), 2.51 (t, J=7.8 Hz, 2H).

EXAMPLE 3(96)3-(2-(4-methyl-2-(3,5-dimethylphenyl)pentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.50 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 7.54 (d, J=2.1 Hz, 1H), 7.35 (d, J=2.1 Hz, 1H),7.08 (d, J=7.8 Hz, 1H), 6.84 (s, 3H), 6.69 (d, J=7.8 Hz, 1H), 6.65 (s,1H), 6.26 (d, J=2.1 Hz, 1H), 5.23 (s, 2H), 4.01-3.89 (m, 2H), 3.12-3.02(m, 1H), 2.90-2.72 (m, 2H), 2.45 (t, J=7.8 Hz, 2H), 2.29 (s, 6H),1.71-1.42 (m, 3H), 0.90-0.87 (m, 6H).

EXAMPLE 3(97)3-(2-(4-methyl-2-(4-fluoro-3-methylphenyl)pentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.54 (dd, J=2.1, 0.5 Hz, 1H), 7.35 (dd, J=2.1,0.5 Hz, 1H), 7.10-6.87 (m, 4H), 6.71 (dd, J=7.4, 1.4 Hz, 1H), 6.64 (d,J=1.4 Hz, 1H), 6.27 (t, J=2.1 Hz, 1H), 5.24 (s, 2H), 3.98 (dd, J=8.9,6.0 Hz, 1H), 3.89 (dd, J=8.9, 7.5 Hz, 1H), 3.09 (m, 1H), 2.89-2.68 (m,2H), 2.41 (t, J=8.0 Hz, 2H), 2.24 (d, J=1.8 Hz, 3H), 1.71-1.37 (m, 3H),0.89 (d, J=6.6 Hz, 3H), 0.88 (d, J=6.6 Hz, 3H).

EXAMPLE 3(98) 2-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)benzyl)benzoicacid

TLC: Rf 0.34 (chloroform:methanol=20:1);

NMR (300 MHz, CDCl₃): δ 8.01 (dd, J=7.8, 1.5 Hz, 1H), 7.54 (d, J=1.8 Hz,1H), 7.40-7.15 (m, 8H), 7.06 (d, J=7.8 Hz, 1H), 6.89 (d, J=7.8 Hz, 1H),6.70-6.65 (m, 2H), 6.25 (t, J=2.1 Hz, 1H), 5.21 (s, 2H), 4.35 (s, 2H),4.08 (t, J=6.9 Hz, 2H), 2.97 (t, J=6.9 Hz, 2H).

EXAMPLE 3(99)2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)benzoicacid

TLC: Rf 0.34 (chloroform:methanol=20:1);

NMR (300 MHz, CDCl₃): δ 7.98 (dd, J=7.8, 1.5 Hz, 1H), 7.80-7.67 (m, 3H),7.60 (s, 1H), 7.53 (d, J=1.8 Hz, 1H), 7.43-7.38 (m, 2H), 7.32-7.18 (m,4H), 6.99 (d, J=7.8 Hz, 1H), 6.87 (d, J=7.8 Hz, 1H), 6.67-6.60 (m, 2H),6.23 (s, 1H), 5.18 (s, 2H), 4.35 (s, 2H), 4.14 (t, J=6.3 Hz, 2H), 3.11(t, J=6.3 Hz, 2H).

EXAMPLE 3(100)2-(2-(4-methyl-2-phenylpentyloxy)-4-(pyrazol-1-ylmethyl)benzyl)benzoicacid

TLC: Rf 0.58 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.04 (d, J=7.5 Hz, 1H), 7.54 (d, J=2.1 Hz,1H), 7.40-7.10 (m, 8H), 6.97 (d, J=7.8 Hz, 1H), 6.90 (d, J=7.2 Hz, 1H),6.70-6.60 (m, 2H), 6.25 (t, J=2.1 Hz, 1H), 5.19 (s, 2H), 4.36 (d, J=16.5Hz, 1H), 4.27 (d, J=16.5 Hz, 1H), 3.94 (d, J=6.3 Hz, 2H), 3.02 (m, 1H),1.62-1.20 (m, 3H), 0.79 (d, J=6.3 Hz, 6H).

EXAMPLE 3(101)2-(2-(4-methyl-2-(3,5-dimethylphenyl)pentyloxy)-4-(pyrazol-1-ylmethyl)benzyl)benzoicacid

TLC: Rf 0.60 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.03 (dd, J=7.5, 1.2 Hz, 1H), 7.54 (d, J=1.8Hz, 1H), 7.40-7.23 (m, 3H), 6.99 (d, J=6.9 Hz, 1H), 6.89 (d, J=8.1 Hz,1H), 6.84-6.76 (m, 3H), 6.68-6.60 (m, 2H), 6.24 (t, J=1.8 Hz, 1H), 5.17(s, 2H), 4.39 (d, J=16.2 Hz, 1H), 4.31 (d, J=16.2 Hz, 1H), 3.90 (d,J=6.3 Hz, 2H), 2.96 (m, 1H), 2.24 (s, 6H), 1.60-1.26 (m, 3H), 0.79 (d,J=6.3 Hz, 6H).

EXAMPLE 3(102)3-(2-(4-methyl-2-(4-methoxy-1,3-dioxaindan-6-yl)pentyloxy)-4-(pyrazol1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.65 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 7.54 (d, J=2.1 Hz, 1H), 7.36 (d, J=2.1 Hz, 1H),7.08 (d, J=7.2 Hz, 1H), 6.70 (d, J=7.2 Hz, 1H), 6.65 (s, 1H), 6.44 (d,J=1.5 Hz, 1H), 6.40 (d, J=1.5 Hz, 1H), 6.27 (t, J=2.1 Hz, 1H), 5.93-5.91(m, 2H), 5.24 (s, 2H), 4.00-3.85 (m, 2H), 3.89 (s, 3H), 3.10-3.00 (m,1H), 2.91-2.71 (m, 2H), 2.43 (t, J=7.5 Hz, 2H), 1.66-1.43 (m, 3H),0.90-0.87 (m, 6H).

EXAMPLE 3(103)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenylaminomethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.75 (m, 3H), 7.73 (s, 1H), 7.49-7.38 (m,3H), 7.22 (t, J=7.8 Hz, 1H), 7.11 (d, J=7.8 Hz, 1H), 6.96 (d, J=7.8 Hz,1H), 6.86-6.74 (m, 4H), 4.30-4.20 (m, 4H), 3.27 (t, J=6.3 Hz, 2H), 2.90(t, J=7.8 Hz, 2H), 2.54 (t, J=7.8 Hz, 2H).

EXAMPLE 3(104)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-methylphenylaminomethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.76 (m, 3H), 7.73 (s, 1H), 7.50-7.38 (m,3H), 7.14-7.04 (m, 3H), 6.92-6.84 (m, 2H), 6.67 (t, J=7.8 Hz, 1H), 6.60(d, J=7.8 Hz, 1H), 4.32-4.22 (m, 4H), 3.26 (t, J=6.3 Hz, 2H), 2.90 (t,J=8.1 Hz, 2H), 2.53 (t, J=8.1 Hz, 2H), 2.15 (s, 3H).

EXAMPLE 3(105)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-3-ylaminomethyl)phenyl)propanoicacid

TLC: Rf 0.41 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.05 (d, J=2.7 Hz, 1H), 7.94 (dd, J=4.5, 1.5 Hz,1H), 7.84-7.74 (m, 3H), 7.72 (brs, 1H), 7.48-7.36 (m, 3H), 7.14-7.04 (m,2H), 6.92-6.78 (m, 3H), 4.28-4.18 (m, 4H), 3.25 (t, J=6.6 Hz, 2H), 2.91(t, J=7.5 Hz, 2H), 2.55 (t, J=7.5 Hz, 2H).

EXAMPLE 3(106)3-(2-(2-(benzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol=9:1);

NMR (300 MHz, CD₃OD): δ 7.85-7.77 (m, 2H), 7.65 (d, J=2.1 Hz, 1H),7.55-7.40 (m, 4H), 7.10 (d, J=7.8 Hz, 1H), 6.82 (s, 1H), 6.70 (d, J=7.5Hz, 1H), 6.30 (dd, J=2.1, 2.1 Hz, 1H), 5.28 (s, 2H), 4.15 (t, J=5.7 Hz,2H), 3.78 (t, J=5.7 Hz, 2H), 2.89 (t, J=7.5 Hz, 2H), 2.52 (t, J=7.5 Hz,2H).

EXAMPLE 3(107)3-(2-(2-(phenylsulfonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol=9:1);

NMR (300 MHz, CD₃OD): δ 7.89-7.84 (m, 2H), 7.64 (d, J=2.1 Hz, 1H),7.58-7.46 (m, 4H), 7.08 (d, J=7.8 Hz, 1H), 6.70 (d, J=7.8 Hz, 1H), 6.66(s, 1H), 6.31 (t, J=2.1 Hz, 1H), 5.26 (s, 2H), 3.93 (t, J=5.7 Hz, 2H),3.28 (m, 2H), 2.83 (t, J=7.5 Hz, 2H), 2.49 (t, J=7.5 Hz, 2H).

EXAMPLE 3(108)3-(2-(2-(N-methyl-N-phenylsulfonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.67 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.80 (d, J=8.1 Hz, 2H), 7.64-7.49 (m, 4H), 7.40(d, J=2.1 Hz, 1H), 7.13 (d, J=7.8 Hz, 1H), 6.76 (d, J=7.8 Hz, 1H), 6.65(d, J=2.1 Hz, 1H), 6.29 (t, J=2.1 Hz, 1H), 5.27 (s, 2H), 4.10 (t, J=5.4Hz, 2H), 3.44 (t, J=5.4 Hz, 2H), 2.90 (t, J=7.5 Hz, 2H), 2.90 (s, 3H),2.61 (t, J=7.5 Hz, 2H).

EXAMPLE 3(109)3-(2-(2-methoxy-3-phenoxypropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.35 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 7.54 (d, J=2.1 Hz, 1H), 7.37 (d, J=2.1 Hz, 1H),7.31-7.28 (m, 2H), 7.12 (d, J=7.2 Hz, 1H), 6.98-6.91 (m, 3H), 6.76-6.71(m, 2H), 6.28 (t, J=2.1 Hz, 1H), 5.26 (s, 2H), 4.20-4.07 (m, 4H),3.97-3.90 (m, 1H), 3.56 (s, 3H), 2.93 (t, J=7.5 Hz, 2H), 2.64-2.58 (m,2H).

EXAMPLE 3(110) 3-(2-(2-ethoxy-3-phenoxypropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.45 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 7.54 (d, J=1.8 Hz, 1H), 7.36 (d, J=1.8 Hz, 1H),7.31-7.27 (m, 2H), 7.12 (d, J=7.5 Hz, 1H), 6.98-6.91 (m, 3H), 6.75-6.71(m, 2H), 6.27 (t, J=1.8 Hz, 1H), 5.26 (s, 2H), 4.16-3.99 (m, 5H), 3.75(q, J=6.9 Hz, 2H), 2.96-2.90 (m, 2H), 2.65-2.59 (m, 2H), 1.24 (t, J=6.9Hz, 3H).

EXAMPLE 3(111)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)-5-chlorophenyl)propanoicacid

TLC: Rf 0.24 (hexane:ethyl acetate=2:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 7.82-7.74 (m, 3H), 7.68 (s, 1H), 7.56 (d, J=2.1Hz, 1H), 7.47-7.38 (m, 3H), 7.36 (dd, J=8.1, 1.8 Hz, 1H), 7.13 (s, 1H),6.51 (s, 1H), 6.28 (t, J=2.1 Hz, 1H), 5.36 (s, 2H), 4.12 (t, J=6.6 Hz,2H), 3.18 (t, J=6.6 Hz, 2H), 2.81 (t, J=7.8 Hz, 2H), 2.47 (t, J=7.8 Hz,2H).

EXAMPLE 3(112)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)-5-methoxyphenyl)propanoicacid

TLC: Rf 0.30 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 7.82-7.74 (m, 3H), 7.69 (bs, 1H), 7.52 (d, J=2.1Hz, 1H), 7.47-7.35 (m, 4H), 6.70 (s, 1H), 6.59 (s, 1H), 6.22 (t, J=2.1Hz, 1H), 5.27 (s, 2H), 4.14 (t, J=6.6 Hz, 2H), 3.76 (s, 3H), 3.18 (t,J=6.6 Hz, 2H), 2.84 (t, J=7.5 Hz, 2H), 2.49 (t, J=7.5 Hz, 2H).

EXAMPLE 3(113)3-(2-(2-(benzimidazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=5:1);

NMR (300 MHz, DMSO-d₆): δ 8.24 (s, 1H), 7.74 (m, 1H), 7.68 (d, J=7.8 Hz,1H), 7.63 (d, J=7.8 Hz, 1H), 7.42 (m, 1H), 7.25 (dd, J=7.8, 7.2 Hz, 1H),7.18 (dd, J=7.8, 7.2 Hz, 1H), 7.02 (d, J=7.8 Hz, 1H), 6.80 (s, 1H), 6.63(d, J=7.8 Hz, 1H), 6.22 (m, 1H), 5.20 (s, 2H), 4.69 (t, J=5.1 Hz, 2H),4.23 (t, J=5.1 Hz, 2H), 2.60 (t, J=7.5 Hz, 2H), 2.26 (t, J=7.5 Hz, 2H).

EXAMPLE 3(114)3-(2-(4-methyl-2-(4-fluoro-3-methylphenyl)pentyloxy)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.57 (chloroform:methanol=10:1).

EXAMPLE 3(115)3-(2-(4-methyl-2-(4-fluoro-3-methylphenyl)pentyloxy)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.57 (chloroform:methanol=10:1).

EXAMPLE 3(116)3-(2-(2-(2-methylbenzimidazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.41 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 7.73 (dd, J=2.2, 0.6 Hz, 1H), 7.59 (m, 1H),7.50 (m, 1H), 7.41 (dd, J=2.2, 0.6 Hz, 1H), 7.22-7.10 (m, 2H), 7.01 (d,J=7.7 Hz, 1H), 6.83 (d, J=1.6 Hz, 1H), 6.63 (dd, J=7.7, 1.6 Hz, 1H),6.22 (t, J=2.2 Hz, 1H), 5.20 (s, 2H), 4.65 (t, J=5.0 Hz, 2H), 4.25 (t,J=5.0 Hz, 2H), 2.60 (s, 3H), 2.57 (t, J=7.7 Hz, 2H), 2.24 (t, J=7.7 Hz,2H).

EXAMPLE 3(117)3-(2-(2-(1H-indazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.58 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 8.02 (d, J=0.9 Hz, 1H), 7.71 (d, J=7.8 Hz, 1H),7.55-7.46 (m, 2H), 7.41-7.31 (m, 2H), 7.12 (m, 1H), 7.04 (d, J=7.5 Hz,1H), 6.70 (d, J=7.5 Hz, 1H), 6.60 (s, 1H), 6.26 (t, J=2.0 Hz, 1H), 5.22(s, 2H), 4.78 (t, J=5.2 Hz, 2H), 4.35 (t, J=5.2 Hz, 2H), 2.67 (t, J=7.7Hz, 2H), 2.28 (t, J=7.7 Hz, 2H).

EXAMPLE 3(118)3-(2-(2-(2H-benzotriazol-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1).

EXAMPLE 3(119)3-(2-(2-(1H-benzotriazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.35 (chloroform:methanol=10:1).

EXAMPLE 3(120)3-(2-(2-((3-methylbenzoyl)amino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.55 (ethyl acetate:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.03 (s, 1H), 8.60-8.56 (m, 1H), 7.78 (d,J=2.1 Hz, 1H), 7.65-7.60 (m, 2H), 7.43-7.42 (m, 1H), 7.33-7.31 (m, 2H),7.07 (d, J=7.8 Hz, 1H), 6.88 (s, 1H), 6.67 (d, J=7.8 Hz, 1H), 6.24-6.23(m, 1H), 5.24 (s, 2H), 4.06 (t, J=5.7 Hz, 2H), 3.65-3.59 (m, 2H), 2.74(t, J=7.5 Hz, 2H), 2.43 (t, J=7.5 Hz, 2H), 2.33 (s, 3H).

EXAMPLE 3(121)3-(2-(2-((3-methoxybenzoyl)amino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.50 (ethyl acetate:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.01 (s, 1H), 8.65-8.61 (m, 1H), 7.78 (d,J=2.1 Hz, 1H), 7.43-7.32 (m, 4H), 7.08-7.05 (m, 2H), 6.88 (s, 1H), 6.67(d, J=7.5 Hz, 1H), 6.24 (t, J=2.1 Hz, 1H), 5.24 (s, 2H), 4.06 (t, J=5.7Hz, 2H), 3.78 (s, 3H), 3.65-3.60 (m, 2H), 2.74 (t, J=7.5 Hz, 2H), 2.42(t, J=7.5 Hz, 2H).

EXAMPLE 3(122)3-(2-(2-((naphthalen-2-ylcarbonyl)amino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.30 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.32 (s, 1H), 7.92-7.82 (m, 4H), 7.58-7.48 (m,3H), 7.36 (d, J=2.1 Hz, 1H), 7.11 (d, J=7.8 Hz, 2H), 6.73 (d, J=7.8 Hz,1H), 6.65 (s, 1H), 6.26 (dd, J=2.1, 2.1 Hz, 1H), 5.24 (s, 2H), 4.10 (t,J=5.1 Hz, 2H), 3.90 (dt, J=5.1, 5.1 Hz, 2H), 2.96 (t, J=7.2 Hz, 2H),2.63 (t, J=7.2 Hz, 2H).

EXAMPLE 3(123)3-(2-(2-((4-methoxybenzoyl)amino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.19 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.77 (d, J=8.7 Hz, 2H), 7.53 (d, J=1.8 Hz, 1H),7.37 (d, J=2.1 Hz, 1H), 7.09 (d, J=7.8 Hz, 1H), 6.96 (m, 1H), 6.88 (d,J=9.0 Hz, 1H), 6.72 (d, J=7.8 Hz, 1H), 6.63 (s, 1H), 6.27 (dd, J=2.1,1.8 Hz, 1H), 5.24 (s, 2H), 4.02 (t, J=4.8 Hz, 2H), 3.81 (s, 3H), 3.80(m, 2H), 2.93 (t, J=7.5 Hz, 2H), 2.60 (t, J=7.5 Hz, 2H).

EXAMPLE 3(124)3-(2-(2-((4-chlorobenzoyl)amino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.20 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.76 (d, J=8.4 Hz, 2H), 7.53 (d, J=2.1 Hz, 1H),7.38-7.32 (m, 3H), 7.16 (m, 1H), 7.10 (d, J=7.8 Hz, 1H), 6.73 (d, J=7.8Hz, 1H), 6.63 (s, 1H), 6.27 (dd, J=2.1, 2.1 Hz, 1H), 5.23 (s, 2H), 4.03(t, J=5.4 Hz, 2H), 3.79 (dt, J=5.4, 5.4 Hz, 2H), 2.94 (t, J=7.2 Hz, 2H),2.60 (t, J=7.2 Hz, 2H).

EXAMPLE 3(125)3-(2-(4-methyl-2-benzoylaminopentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.58 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.80-7.74 (m, 2H), 7.53 (d, J=2.1 Hz, 1H),7.51-7.35 (m, 4H), 7.10 (d, J=7.7 Hz, 1H), 6.73 (d, J=7.7 Hz, 1H), 6.64(s, 1H), 6.48 (d, J=8.7 Hz, 1H), 6.27 (t, J=2.1 Hz, 1H), 5.24 (s, 2H),4.65 (m, 1H), 4.05 (dd, J=9.3, 3.9 Hz, 1H), 3.92 (dd, J=9.3, 1.8 Hz,1H), 2.90 (t, J=7.8 Hz, 2H), 2.69-2.46 (m, 2H), 1.81-1.48 (m, 3H), 0.97(d, J=6.3 Hz, 6H).

EXAMPLE 3(126)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-acetylpiperazin-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.29 (chloroform:methanol=10:1).

EXAMPLE 3(127)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(morpholin-4-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.33 (chloroform:methanol=10:1).

EXAMPLE 3(128)3-(2-(2-(4-methylbenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.20 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.70 (d, J=8.4 Hz, 2H), 7.53 (d, J=2.1 Hz, 1H),7.37 (d, J=2.1 Hz, 1H), 7.19 (d, J=8.1 Hz, 2H), 7.10 (d, J=7.8 Hz, 1H),6.98 (brs, 1H), 6.72 (d, J=7.5 Hz, 1H), 6.63 (s, 1H), 6.27 (t, J=2.1 Hz,1H), 5.24 (s, 2H), 4.03 (t, J=4.8 Hz, 2H), 3.81 (dt, J=5.1, 4.8 Hz, 2H),2.93 (t, J=7.5 Hz, 2H), 2.60 (t, J=7.5 Hz, 2H), 2.36 (s, 3H).

EXAMPLE 3(129)3-(2-(2-(naphthalen-1-ylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.28 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 8.74 (m, 1H), 8.20 (m, 1H), 8.02-7.94 (m, 2H),7.80 (d, J=2.4 Hz, 1H), 7.60-7.50 (m, 4H), 7.43 (d, J=1.8 Hz, 1H), 7.09(d, J=7.5 Hz, 1H), 6.92 (s, 1H), 6.68 (d, J=7.5 Hz, 1H), 6.24 (dd,J=2.4, 1.8 Hz, 1H), 5.26 (s, 2H), 4.13 (t, J=5.7 Hz, 2H), 3.71 (dt,J=5.1, 5.7 Hz, 2H), 2.80 (t, J=7.2 Hz, 2H), 2.45 (m, 2H).

EXAMPLE 3(130)3-(2-(2-(2-benzylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.54 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 8.22 (m, 1H), 7.78 (d, J=2.4 Hz, 1H), 7.43 (d,J=2.1 Hz, 1H), 7.30-7.15 (m, 5H), 7.07 (d, J=8.1 Hz, 1H), 6.83 (s, 1H),6.67 (d, J=8.1 Hz, 1H), 6.24 (dd, J=2.4, 1.8 Hz, 1H), 5.24 (s, 2H), 3.94(t, J=5.4 Hz, 2H), 3.46-3.38 (m, 4H), 2.74 (t, J=7.5 Hz, 2H), 2.45 (t,J=7.5 Hz, 2H).

EXAMPLE 3(131)3-(2-(2-(2-methylbenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.38 (chloroform:methanol=10:1).

EXAMPLE 3(132)3-(2-(2-(2-chlorobenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=10:1).

EXAMPLE 3(133)3-(2-(2-(2-methoxybenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1).

EXAMPLE 3(134)3-(2-phenylcarbamoylmethoxy-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.79(s, 1H), 7.66 (d, J=7.8 Hz, 2H), 7.52 (d,J=2.1 Hz, 1H), 7.38 (d, J=2.1 Hz, 1H), 7.36-7.30 (m, 2H), 7.20-7.10 (m,2H), 6.78 (d, J=7.8 Hz, 1H), 6.61 (s, 1H), 6.27 (t, J=2.1 Hz, 1H), 5.26(s, 2H), 4.45 (s, 2H), 3.06 (t, J=7.2 Hz, 2H), 2.72 (t, J=7.2 Hz, 2H).

EXAMPLE 3(135) 3-(2-(naphthalen-1-ylcarbamoylmethoxy)-4-(pyrazol1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 10.04 (s, 1H), 8.04-7.92 (m, 2H), 7.84-7.76(m, 2H), 7.65 (d, J=7.2 Hz, 1H), 7.58-7.50 (m, 3H), 7.43 (d, J=2.1 Hz,1H), 7.15 (d, J=7.8 Hz, 1H), 6.94 (s, 1H), 6.75 (d, J=7.8 Hz, 1H), 6.22(t, J=2.1 Hz, 1H), 5.28 (s, 2H), 4.85 (s, 2H), 2.90 (t, J=7.8 Hz, 2H),2.55 (t, J=7.8 Hz, 2H).

EXAMPLE 3(136)3-(2-(naphthalen-2-ylcarbamoylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.59 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 10.21 (s, 1H), 8.29 (s, 1H), 7.90-7.80 (m,3H), 7.74 (d, J=1.8 Hz, 1H), 7.61 (dd, J=8.7, 1.8 Hz, 1H), 7.50-7.38 (m,2H), 7.36 (d, J=1.8 Hz, 1H), 7.14 (d, J=7.8 Hz, 1H), 6.85 (s, 1H), 6.72(d, J=7.8 Hz, 1H), 6.16 (dd, J=1.8, 1.8 Hz, 1H), 5.25 (s, 2H), 4.75 (s,2H), 2.86 (t, J=7.2 Hz, 2H), 2.55 (t, J=7.2 Hz, 2H).

EXAMPLE 3(137) 3-(2-(3-phenylpropoxy)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.48 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.35-7.14 (m, 8H), 7.00-6.80 (m, 5H), 4.99 (s,2H), 4.00 (t, J=6.3 Hz, 2H), 3.00-2.95 (m, 2H), 2.82 (dd, J=7.8, 7.5 Hz,2H), 2.72-2.67 (m, 2H), 2.17-2.08 (m, 2H).

EXAMPLE 3(138) 3-(2-(4-phenylbutoxy)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.52 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.34-7.13 (m, 8H), 7.00-6.90 (m, 5H), 5.00 (s,2H), 4.01-3.98 (m, 2H), 2.98-2.92 (m, 2H), 2.70-2.64 (m, 4H), 1.85-1.82(m, 4H).

EXAMPLE 3(139)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-methylpiperazin-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.25 (chloroform:methanol=5:1).

EXAMPLE 3(140)2-((2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)amino)aceticacid hydrochloride

TLC: Rf 0.25 (ethyl acetate:methanol=1:1).

EXAMPLE 3(141)2-(N-methyl-N-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)amino)aceticacid hydrochloride

TLC: Rf 0.30 (ethyl acetate:methanol=1:1).

EXAMPLE 3(142)2-(N-mesyl-N-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)amino)aceticacid

TLC: Rf 0.45 (ethyl acetate:methanol=3:1).

EXAMPLE 3(143)2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzoic acid

TLC: Rf 0.63 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.10 (d, J=7.8 Hz, 1H), 7.88-7.77 (m, 3H), 7.71(s, 1H), 7.59 (d, J=1.5 Hz, 1H), 7.53-7.40 (m, 3H), 7.35 (dd, J=8.4, 1.5Hz, 1H), 6.91 (d, J=8.4 Hz, 1H), 6.79 (s, 1H), 6.33 (t, J=2.1 Hz, 1H),5.34 (s, 2H), 4.45 (t, J=6.6 Hz, 2H), 3.32 (t, J=6.6 Hz, 2H).

EXAMPLE 3(144)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-2-ylaminomethyl)phenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 7.92 (dd, J=4.8, 1.5 Hz, 1H),7.89-7.79 (m, 4H), 7.51-7.41 (m, 3H), 7.33 (m, 1H), 7.01 (d, J=7.5 Hz,1H), 6.97-6.89 (m, 2H), 6.78 (m, 1H), 6.50-6.42 (m, 2H), 4.38 (d, J=6.0Hz, 2H), 4.22 (t, J=6.6 Hz, 2H), 3.19 (t, J=6.6 Hz, 2H), 2.70 (t, J=7.5Hz, 2H), 2.35 (t, J=7.5 Hz, 2H).

EXAMPLE 3(145)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(thiazol-2-ylaminomethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 7.94 (t, J=5.7 Hz, 1H),7.90-7.80 (m, 4H), 7.53-7.41 (m, 3H), 7.04 (d, J=7.5 Hz, 1H), 6.98 (d,J=3.6 Hz, 1H), 6.96 (d, J=1.5 Hz, 1H), 6.79 (m, 1H), 6.58 (d, J=3.6 Hz,1H), 4.35 (d, J=5.7 Hz, 2H), 4.23 (t, J=6.6 Hz, 2H), 3.20 (t, J=6.6 Hz,2H), 2.70 (t, J=7.5 Hz, 2H), 2.36 (t, J=7.5 Hz, 2H).

EXAMPLE 3(146)3-(2-(2-cyclohexyloxyethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.34 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.54 (d, J=1.5 Hz, 1H), 7.36 (d, J=1.5 Hz, 1H),7.12 (d, J=7.8 Hz, 1H), 6.73 (d, J=7.8 Hz, 1H), 6.67 (s, 1H), 6.23 (dd,J=1.5, 1.5 Hz, 1H), 5.26 (s, 2H), 4.05 (t, J=4.8 Hz, 2H), 3.80 (t, J=4.8Hz, 2H), 3.34 (m, 1H), 2.93 (t, J=7.5 Hz, 2H), 2.65 (t, J=7.5 Hz, 2H),1.94 (m, 2H), 1.73 (m, 2H), 1.52 (m, 1H), 1.36-1.16 (m, 5H).

EXAMPLE 3(147)3-(2-(benzylcarbamoylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.55 (d, J=2.1 Hz, 1H), 7.38 (d, J=2.4 Hz, 1H),7.34-7.20 (m, 6H), 7.13 (d, J=7.8 Hz, 1H), 6.78 (d, J=7.8 Hz, 1H), 6.59(s, 1H), 6.29 (dd, J=2.4, 2.1 Hz, 1H), 5.25 (s, 2H), 4.52-4.47 (m, 4H),2.94 (t, J=7.2 Hz, 2H), 2.58 (t, J=7.2 Hz, 2H).

EXAMPLE 3(148)3-(2-((1-phenylethyl)carbamoylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.53 (d, J=1.8 Hz, 1H), 7.35 (d, J=2.1 Hz, 1H),7.32-7.20 (m, 5H), 7.14 (d, J=7.5 Hz, 1H), 7.09 (d, J=8.1 Hz, 1H), 6.77(d, J=7.5 Hz, 1H), 6.55 (s, 1H), 6.27 (dd, J=2.1, 1.8 Hz, 1H), 5.22 (s,2H), 5.20 (m, 1H), 4.43 (d, J=15.0 Hz, 1H), 4.37 (d, J=15.0 Hz, 1H),2.96 (t, J=7.5 Hz, 2H), 2.61 (t, J=7.5 Hz, 2H), 1.49 (d, J=6.9 Hz, 3H).

EXAMPLE 3(149)3-(2-(2-(3-chlorobenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.35 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 11.99 (s, 1H), 8.78 (t, J=5.1 Hz, 1H),7.87-7.78 (m, 3H), 7.60-7.43 (m, 3H), 7.06 (d, J=7.5 Hz, 1H), 6.88 (s,1H), 6.67 (d, J=7.5 Hz, 1H), 6.24 (t, J=2.1 Hz, 1H), 5.24 (s, 2H), 4.07(t, J=5.7 Hz, 2H), 3.66-3.61 (m, 2H), 2.73 (t, J=7.5 Hz, 2H), 2.41 (t,J=7.5 Hz, 2H).

EXAMPLE 3(150)2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyloxy)aceticacid

TLC: Rf 0.25 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 7.83 (m, 3H), 7.68 (s, 1H), 7.56-7.23 (m, 6H),6.80-6.74 (m, 2H), 6.29-6.27 (m, 1H), 5.29 (s, 2H), 4.52 (s, 2H), 4.26(t, J=6.9 Hz, 2H), 4.01 (s, 2H), 3.23 (t, J=6.9 Hz, 2H).

EXAMPLE 3(151)3-(2-(2-(1-oxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.04 (d, J=7.2 Hz, 1H), 7.54 (s, 1H), 7.48-7.04(m, 5H), 6.74 (d, J=7.2 Hz, 1H), 6.65 (s, 1H), 6.27 (m, 1H), 5.25 (s,2H), 4.20-4.08 (m, 2H), 4.05-3.94 (m, 2H), 3.18 (t, J=6.6 Hz, 2H), 3.00(t, J=6.6 Hz, 2H), 2.93-2.80 (m, 2H), 2.66-2.53 (m, 2H).

EXAMPLE 3(152)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-(pyrazol-1-yl)ethyl)phenyl)propanoicacid

TLC: Rf 0.45 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.76 (m, 3H), 7.73 (s, 1H), 7.56-7.37 (m,4H), 7.13 (d, J=1.9 Hz, 1H), 7.02 (d, J=7.5 Hz, 1H), 6.59 (dd, J=7.5,1.5 Hz, 1H), 6.43 (d, J=1.5 Hz, 1H), 6.15 (t, J=1.9 Hz, 1H), 4.29 (t,J=7.4 Hz, 2H), 4.16 (t, J=6.7 Hz, 2H), 3.23 (t, J=6.7 Hz, 2H), 3.08 (t,J=7.4 Hz, 2H), 2.86 (t, J=7.8 Hz, 2H), 2.51 (t, J=7.8 Hz, 2H).

EXAMPLE 3(153)3-(2-(2-(thiophen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol=9:1).

EXAMPLE 3(154)3-(2-(2-(thiophen-3-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol=9:1).

EXAMPLE 3(155)3-(2-(3-cyclohexylpropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.03 (s, 1H), 7.78 (d, J=2.1 Hz, 1H), 7.43(m, 1H), 7.06 (d, J=7.8 Hz, 1H), 6.81 (s, 1H), 6.64 (d, J=7.8 Hz, 1H),6.24 (t, J=2.1 Hz, 1H), 5.24 (s, 2H), 3.88 (t, J=6.3 Hz, 2H), 2.72 (t,J=7.5 Hz, 2H), 2.42 (t, J=7.5 Hz, 2H), 1.70-1.62 (m, 7H), 1.34-1.14 (m,6H), 0.92-0.84 (m, 2H).

EXAMPLE 3(156)3-(2-(2-phenoxyethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.01 (s, 1H), 7.79 (d, J=2.1 Hz, 1H), 7.44(s, 1H), 7.31-7.26 (m, 2H), 7.08 (d, J=7.5 Hz, 1H), 6.98-6.93 (m, 4H),6.68 (d, J=7.5 Hz, 1H), 6.25-6.24 (m, 1H), 5.26 (s, 2H), 4.32-4.26 (m,4H), 2.72 (t, J=7.5 Hz, 2H), 2.45-2.43 (m, 2H).

EXAMPLE 3(157)3-(2-(2-(N-methyl-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.30 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 7.53 (d, J=2.1 Hz, 1H), 7.34 (d, J=2.1 Hz, 1H),7.27-7.19 (m, 2H), 7.11 (d, J=7.8 Hz, 1H), 6.78-6.63 (m, 5H), 6.26 (t,J=2.1 Hz, 1H), 5.23 (s, 2H), 4.09 (t, J=5.4 Hz, 2H), 3.76 (t, J=5.4 Hz,2H), 3.03 (s, 3H), 2.88 (t, J=7.5 Hz, 2H), 2.58 (t, J=7.5 Hz, 2H).

EXAMPLE 3(158)3-(2-(2-phenylethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid

TLC: Rf 0.40 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.39-7.15 (m, 1H), 6.90-6.87 (m, 2H), 5.00 (s,2H), 4.20 (t, J=6.6 Hz, 2H), 3.12 (t, J=6.6 Hz, 2H), 2.93-2.88 (m, 2H),2.58-2.53 (m, 2H).

EXAMPLE 3(159)3-(2-(2-phenylethoxy)-4-(2-chloro-4-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.54 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.34-7.19 (m, 6H), 7.13 (d, J=7.8 Hz, 1H), 7.00(brs, 1H), 6.92 (brd, J=7.8 Hz, 1H), 6.78 (brs, 1H), 6.71 (brd, J=7.8Hz, 1H), 5.06 (s, 2H), 4.22 (t, J=6.6 Hz, 2H), 3.11 (t, J=6.6 Hz, 2H),2.92-2.87 (m, 2H), 2.57-2.52 (m, 2H), 2.29 (s, 3H).

EXAMPLE 3(160)3-(2-(3-phenylpropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.52 (chloroform:methanol=10:1).

EXAMPLE 3(161)3-(2-(4-phenylbutoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.52 (chloroform:methanol=10:1).

EXAMPLE 3(162)(2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoicacid hydrochloride

TLC: Rf 0.46 (chloroform:methanol=8:1);

NMR (300 MHz, CD₃OD): δ 9.01 (s, 1H), 7.94 (d, J=16.2 Hz, 1H), 7.63 (d,J=8.1 Hz, 1H), 7.60-7.55 (m, 2H), 7.03 (s, 1H), 6.94 (d, J=8.1 Hz, 1H),6.51 (d, J=16.2 Hz, 1H), 5.45-5.30 (m, 2H), 4.42-4.20 (m, 2H), 2.70-2.60(m, 2H), 2.26-1.80 (m, 4H), 2.11 (s, 3H), 2.08 (s, 3H), 2.04 (s, 3H),1.35 (s, 3H).

EXAMPLE 3(163)3-(2-(3,3-diphenylpropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.42 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.51 (d, J=2.1 Hz, 1H), 7.32 (d, J=2.1 Hz, 1H),7.30-7.15 (m, 10H), 7.11 (d, J=7.8 Hz, 1H), 6.68 (d, J=7.8 Hz, 1H), 6.54(s, 1H), 6.24 (t, J=2.1 Hz, 1H), 5.20 (s, 2H), 4.24 (t, J=7.8 Hz, 1H),3.87 (t, J=6.3 Hz, 2H), 2.94 (t, J=7.8 Hz, 2H), 2.67 (t, J=7.8 Hz, 2H),2.52 (dt, J=7.8, 6.3 Hz, 2H).

EXAMPLE 3(164)3-(2-(2-(N,N-diphenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

[Salt-Free]

TLC: Rf 0.44 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.52 (d, J=2.1 Hz, 1H), 7.33 (d, J=2.1 Hz, 1H),7.30-7.20 (m, 4H), 7.12-7.02 (m, 5H), 6.98-6.92 (m, 2H), 6.71 (d, J=7.8Hz, 1H), 6.63 (s, 1H), 6.25 (t, J=2.1 Hz, 1H), 5.21 (s, 2H), 4.20-4.10(m, 4H), 2.85 (t, J=7.8 Hz, 2H), 2.54 (t, J=7.8 Hz, 2H).

Sodium Salt:

TLC: Rf 0.50 (chloroform:methanol=10:1).

EXAMPLE 3(165)3-(2-(2-(4-phenylpiperazin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=5:1).

EXAMPLE 3(166)3-(2-(2-(4-phenyl-1,2,3,6-tetrahydropyridin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=5:1).

EXAMPLE 3(167)3-(2-(2-(4-phenylpiperidin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=5:1).

EXAMPLE 3(168)3-(2-(2-(phenoxazin-10-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

[Salt-Free]

TLC: Rf 0.23 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.53 (d, J=2.1 Hz, 1H), 7.35 (d, J=2.1 Hz, 1H),7.12 (d, J=7.5 Hz, 1H), 6.83-6.60 (m, 10H), 6.26 (t, J=2.1 Hz, 1H), 5.24(s, 2H), 4.17 (t, J=5.7 Hz, 2H), 3.98 (t, J=5.7 Hz, 2H), 2.86 (t, J=7.8Hz, 2H), 2.55 (t, J=7.8 Hz, 2H).

Sodium Salt:

TLC: Rf 0.47 (chloroform:methanol=10:1).

EXAMPLE 3(169)4-(2-(2-phenylethoxy)-4-(3-cyanophenoxymethyl)phenyl)butanoic acid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.43-7.08 (m, 10H), 6.94-6.84 (m, 2H), 5.00 (s,2H), 4.18 (t, J=6.8 Hz, 2H), 3.11 (t, J=6.8 Hz, 2H), 2.63 (t, J=7.4 Hz,2H), 2.31 (t, J=7.4 Hz, 2H), 1.94-1.77 (m, 2H).

EXAMPLE 3(170)4-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.63 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.75 (m, 3H), 7.73 (s, 1H), 7.49-7.31 (m,4H), 7.28-7.14 (m, 3H), 7.09 (d, J=8.1 Hz, 1H), 6.92-6.84 (m, 2H), 4.99(s, 2H), 4.27 (t, J=6.6 Hz, 2H), 3.27 (t, J=6.6 Hz, 2H), 2.62 (t, J=7.7Hz, 2H), 2.25 (t, J=7.7 Hz, 2H), 1.90-1.76 (m, 2H).

EXAMPLE 3(171)2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzoylamino)aceticacid

TLC: Rf 0.45 (ethyl acetate:methanol=3:1);

NMR (300 MHz, DMSO-d₆): δ 8.25 (t, J=5.4 Hz, 1H), 7.88-7.76 (m, 6H),7.53-7.45 (m, 4H), 7.10 (s, 1H), 6.79(dd, J=8.1, 1.5 Hz, 1H), 6.27 (t,J=2.1 Hz, 1H), 5.35 (s, 2H), 4.42 (t, J=6.6 Hz, 2H), 3.84 (d, J=5.4 Hz,2H), 3.33-3.29 (m, 2H).

EXAMPLE 3(172)3-(2-(2-(2-methylimidazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.50 (methanol);

NMR (300 MHz, DMSO-d₆): δ 7.77 (d, J=2.1 Hz, 1H), 7.42 (d, J=2.1 Hz,1H), 7.09-7.05 (m, 2H), 6.83 (s, 1H), 6.71-6.65 (m, 2H), 6.24 (t, J=2.1Hz, 1H), 5.23 (s, 2H), 4.28 (t, J=4.8 Hz, 2H), 4.14 (t, J=4.8 Hz, 2H),2.66 (t, J=7.5 Hz, 2H), 2.30-2.26 (m, 5H).

EXAMPLE 3(173)3-(2-(5-phenylpentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.63 (chloroform:methanol=10:1).

EXAMPLE 3(174)3-(2-(6-phenylhexyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.61 (chloroform:methanol=10:1).

EXAMPLE 3(175)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-hydroxymethylphenyl)propanoic acid

TLC: Rf 0.51 (chloroform:methanol=10:1).

EXAMPLE 3(176)3-(2-(3-(N-methyl-N-phenylamino)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.36 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.54 (d, J=1.8 Hz, 1H), 7.36 (d, J=2.4 Hz, 1H),7.28-7.18 (m, 2H), 7.14 (d, J=7.5 Hz, 1H), 6.77-6.62 (m, 5H), 6.27 (dd,J=2.4, 1.8 Hz, 1H), 5.26 (s, 2H), 3.96 (t, J=5.4 Hz, 2H), 3.53 (t, J=7.2Hz, 2H), 2.98 (t, J=7.8 Hz, 2H), 2.93 (s, 3H), 2.67 (t, J=7.2 Hz, 2H),2.05 (m, 2H).

EXAMPLE 3(177)3-(2-(2-(N-ethyl-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

[Salt-Free]

TLC: Rf 0.38 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.53 (d, J=2.1 Hz, 1H), 7.35 (d, J=2.4 Hz, 1H),7.25-7.18 (m, 2H), 7.12 (d, J=7.5 Hz, 1H), 6.77-6.64 (m, 5H), 6.26 (dd,J=2.4, 2.1 Hz, 1H), 5.23 (s, 2H), 4.07 (t, J=6.0 Hz, 2H), 3.71 (t, J=6.0Hz, 2H), 3.46 (q, J=6.9 Hz, 2H), 2.91 (t, J=7.2 Hz, 2H), 2.59 (t, J=7.2Hz, 2H), 1.17 (t, J=6.9 Hz, 2H).

Sodium Salt:

TLC: Rf 0.64 (chloroform:methanol=10:1).

EXAMPLE 3(178)3-(2-(2-(N-(2-hydroxyethyl)-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.41 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.53 (d, J=1.8 Hz, 1H), 7.35 (d, J=2.4 Hz, 1H),7.27-7.21 (m, 2H), 7.11 (t, J=7.8 Hz, 1H), 6.82-6.69 (m, 5H), 6.26 (dd,J=2.4, 1.8 Hz, 1H), 5.22 (s, 2H), 4.13 (t, J=4.8 Hz, 2H), 3.86-3.78 (m,4H), 3.61 (t, J=6.0 Hz, 2H), 2.92 (t, J=7.5 Hz, 2H), 2.57 (t, J=7.5 Hz,2H).

EXAMPLE 3(179)3-(2-(2-(3-(piperidin-1-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.40 (hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.53 (d, J=2.1 Hz, 1H), 7.36 (d, J=2.1 Hz, 1H),7.20 (t, J=7.8 Hz, 1H), 7.11 (d, J=7.8 Hz, 1H), 6.92 (s, 1H), 6.85-6.70(m, 3H), 6.66 (s, 1H), 6.26 (t, J=2.1 Hz, 1H), 5.25 (s, 2H), 4.13 (t,J=6.6 Hz, 2H), 3.15-3.11 (m, 4H), 3.02 (t, J=6.6 Hz, 2H), 2.89 (t, J=7.5Hz, 2H), 2.52 (t, J=7.5 Hz, 2H), 1.76-1.69 (m, 4H), 1.60-1.54 (m, 2H).

EXAMPLE 3(180)3-(2-(2-(3-(morpholin-4-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.25 (hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.53 (d, J=1.8 Hz, 1H), 7.36 (d, J=1.8 Hz, 1H),7.22 (t, J=7.8 Hz, 1H), 7.10 (d, J=7.8 Hz, 1H), 6.84-6.66 (m, 5H), 6.27(t, J=1.8 Hz, 1H), 5.25 (s, 2H), 4.12 (t, J=6.6 Hz, 2H), 3.88-3.85 (m,4H), 3.17-3.14 (m, 4H), 3.03 (t, J=6.6 Hz, 2H), 2.88 (t, J=7.8 Hz, 2H),2.53 (t, J=7.8 Hz, 2H).

EXAMPLE 3(181)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(1-hydroxy-1-methylethyl)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1).

EXAMPLE 3(182)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propynoicacid

TLC: Rf 0.53 (chloroform:methanol:acetic acid=18:1:1).

EXAMPLE 3(183)3-(2-(2-hydroxy-2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.39 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 7.92 (s, 1H), 7.88-7.80 (m, 3H), 7.57-7.44 (m,3H), 7.34 (m, 1H), 7.25-7.12 (m, 4H), 6.93 (d, J=7.8 Hz, 1H), 6.86 (s,1H), 5.32 (dd, J=7.8, 3.6 Hz, 1H), 4.97 (s, 2H), 4.23 (dd, J=9.3, 3.6Hz, 1H), 4.14 (dd, J=9.3, 7.8 Hz, 1H), 3.10-2.90 (m, 2H), 2.63 (m, 2H).

EXAMPLE 3(184)3-(2-(2-(1,2,3,4-tetrahydroisoquinolin-2-yl)ethoxy)-4-(pyrazol1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.30 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.55 (d, J=1.8 Hz, 1H), 7.38 (d, J=2.4 Hz, 1H),7.18-7.03 (m, 5H), 6.75 (d, J=7.5 Hz, 1H), 6.66 (s, 1H), 6.28 (m, 1H),5.27 (s, 2H), 4.09 (t, J=4.5 Hz, 2H), 3.88 (s, 2H), 3.11-2.94 (m, 8H),2.32 (t, J=8.4 Hz, 2H).

EXAMPLE 3(185)3-(2-(2-(9-methylcarbazol-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.36 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.09-7.99 (m, 3H), 7.53 (d, J=1.8 Hz, 1H),7.49-7.05 (m, 6H), 6.74-6.67 (m, 2H), 6.25 (dd, J=2.1, 1.8 Hz, 1H), 5.24(s, 2H), 4.23 (t, J=6.6 Hz, 2H), 3.83 (s, 3H), 3.28 (t, J=6.6 Hz, 2H),2.89 (t, J=7.8 Hz, 2H), 2.52 (t, J=7.8 Hz, 2H).

EXAMPLE 3(186)3-(2-(2-(3-(4-methylpiperazin-1-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.20 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 7.77 (d, J=2.1 Hz, 1H), 7.42 (s, 1H),7.14-7.04 (m, 2H), 6.87-6.63 (m, 5H), 6.23 (t, J=2.1 Hz, 1H), 5.23 (s,2H), 4.08 (t, J=6.6 Hz, 2H), 3.12-3.08 (m, 4H), 2.94 (t, J=6.6 Hz, 2H),2.70 (t, J=7.5 Hz, 2H), 2.44-2.41 (m, 4H), 2.35 (t, J=7.5 Hz, 2H), 2.20(s, 3H).

EXAMPLE 3(187)3-(2-(2-(3-(4-acetylpiperazin-1-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.53 (d, J=2.1 Hz, 1H), 7.35 (d, J=2.1 Hz, 1H),7.21 (t, J=7.8 Hz, 1H), 7.08 (d, J=7.8 Hz, 1H), 6.87-6.65 (m, 5H), 6.26(t, J=2.1 Hz, 1H), 5.24 (s, 2H), 4.11 (t, J=6.0 Hz, 2H), 3.79-3.75 (m,2H), 3.64-3.61 (m, 2H), 3.19-3.11 (m, 4H), 3.03 (t, J=6.0 Hz, 2H), 2.86(t, J=7.8 Hz, 2H), 2.51 (t, J=7.8 Hz, 2H), 2.15 (s, 3H).

EXAMPLE 3(188)3-(2-(2-phenylaminoethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.54 (d, J=1.5 Hz, 1H), 7.36 (d, J=2.1 Hz, 1H),7.22-7.09 (m, 3H), 6.77-6.64 (m, 6H), 6.27 (t, J=2.1 Hz, 1H), 5.25 (s,2H), 4.10 (t, J=8.1 Hz, 2H), 3.53 (t, J=8.1 Hz, 2H), 2.94 (t, J=7.5 Hz,2H), 2.61 (t, J=7.5 Hz, 2H).

EXAMPLE 3(189)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-acetyl-N-methylaminomethy)phenyl)propanoicacid

TLC: Rf 0.45 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.82-7.78 (m, 3H), 7.75 (s, 1H), 7.45-7.41 (m,3H), 7.11 (d, J=7.5 Hz, 0.4H), 7.06 (d, J=7.5 Hz, 0.6H), 6.75 (brs,0.6H), 6.71 (brd, J=7.5 Hz, 0.6H), 6.64 (brd, J=7.5 Hz, 0.4H), 6.59(brs, 0.4H), 4.50 (s, 1.2H), 4.44 (s, 0.8H), 4.27-4.23 (m, 2H),3.29-3.23 (m, 2H), 2.91 (s, 1.2H), 2.90-2.85 (m, 2H), 2.88 (s, 1.8H),2.55-2.49 (m, 2H), 2.13 (s, 3H).

EXAMPLE 3(190)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-ethoxycarbonyl-N-methylaminomethyl)phenyl)propanoicacid

[Salt-Free]

TLC: Rf 0.14 (hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 7.81-7.78 (m, 3H), 7.74 (brs, 1H), 7.45-7.41 (m,3H), 7.07 (d, J=7.5 Hz, 1H), 6.78-6.66 (m, 2H), 4.39 (brs, 2H), 4.25 (t,J=6.6 Hz, 2H), 4.17 (q, J=6.9 Hz, 2H), 3.27 (t, J=6.6 Hz, 2H), 2.91-2.70(m, 5H), 2.55-2.50 (m, 2H), 1.28-1.23 (m, 3H).

Sodium Salt:

TLC: Rf 0.50 (n-hexane:ethyl acetate=1:2).

EXAMPLE 3(191)3-(2-(2-(N-benzyl-N-methylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=10:1).

EXAMPLE 3(192)3-(2-(2-(N-benzyl-N-ethylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=10:1).

EXAMPLE 3(193)3-(2-(2-(N-phenyl-N-propylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.53 (d, J=2.1 Hz, 1H), 7.35 (d, J=2.1 Hz, 1H),7.26-7.16 (m, 2H), 7.11 (d, J=7.8 Hz, 1H), 6.76-6.61 (m, 5H), 6.26 (t,J=2.1 Hz, 1H), 5.23 (s, 2H), 4.07 (t, J=6.0 Hz, 2H), 3.74 (t, J=6.0 Hz,2H), 3.33 (t, J=7.8 Hz, 2H), 2.90 (t, J=7.8 Hz, 2H), 2.59 (t, J=7.5 Hz,2H), 1.72-1.56 (m, 2H), 0.93 (t, J=7.2 Hz, 2H).

EXAMPLE 3(194)3-(2-(2-(6-methoxy-naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

[Salt-Free]

TLC: Rf 0.67 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.72-7.62 (m, 3H), 7.53 (d, J=0.9 Hz, 1H),7.40-7.32 (m, 2H), 7.16-7.05 (m, 3H), 6.74-6.65 (m, 2H), 6.25 (t, J=2.1Hz, 1H), 5.24 (s, 2H), 4.18 (t, J=6.6 Hz, 2H), 3.89 (s, 3H), 3.19 (t,J=6.6 Hz, 2H), 2.87 (t, J=7.5 Hz, 2H), 2.50 (t, J=7.5 Hz, 2H).

Sodium Salt:

TLC: Rf 0.51 (chloroform:methanol=10:1).

EXAMPLE 3(195)3-(2-(2-(carbazol-9-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

[Salt-Free]

TLC: Rf 0.51 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.15 (d, J=8.1 Hz, 2H), 7.77-7.65 (m, 3H),7.51-7.38 (m, 3H), 7.21 (t, J=7.5 Hz, 2H), 6.96 (d, J=7.8 Hz, 1H), 6.82(s, 1H), 6.61 (d, J=7.8 Hz, 1H), 6.23 (brs, 1H), 5.19 (s, 2H), 4.92-4.80(m, 2H), 4.35-4.25 (m, 2H), 2.45 (t, J=7.5 Hz, 2H), 2.12 (t, J=7.5 Hz,2H).

Sodium Salt:

TLC: Rf 0.51 (chloroform:methanol 10:1);

NMR (300 MHz, DMSO-d₆): δ 8.13 (d, J=7.8 Hz, 2H), 7.76-7.68 (m, 3H),7.45-7.40 (m, 2H), 7.38 (s, 1H), 7.19-7.16 (m, 2H), 7.00 (d, J=7.8 Hz,1H), 6.74 (s, 1H), 6.58 (d, J=8.4 Hz, 1H), 6.20 (t, J=2.1 Hz, 1H), 5.16(s, 2H), 4.82-4.76 (m, 2H), 4.26-4.16 (m, 2H), 2.45-2.40 (m, 2H),2.00-1.92 (m, 2H).

EXAMPLE 3(196)3-(2-(2-(9,10-dihydroacridin-9-one-10-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.45 (chloroform:methanol=1:1);

NMR (300 MHz, DMSO-d₆): δ 8.37 (dd, J=8.1 Hz, 2H), 8.05 (d, J=8.7 Hz,2H), 7.90-7.80 (m, 2H), 7.74 (d, J=1.8 Hz, 1H), 7.41 (d, J=1.8 Hz, 1H),7.36 (t, J=7.2 Hz, 2H), 6.99 (d, J=7.5 Hz, 1H), 6.88 (d, J=1.2 Hz, 1H),6.63 (dd, J=7.5, 1.2 Hz, 1H), 6.23 (t, J=1.8 Hz, 1H), 5.20 (s, 2H), 5.08(t, J=5.1 Hz, 2H), 4.43 (t, J=5.1 Hz, 2H), 2.47 (t, J=7.8 Hz, 2H), 2.12(t, J=7.8 Hz, 2H).

EXAMPLE 3(197)3-(2-(2-(N-phenyl-N-methylsulfonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1).

EXAMPLE 3(198)3-(2-(2-(N-acetyl-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=10:1).

EXAMPLE 3(199)3-(2-(2-(N-benzyl-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.23 (n-hexane:ethyl acetate=1:1).

EXAMPLE 3(200)3-(2-(2-(N-(2-cyanoethyl)-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=10:1).

EXAMPLE 3(201)3-(2-(3-(phenoxazin-10-yl)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.55 (dd, J=2.1, 0.6 Hz, 1H), 7.36 (dd, J=2.1,0.6 Hz, 1H), 7.15 (d, J=7.5 Hz, 1H), 6.80-6.71 (m, 3H), 6.68-6.59 (m,5H), 6.56-6.50 (m, 2H), 6.27 (t, J=2.1 Hz, 1H), 5.26 (s, 2H), 4.04 (t,J=5.6 Hz, 2H), 3.78-3.68 (m, 2H), 3.01 (t, J=7.8 Hz, 2H), 2.68 (t, J=7.8Hz, 2H), 2.20-2.08 (m, 2H).

EXAMPLE 3(202)3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-phenylcarbamoyl)phenyl)propanoicacid

TLC: Rf 0.46 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 10.11 (s, 1H), 7.91-7.82 (m, 4H), 7.76-7.69(m, 2H), 7.57-7.41 (m, 5H), 7.38-7.29 (m, 2H), 7.26 (d, J=7.8 Hz, 1H),7.08 (m, 1H), 4.38 (t, J=6.3 Hz, 2H), 3.26 (t, J=6.3 Hz, 2H), 2.80 (t,J=7.6 Hz, 2H), 2.42 (t, J=7.6 Hz, 2H).

REFERENCE EXAMPLE 5 4-acetoxymethyl-2-(t-butoxycarbonyl)phenyl iodide

To a solution of 2-t-butoxycarbonyl-4-methylphenyl iodide (1.0 g) incarbon tetrachloride (10.0 ml) was added N-bromosuccinimide (645 mg) andbenzoyl peroxide (76 mg), the mixture was refluxed for 16 hours. Thereaction mixture was cooled to room temperature and then filtered. Thefiltrate was poured into water and extracted with methylene chloride.The organic layer was dried over anhydrous magnesium sulfate andconcentrated to give the bromide. To a solution of the obtained bromidein N,N-dimethylformamide (3.0 ml) was added potassium acetate (300 mg)and the mixture was stirred at 50° C. for 1 hour. To the reactionmixture was added a saturated aqueous solution of ammonium chloride andthe mixture was extracted with diethyl ether. The organic layer waswashed with a saturated aqueous solution of sodium chloride, dried overanhydrous magnesium sulfate and concentrated. The residue was purifiedby column chromatography on silica gel (n-hexane:ethyl acetate=8:1) togive the title compound (285 mg) having the following physical data.

TLC: Rf 0.23 (n-hexane:ethyl acetate=10:1).

REFERENCE EXAMPLE 63-[4-acetoxymethyl-2-(t-butoxycarbonyl)phenyl]propanoic acid ethyl ester

3-[4-Acetoxymethyl-2-(t-butoxycarbonyl)phenyl]propenoic acid ethyl ester(4.5 g) which is prepared by the same procedure of Example 1 using acompound prepared in Reference Example 5 instead of the compoundprepared in Reference Example 4 was dissolved in mixture oftetrahydrofuran (50 ml) and methanol (13 ml). To the solution was addednickel(II) chloride hexahydrate (3.4 g) at 0° C. followed by sodiumborohydride (2.0 g) portionwise. The mixture was stirred at 0° C. for 20minutes. To the reaction mixture were added acetone and diethyl etherand the mixture was filtered through celite (trademark). The filtratewas extracted with diethyl ether, washed with a saturated aqueoussolution of sodium chloride, dried over anhydrous magnesium sulfate andconcentrated to give the title compound (3.8 g).

TLC: Rf 0.19 (n-hexane:ethyl acetate=5:1).

REFERENCE EXAMPLE 7 3-(4-acetoxymethyl-2-carboxyphenyl)propanoic acidethyl ester

To a solution of the compound prepared in Reference Example 6 (3.8 g) inmethylene chloride (4.0 ml) was added anisole (2.0 ml) andtrifluoroacetic acid (5.0 ml) at room temperature and the mixture wasstirred overnight. The reaction mixture was concentrated and the residuewas purified by column chromatography on silica gel (n-hexane:ethylacetate=5:4→chloroform:methanol=10:1) to give the title compound havingthe following physical data.

TLC: Rf 0.63 (chloroform:methanol=9:1).

REFERENCE EXAMPLE 83-[2-((naphthalen-1-ylmethyl)carbamoyl)-4-acetoxymethylphenyl]propanoicacid ethyl ester

To a solution of the compound prepared in Reference Example 7 (3.2 g) inanhydrous toluene (20 ml) was added oxalyl chloride (1.0 ml) andN,N-dimethylformamide (cat.) at room temperature and the mixture wasstirred for 1 hour. The reaction mixture was concentrated and thenazeotroped with toluene. To the solution of 1-naphthylmethylamine (2.1ml) in methylene chloride (30 ml)-pyridine (1.8 ml) was added thesolution of the residue in methylene chloride (10 ml) at 0° C. and themixture was stirred for 1 hour. To the reaction mixture was added 2Nhydrochlorid acid (7.0 ml) and the mixture was extracted with methylenechloride. The organic layer was washed with water and a saturatedaqueous solution of sodium chloride subsequently and concentrated togive the title compound (4.5 g) having the following physical data.

TLC: Rf 0.25 (n-hexane:ethyl acetate=2:1).

EXAMPLE 43-[2-((naphthalen-1-ylmethyl)carbamoyl)-4-hydroxymethylphenyl]propanoicacid ethyl ester

To a solution of the compound prepared in Reference Example 8 (10.9mmol) in ethanol (40 ml) was added sodium ethoxide (740 mg) and themixture was stirred for 20 minutes. To the reaction mixture was addedacetic acid and the mixture was concentrated. The residue was extractedwith ethyl acetate. The organic layer was washed with water and asaturated aqueous solution of sodium chloride and concentrared. Theresidue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=1:1) to give the title compound (3.2 g) havingthe following physical data.

TLC: Rf 0.20 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.14 (d, J=8.7 Hz, 1H), 7.92-7.79 (m, 2H),7.62-7.40 (m, 3H), 7.36-7.10 (m, 4H), 6.61 (t, J=5.4 Hz, 1H), 5.08 (d,J=5.4 Hz, 2H), 4.59 (s, 2H), 4.03 (q, J=7.2 Hz, 2H), 3.06 (t, J=7.4 Hz,2H), 2.67 (t, J=7.4 Hz, 2H), 1.19 (t, J=7.2 Hz, 3H).

EXAMPLE 53-[2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-methylphenyloxymethyl)phenyl]propanoicacid ethyl ester

To the solution of the compound prepared in Example 4 (300 mg) and2-methylphenol (0.12 ml) in tetrahydrofuran (4 ml) were addedtriphenylphosphine (300 mg) and diethyl azodicarboxylate (0.5 ml, 40%toluene solution) at room temperature and the mixture was stirredovernight. The reaction mixture was concentrated and the residue waspurified by column chromatography on silica gel (n-hexane:ethylacetate=5:1) to give the title compound (330 mg) having the followingphysical data.

TLC: Rf 0.25 (n-hexane:ethyl acetate=3:1);

NMR (300 MHz, CDCl₃): δ 8.15 (d, J=8.1 Hz, 1H), 7.93-7.80 (m, 2H),7.62-7.36 (m, 7H), 7.16-7.06 (m, 2H), 6.89-6.76 (m, 2H), 6.52 (t, J=5.4Hz, 1H), 5.10 (d, J=5.4 Hz, 2H), 4.99 (s, 2H), 4.05 (q, J=7.2 Hz, 2H),3.09 (t, J=7.4 Hz, 2H), 2.69 (t, J=7.4 Hz, 2H), 2.17 (s, 3H), 1.19 (t,J=7.2 Hz, 3H).

EXAMPLE 5(1)˜EXAMPLE 5(83)

Using corresponding compounds, the following compounds were obtained bythe same procedure of Example 5.

EXAMPLE 5(1)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid ethyl ester

TLC: Rf 0.66 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(2)3-(2-((1-methyl-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid ethyl ester

TLC: Rf 0.14 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(3)3-(2-(((1R)-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid ethyl ester

TLC: Rf 0.58 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(4)3-(2-((1-(naphthalen-1-yl)propyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid ethyl ester

TLC: Rf 0.56 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(5)3-(2-(((1S)-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid ethyl ester

TLC: Rf 0.58 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(6)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(pyridin-3-yloxymethyl)phenyl)propanoicacid ethyl ester

TLC: Rf 0.31 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(7)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid ethyl ester

TLC: Rf 0.65 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(8)3-(2-(((1R)-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxyphenyl)propanoicacid ethyl ester

TLC: Rf 0.78 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(9)3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid ethyl ester

TLC: Rf 0.53 (n-hexane:ethyl acetate=3:1).

EXAMPLE 5(10)3-(2-((3-methyl-1-(4-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid ethyl ester

TLC: Rf 0.52 (n-hexane:ethyl acetate=3:1).

EXAMPLE 5(11)3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.74 (chloroform:methanol=10:1).

EXAMPLE 5(12)3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.74 (chloroform:methanol=10:1).

EXAMPLE 5(13)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid methyl ester

TLC: Rf 0.58 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(14)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.78 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(15)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.67 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(16)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.83 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(17)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(pyridin-3-yloxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.21 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(18)3-(2-((3-methyl-1-(4-methoxy-1,3-dioxaindan-6-yl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.70 (n-hexane:ethyl acetate=1:2).

EXAMPLE 5(19)3-(2-((3-methyl-1-(4-methoxy-1,3-dioxaindan-6-yl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.60 (n-hexane:ethyl acetate=1:2).

EXAMPLE 5(20)3-(2-((3-methyl-1-(4-methoxy-1,3-dioxaindan-6-yl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.70 (n-hexane:ethyl acetate=1:2).

EXAMPLE 5(21)3-(2-((3-methyl-1-(4-fluoro-3-methylphenyl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.56 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(22)3-(2-((3-methyl-1-(4-fluoro-3-methylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.48 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(23)3-(2-((3-methyl-1-(3-methylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.70 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(24)3-(2-((3-methyl-1-(3-methoxyphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.61 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(25)3-(1-benzyl-3-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)indol-4-yl)propanoicacid methyl ester

TLC: Rf 0.66 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(26)3-(2-((3-methyl-1-(3,4-dimethoxyphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.45 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(27)3-(2-((3-methyl-1-(3-methyl-4-fluorophenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.43 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(28)3-(2-((3-methyl-1-(3,5-dimethoxyphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.42 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(29)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzylaminophenyl)propanoicacid ethyl ester

TLC: Rf 0.44 (n-hexane:ethyl acetate=3:1).

EXAMPLE 5(30)3-(2-(1-(3,5-dimethylphenyl)butylcarbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.79 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(31)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.56 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(32)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.55 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(33)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.55 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(34)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.56 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(35)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.58 (n-hexane ethyl acetate=2:1).

EXAMPLE 5(36)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.51 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(37)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.25 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(38)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methoxyphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.91 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(39)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.87 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(40)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-4-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.42 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(41)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methyl-4-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.43 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(42)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.42 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(43)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxy-5-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.51 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(44)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.50 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(45)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.52 (n-hexane ethyl acetate=2:1).

EXAMPLE 5(46)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chlorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.59 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(47)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-5-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.46 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(48)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(4-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.49 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(49)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.49 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(50)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.52 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(51)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,4-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.50 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(52)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.57 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(53)3-(2-(((1S)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.57 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(54)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.78 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(55)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.45 (n-hexane:ethyl acetate=3:1).

EXAMPLE 5(56)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.71 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(57)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.51 (n-hexane:ethyl acetate=3:1).

EXAMPLE 5(58)3-(2-((1R-(3,5-dimethylphenyl)cyclohexyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.52 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(59)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.70 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(60)3-(2-(4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.49 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(61)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.59 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(62)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.67 (n-hexane:ethyl acetate=3:1).

EXAMPLE 5(63)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.67 (n-hexane:ethyl acetate=3:1).

EXAMPLE 5(64)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid methyl ester

TLC: Rf 0.67 (toluene:ethyl acetate=2:1).

EXAMPLE 5(65)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chlorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.75 (toluene:ethyl acetate=2:1).

EXAMPLE 5(66)3-(2-(4-(3,5-dimethylphenyl)perhydrothiopyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester methyl ester

TLC: Rf 0.50 (n-hexane:ethyl acetate=3:1).

EXAMPLE 5(67)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.20 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(68)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chloro-5-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.70 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(69)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.69 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(70)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-dichlorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.70 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(71)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid methyl ester

TLC: Rf 0.68 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(72)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(3-chlorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.70 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(73)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(3-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.42 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(74)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.50 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(75)3-(2-((1-methylsulfonyl-4-(3,5-dimethylphenyl)piperidin-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.40 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(76)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-fluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.41 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(77)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.41 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(78)3-(2-((4-(3-methylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.34 (n-hexane:ethyl acetate=2:1).

EXAMPLE 5(79)3-(2-((4-(naphthalen-1-yl)perhydropyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.52 (n-hexane:ethyl acetate=1:1).

EXAMPLE 5(80)3-(2-((1-methyl-4-(3,5-dimethylphenyl)piperidin-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 5(81)3-(2-((1-ethyl-4-(3,5-dimethylphenyl)piperidin-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid methyl ester

TLC: Rf 0.52 (chloroform:methanol=10:1).

EXAMPLE 5(82)2-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxyphenoxy)aceticacid methyl ester

TLC: Rf 0.28 (n-hexane:ethyl acetate=3:1).

EXAMPLE 5(83)2-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-6-fluorobenzyloxy)phenoxy)aceticacid methyl ester

TLC: Rf 0.75 (n-hexane:ethyl acetate=1:1).

EXAMPLE 63-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoicacid

Using the compound prepared in Example 5 (330 mg), the title compound(223 mg) having the following physical data was obtained by the sameprocedure of Example 3.

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.00 (t, J=5.5 Hz, 1H), 8.24-8.16 (m, 1H),8.01-7.94 (m, 1H), 7.91-7.84 (m, 1H), 7.63-7.41 (m, 6H), 7.34 (d, J=8.1Hz, 1H), 7.19-7.10 (m, 2H), 6.99 (d, J=7.8 Hz, 1H), 6.85 (t, J=7.5 Hz,1H), 5.09 (s, 2H), 4.94 (d, J=5.5 Hz, 2H), 2.96 (t, J=7.8 Hz, 2H), 2.55(t, J=7.8 Hz, 2H), 2.16 (s, 3H).

EXAMPLE 6(1)˜EXAMPLE 6(365)

Using the compounds prepared in Example 5(1)˜5(83) or correspondingcompounds, the following compounds were obtained by the same procedureof Example 6 or continued conversion to known salts.

EXAMPLE 6(1)(2E)-3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.35 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.10 (t, J=5.7 Hz, 1H), 8.17 (d, J=7.8 Hz,1H), 8.00-7.82 (m, 5H), 7.65-7.45 (m, 5H), 7.34-7.22 (m, 2H), 6.50 (d,J=15.9 Hz, 1H), 6.29 (t, J=2.1 Hz, 1H), 5.39 (s, 2H), 4.94 (d, J=5.7 Hz,2H).

EXAMPLE 6(2)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.11 (s, 1H), 8.93 (t, J=5.7 Hz, 1H), 8.16(m, 1H), 7.95 (m, 1H), 7.85 (dd, J=7.1, 2.2 Hz, 1H), 7.79 (d, J=2.4 Hz,1H), 7.61-7.42 (m, 5H), 7.28-7.13 (m, 3H), 6.25 (t, J=2.0 Hz, 1H), 5.29(s, 2H), 4.89 (d, J=5.7 Hz, 2H), 2.88 (t, J=7.8 Hz, 2H), 2.48 (m, 2H).

EXAMPLE 6(3)(2E)-3-(2-((naphthalen-2-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.29 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.13 (t, J=6.0 Hz, 1H), 7.96-7.80 (m, 7H),7.60-7.44 (m, 4H), 7.39-7.34 (m, 1H), 7.32-7.24 (m, 1H), 6.52 (d, J=15.9Hz, 1H), 6.31 (t, J=2.0 Hz, 1H), 5.42 (s, 2H), 4.64 (d, J=6.0 Hz, 2H).

EXAMPLE 6(4)(2E)-3-(2-(N-(naphthalen-2-ylmethyl)-N-methylcarbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.33 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.92-7.06 (m, 13H), 6.44 and 6.41 (each d,J=15.9 Hz, 1H), 6.32 and 6.16 (each t, J=2.1 Hz, 1H), 5.38 and 5.28(each s, 2H), 4.95 and 4.42 (each s, 2H), 3.13 and 2.66 (each s, 3H).

EXAMPLE 6(5)(2E)-3-(2-((naphthalen-2-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)-2-propenoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.19 (t, J=5.8 Hz, 1H), 8.02-7.82 (m, 6H),7.64-7.44 (m, 5H), 7.38-7.26 (m, 2H), 7.04 (d, J=7.8 Hz, 2H), 6.96 (t,J=7.4 Hz, 1H), 6.55 (d, J=15.9 Hz, 1H), 5.19 (s, 2H), 4.66 (d, J=5.8 Hz,2H).

EXAMPLE 6(6)(2E)-3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)-2-propenoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.14 (t, J=5.4 Hz, 1H), 8.20 (d, J=8.4 Hz,1H), 8.02-7.84 (m, 4H), 7.66-7.46 (m, 6H), 7.36-7.26 (m, 2H), 7.01 (d,J=7.8 Hz, 2H), 6.96 (t, J=7.5 Hz, 1H), 6.53 (d, J=15.9 Hz, 1H), 5.16 (s,2H), 4.97 (d, J=5.4 Hz, 2H).

EXAMPLE 6(7)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.11 (d, J=8.4 Hz, 1H), 7.92-7.79 (m, 2H),7.62-7.35 (m, 6H), 7.31-7.20 (m, 3H), 6.98-6.84 (m, 3H), 6.37 (t, J=5.1Hz, 1H), 5.08 (d, J=5.1 Hz, 2H), 4.95 (s, 2H), 3.10 (t, J=7.5 Hz, 2H),2.76 (t, J=7.5 Hz, 2H).

EXAMPLE 6(8)(2E)-3-(2-(1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)-2-propenoicacid

TLC: Rf 0.21 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.24 (d, J=8.7 Hz, 1H), 8.14 (d, J=15.9 Hz, 1H),7.88 (d, J=8.4 Hz, 1H), 7.83 (d, J=8.4 Hz, 1H), 7.64-7.42 (m, 6H),7.30-7.22 (m, 3H), 6.99-6.88 (m, 3H), 6.40 (d, J=15.9 Hz, 1H), 6.18 (m,1H), 6.03 (brd, J=7.8 Hz, 1H), 5.04 (s, 2H), 1.84 (d, J=6.6 Hz, 3H).

EXAMPLE 6(9)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.00 (t, J=5.5 Hz, 1H), 8.25-8.16 (m, 1H),8.01-7.93 (m, 1H), 7.88 (d, J=8.1 Hz, 1H), 7.64-7.42 (m, 6H), 7.34 (d,J=8.1 Hz, 1H), 7.02 (d, J=7.5 Hz, 1H), 6.85 (s, 1H), 6.67 (d, J=7.2 Hz,1H), 5.06 (s, 2H), 4.94 (d, J=5.5 Hz, 2H), 2.96 (t, J=7.8 Hz, 2H), 2.55(t, J=7.8 Hz, 2H), 2.26 (s, 3H), 2.10 (s, 3H).

EXAMPLE 6(10)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2,5-dichlorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 12.1 (s, 1H), 9.00 (t, J=6.0 Hz, 1H), 8.17 (m,1H), 7.94 (m, 1H), 7.85 (d, J=7.8 Hz, 1H), 7.59-7.40 (m, 7H), 7.35 (d,J=2.1 Hz, 1H), 7.33 (d, J=7.8 Hz, 1H), 7.03 (dd, J=8.4, 2.1 Hz, 1H),5.19 (s, 2H), 4.91 (d, J=6.0 Hz, 2H), 2.93 (t, J=8.1 Hz, 2H), 2.52 (t,J=8.1 Hz, 2H).

EXAMPLE 6(11)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 12.1 (s, 1H), 8.98 (t, J=5.4 Hz, 1H), 8.18 (m,1H), 7.95 (m, 1H), 7.85 (d, J=7.8 Hz, 1H), 7.60-7.41 (m, 6H), 7.37-7.26(m, 2H), 7.07 (d, J=1.5 Hz, 1H), 6.77 (dd, J=8.1, 1.2 Hz, 1H), 5.13 (s,2H), 4.91 (d, J=5.4 Hz, 2H), 2.94 (t, J=8.1 Hz, 2H), 2.53 (t, J=8.1 Hz,2H), 2.27 (s, 3H).

EXAMPLE 6(12)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.25 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.32 (d, J=8.7 Hz, 1H), 7.88 (d, J=7.8 Hz, 1H),7.80 (d, J=8.4 Hz, 1H), 7.61-7.25 (m, 9H), 7.00-6.90 (m, 3H), 6.38 (d,J=8.7 Hz, 1H), 6.14 (dt, J=8.7, 7.2 Hz, 1H), 4.99 (s, 2H), 3.04 (t,J=7.2 Hz, 2H), 2.74 (t, J=7.2 Hz, 2H), 1.97 (t, J=7.2 Hz, 2H), 1.80 (m,1H), 1.13 (d, J=6.6 Hz, 3H), 1.01 (d, J=6.6 Hz, 3H).

EXAMPLE 6(13)3-(2-((1-methyl-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.15 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.55 (m, 1H), 7.91 (m, 1H), 7.81 (d, J=8.1 Hz,1H), 7.68 (d, J=7.8 Hz, 1H), 7.50-7.23 (m, 8H), 7.00-6.90 (m, 3H), 6.53(s, 1H), 4.99 (s, 2H), 2.98 (t, J=7.5 Hz, 2H), 2.69 (t, J=7.5 Hz, 2H),2.12 (s, 6H).

EXAMPLE 6(14)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2,6-dimethylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.98 (t, J=5.4 Hz, 1H), 8.19 (m, 1H), 7.96 (m,1H), 7.86 (d, J=8.1 Hz, 1H), 7.61-7.44 (m, 6H), 7.33 (d, J=8.7 Hz, 1H),7.07-7.00 (m, 2H), 6.93 (m, 1H), 4.92 (d, J=5.4 Hz, 1H), 4.74 (s, 2H),2.95 (t, J=7.8 Hz, 2H), 2.53 (t, J=7.8 Hz, 2H), 2.23 (s, 6H).

EXAMPLE 6(15)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-chloro-6-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.98 (t, J=5.4 Hz, 1H), 8.19 (m, 1H), 7.95 (m,1H), 7.86 (d, J=8.4 Hz, 1H), 7.61-7.44 (m, 6H), 7.37-7.30 (m, 2H), 7.21(d, J=7.8 Hz, 1H), 7.06 (t, J=8.1 Hz, 1H), 4.92 (d, J=5.4 Hz, 1H), 4.87(s, 2H), 2.95 (t, J=8.4 Hz, 2H), 2.53 (t, J=8.4 Hz, 2H), 2.25 (s, 3H).

EXAMPLE 6(16)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

[Salt-Free]

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.97 (t, J=5.4 Hz, 1H), 8.18 (m, 1H), 7.95 (m,1H), 7.85 (d, J=7.2 Hz, 1H), 7.60-7.30 (m, 11H), 5.13 (s, 2H), 4.91 (d,J=5.4 Hz, 2H), 2.94 (t, J=7.8 Hz, 2H), 2.52 (t, J=7.8 Hz, 2H).

Sodium Salt:

TLC: Rf 0.56 (chloroform:methanol=10:1).

EXAMPLE 6(17)3-(2-(((1R)-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.15 (hexane:ethyl acetate 1:1);

NMR (300 MHz, CDCl₃): δ 8.23 (d, J=7.8 Hz, 1H), 7.89 (d, J=7.5 Hz, 1H),7.83 (d, J=8.4 Hz, 1H), 7.62-7.25 (m, 9H), 6.98-6.88 (m, 3H), 6.36 (d,J=8.4 Hz, 1H), 6.14 (m, 1H), 4.97 (s, 2H), 3.10 (t, J=7.2 Hz, 2H), 2.78(t, J=7.2 Hz, 2H), 1.80 (d, J=6.6 Hz, 3H).

EXAMPLE 6(18)3-(2-((1-(naphthalen-1-yl)propyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.18 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.28 (d, J=8.7 Hz, 1H), 7.88 (d, J=8.1 Hz, 1H),7.81 (d, J=7.8 Hz, 1H), 7.60-7.24 (m, 9H), 7.00-6.89 (m, 3H), 6.37 (d,J=8.7 Hz, 1H), 5.94 (dt, J=8.7, 8.7 Hz, 1H), 4.98 (s, 2H), 3.05 (t,J=7.5 Hz, 2H), 2.75 (t, J=7.5 Hz, 2H), 2.15 (m, 2H), 1.10 (t, J=7.2 Hz,3H).

EXAMPLE 6(19)3-(2-(((1S)-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.15 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.22 (d, J=7.8 Hz, 1H), 7.89 (d, J=7.8 Hz, 1H),7.83 (d, J=8.1 Hz, 1H), 7.62-7.25 (m, 9H), 6.98-6.88 (m, 3H), 6.36 (d,J=7.8 Hz, 1H), 6.14 (m, 1H), 4.97 (s, 2H), 3.09 (t, J=7.5 Hz, 2H), 2.78(t, J=7.5 Hz, 2H), 1.80 (d, J=6.9 Hz, 3H).

EXAMPLE 6(20)3-(2-((1-(naphthalen-2-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.17 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84 (m, 4H), 7.53-7.42 (m, 5H), 7.29 (m, 3H),6.97 (m, 3H), 6.56 (d, J=8.1 Hz, 1H), 5.50 (m, 1H), 5.02 (s, 2H), 3.07(t, J=7.5 Hz, 2H), 2.77 (t, J=7.5 Hz, 2H), 1.70 (d, J=6.9 Hz, 3H).

EXAMPLE 6(21)3-(2-((4-methoxynaphthalen-1-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 8.87 (t, J=5.6 Hz, 1H), 8.19 (dd, J=8.3, 1.4Hz, 1H), 8.12 (d, J=7.5 Hz, 1H), 7.62-7.48 (m, 2H), 7.46-7.36 (m, 3H),7.32-7.23 (m, 3H), 7.00-6.89 (m, 4H), 5.04 (s, 2H), 4.82 (d, J=5.6 Hz,2H), 3.96 (s, 3H), 2.92 (t, J=7.8 Hz, 2H), 2.50 (m, 2H).

EXAMPLE 6(22)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-methylthiophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.34 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.12 (d, J=7.2 Hz, 1H), 7.92 (dd, J=8.1, 1.2 Hz,1H), 7.84 (d, J=8.1 Hz, 1H), 7.64-7.36 (m, 6H), 7.34-7.25 (m, 1H),7.14-7.02 (m, 2H), 6.95 (t, J=7.2 Hz, 1H), 6.82 (d, J=7.2 Hz, 1H), 6.45(brs, 1H), 5.15-5.05 (m, 2H), 5.07 (s, 2H), 3.13 (t, J=7.5 Hz, 2H), 2.80(t, J=7.5 Hz, 2H), 2.28 (s, 3H).

EXAMPLE 6(23)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-mesylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.18 (d, J=8.4 Hz, 1H), 7.94 (dd, J=8.4, 1.8 Hz,1H), 7.93-7.82 (m, 2H), 7.75 (d, J=1.8 Hz, 1H), 7.63-7.37 (m, 6H),7.32-7.25 (m, 1H), 7.15-6.97 (m,3H), 5.19 (s, 2H), 5.10 (d, J=5.4 Hz,2H), 3.16 (t, J=7.5 Hz, 2H), 2.92 (s, 3H), 2.83 (t, J=7.5 Hz, 2H).

EXAMPLE 6(24)4-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)butanoicacid

TLC: Rf 0.59 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.34 (d, J=8.4 Hz, 1H), 7.89 (d, J=7.8 Hz, 1H),7.80 (d, J=7.8 Hz, 1H), 7.63-7.18 (m, 9H), 7.02-6.88 (m, 3H), 6.20-6.00(m, 2H), 4.99 (s, 2H), 2.74 (t, J=7.7 Hz, 2H), 2.27-2.17 (m, 2H),2.00-1.40 (m, 5H), 1.13 (d, J=6.6 Hz, 3H), 1.01 (d, J=6.6 Hz, 3H).

EXAMPLE 6(25)3-(2-((4-fluoronaphthalen-1-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.13 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.14 (m, 2H), 7.68-7.58 (m, 2H), 7.46-7.38 (m,3H), 7.31-7.23 (m, 3H), 7.09 (dd, J=9.9, 8.4 Hz, 1H), 6.98-6.87 (m, 3H),6.39 (t, J=5.1 Hz, 1H), 5.04 (d, J=5.1 Hz, 2H), 4.96 (s, 2H), 3.09 (t,J=6.9 Hz, 2H), 2.77 (t, J=6.9 Hz, 2H).

EXAMPLE 6(26)3-(2-((quinolin-4-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.26 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 9.12 (t, J=5.7 Hz, 1H), 8.85 (d, J=4.5 Hz, 1H),8.24 (d, J=8.1 Hz, 1H), 8.06 (d, J=8.1 Hz, 1H), 7.79 (t, J=7.8 Hz, 1H),7.66 (t, J=8.1 Hz, 1H), 7.55-7.43 (m, 3H), 7.37-7.25 (m, 3H), 7.01 (m,2H), 6.94 (t, J=7.2 Hz, 1H), 5.09 (s, 2H), 4.96 (d, J=5.7 Hz, 2H), 2.94(t, J=7.5 Hz, 2H), 2.52 (t, J=7.5 Hz, 2H).

EXAMPLE 6(27)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.41 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.28 (d, J=8.1 Hz, 1H), 7.87 (m, 1H), 7.79 (d,J=7.5 Hz, 1H), 7.62-7.36 (m, 6H), 7.22-7.06 (m, 3H), 6.65 (d, J=8.7 Hz,1H), 6.27 (t, J=2.1 Hz, 1H), 6.19 (m, 1H), 5.25 (s, 2H), 2.98 (t, J=7.5Hz, 2H), 2.68 (t, J=7.5 Hz, 2H), 1.92 (t, J=7.1 Hz, 2H), 1.78 (m, 1H),1.11 (d, J=6.6 Hz, 3H), 0.99 (d, J=6.6 Hz, 3H).

EXAMPLE 6(28)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.23 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.01 (t, J=4.8 Hz, 1H), 8.17 (dd, J=7.8, 1.5Hz, 1H), 7.94 (d, J=6.9 Hz, 1H), 7.85 (d, J=7.2 Hz, 1H), 7.74 (d, J=7.5Hz, 1H), 7.65 (t, J=7.2 Hz, 1H), 7.60-7.44 (m, 6H), 7.33 (m, 2H), 7.09(t, J=7.8 Hz, 1H), 5.26 (s, 2H), 4.91 (d, J=4.8 Hz, 2H), 2.93 (t, J=8.1Hz, 2H), 2.52 (t, J=8.1 Hz, 2H).

EXAMPLE 6(29)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.20 (chloroform:methanol=10:1);

NMR (300 z, CDCl₃): δ 8.12 (d, J=7.8 Hz, 1H), 7.90 (d, J=7.8 Hz, 1H),7.84 (d, J=8.4 Hz, 1H), 7.62-7.40 (m, 6H), 7.36-7.26 (m, 2H), 7.15 (ddd,J=8.7, 8.7, 3.0 Hz, 1H), 6.88 (m, 2H), 6.39 (t, J=4.8 Hz, 1H), 5.10 (d,J=4.8 Hz, 2H), 5.05 (s, 2H), 3.12 (t, J=7.5 Hz, 2H), 2.79 (t, J=7.5 Hz,2H).

EXAMPLE 6(30)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(pyridin-3-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.54 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.09 (d, J=8.1 Hz, 1H), 8.36 (d, J=3.3 Hz,1H), 8.27-8.16 (m, 2H), 7.97 (d, J=7.8 Hz, 1H), 7.84 (d, J=8.1 Hz, 1H),7.68-7.43 (m, 6H), 7.41-7.30 (m, 3H), 5.93 (m, 1H), 5.19 (s, 2H),2.98-2.80 (m, 2H), 2.62-2.38 (m, 2H), 1.97-1.76 (m, 2H), 1.59 (m, 1H),1.11 (d, J=6.0 Hz, 3H), 0.93 (d, J=6.0 Hz, 3H).

EXAMPLE 6(31)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-formylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 10.44 (s, 1H), 9.02 (t, J=6.0 Hz, 1H), 8.19(m, 1H), 7.97 (m, 1H), 7.87 (m, 1H), 7.78-7.42 (m, 8H), 7.40-7.28 (m,2H), 7.11 (t, J=7.5 Hz, 1H), 5.27 (s, 2H), 4.94 (d, J=6.0 Hz, 2H) 2.96(t, J=7.8 Hz, 2H), 2.55 (t, J=7.8 Hz, 2H).

EXAMPLE 6(32)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-hydroxymethylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.00 (t, J=5.7 Hz, 1H), 8.20 (d, J=7.8 Hz,1H), 7.97 (m, 1H), 7.87 (m, 1H), 7.66-7.30 (m, 8H), 7.20 (m, 1H), 7.02(d, J=8.1 Hz, 1H), 6.96 (t, J=7.5 Hz 1H), 5.10 (s, 2H), 5.03 (brs, 1H),4.94 (d, J=5.7 Hz, 2H), 4.57 (s, 2H), 2.96 (t, J=8.0 Hz, 2H), 2.54 (t,J=8.0 Hz, 2H).

EXAMPLE 6(33)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.31 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.45-7.25 (m, 10H), 7.02-6.93 (m, 3H), 6.40 (d,J=7.2 Hz, 1H), 5.23 (m, 1H), 5.02 (s, 2H), 3.01 (dt, J=2.7, 7.8 Hz, 2H),2.72 (t, J=7.8 Hz, 2H), 1.85-1.65 (m, 2H), 1.60 (m, 1H), 0.98 (d, J=6.3Hz, 6H).

EXAMPLE 6(34)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-acetylaminophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.07 (s, 1H), 9.00-8.92 (m, 1H), 8.17 (d,J=7.2 Hz, 1H), 7.98-7.91 (m, 1H), 7.88-7.76 (m, 2H), 7.68-7.40 (m, 6H),7.30 (d, J=8.1 Hz, 1H), 7.10-6.96 (m, 2H), 6.92-6.83 (m, 1H), 5.14 (s,2H), 4.92 (d, J=5.4 Hz, 2H), 2.94 (t, J=7.5 Hz, 2H), 2.52 (t, J=7.5 Hz,2H), 2.01 (s, 3H).

EXAMPLE 6(35)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.11 (d, J=8.4 Hz, 1H), 7.92-7.80 (m, 2H),7.61-7.36 (m, 6H), 7.29-7.23 (m, 1H), 6.93-6.78 (m, 4H), 6.42 (m, 1H),5.08 (d, J=5.4 Hz, 2H), 5.04 (s, 2H), 3.75 (s, 3H), 3.11 (t, J=7.2 Hz,2H), 2.78 (t, J=7.2 Hz, 2H).

EXAMPLE 6(36)3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-methoxymethylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.62 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.03 (brs, 1H), 8.20 (m, 1H), 7.97 (m, 1H),7.87 (m, 1H), 7.64-7.39 (m, 6H), 7.38-7.20 (m, 3H), 7.06 (d, J=8.1 Hz,1H), 6.95 (t, J=7.5 Hz, 1H), 5.11 (s, 2H), 4.93 (d, J=5.4 Hz, 2H), 4.43(s, 2H), 3.26 (s, 3H), 2.95 (t, J=7.8 Hz, 2H), 2.66-2.36 (m, 2H).

EXAMPLE 6(37)3-(2-((3-methyl-1-(4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.091 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.45-7.38 (m, 2H), 7.34-7.23 (m, 5H), 7.03-6.93(m, 3H), 6.88 (d, J=8.7 Hz, 2H), 6.33 (d, J=8.1 Hz, 1H), 5.19 (dt,J=8.1, 8.1 Hz, 1H), 5.02 (s, 2H), 3.80 (s, 3H), 3.01 (dt, J=3.0, 7.2 Hz,2H), 2.72 (t, J=7.2 Hz, 2H), 1.85-1.65 (m, 2H), 1.63 (m, 1H), 0.97 (d,J=6.6 Hz, 6H).

EXAMPLE 6(38)3-(2-(((1R)-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.17 (d, J=8.1 Hz, 1H), 7.90-7.76 (m, 2H),7.60-7.40 (m, 4H), 7.36-7.23 (m, 2H), 7.19 (d, J=8.3 Hz, 1H), 7.10 (m,1H), 7.00-6.88 (m, 4H), 6.30 (d, J=8.1 Hz, 1H), 6.10 (m, 1H), 3.10-2.98(m, 2H), 2.80-2.68 (m, 2H), 1.77 (d, J=6.6 Hz, 3H).

EXAMPLE 6(39)3-(2-(((1R)-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-(pyridin-2-yloxy)phenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.19 (d, J=8.4 Hz, 1H), 8.10 (m, 1H), 7.86 (m,1H), 7.78 (d, J=7.8 Hz, 1H), 7.68 (m, 1H), 7.59-7.40 (m, 4H), 7.28-7.20(m, 1H), 7.12-7.04 (m, 2H), 6.99 (m, 1H), 6.89 (d, J=8.4 Hz, 1H), 6.61(d, J=8.1 Hz, 1H), 6.10 (m, 1H), 3.10-3.00 (m, 2H), 2.76-2.66 (m, 2H),1.76 (d, J=6.6 Hz, 3H).

EXAMPLE 6(40)3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.44 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.24 (m, 7H), 7.08-6.93 (m, 5H), 6.40 (d,J=8.4 Hz, 1H), 5.21 (q, J=8.1 Hz, 1H), 5.02 (s, 2H), 3.05-2.95 (m, 2H),2.76-2.67 (m, 2H), 1.86-1.51 (m, 3H), 0.98 (d, J=6.6 Hz, 6H).

EXAMPLE 6(41)3-(2-((3-methyl-1-(4-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.44 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.12 (m, 9H), 7.02-6.92 (m, 3H), 6.33 (d,J=8.4 Hz, 1H), 5.20 (q, J=7.8 Hz, 1H), 5.02 (s, 2H), 3.07-2.95 (m, 2H),2.78-2.69 (m, 2H), 2.34 (s, 2H), 1.88-1.44 (m, 3H), 0.98 (d, J=6.3 Hz,6H).

EXAMPLE 6(42)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyridin-3-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.30 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.35-8.30 (m, 1H), 8.23 (dd, J=4.2, 1.8 Hz, 1H),7.44-7.22 (m, 10H), 6.84 (brd, J=9.0 Hz, 1H), 5.24 (q, J=6.9 Hz, 1H),5.06 (s, 2H), 3.01 (t, J=7.2 Hz, 2H), 2.75 (t, J=7.2 Hz, 2H), 2.30-1.52(m, 3H), 0.98 (d, J=6.6 Hz, 6H).

EXAMPLE 6(43)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyridin-4-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.23 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.44-8.30 (m, 2H), 7.78 (brd, J=8.1 Hz, 1H),7.44-7.23 (m, 8H), 6.93-6.82 (m, 2H), 5.24 (q, J=8.1 Hz, 1H), 5.14 (s,2H), 2.97 (t, J=6.3 Hz, 2H), 2.85-2.74 (m, 2H), 2.30-1.40 (m, 3H), 0.97(d, J=6.6 Hz, 6H).

EXAMPLE 6(44)3-(2-((1-phenylethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.63 (chloroform:methanol=5:1);

NMR (300 MHz, DMSO-d₆): δ 8.92 (d, J=7.8 Hz, 1H), 7.48-7.20 (m, 10H),7.07-6.91 (m, 3H), 5.13 (m, 1H), 5.09 (s, 2H), 2.87 (t, J=7.9 Hz, 2H),2.60-2.40 (m, 2H), 1.44 (d, J=7.2 Hz, 3H).

EXAMPLE 6(45)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyridin-2-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.59 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.16 (dd, J=5.1, 1.2 Hz, 1H), 7.65-7.55 (m, 1H),7.50-7.40 (m, 2H), 7.40-7.24 (m, 6H), 6.94-6.86 (m, 1H), 6.79 (d, J=8.4Hz, 1H), 6.41 (brd, J=8.4 Hz, 1H), 5.34 (s, 2H), 5.24 (q, J=8.4 Hz, 1H),3.08-2.90 (m, 2H), 2.72 (t, J=7.2 Hz, 2H), 2.00-1.40 (m, 3H), 0.98 (d,J=6.6 Hz, 6H).

EXAMPLE 6(46)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenylaminomethylphenyl)propanoicacid

TLC: Rf 0.45 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.10 (m, 10H), 6.73 (t, J=7.5 Hz, 1H), 6.61(d, J=7.5 Hz, 2H), 6.37 (d, J=8.4 Hz, 1H), 5.21 (q, J=7.2 Hz, 1H), 4.29(s, 2H), 3.05-2.87 (m, 2H), 2.76-2.60 (m, 2H), 1.84-1.47 (m, 3H), 0.96(d, J=6.6 Hz, 6H).

EXAMPLE 6(47)2-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenoxy)aceticacid

TLC: Rf 0.28 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 9.17 (d, J=8.1 Hz, 1H), 7.95 (d, J=2.1 Hz, 1H),7.54 (dd, J=8.4, 2.1 Hz, 1H), 7.40-7.13 (m, 8H), 7.00-6.87 (m, 3H), 5.12(m, 1H), 5.05 (s, 2H), 4.92 (s, 2H), 1.84 (m, 1H), 1.68-1.48 (m, 2H),0.90 (d, J=6.3 Hz, 3H), 0.89 (d, J=6.3 Hz, 3H).

EXAMPLE 6(48)3-(2-((1-phenylpropyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.47 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.83 (d, J=8.4 Hz, 1H), 7.44-7.18 (m, 10H),7.03-6.90 (m, 3H), 5.08 (s, 2H), 4.86 (m, 1H), 2.84 (t, J=7.8 Hz, 2H),2.46 (t, J=7.8 Hz, 2H), 1.82-1.64 (m, 2H), 0.90 (t, J=7.5 Hz, 3H).

EXAMPLE 6(49)3-(2-((1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.47 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.47-7.24 (m, 10H), 7.02-6.91 (m, 3H), 6.41 (d,J=8.1 Hz, 1H), 5.15 (q, J=7.8 Hz, 1H), 5.03 (s, 2H), 3.08-2.97 (m, 2H),2.78-2.69 (m, 2H), 1.98-1.74 (m, 2H), 1.52-1.23 (m, 2H), 0.96 (t, J=7.2Hz, 3H).

EXAMPLE 6(50)3-(2-((3-methylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.36 (hexane:ethyl acetate=1:3);

NMR (300 MHz, CDCl₃): δ 7.45-7.40 (m, 2H), 7.34-7.26 (m, 3H), 7.02-6.93(m, 3H), 6.14 (m, 1H), 5.03 (s, 2H), 3.50-3.41 (m, 2H), 3.08 (t, J=7.4Hz, 2H), 2.79 (t, J=7.4 Hz, 2H), 1.68 (m, 1H), 1.55-1.46 (m, 2H), 0.95(d, J=6.6 Hz, 6H).

EXAMPLE 6(51)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyrimidin-2-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.53 (d, J=4.5 Hz, 2H), 7.52-7.46 (m, 2H),7.40-7.20 (m, 6H), 6.97 (t, J=4.5 Hz, 1H), 6.45 (brd, J=7.8 Hz, 1H),5.40 (s, 2H), 5.28-5.18 (m, 1H), 3.01 (dt, J=2.7, 7.5 Hz, 2H), 2.72 (t,J=7.5 Hz, 2H), 1.90-1.40 (m, 3H), 0.99 (d, J=6.6 Hz, 6H).

EXAMPLE 6(52)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyrazin-2-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.27 (d, J=1.2 Hz, 1H), 8.15 (d, J=2.7 Hz, 1H),8.09 (dd, J=2.7, 1.2 Hz, 1H), 7.48-7.42 (m, 2H), 7.42-7.24 (m, 6H), 6.44(brd, J=8.1 Hz, 1H), 5.35 (s, 2H), 5.30-5.20 (m, 1H), 3.06-2.96 (m, 2H),2.80-2.70 (m, 2H), 1.88-1.40 (m, 3H), 0.99 (d, J=6.6 Hz, 6H).

EXAMPLE 6(53)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methylpyridin-3-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.28 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.00 (dd, J=4.8, 1.2 Hz, 1H), 7.43-7.14 (m,1H), 5.13 (s, 2H), 5.05 (m, 1H), 2.89-2.76 (m, 2H), 2.48-2.35 (m, 2H),2.39(s, 3H), 1.81-1.54 (m, 2H), 1.44 (m, 1H), 0.93 (d, J=6.6 Hz, 3H),0.90 (d, J=6.6 Hz, 3H).

EXAMPLE 6(54)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenylthiomethylphenyl)propanoicacid

TLC: Rf 0.34 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.75 (d, J=8.7 Hz, 1H), 7.38-7.13 (m, 13H),5.03 (m, 1H), 4.24 (s, 2H), 2.84-2.73 (m, 2H), 2.47-2.37 (m, 2H),1.79-1-54 (m, 2H), 1.42 (m, 1H), 0.92 (d, J=6.9 Hz, 3H), 0.90 (d, J=6.9Hz, 3H).

EXAMPLE 6(55)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(thiazol-2-ylthiomethyl)phenyl)propanoicacid

TLC: Rf 0.34 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.77 (d, J=8.7 Hz, 1H), 7.72 (d, J=3.3 Hz,1H), 7.66 (d, J=3.3 Hz, 1H), 7.39-7.18 (m, 8H), 5.03 (m, 1H), 4.48 (s,2H), 2.84-2.72 (m, 2H), 2.48-2.38 (m, 2H), 1.79-1-54 (m, 2H), 1.42 (m,1H), 0.92 (d, J=6.6 Hz, 3H), 0.90 (d, J=6.6 Hz, 3H).

EXAMPLE 6(56)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(1-methylimidazol-2-ylthiomethyl)phenyl)propanoicacid

TLC: Rf 0.28 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.70 (d, J=8.1 Hz, 1H), 7.38-7.14 (m, 8H),7.08 (s, 1H), 6.93 (t, J=1.2 Hz, 1H), 5.02 (m, 1H), 4.18 (s, 2H), 3.37(s, 3H), 2.85-2.73 (m, 2H), 2.48-2.37 (m, 2H), 1.80-1-55 (m, 2H), 1.43(m, 1H), 0.93 (d, J=6.6 Hz, 3H), 0.90 (d, J=6.6 Hz, 3H).

EXAMPLE 6(57)3-(2-((2-cyclopropyl-1-phenylethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

[Salt-Free]

TLC: Rf 0.37 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.74 (m, 1H), 7.48-7.22 (m, 9H), 7.00-6.93 (m,3H), 6.62 (d, J=7.2 Hz, 1H), 5.25 (dt, J=7.2, 7.5 Hz, 1H), 5.02 (s, 2H),3.03 (t, J=7.2 Hz, 2H), 2.74 (t, J=7.2 Hz, 2H), 1.88-1.72 (m, 2H), 0.66(m, 1H), 0.55-0.40 (m, 2H), 0.20-0.01 (m, 2H).

Sodium Salt:

TLC: Rf 0.44 (chloroform:methanol=9:1).

EXAMPLE 6(58)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-benzyloxyphenyl)propanoicacid

TLC: Rf 0.41 (chloroform:methanol=9:1).

NMR (300 MHz, CDCl₃): δ 7.44-7.24 (m, 10H), 7.18 (d, J=9.0 Hz, 1H),7.00-6.92 (m, 2H), 6.32 (brd, J=8.4 Hz, 1H), 5.26-5.16 (m, 1H), 5.04 (s,2H), 3.00-2.90 (m, 2H), 2.70 (t, J=6.9 Hz, 2H), 1.84-1.44 (m, 3H), 0.98(d, J=6.6 Hz, 6H).

EXAMPLE 6(59)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.50-7.24 (m, 8H), 7.22-7.10 (m, 2H), 6.95-6.80(m, 2H), 6.34 (brd, J=8.1 Hz, 1H), 5.30-5.20 (m, 1H), 5.05 (s, 2H),3.10-2.95 (m, 2H), 2.74 (t, J=7.8 Hz, 2H), 2.27 (s, 3H), 1.90-1.50 (m,3H), 1.00 (d, J=6.6 Hz, 3H), 0.99 (d, J=6.6 Hz, 3H).

EXAMPLE 6(60)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.48-7.24 (m, 8H), 7.00-6.84 (m, 4H), 6.44 (brd,J=8.4 Hz, 1H), 5.30-5.15 (m, 1H), 5.09 (s, 2H), 3.86 (s, 3H), 3.08-2.95(m, 2H), 2.72 (t, J=7.8 Hz, 2H), 1.90-1.50 (m, 3H), 0.98 (d, J=6.6 Hz,6H).

EXAMPLE 6(61)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-hydroxyphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.44 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.45-7.24 (m, 8H), 7.00-6.80 (m, 4H), 6.43 (brd,J=8.1 Hz, 1H), 5.80-5.50 (brs, 1H), 5.30-5.20 (m, 1H), 5.07 (s, 2H),3.10-2.97 (m, 2H), 2.74 (t, J=7.2 Hz, 2H), 1.90-1.50 (m, 3H), 0.99 (d,J=6.6 Hz, 6H).

EXAMPLE 6(62)3-(2-((2-phenylethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.42 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.42-7.20 (m, 10H), 7.00-6.90 (m, 3H), 6.25 (m,1H), 4.98 (s, 2H), 3.72 (dt, J=6.9, 6.0 Hz, 2H), 3.01 (t, J=7.2 Hz, 2H),2.94 (t, J=6.9 Hz, 2H), 2.74 (t, J=7.2 Hz, 2H).

EXAMPLE 6(63) 3-(2-benzylcarbamoyl-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.42 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.25 (m, 10H), 6.99-6.92 (m, 3H), 6.48 (m,1H), 5.00 (s, 2H), 4.61 (d, J=5.7 Hz, 2H), 3.10 (t, J=7.5 Hz, 2H), 2.77(t, J=7.5 Hz, 2H).

EXAMPLE 6(64)3-(2-((3-methyl-1-phenyl-3-butenyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.24 (m, 10H), 7.04-6.92 (m, 3H), 6.43(brd, J=7.5 Hz, 1H), 5.42-5.32 (m, 1H), 5.04 (s, 2H), 4.86 (brs, 1H),4.79 (brs, 1H), 3.04 (t, J=7.2 Hz, 2H), 2.74 (t, J=7.2 Hz, 2H),2.64-2.50 (m, 2H), 1.81 (s, 3H).

EXAMPLE 6(65) 3-(2-phenylcarbamoyl-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.42 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃+CD₃OD): δ 7.70-7.61 (m, 3H), 7.46 (m, 1H), 7.39-7.27(m, 5H), 7.14 (m, 1H), 7.00-6.95 (m, 3H), 5.06 (s, 2H), 3.11 (t, J=6.9Hz, 2H), 2.83 (t, J=6.9 Hz, 2H).

EXAMPLE 6(66)3-(2-((3-methyl-1-(4-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.39 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.61 (d, J=8.1 Hz, 2H), 7.51-7.40 (m, 4H),7.35-7.25 (m, 3H), 7.02-6.93 (m, 3H), 6.54 (d, J=8.1 Hz, 1H), 5.26 (m,1H), 5.03 (s, 2H), 3.01 (t, J=7.2 Hz, 2H), 2.76-2.68 (m, 2H), 1.84-1.55(m, 3H), 0.99 (d, J=6.3 Hz, 3H), 0.98 (d, J=6.3 Hz, 3H).

EXAMPLE 6(67)3-(2-((3-methyl-1-(4-ethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.45-7.37 (m, 2H), 7.34-7.24 (m, 5H), 7.02-6.92(m, 3H), 6.87 (d, J=8.4 Hz, 2H), 6.31 (d, J=8.4 Hz, 1H), 5.18 (m, 1H),5.01 (s, 2H), 4.02 (q, J=6.9 Hz, 2H), 3.06-2.98 (m, 2H), 2.76-2.68 (m,2H), 1.85-1.50 (m, 3H), 1.40 (t, J=6.9 Hz, 3H), 0.97 (d, J=6.6 Hz, 6H).

EXAMPLE 6(68)3-(2-((3-methyl-1-(3-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=9:1).

EXAMPLE 6(69)3-(2-((3-methyl-1-(3-chlorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=9:1).

EXAMPLE 6(70)3-(2-((3-methyl-1-(4-chlorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=9:1).

EXAMPLE 6(71)3-(2-((3-methyl-1-(3-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=9:1).

EXAMPLE 6(72)3-(2-((3-methyl-1-(3-chloro-4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=9:1).

EXAMPLE 6(73)3-(2-((3-methyl-1-(3-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(74)3-(2-((3-methyl-1-(3,4,5-trifluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(75)3-(2-((3-methyl-1-(3,5-ditrifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(76)3-(2-((3-methyl-1-(3-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(77)3-(2-((3-methyl-1-(4-ethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(78)3-(2-((3-methyl-1-(4-butylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(79)3-(2-((3-methyl-1-(4-fluoro-3-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(80)3-(2-((3-methyl-1-(3-fluoro-4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(81)3-(2-((3-methyl-1-(3-fluoro-4-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(82)3-(2-((3-methyl-1-(4-chloro-3-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(83)3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.69 (chloroform:methanol=10:1).

EXAMPLE 6(84)3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.67 (chloroform:methanol=10:1).

EXAMPLE 6(85)3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.66 (chloroform:methanol=10:1).

EXAMPLE 6(86)3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.64 (chloroform:methanol=10:1).

EXAMPLE 6(87)3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.66 (chloroform:methanol=10:1).

EXAMPLE 6(88)3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(pyridin-3-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1).

EXAMPLE 6(89)3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.60 (chloroform:methanol=10:1).

EXAMPLE 6(90)3-(2-((3-methyl-1-(4-t-butylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.72 (chloroform:methanol=10:1).

EXAMPLE 6(91)3-(2-((3-methyl-1-(2-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.68 (chloroform:methanol=10:1).

EXAMPLE 6(92)3-(2-((3-methyl-1-(4-fluoro-2-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.68 (chloroform:methanol=10:1).

EXAMPLE 6(93)3-(2-((3-methyl-1-(3-ethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(94)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(95)3-(2-((3-methyl-1-(3,5-dimethyl-4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(96)3-(2-((3-methyl-1-(5-methyl-2-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(97)3-(2-((3-methyl-1-(4-propylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(98)3-(2-((3-methyl-1-(3-trifluoromethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(99)3-(2-((3-methyl-1-(3-isopropylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(100)3-(2-((3-methyl-1-(3-isopropyloxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(101)3-(2-((3-methyl-1-(1,3-dioxaindan-5-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(102)3-(2-((3-methyl-1-(4-propoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(103)3-(2-((3-methyl-1-(2-fluoro-4-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(104)3-(2-((3-methyl-1-(4-trifluoromethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(105)3-(2-((3-methyl-1-(2,5-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(106)3-(2-((3-methyl-1-(1,4-benzodioxan-6-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(107)3-(2-((3-methyl-1-(4-difluoromethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(108)3-(2-((3-methyl-1-(3,4,5-trimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(109)3-(2-((3-methyl-1-(2-chloro-3,4-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(110)3-(2-((3-methyl-1-(4-isobutylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(111)3-(2-((3-methyl-1-(2-fluoro-5-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(112)3-(2-((3-methyl-1-(2-chloro-6-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(113)3-(2-((3-methyl-1-(2-chloro-5-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(114)3-(2-((3-methyl-1-(2-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(115)2-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methylphenoxymethyl)phenoxy)aceticacid

TLC: Rf 0.50 (ethyl acetate:methanol 5:1).

EXAMPLE 6(116)2-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenoxy)aceticacid

TLC: Rf 0.40 (ethyl acetate:methanol=5:1).

EXAMPLE 6(117)3-(2-((3-methyl-1-(4-acetylaminophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.10 (chloroform:methanol=9:1).

EXAMPLE 6(118)3-(2-((3-methyl-1-(3-fluoro-4-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(119)3-(2-((3-methyl-1-(4,5-dimethoxy-2-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(120)3-(2-((3-methyl-1-(2-fluoro-4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(121)3-(2-((3-methyl-1-(3,4-difluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(122)3-(2-((3-methyl-1-(4-methoxy-1,3-dioxaindan-6-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(123)3-(2-((3-methyl-1-(3-ethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.59 (chloroform:methanol=10:1).

EXAMPLE 6(124)3-(2-((3-methyl-1-(4-trifluoromethylthiophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1).

EXAMPLE 6(125)3-(2-((3-methyl-1-(2-difluoromethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.38 (chloroform:methanol=10:1).

EXAMPLE 6(126)3-(2-((3-methyl-1-(2,3,5,6-tetrafluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(127)3-(2-((3-methyl-1-(2-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(128)3-(2-((3-methyl-1-(2,5-difluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(129)3-(2-((3-methyl-1-(2-fluoro-5-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(130)3-(2-((3-methyl-1-(3,4-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(131)3-(2-((3-methyl-1-(2,4-difluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(132)3-(2-((3-methyl-1-(2,3,6-trifluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(133)3-(2-((3-methyl-1-(4-chloro-2-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(134)3-(2-((3-methyl-1-(2,4,5-trifluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(135)3-(2-((3-methyl-1-(2,3-difluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(136)3-(2-((3-methyl-1-(2-chloro-4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(137)3-(2-((3-methyl-1-(2,4,6-trifluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(138)3-(2-((3-methyl-1-(2,3-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(139)3-(2-((3-methyl-1-(4-diethylaminophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(140)3-(2-((3-methyl-1-(2,3,4,5,6-pentafluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(141)(2E)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)-2-propenoicacid

TLC: Rf 0.55 (chloroform:methanol=10:1).

EXAMPLE 6(142)3-(2-((3-methyl-1-(4-mesylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(143)3-(2-((3-methyl-1-(3-fluoro-2-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(144)3-(2-((3-methyl-1-(2,3,4-trifluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(145)3-(2-((3-methyl-1-(4-(pyrrolidin-1-yl)phenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(146)3-(2-((3-methyl-1-(4-dimethylaminophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(147)3-(2-((3-methyl-1-(4-dimethylamino-2-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(148)3-(2-((3-methyl-1-(2,4-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(149)3-(2-((3-methyl-1-(4-butoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(150)3-(2-((3-methyl-1-(4-ethoxy-3-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(151)3-(2-((3-methyl-1-(4-isopropyloxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(152)3-(2-((3-methyl-1-(3,4-diethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(153)3-(2-((3-methyl-1-(2,3,4-trimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(154)3-(2-((3-methyl-1-(2,4-dimethoxy-3-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(155)3-(2-((3-methyl-1-(thiophen-2-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(156)3-(2-((3-methyl-1-(2,4,5-trimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(157)3-(2-((3-methyl-1-(3-methylthiophen-2-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(158)3-(2-((3-methyl-1-(2,3-dimethyl-4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(159)3-(2-((3-methyl-1-(2,5-dimethyl-4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(160)3-(2-((3-methyl-1-(4-methoxy-3-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(161)3-(2-((3-methyl-1-(5-methylfuran-2-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(162)3-(2-((3-methyl-1-(2,4-diethoxy-3-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(163)3-(2-((3-methyl-1-(1-methylpyrrol-2-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(164)3-(2-((3-methyl-1-(4-ethylthiophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(165)3-(2-((3-methyl-1-(3-trifluoromethylthiophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(166)3-(2-((3-methyl-1-(4-methylthiophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(167)3-(2-((3-methyl-1-(4-cyanophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.40(

10:1).

EXAMPLE 6(168)3-(2-((3-methyl-1-(thiophen-3-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(169)3-(2-((3-methyl-1-(2,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(170)3-(2-((3-methyl-1-(3,4-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(171)3-(2-((3-methyl-1-(1,3-dioxaindan-4-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(172)3-(2-(N-benzyl-N-methylcarbamoyl)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.45 (chloroform:methanol=10:1).

EXAMPLE 6(173)3-(2-(N-benzyl-N-propylcarbamoyl)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.50 (chloroform:methanol=10:1).

EXAMPLE 6(174)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-benzyloxymethylphenyl)propanoicacid

TLC: Rf 0.41 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.42-7.19 (m, 13H), 6.36 (d, J=8.7 Hz, 1H), 5.24(m, 1H), 4.57 (s, 2H), 4.52 (s, 2H), 3.04-2.96 (m, 2H), 2.75-2.66 (m,2H), 1.86-1.52 (m, 3H), 0.99 (d, J=6.5 Hz, 3H), 0.98 (d, J=6.5 Hz, 3H).

EXAMPLE 6(175)3-(2-((3-methyl-1-(3-fluoro-5-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(176)3-(2-((3-methyl-1-(4-fluoro-2-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(177)3-(2-((3-methyl-1-(2,4-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(178)3-(2-((3-methyl-1-(2,4-ditrifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(179)3-(2-((3-methyl-1-(2-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(180)3-(2-((3-methyl-1-(2,3-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 6(181)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(furan-2-ylcarbonylaminomethyl)phenyl)propanoicacid

TLC: Rf 0.29 (chloroform:methanol=10:1).

EXAMPLE 6(182)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.36 (chloroform:methanol=9:1).

EXAMPLE 6(183)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-phenylethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.23 (m, 7H), 7.22-7.15 (m, 3H), 7.13-7.07(m, 2H), 6.88 (s, 1H), 6.05 (d, J=8.7 Hz, 1H), 5.20 (m, 1H), 3.01-2.92(m, 2H), 2.88 (s, 4H), 2.74-2.66 (m, 2H), 1.82-1.59 (m, 3H), 0.99 (d,J=6.6 Hz, 3H), 0.98 (d, J=6.6 Hz, 3H).

EXAMPLE 6(184)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-cyclopropylmethoxymethylphenyl)propanoicacid

TLC: Rf 0.45 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.06 (s, 1H), 8.78 (d, J=8.4 Hz, 1H),7.38-7.18 (m, 8H), 5.09-5.01 (m, 1H), 4.45 (s, 2H), 3.28 (d, J=6.6 Hz,2H), 2.85-2.79 (m, 2H), 2.46-2.41 (m, 2H), 1.80-1.58 (m, 2H), 1.48-1.39(m, 1H), 1.80-0.98 (m, 1H), 0.94-0.89 (m, 6H), 0.49-0.43 (m, 2H),0.19-0.14 (m, 2H).

EXAMPLE 6(185)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.58 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.48-7.06 (m, 7H), 6.95 (s, 2H), 6.90 (s, 1H),6.42 (m, 1H), 5.16 (m, 1H), 5.00 (s, 2H), 3.10-2.92 (m, 2H), 2.78-2.62(m, 2H), 2.29 (s, 6H), 1.86-1.48 (m, 3H), 0.97 (d, J=6.3 Hz, 6H).

EXAMPLE 6(186)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.62 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.39 (m, 2H), 7.31-7.22 (m, 1H), 7.20-7.11(m, 2H), 6.95 (s, 2H), 6.93-6.82 (m, 3H), 6.26 (d, J=8.4 Hz, 1H), 5.17(m, 1H), 5.04 (s, 2H), 3.14-2.99 (m, 2H), 2.78-2.67 (m, 2H), 2.31 (s,6H), 2.27 (s, 3H), 1.85-1.52 (m, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.98 (d,J=6.6 Hz, 3H).

EXAMPLE 6(187)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.53 (d, J=1.8 Hz, 1H), 7.43 (dd, J=7.5, 1.8 Hz,1H), 7.33-7.22 (m, 2H), 6.96 (s, 2H), 6.91 (s, 1H), 6.79 (s, 1H), 6.75(m, 1H), 6.30 (d, J=8.4 Hz, 1H), 5.17 (m, 1H), 5.09 (s, 2H), 3.12-2.98(m, 2H), 2.78-2.69 (m, 2H), 2.31 (s, 9H), 1.86-1.55 (m, 3H), 0.99 (d,J=6.3 Hz, 3H), 0.98 (d, J=6.3 Hz, 3H).

EXAMPLE 6(188)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(pyridin-3-yloxymethyl)phenyl)propanoicacid

TLC: Rf 0.37 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.79 (d, J=8.7 Hz, 1H), 8.36 (d, J=2.7 Hz,1H), 8.19 (m, 1H), 7.50-7.41 (m, 2H), 7.39-7.29 (m, 3H), 6.97 (s, 2H),6.86 (s, 1H), 5.19 (s, 2H), 4.99 (m, 1H), 2.92-2.80 (m, 2H), 2.55-2.42(m, 2H), 2.26 (s, 6H), 1.82-1.55 (m, 2H), 1.42 (m, 1H), 0.93 (t, J=7.3Hz, 6H).

EXAMPLE 6(189)3-(2-((3-methyl-1-(4-methoxy-1,3-dioxaindan-6-yl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.42 (m, 2H), 7.31-7.11 (m, 2H), 6.94-6.84(m, 2H), 6.55 (d, J=9.9 Hz, 2H), 6.32 (d, J=8.4 Hz, 1H), 5.95 (s, 2H),5.15 (m, 1H), 5.05 (s, 2H), 3.91 (s, 3H), 3.03 (t, J=7.2 Hz, 2H), 2.75(t, J=7.2 Hz, 2H), 2.27 (s, 3H), 1.85-1.50 (m, 3H), 0.98 (d, J=6.0 Hz,6H).

EXAMPLE 6(190)3-(2-((3-methyl-1-(4-methoxy-1,3-dioxaindan-6-yl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.12 (m, 7H), 6.56 (dd, J=10.5, 1.5 Hz,2H), 6.46 (d, J=8.4 Hz, 1H), 5.94 (s, 2H), 5.13 (m, 1H), 5.03 (s, 2H),3.90 (s, 3H), 3.02 (t, J=7.2 Hz, 2H), 2.74 (t, J=7.2 Hz, 2H), 1.85-1.55(m, 3H), 0.97 (d, J=6.6 Hz, 6H).

EXAMPLE 6(191)3-(2-((3-methyl-1-(4-methoxy-1,3-dioxaindan-6-yl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.51 (s, 1H), 7.44 (d, J=7.8 Hz, 1H), 7.30-7.23(m, 3H), 6.79 (s, 1H), 6.75 (d, J=8.4 Hz, 1H) 6.55 (d, J=7.2 Hz, 2H),6.36 (d, J=8.7 Hz, 1H), 5.95 (s, 2H), 5.13 (m, 1H), 5.09 (s, 2H), 3.91(s, 3H), 3.04 (t, J=7.2 Hz, 2H), 2.74 (t, J=7.2 Hz, 2H), 2.27 (s, 3H),1.82-1.50 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 6(192)3-(2-((3-methyl-1-(3,5-dichlorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.48-7.42 (m, 2H), 7.35-7.24 (m, 6H), 7.02-6.94(m, 3H), 6.58 (d, J=8.4 Hz, 1H), 5.20-5.10 (m, 1H), 5.05 (s, 2H),3.05-2.97 (m, 2H), 2.85-2.70 (m, 2H), 1.80-1.40 (m, 3H), 0.99 (d, J=5.7Hz, 3H), 0.98 (d, J=5.7 Hz, 3H).

EXAMPLE 6(193)3-(2-((3-methyl-1-(3-chloro-5-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.50-7.40 (m, 2H), 7.35-7.15 (m, 6H), 7.05-6.94(m, 3H), 6.80-6.70 (m, 1H), 6.00-5.85 (m, 1H), 5.04 (s, 2H), 3.10-3.00(m, 2H), 2.80-2.70 (m, 2H), 2.00-1.40 (m, 3H), 1.02 (d, J=6.0 Hz, 3H),1.01 (d, J=6.0 Hz, 3H).

EXAMPLE 6(194)3-(2-((3-methyl-1-(4-fluoro-3-methylphenyl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.23 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.45-7.42 (m, 2H), 7.28 (m, 1H), 7.20-7.10 (m,4H), 6.97 (m, 1H), 6.92-6.84 (m, 2H), 6.30 (brd, J=8.7 Hz, 1H), 5.17 (m,1H), 5.05 (s, 2H), 3.08-2.95 (m, 2H), 2.75-2.71 (m, 2H), 2.27 (s, 6H),1.82-1.55 (m, 3H), 0.99 (d, J=6.3 Hz, 3H), 0.98 (d, J=6.3 Hz, 3H).

EXAMPLE 6(195)3-(2-((3-methyl-1-(4-fluoro-3-methylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.23 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.52 (brs, 1H), 7.43 (m, 1H), 7.30-7.24 (m, 2H),7.18-7.11 (m, 2H), 6.97 (m, 1H), 6.79 (brs, 1H), 6.75 (brd, J=7.8 Hz,1H), 6.34 (brd, J=8.1 Hz, 1H), 5.16 (m, 1H), 5.09 (s, 2H), 3.11-2.96 (m,2H), 2.75-2.70 (m, 2H), 2.32 (s, 3H), 2.27 (d, J=1.5 Hz, 3H), 1.87-1.54(m, 3H), 0.99 (d, J=6.3 Hz, 3H), 0.98 (d, J=6.3 Hz, 3H).

EXAMPLE 6(196)3-(2-((3-methyl-1-(3,5-difluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.48-7.40 (m, 2H), 7.35-7.24 (m, 3H), 7.02-6.94(m, 3H), 6.94-6.84 (m, 2H), 6.76-6.66 (m, 1H), 6.54 (brd, J=8.4 Hz, 1H),5.23-5.13 (m, 1H), 5.04 (s, 2H), 3.02 (t, J=7.2 Hz, 2H), 2.80-2.70 (m,2H), 1.80-1.40 (m, 3H), 0.99 (d, J=6.0 Hz, 3H), 0.98 (d, J=6.0 Hz, 3H).

EXAMPLE 6(197)3-(2-((3-methyl-1-(3,5-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.47-7.40 (m, 2H), 7.34-7.20 (m, 3H), 7.02-6.90(m, 3H), 6.51 (d, J=2.1 Hz, 2H), 6.40-6.35 (m, 2H), 5.20-5.10 (m, 1H),5.03 (s, 2H), 3.79 (s, 6H), 3.08-3.00 (m, 2H), 2.76 (t, J=7.5 Hz, 2H),1.80-1.50 (m, 3H), 0.99 (d, J=6.3 Hz, 6H).

EXAMPLE 6(198)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(1-phenoxyethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.18 (m, 10H), 6.94-6.82 (m, 3H), 6.25 (d,J=8.4 Hz, 1H), 5.30 (q, J=6.6 Hz, 1H), 5.22 (m, 1H), 2.96 (m, 2H), 2.70(m, 2H), 1.80-1.45 (m, 3H), 1.62 (m, 3H), 1.00-0.95 (m, 6H).

EXAMPLE 6(199)3-(2-((2-methoxy-2-phenylethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.39 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.27 (m, 10H), 7.02-6.95 (m, 3H), 6.51 (m,1H), 5.03 (s, 2H), 4.41 (dd, J=8.4, 3.9 Hz, 1H), 3.87 (ddd, J=13.5, 6.9,3.9 Hz, 1H), 3.46 (ddd, J=13.5, 8.4, 4.5 Hz, 1H), 3.28 (s, 3H), 3.07 (t,J=7.5 Hz, 2H), 2.76 (t, J=7.5 Hz, 2H).

EXAMPLE 6(200)3-(2-((2-phenylpropyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.34 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.20 (m, 10H), 7.02-6.91 (m, 3H), 6.03 (dd,J=6.0, 5.7 Hz, 1H), 4.96 (s, 2H), 3.80 (ddd, J=13.5, 6.0, 6.0 Hz, 1H),3.48 (ddd, J=13.5, 9.3, 5.7 Hz, 1H), 3.10 (m, 1H), 2.95 (t, J=7.5 Hz,2H), 2.71 (t, J=7.5 Hz, 2H), 1.34 (d, J=6.9 Hz, 3H).

EXAMPLE 6(201)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-phenoxyethyl)phenyl)propanoicacid

TLC: Rf 0.38 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.38-7.18 (m, 10H), 6.98-6.84 (m, 3H), 6.30 (d,J=8.1 Hz, 1H), 5.23 (dt, J=8.1, 6.3 Hz, 1H), 4.16 (t, J=6.9 Hz, 2H),3.07 (t, J=6.9 Hz, 2H), 2.99 (dt, J=3.3, 6.9 Hz, 2H), 2.72 (t, J=6.9 Hz,2H), 1.82-1.50 (m, 3H), 0.98 (d, J=6.6 Hz, 6H).

EXAMPLE 6(202)3-(2-(3-phenylmorpholin-4-ylcarbonyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.31 (chloroform:methanol=10:1).

EXAMPLE 6(203)3-(2-(4-phenoxypiperidin-1-ylcarbonyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.38 (chloroform:methanol=10:1).

EXAMPLE 6(204)3-(2-((2-methoxy-1-(3,5-dimethylphenyl)ethyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.39 (hexane:ethyl acetate=1:1).

EXAMPLE 6(205)3-(2-((4-methyl-2-phenylpentyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.44 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.15 (m, 10H), 7.10-6.90 (m, 3H), 5.92 (t,J=5.4 Hz, 1H), 4.95 (s, 2H), 3.86 (ddd, J=13.5, 5.4, 5.4 Hz, 1H), 3.40(ddd, J=13.5, 9.9, 5.4 Hz, 1H), 3.01 (m, 1H), 2.94 (t, J=7.2 Hz, 2H),2.71 (t, J=7.2 Hz, 2H), 1.65-1.40 (m, 3H), 0.89 (d, J=6.6 Hz, 3H), 0.87(d, J=6.6 Hz, 3H).

EXAMPLE 6(206)3-(2-diphenylmethylcarbamoyl-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.42 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.39 (d, J=8.7 Hz, 1H), 7.43-7.20 (m, 15H),7.03-6.90 (m, 3H), 6.36 (d, J=8.7 Hz, 1H), 5.07 (s, 2H), 2.85 (t, J=7.8Hz, 2H), 2.44 (m, 2H).

EXAMPLE 6(207)3-(2-((2-cyclopropyl-1-(3,5-dimethylphenyl)ethyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.57 (s, 1H), 7.44 (d, J=8.1 Hz, 1H), 7.32-7.24(m, 2H), 6.96 (s, 2H), 6.91 (s, 1H), 6.79 (s, 1H), 6.74 (d, J=8.1 Hz,1H), 6.45 (d, J=8.1 Hz, 1H), 5.18 (m, 1H), 5.10 (s, 2H), 3.07 (m, 2H),2.76 (t, J=7.2 Hz, 2H), 2.31 (s, 9H), 1.76 (m, 2H), 0.69 (m, 1H),0.55-0.40 (m, 2H), 0.22-0.06 (m, 2H).

EXAMPLE 6(208)3-(2-((1-(3,5-dimethylphenyl)ethyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.46 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.53 (s, 1H), 7.44 (d, J=7.8 Hz, 1H), 7.30-7.23(m, 2H), 6.99 (s, 2H), 6.92 (s, 1H), 6.78 (s, 1H), 6.74 (d, J=7.8 Hz,1H), 6.36 (d, J=7.5 Hz, 1H), 5.23 (dq, J=7.5, 6.9 Hz, 1H), 5.08 (s, 2H),3.08 (t, J=7.5 Hz, 2H), 2.77 (t, J=7.5 Hz, 2H), 2.32 (s, 6H), 2.31 (s,3H), 1.57 (d, J=6.9 Hz, 3H).

EXAMPLE 6(209)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethyl-5-methoxyphenyl)propanoicacid

TLC: Rf 0.28 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 7.46 (s, 1H), 7.38-7.22 (m, 7H), 7.02-6.94 (m,3H), 6.78 (s, 1H), 6.19 (d, J=8.4 Hz, 1H), 5.19 (m, 1H), 5.06 (s, 2H),3.87 (s, 3H), 3.06 (m, 2H), 2.76 (t, J=7.5 Hz, 2H), 1.82-1.50 (m, 3H),0.972 (d, J=6.6 Hz, 3H), 0.969 (d, J=6.6 Hz, 3H).

EXAMPLE 6(210)3-(2-((1-methyl-2-phenylethyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.34 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.43-7.16 (m, 10H), 7.03-6.92 (m, 3H), 5.99 (d,J=8.1 Hz, 1H), 4.98 (s, 2H), 4.49 (m, 1H), 3.00-2.90 (m, 2H), 2.87 (d,J=6.6 Hz, 2H), 2.80-2.65 (m, 2H), 1.26 (d, J=6.6 Hz, 3H).

EXAMPLE 6(211)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(benzothiazol-2-yl)phenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol=10:1).

EXAMPLE 6(212)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(1,3-dioxaindan-2-yl)phenyl)propanoicacid

TLC: Rf 0.46 (chloroform:methanol=10:1).

EXAMPLE 6(213)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(indol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol 10:1).

EXAMPLE 6(214)3-(2-((4-methyl-1-phenylpentan-2-yl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.43-7.16 (m, 10H), 7.04-6.93 (m, 3H), 5.76 (d,J=9.0 Hz, 1H), 4.99 (s, 2H), 4.53 (m, 1H), 3.02-2.66 (m, 6H), 1.72 (m,1H), 1.52-1.35 (m, 2H), 0.97 (d, J=6.0 Hz, 3H), 0.95 (d, J=6.0 Hz, 3H).

EXAMPLE 6(215)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethyl-5-methylphenyl)propanoicacid

TLC: Rf 0.23 (hexane:ethyl acetate=2:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 7.40 (s, 1H), 7.36-7.25 (m, 7H), 7.12 (s, 1H),7.03-6.95 (m, 3H), 6.31 (d, J=8.1 Hz, 1H), 5.21 (m, 1H), 4.99 (s, 2H),3.01 (m, 2H), 2.74 (t, J=7.5 Hz, 2H), 2.35 (s, 3H), 1.85-1.55 (m, 3H),0.97 (d, J=6.6 Hz, 6H).

EXAMPLE 6(216)3-(2-((naphthalen-2-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.37 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 12.14 (brs, 1H), 9.01 (t, J=5.7 Hz, 1H),7.95-7.77 (m, 5H), 7.57-7.44 (m, 4H), 7.33-7.26 (m, 2H), 7.20 (d, J=8.1Hz, 1H), 6.28 (m, 1H), 5.34 (s, 2H), 4.60 (d, J=5.7 Hz, 2H), 2.92 (t,J=7.8 Hz, 2H), 2.57-2.48 (m, 2H).

EXAMPLE 6(217)3-(2-((3-methyl-1-phenylbutyl)sulfamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.46 (chloroform:methanol=5:1);

NMR (300 MHz, CDCl₃): δ 7.77 (s, 1H), 7.43 (d, J=8.1 Hz, 1H), 7.38-7.25(m, 2H), 7.20-6.90 (m, 9H), 6.10-5.95 (m, 1H), 4.94 (s, 2H), 4.32 (q,J=7.5 Hz, 1H), 3.25-3.00 (m, 2H), 2.72 (ddd, J=16.2, 10.2, 5.7 Hz, 1H),2.51 (ddd, J=16.2, 10.5, 5.7 Hz, 1H), 1.80-1.40 (m, 3H), 0.88 (d, J=6.6Hz, 3H), 0.85 (d, J=6.6 Hz, 3H).

EXAMPLE 6(218)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.54 (chloroform:methanol=10:1).

EXAMPLE 6(219)3-(2-((3-methyl-1-(3,5-dimethoxyphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=10:1).

EXAMPLE 6(220)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-3-methyl-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.38 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 7.40-7.25(m, 8H), 7.07 (d, J=8.1 Hz, 1H),7.01-6.93 (m, 3H), 6.18 (d, J=8.7 Hz, 1H), 5.29 (m, 1H), 4.96 (s, 2H),2.90 (m, 2H), 2.62 (m, 2H), 2.22 (bs, 3H), 1.90-1.55 (m, 3H), 0.99 (d,J=6.3 Hz, 3H), 0.98 (d, J=6.3 Hz, 3H).

EXAMPLE 6(221)2-(2-(3-methyl-1-phenylbutyl)carbamoyl-4-phenoxymethylbenzyloxy)aceticacid

TLC: Rf 0.44 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.57 (d, J=1.5 Hz, 1H), 7.49 (dd, J=7.8, 1.5 Hz,1H), 7.39-7.24 (m, 8H), 7.03-6.92 (m, 3H), 6.65 (d, J=8.4 Hz, 1H), 5.24(m, 1H), 5.08 (s, 2H), 4.67 (d, J=11 Hz, 1H), 4.56 (d, J=11 Hz, 1H),3.99 (d, J=17 Hz, 1H), 3.94 (d, J=17 Hz, 1H), 1.89-1.52 (m, 3H), 0.99(d, J=6.5 Hz, 3H), 0.98 (d, J=6.5 Hz, 3H).

EXAMPLE 6(222)3-(2-((3-hydroxy-3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1).

EXAMPLE 6(223)4-(3-methyl-1-phenylbutylcarbamoyl)-2-benzofurancarboxylic acid

TLC: Rf 0.29 (chloroform:methanol:acetic acid=90:10:1);

NMR (300 MHz, DMSO-d₆): δ 8.94 (d, J=8.7 Hz, 1H), 7.90-7.82 (m, 2H),7.79 (d, J=0.6 Hz, 1H), 7.59 (t, J=8.0 Hz, 1H), 7.45-7.39 (m, 2H),7.36-7.28 (m, 2H), 7.22 (m, 1H), 5.15 (m, 1H), 1.87 (m, 1H), 1.70-1.48(m, 2H), 0.93 (d, J=6.3 Hz, 6H).

EXAMPLE 6(224)7-(3-methyl-1-phenylbutylcarbamoyl)-2-benzofurancarboxylic acid

TLC: Rf 0.53 (chloroform:methanol:acetic acid=90:10:1);

NMR (300 MHz, DMSO-d₆): δ 8.74 (d, J=8.1 Hz, 1H), 7.91 (d, J=8.1 Hz,1H), 7.76-7.69 (m, 2H), 7.50-7.18 (m, 6H), 5.14 (m, 1H), 1.88-1.71 (m,2H), 1.52 (m, 1H), 0.95 (d, J=6.2 Hz, 3H), 0.93 (d, J=6.2 Hz, 3H).

EXAMPLE 6(225) 2-(7-(3-methyl-1-phenylbutylcarbamoyl)indol-1-yl)aceticacid

TLC: Rf 0.35 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.56 (s, 1H), 8.99 (d, J=8.7 Hz, 1H), 7.65(d, J=7.8 Hz, 1H), 7.41-7.31 (m, 5H), 7.25-7.20 (m, 1H), 7.14 (d, J=6.6Hz, 1H), 7.05 (t, J=7.8 Hz, 1H), 6.52 (d, J=3.0 Hz, 1H), 5.17 (d, J=18.3Hz, 1H), 5.12-5.06 (m, 1H), 4.97 (d, J=18.3 Hz, 1H), 1.84-1.74 (m, 1H),1.68-1.55 (m, 1H), 1.50-1.41 (m, 1H), 0.95 (d, J=6.3 Hz, 3H), 0.91 (d,J=6.3 Hz, 3H).

EXAMPLE 6(226) 2-(7-(3-methyl-1-phenylbutylcarbamoyl)indol-3-yl)aceticacid

TLC: Rf 0.60 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 10.25 (brs, 1H), 7.76 (d, J=7.8 Hz, 1H),7.40-7.23 (m, 7H), 7.11 (t, J=7.8 Hz, 1H), 6.98 (d, J=6.9 Hz, 1H),5.31-5.23 (m, 1H), 3.80 (s, 2H), 1.89-1.58 (m, 3H), 1.01-0.97 (m, 6H).

EXAMPLE 6(227) 7-(3-methyl-1-phenylbutylcarbamoyl)naphthalenecarboxylicacid

TLC: Rf 0.33 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.31 (s, 1H), 8.96 (d, J=8.4 Hz, 1H),8.24-8.13 (m, 2H), 8.08 (d, J=8.7 Hz, 1H), 7.97 (d, J=8.7 Hz, 1H), 7.66(m, 1H), 7.47-7.17 (m, 5H), 5.14 (m, 1H), 1.88 (m, 1H), 1.67(m, 1H),1.54 (m, 1H), 0.94 (d, J=6.3 Hz, 6H).

EXAMPLE 6(228)2-(1-benzyl-3-(3-methyl-1-phenylbutylcarbamoyl)indol-4-yl)acetic acid

TLC: Rf 0.38 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, DMSO-d₆): δ 12.24 (brs, 1H), 8.56 (brd, J=8.7 Hz, 1H),8.01 (s, 1H), 7.50-7.20 (m, 1H), 7.09 (t, J=7.5 Hz, 1H), 6.92 (d, J=7.5Hz, 1H), 5.47 (s, 2H), 5.20-5.05 (m, 1H), 4.24 (d, J=15.3 Hz, 1H), 4.01(d, J=15.3 Hz, 1H), 1.90-1.45 (m, 3H), 0.95 (t, J=6.0 Hz, 6H).

EXAMPLE 6(229)3-(1-benzyl-3-(3-methyl-1-phenylbutylcarbamoyl)indol-4-yl)propanoic acid

TLC: Rf 0.33 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, DMSO-d₆): δ 11.84 (brs, 1H), 8.48 (brd, J=8.4 Hz, 1H),7.87 (s, 1H), 7.50-7.20 (m, 1H), 7.04 (t, J=7.2 Hz, 1H), 6.89 (d, J=7.2Hz, 1H), 5.45 (s, 2H), 5.20-5.05 (m, 1H), 3.40-3.10 (m, 2H), 2.38 (dt,J=2.4, 7.8 Hz, 2H), 1.90-1.45 (m, 3H), 0.95 (t, J=6.3 Hz, 6H).

EXAMPLE 6(230)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methoxymethylphenyl)propanoicacid

TLC: Rf 0.27 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, DMSO-d₆): δ 8.82 (d, J=8.7 Hz, 1H), 7.41-7.16 (m, 8H),5.07 (m, 1H), 4.40 (s, 2H), 3.30 (s, 3H), 2.92-2.75 (m, 2H), 2.55-2.40(m, 2H), 1.85-1.40 (m, 3H), 0.98-0.89 (m, 6H).

EXAMPLE 6(231) 2-(7-(3-methyl-1-phenylbutylcarbamoyl)indolin-1-yl)aceticacid

TLC: Rf 0.40 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.26 (s, 1H), 8.73 (d, J=7.8 Hz, 1H),7.36-7.28 (m, 4H), 7.22-7.16 (m, 1H), 7.06 (d, J=7.2 Hz, 1H), 6.93 (d,J=7.2 Hz, 1H), 6.57 (t, J=7.5 Hz, 1H), 5.04-4.96 (m, 1H), 4.11 (d,J=18.3 Hz, 1H), 3.85 (d, J=18.3 Hz, 1H), 3.47 (t, J=8.4 Hz, 2H),2.96-2.90 (m, 2H), 1.80-1.34 (m, 3H), 0.92-0.88 (m, 6H).

EXAMPLE 6(232)3-(7-(3-methyl-1-phenylbutylcarbamoyl)indolin-1-yl)propanoic acid

TLC: Rf 0.70 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.09 (brs, 1H), 8.73 (d, J=9.0 Hz, 1H),7.38-7.18 (m, 5H), 7.05 (d, J=7.5 Hz, 1H), 6.90 (d, J=7.5 Hz, 1H), 6.57(t, J=7.5 Hz, 1H), 5.04-4.95 (m, 1H), 3.41-3.35 (m, 2H), 3.23 (t, J=7.5Hz, 2H), 2.90-2.84 (m, 2H), 2.30-2.24 (m, 2H), 1.80-1.41 (m, 3H), 0.90(d, J=6.3 Hz, 6H).

EXAMPLE 6(233)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-cyanophenyl)propanoic acid

TLC: Rf 0.42 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.65-7.58 (m, 2H), 7.41-7.25 (m, 6H), 6.50 (d,J=8.1 Hz, 1H), 5.22 (m, 1H), 3.09-2.97 (m, 2H), 2.77-2.65 (m, 2H),1.87-1.52 (m, 3H), 0.99 (d, J=6.6 Hz, 6H).

EXAMPLE 6(234)1-benzyl-3-(3-methyl-1-phenylbutylcarbamoyl)-5-indolecarboxylici acid

TLC: Rf 0.47 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 8.81 (s, 1H), 8.39-8.31 (m, 2H), 7.75 (dd,J=8.9, 1.5 Hz, 1H), 7.59 (d, J=8.9 Hz, 1H), 7.43-7.16 (m, 10H), 5.51 (s,2H), 5.13 (m, 1H), 1.79 (m, 1H), 1.69-1.48 (m, 2H), 0.93 (d, J=6.6 Hz,6H).

EXAMPLE 6(235)3-(8-(3-methyl-1-phenylbutylcarbamoyl)-1,2,3,4-tetrahydroquinolin-1-yl)propanoicacid

TLC: Rf 0.56 (methylene chloride:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.75 (d, J=8.1 Hz, 1H), 7.40-7.27 (m, 4H),7.23 (m, 1H), 7.03-6.94 (m, 2H), 6.69 (t, J=7.5 Hz, 1H), 4.98 (m, 1H),3.22-3.02 (m, 4H), 2.67 (t, J=6.0 Hz, 2H), 2.40-2.17 (m, 2H), 1.84-1.67(m, 3H), 1.62-1.42 (m, 2H), 0.91 (d, J=6.3 Hz, 3H), 0.90 (d, J=6.3 Hz,3H).

EXAMPLE 6(236)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methylsulfonylaminophenyl)propanoicacid

TLC: Rf 0.55 (ethyl acetate).

EXAMPLE 6(237)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(N-methyl-N-methylsulfonylamino)phenyl)propanoicacid

TLC: Rf 0.55 (ethyl acetate).

EXAMPLE 6(238)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methoxycarbonylaminophenyl)propanoicacid

TLC: Rf 0.65 (ethyl acetate).

EXAMPLE 6(239)3-(2-((3-methyl-1-(3-methylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.43-7.06 (m, 11H), 6.40 (d, J=8.7 Hz, 1H), 5.21(dt, J=8.7, 8.7 Hz, 1H), 5.04 (s, 2H), 3.03 (m, 2H), 2.74 (t, J=7.5 Hz,2H), 2.35 (s, 3H), 1.85-1.58 (m, 3H), 0.99 (d, J=6.3 Hz, 6H).

EXAMPLE 6(240)3-(2-((3-methyl-1-(3-methoxyphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.43 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.42-7.15 (m, 8H), 6.95 (d, J=7.8 Hz, 1H), 6.91(m, 1H), 6.81 (dd, J=8.4, 2.7 Hz, 1H), 6.45 (d, J=8.1 Hz, 1H), 5.22 (dt,J=8.1, 8.1 Hz, 1H), 5.03 (s, 2H), 3.81 (s, 3H), 3.02 (t, J=7.2 Hz, 2H),2.74 (t, J=7.2 Hz, 2H), 1.83-1.58 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 6(241)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-dibenzylaminophenyl)propanoicacid

TLC: Rf 0.50 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, DMSO-d₆): δ 11.94 (s, 1H), 8.56 (d, J=8.7 Hz, 1H),7.35-7.18 (m, 15H), 6.96 (d, J=8.4 Hz, 1H), 6.62 (dd, J=8.4, 2.7 Hz,1H), 6.56 (d, J=2.7 Hz, 1H), 4.98-4.90 (m, 1H), 4.72 (s, 4H), 2.72-2.58(m, 2H), 2.34 (t, J=7.8 Hz, 2H), 1.73-1.50 (m, 2H), 1.40-1.31 (m, 1H),0.86-0.83 (m, 6H).

EXAMPLE 6(242)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenylsulfonyloxyphenyl)propanoicacid

TLC: Rf 0.31 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.81 (m, 2H), 7.65 (m, 1H), 7.55-7.49 (m,2H), 7.39-7.26 (m, 5H), 7.18 (d, J=8.4 Hz, 1H), 6.97 (dd, J=8.4, 2.4 Hz,1H), 6.90 (d, J=2.4 Hz, 1H), 6.39 (d, J=8.1 Hz, 1H), 5.16 (m, 1H),2.98-2.93 (m, 2H), 2.68-2.62 (m, 2H), 1.81-1.63 (m, 2H), 1.55 (m, 1H),0.98 (d, J=6.6 Hz, 3H), 0.96 (d, J=6.6 Hz, 3H).

EXAMPLE 6(243) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-isopropylsulfonyloxyphenyl)propanoic acid

TLC: Rf 0.28 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.36-7.35 (m, 4H), 7.31-7.23 (m, 4H), 6.61 (brd,J=8.4 Hz, 1H), 5.21 (m, 1H), 3.48 (quint, J=6.9 Hz, 1H), 3.01-2.95 (m,2H), 2.71-2.66 (m, 2H), 1.85-1.66 (m, 2H), 1.58 (m, 1H), 1.55 (d, J=6.9Hz, 6H), 0.99 (d, J=6.6 Hz, 3H), 0.97 (d, J=6.6 Hz, 3H).

EXAMPLE 6(244)3-(1-benzyl-3-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)indol-4-yl)propanoicacid

TLC: Rf 0.34 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.43 (s, 1H), 7.36-7.02 (m, 8H), 6.95 (s, 2H),6.92 (s, 1H), 6.25 (d, J=8.4 Hz, 1H), 5.31 (s, 2H), 5.17 (dt, J=8.4, 8.4Hz, 1H), 3.33 (m, 2H), 2.77 (t, J=8.1 Hz, 2H), 2.31 (s, 6H), 1.80-1.50(m, 3H), 0.99 (d, J=6.3 Hz, 3H), 0.98 (d, J=6.3 Hz, 3H).

EXAMPLE 6(245)3-(1-(3-cyanobenzyl)-3-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)indol-4-yl)propanoicacid

TLC: Rf 0.34 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.60 (d, J=8.1 Hz, 1H), 7.48-6.90 (m, 10H), 6.28(d, J=8.4 Hz, 1H), 5.35 (s, 2H), 5.19 (dt, J=8.4, 8.4 Hz, 1H), 3.32 (m,2H), 2.78 (t, J=8.1 Hz, 2H), 2.32 (s, 6H), 1.93-1.60 (m, 3H), 1.00 (d,J=6.3 Hz, 3H), 0.99 (d, J=6.3 Hz, 3H).

EXAMPLE 6(246)2-(8-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)-1,2,3,4-tetrahydroquinolin-1-yl)aceticacid

TLC: Rf 0.33 (methylene chloride:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.94 (m, 1H), 7.14 (m, 1H), 7.01 (m, 1H), 6.97(s, 2H), 6.84 (s, 1H), 6.72 (m, 1H), 4.92 (m, 1H), 3.67 (d, J=17.4 Hz,1H), 3.57 (d, J=17.4 Hz, 1H), 3.30-3.04 (m, 2H), 2.76-2.66 (m, 2H), 2.25(s, 6H), 1.96-1.68 (m, 3H), 1.66-1.34 (m, 2H), 0.91 (d, J=6.0 Hz, 3H),0.90 (d, J=6.0 Hz, 3H).

EXAMPLE 6(247)2-(7-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)indolin-1-yl)aceticacid

TLC: Rf 0.60 (n-hexane:ethyl acetate=2:1);

NMR (300 MHz, DMSO-d₆): δ 12.22 (brs, 1H), 8.63 (d, J=7.8 Hz, 1H),7.07-6.82 (m, 5H), 6.57 (t, J=7.5 Hz, 1H), 4.97-4.89 (m, 1H), 4.12 (d,J=18.3 Hz, 1H), 3.81 (d, J=18.3 Hz, 1H), 3.47 (t, J=8.7 Hz, 2H),2.96-2.90 (m, 2H), 2.24 (s, 6H), 1.78-1.68 (m, 1H), 1.62-1.54 (m, 1H),1.40-1.30 (m, 1H), 0.91-0.87 (m, 6H).

EXAMPLE 6(248)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-benzylaminophenyl)propanoicacid

TLC: Rf 0.55 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.20 (m, 10H), 7.03 (d, J=8.1 Hz, 1H), 6.62(dd, J=8.1, 2.4 Hz, 1H), 6.54 (d, J=2.4 Hz, 1H), 6.22 (d, J=8.7 Hz, 1H),5.18 (q, J=8.4 Hz, 1H), 4.30 (s, 2H), 2.86 (t, J=7.2 Hz, 2H), 2.66 (t,J=7.2 Hz, 2H), 1.80-1.50 (m, 3H), 0.96 (d, J=6.3 Hz, 6H).

EXAMPLE 6(249)3-(2-((3-methyl-1-(3,4-dimethoxyphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.45 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.44-7.34 (m, 3H), 7.32-7.24 (m, 2H), 7.20-7.14(m, 2H), 6.94-6.88 (m, 2H), 6.84 (d, J=8.7 Hz, 1H), 6.42 (d, J=8.4 Hz,1H), 5.20 (q, J=7.2 Hz, 1H), 5.02 (s, 2H), 3.88 (s, 3H), 3.86 (s, 3H),3.01 (t, J=8.1 Hz, 2H), 2.73 (t, J=8.1 Hz, 2H), 1.90-1.50 (m, 3H), 0.99(d, J=6.3 Hz, 6H).

EXAMPLE 6(250)3-(3-benzyl-1-(3-methyl-1-phenylbutylcarbamoylmethyl)indol-7-yl)propanoicacid

TLC: Rf 0.44 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.47 (d, J=7.2 Hz, 1H), 7.40-7.15 (m, 9H), 7.09(t, J=7.2 Hz, 1H), 7.01 (d, J=7.2 Hz, 1H), 6.90-6.80 (m, 2H), 6.67 (s,1H), 5.17 (brd, J=8.4 Hz, 1H), 5.02-4.83 (m, 3H), 4.09 (s, 2H), 3.11(dd, J=8.7, 5.7 Hz, 2H), 2.59 (dd, J=8.7, 6.9 Hz, 2H), 1.35-1.15 (m,2H), 1.15-0.97 (m, 1H), 0.77 (d, J=6.6 Hz, 3H), 0.72 (d, J=6.6 Hz, 3H).

EXAMPLE 6(251)3-(2-((3-methyl-1-(3-methyl-4-fluorophenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.35 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.42-7.35 (m, 3H), 7.31-7.25 (m, 2H), 7.21-7.11(m, 4H), 6.96 (dd, J=8.7, 8.7 Hz, 1H), 6.46 (d, J=8.4 Hz, 1H), 5.17 (m,1H), 5.03 (s, 2H), 3.06-2.95 (m, 2H), 2.76-2.64 (m, 2H), 2.26 (d, J=1.5Hz, 3H), 1.81-1.53 (m, 3H), 0.97 (d, J=6.6 Hz, 6H).

EXAMPLE 6(252)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methylsulfonyloxyphenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.36-7.34 (m, 4H), 7.30-7.24 (m, 4H), 6.67 (brd,J=8.1 Hz, 1H), 5.21 (m, 1H), 3.14 (s, 3H), 3.02-2.91 (m, 2H), 2.70-2.64(m, 2H), 1.85-1.67 (m, 2H), 1.58 (m, 1H), 0.97 (d, J=6.0 Hz, 6H).

EXAMPLE 6(253)3-(2-((3-methyl-1-(3,5-dimethoxyphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.44-7.14 (m, 7H), 6.52 (s, 2H), 6.48 (d, J=8.4Hz, 1H), 6.37 (s, 1H), 5.17 (m, 1H), 5.03 (s, 2H), 3.79 (s, 6H), 3.03(t, J=7.2 Hz, 2H), 2.75 (t, J=7.2 Hz, 2H), 1.83-1.56 (m, 3H), 0.98 (d,J=6.3 Hz, 6H).

EXAMPLE 6(254)8-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)-2-naphthalenecarboxylicacid

TLC: Rf 0.67 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.97 (d, J=8.4 Hz, 1H), 8.80 (s, 1H),8.12-7.95 (m, 3H), 7.73-7.58 (m, 2H), 7.02 (s, 2H), 6.87 (s, 1H), 5.12(m, 1H), 2.27 (s, 6H), 1.84-1.65 (m, 2H), 1.54-1.39 (m, 1H), 1.00 (d,J=6.0 Hz, 3H), 0.93 (d, J=6.0 Hz, 3H).

EXAMPLE 6(255)7-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)-2-benzofurancarboxylicacid

TLC: Rf 0.55 (chloroform:methanol:acetic acid=90:10:1);

NMR (300 MHz, CDCl₃): δ 8.29 (dd, J=7.7, 1.3 Hz, 1H), 7.93 (d, J=7.8 Hz,1H), 7.85 (dd, J=7.7, 1.3 Hz, 1H), 7.74 (s, 1H), 7.45 (t, J=7.7 Hz, 1H),7.07 (s, 2H), 6.89 (s, 1H), 5.28 (m, 1H), 2.32 (s, 6H), 2.00-1.66 (m,3H), 1.02 (d, J=8.3 Hz, 3H), 1.00 (d, J=8.3 Hz, 3H).

EXAMPLE 6(256)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxycarbonylaminophenyl)propanoicacid

TLC: Rf 0.61 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.24 (m, 6H), 7.16-7.08 (m, 1H), 6.98-6.80(m, 4H), 6.56-6.42 (m, 1H), 5.17 (s, 2H), 5.13 (q, J=7.2 Hz, 1H),3.00-2.85 (m, 2H), 2.70-2.55 (m, 2H), 2.29 (s, 6H), 1.80-1.50 (m, 3H),0.96 (d, J=5.4 Hz, 6H).

EXAMPLE 6(257)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzylaminophenyl)propanoicacid

TLC: Rf 0.57 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.38-7.24 (m, 5H), 7.03 (d, J=8.4 Hz, 1H), 6.91(s, 3H), 6.62 (dd, J=8.4, 2.4 Hz, 1H), 6.55 (d, J=2.4 Hz, 1H), 6.15 (d,J=8.4 Hz, 1H), 5.11 (q, J=8.4 Hz, 1H), 4.30 (s, 2H), 2.88 (t, J=7.5 Hz,2H), 2.67 (t, J=7.5 Hz, 2H), 2.30 (s, 6H), 1.80-1.50 (m, 3H), 0.96 (d,J=6.3 Hz, 6H).

EXAMPLE 6(258)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(isoindolin-2-yl)phenyl)propanoicacid

TLC: Rf 0.47 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.25 (m, 4H), 7.16 (d, J=8.4 Hz, 1H), 6.98(s, 2H), 6.92 (s, 1H), 6.67 (dd, J=8.4, 2.4 Hz, 1H), 6.60 (d, J=2.4 Hz,1H), 6.40 (d, J=8.4 Hz, 1H), 5.19 (q, J=8.4 Hz, 1H), 4.62 (s, 4H), 2.92(t, J=7.2 Hz, 2H), 2.72 (t, J=7.2 Hz, 2H), 2.32 (s, 6H), 1.85-1.55 (m,3H), 1.00 (d, J=6.3 Hz, 6H).

EXAMPLE 6(259)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxycarbonylaminophenyl)propanoicacid

TLC: Rf 0.47 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.52 (s, 1H), 7.42-7.32 (m, 3H), 7.28-7.10 (m,4H), 6.94 (s, 2H), 6.88 (s, 1H), 6.48 (d, J=8.7 Hz, 1H), 5.13 (q, J=8.7Hz, 1H), 3.00-2.90 (m, 2H), 2.70-2.60 (m, 2H), 2.28 (s, 6H), 1.80-1.50(m, 3H), 0.95 (d, J=6.3 Hz, 6H).

EXAMPLE 6(260)2-(7-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)benzofuran-2-yl)aceticacid

TLC: Rf 0.48 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.03 (dd, J=7.7, 1.3 Hz, 1H), 7.69 (d, J=7.8 Hz,1H), 7.64 (dd, J=7.7, 1.3 Hz, 1H), 7.31 (t, J=7.7 Hz, 1H), 6.99 (s, 2H),6.86 (s, 1H), 6.75 (s, 1H), 5.23 (m, 1H), 3.93 (s, 2H), 2.29 (s, 6H),1.91-1.59 (m, 3H), 0.97 (d, J=6.2 Hz, 3H), 0.95 (d, J=6.2 Hz, 3H).

EXAMPLE 6(261)3-(2-((3-methyl-1-(3,5-difluorophenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.51 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.45-7.15 (m, 8H), 6.90 (t, J=8.4 Hz, 2H), 6.65(d, J=8.4 Hz, 1H), 5.72 (q, J=8.4 Hz, 1H), 5.05 (s, 2H), 3.04 (t, J=7.2Hz, 2H), 2.72 (t, J=7.2 Hz, 2H), 1.95-1.80 (m, 1H), 1.80-1.65 (m, 1H),1.65-1.50 (m, 1H), 1.00 (d, J=6.0 Hz, 3H), 0.98 (d, J=6.0 Hz, 3H).

EXAMPLE 6(262)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzoylaminophenyl)propanoicacid

TLC: Rf 0.46 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.10-8.00 (m, 1H), 7.85 (d, J=8.0 Hz, 2H), 7.71(s, 1H), 7.60-7.42 (m, 4H), 7.24-7.18 (m, 1H), 6.96 (s, 2H), 6.89 (s,1H), 6.70-6.62 (m, 1H), 5.14 (q, J=7.5 Hz, 1H), 3.05-2.95 (m, 2H),2.75-2.65 (m, 2H), 2.30 (s, 6H), 1.85-1.55 (m, 3H), 0.97 (d, J=6.6 Hz,6H).

EXAMPLE 6(263)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(N-benzyl-N-methylamino)phenyl)propanoicacid

TLC: Rf 0.57 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.36-7.16 (m, 5H), 7.06 (d, J=8.7 Hz, 1H), 6.89(s, 3H), 6.72 (dd, J=8.7, 3.0 Hz, 1H), 6.64 (d, J=3.0 Hz, 1H), 6.12 (d,J=8.4 Hz, 1H), 5.10 (q, J=8.4 Hz, 1H), 4.50 (s, 2H), 3.04 (s, 3H), 2.88(t, J=7.5 Hz, 2H), 2.67 (t, J=7.5 Hz, 2H), 2.29 (s, 6H), 1.80-1.45 (m,3H), 0.96 (d, J=6.6 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H).

EXAMPLE 6(264)2-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenoxy)aceticacid

TLC: Rf 0.38 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.01 (s, 2H), 7.51 (dd, J=7.6, 2.3 Hz, 1H),7.32-7.22 (m, 2H), 7.13-6.84 (m, 7H), 5.22 (m, 1H), 5.00 (s, 2H), 4.78(s, 2H), 2.28 (s, 6H), 1.94-1.54 (m, 3H), 0.95 (d, J=6.0 Hz, 6H).

EXAMPLE 6(265)2-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenoxy)aceticacid

TLC: Rf 0.38 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.29 (d, J=7.5 Hz, 1H), 8.10 (d, J=1.2 Hz, 1H),7.48 (dd, J=7.6, 2.3 Hz, 1H), 7.35 (t, J=8.4 Hz, 1H), 7.24 (m, 1H),7.18-7.10 (m, 2H), 7.01 (s, 2H), 6.93 (d, J=8.4 Hz, 1H), 6.85 (s, 1H),5.22 (m, 1H), 5.00 (s, 2H), 4.79 (s, 2H), 2.27 (s, 6H), 1.97-1.57 (m,3H), 0.95 (d, J=6.3 Hz, 611).

EXAMPLE 6(266)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenylcarbamoylphenyl)propanoicacid

TLC: Rf 0.41 (methylene chloride:methanol=9:1);

NMR (300 MHz, CD₃OD): δ 8.92 (d, J=8.7 Hz, 1H), 7.92 (dd, J=8.1, 2.1 Hz,1H), 7.85 (d, J=2.1 Hz, 1H), 7.66 (d, J=8.4 Hz, 2H), 7.46 (d, J=8.1 Hz,1H), 7.35 (t, J=8.4 Hz, 2H), 7.14 (t, J=8.4 Hz, 1H), 7.00 (s, 2H), 6.89(s, 1H), 5.15-5.05 (m, 1H), 3.01 (t, J=7.2 Hz, 2H), 2.55 (t, J=7.2 Hz,2H), 2.30 (s, 6H), 1.90-1.50 (m, 3H), 1.01 (d, J=6.3 Hz, 3H), 0.99 (d,J=6.3 Hz, 3H).

EXAMPLE 6(267)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(N-acetyl-N-benzylamino)phenyl)propanoicacid

TLC: Rf 0.44 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.30-7.10 (m, 6H), 7.10-7.00 (m, 1H), 7.00-6.85(m, 3H), 6.68 (s, 1H), 5.86 (d, J=8.1 Hz, 1H), 5.06 (q, J=8.1 Hz, 1H),4.83 (s, 2H), 3.05-2.95 (m, 2H), 2.70-2.60 (m, 2H), 2.31 (s, 6H), 1.85(s, 3H), 1.70-1.40 (m, 3H), 0.96 (d, J=6.3 Hz, 3H), 0.95 (d, J=6.3 Hz,3H).

EXAMPLE 6(268)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-((N-phenylamino)carbonylamino)phenyl)propanoicacid

TLC: Rf 0.44 (methylene chloride:methanol=9:1);

NMR (300 MHz, CD₃OD): δ 7.46-7.34 (m, 4H), 7.32-7.20 (m, 3H), 7.05-6.98(m, 3H), 6.88 (s, 1H), 5.08 (dd, J=9.6, 6.0 Hz, 1H), 2.90 (t, J=7.5 Hz,2H), 2.50 (t, J=7.5 Hz, 2H), 2.30 (s, 6H), 1.85-1.50 (m, 3H), 1.00 (d,J=6.0 Hz, 3H), 0.98 (d, J=6.0 Hz, 3H).

EXAMPLE 6(269)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenylsulfonylaminophenyl)propanoicacid

TLC: Rf 0.48 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.71 (d, J=7.5 Hz, 2H), 7.52 (t, J=7.5 Hz, 1H),7.40 (t, J=7.5 Hz, 2H), 7.20-7.12 (m, 1H), 7.10-7.00 (m, 2H), 6.96-6.88(m, 4H), 6.42 (d, J=8.7 Hz, 1H), 5.09 (q, J=8.7 Hz, 1H), 2.95-2.85 (m,2H), 2.65-2.55 (m, 2H), 2.30 (s, 6H), 1.80-1.50 (m, 3H), 0.96 (d, J=6.3Hz, 6H).

EXAMPLE 6(270)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(N-benzyl-N-methylsulfonylamino)phenyl)propanoicacid

TLC: Rf 0.56 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.30-7.16 (m, 7H), 7.12 (d, J=3.0 Hz, 1H), 6.91(s, 3H), 6.18 (d, J=8.7 Hz, 1H), 5.09 (q, J=8.7 Hz, 1H), 4.80 (s, 2H),3.00-2.90 (m, 5H), 2.66 (t, J=7.5 Hz, 2H), 2.31 (s, 6H), 1.80-1.50 (m,3H), 0.97 (d, J=6.3 Hz, 3H), 0.96 (d, J=6.3 Hz, 3H).

EXAMPLE 6(271)3-(3-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-5-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.65 (d, J=8.4 Hz, 1H), 7.76 (s, 1H), 7.71 (s,1H), 7.54-7.33 (m, 5H), 6.97 (s, 2H), 6.83 (s, 1H), 5.17 (s, 2H), 5.02(m, 1H), 2.89 (t, J=7.5 Hz, 2H), 2.58 (t, J=7.5 Hz, 2H), 2.24 (s, 6H),1.81 (m, 1H), 1.66-1.43 (m, 2H), 0.91 (d, J=6.0 Hz, 3H), 0.89 (d, J=6.0Hz, 3H).

EXAMPLE 6(272)3-(3-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-5-(3-cyanophenoxymethyl)phenyl)propenoicacid

TLC: Rf 0.50 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.76 (d, J=8.4 Hz, 1H), 8.17 (s, 1H), 7.95 (s,1H), 7.91 (s, 1H), 7.64 (d, J=15.9 Hz, 1H), 7.60-7.34 (m, 4H), 6.97 (s,2H), 6.84 (s, 1H), 6.84 (d, J=15.9 Hz, 1H), 5.23 (s, 2H), 5.04 (m, 1H),2.24 (s, 6H), 1.82 (m, 1H), 1.68-1.45 (m, 2H), 0.92 (d, J=6.0 Hz, 3H),0.90 (d, J=6.0 Hz, 3H).

EXAMPLE 6(273)4-(3-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-5-(3-cyanophenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.67 (d, J=8.4 Hz, 1H), 7.76 (s, 1H), 7.67 (s,1H), 7.55-7.33 (m, 5H), 6.97 (s, 2H), 6.83 (s, 1H), 5.18 (s, 2H), 5.03(m, 1H), 2.65 (t, J=7.8 Hz, 2H), 2.28-2.19 (m, 2H), 2.24 (s, 6H),1.89-1.74 (m, 3H), 1.66-1.43 (m, 2H), 0.91 (d, J=6.0 Hz, 3H), 0.89 (d,J=6.0 Hz, 3H).

EXAMPLE 6(274)3-(2-(1-(3,5-dimethylphenyl)butylcarbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.64 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.44-7.24 (m, 5H), 7.22-7.14 (m, 2H), 6.94 (s,2H), 6.91 (s, 1H), 6.39 (d, J=8.4 Hz, 1H), 5.07 (q, J=8.4 Hz, 1H), 5.03(s, 2H), 3.04 (t, J=7.2 Hz, 2H), 2.73 (t, J=7.2 Hz, 2H), 2.30 (s, 6H),2.00-1.75 (m, 2H), 1.50-1.25 (m, 2H), 0.95 (t, J=7.5 Hz, 3H).

EXAMPLE 6(275)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethylcarbonyl)phenyl)propanoicacid

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.88 (d, J=8.7 Hz, 1H), 8.02 (dd, J=7.8, 2.1Hz, 1H), 7.83 (d, J=2.1 Hz, 1H), 7.72 (d, J=2.1 Hz, 1H), 7.49 (d, J=7.8Hz, 1H), 7.47 (d, J=2.1 Hz, 1H), 6.96 (s, 2H), 6.85 (s, 1H), 6.30 (t,J=2.1 Hz, 1H), 5.82 (s, 2H), 4.98 (m, 1H), 2.93 (t, J=7.8 Hz, 2H), 2.46(t, J=7.8 Hz, 2H), 2.25 (s, 6H), 1.80-1.55 (m, 2H), 1.44 (m, 1H), 0.93(d, J=6.6 Hz, 3H), 0.91 (d, J=6.6 Hz, 3H).

EXAMPLE 6(276)3-(2-((1-(3,5-dimethylphenyl)propyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.74 (d, J=8.4 Hz, 1H), 7.56-7.28 (m, 7H),6.95 (s, 2H), 6.84 (s, 1H), 5.16 (s, 2H), 4.77 (m, 1H), 2.85 (t, J=7.8Hz, 2H), 2.46 (t, J=7.8 Hz, 2H), 2.24 (s, 6H), 1.80-1.63 (m, 2H), 0.89(t, J=7.2 Hz, 3H).

EXAMPLE 6(277)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-phenylvinyl)phenyl)propanoicacid

TLC: Rf 0.51 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.54-7.42 (m, 4H), 7.40-7.32 (m, 2H), 7.32-7.22(m, 2H), 7.09 (d, J=16.5 Hz, 1H), 7.03 (d, J=16.5 Hz, 1H), 6.98 (s, 2H),6.92 (s, 1H), 6.35 (d, J=8.7 Hz, 1H), 5.19 (q, J=8.7 Hz, 1H), 3.01 (t,J=7.5 Hz, 2H), 2.72 (t, J=7.5 Hz, 2H), 2.32 (s, 6H), 1.85-1.60 (m, 3H),0.99 (d, J=6.3 Hz, 6H).

EXAMPLE 6(278)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-(pyrazol-1-yl)ethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.50 (s, 1H), 7.17-6.88 (m, 6H), 6.75 (s, 1H),6.23 (d, J=8.7 Hz, 1H), 6.12 (t, J=2.1 Hz, 1H), 5.12 (m, 1H), 4.29 (t,J=6.9 Hz, 2H), 3.08 (t, J=6.9 Hz, 2H), 2.98 (t, J=7.2 Hz, 2H), 2.70 (t,J=7.2 Hz, 2H), 2.32 (s, 6H), 1.84-1.52 (m, 3H), 0.99 (d, J=6.6 Hz, 6H).

EXAMPLE 6(279)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.44 (s, 1H), 7.42 (d, J=8.1 Hz, 1H), 7.28 (d,J=8.1 Hz, 1H), 7.15-6.87 (m, 4H), 6.96 (s, 2H), 6.91 (s, 1H), 6.31 (d,J=8.7 Hz, 1H), 5.16 (m, 1H), 5.09 (s, 2H), 3.08-2.97 (m, 2H), 2.72 (t,J=7.2 Hz, 2H), 2.31 (s, 6H), 1.85-1.56 (m, 3H), 0.99 (d, J=6.3 Hz, 6H).

EXAMPLE 6(280)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.52 (s, 1H), 7.46-7.35 (m, 2H), 7.28 (d, J=8.1Hz, 1H), 7.21 (m, 1H), 7.00-6.87 (m, 2H), 6.95 (s, 2H), 6.91 (s, 1H),6.29 (d, J=8.4 Hz, 1H), 5.16 (m, 1H), 5.12 (s, 2H), 3.09-2.97 (m, 2H),2.73 (t, J=7.2 Hz, 2H), 2.31 (s, 6H), 1.86-1.58 (m, 3H), 0.99 (d, J=6.3Hz, 6H).

EXAMPLE 6(281)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.54 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.42 (s, 1H), 7.41 (d, J=7.8 Hz, 1H), 7.29 (d,J=7.8 Hz, 1H), 7.00-6.73 (m, 3H), 6.96 (s, 2H), 6.91 (s, 1H), 6.32 (d,J=8.1 Hz, 1H), 5.16 (m, 1H), 5.05 (s, 2H), 3.08-2.98 (m, 2H), 2.73 (t,J=6.6 Hz, 2H), 2.31 (s, 6H), 1.84-1.56 (m, 3H), 0.99 (d, J=6.3 Hz, 6H).

EXAMPLE 6(282)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.42-7.18 (m, 5H), 6.95 (s, 2H), 6.91 (s, 1H),6.76-6.63 (m, 2H), 6.30 (d, J=8.7 Hz, 1H), 5.16 (m, 1H), 5.00 (s, 2H),3.07-2.96 (m, 2H), 2.73 (t, J=6.9 Hz, 2H), 2.31 (s, 6H), 1.84-1.54 (m,3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 6(283)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.99 (d, J=6.32 Hz, 6H), 1.70 (m, 3H), 2.31 (s,6H), 2.72 (t, J=7.00 Hz, 2H), 3.03 (m, 2H), 5.06 (s, 2H), 5.16 (m, 1H),6.31 (d, J=8.24 Hz, 1H), 6.61 (m, 1H), 6.73 (m, 1H), 6.90 (s, 1H), 6.96(s, 2H), 7.04 (m, 1H), 7.29 (d, J=8.24 Hz, 1H), 7.41 (m, 2H).

EXAMPLE 6(284)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol 10:1);

NMR (300 MHz, CDCl₃): δ 7.49 (s, 1H), 7.42 (d, J=7.8 Hz, 1H), 7.37-7.23(m, 2H), 6.96 (s, 2H), 6.91 (s, 1H), 6.74-6.62 (m, 2H), 6.30 (d, J=8.7Hz, 1H), 5.17 (m, 1H), 5.08 (s, 2H), 3.08-2.98 (m, 2H), 2.73 (t, J=7.5Hz, 2H), 2.31 (s, 6H), 1.85-1.58 (m, 3H), 0.99 (d, J=6.3 Hz, 3H), 0.98(d, J=6.3 Hz, 3H).

EXAMPLE 6(285)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.22 (n-hexane:ethyl acetate 1:1);

NMR (300 MHz, CDCl₃): δ 7.60-7.50 (m, 3H), 7.39 (m, 1H), 7.27 (d, J=7.8Hz, 1H), 7.08-6.96 (m, 4H), 6.90 (brs, 1H), 6.53 (brd, J=8.7 Hz, 1H),5.18 (m, 1H), 5.16 (s, 2H), 3.07-3.02 (m, 2H), 2.76-2.71 (m, 2H), 2.31(s, 6H), 1.90-1.57 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 6(286)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.25 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.62-7.57 (m, 2H), 7.41-7.38 (m, 2H), 7.29 (m,1H), 7.02-6.98 (m, 2H), 6.95 (brs, 2H), 6.91 (brs, 1H), 6.35 (brd, J=8.4Hz, 1H), 5.17 (m, 1H), 5.06 (s, 2H), 3.06-3.01 (m, 2H), 2.76-2.71 (m,2H), 2.31 (s, 6H), 1.83-1.55 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 6(287)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methoxyphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.38 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.41-7.39 (m, 2H), 7.27 (d, J=7.8 Hz, 1H), 6.95(brs, 2H), 6.91-6.82 (m, 5H), 6.28 (brd, J=8.4 Hz, 1H), 5.16 (m, 1H),4.97 (s, 2H), 3.77 (s, 3H), 3.06-3.00 (m, 2H), 2.74-2.69 (m, 2H), 2.31(s, 6H), 1.83-1.56 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 6(288)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methoxyphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.38 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.45-7.38 (m, 2H), 7.31-7.11 (m, 2H), 6.95 (s,2H), 6.90 (s, 1H), 6.59-6.50 (m, 3H), 6.28 (d, J=8.4 Hz, 1H), 5.17 (m,1H), 5.00 (s, 2H), 3.79 (s, 3H), 3.11-2.92 (m, 2H), 2.72 (t, J=7.2 Hz,2H), 2.31 (s, 6H), 1.85-1.52 (m, 3H), 0.98 (d, J=6.6 Hz, 6H).

EXAMPLE 6(289)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.38 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.47-7.38 (m, 2H), 7.29-7.11 (m, 2H), 6.95 (s,2H), 6.90 (s, 1H), 6.85-6.72 (m, 3H), 6.29 (d, J=9.0 Hz, 1H), 5.16 (m,1H), 4.99 (s, 2H), 3.11-2.92 (m, 2H), 2.71 (t, J=7.5 Hz, 2H), 2.33 (s,3H), 2.30 (s, 6H), 1.86-1.51 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 6(290)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxy-5-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.33 (n-hexane:ethyl acetate=1:1).

EXAMPLE 6(291)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.38 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.47-7.39 (m, 2H), 7.25 (m, 1H), 7.01-6.82 (m,7H), 6.28 (d, J=8.7 Hz, 1H), 5.17 (m, 1H), 5.09 (s, 2H), 3.86 (s, 3H),3.10-2.92 (m, 2H), 2.71 (t, J=7.4 Hz, 2H), 2.30 (s, 6H), 1.86-1.53 (m,3H), 0.98 (d, J=5.7 Hz, 6H).

EXAMPLE 6(292)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-acetylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.30 (n-hexane:ethyl acetate=1:1).

EXAMPLE 6(293)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-4-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.31 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.32 (brs, 1H), 7.13-7.05 (m, 3H), 6.94-6.91 (m,3H), 6.81-6.73 (m, 3H), 5.10 (m, 1H), 4.78 (s, 2H), 2.84-2.79 (m, 2H),2.43-2.39 (m, 2H), 2.21 (s, 6H), 1.78-1.50 (m, 3H), 0.89-0.87 (m, 6H).

EXAMPLE 6(294)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methyl-4-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.31 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, DMSO-d₆): δ 7.34-7.17 (m, 3H), 7.04-6.93 (m, 5H), 6.82(brs, 1H), 5.03 (s, 2H), 4.97 (m, 1H), 2.80-2.76 (m, 2H), 2.43-2.39 (m,2H), 2.23 (s, 6H), 2.17 (s, 3H), 1.80-1.60 (m, 2H), 1.41 (m, 1H), 0.91(d, J=6.6 Hz, 3H), 0.89 (d, J=6.6 Hz, 3H).

EXAMPLE 6(295)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.34 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, DMSO-d₆): δ 9.94 (brs, 1H), 7.38-7.33 (m, 2H), 7.28 (d,J=7.8 Hz, 1H), 7.01-6.99 (m, 3H), 6.83 (d, J=7.5 Hz, 2H), 6.64 (d, J=7.8Hz, 1H), 5.03 (s, 2H), 4.97 (m, 1H), 2.84-2.77 (m, 2H), 2.44-2.40 (m,2H), 2.24 (s, 6H), 2.12 (s, 3H), 1.78 (s, 3H), 1.77-1.58 (m, 2H), 1.41(m, 1H), 0.91 (d, J=6.6 Hz, 3H), 0.89 (d, J=6.6 Hz, 3H).

EXAMPLE 6(296)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-carbamoylmethylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.36 (chloroform:methanol=10:1).

EXAMPLE 6(297)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxy-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.76 (d, J=8.4 Hz, 1H), 7.40 (d, J=8.7 Hz,1H), 7.31 (s, 1H), 7.30 (d, J=8.7 Hz, 1H), 6.95 (s, 2H), 6.89 (s, 1H),6.84 (d, J=8.7 Hz, 1H), 6.83 (s, 1H), 6.69 (d, J=8.7 Hz, 1H), 5.02 (s,2H), 4.96 (m, 1H), 3.69 (s, 3H), 2.84 (t, J=8.1 Hz, 2H), 2.45 (t, J=8.1Hz, 2H), 2.24 (s, 6H), 2.21 (s, 3H), 1.78-1.57 (m, 2H), 1.39 (m, 1H),0.92 (d, J=6.3 Hz, 3H), 0.89 (d, J=6.3 Hz, 3H).

EXAMPLE 6(298)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): 8.74 (d, J=8.7 Hz, 1H), 7.39 (d, J=8.1 Hz, 1H),7.30 (s, 1H), 7.29 (d, J=8.1 Hz, 1H), 7.08 (d, J=8.4 Hz, 2H), 6.95 (s,2H), 6.88 (d, J=8.4 Hz, 2H), 6.84 (s, 1H), 5.05 (s, 2H), 4.96 (m, 1H),2.83 (t, J=8.1 Hz, 2H), 2.44 (t, J=8.1 Hz, 2H), 2.24 (s, 6H), 2.22 (s,3H), 1.80-1.55 (m, 2H), 1.40 (m, 1H), 0.91 (d, J=6.3 Hz, 3H), 0.89 (d,J=6.3 Hz, 3H).

EXAMPLE 6(299)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.74 (d, J=8.7 Hz, 1H), 7.39 (d, J=7.5 Hz,1H), 7.31 (s, 1H), 7.29 (d, J=7.5 Hz, 1H), 7.16-7.06(m, 2H), 7.04-6.96(m, 2H), 6.95 (s, 2H), 6.83 (s, 1H), 5.06 (s, 2H), 4.96 (m, 1H), 2.83(t, J=8.1 Hz, 2H), 2.44 (t, J=8.1 Hz, 2H), 2.24 (s, 6H), 1.80-1.54 (m,2H), 1.40 (m, 1H), 0.91 (d, J=6.3 Hz, 3H), 0.89 (d, J=6.3 Hz, 3H).

EXAMPLE 6(300)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methoxy-5-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.52 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.41-7.28 (m, 2H), 7.38 (brs, 1H), 6.96 (brs,2H), 6.91 (brs, 1H), 6.80 (m, 2H), 6.71 (m, 1H), 6.38 (d, J=8.4 Hz, 1H),5.17 (m, 1H), 5.00 (s, 2H), 3.80 (s, 3H), 3.05-3.00 (m, 2H), 2.76-2.70(m, 2H), 2.31 (s, 6H), 1.86-1.56 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 6(301)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chlorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.44-7.37 (m, 2H), 7.32-7.17 (m, 2H), 7.00-6.81(m, 6H), 6.29 (d, J=8.7 Hz, 1H), 5.17 (m, 1H), 5.00 (s, 2H), 3.09-2.97(m, 2H), 2.73 (t, J=7.1 Hz, 2H), 2.31 (s, 6H), 1.87-1.52 (m, 3H), 0.99(d, J=6.3 Hz, 6H).

EXAMPLE 6(302)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.38 (m, 2H), 7.28 (d, J=7.8 Hz, 1H),7.02-6.88 (m, 4H), 6.81 (d, J=8.1 Hz, 1H), 6.72 (m, 1H), 6.29 (d, J=8.7Hz, 1H), 5.17 (m, 1H), 5.07 (s, 2H), 3.12-2.95 (m, 2H), 2.72 (t, J=6.9Hz, 2H), 2.31 (s, 6H), 2.29 (s, 3H), 1.85-1.53 (m, 3H), 0.99 (d, J=6.3Hz, 6H).

EXAMPLE 6(303)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,4,5,6-pentafluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=10:1).

EXAMPLE 6(304)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,6-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.46 (chloroform:methanol=10:1).

EXAMPLE 6(305)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chlorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.46 (chloroform:methanol=10:1).

EXAMPLE 6(306)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.57 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.45-7.38 (m, 2H), 7.29 (d, J=7.2 Hz, 1H),7.02-6.89 (m, 4H), 6.85-6.73 (m, 2H), 6.32 (d, J=8.7 Hz, 1H), 5.17 (m,1H), 5.10 (s, 2H), 3.07-2.95 (m, 2H), 2.73 (t, J=7.2 Hz, 2H), 2.31 (s,6H), 1.86-1.53 (m, 3H), 0.99 (d, J=6.3 Hz, 6H).

EXAMPLE 6(307)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.57 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.42-7.35 (m, 2H), 7.30 (d, J=7.5 Hz, 1H), 6.95(s, 2H), 6.91 (s, 1H), 6.54-6.40 (m, 3H), 6.32 (d, J=8.7 Hz, 1H), 5.17(m, 1H), 4.97 (s, 2H), 3.12-2.94 (m, 2H), 2.73 (t, J=7.3 Hz, 2H), 2.31(s, 6H), 1.87-1.52 (m, 3H), 0.99 (d, J=6.3 Hz, 6H).

EXAMPLE 6(308)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(4-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 1.01 (d, J=6.59 Hz, 3H) 1.13 (d, J=6.59 Hz, 3H)1.82 (m, 1H) 1.97 (m, 2H) 2.74 (t, J=7.20 Hz, 2H) 3.03 (t, J=7.20 Hz,2H) 4.97 (s, 2H) 6.14 (m, 1H) 6.35 (d, J=8.52 Hz, 1H) 6.66 (m, 3H) 7.42(m, 8H) 7.80 (d, J=7.69 Hz, 1H) 7.88 (d, J=7.69 Hz, 1H) 8.32 (d, J=8.24Hz, 1H).

EXAMPLE 6(309)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 1.01 (d, J=6.59 Hz, 3H) 1.14 (d, J=6.59 Hz, 3H)1.82 (m, 1H) 1.97 (t, J=7.14 Hz, 2H) 2.73 (t, J=7.42 Hz, 2H) 3.03 (t,J=7.42 Hz, 2H) 5.02 (s, 2H) 6.14 (m, 1H) 6.38 (d, J=8.52 Hz, 1H) 6.60(m, 1H) 6.70 (m, 1H) 7.02 (m, 1H) 7.47 (m, 7H) 7.80 (d, J=7.97 Hz, 1H)7.87 (d, J=7.42 Hz, 1H) 8.32 (d, J=8.79 Hz, 1H).

EXAMPLE 6(310)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 0.91 (d, J=6.32 Hz, 3H) 1.08 (d, J=6.32 Hz,3H) 1.57 (m, 1H) 1.89 (m, 2H) 2.48 (m, 2H) 2.85 (m, 2H) 5.14 (s, 2H)5.94 (m, 1H) 7.48 (m, 12H) 7.81 (d, J=8.24 Hz, 1H) 7.94 (d, J=7.97 Hz,1H) 8.22 (d, J=8.52 Hz, 1H).

EXAMPLE 6(311)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,4-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.31 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.32 Hz, 6H) 1.69 (m, 3H) 2.31 (s,6H) 2.72 (m, 2H) 3.02 (m, 2H) 4.95 (s, 2H) 5.17 (m, 1H) 6.34 (d, J=8.24Hz, 1H) 6.64 (m, 1H) 6.77 (ddd, J=11.81, 6.59, 3.02 Hz, 1H) 6.91 (s, 1H)6.95 (s, 2H) 7.07 (m, 1H) 7.32 (m, 3H).

EXAMPLE 6(312)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methyl-4-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.33 (methylene chloride:methanol=9:1).

EXAMPLE 6(313)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-6-methoxyphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.33 (methylene chloride:methanol=9:1).

EXAMPLE 6(314)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,6-trifluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.33 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.99 (d, J=6.32 Hz, 6H) 1.71 (m, 3H) 2.31 (s,6H) 2.71 (m, 2H) 3.03 (m, 2H) 5.16 (m, 3H) 6.27 (d, J=8.52 Hz, 1H) 6.83(m, 2H) 6.91 (s, 1H) 6.96 (s, 2H) 7.26 (m, 1H) 7.40 (m, 1H) 7.47 (m,1H).

EXAMPLE 6(315)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,5,6-tetrafluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.33 (chloroform:methanol=9:1).

EXAMPLE 6(316)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluoro-4-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.55 (n-hexane:ethyl acetate 1:1).

EXAMPLE 6(317)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-carbamoylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.23 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 0.91 (m, 6H), 1.39 (m, 1H), 1.68 (m, 2H), 2.24(s, 6H), 2.44 (m, 2H), 2.84 (t, J=7.97 Hz, 2H), 4.97 (m, 1H), 5.13 (s,2H), 6.83 (s, 1H), 6.95 (s, 2H), 7.14 (m, 1H), 7.42 (m, 7H), 7.94 (s,1H) 8.76 (d, J=8.52 Hz, 1H), 12.07 (s, 1H).

EXAMPLE 6(318)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methylcarbamoylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.17 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 0.90 (m, 6H), 1.40 (m, 1H), 1.67 (m, 2H), 2.24(s, 6H), 2.43 (m, 2H), 2.76 (d, J=4.40 Hz, 3H), 2.84 (m, 2H), 4.97 (m,1H), 5.13 (s, 2H), 6.83 (s, 1H), 6.95 (s, 2H), 7.13 (m, 1H), 7.39 (m,6H) 8.40 (m, 1H), 8.75 (d, J=8.52 Hz, 1H), 12.08 (s, 1H).

EXAMPLE 6(319)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-dimethylcarbamoylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.44 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.96 (d, J=6.32 Hz, 3H), 0.97 (d, J=6.32 Hz,3H), 1.69 (m, 3H), 2.29 (s, 6H), 2.68 (m, 2H), 2.98 (m, 5H), 3.08 (s,3H), 4.98 (s, 2H), 5.16 (m, 1H), 6.85 (m, 2H), 6.97 (m, 5H), 7.28 (m,4H).

EXAMPLE 6(320)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-hydroxymethylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.97 (m, 6H), 1.69 (m, 3H), 2.29 (s, 6H), 2.67(m, 2H), 3.00 (m, 2H), 4.62 (s, 2H), 4.98 (s, 2H), 5.16 (m, 1H), 6.52(d, J=8.52 Hz, 1H), 6.89 (m, 6H), 7.24 (m, 2H), 7.38 (m, 2H).

EXAMPLE 6(321)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methoxymethylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.24 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.32 Hz, 6H), 1.70 (m, 3H), 2.31 (s,6H), 2.72 (m, 2H), 3.03 (m, 2H), 3.38 (s, 3H), 4.43 (s, 2H), 5.02 (s,2H), 5.17 (m, 1H), 6.32 (d, J=8.52 Hz, 1H), 6.90 (m, 6H), 7.26 (m, 2H),7.42 (m, 2H).

EXAMPLE 6(322)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.44 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.45-7.38 (m, 2H), 7.29 (d, J=7.8 Hz, 1H), 7.04(m, 1H), 6.96 (s, 2H), 6.91 (s, 1H), 6.73 (m, 1H), 6.62 (m, 1H), 6.31(d, J=8.4 Hz, 1H), 5.17 (m, 1H), 5.06 (s, 2H), 3.11-2.93 (m, 2H), 2.72(t, J=6.0 Hz, 2H), 2.31 (s, 6H), 1.84-1.52 (m, 3H), 0.99 (d, J=6.3 Hz,6H).

EXAMPLE 6(323)3-(2-(((1S)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.44 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.45-7.38 (m, 2H), 7.29 (d, J=7.8 Hz, 1H), 7.04(m, 1H), 6.96 (s, 2H), 6.91 (s, 1H), 6.73 (m, 1H), 6.62 (m, 1H), 6.31(d, J=8.4 Hz, 1H), 5.17 (m, 1H), 5.06 (s, 2H), 3.11-2.93 (m, 2H), 2.72(t, J=6.0 Hz, 2H), 2.31 (s, 6H), 1.84-1.52 (m, 3H), 0.99 (d, J=6.3 Hz,6H).

EXAMPLE 6(324)2-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-phenylethyl)phenoxy)aceticacid

TLC: Rf 0.40 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.95 (d, J=6.04 Hz, 6H), 1.62 (m, 2H), 1.82 (m,1H), 2.29 (s, 6H), 2.87 (s, 4H), 4.74 (s, 2H), 5.19 (m, 1H), 6.82 (d,J=8.24 Hz, 1H), 6.88 (brs, 1H), 6.97 (brs, 2H), 7.10 (m, 2H), 7.18 (m,2H), 7.27 (m, 2H), 7.47 (m, 2H).

EXAMPLE 6(325%3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.63 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.38 (m, 2H), 7.28 (d, J=7.8 Hz, 1H),7.14-6.88 (m, 7H), 6.31 (d, J=7.8 Hz, 1H), 5.15 (q, J=7.8 Hz, 1H), 5.09(s, 2H), 3.12-2.95 (m, 2H), 2.72 (t, J=7.2 Hz, 2H), 2.31 (s, 6H),1.85-1.55 (m, 3H), 0.98 (d, J=5.7 Hz, 6H).

EXAMPLE 6(326)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.56 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.42-7.37 (m, 2H), 7.30-7.26 (m, 1H), 7.02-6.85(m, 7H), 6.30 (d, J=8.1 Hz, 1H), 5.16 (q, J=8.1 Hz, 1H), 4.98 (s, 2H),3.10-2.95 (m, 2H), 2.73 (t, J=6.9 Hz, 2H), 2.30 (s, 6H), 1.85-1.50 (m,3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 6(327)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.64 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.44-7.39 (m, 2H), 7.28-7.23 (m, 1H), 7.00-6.80(m, 7H), 6.32 (d, J=8.7 Hz, 1H), 5.15 (q, J=8.7 Hz, 1H), 5.09 (s, 2H),3.86 (s, 3H), 3.10-2.95 (m, 2H), 2.71 (t, J=7.5 Hz, 2H), 2.30 (s, 6H),1.80-1.55 (m, 3H), 0.97 (d, J=6.3 Hz, 6H).

EXAMPLE 6(328)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.54 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.44-7.40 (m, 2H), 7.30-7.26 (m, 1H), 7.20-7.12(m, 2H), 6.96-6.83 (m, 5H), 6.25 (d, J=8.7 Hz, 1H), 5.16 (q, J=8.7 Hz,1H), 5.04 (s, 2H), 3.13-2.95 (m, 2H), 2.73 (t, J=7.2 Hz, 2H), 2.31 (s,6H), 2.27 (s, 3H), 1.85-1.55 (m, 3H), 0.99 (d, J=6.3 Hz, 3H), 0.98 (d,J=6.3 Hz, 3H).

EXAMPLE 6(329)3-(2-diphenylmethylcarbamoyl-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.30 (hexane:ethyl acetate=1:1);

NMR (300 MHz, DMSO-d₆): δ 2.42 (m, 2H), 2.72 (m, 2H), 5.11 (s, 2H), 6.43(d, J=9.07 Hz, 1H), 6.74 (m, 1H), 7.24 (m, 10H), 7.38 (m, J=6.87 Hz,2H), 7.54-7.52 (m, 4H).

EXAMPLE 6(330)3-(2-((1-(3,5-dimethylphenyl)cyclohexyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 1.75 (m, 8H), 2.31 (s, 6H), 2.46 (s, 2H), 2.71(t, J=7.42 Hz, 2H), 3.05 (t, J=7.42 Hz, 2H), 5.12 (s, 2H), 6.18 (s, 1H),6.63 (m, 1H), 6.76 (m, 1H), 6.88 (s, 1H) 7.04 (m, 1H), 7.08 (s, 2H),7.31 (d, J=7.97 Hz, 1H), 7.42 (m, 1H), 7.55 (s, 1H).

EXAMPLE 6(331)3-(2-((1-(3,5-dimethylphenyl)cyclopentyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 1.88 (m, 4H), 2.16 (m, 2H), 2.31 (s, 6H), 2.46(m, 2H), 2.70 (t, J=7.55 Hz, 2H), 3.02 (t, J=7.42 Hz, 2H), 5.08 (s, 2H),6.63 (m, 1H), 6.75 (m, 1H), 6.88 (s, 1H) 7.02 (d, J=5.22 Hz, 1H), 7.05(dd, J=5.36, 1.51 Hz, 1H), 7.08 (s, 2H), 7.29 (d, J=7.69 Hz, 1H), 7.40(m, 1H), 7.45 (s, 1H).

EXAMPLE 6(332)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.32 Hz, 6H), 1.70 (m, 3H), 2.31 (s,6H), 2.72 (m, 2H), 3.03 (m, 2H), 5.00 (s, 2H), 5.16 (m, 1H), 6.31 (d,J=8.24 Hz, 1H), 6.70 (m, 3H), 6.91 (s, 1H), 6.95 (s, 2H), 7.25 (m, 2H),7.40 (m, 2H).

EXAMPLE 6(333)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-ethoxyphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.58 (chloroform:methanol=1:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.32 Hz, 6H), 1.42 (t, J=6.90 Hz,3H), 1.55-1.83 (m, 3H), 2.31 (s, 6H), 2.71 (t, J=7.42 Hz, 2H), 3.00-3.06(m, 2H), 4.09 (q, J=6.90 Hz, 2H), 5.08 (s, 2H), 5.16 (m, 1H), 6.32 (d,J=8.24 Hz, 1H), 6.84-6.95 (m, 7H), 7.26 (t, J=4.26 Hz, 1H), 7.43-7.42(m, 2H).

EXAMPLE 6(334)3-(2-((N-(2-methylpropyl)-N-(3,5-dimethylphenyl)amino)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.41 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 1.04 (d, J=6.87 Hz, 6H), 2.07 (m, 1H), 2.26 (s,6H), 2.81 (t, J=7.42 Hz, 2H), 3.15 (t, J=7.42 Hz, 2H), 3.39 (d, J=7.42Hz, 2H), 5.12 (s, 2H), 6.52 (s, 1H), 6.54 (s, 2H), 6.63 (m, 1H), 6.76(m, 1H), 7.05 (m, 1H), 7.38 (d, J=7.97 Hz, 1H), 7.48 (dd, J=7.97, 1.10Hz, 1H), 7.57 (d, J=1.10 Hz, 1H), 7.70 (s, 1H).

EXAMPLE 6(335)3-(2-(1-ethyl-1-(3,5-dimethylphenyl)propyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.41 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 0.82 (t, J=7.28 Hz, 6H), 2.20 (m, 4H), 2.31 (s,6H), 2.76 (t, J=7.49 Hz, 2H), 3.09 (t, J=7.49 Hz, 2H), 5.10 (s, 2H),6.13 (s, 1H), 6.62 (m, 1H), 6.76 (m, 1H), 6.88 (s, 1H), 6.97 (s, 2H),7.04 (m, 1H), 7.32 (d, J=7.97 Hz, 1H), 7.43 (dd, J=7.97, 1.37 Hz, 1H),7.54 (d, J=1.37 Hz, 1H).

EXAMPLE 6(336)3-(2-(4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 2.23 (m, 2H), 2.32 (s, 6H), 2.47 (m, 2H), 2.71(t, J=7.28 Hz, 2H), 3.03 (t, J=7.28 Hz, 2H), 3.84 (m, 4H), 5.09 (s, 2H),6.50 (s, 1H), 6.63 (m, 1H), 6.75 (m, 1H), 6.91 (s, 1H), 7.05 (m, 1H),7.09 (s, 2H), 7.30 (d, J=7.80 Hz, 1H), 7.43 (dd, J=7.80, 1.10 Hz,1H),7.54 (d, J=1.10 Hz, 1H).

EXAMPLE 6(337)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.59 Hz, 6H), 1.70 (m, 3H), 2.31 (s,6H), 2.72 (m, 2H), 3.03 (m, 2H), 5.03 (s, 2H), 5.17 (m, 1H), 6.37 (d,J=8.79 Hz, 1H), 6.91 (s, 1H), 6.96 (s, 2H), 7.17 (m, 2H), 7.28 (m, 2H),7.39 (m, 3H).

EXAMPLE 6(338)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.99 (d, J=6.32 Hz, 6H), 1.70 (m, 3H), 2.31 (s,6H), 2.71 (m, 2H), 3.03 (m, 2H), 5.04 (s, 2H), 5.16 (m, 1H), 6.34 (d,J=8.24 Hz, 1H), 6.77 (m, 1H), 6.90 (m, 5H), 7.27 (m, 1H), 7.39 (m, 2H).

EXAMPLE 6(339)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.18 Hz, 3H), 0.99 (d, J=6.18 Hz,3H), 1.71 (m, 3H), 2.22 (s, 3H), 2.30 (s, 6H), 2.31 (s, 3H), 2.72 (t,J=7.55 Hz, 2H), 3.04 (m, 2H), 5.02 (s, 2H), 5.15 (m, 1H), 6.27 (d,J=8.79 Hz, 1H), 6.71 (m, 2H), 6.90 (s, 1H), 6.95 (s, 2H), 7.04 (d,J=7.14 Hz, 1H), 7.28 (d, J=7.69 Hz, 1H), 7.42 (m, 2H).

EXAMPLE 6(340)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.18 Hz, 3H), 0.99 (d, J=6.18 Hz,3H), 1.71 (m, 3H), 2.31 (s, 6H), 2.72 (t, J=7.14 Hz, 2H), 3.04 (m, 2H),5.12 (s, 2H), 5.16 (m, 1H), 6.32 (d, J=8.52 Hz, 1H), 6.94 (m, 5H), 7.21(m, 1H), 7.28 (d, J=7.97 Hz, 1H), 7.41 (m, 2H), 7.52 (d, J=1.65 Hz, 1H).

EXAMPLE 6(341)3-(2-(1-methyl-1-(3,5-dimethylphenyl)ethyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 1.80 (s, 6H), 2.32 (s, 6H), 2.75 (t, J=7.42 Hz,2H), 3.08 (t, J=7.42 Hz, 2H), 5.08 (s, 2H), 6.33 (s, 1H), 6.62 (m, 1H),6.75 (m, 1H), 6.90 (s, 1H), 7.03 (m, 1H), 7.07 (s, 2H), 7.30 (d, J=7.98Hz, 1H), 7.41 (dd, J=7.98, 1.51 Hz, 1H), 7.49 (d, J=1.51 Hz, 1H).

EXAMPLE 6(342)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.32 Hz, 6H), 1.70 (m, 3H), 2.31 (s,6H), 2.73 (m, 2H), 3.03 (m, 2H), 5.02 (s, 2H), 5.16 (m, 1H), 6.28 (d,J=8.24 Hz, 1H), 6.91 (s, 1H), 6.97 (m, 5H), 7.29 (m, 3H), 7.42 (m, 2H).

EXAMPLE 6(343)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-ethylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.98 (dd, J=6.18, 2.61 Hz, 6H), 1.20 (t, J=7.55Hz, 3H), 1.70 (m, 3H), 2.30 (s, 6H), 2.71 (m, 4H), 3.03 (m, 2H), 5.05(s, 2H), 5.17 (m, 1H), 6.23 (d, J=8.52 Hz, 1H), 6.90 (m, 5H), 7.16 (m,2H), 7.28 (d, J=8.52 Hz, 1H), 7.42 (m, 2H).

EXAMPLE 6(344)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chlorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.99 (d, J=6.32 Hz, 6H), 1.70 (m, 3H), 2.31 (s,6H), 2.72 (m, 2H), 3.03 (m, 2H), 5.00 (s, 2H), 5.17 (m, 1H), 6.30 (d,J=8.79 Hz, 1H), 6.84 (m, 1H), 6.91 (s, 1H), 6.96 (m, 4H), 7.24 (m, 2H),7.40 (m, 2H).

EXAMPLE 6(345)3-(2-(4-(3,5-dimethylphenyl)perhydrothiopyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.58 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 2.25 (m, 2H), 2.31 (s, 6H), 2.61 (m, 2H), 2.76(m, 4H), 3.03 (m, 4H), 5.11 (s, 2H), 6.28 (s, 1H), 6.63 (m, 1H), 6.77(m,1H), 6.90 (s, 1H), 7.06 (m, 3H), 7.32 (d, J=7.97 Hz, 1H), 7.44 (dd,J=7.97, 1.80 Hz, 1H), 7.57 (d, J=1.80 Hz, 1H).

EXAMPLE 6(346)3-(2-(1-benzyl-4-(3,5-dimethylphenyl)piperidin-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=6:1);

NMR (300 MHz, CD₃OD): δ 2.17 (m, 2H), 2.29 (s, 6H), 2.61 (t, J=7.42 Hz,2H), 2.76 (m, 2H), 2.95 (m, 4H), 3.16 (m, 2H), 4.06 (s, 2H), 5.13 (s,2H), 6.64 (m, 1H), 6.90 (s, 1H), 6.97 (m, 1H), 7.09 (m, 3H), 7.43 (m,8H).

EXAMPLE 6(347)3-(2-(1,1-dione-4-(3,5-dimethylphenyl)perhydrothiopyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 2.31 (s, 6H), 2.75 (m, 4H), 3.04 (m, 6H), 3.40(m, 2H), 5.07 (s, 2H), 6.62 (m, 1H), 6.76 (m, 1H), 6.94 (s, 1H), 7.03(m, 4H), 7.30 (d, J=7.97 Hz, 1H), 7.45 (m, 1H), 7.51 (m, 1H).

EXAMPLE 6(348)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.24 (n-hexane:ethyl acetate:acetic acid=100:100:1);

NMR (300 MHz, DMSO-d₆): δ 1.93 (m, 2H), 2.26 (s, 6H), 2.39 (m, 2H), 2.49(m, 2H), 2.86 (m, 2H), 3.74 (m, 4H), 5.20 (s, 2H), 6.84 (s, 1H), 7.04(s, 2H), 7.42 (m, 7H), 8.59 (s, 1H), 12.09 (s, 1H).

EXAMPLE 6(349)3-(2-((2,6-dimethyl-4-(3,5-dimethylphenyl)-4-heptyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.66 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 0.75 (d, J=6.59 Hz, 6H), 0.84 (d, J=6.59 Hz,6H), 1.58 (m, 2H), 2.11 (dd, J=14.28, 5.22 Hz, 2H), 2.22 (dd, J=14.28,6.06 Hz, 2H), 2.31 (s, 6H), 2.79 (t, J=7.55 Hz, 2H), 3.11 (t, J=7.55 Hz,2H), 5.12 (s, 2H), 6.25 (s, 1H), 6.62 (m, 1H), 6.76 (m, 1H), 6.86 (s,1H), 6.94 (s, 2H), 7.04 (m, 1H), 7.34 (d, J=7.91 Hz, 1H), 7.44 (dd,J=7.91, 1.65 Hz, 1H), 7.57 (d, J=1.65 Hz, 1H).

EXAMPLE 6(350)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chloro-5-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.41 (n-hexane:ethyl acetate:acetic acid=100:100:1);

NMR (300 MHz, CDCl₃): δ 2.24 (m, 2H), 2.32 (s, 6H), 2.46 (m, 2H), 2.70(t, J=7.42 Hz, 2H), 3.03 (t, J=7.42 Hz, 2H), 3.83 (m, 2H), 3.93 (m, 2H),5.12 (s, 2H), 6.47 (s, 1H), 6.67 (m, 1H), 6.73 (dd, J=10.03, 2.61 Hz,1H), 6.91 (s, 1H), 7.09 (s, 2H), 7.33 (m, 2H), 7.43 (m, 1H), 7.62 (d,J=1.65 Hz, 1H).

EXAMPLE 6(351)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.39 (n-hexane:ethyl acetate:acetic acid=100:100:1);

NMR (300 MHz, CDCl₃): δ 2.23 (m, 2H), 2.32 (s, 6H), 2.33 (s, 3H), 2.46(dd, J=13.32, 1.51 Hz, 2H), 2.69 (t, J=7.28 Hz, 2H), 3.03 (t, J=7.28 Hz,2H), 3.83 (m, 2H), 3.92 (m, 2H), 5.12 (s, 2H), 6.46 (s, 1H), 6.75 (m,1H), 6.81 (s, 1H), 6.90 (s, 1H), 7.09 (s, 2H), 7.27 (m, 2H), 7.43 (m,1H), 7.66 (s, 1H).

EXAMPLE 6(352)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-dichlorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.39 (n-hexane:ethyl acetate:acetic acid=100:100:1);

NMR (300 MHz, CDCl₃): δ 2.25 (m, 2H), 2.32 (s, 6H), 2.47 (m, 2H), 2.71(t, J=7.14 Hz, 2H), 3.04 (t, J=7.14 Hz, 2H), 3.83 (t, J=10.30 Hz, 2H),3.93 (m, 2H), 5.12 (s, 2H), 6.46 (s, 1H), 6.95 (m, 3H), 7.09 (s, 2H),7.32 (m, 2H), 7.43 (m, 1H), 7.63 (d, J=1.65 Hz, 1H).

EXAMPLE 6(353)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.36 (n-hexane:ethyl acetate:acetic acid=100:100:1);

NMR (300 MHz, CDCl₃): δ 2.23 (m, 2H), 2.31 (s, 6H), 2.46 (m, 2H), 2.69(t, J=7.28 Hz, 2H), 3.02 (t, J=7.28 Hz, 2H), 3.79 (m, 2H), 3.91 (m, 2H),5.05 (s, 2H), 6.48 (s, 1H), 6.90 (s, 1H), 6.99 (m, 3H), 7.08 (s, 2H),7.30 (m, 3H), 7.43 (m, 1H), 7.50 (s, 1H).

EXAMPLE 6(354)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(3-chlorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.35 (n-hexane:ethyl acetate:acetic acid=100:100:1);

NMR (300 MHz, CDCl₃): δ 2.24 (m, 2H), 2.32 (s, 6H), 2.48 (d, J=15.11 Hz,2H), 2.71 (t, J=7.14 Hz, 2H), 3.02 (t, J=7.14 Hz, 2H), 3.79 (m, 2H) 3.92(m, 2H), 5.03 (s, 2H), 6.50 (s, 1H), 6.85 (m, 1H), 6.91 (s, 1H), 6.97(m, 2H), 7.08 (s, 2H), 7.22 (m, 1H), 7.30 (d, J=7.97 Hz, 1H), 7.41 (m,1H) 7.47 (s, 1H).

EXAMPLE 6(355)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(3-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 2.27 (m, 8H), 2.45 (m, 2H), 2.72 (t, J=7.28 Hz,2H), 3.03 (t, J=7.28 Hz, 2H), 3.87 (m, 4H), 5.04 (s, 2H), 6.48 (s, 1H),6.72 (m, 3H), 6.91 (s, 1H), 7.09 (s, 2H), 7.22 (m, 1H), 7.30 (d, J=8.24Hz, 1H), 7.43 (d, J=7.97 Hz, 1H), 7.48 (s, 1H).

EXAMPLE 6(356)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 2.26 (s, 6H), 2.28 (m, 2H), 2.32 (s, 6H), 2.44(m, 2H), 2.72 (t, J=7.35 Hz, 2H), 3.04 (t, J=7.35 Hz, 2H), 3.82 (m, 2H)3.93 (m, 2H), 5.06 (s, 2H), 6.40 (s, 1H), 6.73 (m, 2H), 6.91 (s, 1H),7.06 (d, J=7.69 Hz, 1H), 7.09 (s, 2H), 7.30 (d, J=7.69 Hz, 1H), 7.45(dd, J=7.69, 1.65 Hz, 1H), 7.56 (d, J=1.65 Hz, 1H).

EXAMPLE 6(357)3-(2-((1-methylsulfonyl-4-(3,5-dimethylphenyl)piperidin-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 2.24 (m, 2H), 2.32 (s, 6H), 2.70 (m, 4H), 2.78(s, 3H), 3.03 (t, J=7.14 Hz, 2H), 3.13 (t, J=11.13 Hz, 2H), 3.68 (m,2H), 5.07 (s, 2H), 6.52 (s, 1H), 6.63 (m, 1H), 6.75 (m, 1H), 6.92 (s,1H), 7.03 (m, 1H), 7.08 (s, 2H), 7.29 (d, J=7.97 Hz, 1H), 7.41 (d,J=7.97 Hz, 1H), 7.51 (s, 1H).

EXAMPLE 6(358)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-fluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 2.26 (m, 2H), 2.32 (s, 6H), 2.45 (m, 2H), 2.71(t, J=7.14 Hz, 2H) 3.03 (t, J=7.14 Hz, 2H), 3.82 (m, 4H), 5.13 (s, 2H),6.48 (s, 1H), 7.02 (m, 7H), 7.30 (d, J=7.69 Hz, 1H), 7.44 (d, J=7.69 Hz,1H), 7.56 (s, 1H).

EXAMPLE 6(359)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 2.25 (m, 2H), 2.32 (s, 6H), 2.46 (m, 2H), 2.70(t, J=7.42 Hz, 2H) 3.03 (t, J=7.42 Hz, 2H), 3.85 (m, 2H), 3.93 (m, 2H),5.15 (s, 2H), 6.45 (s, 1H), 6.91 (s, 1H), 6.97 (m, 2H), 7.09 (s, 2H),7.22 (m, 1H), 7.30 (d, J=7.97 Hz, 1H), 7.42 (m, 2H), 7.65 (s, 1H).

EXAMPLE 6(360)3-(2-((4-(3-methylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 2.25 (m, 2H), 2.36 (s, 3H), 2.50 (m, 2H), 2.70(t, J=7.21 Hz, 2H), 3.01 (t, J=7.21 Hz, 2H), 3.88 (m, 4H), 5.08 (s, 2H),6.57 (s, 1H), 6.63 (m, 1H), 6.76 (m, 1H), 7.05 (m, 2H), 7.27 (m, 4H),7.42 (dd, J=8.12, 1.71 Hz, 1H), 7.52 (d, J=1.71 Hz, 1H).

EXAMPLE 6(361)3-(2-((4-(naphthalen-1-yl)perhydropyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 2.50 (m, 4H), 2.85 (m, 4H), 3.97 (m, 4H), 5.02(s, 2H), 6.64 (m, 1H), 6.73 (m, 1H), 7.07 (m, 2H), 7.23 (d, J=7.69 Hz,1H), 7.43 (m, 5H), 7.74 (d, J=7.42 Hz, 1H), 7.80 (d, J=7.97 Hz, 1H),7.89 (m, 1H), 8.42 (m, 1H).

EXAMPLE 6(362)3-(2-((1-methyl-4-(3,5-dimethylphenyl)piperidin-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.37 (chloroform:methanol:28% ammonia water=40:10:1);

NMR (300 MHz, DMSO-d₆): δ 1.85 (m, 2H), 2.19 (s, 3H), 2.25 (s, 6H), 2.29(m, 2H), 2.46 (m, 4H), 2.65 (m, 2H), 2.89 (t, J=7.83 Hz, 2H), 5.21 (s,2H), 6.77 (m, 1H), 6.82 (s, 1H), 7.03 (s, 2H), 7.29 (m, 5H), 8.50 (s,1H).

EXAMPLE 6(363)3-(2-((1-ethyl-4-(3,5-dimethylphenyl)piperidin-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

TLC: Rf 0.39 (chloroform:methanol=5:1);

NMR (300 MHz, CD₃OH): δ 1.29 (t, J=7.28 Hz, 3H), 2.20 (m, 2H), 2.31 (s,6H), 2.62 (t, J=7.14 Hz, 2H), 2.85 (m, 2H), 2.98 (t, J=7.14 Hz, 2H),3.03 (m, 4H), 3.34 (m, 2H), 5.12 (s, 2H), 6.63 (m, 1H), 6.92 (s, 1H),6.96 (m, 1H), 7.08 (m, 1H), 7.14 (s, 2H), 7.40 (m, 3H).

EXAMPLE 6(364)2-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxyphenoxy)aceticacid

TLC: Rf 0.42 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.95 (d, J=6.32 Hz, 6H), 1.63 (m, 2H), 1.84 (m,1H), 2.28 (s, 6H), 4.73 (s, 2H), 5.03 (s, 2H), 5.19 (m, 1H), 6.85 (d,J=8.70 Hz, 1H), 6.87 (s, 1H), 6.98 (s, 2H) 7.02 (dd, J=8.70, 3.02 Hz,1H), 7.35 (m, 5H), 7.57 (d, J=3.02 Hz, 1H), 7.94 (d, J=8.52 Hz, 1H).

EXAMPLE 6(365)2-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-6-fluorobenzyloxy)phenoxy)aceticacid

TLC: Rf 0.42 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.96 (d, J=6.32 Hz, 6H), 1.66 (m, 2H), 1.84 (m,1H), 2.30 (s, 6H), 4.76 (s, 2H), 5.16 (s, 2H), 5.20 (m, 1H), 7.01 (m,6H), 7.28 (m, 2H), 7.49 (d, J=3.02 Hz, 1H) 7.54 (d, J=7.97 Hz, 1H).

REFERENCE EXAMPLE 9 4-(t-butoxycarbonyl)-2-nitrophenyl iodide

Using 4-carboxy-2-nitroaniline instead of 4-amino-3-hydroxybenzoic acidmethyl ester and using t-butanol instead of methanol, the title compoundhaving the following physical data was obtained by the same proceduresas a series of reactions of Reference Example 2→Reference Example 1.

TLC: Rf 0.50 (hexane:ethyl acetate=9:1).

REFERENCE EXAMPLE 10 4-[4-(t-butoxycarbonyl)-2-nitrophenyl]butanoic acidmethyl ester

To a suspension of zinc powder (activated, 19.6 g) in tetrahydrofuran(100 ml) was added dibromoethane (0.1 ml) and the mixture was refluxedfor 5 minutes. To the mixture was added trimethylsilylchloride (0.1 ml)and the mixture was stirred for 5 minutes. Under refluxing condition, tothe mixture was added a solution of methyl 4-iodobutanoate (45.6 g) intetrahydrofuran (100 ml) slowly. The reaction mixture was refluxed for 3hours. The mixture was allowed to stand to give a solution of methyl4-iodobutanoate zincate in tetrahydrofuran. At the same time, to asolution of the compound prepared in Reference Example 9 (34.9 g) intetrahydrofuran (100 ml) was added(1,1′-bis(diphenylphosphino)ferrocene)palladium(II) dichloride (2.20 g).To the suspension was added dropwise the above-mentioned solution ofmethyl 4-iodobutanoate zincate in tetrahydrofuran (equivalent to 200mmol) at room temperature during 15 minutes. The mixture was stirred atroom temperature for 30 minutes and then stirred at 60° C. for 30minutes. After cooling, to the mixture was added a saturated aqueoussolution of ammonium chloride. An appeared insoluble material wasremoved and then the mixture was extracted with ethyl acetate. Theorganic layer was washed with water and a saturated aqueous solution ofsodium chloride subsequently, dried over anhydrous magnesium sulfate andconcentrated. The residue was purified by column chromatography onsilica gel (hexane:ethyl acetate=9:1→4:1) to give the title compound(24.47 g) having the following physical data.

TLC: Rf 0.24 (hexane:ethyl acetate=9:1).

REFERENCE EXAMPLE 11 4-(4-carboxy-2-nitrophenyl)butanoic acid methylester

To a solution of the compound prepared in Reference Example 10 (24.4 g)in anisole (38 ml) was added trifluoroacetic acid (29 ml) and themixture was stirred at 60° C. for 1 hour. The reaction mixture wascooled, added water and hexane and then removed hexane layer (toplayer). The remaining layer was extracted with ethyl acetate. Theorganic layer was washed with water and a saturated aqueous solution ofsodium chloride, dried over anhydrous magnesium sulfate andconcentrated. The residue was recrystallized from ethyl acetate-hexaneto give the title compound (16.72 g) having the following physical data.

TLC: Rf 0.31 (hexane:ethyl acetate=1:1).

REFERENCE EXAMPLE 12 4-(4-hydroxymethyl-2-nitrophenyl)butanoic acidmethyl ester

To a solution of the compound prepared in Reference Example 11 (15.58g), triethylamine (10.6 ml) in tetrahydrofuran (60 ml) was added ethylchloroformate (6.2 ml) under ice-cooling, and the mixture was stirredfor 1 hour. The mixture was filtered and the obtained filtrate was addeddropwise to a solution of sodium borohydride (11.1 g) in water (60 ml)under ice-cooling. The mixture was stirred for 30 minutes. To thereaction mixture was added 1N hydrochloric acid slowly and then themixture was extracted with ethyl acetate. The organic layer was washedwith water and a saturated aqueous solution of sodium chloride, driedand concentrated. The residue was purified by column chromatography onsilica gel (hexane:ethyl acetate=2:1→1:1) to give the title compound(12.26 g) having the following physical data.

TLC: Rf 0.46 (hexane:ethyl acetate=1:1).

REFERENCE EXAMPLE 134-[4-(t-butyldimethylsilyloxymethyl)-2-nitrophenyl]butanoic acid methylester

To the compound prepared in Reference Example 12 (4.078 g) and imidazole(1.646 g) in N,N-dimethylformamide (20 ml) was addedt-butyldimethylsilyl chloride (2.664 g) under ice-cooling, and themixture was stirred at room temperature overnight. To the reactionmixture was added water and the mixture was extracted with hexane. Theorganic layer was washed with water, dried over anhydrous magnesiumsulfate and concentrated to give the title compound (6.02 g) having thefollowing physical data.

TLC: Rf 0.69 (hexane:ethyl acetate=3:1).

REFERENCE EXAMPLE 144-[2-amino-4-(t-butyldimethylsilyloxymethyl)phenyl]butanoic acid methylester

To a solution of the compound prepared in Reference Example 13 (6.02 g)in methanol (30 ml) was added 10% palladium carbon (420 mg) and themixture was stirred at room temperature for 1 hour under an atmosphereof hydrogen. The reaction mixture was filtered and the filtrate wasconcentrated to give the title compound (5.43 g) having the followingphysical data.

TLC: Rf 0.38 (hexane:ethyl acetate=4:1).

REFERENCE EXAMPLE 154-[4-(t-butyldimethylsilyloxymethyl)-2-[1-(1-naphthyl)ethylcarbonylamino]phenyl]butanoicacid methyl ester

To a solution of the compound prepared in Reference Example 14 (5.43 g)and pyridine (2.60 ml) in methylene chloride (20 ml) was added dropwisea solution of α-methyl-1-naphthylacetyl chloride (3.52 g) in methylenechloride (10 ml) under an atmosphere of argon and the mixture wasstirred at room temperature for 30 minutes. To the reaction mixture wasadded a saturated aqueous solution of sodium bicarbonate and the mixturewas extracted with ethyl acetate. The organic layer was washed withwater and a saturated aqueous solution of sodium chloride subsequently,dried over anhydrous magnesium sulfate and concentrated to give thetitle compound having the following physical data.

TLC: Rf 0.39 (hexane:ethyl acetate=4:1).

EXAMPLE 74-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-hydroxymethylphenyl)butanoicacid methyl ester

To a solution of the compound prepared in Reference Example 15 intetrahydrofuran (30 ml) was added tetrabutylammonium fluoride (24 ml)and the mixture was stirred at room temperature overnight. To thereaction mixture was added water and the appeared solid was collected byfiltration. The solid was dissolved in ethyl acetate. The solution wasdried and then concentrated. The residue was recrystallized from ethylacetate-hexane to give the title compound (5.02 g).

TLC: Rf 0.27 (hexane:ethyl acetate=1:1).

EXAMPLE 7(a)4-(2-(1-(1-naphthyl)ethyl)carbonylamino-4-hydroxymethylphenyl)butanoicacid methyl ester

To a solution of the compound prepared in Reference Example 15 intetrahydrofuran (30 ml) was added tetrabutylammonium fluoride (24 ml)and the mixture was stirred at room temperature overnight. To thereaction mixture was added water and the appeared solid was collected byfiltration. The solid was dissolved in ethyl acetate. The solution wasdried and then concentrated. The residue was recrystallized from ethylacetate-hexane to give the title compound (5.02 g).

TLC: Rf 0.27 (hexane:ethyl acetate=1:1).

EXAMPLE 7(b)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-ethoxyphenoxymethyl)phenyl)butanoicacid methyl ester

Using the compounds prepared in Example 7(a) or corresponding compounds,the title compounds having the following physical data were obtained bythe same procedure of Example 5.

TLC: Rf 0.47 (n-hexane:ethyl acetate=2:1).

EXAMPLE 7(b-1)˜7(b-2)

Using corresponding compounds, the following compounds were obtained bythe same procedure of Example 7(b).

EXAMPLE 7(b-1)2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-phenoxymethylbenzyl)benzoicacid methyl ester

TLC: Rf 0.52 (n-hexane:ethyl acetate=3:1).

EXAMPLE 7(b-2)2-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-phenoxymethylbenzyl)benzoicacid methyl ester

TLC: Rf 0.56 (n-hexane:ethyl acetate=2:1).

EXAMPLE 84-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-ethoxyphenoxymethyl)phenyl)butanoicacid

Using the compounds prepared in Example 7(b) or corresponding compounds,the title compounds having the following physical data were obtained bythe same procedure of Example 3.

TLC: Rf 0.45 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.08(br, 1H), 9.58(s, 1H), 8.32(d, J=8.1 Hz,1H), 7.94(m, 1H), 7.83(d, J=8.1 Hz, 1H), 7.62-7.46(m, 4H), 7.38(bs, 1H),7.16(m, 2H), 6.88(d, J=9.0 Hz, 2H), 6.81(d, J=9.0 Hz, 2H), 4.94(s, 2H),4.71(q, J=6.9 Hz, 1H), 3.91(q, J=6.9 Hz, 2H), 2.43(m, 2H), 2.02(t, J=7.5Hz, 2H), 1.60(d, J=6.9 Hz, 3H), 1.56(m, 2H), 1.27(t, J=6.9 Hz, 3H).

EXAMPLE 8(1)˜EXAMPLE 8(136)

Using the compounds prepared in Example 7(b-1) or 7(b-2) orcorresponding compounds, the title compounds were obtained by the sameprocedure of Example 8.

EXAMPLE 8(1)(2E)-3-(2-((2-(naphthalen-2-yl)acetyl)amino)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.42 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 10.12 (bs, 1H), 7.94-7.70 (m, 7H), 7.57-7.41(m, 4H), 7.24 (s, 1H), 7.02 (d, J=8.1 Hz, 1H), 6.46 (d, J=16 Hz, 1H),6.25 (t, J=2.0 Hz, 1H), 5.32 (s, 2H), 3.85 (s, 2H).

EXAMPLE 8(2)2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-hydroxymethylbenzyl)benzoicacid

TLC: Rf 0.50 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.62 (s, 1H), 8.32 (d, J=8.4 Hz, 1H), 7.91 (d,J=8.1 Hz, 1H), 7.78 (d, J=8.7 Hz, 1H), 7.75 (m, 1H), 7.65-7.39 (m, 4H),7.34 (s, 1H), 7.23 (m, 2H), 7.00 (d, J=8.1 Hz, 1H), 6.88 (d, J=7.8 Hz,1H), 6.79 (m, 1H), 5.12 (t, J=5.7 Hz, 1H), 4.60 (m, 1H), 4.41 (d, J=5.4Hz, 1H), 4.30 (d, J=16.2 Hz, 1H), 4.18 (d, J=16.2 Hz, 1H), 1.93 (m, 1H),1.47 (m, 2H), 0.92 (d, J=6.3 Hz, 3H), 0.80 (d, J=6.3 Hz, 3H).

EXAMPLE 8(3)2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-mesyloxybenzyl)benzoicacid

TLC: Rf 0.62 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 8.15 (s, 1H), 8.10-7.98 (m, 2H), 7.83 (m 1H),7.67 (m, 1H), 7.60-7.41 (m, 3H), 7.32-7.20 (m, 3H), 7.17-6.96 (m, 3H),6.81 (d, J=7.2 Hz, 1H), 4.37 (t, J=7.5 Hz, 1H), 4.08 (d, J=16.2 Hz, 1H),3.80 (d, J=16.2 Hz, 1H), 3.18 (s, 3H), 2.14 (m, 1H), 1.73 (m, 1H), 1.59(m, 1H), 0.96 (d, J=6.6 Hz, 3H), 0.89 (d, J=6.6 Hz, 3H).

EXAMPLE 8(4)2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-acetylaminobenzyl)benzoicacid

TLC: Rf 0.54 (chloroform:methanol=8:1);

NMR (300 MHz, DMSO-d₆): δ 9.85 (s, 1H), 9.67 (bs, 1H), 8.32 (d, J=8.4Hz, 1H), 7.91 (d, J=7.8 Hz, 1H), 7.78 (d, J=8.1 Hz, 1H), 7.73 (m, 1H),7.64-7.35 (m, 6H), 7.28-7.15 (m, 2H), 6.86 (d, J=8.4 Hz, 1H), 6.78 (m,1H), 4.60 (m, 1H), 4.26 (d, J=16.5 Hz, 1H), 4.13 (d, J=16.5 Hz, 1H),1.97 (s, 3H), 1.92 (m, 1H), 1.52-1.36 (m, 2H), 0.92 (d, J=6.3 Hz, 3H),0.80 (d, J=6.3 Hz, 3H).

EXAMPLE 8(5)2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-mesylaminobenzyl)benzoicacid

TLC: Rf 0.54 (chloroform:methanol=8:1);

NMR (300 MHz, CDCl₃): δ 8.05 (d, J=8.1 Hz, 1H), 7.97 (bs, 2H), 7.82 (d,J=7.5 Hz, 1H), 7.68 (d, J=7.5 Hz, 1H), 7.63 (d, J=7.8 Hz, 1H), 7.55-7.40(m, 2H), 7.35-7.21 (m,3H), 7.15 (m, 1H), 7.08-6.96 (m, 2H), 6.83 (d,J=8.1 Hz, 1H), 6.64 (s, 1H), 4.38 (t, J=7.2 Hz, 1H), 4.02 (d, J=16.5 Hz,1H), 3.78 (d, J=16.5 Hz, 1H), 2.99 (s, 3H), 2.15 (m, 1H), 1.75 (m, 1H),1.60 (m, 1H), 0.96 (d, J=6.6 Hz, 3H), 0.89 (d, J=6.6 Hz, 3H).

EXAMPLE 8(6)2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-(N-mesyl-N-methylamino)benzyl)benzoicacid

TLC: Rf 0.59 (chloroform:methanol=8:1);

NMR (300 MHz, CDCl₃): δ 8.20 (d, J=2.1 Hz, 1H), 8.07 (m, 1H), 8.04 (m,1H), 7.84 (m, 1H), 7.69 (d, J=6.9 Hz, 1H), 7.59 (d, J=7.5 Hz, 1H),7.55-7.44 (m, 2H), 7.34-7.23 (m, 3H), 7.18-7.10 (m, 2H), 7.05 (d, J=8.4Hz, 1H), 6.87 (d, J=7.8 Hz, 1H), 4.38 (t, J=7.2 Hz, 1H), 4.06 (d, J=16.5Hz, 1H), 3.80 (d, J=16.5 Hz, 1H), 3.32 (m, 3H), 2.89 (s, 3H), 2.15 (m,1H), 1.76 (m, 1H), 1.61 (m, 1H), 0.97 (d, J=6.6 Hz, 3H), 0.91 (d, J=6.6Hz, 3H).

EXAMPLE 8(7)2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-(pyrazol-1-ylmethyl)benzyl)benzoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.05 (m, 1H), 7.99 (s, 1H), 7.91 (s, 1H), 7.80(m, 1H), 7.66 (d, J=7.8 Hz, 1H), 7.58 (m, 2H), 7.49-7.38 (m, 3H),7.34-7.07 (m, 4H), 6.82 (d, J=7.5 Hz, 1H), 6.77 (d, J=7.5 Hz, 1H), 6.63(d, J=8.1 Hz, 1H), 6.29 (s, 1H), 5.23 (s, 2H), 4.33 (m, 1H), 3.86 (d,J=16.8 Hz, 1H), 3.69 (d, J=16.8 Hz, 1H), 2.12 (m, 1H), 1.69 (m, 1H),1.56 (m, 1H), 0.93 (d, J=6.3 Hz, 3H), 0.86 (d, J=6.3 Hz, 3H).

EXAMPLE 8(8)2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-methoxymethylbenzyl)benzoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.08 (bs, 1H), 8.05 (d, J=7.8 Hz, 1H), 7.81 (m,1H), 7.72 (m, 1H), 7.74-7.58 (m, 2H), 7.46 (m, 2H), 7.32-7.08 (m, 4H),7.03 (m, 2H), 6.80 (d, J=7.8 Hz, 1H), 4.43 (s, 2H), 4.34 (t, J=7.5 Hz,1H), 4.07 (d, J=16.5 Hz, 1H), 3.84 (d, J=16.5 Hz, 1H), 3.39 (s, 3H),2.16 (m, 1H), 1.72 (m, 1H), 1.61(m, 1H), 0.96 (d, J=6.3 Hz, 3H), 0.89(d, J=6.3 Hz, 3H).

EXAMPLE 8(9)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-hydroxymethylphenyl)butanoicacid

TLC: Rf 0.45 (ethyl acetate);

NMR (300 MHz, CD₃OD): δ 8.30-8.25 (m, 1H), 7.92-7.87 (m, 1H), 7.81 (t,J=8.1 Hz, 1H), 7.67-7.44 (m, 4H), 7.33 (s, 1H), 7.13-7.08 (m, 2H), 4.71(q, J=7.2 Hz, 1H), 4.53 (s, 2H), 2.34-2.27 (m, 2H), 1.96 (t, J=7.2 Hz,2H), 1.73 (d, J=7.2 Hz, 3H), 1.55-1.44 (m, 2H).

EXAMPLE 8(10)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-methoxymethylphenyl)butanoicacid

TLC: Rf 0.40 (hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 8.14 (d, J=7.5 Hz, 1H), 7.93-7.84 (m, 3H), 7.63(d, J=6.6 Hz, 1H), 7.58-7.50 (m, 3H), 7.12 (s, 1H), 7.02-6.95 (m, 2H),4.57 (q, J=6.9 Hz, 1H), 4.39 (s, 2H), 3.36 (s, 3H), 1.94-1.89 (m, 4H),1.83 (d, J=6.9 Hz, 3H), 1.30-1.20 (m, 2H).

EXAMPLE 8(11)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenoxymethylphenyl)butanoicacid

TLC: Rf 0.55 (hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 8.14 (d, J=8.1 Hz, 1H), 7.98 (s, 1H), 7.93-7.84(m, 2H), 7.63 (d, J=6.6 Hz, 1H), 7.58-7.50 (m, 3H), 7.30-7.24 (m, 2H),7.13-7.09 (m, 2H), 7.01-6.92 (m, 4H), 4.99 (s, 2H), 4.57 (q, J=7.2 Hz,1H), 1.95-1.90 (m, 4H), 1.84 (d, J=7.2 Hz, 3H), 1.30-1.20 (m, 2H).

EXAMPLE 8(12)2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-mesylmethylbenzyl)benzoicacid

TLC: Rf 0.47 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.72 (bs, 1H), 8.32 (m, 1H), 7.91 (d, J=7.8Hz, 1H), 7.79-7.74 (m, 2H), 7.63-7.39 (m, 5H), 7.30-7.20 (m, 2H), 7.08(dd, J=7.8, 1.8 Hz, 1H), 6.91 (d, J=7.8 Hz, 1H), 6.80 (m, 1H), 4.63 (dd,J=8.7, 4.8 Hz, 1H), 4.40 (s, 2H), 4.32 (d, J=16.2 Hz, 1H), 4.19 (d,J=16.2 Hz, 1H), 2.87 (s, 3H), 1.91 (m, 1H), 1.56-1.36 (m, 2H), 0.92 (d,J=6.3 Hz, 1H), 0.80 (d, J=6.3 Hz, 1H).

EXAMPLE 8(13)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-methylthiomethylphenyl)butanoicacid

TLC: Rf 0.35 (hexane:ethyl acetate=1:1);

NMR (300 MHz, DMSO-d₆): δ 12.03 (s, 1H), 9.45 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.94 (dd, J=8.1, 1.5 Hz, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.47(m, 4H), 7.24 (d, J=1.8 Hz, 1H), 7.10 (d, J=7.8 Hz, 1H), 7.04 (dd,J=7.8, 1.8 Hz, 1H), 4.69 (q, J=6.9 Hz, 1H), 3.61 (s, 2H), 2.40 (m, 2H),2.01 (t, J=7.5 Hz, 2H), 1.92 (s, 3H), 1.60 (d, J=6.9 Hz, 3H), 1.55 (m,2H).

EXAMPLE 8(14)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-methylsulfinylmethylphenyl)butanoicacid

TLC: Rf 0.63 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.03 (s, 1H), 9.52 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.94 (dd, J=8.1, 1.5 Hz, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.63-7.47(m, 4H), 7.26 (s, 1H), 7.16 (d, J=7.8 Hz, 1H), 7.05 (dd, J=7.8, 1.5 Hz,1H), 4.70 (q, J=6.9 Hz, 1H), 4.05 (d, J=12.6 Hz, 1H), 3.85 (d, J=12.6Hz, 1H), 2.45 (s, 3H), 2.42 (m, 2H), 2.02 (t, J=7.2 Hz, 2H), 1.60 (d,J=6.9 Hz, 3H), 1.55 (m, 2H).

EXAMPLE 8(15)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-mesylmethylphenyl)butanoicacid

TLC: Rf 0.51 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 9.55 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.95 (m, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.63-7.47 (m, 4H), 7.35(d, J=1.2 Hz, 1H), 7.19 (d, J=7.8 Hz, 1H), 7.14 (dd, J=7.8, 1.2 Hz, 1H),4.71 (q, J=6.9 Hz, 1H), 4.40 (s, 2H), 2.87 (s, 3H), 2.42 (m, 2H), 2.03(t, J=7.2 Hz, 2H), 1.60 (d, J=6.9 Hz, 3H), 1.57 (m, 2H).

EXAMPLE 8(16)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-aminomethylphenyl)butanoicacid

TLC: Rf 0.10 (chloroform:methanol=5:1);

NMR (300 MHz, DMSO-d₆): δ 8.39 (d, J=9.1 Hz, 1H), 7.93 (d, J=7.2 Hz,1H), 7.82 (d, J=7.2 Hz, 1H), 7.63-7.47 (m, 4H), 7.45 (brs, 1H), 7.14 (s,2H), 4.84 (q, J=6.9 Hz, 1H), 3.80 (s, 2H), 2.59-2.42 (m, 2H), 2.01 (t,J=7.2 Hz, 2H), 1.60 (d, J=6.9 Hz, 3H), 1.62-1.56 (m, 2H).

EXAMPLE 8(17)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-acetylaminomethylphenyl)butanoicacid

TLC: Rf 0.9 (chloroform:methanol=5:1);

NMR (300 MHz, DMSO-d₆): δ 9.46 (brs, 1H), 8.34-8.25 (m, 2H), 7.94 (d,J=8.1 Hz, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.61-7.47 (m, 4H), 7.16 (brs,1H), 7.09 (d, J=7.8 Hz, 1H), 6.98 (d, J=8.1 Hz, 1H), 4.68 (q, J=7.2 Hz,1H), 4.15 (d, J=5.7 Hz, 2H), 2.44-2.35 (m, 2H), 2.00 (t, J=7.2 Hz, 2H),1.82 (s, 3H), 1.59 (d, J=6.6 Hz, 3H), 1.56-1.48 (m, 2H).

EXAMPLE 8(18)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-mesylaminomethylphenyl)butanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 9.51 (s, 1H), 8.32 (d, J=8.1 Hz, 1H), 7.95 (d,J=7.8 Hz, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.48 (m, 5H), 7.28 (brs,1H), 7.14 (d, J=7.5 Hz, 1H), 7.08 (dd, J=7.8, 1.5 Hz, 1H), 4.70 (q,J=7.2 Hz, 1H), 4.06 (d, J=6.3 Hz, 2H), 2.81 (s, 3H), 2.45-2.37 (m, 2H),2.01 (t, J=7.5 Hz, 2H), 1.60 (d, J=6.9 Hz, 3H), 1.61-1.50 (m, 2H).

EXAMPLE 8(19)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(N-mesyl-N-methylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.58 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.13 (d, J=8.7 Hz, 1H), 7.93-7.85 (m, 3H), 7.63(d, J=6.3 Hz, 1H), 7.59-7.49 (m, 3H), 7.17 (brs, 1H), 7.05 (dd, J=8.1,1.5 Hz, 1H), 6.99 (d, J=8.1 Hz, 1H), 4.57 (q, J=7.5 Hz, 1H), 4.25 (s,2H), 2.83 (s, 3H), 2.76 (s, 3H), 1.94-1.89 (m, 4H), 1.83 (d, J=6.9 Hz,3H), 1.31-1.22 (m, 2H).

EXAMPLE 8(20)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzoylaminophenyl)butanoicacid

TLC: Rf 0.65 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.03 (s, 1H), 10.18 (s, 1H), 9.53 (s, 1H),8.33 (d, J=8.7 Hz, 1H), 7.96-7.91 (m, 3H), 7.84 (d, J=8.1 Hz, 1H), 7.72(d, J=2.4 Hz, 1H), 7.61-7.47 (m, 8H), 7.13 (d, J=8.4 Hz, 1H), 4.71 (q,J=7.2 Hz, 1H), 2.44-2.38 (m, 2H), 2.03 (t, J=7.5 Hz, 2H), 1.62-1.55 (m,5H).

EXAMPLE 8(21)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylsulfonylaminophenyl)butanoicacid

TLC: Rf 0.65 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 8.11-8.07 (m, 1H), 7.92-7.76 (m, 4H), 7.66 (s,1H), 7.59-7.47 (m, 5H), 7.42-7.37 (m, 2H), 7.16 (s, 1H), 6.99 (s, 1H),6.92 (dd, J=8.1, 2.1 Hz, 1H), 6.84 (d, J=8.4 Hz, 1H), 4.56 (q, J=7.2 Hz,1H), 1.91-1.78 (m, 7H), 1.23-1.12 (m, 2H).

EXAMPLE 8(22)4-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-phenoxymethylphenyl)butanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.57 (s, 1H), 8.39 (d, J=8.1 Hz, 1H), 7.93 (d,J=7.8 Hz, 1H), 7.81 (d, J=8.1 Hz, 1H), 7.66 (d, J=7.2 Hz, 1H), 7.63-7.44(m, 3H), 7.33-7.13 (m, 5H), 6.98-6.87 (m, 3H), 5.00 (s, 2H), 4.67 (m,1H), 2.45-2.33 (m, 2H), 2.12 (m, 1H), 1.98-1.89 (m, 2H), 1.66-1.43 (m,4H), 1.05 (d, J=6.3 Hz, 3H), 0.91 (d, J=6.3 Hz, 3H).

EXAMPLE 8(23)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-oxopyridin-1-ylmethyl)phenyl)butanoicacid

TLC: Rf 0.35 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.02 (s, 1H), 9.47 (s, 1H), 8.29 (d, J=8.1Hz, 1H), 7.94 (d, J=7.8 Hz, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.73 (dd,J=6.6, 2.1 Hz, 1H), 7.60-7.46 (m, 4H), 7.42-7.34 (m, 1H), 7.23 (d, J=1.8Hz, 1H), 7.12 (d, J=8.1 Hz, 1H), 7.02 (dd, J=8.1, 1.8 Hz, 1H), 6.38 (d,J=9.0 Hz, 1H), 6.20 (dt, J=1.5, 6.6 Hz, 1H), 5.01 (s, 2H), 4.69-4.64 (m,1H), 2.40-2.35 (m, 2H), 1.99 (t, J=7.5 Hz, 2H), 1.59-1.50 (m, 5H).

EXAMPLE 8(24)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(pyridin-3-yloxymethyl)phenyl)butanoicacid

TLC: Rf 0.60 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 9.52 (s, 1H), 8.32-8.29 (m,2H), 8.15 (d, J=4.5 Hz, 1H), 7.95 (dd, J=7.8, 1.5 Hz, 1H), 7.83 (d,J=8.1 Hz, 1H), 7.61-7.40 (m, 6H), 7.31 (dd, J=8.1, 4.5 Hz, 1H), 7.19 (s,2H), 5.10 (s, 2H), 4.70 (q, J=7.2 Hz, 1H), 2.44-2.41 (m, 2H), 2.02 (t,J=7.2 Hz, 2H), 1.61-1.51 (m, 5H).

EXAMPLE 8(25)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylthiomethylphenyl)butanoicacid

TLC: Rf 0.50 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.00 (br s, 1H), 9.46 (s, 1H), 8.30 (d, J=8.4Hz, 1H), 7.95 (d, J=7.8 Hz, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.61-7.47 (m,4H), 7.32-7.23 (m, 5H), 7.17-7.12 (m, 1H), 7.08 (s, 2H), 4.68 (q, J=6.9Hz, 1H), 4.17 (s, 2H), 2.41-2.36 (m, 2H), 2.00 (t, J=7.5 Hz, 2H), 1.59(d, J=6.9 Hz, 3H), 1.56-1.51 (m, 2H).

EXAMPLE 8(26)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylaminomethylphenyl)butanoicacid

TLC: Rf 0.50 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.02 (s, 1H), 9.44 (s, 1H), 8.29 (d, J=7.8Hz, 1H), 7.95-7.92 (m, 1H), 7.82 (d, J=7.8 Hz, 1H), 7.58-7.46 (m, 4H),7.28 (s, 1H), 7.09 (s, 2H), 7.03-6.97 (m, 2H), 6.53-6.45 (m, 3H), 6.17(t, J=6.0 Hz, 1H), 4.67 (q, J=7.2 Hz, 1H), 4.16 (d, J=6.0 Hz, 2H),2.40-2.35 (m, 2H), 2.00 (t, J=7.5 Hz, 2H), 1.60-1.50 (m, 5H).

EXAMPLE 8(27)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylsulfinylmethylphenyl)butanoicacid

TLC: Rf 0.40 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.03 (s, 1H), 9.50 (s, 1H), 8.31 (d, J=8.4Hz, 1H), 7.97-7.94 (m, 1H), 7.84 (d, J=7.8 Hz, 1H), 7.60-7.46 (m, 9H),7.14-7.13 (m, 1H), 7.06 (d, J=7.8 Hz, 1H), 6.86-6.83 (m, 1H), 4.69 (q,J=6.9 Hz, 1H), 4.20-4.15 (m, 1H), 3.98-3.92 (m, 1H), 2.43-2.39 (m, 2H),2.03-1.98 (m, 2H), 1.60-1.52 (m, 5H).

EXAMPLE 8(28)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylsulfonylmethylphenyl)butanoicacid

TLC: Rf 0.60 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.03 (s, 1H), 9.50 (s, 1H), 8.30 (d, J=8.4Hz, 1H), 7.95 (d, J=7.8 Hz, 1H), 7.84 (d, J=7.5 Hz, 1H), 7.73-7.48 (m,9H), 7.15 (s, 1H), 7.07 (d, J=8.1 Hz, 1H), 6.88 (dd, J=7.8, 1.5 Hz, 1H),4.68 (q, J=7.2 Hz, 1H), 4.58 (s, 2H), 2.42-2.38 (m, 2H), 1.99 (t, J=7.5Hz, 2H), 1.60-1.51 (m, 5H).

EXAMPLE 8(29)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzyloxyphenyl)butanoicacid

TLC: Rf 0.13 (hexane:ethyl acetate=2:1);

NMR (300 MHz, DMSO-d₆): δ 9.39 (brs, 1H), 8.29 (d, J=8.7 Hz, 1H), 7.94(d, J=7.8 Hz, 1H), 7.83 (d, J=7.5 Hz, 1H), 7.62-7.46 (m, 4H), 7.43-7.28(m, 5H), 7.06-7.03 (m, 2H), 6.77 (dd, J=8.4, 2.4 Hz, 1H), 5.01 (s, 2H),4.70 (q, J=7.2 Hz, 1H), 2.36 (m, 2H), 2.01 (t, J=7.2 Hz, 2H), 1.59 (d,J=7.2 Hz, 3H), 1.56-1.45 (m, 2H).

EXAMPLE 8(30)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenoxyphenyl)butanoic acid

TLC: Rf 0.15 (hexane:ethyl acetate=2:1);

NMR (300 MHz, DMSO-d₆): δ 9.44 (brs, 1H), 8.26 (brd, J=8.1 Hz, 1H), 7.93(m, 1H), 7.82 (brd, J=7.5 Hz, 1H), 7.59-7.45 (m, 4H), 7.40-7.32 (m, 2H),7.15 (d, J=8.4 Hz, 1H), 7.13-7.08 (m, 2H), 6.98-6.95 (m, 2H), 6.76 (dd,J=8.4, 2.7 Hz, 1H), 4.69 (q, J=6.9 Hz, 1H), 2.45-2.40 (m, 2H), 2.04 (t,J=7.5 Hz, 2H), 1.60-1.52 (m, 2H), 1.57 (d, J=6.9 Hz, 3H).

EXAMPLE 8(31)3-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.54 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.20 (d, J=8.4 Hz, 1H), 7.88-7.70 (m, 4H), 7.63(d, J=6.9 Hz, 1H), 7.56-7.40 (m, 3H), 7.30-7.20 (m, 2H), 7.13 (m, 1H),7.03 (d, J=7.5 Hz, 1H), 6.97-6.87 (m, 3H), 4.96 (s, 2H), 4.49 (t, J=7.4Hz, 1H), 2.41-2.14 (m, 5H), 2.01 (m, 1H), 1.70 (m, 1H), 1.00 (d, J=6.6Hz, 3H), 0.97 (d, J=6.6 Hz, 3H).

EXAMPLE 8(32)4-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-(pyrazol-1-ylmethyl)phenyl)butanoicacid

TLC: Rf 0.36 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.21 (d, J=7.2 Hz, 1H), 7.90 (m, 2H), 7.82 (d,J=7.8 Hz, 1H), 7.64 (d, J=7.2 Hz, 1H), 7.58-7.40 (m, 5H), 6.92 (d, J=8.1Hz, 1H), 6.78 (d, J=7.8 Hz, 1H), 6.26 (t, J=2.1 Hz, 1H), 5.25 (s, 2H),4.55 (t, J=7.2 Hz, 1H), 2.30 (m, 2H), 2.05-1.80 (m, 3H), 1.68 (m, 2H),1.28 (m, 2H), 1.01 (d, J=6.6 Hz, 3H), 0.96 (d, J=6.6 Hz, 3H).

EXAMPLE 8(33)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylphenyl)butanoic acid

TLC: Rf 0.29 (hexane:ethyl acetate=1:1);

NMR (300 MHz, DMSO-d₆): δ 12.05 (s, 1H), 9.54 (s, 1H), 8.33 (d, J=8.1Hz, 1H), 7.95 (m, 1H), 7.84 (d, J=8.1 Hz, 1H), 7.64-7.37 (m, 10H), 7.33(m, 1H), 7.25 (d, J=8.1 Hz, 1H), 4.73 (q, J=6.9 Hz, 1H), 2.45 (m, 2H),2.05 (t, J=7.2 Hz, 2H), 1.62 (d, J=6.9 Hz, 3H), 1.60 (m, 2H).

EXAMPLE 8(34)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzoylaminomethylphenyl)butanoicacid

TLC: Rf 0.60 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 11.94 (br s, 1H), 9.51 (s, 1H), 9.00 (t, J=6.9Hz, 1H), 8.29 (d, J=7.2 Hz, 1H), 7.95-7.80 (m, 4H), 7.57-7.44 (m, 7H),7.24 (s, 1H), 7.12-7.05 (m, 2H), 4.68 (q, J=6.9 Hz, 1H), 4.39 (d, J=6.9Hz, 2H), 2.42-2.37 (m, 2H), 2.00 (t, J=7.2 Hz, 2H), 1.59-1.50 (m, 5H).

EXAMPLE 8(35)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(pyridin-4-yloxymethyl)phenyl)butanoicacid

TLC: Rf 0.50 (ethyl acetate:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.03 (br s, 1H), 9.54 (s, 1H), 8.52 (d, J=6.9Hz, 2H), 8.31 (d, J=7.8 Hz, 1H), 7.94 (dd, J=7.8, 1.5 Hz, 1H), 7.83 (d,J=7.8 Hz, 1H), 7.61-7.47 (m, 4H), 7.43 (s, 1H), 7.25-7.22 (m, 4H), 5.22(s, 2H), 4.71 (q, J=7.2 Hz, 1H), 2.46-2.44 (m, 2H), 2.03 (t, J=7.2 Hz,2H), 1.69-1.51 (m, 5H).

EXAMPLE 8(36)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-phenoxyethyl)phenyl)butanoicacid

TLC: Rf 0.22 (hexane:ethyl acetate=1:1);

NMR (300 Hz, CD₃OD): δ 8.28 (brd, J=8.7 Hz, 1H), 7.91 (brd, J=8.1 Hz,1H), 7.82 (brd, J=8.4 Hz, 1H), 7.65 (brd, J=6.6 Hz, 1H), 7.60-7.47 (m,4H), 7.29 (brs, 1H), 7.22 (brt, J=8.7 Hz, 2H), 7.09 (brs, 2H), 6.90-6.85(m, 3H), 4.72 (q, J=7.2 Hz, 1H), 4.13 (t, J=6.9 Hz, 2H), 3.02-2.97 (m,2H), 2.33-2.28 (m, 2H), 1.96-1.94 (m, 2H), 1.73 (d, J=7.2 Hz, 3H),1.53-1.48 (m, 2H).

EXAMPLE 8(37)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(pyridin-2-yloxymethyl)phenyl)butanoicacid

TLC: Rf 0.35 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 9.50 (s, 1H), 8.30 (d, J=8.7Hz, 1H), 8.15 (dd, J=5.4, 1.5 Hz, 1H), 7.95 (d, J=7.8 Hz, 1H), 7.83 (d,J=7.8 Hz, 1H), 7.7-7.67 (m, 1H), 7.61-7.47 (m, 4H), 7.36 (s, 1H),7.21-7.14 (m, 2H), 6.99-6.95 (m, 1H), 6.83 (d, J=8.4 Hz, 1H), 5.26 (s,2H), 4.69 (q, J=7.2 Hz, 1H), 2.44-2.39 (m, 2H), 2.02 (t, J=7.8 Hz, 2H),1.61-1.53 (m, 5H).

EXAMPLE 8(38)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(N-methyl-N-phenylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.50 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.02 (s, 1H), 9.43 (s, 1H), 8.28 (d, J=7.5Hz, 1H), 7.95-7.92 (m, 1H), 7.82 (d, J=8.1 Hz, 1H), 7.56-7.45 (m, 4H),7.18-7.07 (m, 4H), 6.93 (dd, J=7.8, 1.5 Hz, 1H), 6.67 (d, J=8.1 Hz, 2H),6.59 (t, J=7.2 Hz, 1H), 4.66 (q, J=7.2 Hz, 1H), 4.47 (s, 2H), 2.95 (s,3H), 2.40-2.34 (m, 2H), 2.00 (t, J=7.5 Hz, 2H), 1.58-1.51 (m, 5H).

EXAMPLE 8(39)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(N-benzoyl-N-methylamino)phenyl)butanoicacid

TLC: Rf 0.35 (hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 8.12 (m, 1H), 7.95-7.82 (m, 3H), 7.63-7.48 (m,4H), 7.33-7.10 (m, 6H), 6.73 (d, J=7.8 Hz, 1H), 6.52 (m, 1H), 4.57 (q,J=7.2 Hz, 1H), 3.45 (s, 3H), 1.95-1.75 (m, 4H), 1.81 (d, J=7.2 Hz, 3H),1.20 (m, 2H).

EXAMPLE 8(40)3-(2-((4-methyl-2-phenylpentanoyl)amino)-4-phenoxyphenyl)propanoic acid

TLC: Rf 0.71 (chloroform:methanol 10:1);

NMR (300 MHz, CDCl₃): δ 8.16 (s, 1H), 7.51 (d, J=2.1 Hz, 1H), 7.44-7.20(m, 7H), 7.12-6.93 (m, 4H), 6.70 (dd, J=8.4, 2.7 Hz, 1H), 3.67 (t, J=7.8Hz, 1H), 2.65-2.45 (m, 4H), 2.09 (m, 1H), 1.79 (m, 1H), 1.52 (m, 1H),0.93 (d, J=6.6 Hz, 3H), 0.92 (d, J=6.6 Hz, 3H).

EXAMPLE 8(41)4-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-phenoxymethylphenyl)butanoicacid

TLC: Rf 0.55 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.57 (brs, 1H), 8.36 (d, J=7.2 Hz, 1H), 8.09(m, 1H), 7.72-7.62 (m, 2H), 7.55 (dd, J=7.8, 5.4 Hz, 1H), 7.38-7.23 (m,4H), 7.18 (brs, 2H), 7.09-6.89 (m, 3H), 5.01 (s, 2H), 4.66 (q, J=6.6 Hz,1H), 2.48-2.40 (m, 2H), 2.04-1.99 (m, 2H), 1.59 (d, J=6.6 Hz, 3H),1.58-1.53 (m, 2H).

EXAMPLE 8(42)4-(2-((2-phenylpropanoyl)amino)-4-phenoxymethylphenyl)butanoic acid

TLC: Rf 0.56 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.41 (brs, 1H), 7.41-7.39 (m, 3H), 7.34-7.23(m, 5H), 7.20-7.15 (m, 2H), 6.99-6.96 (m, 2H), 6.92 (m, 1H), 5.01 (s,2H), 3.90 (q, J=7.2 Hz, 1H), 2.43-2.38 (m, 2H), 2.04 (t, J=7.2 Hz, 2H),1.56-1.48 (m, 2H), 1.41 (d, J=7.2 Hz, 3H).

EXAMPLE 8(43)3-(2-((4-methyl-2-phenylpentanoyl)amino)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.42 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.20 (s, 1H), 7.81 (s, 1H), 7.45-7.09 (m, 9H),6.98-6.90 (m, 3H), 4.98 (s, 2H), 3.69 (t, J=7.7 Hz, 1H), 2.67-2.53 (m,4H), 2.14 (m, 1H), 1.80 (m, 1H), 1.55 (m, 1H), 0.95 (d, J=6.6 Hz, 3H),0.94 (d, J=6.6 Hz, 3H).

EXAMPLE 8(44)3-(2-((2-phenylpentanoyl)amino)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.46 (chloroform:methanol=10:1);

NMR (300 Hz, CDCl₃): δ 8.23 (s, 1H), 7.83 (s, 1H), 7.45-7.10 (m, 9H),6.99-6.90 (m, 3H), 4.99 (s, 2H), 3.60 (t, J=7.5 Hz, 1H), 2.70-2.54 (m,4H), 2.25 (m, 1H), 1.87 (m, 1H), 1.58-1.24 (m, 2H), 0.95 (t, J=7.5 Hz,3H).

EXAMPLE 8(45)3-(2-((2-phenylpropanoyl)amino)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.41 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.11 (brs, 1H), 7.85 (s, 1H), 7.46-7.24 (m, 7H),7.22-7.10 (m, 2H), 6.98-6.90 (m, 3H), 5.00 (s, 2H), 3.81 (q, J=6.9 Hz,1H), 2.65-2.50 (m, 4H), 1.64 (d, J=6.9 Hz, 3H).

EXAMPLE 8(46)3-(2-((2-phenylbutanoyl)amino)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.37 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.27 (brs, 1H), 7.83 (s, 1H), 7.46-7.23 (m, 7H),7.23-7.10 (m, 2H), 7.00-6.90 (m, 3H), 4.99 (s, 2H), 3.49 (t, J=7.5 Hz,1H), 2.70-2.54 (m, 4H), 2.40-2.22 (m, 1H), 2.00-1.82 (m, 1H), 0.97 (t,J=7.5 Hz, 3H).

EXAMPLE 8(47)4-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-phenoxyphenyl)butanoicacid

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.50 (s, 1H), 8.37 (d, J=8.4 Hz, 1H), 7.93 (d,J=8.1 Hz, 1H), 7.80 (d, J=8.1 Hz, 1H), 7.64-7.31 (m, 6H), 7.17-6.92 (m,5H), 6.76 (dd, J=8.1, 2.4 Hz, 1H), 4.68 (m, 1H), 2.46-2.32 (m, 2H), 2.08(m, 1H), 1.96 (t, J=7.2 Hz, 2H), 1.68-1.41 (m, 4H), 1.02 (d, J=6.3 Hz,3H), 0.89 (d, J=6.3 Hz, 3H).

EXAMPLE 8(48)4-(2-((4-methyl-2-phenylpentanoyl)amino)-4-phenoxyphenyl)butanoic acid

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.40 (s, 1H), 7.40-7.04 (m, 10H), 6.98-6.62(m, 2H), 6.74 (dd, J=8.4, 2.7 Hz, 1H), 3.88 (m, 1H), 2.42 (t, J=7.8 Hz,2H), 2.07 (t, J=7.2 Hz, 2H), 1.94 (m, 1H), 1.60-1.35 (m, 4H), 0.91 (d,J=6.3 Hz, 3H), 0.87 (d, J=6.3 Hz, 3H).

EXAMPLE 8(49)4-(2-((2-phenylpropanoyl)amino)-4-phenylaminomethylphenyl)butanoic acid

TLC: Rf 0.53 (hexane:ethyl acetate=1:3);

NMR (300 MHz, DMSO-d₆): δ 12.02 (brs, 1H), 9.34 (s, 1H), 7.42-7.18 (m,6H), 7.09 (m, 2H), 7.00 (m, 2H), 6.56-6.44 (m, 3H), 6.17 (t, J=5.7 Hz,1H), 4.16 (d, J=5.7 Hz, 2H), 3.87 (q, J=6.9 Hz, 1H), 2.35 (m, 2H), 2.01(t, J=7.2 Hz, 2H), 1.50 (m, 2H), 1.40 (d, J=6.9 Hz, 3H).

EXAMPLE 8(50)4-(2-((2-phenylpropanoyl)amino)-4-benzoylaminomethylphenyl)butanoic acid

TLC: Rf 0.27 (hexane:ethyl acetate=1:3);

NMR (300 MHz, DMSO-d₆): δ 12.02 (brs, 1H), 9.36 (s, 1H), 9.01 (t, J=6.0Hz, 1H), 7.90-7.84 (m, 2H), 7.56-7.36 (m, 5H), 7.34-7.18 (m, 4H),7.13-7.03 (m, 2H), 4.40 (d, J=6.0 Hz, 2H), 3.87 (q, J=7.2 Hz, 1H), 2.36(m, 2H), 2.01 (t, J=7.5 Hz, 2H), 1.50 (m, 2H), 1.40 (d, J=7.2 Hz, 3H).

EXAMPLE 8(51)4-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-benzoylaminomethylphenyl)butanoicacid

TLC: Rf 0.51 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.52 (brs, 1H), 9.01 (m, 1H), 8.34 (m, 1H),8.08 (m, 1H), 7.88-7.84 (m, 2H), 7.68-7.61 (m, 2H), 7.56-7.44 (m, 4H),7.28 (dd, J=10.8, 7.8 Hz, 1H), 7.21 (brs, 1H), 7.13-7.06 (m, 2H), 4.63(q, J=6.9 Hz, 1H), 4.39 (d, J=5.7 Hz, 2H), 2.43-2.38 (m, 2H), 2.04-1.93(m, 2H), 1.57 (d, J=6.9 Hz, 3H), 1.53-1.49 (m, 2H).

EXAMPLE 8(52)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylsulfonylaminomethylphenyl)butanoicacid

TLC: Rf 0.31 (hexane:ethyl acetate=1:3);

NMR (300 MHz, DMSO-d₆): δ 12.03 (s, 1H), 9.45 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 8.11 (t, J=6.3 Hz, 1H), 7.95 (m, 1H), 7.84 (d, J=8.1 Hz, 1H),7.80-7.74 (m, 2H), 7.63-7.47 (m, 7H), 7.20 (d, J=1.5 Hz, 1H), 7.05 (d,J=7.8 Hz, 1H), 6.95 (dd, J=7.8, 1.5 Hz, 1H), 4.69 (q, J=6.9 Hz, 1H),3.89 (d, J=6.3 Hz, 2H), 2.37 (m, 2H), 1.99 (t, J=7.5 Hz, 2H), 1.60 (d,J=6.9 Hz, 3H), 1.52 (m, 2H).

EXAMPLE 8(53)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzylcarbamoylphenyl)butanoicacid

TLC: Rf 0.21 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.06 (s, 1H), 9.62 (s, 1H), 8.99 (t, J=6.0Hz, 1H), 8.32 (d, J=8.1 Hz, 1H), 7.95 (m, 1H), 7.84 (d, J=8.1 Hz, 1H),7.79 (d, J=1.8 Hz, 1H), 7.67 (dd, J=7.8, 1.8 Hz, 1H), 7.63-7.47 (m, 4H),7.35-7.18 (m, 6H), 4.71 (q, J=6.9 Hz, 1H), 4.44 (d, J=6.0 Hz, 2H), 2.46(m, 2H), 2.02 (t, J=7.5 Hz, 2H), 1.61 (d, J=6.9 Hz, 3H), 1.57 (m, 2H).

EXAMPLE 8(54)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylcarbamoylphenyl)butanoicacid

TLC: Rf 0.32 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.07 (s, 1H), 10.19 (s, 1H), 9.66 (s, 1H),8.33 (d, J=8.1 Hz, 1H), 7.96 (d, J=8.1 Hz, 1H), 7.88-7.82 (m, 2H),7.77-7.70 (m, 3H), 7.64-7.48 (m, 4H), 7.37-7.28 (m, 3H), 7.08 (m, 1H),4.73 (q, J=6.9 Hz, 1H), 2.50 (m, 2H), 2.04 (t, J=7.5 Hz, 2H), 1.62 (d,J=6.9 Hz, 3H), 1.59 (m, 2H).

EXAMPLE 8(55)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzyloxymethylphenyl)butanoicacid

TLC: Rf 0.29 (hexane:ethyl acetate=1:2); .

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 9.49 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.95 (m, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.46 (m, 4H),7.38-7.24 (m, 6H), 7.17-7.06 (m, 2H), 4.69 (q, J=6.9 Hz, 1H), 4.49 (s,2H), 4.45 (s, 2H), 2.43 (m, 2H), 2.02 (t, J=7.5 Hz, 2H), 1.60 (d, J=6.9Hz, 3H), 1.56 (m, 2H).

EXAMPLE 8(56)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzylaminomethylphenyl)butanoicacid

TLC: Rf 0.67 (chloroform:methanol=4:1);

NMR (300 MHz, DMSO-d₆): δ 9.54 (s, 1H), 8.32 (d, J=8.1 Hz, 1H), 7.95 (m,1H), 7.84 (d, J=8.1 Hz, 1H), 7.62-7.46 (m, 4H), 7.42-7.28 (m, 6H), 7.16(m, 2H), 4.72 (q, J=6.9 Hz, 1H), 3.87 (bs, 2H), 3.82 (bs, 2H), 2.43 (m,2H), 2.03 (t, J=7.5 Hz, 2H), 1.60 (d, J=6.9 Hz, 3H), 1.56 (m, 2H).

EXAMPLE 8(57)4-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-phenylaminomethylphenyl)butanoicacid

TLC: Rf 0.26 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.51 (brs, 1H), 8.35 (m, 1H), 8.09 (m, 1H),7.69-7.61 (m, 2H), 7.54 (dd, J=7.8, 6.0 Hz, 1H), 7.34-7.27 (m, 2H), 7.10(s, 2H), 7.00 (dd, J=8.4, 7.5 Hz, 2H), 6.52-6.44 (m, 3H), 6.17 (t, J=7.2Hz, 1H), 4.64 (q, J=7.2 Hz, 1H), 4.16 (d, J=6.0 Hz, 2H), 2.43-2.35 (m,2H), 2.01-1.96 (m, 2H), 1.58 (d, J=7.2 Hz, 3H), 1.55-1.50 (m, 2H).

EXAMPLE 8(58)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-cyanophenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.17 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.14 (d, J=7.5 Hz, 1H), 8.05 (brs, 1H), 7.92 (m,1H), 7.86 (d, J=7.8 Hz, 1H), 7.66-7.50 (m, 6H), 7.25 (brs, 1H),7.06-6.97 (m, 4H), 5.04 (s, 2H), 4.59 (q, J=6.9 Hz, 1H), 1.97-1.89 (m,4H), 1.83 (d, J=6.9 Hz, 3H), 1.30-1.21 (m, 2H).

EXAMPLE 8(59)4-(2-((2-(benzothiophen-3-yl)propanoyl)amino)-4-phenylaminomethylphenyl)butanoicacid

TLC: Rf 0.51 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.51 (s, 1H), 8.01-7.96 (m, 2H), 7.58 (s, 1H),7.43-7.34 (m, 2H), 7.30 (s, 1H), 7.11 (s, 2H), 7.02 (t, J=7.8 Hz, 2H),6.57-6.49 (m, 3H), 4.29 (q, J=6.9 Hz, 1H), 4.1-7 (s, 2H), 2.40 (dd,J=9.3, 6.6 Hz, 2H), 2.04-1.99 (m, 2H), 1.58 (d, J=6.9 Hz, 3H), 1.57-1.50(m, 2H).

EXAMPLE 8(60)2-(2-((2-phenylpropanoyl)amino)-4-phenoxymethylbenzyl)benzoic acid

TLC: Rf 0.33 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.97 (s, 1H), 9.49 (s, 1H), 7.81 (dd, J=7.8,1.5 Hz, 1H), 7.53 (d, J=1.5 Hz, 1H), 7.39-7.10 (m, 10H), 7.00-6.88 (m,5H), 5.00 (s, 2H), 4.24 (s, 2H), 3.84 (q, J=6.9 Hz, 1H), 1.33 (d, J=6.9Hz, 3H).

EXAMPLE 8(61)2-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenoxymethylbenzyl)benzoicacid

TLC: Rf 0.33 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.95 (s, 1H), 9.62 (s, 1H), 8.20 (m, 1H),7.91 (m, 1H), 7.82-7.76 (m, 2H), 7.55-7.23 (m, 9H), 7.13 (dd, J=8.1, 1.5Hz, 1H), 7.00-6.87 (m, 5H), 5.01 (s, 2H), 4.64 (q, J=6.9 Hz, 1H), 4.28(d, J=16.5 Hz, 1H), 4.22 (d, J=16.5 Hz, 1H), 1.47 (d, J=6.9 Hz, 3H).

EXAMPLE 8(62)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-ethoxycarbonylaminomethylphenyl)butanoicacid

TLC: Rf 0.56 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.59 (brs, 1H), 8.32 (d, J=8.4 Hz, 1H), 7.94(d, J=8.4 Hz, 1H), 7.83 (d, J=7.5 Hz, 1H), 7.62-7.47 (m, 5H), 7.18 (brs,1H), 7.09 (d, J=7.5 Hz, 1H), 6.98 (d, J=7.5 Hz, 1H), 4.71 (q, J=6.9 Hz,1H), 4.07 (d, J=6.0 Hz, 2H), 3.96 (q, J=7.2 Hz, 2H), 2.42-2.37 (m, 2H),2.02-1.97 (m, 2H), 1.59 (d, J=7.2 Hz, 3H), 1.61-1.51 (m, 2H), 1.13 (t,J=7.2 Hz, 3H).

EXAMPLE 8(63)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(furan-2-ylcarbonylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.39 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.50 (s, 1H), 8.88 (t, J=6.0 Hz, 1H), 8.29 (d,J=8.1 Hz, 1H), 7.92 (m, 1H), 7.85-7.81 (m, 2H), 7.57-7.45 (m, 4H), 7.20(brs, 1H), 7.11-7.09 (m, 2H), 7.03 (dd, J=7.8, 1.5 Hz, 1H), 6.61 (dd,J=3.3, 1.5 Hz, 1H), 4.67 (q, J=7.2 Hz, 1H), 4.32 (d, J=6.0 Hz, 2H), 2.38(dd, J=8.7, 7.2 Hz, 2H), 1.99 (t, J=7.5 Hz, 2H), 1.58 (d, J=7.2 Hz, 3H),1.58-1.50 (m, 2H).

EXAMPLE 8(64)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-fluorobenzoylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.43 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.49 (s, 1H), 9.11 (t, J=6.0 Hz, 1H), 8.29 (d,J=7.8 Hz, 1H), 7.93 (m, 1H), 7.81 (d, J=8.1 Hz, 1H), 7.72 (d, J=7.5 Hz,1H), 7.66 (dd, J=9.9, 1.5 Hz, 1H), 7.57-7.42 (m, 5H), 7.39 (m, 1H), 7.23(brs, 1H), 7.11 (d, J=7.8 Hz, 1H), 7.07 (d, J=7.8 Hz, 1H), 4.67 (q,J=7.2 Hz, 1H), 4.40 (d, J=5.7 Hz, 2H), 2.40 (dd, J=8.7, 7.2 Hz, 2H),2.01 (t, J=7.2 Hz, 2H), 1.58 (d, J=7.2 Hz, 3H), 1.57-1.49 (m, 2H).

EXAMPLE 8(65) 3-(2-phenylsulfonylamino-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1);

NMR (300 MHz, CD₃OD): δ 7.66-7.63 (m, 2H), 7.56-7.53 (m, 2H), 7.46-7.40(m, 2H), 7.27-7.19 (m, 4H), 7.11 (s, 1H), 6.94-6.87 (m, 3H), 4.94 (s,2H), 2.70 (t, J=7.8 Hz, 2H), 2.41 (t, J=7.8 Hz, 2H).

EXAMPLE 8(66)3-(2-(N-benzylsulfonyl-N-methylamino)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 7.40-7.18 (m, 10H), 7.02-6.90 (m, 3H), 5.02(s, 2H), 4.80-4.40 (m, 2H), 3.15 (s, 3H), 3.00-2.60 (m, 2H), 2.52 (t,J=8.7 Hz, 2H).

EXAMPLE 8(67)(2E)-3-(2-(N-benzylsulfonyl-N-methylamino)-4-phenoxymethylphenyl)-2-propenoicacid

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 7.91 (d, J=8.1 Hz, 1H), 7.83 (d, J=16.0 Hz,1H), 7.50-7.20 (m, 9H), 7.01 (d, J=8.1 Hz, 2H), 6.94 (t, J=7.4 Hz, 1H),6.53 (d, J=16.0 Hz, 1H), 5.09 (s, 2H), 4.59 (brs, 2H), 3.16 (s, 3H).

EXAMPLE 8(68)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-methoxybenzoylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.44 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.50 (brs, 1H), 9.00 (t, J=6.0 Hz, 1H), 8.29(d, J=8.1 Hz, 1H), 7.93 (m, 1H), 7.81 (d, J=8.1 Hz, 1H), 7.58-7.34 (m,7H), 7.23 (brs, 1H), 7.12-7.05 (m, 3H), 4.67 (q, J=7.2 Hz, 1H), 4.39 (d,J=6.3 Hz, 2H), 3.79 (s, 3H), 2.39 (dd, J=9.6, 6.0 Hz, 2H), 2.01 (t,J=7.5 Hz, 2H), 1.58 (d, J=7.2 Hz, 3H), 1.57-1.50 (m, 2H).

EXAMPLE 8(69)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-cyclopropylcarbonylaminomethylphenyl)butanoicacid

TLC: Rf 0.40 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.51 (s, 1H), 8.53 (t, J=6.0 Hz, 1H), 8.31 (d,J=8.1 Hz, 1H), 7.94 (d, J=7.5 Hz, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.61-7.47(m, 4H), 7.16 (m, 1H), 7.10 (d, J=7.5 Hz, 1H), 6.99 (d, J=7.5 Hz, 1H),4.69 (q, J=6.9 Hz, 1H), 4.19 (d, J=5.7 Hz, 2H), 2.39 (dd, J=9.3, 6.0 Hz,2H), 2.00 (t, J=7.5 Hz, 2H), 1.59 (d, J=6.9 Hz, 3H), 1.60-1.51 (m, 3H),0.70-0.60 (m, 4H).

EXAMPLE 8(70)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(thiophen-2-ylcarbonylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.42 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.50 (brs, 1H), 9.01 (t, J=6.0 Hz, 1H), 8.29(d, J=6.0 Hz, 1H), 7.94 (m, 1H), 7.82 (d, J=7.8 Hz, 1H), 7.78-7.75 (m,2H), 7.57-7.44 (m, 4H), 7.22 (brs, 1H), 7.16-7.07 (m, 2H), 7.05 (dd,J=7.8, 1.5 Hz, 1H), 4.67 (q, J=6.9 Hz, 1H), 4.36 (d, J=6.0 Hz, 2H), 2.39(dd, J=8.7, 6.6 Hz, 2H), 2.00 (t, J=7.5 Hz, 2H), 1.58 (d, J=7.2 Hz, 3H),1.56-1.49 (m, 2H).

EXAMPLE 8(71)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-methylbenzoylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.22 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.06 (br, 1H), 9.47 (s, 1H), 8.95 (t, J=6.0Hz, 1H), 8.29 (m, 1H), 7.93 (m, 1H), 7.82 (d, J=7.8 Hz, 1H), 7.70-7.63(m, 2H), 7.59-7.43 (m, 4H), 7.36-7.32 (m, 2H), 7.22 (bs, 1H), 7.11 (d,J=8.1 Hz, 1H), 7.06 (dd, J=8.1, 1.5 Hz, 1H), 4.67 (q, J=6.9 Hz, 1H),4.38 (d, J=6.0 Hz, 2H), 2.39 (m, 2H), 2.35 (s, 3H), 2.01 (t, J=7.2 Hz,2H), 1.58 (d, J=6.9 Hz, 3H), 1.54 (m, 2H).

EXAMPLE 8(72)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-chlorobenzoylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.29 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.03 (br, 1H), 9.47 (s, 1H), 9.14 (t, J=6.0Hz, 1H), 8.29 (m, 1H), 7.96-7.79 (m, 4H), 7.64-7.43 (m, 6H), 7.22 (bs,1H), 7.12 (d, J=8.1 Hz, 1H), 7.06 (dd, J=8.1, 1.5 Hz, 1H), 4.67 (q,J=6.9 Hz, 1H), 4.39 (d, J=6.0 Hz, 2H), 2.39 (m, 2H), 2.01 (t, J=7.2 Hz,2H), 1.58 (d, J=6.9 Hz, 3H), 1.54 (m, 2H).

EXAMPLE 8(73)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-cyanobenzoylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.46 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.49 (s, 1H), 9.22 (m, 1H), 8.30-8.28 (m, 2H),8.17 (d, J=7.8 Hz, 1H), 7.99 (d, J=7.5 Hz, 1H), 7.93 (d, J=8.1 Hz, 1H),7.82 (d, J=8.1 Hz, 1H), 7.70 (t, J=7.5 Hz, 1H), 7.58-7.44 (m, 4H), 7.24(s, 1H), 7.12 (d, J=7.8 Hz, 1H), 7.08 (d, J=7.8 Hz, 1H), 4.67 (q, J=6.9Hz, 1H), 4.41 (d, J=5.7 Hz, 2H), 2.43-2.37 (m, 2H), 2.01 (t, J=7.2 Hz,2H), 1.58 (d, J=6.9 Hz, 3H), 1.58-1.49 (m, 2H).

EXAMPLE 8(74)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-fluorobenzoylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.51 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.49 (s, 1H), 9.03 (t, J=6.0 Hz, 1H), 8.29 (d,J=7.8 Hz, 1H), 7.98-7.90 (m, 3H), 7.82 (d, J=8.1 Hz, 1H), 7.57-7.44 (m,4H), 7.30 (dd, J=9.3, 7.8 Hz, 2H), 7.22 (s, 1H), 7.11 (d, J=8.1 Hz, 1H),7.06 (d, J=8.1 Hz, 1H), 4.71 (q, J=6.9 Hz, 1H), 4.39 (d, J=6.3 Hz, 2H),2.42-2.37 (m, 2H), 2.01 (t, J=7.5 Hz, 2H), 1.58 (d, J=6.9 Hz, 3H),1.57-1.50 (m, 2H).

EXAMPLE 8(75)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-fluorobenzoylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.51 (s, 1H), 8.83 (m, 1H), 8.31 (d, J=8.1 Hz,1H), 7.94 (dd, J=7.8, 1.5 Hz, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.64-7.45 (m,6H), 7.31-7.24 (m, 3H), 7.13 (d, J=7.8 Hz, 1H), 7.08 (dd, J=7.8, 1.2 Hz,1H), 4.69 (q, J=6.9 Hz, 1H), 4.38 (d, J=6.0 Hz, 2H), 2.43-2.38 (m, 2H),2.02 (t, J=7.5 Hz, 2H), 1.59 (d, J=6.9 Hz, 3H), 1.57-1.51 (m, 2H).

EXAMPLE 8(76)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-chloro-4-fluorobenzoylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.49 (s, 1H), 9.14 (t, J=6.0 Hz, 1H), 8.29 (d,J=8.4 Hz, 1H), 8.08 (dd, J=7.2, 2.1 Hz, 1H), 7.93 (d, J=9.0 Hz, 1H),7.90 (m, 1H), 7.82 (d, J=7.8 Hz, 1H), 7.58-7.45 (m, 5H), 7.23 (brs, 1H),7.11 (d, J=7.8 Hz, 1H), 7.06 (d, J=8.4 Hz, 1H), 4.67 (q, J=6.9 Hz, 1H),4.39 (d, J=8.7 Hz, 2H), 2.40 (dd, J=9.0, 6.0 Hz, 2H), 2.01 (t, J=7.5 Hz,2H), 1.58 (d, J=6.9 Hz, 3H), 1.57-1.52 (m, 2H).

EXAMPLE 8(77)4-(2-((2-(2-chlorophenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoicacid

TLC: Rf 0.40 (hexane:ethyl acetate:acetic acid=1:1:0.01);

NMR (300 MHz, DMSO-d₆): δ 12.50 (bs, 1H), 9.50 (s, 1H), 7.50 (dd, J=7.8,2.1 Hz, 1H), 7.44 (dd, J=7.8, 2.1 Hz, 1H), 7.40-7.23 (m, 5H), 7.21 (m,2H), 7.01-6.89 (m, 3H), 5.02 (s, 2H), 4.26 (q, J=7.2 Hz, 1H), 2.50 (m,2H), 2.14 (t, J=7.2 Hz, 2H), 1.64 (m, 2H), 1.48 (d, J=7.2 Hz, 3H).

EXAMPLE 8(78)4-(2-((2-(3-chlorophenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoicacid

TLC: Rf 0.44 (hexane:ethyl acetate:acetic acid=1:1:0.01);

NMR (300 MHz, DMSO-d₆): δ 12.05 (bs, 1H), 9.48 (s, 1H), 7.45 (s, 1H),7.38-7.16 (m, 8H), 7.00-6.88 (m, 3H), 5.02 (s, 2H), 3.92 (q, J=7.2 Hz,1H), 2.42 (m, 2H), 2.07 (t, J=7.2 Hz, 2H), 1.54 (m, 2H), 1.42 (d, J=7.2Hz, 3H).

EXAMPLE 8(79)4-(2-((2-(4-chlorophenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoicacid

TLC: Rf 0.46 (hexane:ethyl acetate:acetic acid=1:1:0.01);

NMR (300 MHz, DMSO-d₆): δ 12.06 (bs, 1H), 9.46 (s, 1H), 7.44-7.35 (m,5H), 7.31-7.15 (m, 4H), 7.00-6.88 (m, 3H), 5.01 (s, 2H), 3.91 (q, J=6.9Hz, 1H), 2.42 (m, 2H), 2.07 (t, J=6.9 Hz, 2H), 1.55 (m, 2H), 1.41 (d,J=6.9 Hz, 3H).

EXAMPLE 8(80)4-(2-((2-(4-fluorophenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoicacid

TLC: Rf 0.44 (hexane:ethyl acetate:acetic acid=1:1:0.01);

NMR (300 MHz, DMSO-d₆): δ 12.05 (bs, 1H), 9.43 (s, 1H), 7.46-7.36 (m,3H), 7.31-7.23 (m, 2H), 7.22-7.10 (m, 4H), 7.00-6.88 (m, 3H), 5.01 (s,2H), 3.91 (q, J=6.9 Hz, 1H), 2.42 (m, 2H), 2.06 (t, J=7.5 Hz, 2H), 1.53(m, 2H), 1.40 (d, J=6.9 Hz, 3H).

EXAMPLE 8(81)4-(2-((2-(4-methoxyphenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoicacid

TLC: Rf 0.40 (hexane:ethyl acetate:acetic acid=1:1:0.01);

NMR (300 MHz, DMSO-d₆): δ 12.05 (bs, 1H), 9.33 (s, 1H), 7.38 (s, 1H),7.34-7.23 (m, 4H), 7.17 (m, 2H), 7.00-6.85 (m, 5H), 5.01 (s, 2H), 3.83(q, J=6.9 Hz, 1H), 3.72 (s, 3H), 2.41 (m, 2H), 2.05 (t, J=7.5 Hz, 2H),1.53 (m, 2H), 1.38 (d, J=6.9 Hz, 3H).

EXAMPLE 8(82)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-ethoxybenzoylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.44 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.50 (s, 1H), 8.98 (t, J=5.7 Hz, 1H), 8.29 (d,J=7.8 Hz, 1H), 7.93 (d, J=7.2 Hz, 1H), 7.81 (d, J=7.8 Hz, 1H), 7.57-7.36(m, 7H), 7.23 (s, 1H), 7.12-7.04 (m, 3H), 4.67 (q, J=6.0 Hz, 1H), 4.38(d, J=5.7 Hz, 2H), 4.05 (q, J=6.9 Hz, 2H), 2.40 (dd, J=8.7, 7.2 Hz, 2H),2.01 (t, J=7.5 Hz, 2H), 1.58 (d, J=6.9 Hz, 3H), 1.57-1.50 (m, 2H), 1.33(t, J=6.9 Hz, 3H).

EXAMPLE 8(83)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3,5-difluorobenzoylaminomethyl)phenyl)butanoicacid

TLC: Rf 0.56 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.50 (s, 1H), 9.18 (t, J=6.0 Hz, 1H), 8.29 (d,J=8.1 Hz, 1H), 7.93 (d, J=7.2 Hz, 1H), 7.82 (d, J=7.8 Hz, 1H), 7.60-7.44(m, 7H), 7.23 (brs, 1H), 7.11 (d, J=8.1 Hz, 1H), 7.07 (d, J=8.1 Hz, 1H),4.67 (q, J=6.9 Hz, 1H), 4.39 (d, J=5.7 Hz, 2H), 2.40 (dd, J=9.0, 6.3 Hz,2H), 2.01 (t, J=7.2 Hz, 2H), 1.58 (d, J=6.9 Hz, 3H), 1.57-1.50 (m, 2H).

EXAMPLE 8(84)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-fluorophenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.62 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.54 (s, 1H), 8.33 (d, J=8.7 Hz, 1H), 7.94 (d,J=6.9 Hz, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.61-7.47 (m, 4H), 7.38 (s, 1H),7.29 (m, 1H), 7.19 (s, 2H), 6.90-6.80 (m, 2H), 6.75 (m, 1H), 5.03 (s,2H), 4.70 (q, J=6.9 Hz, 1H), 2.44 (dd, J=9.0, 5.1 Hz, 2H), 2.03 (t,J=7.5 Hz, 2H), 1.60 (d, J=6.9 Hz, 3H), 1.59-1.52 (m, 2H).

EXAMPLE 8(85)4-(2-((2-(4-methylphenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoicacid

TLC: Rf 0.24 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 9.34 (s, 1H), 7.37 (bs, 1H),7.32-7.08 (m, 8H), 7.00-6.88 (m, 3H), 5.01 (s, 2H), 3.84 (q, J=6.9 Hz,1H), 2.39 (m, 2H), 2.26 (s, 3H), 2.02 (t, J=7.5 Hz, 2H), 1.51 (m, 2H),1.38 (d, J=6.9 Hz, 3H).

EXAMPLE 8(86)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-cyano-2-methoxyphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.34 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.04 (br, 1H), 9.55 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.94 (m, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.46 (m, 4H),7.41-7.35 (m, 3H), 7.22-7.14 (m, 3H), 5.10 (s, 2H), 4.70 (q, J=6.9 Hz,1H), 3.78 (s, 3H), 2.44 (m, 2H), 2.03 (t, J=7.5 Hz, 2H), 1.60 (d, J=6.9Hz, 3H), 1.57 (m, 2H).

EXAMPLE 8(87)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-acetylphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.40 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 9.52 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.94 (m, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.39 (m, 8H),7.28-7.16 (m, 3H), 5.10 (s, 2H), 4.70 (q, J=6.9 Hz, 1H), 2.55 (s, 3H),2.44 (m, 2H), 2.03 (t, J=7.2 Hz, 2H), 1.60 (d, J=6.9 Hz, 3H), 1.56 (m,2H).

EXAMPLE 8(88)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-isopropyl-5-methylphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.26 (hexane ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 9.51 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.95 (m, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.47 (m, 4H), 7.37(s, 1H), 7.18 (m, 2H), 6.65-6.59 (m, 3H), 4.96 (s, 2H), 4.69 (q, J=6.9Hz, 1H), 2.77 (m, 1H), 2.43 (m, 2H), 2.22 (s, 3H), 2.03 (t, J=7.2 Hz,2H), 1.60 (d, J=6.9 Hz, 3H), 1.56 (m, 2H), 1.14 (d, J=6.9 Hz, 6H).

EXAMPLE 8(89)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2,4,6-trifluorophenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.28 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.12 (br, 1H), 9.70 (bs, 1H), 8.33 (d, J=8.1Hz, 1H), 7.94 (m, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.40 (m, 5H),7.28-7.10 (m, 4H), 5.01 (s, 2H), 4.74 (q, J=6.9 Hz, 1H), 2.45 (m, 2H),2.0.1 (t, J=7.5 Hz, 2H), 1.60 (d, J=6.9 Hz, 3H), 1.56 (m, 2H).

EXAMPLE 8(90)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-trifluoromethylthiophenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.24 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.05 (bs, 1H), 9.52 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.94 (m, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62 (d, J=8.4 Hz, 2H),7.60-7.46 (m, 4H), 7.39 (s, 1H), 7.20 (m, 2H), 7.12 (d, J=8.4 Hz, 2H),5.09 (s, 2H), 4.70 (q, J=6.9 Hz, 1H), 2.44 (m, 2H), 2.03 (t, J=7.2 Hz,2H), 1.60 (d, J=6.9 Hz, 3H), 1.56 (m, 2H).

EXAMPLE 8(91)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-bromophenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.54 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.54 (s, 1H), 8.31 (d, J=8.1 Hz, 1H), 7.94(dd, J=7.8, 1.5 Hz, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.61-7.47 (m, 4H),7.45-7.40 (m, 2H), 7.37 (s, 1H), 7.17 (d, J=0.9 Hz, 2H), 6.96-6.93 (m,2H), 5.01 (s, 2H), 4.70 (q, J=6.9 Hz, 1H), 2.44 (dd, J=8.7, 6.0 Hz, 2H),2.02 (t, J=7.5 Hz, 2H), 1.59 (d, J=6.9 Hz, 3H), 1.58-1.52 (m, 2H).

EXAMPLE 8(92)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-methoxyphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.54 (s, 1H), 8.31 (d, J=8.4 Hz, 1H), 7.94 (d,J=7.2 Hz, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.60-7.47 (m, 4H), 7.37 (s, 1H),7.18-7.13 (m, 3H), 6.56-6.48 (m, 3H), 4.99 (s, 2H), 4.70 (q, J=6.9 Hz,1H), 3.70 (s, 3H), 2.43 (dd, J=8.7, 5.7 Hz, 2H), 2.02 (t, J=7.5 Hz, 2H),1.60 (d, J=6.9 Hz, 3H), 1.59-1.51 (m, 2H).

EXAMPLE 8(93)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-methoxyphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.59 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.55 (s, 1H), 8.33 (d, J=8.4 Hz, 1H), 7.94(dd, J=7.8, 1.8 Hz, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.61-7.47 (m, 4H), 7.37(s, 1H), 7.18 (s, 2H), 6.98 (dd, J=7.5, 1.8 Hz, 1H), 6.95 (dd, J=7.5,2.4 Hz, 1H), 6.91-6.80 (m, 2H), 4.98 (s, 2H), 4.70 (q, J=7.2 Hz, 1H),3.74 (s, 3H), 2.46-2.41 (m, 2H), 2.03 (t, J=7.5 Hz, 2H), 1.60 (d, J=7.2Hz, 3H), 1.59-1.52 (m, 2H).

EXAMPLE 8(94)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-methylbenzothiazol-5-yloxymethyl)phenyl)butanoicacid

TLC: Rf 0.18 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.05 (bs, 1H), 9.53 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.94 (m, 1H), 7.86 (d, J=8.7 Hz, 1H), 7.83 (d, J=8.1 Hz, 1H),7.62-7.46 (m, 5H), 7.41 (d, J=1.5 Hz, 1H), 7.23 (dd, J=7.8, 1.5 Hz, 1H),7.18 (d, J=7.8 Hz, 1H), 7.06 (dd, J=8.7, 2.4 Hz, 1H), 5.11 (s, 2H), 4.70(q, J=6.9 Hz, 1H), 2.75 (s, 3H), 2.43 (m, 2H), 2.02 (t, J=7.5 Hz, 2H),1.60 (d, J=6.9 Hz, 3H), 1.56 (m, 2H).

EXAMPLE 8(95)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-(1,2,4-triazol-1-yl)phenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.11 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.05 (s, 1H), 9.52 (s, 1H), 9.15 (s, 1H),8.31 (d, J=8.1 Hz, 1H), 8.17 (s, 1H), 7.94 (m, 1H), 7.83 (d, J=8.1 Hz,1H), 7.74 (d, J=9.0 Hz, 2H), 7.62-7.46 (m, 4H), 7.41 (bs, 1H), 7.25-7.16(m, 2H), 7.15 (d, J=9.0 Hz, 2H), 5.09 (s, 2H), 4.70 (q, J=6.9 Hz, 1H),2.43 (m, 2H), 2.03 (t, J=7.5 Hz, 2H), 1.60 (d, J=6.9 Hz, 3H), 1.57 (m,2H).

EXAMPLE 8(96)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-ethoxyphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.45 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 9.51 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.94 (m, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.46 (m, 4H), 7.38(bs, 1H), 7.18 (m, 2H), 7.01-6.92 (m, 2H), 6.90-6.78 (m, 2H), 5.00 (s,2H), 4.70 (q, J=6.9 Hz, 1H), 3.98 (q, J=6.9 Hz, 2H), 2.43 (m, 2H), 2.03(t, J=7.5 Hz, 2H), 1.60 (d, J=6.9 Hz, 3H), 1.57 (m, 2H), 1.26 (t, J=6.9Hz, 3H).

EXAMPLE 8(97)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-methoxy-5-methylphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.41 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.05 (bs, 1H), 9.53 (s, 1H), 8.32 (d, J=8.1Hz, 1H), 7.94 (m, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.46 (m, 4H), 7.36(bs, 1H), 7.18 (m, 2H), 6.85 (d, J=2.1 Hz, 1H), 6.82 (d, J=8.1 Hz, 1H),6.68 (m, 1H), 4.95 (s, 2H), 4.70 (q, J=6.9 Hz, 1H), 3.68 (s, 3H), 2.44(m, 2H), 2.19 (s, 3H), 2.03 (t, J=7.5 Hz, 2H), 1.60 (d, J=6.9 Hz, 3H),1.57 (m, 2H).

EXAMPLE 8(98)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3,5-dimethoxyphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.40 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 9.51 (s, 1H), 8.30 (d, J=8.1Hz, 1H), 7.94 (m, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.46 (m, 4H), 7.35(bs, 1H), 7.17 (m, 2H), 6.14 (d, J=2.1 Hz, 2H), 6.07 (t, J=2.1 Hz, 1H),4.96 (s, 2H), 4.69 (q, J=6.9 Hz, 1H), 3.67 (s, 6H), 2.42 (m, 2H), 2.02(t, J=7.2 Hz, 2H), 1.59 (d, J=6.9 Hz, 3H), 1.55 (m, 2H).

EXAMPLE 8(99)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-fluoro-6-methoxyphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.40 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.04 (s, 1H), 9.51 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.95 (m, 1H), 7.84 (d, J=8.1 Hz, 1H), 7.62-7.47 (m, 4H), 7.38(bs, 1H), 7.16 (m, 2H), 7.03 (m, 1H), 6.90-6.76 (m, 2H), 4.92 (s, 2H),4.70 (q, J=6.9 Hz, 1H), 3.78 (s, 3H), 2.43 (m, 2H), 2.02 (t, J=7.5 Hz,2H), 1.60 (d, J=6.9 Hz, 3H), 1.56 (m, 2H).

EXAMPLE 8(100)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-isopropyloxyphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.53 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.05 (s, 1H), 9.51 (s, 1H), 8.31 (d, J=8.1Hz, 1H), 7.94 (m, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.46 (m, 4H), 7.39(bs, 1H), 7.18 (m, 2H), 7.02-6.92 (m, 2H), 6.89-6.81 (m, 2H), 5.00 (s,2H), 4.70 (q, J=6.9 Hz, 1H), 4.47 (m, 1H), 2.43 (m, 2H), 2.03 (t, J=7.5Hz, 2H), 1.60 (d, J=6.9 Hz, 3H), 1.57 (m, 2H), 1.18 (d, J=6.0 Hz, 6H).

EXAMPLE 8(101)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-acetyl-5-methoxyphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.35 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.05 (s, 1H), 9.51 (s, 1H), 8.30 (d, J=8.1Hz, 1H), 7.94 (m, H), 7.83 (d, J=8.1 Hz, 1H), 7.65 (d, J=8.7 Hz, 1H),7.62-7.45 (m, 5H), 7.26 (dd, J=7.8, 1.8 Hz, 1H), 7.20 (d, J=7.8 Hz, 1H),6.73 (d, J=2.4 Hz, 1H), 6.59 (dd, J=8.7, 2.4 Hz, 1H), 5.19 (s, 2H), 4.70(q, J=6.9 Hz, 1H), 3.80 (s, 3H), 2.44 (m, 2H), 2.42 (s, 3H), 2.05 (t,J=7.2 Hz, 2H), 1.60 (d, J=6.9 Hz, 3H), 1.58 (m, 2H).

EXAMPLE 8(102)2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-phenoxymethylbenzyl)benzoicacid

TLC: Rf 0.70 (chloroform:methanol=10:1).

EXAMPLE 8(103)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-chloro-4,5-dimethylphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.72 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.55 (s, 1H), 8.31 (d, J=8.4 Hz, 1H), 7.94 (d,J=8.7 Hz, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.60-7.47 (m, 4H), 7.39 (s, 1H),7.19-7.17 (m, 3H), 7.02 (s, 1H), 5.06 (s, 2H), 4.70 (q, J=6.9 Hz, 1H),2.44-2.42 (m, 2H), 2.16 (s, 3H), 2.11 (s, 3H), 2.04 (t, J=7.5 Hz, 2H),1.59 (d, J=6.9 Hz, 3H), 1.59-1.52 (m, 2H).

EXAMPLE 8(104)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(1-oxo-1,2,3,4-tetrahydronaphthalen-6-yloxymethyl)phenyl)butanoicacid

TLC: Rf 0.62 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.56 (s, 1H), 8.31 (d, J=8.1 Hz, 1H), 7.94 (d,J=6.9 Hz, 1H), 7.84-7.78 (m, 2H), 7.59-7.47 (m, 4H), 7.40 (s, 1H), 7.19(brs, 2H), 6.93-6.91 (m, 2H), 5.10 (s, 2H), 4.70 (q, J=6.9 Hz, 1H), 2.88(t, J=6.0 Hz, 2H), 2.53-2.50 (m, 2H), 2.44 (dd, J=8.7, 5.4 Hz, 2H),2.05-1.97 (m, 4H), 1.60 (d, J=6.9 Hz, 3H), 1.59-1.52 (m, 2H).

EXAMPLE 8(105)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-cyanophenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.62 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.53 (s, 1H), 8.30 (d, J=8.1 Hz, 1H), 7.94 (d,J=7.5 Hz, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.62-7.45 (m, 6H), 7.43-7.36 (m,2H), 7.32 (m, 1H), 7.20 (s, 2H), 5.09 (s, 2H), 4.70 (q, J=6.9 Hz, 1H),2.48-2.41 (m, 2H), 2.03 (t, J=7.5 Hz, 2H), 1.60 (d, J=6.6 Hz, 3H),1.58-1.54 (m, 2H).

EXAMPLE 8(106)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-chloro-5-methoxyphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.59 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.55 (s, 1H), 8.31 (d, J=8.4 Hz, 1H), 7.94 (d,J=7.2 Hz, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.61-7.47 (m, 4H), 7.37 (s, 1H),7.18 (s, 2H), 6.63 (m, 1H), 6.59 (m, 1H), 6.52 (m, 1H), 5.02 (s, 2H),4.70 (q, J=6.6 Hz, 1H), 3.72 (s, 3H), 2.49-2.41 (m, 2H), 2.02 (t, J=7.2Hz, 2H), 1.60 (d, J=6.6 Hz, 3H), 1.59-1.51 (m, 2H).

EXAMPLE 8(107)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-ethyl-2-methoxyphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.54 (s, 1H), 8.31 (d, J=8.1 Hz, 1H), 7.95 (d,J=7.8 Hz, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.61-7.47 (m, 4H), 7.36 (s, 1H),7.17 (s, 2H), 6.88 (d, J=8.4 Hz, 1H), 6.80 (d, J=1.5 Hz, 1H), 6.65 (dd,J=8.4, 1.5 Hz, 1H), 4.94 (s, 2H), 4.69 (q, J=6.9 Hz, 1H), 3.72 (s, 3H),2.52 (q, J=7.5 Hz, 2H), 2.43 (dd, J=8.7, 5.4 Hz, 2H), 2.03 (t, J=7.5 Hz,2H), 1.60 (d, J=6.9 Hz, 3H), 1.59-1.52 (m, 2H), 1.14 (t, J=7.5 Hz, 3H).

EXAMPLE 8(108)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-acetylamino-2-chlorophenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.95 (s, 1H), 9.56 (s, 1H), 8.31 (d, J=8.4 Hz,1H), 7.94 (d, J=8.4 Hz, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.76 (d, J=2.4 Hz,1H), 7.61-7.47 (m, 4H), 7.39 (brs, 1H), 7.34 (dd, J=8.7, 2.4 Hz, 1H),7.19 (s, 2H), 7.13 (d, J=8.7 Hz, 1H), 5.07 (s, 2H), 4.70 (q, J=6.9 Hz,1H), 2.47-2.41 (m, 2H), 2.03 (t, J=7.5 Hz, 2H), 2.00 (s, 3H), 1.59 (d,J=6.9 Hz, 3H), 1.59-1.53 (m, 2H).

EXAMPLE 8(109)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-methylthiophenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.62 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.56 (s, 1H), 8.31 (d, J=8.1 Hz, 1H), 7.94 (d,J=7.2 Hz, 1H), 7.83 (d, J=8.1 Hz, 1H), 7.62-7.47 (m, 4H), 7.39 (s, 1H),7.24-6.93 (m, 6H), 5.08 (s, 2H), 4.70 (q, J=6.9 Hz, 1H), 2.47-2.40 (m,2H), 2.35 (s, 3H), 2.04 (t, J=7.5 Hz, 2H), 1.59 (d, J=6.9 Hz, 3H),1.59-1.53 (m, 2H).

EXAMPLE 8(110)4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-butanoylphenoxymethyl)phenyl)butanoicacid

TLC: Rf 0.62 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 9.55 (s, 1H), 8.31 (d, J=8.1 Hz, 1H),7.96-7.90 (m, 3H), 7.83 (d, J=7.8 Hz, 1H), 7.61-7.47 (m, 4H), 7.40 (brs,1H), 7.19 (s, 2H), 7.07 (d, J=9.0 Hz, 2H), 5.12 (s, 2H), 4.70 (q, J=6.9Hz, 1H), 2.91 (t, J=7.2 Hz, 2H), 2.44 (dd, J=8.7, 5.7 Hz, 2H), 2.03 (t,J=7.2 Hz, 2H), 1.68-1.52 (m, 4H), 1.60 (d, J=6.9 Hz, 3H), 0.90 (t, J=7.5Hz, 3H).

EXAMPLE 8(111)(2E)-3-(2-((4-methyl-2-phenylpentanoyl)amino)-4-phenoxymethylphenyl)-2-propenoicacid

TLC: Rf 0.39 (chloroform:methanol=9:1).

EXAMPLE 8(112)4-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-(pyrazol-1-ylmethyl)phenyl)butanoicacid

TLC: Rf 0.30 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.03 (s, 1H), 9.51 (s, 1H), 8.34 (d, J=8.1Hz, 1H), 8.11-8.08 (m, 1H), 7.77 (d, J=2.1 Hz, 1H), 7.72-7.62 (m, 2H),7.54 (dd, J=8.1, 5.7 Hz, 1H), 7.42 (d, J=2.1 Hz, 1H), 7.32 (dd, J=10.5,8.1 Hz, 1H), 7.15-7.10 (m, 2H), 6.95 (dd, J=8.1, 1.5 Hz, 1H), 6.23 (t,J=2.1 Hz, 1H), 5.24 (s, 2H), 4.63 (q, J=6.9 Hz, 1H), 2.38 (t, J=7.8 Hz,2H), 1.98 (t, J=7.8 Hz, 2H), 1.58 (d, J=6.9 Hz, 3H), 1.54-1.49 (m, 2H).

EXAMPLE 8(113)3-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.39 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, DMSO-d₆): δ 12.13 (s, 1H), 9.64 (s, 1H), 8.34 (m, 1H),8.10 (m, 1H), 7.74-7.61 (m, 2H), 7.54 (dd, J=8.1, 5.7 Hz, 1H), 7.36-7.17(m, 6H), 6.99-6.88 (m, 3H), 5.01 (s, 2H), 4.66 (q, J=6.9 Hz, 1H), 2.72(t, J=7.5 Hz, 2H), 2.36 (t, J=7.5 Hz, 2H), 1.59 (d, J=6.9 Hz, 3H).

EXAMPLE 8(114)3-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-phenylaminomethylphenyl)propanoicacid

TLC: Rf 0.33 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, DMSO-d₆): δ 12.12 (br, 1H), 9.67 (bs, 1H), 8.33 (m, 1H),8.09 (m, 1H), 7.71-7.60 (m, 2H), 7.53 (dd, J=7.2, 6.6 Hz, 1H), 7.34-7.22(m, 2H), 7.17-7.07 (m, 2H), 7.04-6.95 (m, 2H), 6.55-6.44 (m, 3H), 6.17(t, J=5.7 Hz, 1H), 4.63 (q, J=6.9 Hz, 1H), 4.16 (d, J=5.7 Hz, 2H), 2.67(t, J=7.5 Hz, 2H), 2.33 (t, J=7.5 Hz, 2H), 1.58 (d, J=6.9 Hz, 3H).

EXAMPLE 8(115)3-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-(pyrazol1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.19 (hexane:ethyl acetate=1:2, 0.5% acetic acid);

NMR (300 MHz, DMSO-d₆): δ 12.12 (br, 1H), 9.64 (bs, 1H), 8.32 (m, 1H),8.09 (m, 1H), 7.76 (d, J=2.1 Hz, 1H), 7.73-7.61 (m, 2H), 7.53 (dd,J=7.8, 5.7 Hz, 1H), 7.42 (d, J=2.1 Hz, 1H), 7.30 (dd, J=10.5, 7.8 Hz,1H), 7.16 (d, J=7.8 Hz, 1H), 7.13 (d, J=1.5 Hz, 1H), 6.95 (dd, J=7.8,1.5 Hz, 1H), 6.23 (t, J=2.1 Hz, 1H), 5.24 (s, 2H), 4.63 (q, J=6.9 Hz,1H), 2.67 (t, J=7.8 Hz, 2H), 2.34 (t, J=7.8 Hz, 2H), 1.57 (d, J=6.9 Hz,3H).

EXAMPLE 8(116)2-(2-((2-(4-fluoronaphthalen-1-yl)acetyl)amino)-4-phenoxymethylbenzyl)benzoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.79 (s, 1H), 8.12-8.02 (m, 2H), 7.87 (m, 1H),7.67-7.52 (m, 3H), 7.47-7.11 (m, 7H), 7.06-6.87 (m, 5H), 5.02 (s, 2H),4.35 (s, 2H), 4.11 (s, 2H).

EXAMPLE 8(117)2-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-phenoxymethylbenzyl)benzoicacid

TLC: Rf 0.60 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.70 (s, 1H), 8.26 (m, 1H), 8.07 (m, 1H), 7.79(m, 1H), 7.68-7.53 (m, 3H), 7.45 (m, 1H), 7.41-7.21 (m, 5H), 7.16 (m,1H), 7.04-6.86 (m, 5H), 5.03 (s, 2H), 4.62 (q, J=6.9 Hz, 1H), 4.27 (s,2H), 1.48 (d, J=6.9 Hz, 3H).

EXAMPLE 8(118)2-(2-((4-methyl-2-phenylpentanoyl)amino)-4-phenoxymethylbenzyl)benzoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.15 (brs, 1H), 8.00-7.94 (m, 1H), 7.94-7.88 (m,1H), 7.44-7.34 (m, 1H), 7.32-7.02 (m, 1H), 7.00-6.90 (m, 3H), 5.02 (s,2H), 4.20 (s, 2H), 3.55 (t, J=7.5 Hz, 1H), 2.00-1.30 (m, 3H), 0.85 (d,J=6.0 Hz, 6H).

EXAMPLE 8(119)2-(2-((4-methyl-2-(3,5-dimethylphenyl)pentanoyl)amino)-4-phenoxymethylbenzyl)benzoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.16 (brs, 1H), 7.95 (d, J=7.5 Hz, 1H), 7.84(brs, 1H), 7.42-7.34 (m, 1H), 7.32-6.90 (m, 9H), 6.81 (s, 3H), 5.02 (s,2H), 4.25 (d, J=16.2 Hz, 1H), 4.15 (d, J=16.2 Hz, 1H), 3.47 (t, J=7.8Hz, 1H), 2.22 (s, 6H), 2.04-1.90 (m, 1H), 1.66-1.55 (m, 1H), 1.50-1.30(m, 1H), 0.85 (d, J=6.6 Hz, 6H).

EXAMPLE 8(120)2-(2-((2-(naphthalen-1-yl)acetyl)amino)-4-phenoxymethylbenzyl)benzoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.08 (s, 1H), 8.00-7.89 (m, 2H), 7.82-7.73 (m,1H), 7.72-7.66 (m, 1H), 7.52 (brs, 1H), 7.49-7.38 (m, 2H), 7.34-7.18 (m,5H), 7.16-7.10 (m, 1H), 7.02-6.90 (m, 4H), 6.84-6.76 (m, 1H), 5.01 (s,2H), 4.09 (s, 2H), 3.88 (s, 2H).

EXAMPLE 8(121)3-(2-((4-methyl-2-(4-fluoro-3-methylphenyl)pentanoyl)amino)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.41 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 8.23 (s, 1H), 7.80 (s, 1H), 7.33-7.09 (m, 6H),7.00-6.90 (m, 4H), 4.98 (s, 2H), 3.62 (t, J=7.7 Hz, 1H), 2.70-2.55 (m,4H), 2.25 (s, 3H), 2.10 (m, 1H), 1.74 (m, 1H), 1.54 (m, 1H), 0.95 (d,J=6.6 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H).

EXAMPLE 8(122)3-(2-((4-methyl-2-(3,5-dimethylphenyl)pentanoyl)amino)-4-phenoxymethylphenyl)propanoicacid

TLC: Rf 0.30 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.09 (s, 1H), 9.51 (s, 1H), 7.30-7.15 (m,5H), 6.99-6.84 (m, 6H), 5.00 (s, 2H), 3.79-3.74 (m, 1H), 2.70 (t, J=7.5Hz, 2H), 2.32 (t, J=7.5 Hz, 2H), 2.24 (s, 6H), 2.02-1.94 (m, 1H),1.54-1.39 (m, 2H), 0.93 (d, J=6.0 Hz, 3H), 0.89 (d, J=6.0 Hz, 3H).

EXAMPLE 8(123)3-(2-((4-methyl-2-(4-methoxy-1,3-dioxaindan-6-yl)pentanoyl)amino)-4-phenoxymethylphenyl)propanoicacid

[Salt-Free]

TLC: Rf 0.50 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 8.29 (s, 1H), 7.82 (s, 1H), 7.30-7.12 (m, 4H),6.97-6.93 (m, 3H), 6.61 (d, J=6.0 Hz, 2H), 5.93 (s, 2H), 4.99 (s, 2H),3.89 (s, 3H), 3.58 (t, J=7.5 Hz, 1H), 2.70-2.64 (m, 4H), 2.12-2.02 (m,1H), 1.79-1.69 (m, 1H), 1.61-1.52 (m, 1H), 0.96-0.93 (m, 6H).

Sodium Salt:

TLC: Rf 0.35 (n-hexane:ethyl acetate=1:2).

EXAMPLE 8(124)2-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-methylphenoxymethyl)benzyl)benzoicacid

TLC: Rf 0.26 (hexane:ethyl acetate=2:1, 0.5% acetic acid);

NMR (300 MHz, DMSO-d₆): δ 12.94 (bs, 1H), 9.62 (bs, 1H), 8.21 (m, 1H),7.92 (m, 1H), 7.83-7.77 (m, 2H), 7.57-7.25 (m, 7H), 7.17-7.07 (m, 3H),7.00-6.79 (m, 4H), 5.03 (s, 2H), 4.64 (q, J=6.9 Hz, 1H), 4.28 (d, J=16.5Hz, 1H), 4.23 (d, J=16.5 Hz, 1H), 2.15 (s, 3H), 1.48 (d, J=6.9 Hz, 3H).

EXAMPLE 8(125)2-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-chloro-5-methylphenoxymethyl)benzyl)benzoicacid

TLC: Rf 0.23 (hexane:ethyl acetate=2:1, 0.5% acetic acid);

NMR (300 MHz, DMSO-d₆): δ 12.94 (bs, 1H), 9.64 (bs, 1H), 8.22 (m, 1H),7.92 (m, 1H), 7.83-7.77 (m, 2H), 7.58-7.25 (m, 8H), 7.15 (dd, J=8.1, 1.5Hz, 1H), 7.06 (d, J=1.5 Hz, 1H), 6.97-6.88 (m, 2H), 6.76 (dd, J=8.1, 1.5Hz, 1H), 5.09 (s, 2H), 4.65 (q, J=7.5 Hz, 1H), 4.29 (d, J=16.5 Hz, 1H),4.23 (d, J=16.5 Hz, 1H), 2.26 (s, 3H), 1.48 (d, J=7.5 Hz, 3H).

EXAMPLE 8(126)2-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-cyanophenoxymethyl)benzyl)benzoicacid

TLC: Rf 0.17 (hexane:ethyl acetate=2:1, 0.5% acetic acid);

NMR (300 MHz, DMSO-d₆): δ 12.95 (s, 1H), 9.63 (s, 1H), 8.20 (m, 1H),7.91 (m, 1H), 7.83-7.76 (m, 2H), 7.57-7.25 (m, 1H), 7.14 (dd, J=8.1, 1.5Hz, 1H), 6.96-6.87 (m, 2H), 5.09 (s, 2H), 4.64 (q, J=6.9 Hz, 1H), 4.29(d, J=16.5 Hz, 1H), 4.22 (d, J=16.5 Hz, 1H), 1.47 (d, J=6.9 Hz, 3H).

EXAMPLE 8(127)2-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(pyridin-3-yloxymethyl)benzyl)benzoicacid

TLC: Rf 0.44 (ethyl acetate, 0.5% acetic acid);

NMR (300 MHz, DMSO-d₆): δ 12.95 (bs, 1H), 9.75 (bs, 1H), 8.31 (bs, 1H),8.23-8.12 (m, 2H), 7.91 (m, 1H), 7.82-7.75 (m, 2H), 7.57 (bs, 1H),7.54-7.24 (m, 8H), 7.14 (m, 1H), 6.96-6.88 (m, 2H), 5.09 (s, 2H), 4.66(q, J=6.9 Hz, 1H), 4.29 (d, J=16.5 Hz, 1H), 4.22 (d, J=16.5 Hz, 1H),1.47 (d, J=6.9 Hz, 3H).

EXAMPLE 8(128)4-(2-(naphthalen-1-yl)carbonylamino-4-cyanophenyl)butanoic acid

TLC: Rf 0.30 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.10 (s, 1H), 10.30 (s, 1H), 8.29-8.26 (m,1H), 8.10-8.00 (m, 3H), 7.83 (dd, J=7.2, 0.9 Hz, 1H), 7.70 (dd, J=7.8,1.8 Hz, 1H), 7.65-7.58 (m, 3H), 7.52 (d, J=8.1 Hz, 1H), 2.78 (t, J=7.8Hz, 2H), 2.26 (t, J=7.5 Hz, 2H), 1.88-1.78 (m, 2H).

EXAMPLE 8(129)7-((2-(naphthalen-1-yl)acetyl)amino)-2-benzofurancarboxylic acid

TLC: Rf 0.43 (chloroform:methanol:acetic acid=90:10:1);

NMR (300 MHz, DMSO-d₆): δ 10.56 (s, 1H), 8.18 (d, J=8.1 Hz, 1H),7.97-7.81 (m, 3H), 7.70 (d, J=0.6 Hz, 1H), 7.62-7.43 (m, 5H), 7.26 (t,J=7.8 Hz, 1H), 4.31 (s, 2H).

EXAMPLE 8(130)7-((2-(naphthalen-1-yl)propanoyl)amino)-2-benzofurancarboxylic acid

TLC: Rf 0.46 (chloroform:methanol:acetic acid=90:10:1);

NMR (300 MHz, DMSO-d₆): δ 10.4 (s, 1H), 8.32 (d, J=8.4 Hz, 1H), 7.94 (d,J=8.4 Hz, 1H), 7.86-7.78 (m, 2H), 7.69-7.45 (m, 6H), 7.27 (m, 1H), 4.91(q, J=6.9 Hz, 1H), 1.58 (d, J=6.9 Hz, 3H).

EXAMPLE 8(131)7-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-2-benzofurancarboxylicacid

TLC: Rf 0.48 (chloroform:methanol:acetic acid=90:10:1);

NMR (300 MHz, DMSO-d₆): δ 10.5 (s, 1H), 8.42 (d, J=8.4 Hz, 1H), 7.94 (d,J=8.1 Hz, 1H), 7.86 (d, J=7.8 Hz, 1H), 7.82 (d, J=7.8 Hz, 1H), 7.74-7.60(m, 3H), 7.58-7.44 (m, 3H), 7.27 (m, 1H), 4.93 (m, 1H), 2.12 (m, 1H),1.76-1.53 (m, 2H), 1.07 (d, J=6.3 Hz, 3H), 0.93 (d, J=6.3 Hz, 3H).

EXAMPLE 8(132) 2-(1-(2-(naphthalen-1-yl)propionyl)indol-3-yl)acetic acid

TLC: Rf 0.29 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 8.62 (d, J=8.4 Hz, 1H), 8.18 (d, J=8.4 Hz, 1H),7.90 (d, J=8.4 Hz, 1H), 7.75 (d, J=8.4 Hz, 1H), 7.63 (m, 1H), 7.53 (dd,J=7.8, 7.8 Hz, 1H), 7.46-7.25 (m, 5H), 7.15 (s, 1H), 5.18 (q, J=6.9 Hz,1H), 3.54 (d, J=17.1 Hz, 1H) 3.46 (d, J=17.1 Hz, 1H), 1.73 (d, J=6.9 Hz,3H).

EXAMPLE 8(133)2-(2-methyl-1-(2-(naphthalen-1-yl)propionyl)indol-3-yl)acetic acid

TLC: Rf 0.33 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 8.00 (d, J=8.4 Hz, 1H), 7.89 (d, J=8.4 Hz, 1H),7.79 (d, J=7.8 Hz, 1H), 7.75 (d, J=8.1 Hz, 1H), 7.60-7.35 (m, 5H), 7.18(dd, J=7.5, 7.5 Hz, 1H), 7.08 (dd, J=7.8, 7.8 Hz, 1H), 5.37 (q, J=6.6Hz, 1H), 3.63 (s, 2H), 2.48 (s, 3H), 1.78 (d, J=6.6 Hz, 3H).

EXAMPLE 8(134) 3-(1-(2-(naphthalen-1-yl)propionyl)indol-3-yl)propanoicacid

TLC: Rf 0.22 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 8.60 (d, J=7.8 Hz, 1H), 8.20 (d, J=8.1 Hz, 1H),7.92 (d, J=7.8 Hz, 1H), 7.76 (dd, J=7.5, 2.1 Hz, 1H), 7.67 (m, 1H), 7.57(dd, J=7.5, 7.5 Hz, 1H), 7.46-7.24 (m, 5H), 6.95 (s, 1H), 5.14 (q, J=6.9Hz, 1H), 2.88-2.73 (m, 2H), 2.45 (t, J=7.5 Hz, 2H), 1.74 (d, J=6.9 Hz,3H).

EXAMPLE 8(135)3-(2-methyl-1-(2-(naphthalen-1-yl)propionyl)indol-3-yl)propanoic acid

TLC: Rf 0.46 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 8.00 (d, J=8.1 Hz, 1H), 7.89 (d, J=8.1 Hz, 1H),7.84 (d, J=8.1 Hz, 1H), 7.75 (d, J=8.1 Hz, 1H), 7.60-7.34 (m, 5H), 7.18(dd, J=7.5, 7.5 Hz, 1H), 7.09 (dd, J=7.5, 7.5 Hz, 1H), 5.38 (q, J=6.6Hz, 1H), 2.94 (t, J=7.5 Hz, 2H), 2.57 (t, J=7.5 Hz, 2H), 2.46 (s, 3H),1.78 (d, J=6.6 Hz, 3H).

EXAMPLE 8(136)3-(6-cyano-1-(2-(naphthalen-1-yl)propionyl)indol-3-yl)propanoic acid

TLC: Rf 0.44 (n-hexane:ethyl acetate:acetic acid=100:100:1);

NMR (300 MHz, DMSO-d₆): δ 8.72 (s, 1H), 8.30 (d, J=8.7 Hz, 1H), 7.98 (d,J=8.1 Hz, 1H), 7.85 (d, J=7.5 Hz, 1H), 7.81-7.77 (m, 2H), 7.69-7.55 (m,3H), 7.47-7.39 (m, 2H), 5.59 (q, J=6.9 Hz, 1H), 2.86-2.67 (m, 2H),2.53-2.35 (m, 2H), 1.64 (d, J=6.9 Hz, 3H).

REFERENCE EXAMPLE 16 methyl 4-hydroxymethyl-2-iodobenzoate

Using methyl 2-amino-4-carboxybenzoate, the title compounds having thefollowing physical data were obtained by the same procedures as a seriesof reactions of Reference Example 2→Reference Example 12.

NMR (300 MHz, CDCl₃): δ 8.02-8.01 (m, 1H), 7.81 (d, J=8.1 Hz, 1H),7.41-7.37 (m, 1H), 4.71 (s, 2H), 3.93 (s, 3H).

REFERENCE EXAMPLE 17 methyl 2-iodo-4-phenoxymethylbenzoate

To a solution of the compound prepared in Reference Example 16 (3.66 g)in methylene chloride (20 ml) was added mesyl chloride (1.07 ml) andtriethylamine (1.92 ml) at 0° C. under an atmosphere of argon. Themitxture was stirred for 10 minutes. To the mixture was added water andthe mixture was extracted with ethyl acetate. The organic layer waswashed with water and a saturated aqueous solution of sodium chloride,dried over anhydrous magnesium sulfate and concentrated to give themesylate. To a suspension of sodium hydride (525 mg, 63.1%) inN,N-dimethylformamide (5 ml) was added phenol (1.30 g) and the mixturewas stirred at room temperature for 1 hour. To the mixture was added theabove-menthioned solution of the mesylate in N,N-dimethylformamide (10ml) and the mixture was stirred at room temperature for 10 minutes. Tothe reaction mixture was added 1N hydrochloric acid, the mixture wasextracted with ethyl acetate, The organic layer was washed with waterand a saturated aqueous solution of sodium chloride subsequently, driedover anhydrous magnesium sulfate and then concentrated. The residue waspurified by column chromatography on silica gel to give the titlecompound (4.44 g) having the following physical data.

NMR (300 MHz, CDCl₃): δ 8.08 (s, 1H), 7.82 (d, J=8.1 Hz, 1H), 7.48-7.45(m, 1H), 7.33-7.28 (m, 2H), 7.02-6.94 (m, 3H), 5.95 (s, 2H), 3.93 (s,3H).

REFERENCE EXAMPLE 182-(naphthalen-2-ylmethyl)-4-phenoxymethylbenzylalcohol

To the suspension of zinc (710 mg) in tetrahydrofuran (2 ml) was addeddibromoethane (1 drop) under an atmosphere of argon. The mixture washeated and then added trimethylsilyl chloride (1 drop). The reactionmixture was cooled to 0° C. and added dropwise a solution of2-bromomethylnaphthalene (1.20 g) in tetrahydrofuran (3 ml). The mixturewas stirred at room temperature for 1.5 hour to give the zinc reagent.To a solution of [bis(benzylidene)acetone]palladium (156 mg) anddiphenylphosphinoferrocene (151 mg) in tetrahydrofuran (2 ml) was addedthe compound prepared in Reference Example 17 (1.00 g) intetrahydrofuran (3 ml) under an atmosphere of argon. To the mixture wasadded the above-mentioned zinc reagent. The mixture was stirred at roomtemperature for 30 minutes. To the mixture was added a saturated aqueoussolution of ammonium chloride. The mixture was extracted with ethylacetate. The organic layer was washed with water and a saturated aqueoussolution of sodium chloride subsequently, dried over anhydrous magnesiumsulfate and concentrated. The residue was purified by columnchromatography on silica gel to give methyl2-(2-naphthylmethyl)-4-phenoxymethylbenzoate. To a suspension of lithiumalminium hydride (206 mg) in (2 ml) was added dropwise a solution of theabove-mentioned methyl 2-(2-naphthylmethyl)-4-phenoxymethylbenzoate indiethyl ether (3 ml)-tetrahydrofuran (3 ml) under an atmosphere ofargon. The mixture was stirred for 30 minutes. To the mixture was added1N hydrochloric acid. The mixture was extracted with ethyl acetate. Theorganic layer was washed with water and a saturated aqueous solution ofsodium chloride subsequently, dried over anhydrous magnesium sulfate andconcentrated. The residue was purified by column chromatography onsilica gel to give the title compound (974 mg) having the followingphysical data.

NMR (300 MHz, CDCl₃): δ 7.82-7.71 (m, 3H), 7.53-7.35 (m, 5H), 7.30-7.25(m, 4H), 6.98-6.93 (m, 3H), 5.04 (s, 2H), 4.69 (d, J=4.8 Hz, 2H), 4.26(s, 2H), 1.46-1.44 (m, 1H).

REFERENCE EXAMPLE 192-(naphthalen-2-ylmethyl)-4-phenoxymethylbenzaldehyde

To a solution of the compound prepared in Reference Example 18 (974 mg)in ethyl acetate (5 ml) were added dimethylsulfoxide (1 ml),triethylamine (1.17 ml) and pyridinium sulfate (671 mg) at 0° C. underan atmosphere of argon. The mixture was stirred at room temperature for1 hour. To the reaction mixture was added water. The mixture wasextracted with ethyl acetate. The organic layer was washed with waterand a saturated aqueous solution of sodium chloride subsequently, driedover anhydrous magnesium sulfate and concentrated. The residue waspurified by column chromatography on silica gel to give the titlecompound (871 mg) having the following physical data.

NMR (300 MHz, CDCl₃): δ 10.27 (s, 1H), 7.90 (d, J=7.5 Hz, 1H), 7.80-7.70(m, 3H), 7.53-7.25 (m, 8H), 7.00-6.92 (m, 3H), 5.10 (s, 2H), 4.62 (s,2H).

EXAMPLE 9(2E)-3-(2-(naphthalen-2-ylmethyl)-4-phenoxymethylphenyl)-2-propenoicacid

To a solution of the compound prepared in Reference Example 19 (871 mg)in pyridine (5 ml) were added malonic acid (574 mg) and piperidine (0.16ml). The mixture was stirred at 120° C. overnight. To the reactionmixture was added 1N hydrochloric acid. The mixture was extracted withethyl acetate. The organic layer was washed with water and a saturatedaqueous solution of sodium chloride subsequently, dried over anhydrousmagnesium sulfate and concentrated. The residue was washed withn-hexane-ethyl acetate to give the title compound (810 mg) having thefollowing physical data.

TLC: Rf 0.60 (ethyl acetate);

NMR (300 MHz, CDCl₃); 8.17 (d, J=15.6 Hz, 1H), 7.80-7.65 (m, 4H), 7.52(s, 1H), 7.44-7.37 (m, 3H), 7.31-7.25 (m, 4H), 6.99-6.93 (m, 3H), 6.35(d, J=15.6 Hz, 1H), 5.05 (s, 2H), 4.31 (s, 2H).

EXAMPLE 9(1)˜EXAMPLE 9(6)

Using corresponding compounds, the following compounds were obtained bythe same procedure of Example 9.

EXAMPLE 9(1)(2E)-3-(2-(naphthalen-2-ylmethyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.50 (ethyl acetate).

EXAMPLE 9(2) (2E)-3-(2-benzyl-4-phenoxymethylphenyl)-2-propenoic acid

TLC: Rf 0.24 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.10 (d, J=15.9 Hz, 1H), 7.64 (d, J=8.1 Hz, 1H),7.40-7.10 (m, 9H), 7.00-6.93 (m, 3H), 6.34 (d, J=15.9 Hz, 1H), 5.06 (s,2H), 4.15 (s, 2H).

EXAMPLE 9(3)3-(2-(naphthalen-2-ylmethyl)-4-phenoxymethylphenyl)propanoic acid

TLC: Rf 0.65 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.10 (s, 1H), 7.87-7.75 (m, 3H), 7.58 (s,1H), 7.49-7.41 (m, 2H), 7.31-7.22 (m, 6H), 6.97-6.89 (m, 3H), 5.02 (s,2H), 4.18 (s, 2H), 2.84 (t, J=8.1 Hz, 2H), 2.39 (t, J=8.1 Hz, 2H).

EXAMPLE 9(4)3-(2-(naphthalen-2-ylmethyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.45 (ethyl acetate);

NMR (300 MHz, DMSO-d₆): δ 12.08 (s, 1H), 7.87-7.76 (m, 4H), 7.56 (s,1H), 7.48-7.41 (m, 3H), 7.27 (dd, J=8.1, 1.5 Hz, 1H), 7.17 (d, J=8.1 Hz,1H), 7.08 (s, 1H), 6.99 (dd, J=8.1, 1.5 Hz, 1H), 6.22 (t, J=2.1 Hz, 1H),5.25 (s, 2H), 4.14 (s, 2H), 2.80 (t, J=7.8 Hz, 2H), 2.36 (t, J=7.8 Hz,2H).

EXAMPLE 9(5)(2E)-3-(2-(3-phenylpropyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid

TLC: Rf 0.35 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 8.01 (d, J=15.9 Hz, 1H), 7.59-7.53 (m, 2H), 7.40(d, J=2.1 Hz, 1H), 7.32-7.25 (m, 2H), 7.22-7.14 (m, 3H), 7.08-7.02 (m,2H), 6.35 (d, J=15.9 Hz, 1H), 6.30 (t, J=2.1 Hz, 1H), 5.32 (s, 2H), 2.75(t, J=7.5 Hz, 2H), 2.66 (t, J=7.5 Hz, 2H), 1.89 (m, 2H).

EXAMPLE 9(6)2-(2-(3-(naphthalen-2-yl)propyl)-4-(pyrazol-1-ylmethyl)phenoxy)aceticacid

TLC: Rf 0.20 (chloroform:methanol=10:1).

EXAMPLE 10(2E)-N-phenylsulfonyl-3-(2-(naphthalen-2-ylmethyl)-4-phenoxymethylphenyl)-2-propenamide

To a solution of the compound prepared in Example 9 (200 mg) inN,N-dimethylformamide (1 ml) were added benzenesulfonamide (120 mg),1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (146 mg)and dimethylaminopyridine (19 mg). The mixture was stirred at roomtemperature overnight. To the reaction mixture was added water. Themixture was extracted with ethyl acetate. The organic layer was washedwith water and a saturated aqueous solution of sodium chloridesubsequently, dried over anhydrous magnesium sulfate and concentrated.The residue was purified by column chromatography on silica gel to givethe title compound (151 mg) having the following physical data.

TLC: Rf 0.55 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, DMSO-d₆): δ 12.27 (s, 1H), 7.94-7.22 (m, 18H), 6.97-6.89(m, 3H), 6.46 (d, J=15.6 Hz, 1H), 5.10 (s, 2H), 4.26 (s, 2H).

EXAMPLE 10(1)˜EXAMPLE 10(225)

Using corresponding compounds, the following compounds were obtained bythe same procedure of Example 10 or continued conversion to known salts.

EXAMPLE 10(1)N-mesyl-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.39 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.89-7.78 (m, 3H), 7.70 (s, 1H), 7.55-7.35 (m,5H), 7.04 (d, J=7.8 Hz, 1H), 6.72 (m, 2H), 6.28 (t, J=1.5 Hz, 1H), 5.26(s, 2H), 4.29 (t, J=6.3 Hz, 2H), 3.26 (t, J=6.3 Hz, 2H), 3.04 (s, 3H),2.78 (t, J=7.2 Hz, 2H), 2.10 (t, J=7.2 Hz, 2H).

EXAMPLE 10(2)N-phenylsulfonyl-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.44 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.95-7.75 (m, 5H), 7.68 (s, 1H), 7.64-7.35 (m,8H), 6.90 (d, J=7.5 Hz, 1H), 6.67 (s, 1H), 6.62 (d, J=7.5 Hz, 1H), 6.28(t, J=2.1 Hz, 1H), 5.24 (s, 2H), 4.25 (t, J=6.3 Hz, 2H), 3.23 (t, J=6.3Hz, 2H), 2.69 (t, J=7.5 Hz, 2H), 2.05 (t, J=7.5 Hz, 2H).

EXAMPLE 10(3)N-phenylsulfonyl-3-(2-((3-methylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.37 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.94-7.88 (m, 2H), 7.56 (m, 1H), 7.48-7.40 (m,3H), 7.38-7.28 (m, 3H), 7.16 (d, J=7.2 Hz, 1H), 7.04-6.95 (m, 3H), 6.03(m, 1H), 5.03 (s, 2H), 3.56-3.46 (m, 2H), 2.97 (t, J=7.6 Hz, 2H), 2.66(t, J=7.6 Hz, 2H), 1.70 (m, 1H), 1.58-1.49 (m, 2H), 0.98 (d, J=6.6 Hz,6H).

EXAMPLE 10(4)N-phenylsulfonyl-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.40 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 10.15 (s, 1H), 7.91-7.88 (m, 2H), 7.59-7.53 (m,1H), 7.47-7.30 (m, 8H), 7.15-6.95 (m, 6H), 6.27 (d, J=8.1 Hz, 1H), 5.25(q, J=8.1 Hz, 1H), 5.02 (s, 2H), 2.95-2.78 (m, 2H), 2.57-2.51 (m, 2H),1.86-1.52 (m, 3H), 1.02-0.99 (m, 6H).

EXAMPLE 10(5)N-methyl-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.52 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.45-7.22 (m, 7H), 7.09-6.93 (m, 6H), 5.86 (m,1H), 5.19 (m, 1H), 5.02 (s, 2H), 3.05-2.85 (m, 2H), 2.68 (d, J=4.5 Hz,3H), 2.52 (t, J=7.5 Hz, 2H), 1.81 (m, 1H), 1.73-1.53 (m, 2H), 0.98 (t,J=6.6 Hz, 6H).

EXAMPLE 10(6)N-(pyridin-2-yl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.40 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.28-8.25 (m, 1H), 8.16-8.10 (m, 2H), 7.71-7.64(m, 1H), 7.45-7.27 (m, 7H), 7.04-6.94 (m, 6H), 6.87 (d, J=8.1 Hz, 1H),5.24 (q, J=8.1 Hz, 1H), 5.02 (s, 2H), 3.15-2.98 (m, 2H), 2.75 (t, J=7.5Hz, 2H), 1.88-1.78 (m, 1H), 1.74-1.57 (m, 2H), 1.00-0.97 (m, 6H).

EXAMPLE 10(7)N-(4-trifluoromethylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.60 (chloroform:methanol=10:1).

EXAMPLE 10(8)N-(naphthalen-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.62 (chloroform:methanol=10:1).

EXAMPLE 10(9)N-(3-chloro-4-methylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.62 (chloroform:methanol=10:1).

EXAMPLE 10(10)N-(4-ethylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.64 (chloroform:methanol=10:1).

EXAMPLE 10(11)N-hydroxy-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.60 (ethyl acetate).

EXAMPLE 10(12)N-isopropylsulfonyl-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.80 (chloroform:methanol=10:1).

EXAMPLE 10(13)N-(4-mesylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.61 (chloroform:methanol=10:1).

EXAMPLE 10(14)N-((1,1′-biphenyl-4-yl)sulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.80 (chloroform:methanol=10:1).

EXAMPLE 10(15)N-((1,1′-biphenyl-2-yl)sulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.57 (chloroform:methanol=10:1).

EXAMPLE 10(16)N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.57 (chloroform:methanol=10:1).

EXAMPLE 10(17)N-(2,6-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.55 (chloroform:methanol=10:1).

EXAMPLE 10(18)N-(2,5-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.59 (chloroform:methanol=10:1).

EXAMPLE 10(19)N-(2,5-dimethoxyphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.52 (chloroform:methanol=10:1).

EXAMPLE 10(20)N-((E)-2-phenylethenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.78 (chloroform:methanol=10:1).

EXAMPLE 10(21)N-(furan-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.61 (chloroform:methanol=10:1).

EXAMPLE 10(22)N-(thiophen-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.62 (chloroform:methanol=10:1).

EXAMPLE 10(23)N-(7-chlorobenzofurazan-4-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.56 (chloroform:methanol=10:1).

EXAMPLE 10(24)N-(3,4-dichlorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.70 (chloroform:methanol=10:1).

EXAMPLE 10(25)N-(4-methoxyphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.61 (chloroform:methanol=10:1).

EXAMPLE 10(26)N-(3-methylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.65 (chloroform:methanol=10:1).

EXAMPLE 10(27)N-(2-fluorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.62 (chloroform:methanol=10:1).

EXAMPLE 10(28)N-(4-cyanophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.59 (chloroform:methanol=10:1).

EXAMPLE 10(29)N-(3-cyanophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.59 (chloroform:methanol=10:1).

EXAMPLE 10(30)N-(2-chloro-4-cyanophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.61 (chloroform:methanol=10:1).

EXAMPLE 10(31)N-(3-methoxyphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.58 (chloroform:methanol=10:1).

EXAMPLE 10(32)N-(4-butoxyphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.65 (chloroform:methanol=10:1).

EXAMPLE 10(33)N-(4-fluorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.68 (chloroform:methanol=10:1).

EXAMPLE 10(34)N-(2-chloro-6-methylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.67 (chloroform:methanol=10:1).

EXAMPLE 10(35)N-(2-trifluoromethylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.62 (chloroform:methanol=10:1).

EXAMPLE 10(36)N-(3-trifluoromethylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.67 (chloroform:methanol=10:1).

EXAMPLE 10(37)N-(4-propylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.71 (chloroform:methanol 10:1).

EXAMPLE 10(38)N-(4-isopropylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.69 (chloroform:methanol=10:1).

EXAMPLE 10(39)N-(naphthalen-1-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.76 (chloroform:methanol=10:1).

EXAMPLE 10(40)N-(4-butylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.71 (chloroform:methanol=10:1).

EXAMPLE 10(41)N-(5-benzoylaminomethylthiophen-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.58 (chloroform:methanol=10:1).

EXAMPLE 10(42)N-phenylsulfonyl-2-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenoxy)acetamide

TLC: Rf 0.65 (ethyl acetate:methanol=5:1).

EXAMPLE 10(43)N-phenylsulfonyl-2-(2-((3-methyl-1′-phenylbutyl)carbamoyl)-4-(2-methylphenoxymethyl)phenoxy)acetamide

TLC: Rf 0.65 (ethyl acetate:methanol=5:1).

EXAMPLE 10(44)N-phenylsulfonyl-2-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenoxy)acetamide

TLC: Rf 0.60 (ethyl acetate:methanol=5:1).

EXAMPLE 10(45)N-(5-methylfuran-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.80 (chloroform:methanol=10:1).

EXAMPLE 10(46)N-(thiophen-3-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.80 (chloroform:methanol=10:1).

EXAMPLE 10(47)N-(furan-3-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.78 (chloroform:methanol=10:1).

EXAMPLE 10(48)N-(1-methylpyrrol-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.60 (chloroform:methanol=10:1).

EXAMPLE 10(49)N-(3,5-dimethylisoxazol-4-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.80 (chloroform:methanol=10:1).

EXAMPLE 10(50)N-benzylsulfonyl-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.81 (chloroform:methanol=10:1).

EXAMPLE 10(51)N-(5-dimethylaminonaphthalen-1-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.66 (chloroform:methanol=10:1).

EXAMPLE 10(52)N-(4-acetylaminophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.80 (chloroform:methanol=10:1).

EXAMPLE 10(53)N-(4-chlorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.80 (chloroform:methanol=10:1).

EXAMPLE 10(54)N-(2-methoxycarbonylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.79 (chloroform:methanol=10:1).

EXAMPLE 10(55)N-(3-(3-methyl-5-oxopyrazol-1-yl)phenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.79 (chloroform:methanol 10:1).

EXAMPLE 10(56)N-(tetrazol-5-yl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.65 (ethyl acetate:methanol=3:1).

EXAMPLE 10(57)(2E)-N-phenylsulfonyl-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)-2-propenamide

TLC: Rf 0.57 (chloroform:methanol=10:1).

EXAMPLE 10(58)N-(pyridin-2-yl)-3-(2-(4-methyl-2-phenylpentyloxy)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.35 (hexane:ethyl acetate=3:1).

EXAMPLE 10(59)N-(tetrazol-5-yl)-3-(2-(4-methyl-2-phenylpentyloxy)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.25 (ethyl acetate).

EXAMPLE 10(60)N-phenylsulfonyl-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.41 (hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 7.95-7.77 (m, 5H), 7.70 (brs, 1H), 7.63-7.40 (m,7H), 7.33-7.27 (m, 2H), 7.00-6.93 (m, 5H), 6.81 (m, 1H), 4.99 (s, 2H),4.34 (t, J=6.3 Hz, 2H), 3.27 (t, J=6.3 Hz, 2H), 2.73 (m, 2H), 2.10 (m,2H).

EXAMPLE 10(61)(2E)-N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(naphthalen-2-ylmethyl)-4-phenoxymethylphenyl)-2-propenamide

TLC: Rf 0.40 (hexane:ethyl acetate=1:1).

EXAMPLE 10(62)(2E)-N-phenylsulfonyl-3-(2-(naphthalen-2-ylmethyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide

TLC: Rf 0.75 (ethyl acetate).

EXAMPLE 10(63)(2E)-N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(naphthalen-2-ylmethyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide

TLC: Rf 0.60 (ethyl acetate).

EXAMPLE 10(64)N-phenylsulfonyl-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.57 (chloroform:methanol=9:1).

EXAMPLE 10(65)N-(tetrazol-5-yl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol1-ylmethyl)phenyl)propanamide

TLC: Rf 0.55 (chloroform:methanol:acetic acid=90:10:1);

NMR (300 MHz, DMSO-d₆): δ 7.86-7.74 (m, 6H), 7.52-7.33 (m, 4H), 7.06 (d,J=7.4 Hz, 1H), 6.87 (s, 1H), 6.65 (d, J=7.4 Hz, 1H), 6.23 (t, J=2.0 Hz,1H), 5.24 (s, 2H), 4.19 (t, J=6.2 Hz, 2H), 3.18 (t, J=6.2 Hz, 2H),2.84-2.73 (m, 2H), 2.61-2.52 (m, 2H).

EXAMPLE 10(66)N-(tetrazol-5-yl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.65 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 7.84-7.68 (m, 4H), 7.51-7.20 (m, 5H),7.13-6.87 (m, 6H), 5.01 (s, 2H), 4.98 (m, 1H), 4.27 (t, J=6.3 Hz, 2H),3.20 (t, J=6.3 Hz, 2H), 2.85-3.18 (m, 2H), 2.61-2.55 (m, 2H).

EXAMPLE 10(67)N-phenylsulfonyl-3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.61 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.98 (d, J=7.5 Hz, 2H), 7.73 (s, 1H), 7.66-7.48(m, 4H), 7.37 (d, J=1.5 Hz, 1H), 7.34-7.20 (m, 4H), 6.89 (d, J=7.2 Hz,1H), 6.66 (s, 1H), 6.62 (d, J=7.5 Hz, 1H), 6.29 (t, J=1.5 Hz, 1H), 5.24(s, 2H), 4.17 (t, J=6.3 Hz, 2H), 3.07 (t, J=6.3 Hz, 2H), 2.71 (t, J=7.5Hz, 2H), 2.14 (t, J=7.5 Hz, 2H).

EXAMPLE 10(68) N-(tetrazol-5-yl)-3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.40 (chloroform:methanol=4:1);

NMR (300 MHz, DMSO-d₆): δ 7.77 (d, J=2.1 Hz, 1H), 7.43 (d, J=1.5 Hz,1H), 7.34-7.23 (m, 5H), 7.18 (d, J=6.3 Hz, 1H), 7.07 (d, J=7.8 Hz, 1H),6.85 (s, 1H), 6.65 (d, J=7.8 Hz, 1H), 6.23 (t, J=1.8 Hz, 1H), 5.24 (s,2H), 4.09 (t, J=6.3 Hz, 2H), 3.00 (t, J=6.3 Hz, 2H), 2.75 (t, J=7.5 Hz,2H), 2.51 (t, J=7.5 Hz, 2H).

EXAMPLE 10(69)N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.13 (d, J=2.7 Hz, 1H), 7.97 (s, 1H), 7.62 (dd,J=8.7, 2.4 Hz, 1H), 7.56 (d, J=1.8 Hz, 1H), 7.40 (d, J=1.8 Hz, 1H),7.39-7.25 (m, 5H), 6.95 (d, J=8.4 Hz, 1H), 6.78 (d, J=9.0 Hz, 1H),6.66-6.62 (m, 2H), 6.30 (t, J=2.1 Hz, 1H), 5.24 (s, 2H), 4.17 (t, J=6.3Hz, 2H), 3.75 (s, 3H), 3.08 (t, J=6.3 Hz, 2H), 2.73 (t, J=7.5 Hz, 2H),2.29 (t, J=7.5 Hz, 2H).

EXAMPLE 10(70)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.80 (chloroform:methanol=10:1).

EXAMPLE 10(71)N-(7-chlorobenzofurazan-4-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.56 (chloroform:methanol=10:1).

EXAMPLE 10(72)N-(3,4-dichlorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.63 (chloroform:methanol=10:1).

EXAMPLE 10(73)N-(3-cyanophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.55 (chloroform:methanol=10:1).

EXAMPLE 10(74)N-(3-chloro-4-methylphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.59 (chloroform:methanol=10:1).

EXAMPLE 10(75)N-(3-chloro-4-fluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.58 (chloroform:methanol=10:1).

EXAMPLE 10(76)N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol1-ylmethyl)phenyl)propanamide

TLC: Rf 0.58 (chloroform:methanol=10:1).

EXAMPLE 10(77)N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.61 (chloroform:methanol=10:1).

EXAMPLE 10(78)N-phenylsulfonyl-3-(2-(2-phenylethoxy)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.43 (hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 8.00-7.92 (m, 2H), 7.73 (brs, 1H), 7.62 (m, 1H),7.56-7.48 (m, 2H), 7.35-7.24 (m, 7H), 7.00-6.90 (m, 5H), 6.82 (d, J=7.2Hz, 1H), 4.99 (s, 2H), 4.26 (t, J=6.3 Hz, 2H), 3.11 (t, J=6.3 Hz, 2H),2.77-2.72 (m, 2H), 2.21-2.16 (m, 2H).

EXAMPLE 10(79)(2E)-N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-benzyl-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide

TLC: Rf 0.41 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.18 (d, J=2.7 Hz, 1H), 7.92 (d, J=15.6 Hz, 1H),7.65 (dd, J=8.7, 2.7 Hz, 1H), 7.55 (d, J=1.2 Hz, 1H), 7.45 (d, J=8.7 Hz,1H), 7.40 (d, J=2.4 Hz, 1H), 7.30-7.14 (m, 4H), 7.05-7.00 (m, 3H), 6.87(d, J=9.3 Hz, 1H), 6.39 (d, J=15.6 Hz, 1H), 6.29 (t, J=2.4 Hz, 1H), 5.30(s, 2H), 4.02 (s, 2H), 3.86 (s, 3H).

EXAMPLE 10(80)(2E)-N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-benzyl-4-phenoxymethylphenyl)-2-propenamide

TLC: Rf 0.43 (hexane:ethyl acetate=1:3);

NMR (300 MHz, CD₃OD): δ 8.04 (d, J=2.4 Hz, 1H), 7.88 (d, J=15.6 Hz, 1H),7.65-7.58 (m, 2H), 7.34-6.87 (m, 13H), 6.44 (d, J=15.6 Hz, 1H), 5.05 (s,2H), 4.09 (s, 2H), 3.81 (s, 3H).

EXAMPLE 10(81)N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(naphthalen-2-ylmethyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.60 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.22 (s, 1H), 7.86-7.73 (m, 5H), 7.52 (s,1H), 7.49-7.41 (m, 2H), 7.28-7.06 (m, 7H), 6.96-6.89 (m, 3H), 5.00 (s,2H), 4.10 (s, 2H), 3.76 (s, 3H), 2.74 (t, J=7.8 Hz, 2H), 2.45-2.43 (m,2H).

EXAMPLE 10(82)N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(naphthalen-2-ylmethyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.30 (hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 12.21 (br s, 1H), 7.86-7.73 (m, 6H), 7.51-7.43(m, 4H), 7.22 (dd, J=8.7, 1.8 Hz, 1H), 7.10-7.00 (m, 3H), 6.91 (dd, 8.1,1.8 Hz, 1H), 6.23 (t, J=2.1 Hz, 1H), 5.23 (s, 2H), 4.05 (s, 2H), 3.68(s, 3H), 2.73-2.68 (m, 2H), 2.41 (t, J=7.2 Hz, 2H).

EXAMPLE 10(83)N-(3-chloro-4-fluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide

TLC: Rf 0.65 (chloroform:methanol=10:1).

EXAMPLE 10(84)N-(3-cyanophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide

TLC: Rf 0.63 (chloroform:methanol=10:1).

EXAMPLE 10(85)N-(3,4-dichlorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide

TLC: Rf 0.62 (chloroform:methanol=1:1).

EXAMPLE 10(86)N-(3-chloro-4-methylphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide

TLC: Rf 0.64 (chloroform:methanol=10:1).

EXAMPLE 10(87)N-(7-chlorobenzofurazan-4-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide

TLC: Rf 0.66 (chloroform:methanol=10:1).

EXAMPLE 10(88)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide

TLC: Rf 0.64 (chloroform:methanol=10:1).

EXAMPLE 10(89)N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide

TLC: Rf 0.65 (chloroform:methanol=10:1).

EXAMPLE 10(90)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.41 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84 (m, 1H), 7.83-7.73 (m, 2H), 7.55 (d, J=1.8Hz, 1H), 7.40 (d, J=2.7 Hz, 1H), 7.37-7.23 (m, 6H), 6.89 (d, J=7.5 Hz,1H), 6.67 (s, 1H), 6.63 (d, J=7.5 Hz, 1H), 6.29 (m, 1H), 5.25 (s, 2H),4.20 (t, J=6.3 Hz, 2H), 3.08 (t, J=6.3 Hz, 2H), 2.70 (t, J=7.5 Hz, 2H),2.14 (t, J=7.5 Hz, 2H).

EXAMPLE 10(91)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(benzimidazol-1-yl)ethoxy)-4-(pyrazol1-ylmethyl)phenyl)propanamide

TLC: Rf 0.38 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.06 (s, 1H), 8.04-7.94 (m, 2H), 7.84 (m, 1H),7.52 (d, J=2.1 Hz, 1H), 7.45-7.28 (m, 5H), 7.02 (d, J=7.5 Hz, 1H), 6.69(d, J=7.5 Hz, 1H), 6.54 (s, 1H), 6.26 (m, 1H), 5.20 (s, 2H), 4.64 (t,J=4.8 Hz, 2H), 4.15 (t, J=4.8 Hz, 2H), 2.71 (t, J=8.1 Hz, 2H), 1.81 (t,J=8.1 Hz, 2H).

EXAMPLE 10(92)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(benzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.50 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 7.85-7.80 (m, 4H), 7.56-7.39 (m, 5H), 6.99 (d,J=7.5 Hz, 1H), 6.70-6.61 (m, 3H), 6.28 (t, J=2.1 Hz, 1H), 5.25 (s, 2H),4.05-3.96 (m, 4H), 2.75-2.69 (m, 2H), 2.43-2.37 (m, 2H).

EXAMPLE 10(93)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(2H-benzotriazol-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.60 (ethyl acetate:methanol=20:1).

EXAMPLE 10(94)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(1H-benzotriazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.44 (ethyl acetate:methanol=20:1).

EXAMPLE 10(95)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(2-methylbenzimidazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CD₃OD): δ 7.87-7.48 (m, 6H), 7.43-7.18 (m, 3H), 6.93 (d,J=7.2 Hz, 1H), 6.70 (s, 1H), 6.61 (d, J=7.2 Hz, 1H), 6.32 (t, J=2.1 Hz,1H), 5.21 (s, 2H), 4.69 (t, J=4.8 Hz, 2H), 4.33 (t, J=4.8 Hz, 2H),2.77-2.54 (m, 5H), 2.34-2.13 (m, 2H).

EXAMPLE 10(96)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(1H-indazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.63 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.12 (s, 1H), 7.97-7.83 (m, 2H), 7.79 (d, J=7.8Hz, 1H), 7.55-7.41 (m, 3H), 7.37-7.18 (m, 3H), 6.95 (d, J=7.8 Hz, 1H),6.66 (d, J=7.2 Hz, 1H), 6.56 (s, 1H), 6.26 (t, J=2.1 Hz, 1H), 5.20 (s,2H), 4.86 (t, J=4.5 Hz, 2H), 4.32 (t, J=4.5 Hz, 2H), 2.82-2.69 (m, 2H),2.42-2.29 (m, 2H).

EXAMPLE 10(97)(2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide

TLC: Rf 0.55 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.46 (brs, 1H), 8.07-7.95 (m, 1H), 7.95-7.65(m, 8H), 7.55-7.35 (m, 5H), 6.98 (s, 1H), 6.72 (d, J=7.2 Hz, 1H), 6.68(d, J=15.9 Hz, 1H), 6.25 (t, J=2.1 Hz, 1H), 5.32 (s, 2H), 4.28 (t, J=7.2Hz, 2H), 3.28 (t, J=7.2 Hz, 2H).

EXAMPLE 10(98)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-methylpiperazin1-ylmethyl)phenyl)propanamide

TLC: Rf 0.47 (chloroform:methanol=3:1).

EXAMPLE 10(99)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-acetylpiperazin-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.33 (chloroform:methanol=10:1).

EXAMPLE 10(100)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(morpholin-4-ylmethyl)phenyl)propanamide

TLC: Rf 0.57 (ethyl acetate:methanol=10:1).

EXAMPLE 10(101)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-3-yloxymethyl)phenyl)propanamide

TLC: Rf 0.50 (ethyl acetate).

EXAMPLE 10(102)N-phenylsulfonyl-2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)acetamide

TLC: Rf 0.50 (hexane:ethyl acetate=1:3).

EXAMPLE 10(103)N-phenylsulfonyl-4-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)butanamide

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.00 (d, J=6.9 Hz, 2H), 7.86-7.76 (m, 3H), 7.70(s, 2H), 7.64-7.36 (m, 7H), 6.91 (d, J=7.8 Hz, 1H), 6.71-6.65 (m, 2H),6.28 (dd, J=1.8, 1.8 Hz, 1H), 5.25 (s, 2H), 4.23 (t, J=6.6 Hz, 2H), 3.21(t, J=6.6 Hz, 2H), 2.42 (t, J=7.2 Hz, 2H), 1.80 (t, J=7.2 Hz, 2H), 1.59(m, 2H).

EXAMPLE 10(104)N-(3,4-difluorophenylsulfonyl)-4-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)butanamide

TLC: Rf 0.56 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 7.98-7.65 (m, 8H), 7.50-7.40 (m, 4H), 6.90 (d,J=7.8 Hz, 1H), 6.84 (s, 1H), 6.63 (d, J=7.8 Hz, 1H), 6.23 (dd, J=2.1,2.1 Hz, 1H), 5.23 (s, 2H), 4.16 (t, J=6.3 Hz, 2H), 3.15 (t, J=6.3 Hz,2H), 2.34 (t, J=7.5 Hz, 2H), 2.14 (t, J=7.5 Hz, 2H), 1.55 (m, 2H).

EXAMPLE 10(105)N-(pyridin-3-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.49 (chloroform:methanol=10:1).

EXAMPLE 10(106)N-(1-methylpyrrol-2-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.70 (chloroform:methanol=10:1).

EXAMPLE 10(107)N-(4-methylthiazol-2-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.52 (chloroform:methanol=10:1).

EXAMPLE 10(108)N-(3,5-dimethylisoxazol-4-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol1-ylmethyl)phenyl)propanamide

TLC: Rf 0.71 (chloroform:methanol=10:1).

EXAMPLE 10(109)N-(pyridin-2-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.51 (chloroform:methanol=10:1).

EXAMPLE 10(109) N-(1-methylimidazol-2-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.48 (chloroform:methanol=10:1).

EXAMPLE 10(111)N-phenylsulfonyl-2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzamide

TLC: Rf 0.66 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 10.35 (bs, 1H), 7.99 (d, J=8.4 Hz, 1H),7.93-7.78 (m, 6H), 7.61-7.28 (m, 8H), 6.84 (d, J=8.1 Hz, 1H), 6.78 (s,1H), 6.31 (t, J=2.1 Hz, 1H), 5.31 (s, 2H), 4.47 (t, J=6.3 Hz, 2H), 3.42(t, J=6.3 Hz, 2H).

EXAMPLE 10(112)N-(5-methylfuran-2-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.40 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.88-7.77 (m, 4H), 7.68 (brs, 1H), 7.54 (d,J=1.5 Hz, 1H), 7.53-7.45 (m, 2H), 7.42-7.36 (m, 2H), 7.16 (d, J=3.6 Hz,1H), 6.97 (d, J=8.1 Hz, 1H), 6.67-6.65 (m, 2H), 6.27 (t, J=2.1 Hz, 1H),6.11 (d, J=3.3 Hz, 1H), 5.24 (s, 2H), 4.24 (t, J=6.3 Hz, 2H), 3.23 (t,J=6.3 Hz, 2H), 2.74 (t, J=7.5 Hz, 2H), 2.34 (s, 3H), 2.17 (t, J=7.5 Hz,2H).

EXAMPLE 10(113)N-(furan-3-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.30 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.01 (m, 1H), 7.87-7.77 (m, 4H), 7.69 (brs, 1H),7.54 (m, 1H), 7.53-7.44 (m, 2H), 7.41-7.37 (m, 3H), 6.92 (d, J=7.5 Hz,1H), 6.67 (d, J=1.5 Hz, 1H), 6.65-6.61 (m, 2H), 6.28 (t, J=2.1 Hz, 1H),5.24 (s, 2H), 4.25 (t, J=6.3 Hz, 2H), 3.23 (t, J=6.3 Hz, 2H), 2.73 (t,J=7.5 Hz, 2H), 2.09 (t, J=7.5 Hz, 2H).

EXAMPLE 10(114)N-(thiophen-3-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.35 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.10 (dd, J=3.0, 1.5 Hz, 1H), 7.87-7.77 (m, 4H),7.68 (brs, 1H), 7.54 (m, 1H), 7.52-7.45 (m, 2H), 7.41-7.30 (m, 4H), 6.89(d, J=7.8 Hz, 1H), 6.67 (brs, 1H), 6.62 (d, J=7.8 Hz, 1H), 6.28 (t,J=2.1 Hz, 1H), 5.24 (s, 2H), 4.24 (t, J=6.3 Hz, 2H), 3.23 (t, J=6.3 Hz,2H), 2.71 (t, J=7.5 Hz, 2H), 2.09 (t, J=7.5 Hz, 2H).

EXAMPLE 10(115)N-(2,5-dimethoxyphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.26 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.16 (brs, 1H), 7.86-7.76 (m, 3H), 7.67 (brs,1H), 7.54-7.52 (m, 2H), 7.51-7.43 (m, 2H), 7.39-7.35 (m, 2H), 7.05 (dd,J=9.3, 3.0 Hz, 1H), 6.94 (d, J=7.2 Hz, 1H), 6.80 (d, J=9.1 Hz, 1H),6.65-6.62 (m, 2H), 6.27 (t, J=2.1 Hz, 1H), 5.23 (s, 2H), 4.18 (t, J=6.6Hz, 2H), 3.78 (s, 3H), 3.67 (s, 3H), 3.19 (t, J=6.6 Hz, 2H), 2.74 (t,J=7.5 Hz, 2H), 2.33 (t, J=7.5 Hz, 2H).

EXAMPLE 10(116)N-(4-methoxyphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.34 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.87-7.76 (m, 6H), 7.67 (brs, 1H), 7.53 (m, 1H),7.52-7.45 (m, 2H), 7.40-7.37 (m, 2H), 6.95-6.88 (m, 3H), 6.66 (brs, 1H),6.62 (d, J=7.2 Hz, 1H), 6.28 (t, J=2.1 Hz, 1H), 5.24 (s, 2H), 4.23 (t,J=6.3 Hz, 2H), 3.84 (s, 3H), 3.21 (t, J=6.3 Hz, 2H), 2.70 (t, J=7.5 Hz,2H), 2.07 (t, J=7.5 Hz, 2H).

EXAMPLE 10(117)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-cyclohexyloxyethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.63 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.64-7.56 (m, 2H), 7.54 (d, J=1.2 Hz, 1H), 7.40(d, J=1.8 Hz, 1H), 7.20 (m, 1H), 6.88 (d, J=7.8 Hz, 1H), 6.62 (d, J=7.8Hz, 1H), 6.57 (s, 1H), 6.28 (dd, J=1.8, 1.2 Hz, 1H), 5.25 (s, 2H), 4.10(m, 2H), 3.91 (m, 2H), 3.45 (m, 1H), 2.86 (t, J=6.9 Hz, 2H), 2.71 (t,J=6.9 Hz, 2H), 2.05 (m, 2H), 1.80 (m, 2H), 1.42-1.15 (m, 6H).

EXAMPLE 10(118)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(piperidin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.38 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.63-7.56 (m, 2H), 7.53 (d, J=2.1 Hz, 1H), 7.40(d, J=2.1 Hz, 1H), 7.15 (m, 1H), 7.10 (d, J=7.8 Hz, 1H), 6.80 (d, J=7.8Hz, 1H), 6.62 (s, 1H), 6.28 (dd, J=2.1, 2.1 Hz, 1H), 5.27 (s, 2H), 4.18(t, J=5.1 Hz, 2H), 3.50 (t, J=5.1 Hz, 2H), 3.24 (brs, 4H), 2.91 (m, 2H),2.46 (m, 2H), 2.15-2.00 (m, 4H), 1.65 (m, 2H).

EXAMPLE 10(119)N-phenylsulfonyl-3-(2-(2-(3-methoxybenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.50 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 11.00 (s, 1H), 8.01-7.98 (m, 2H), 7.61-7.32 (m,8H), 7.09-7.05 (m, 1H), 6.97 (d, J=7.5 Hz, 1H), 6.76-6.59 (m, 3H), 6.28(t, J=2.1 Hz, 1H), 5.24 (s, 2H), 4.03-4.00 (m, 2H), 3.95-3.90 (m, 2H),3.87 (s, 3H), 2.75-2.70 (m, 2H), 2.42-2.36 (m, 2H).

EXAMPLE 10(120)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-methoxybenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.50 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 11.45 (s, 1H), 7.86-7.81 (m, 2H), 7.55-7.22 (m,6H), 7.11-7.07 (m, 1H), 6.99 (d, J=7.5 Hz, 1H), 6.70-6.58 (m, 3H), 6.28(t, J=2.1 Hz, 1H), 5.25 (s, 2H), 4.06-3.94 (m, 4H), 3.88 (s, 3H),2.74-2.69 (m, 2H), 2.42-2.36 (m, 2H).

EXAMPLE 10(121)N-(3,4-difluorophenylsulfonyl)-3-(3-(3-phenylpropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.50 (chloroform:methanol=10:1).

EXAMPLE 10(122)N-(3,4-difluorophenylsulfonyl)-3-(3-(3-(naphthalen-1-yl)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.53 (chloroform:methanol=10:1).

EXAMPLE 10(123)N-phenylsulfonyl-3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.51 (chloroform:methanol=10:1).

EXAMPLE 10(124)N-(3,4-difluorophenylsulfonyl)-3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.51 (chloroform:methanol=10:1).

EXAMPLE 10(125)N-phenylsulfonyl-3-(2-((naphthalen-2-ylmethyl)carbamoyl)-4-(pyrazol1-ylmethyl)phenyl)propanamide

TLC: Rf 0.30 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.96 (t, J=5.7 Hz, 1H), 7.94-7.41 (m, 14H),7.21 (s, 1H), 7.11 (s, 2H), 6.29 (t, J=1.8 Hz, 1H), 5.32 (s, 2H), 4.57(d, J=5.7 Hz, 2H), 2.81 (t, J=7.4 Hz, 2H), 2.54 (t, J=7.4 Hz, 2H).

EXAMPLE 10(126)N-(3,4-difluorophenylsulfonyl)-3-(2-((naphthalen-2-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.28 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.98 (t, J=5.7 Hz, 1H), 8.00-7.64 (m, 8H),7.57-7.42 (m, 4H), 7.28 (s, 1H), 7.20-7.10 (m, 2H), 6.28 (t, J=2.1 Hz,1H), 5.33 (s, 2H), 4.57 (d, J=5.7 Hz, 1H), 2.83 (t, J=7.1 Hz, 2H), 2.57(t, J=7.1 Hz, 2H).

EXAMPLE 10(127)N-phenylsulfonyl-3-(2-(benzylcarbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.67 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.10 (brs, 1H), 8.84 (t, J=6.0 Hz, 1H),7.90-7.88 (m, 2H), 7.81 (m, 1H), 7.71 (m, 1H), 7.63-7.57 (m, 2H), 7.45(brs, 1H), 7.27-7.21 (m, 6H), 7.08 (brs, 2H), 6.27 (t, J=2.1 Hz, 1H),5.29 (s, 2H), 4.37 (d, J=6.0 Hz, 2H), 2.77-2.72 (m, 2H), 2.50-2.45 (m,2H).

EXAMPLE 10(128)N-(3,4-difluorophenylsulfonyl)-3-(2-(benzylcarbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.64 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.30 (brs, 1H), 8.86 (t, J=6.3 Hz, 1H), 7.93(m, 1H), 7.82-7.66 (m, 3H), 7.45 (brs, 1H), 7.31-7.20 (m, 6H), 7.15-7.08(m, 2H), 6.26 (m, 1H), 5.29 (s, 2H), 4.38 (d, J=6.0 Hz, 2H), 2.79-2.74(m, 2H), 2.54-2.49 (m, 2H).

EXAMPLE 10(129)N-(3,4-difluorophenylsulfonyl)-3-(3-(3-(naphthalen-2-yl)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.51 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 9.22 (brs, 1H), 7.90-7.70 (m, 5H), 7.60 (s, 1H),7.51 (d, J=1.5 Hz, 1H), 7.50-7.40 (m, 3H), 7.40-7.20 (m, 2H), 6.82 (d,J=7.8 Hz, 1H), 6.48 (s, 1H), 6.47 (d, J=7.8 Hz, 1H), 6.26 (t, J=1.8 Hz,1H), 5.29 (s, 2H), 3.90 (t, J=7.5 Hz, 2H), 2.91 (t, J=7.5 Hz, 2H), 2.76(t, J=7.5 Hz, 2H), 2.37 (t, J=7.5 Hz, 2H), 2.30-2.10 (m, 2H).

EXAMPLE 10(130)N-phenylsulfonyl-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.65 (chloroform:methanol=10:1).

EXAMPLE 10(131)N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.62 (chloroform:methanol=10:1).

EXAMPLE 10(132)N-phenylsulfonyl-3-(2-((3-methyl-1-(3,5-dimethoxyphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.64 (chloroform:methanol=10:1).

EXAMPLE 10(133)N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(3,5-dimethoxyphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.62 (chloroform:methanol=10:1).

EXAMPLE 10(134)(2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-acetylpiperazin-1-ylmethyl)phenyl)-2-propenamide

TLC: Rf 0.58 (chloroform:methanol=10:1).

EXAMPLE 10(135)(2E)-N-phenylsulfonyl-3-(2-(N-benzylsulfonyl-N-methylamino)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide

TLC: Rf 0.45 (chloroform:methanol=10:1).

EXAMPLE 10(136)(2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(N-benzylsulfonyl-N-methylamino)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide

TLC: Rf 0.49 (chloroform:methanol=10:1).

EXAMPLE 10(137)N-(3,4-difluorophenylsulfonyl)-3-(2-((2-(naphthalen-1-yl)acetyl)amino)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.44 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 12.3 (s, 1H), 9.90 (s, 1H), 8.12 (m, 1H),7.96-7.40 (m, 1H) 7.27 (s, 1H), 7.06 (d, J=8.1 Hz, 1H), 6.87 (d, J=8.1Hz, 1H), 6.22 (dd, J=2.1, 1.8 Hz, 1H), 5.21 (s, 2H), 4.13 (s, 2H), 2.68(m, 2H), 2.40 (m, 2H).

EXAMPLE 10(138)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(thiophen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.27 (hexane:ethyl acetate=1:1).

EXAMPLE 10(139)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(thiophen-3-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.28 (hexane:ethyl acetate=1:1).

EXAMPLE 10(140)N-(tetrazol-5-yl)-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanamide

TLC: Rf 0.33 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.62 (s, 1H), 7.44 (m, 1H), 7.34-7.22 (m, 2H),6.98 (s, 2H), 6.88 (s, 1H), 6.79 (s, 1H), 6.76 (d, J=8.1 Hz, 1H), 6.34(d, J=8.4 Hz, 1H), 5.24 (m, 1H), 5.09 (s, 2H), 3.24-2.98 (m, 2H),2.94-2.72 (m, 2H), 2.32 (s, 3H), 2.28 (s, 6H), 1.90-1.50 (m, 3H),1.06-0.97 (m, 6H).

EXAMPLE 10(141)N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanamide

TLC: Rf 0.57 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.70-7.55 (m, 3H), 7.35 (d, J=8.1 Hz, 1H),7.31-7.24 (m, 1H), 7.21-7.10 (m, 2H), 6.99 (s, 2H), 7.00-6.92 (m, 1H),6.82 (s, 1H), 6.77 (d, J=8.1 Hz, 1H), 6.28 (d, J=8.4 Hz, 1H), 5.21 (m,1H), 5.09 (s, 2H), 3.02-2.81 (m, 2H), 2.67-2.52 (m, 2H), 2.34 (s, 9H),1.90-1.45 (m, 3H), 1.02 (d, J=6.0 Hz, 6H).

EXAMPLE 10(142)N-(3,4-difluorophenylsulfonyl)-2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyloxy)acetamide

TLC: Rf 0.34 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.86-7.66 (m, 6H), 7.57 (d, J=1.8 Hz, 1H),7.49-7.38 (m, 4H), 7.30-7.13 (m, 2H), 6.82-6.75 (m, 2H), 6.30 (t, J=2.1Hz, 1H), 5.31 (s, 2H), 4.44 (s, 2H), 4.36 (t, J=6.6 Hz, 2H), 3.85 (s,2H), 3.27 (t, J=6.6 Hz, 2H).

EXAMPLE 10(143)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-dimethylaminomethylphenyl)propanamide

TLC: Rf 0.52 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 8.31 (s, 1H), 7.86-7.73 (m, 5H), 7.62 (m, 1H),7.51-7.42 (m, 4H), 7.04 (d, J=8.1 Hz, 1H), 6.99 (brs, 1H), 6.80 (d,J=8.1 Hz, 1H), 4.22-4.18 (m, 2H), 3.97 (brs, 2H), 3.23-3.19 (m, 2H),2.69-2.64 (m, 2H), 2.55 (s, 6H), 2.26-2.20 (m, 2H).

EXAMPLE 10(144)N-(3,4-difluorophenylsulfonyl)-3-(2-(3-cyclohexylpropoxy)-4-(pyrazol1-ylmethyl)phenyl)propanamide

TLC: Rf 0.60 (chloroform:methanol 9:1);

NMR (300 MHz, CDCl₃): δ 8.86 (br s, 1H), 7.83-7.72 (m, 2H), 7.54 (d,J=2.1 Hz, 1H), 7.42 (d, J=2.1 Hz, 1H), 7.32-7.23 (m, 1H), 6.88 (d, J=7.8Hz, 1H), 6.66 (s, 1H), 6.61 (d, J=7.8 Hz, 1H), 6.30 (t, J=2.1 Hz, 1H),5.27 (s, 2H), 3.88 (t, J=6.6 Hz, 2H), 2.82 (t, J=7.2 Hz, 2H), 2.50 (t,J=7.2 Hz, 2H), 1.78-1.69 (m, 7H), 1.30-1.19 (m, 6H), 0.94-0.84 (m, 2H).

EXAMPLE 10(145)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-phenoxyethoxy)-4-(pyrazol1-ylmethyl)phenyl)propanamide

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.95 (br s, 1H), 7.64-7.54 (m, 3H), 7.42 (d,J=2.1 Hz, 1H), 7.36-7.30 (m, 2H), 7.24-7.15 (m, 1H), 7.06-6.93 (m, 4H),6.70-6.66 (m, 2H), 6.29 (t, J=2.1 Hz, 1H), 5.28 (s, 2H), 4.38-4.35 (m,2H), 4.30-4.28 (m, 2H), 2.84 (t, J=7.2 Hz, 2H), 2.52 (t, J=7.2 Hz, 2H).

EXAMPLE 10(146)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-methyl-2-oxoimidazolidin-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.42 (hexane:ethyl acetate:methanol=2:6:1).

EXAMPLE 10(147)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-benzoylaminophenyl)propanamide

TLC: Rf 0.50 (chloroform:methanol=19:1).

EXAMPLE 10(148)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylsulfonylaminophenyl)propanamide

TLC: Rf 0.38 (chloroform:methanol=9:1).

EXAMPLE 10(149)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-mesylaminophenyl)propanamide

TLC: Rf 0.29 (chloroform:methanol=9:1).

EXAMPLE 10(150)N-(3,4-difluorophenylsulfonyl)-3-(2-(naphthalen-1-ylcarbamoylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.44 (hexane:ethyl acetate:methanol=2:6:1).

EXAMPLE 10(151)N-(3,4-difluorophenylsulfonyl)-3-(2-(benzylcarbamoylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.37 (hexane:ethyl acetate:methanol=2:6:1).

EXAMPLE 10(152)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-methylbenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.40 (hexane:ethyl acetate:methanol=2:6:1).

EXAMPLE 10(153)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-chlorobenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.44 (hexane:ethyl acetate:methanol=2:6:1).

EXAMPLE 10(154)N-(3,4-difluorophenylsulfonyl)-3-(2-(3-phenylpropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.77 (chloroform:methanol=10:1).

EXAMPLE 10(155)N-(3,4-difluorophenylsulfonyl)-3-(2-(4-phenylbutoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.76 (chloroform:methanol=10:1).

EXAMPLE 10(156)(2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-oxopyrrolidin-1-ylmethyl)phenyl)-2-propenamide

TLC: Rf 0.70 (chloroform:methanol=10:1).

EXAMPLE 10(157)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-(piperidin-1-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

[Salt-Free]

TLC: Rf 0.45 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.74-7.68 (m, 2H), 7.55 (s, 1H), 7.40 (d, J=2.1Hz, 1H), 7.27-7.19 (m, 2H), 6.95-6.93 (m, 2H), 6.85 (s, 1H), 6.77 (d,J=7.5 Hz, 1H), 6.66-6.61 (m, 2H), 6.29 (t, J=2.1 Hz, 1H), 5.26 (s, 2H),4.21 (t, J=6.0 Hz, 2H), 3.25-3.22 (m, 4H), 3.03 (t, J=6.0 Hz, 2H), 2.66(t, J=7.5 Hz, 2H), 2.15 (t, J=7.5 Hz, 2H), 1.76-1.70 (m, 4H), 1.64-1.58(m, 2H).

Sodium Salt:

TLC: Rf 0.50 (n-hexane:ethyl acetate=1:2).

EXAMPLE 10(158)(2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-cyanomethylphenyl)-2-propenamide

TLC: Rf 0.71 (chloroform:methanol=10:1).

EXAMPLE 10(159)N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(morpholin-4-ylmethyl)phenyl)propanamide

TLC: Rf 0.48 (ethyl acetate:methanol=10:1).

EXAMPLE 10(160)N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanamide

TLC: Rf 0.29 (hexane:ethyl acetate=1:1).

EXAMPLE 10(161)N-(3,4-difluorophenylsulfonyl)-2-(2-(3-(naphthalen-2-yl)propyl)-4-(pyrazol1-ylmethyl)phenoxy)acetamide

TLC: Rf 0.34 (ethyl acetate).

EXAMPLE 10(162)(2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(thiophen-3-ylmethyl)phenyl)-2-propenamide

TLC: Rf 0.65 (hexane:ethyl acetate=1:1).

EXAMPLE 10(163)(2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-benzylphenyl)-2-propenamide

TLC: Rf 0.64 (hexane:ethyl acetate=1:1).

EXAMPLE 10(164)(2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-benzoyl-N-methylaminomethyl)phenyl)-2-propenamide

TLC: Rf 0.49 (hexane:ethyl acetate=1:3).

EXAMPLE 10(165)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-phenylethoxy)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanamide

TLC: Rf 0.74 (hexane:ethyl acetate 1:1);

NMR (300 MHz, CDCl₃): δ 7.83-7.70 (m, 3H), 7.40-7.24 (m, 7H), 7.05 (s,1H), 6.93 (d, J=7.8 Hz, 1H), 6.84-6.80 (m, 2H), 6.73 (d, J=7.8 Hz, 1H),5.06 (s, 2H), 4.31 (t, J=6.3 Hz, 2H), 3.13 (t, J=6.3 Hz, 2H), 2.76-2.71(m, 2H), 2.31 (s, 3H), 2.20-2.15 (m, 2H).

EXAMPLE 10(166)N-(3,4-difluorophenylsulfonyl)-2-(N′-methyl-N′-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)amino)acetamide

TLC: Rf 0.73 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.94 (m, 1H), 7.89-7.74 (m, 4H), 7.64 (s, 1H),7.54 (d, J=1.8 Hz, 1H), 7.52-7.41 (m, 2H), 7.37 (d, J=2.4 Hz, 1H),7.35-7.16 (m, 2H), 6.93 (d, J=1.3 Hz, 1H), 6.81-6.71 (m, 2H), 6.27 (t,J=1.8 Hz, 1H), 5.23 (s, 2H), 4.24 (t, J=7.5 Hz, 2H), 3.47 (s, 2H), 3.18(t, J=7.5 Hz, 2H), 2.64 (s, 3H).

EXAMPLE 10(167)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N′-acetyl-N′-methylaminomethyl)phenyl)propanamide

TLC: Rf 0.46 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.88-7.69 (m, 6H), 7.51-7.38 (m, 3H), 7.26 (m,1H), 6.96 (d, J=7.5 Hz, 0.4H), 6.87 (d, J=7.2 Hz, 0.6H), 6.70 (s, 0.6H),6.60-6.56 (m, 1.4H), 4.44 (s, 2H), 4.28 (t, J=6.0 Hz, 0.8H), 4.20 (t,J=6.3 Hz, 1.2H), 3.27 (t, J=6.0 Hz, 0.8H), 3.22 (t, J=6.3 Hz, 1.2H),2.88 (s, 1.2H), 2.87 (s, 1.8H), 2.75 (t, J=7.5 Hz, 2H), 2.25 (t, J=7.5Hz, 1.2H), 2.17-2.12 (m, 3.8H).

EXAMPLE 10(168)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N′-ethoxycarbonyl-N′-methylamino methyl)phenyl)propanamide

TLC: Rf 0.48 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.86-7.68 (m, 6H), 7.53-7.41 (m, 3H), 7.25 (m,1H), 6.90 (d, J=7.2 Hz, 1H), 6.77-6.63 (m, 2H), 4.39 (s, 2H), 4.34-4.30(m, 2H), 4.18 (q, J=7.2 Hz, 2H), 3.30-3.26 (m, 2H), 2.82 (brs, 3H),2.73-2.68 (m, 2H), 2.11-2.07 (m, 2H), 1.27 (t, J=7.2 Hz, 3H).

EXAMPLE 10(169)N-(3,4-difluorophenylsulfonyl)-3-(2-((2E)-3-phenyl-2-propenyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.40 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 9.01 (br, 1H), 7.82-7.69 (m, 2H), 7.53 (d, J=2.1Hz, 1H), 7.42-7.17 (m, 7H), 6.92 (d, J=7.5 Hz, 1H), 6.73-6.62 (m, 3H),6.34 (dt, J=15.9, 5.7 Hz, 1H), 6.27 (t, J=2.1 Hz, 1H), 5.28 (s, 2H),4.63 (dd, J=5.7, 1.2 Hz, 2H), 2.86 (t, J=7.5 Hz, 2H), 2.51 (t, J=7.5 Hz,2H).

EXAMPLE 10(170)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(N′-methyl-N′-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.33 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 7.81-7.70 (m, 2H), 7.53 (d, J=2.1 Hz, 1H), 7.39(d, J=2.1 Hz, 1H), 7.31-7.20 (m, 3H), 6.89 (d, J=7.5 Hz, 1H), 6.80-6.70(m, 3H), 6.68-6.60 (m, 2H), 6.29 (t, J=2.1 Hz, 1H), 5.24 (s, 2H), 4.10(t, J=5.4 Hz, 2H), 3.75 (t, J=5.4 Hz, 2H), 2.98 (s, 3H), 2.72 (t, J=7.5Hz, 2H), 2.30 (t, J=7.5 Hz, 2H).

EXAMPLE 10(171)(2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(3-phenylpropyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide

TLC: Rf 0.33 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 10.6 (br, 1H), 8.01-7.89 (m, 2H), 7.73 (d,J=15.6 Hz, 1H), 7.58 (d, J=2.1 Hz, 1H), 7.55 (d, J=2.1 Hz, 1H),7.37-7.25 (m, 3H), 7.23-7.13 (m, 3H), 7.10-7.00 (m, 2H), 6.71 (m, 1H),6.36 (t, J=2.1 Hz, 1H), 5.69 (d, J=15.6 Hz, 1H), 5.34 (s, 2H), 2.65-2.55(m, 4H), 1.76 (m, 2H).

EXAMPLE 10(172)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-phenylethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide

TLC: Rf 0.52 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.83-7.76 (m, 2H), 7.41-7.25 (m, 8H), 7.20-7.18(m, 2H), 6.97 (d, J=7.5 Hz, 1H), 6.89 (brs, 1H), 6.82 (d, J=7.5 Hz, 1H),5.01 (s, 2H), 4.28 (t, J=6.3 Hz, 2H), 3.13 (t, J=6.3 Hz, 2H), 2.76 (t,J=7.5 Hz, 2H), 2.20 (t, J=7.5 Hz, 2H).

EXAMPLE 10(173)N-benzyl-N-hydroxy-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.45 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.80-7.65 (m, 4H), 7.55 (s, 1H), 7.50-7.20 (m,8H), 7.08 (d, J=7.5 Hz, 1H), 6.91 (m, 1H), 6.71 (d, J=6.6 Hz, 1H), 6.66(s, 1H), 6.27 (dd, J=2.1, 2.1 Hz, 1H), 5.25 (s, 2H), 4.14 (m, 4H), 3.17(m, 2H), 2.93 (s, 2H), 2.39 (m, 2H).

EXAMPLE 10(174)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(thiazol-2-ylaminomethyl)phenyl)propanamide

TLC: Rf 0.50 (hexane:ethyl acetate=1:2, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 7.89-7.65 (m, 6H), 7.53-7.46 (m, 2H), 7.40 (dd,J=8.4, 1.5 Hz, 1H), 7.28-7.18 (m, 1H), 7.11 (d, J=3.6 Hz, 1H), 6.91 (d,J=7.5 Hz, 1H), 6.86 (bs, 1H), 6.76 (d, J=7.5 Hz, 1H), 6.50 (d, J=3.6 Hz,1H), 4.41 (s, 2H), 4.31 (t, J=6.6 Hz, 2H), 3.25 (t, J=6.6 Hz, 2H), 2.70(t, J=7.2 Hz, 2H), 2.08 (t, J=7.2 Hz, 2H).

EXAMPLE 10(175)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxyphenyl)propanamide

TLC: Rf 0.75 (hexane:ethyl acetate=1:1).

EXAMPLE 10(176)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-2-yloxy)phenyl)propanamide

TLC: Rf 0.50 (hexane:ethyl acetate=1:1).

EXAMPLE 10(177)N-(3,4-difluorophenylsulfonyl)-5-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)pentanamide

[Salt-Free]

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.90-7.74 (m, 3H), 7.72-7.63 (m, 3H), 7.58-7.38(m, 6H), 6.95 (d, J=7.8 Hz, 1H), 6.72-6.66 (m, 2H), 6.28 (dd, J=2.1, 1.8Hz, 1H), 5.29 (s, 2H), 4.25 (t, J=6.6 Hz, 2H), 3.22 (t, J=6.6 Hz, 2H),2.40 (t, J=7.2 Hz, 2H), 1.63 (t, J=7.2 Hz, 2H), 1.35-1.18 (m, 4H).

Sodium Salt:

TLC: Rf 0.64 (chloroform:methanol=10:1).

EXAMPLE 10(178)(2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(pyrazol-1-ylmethyl)-3-(2-(naphthalen-2-yl)ethoxy)thiophen-4-yl)-2-propenamide

[Salt-Free]

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.01 (m, 1H), 7.95-7.65 (m, 7H), 7.54-7.37 (m,6H), 6.62 (d, J=15.6 Hz, 1H), 6.16 (t, J=2.1 Hz, 1H), 5.23 (s, 2H), 4.22(t, J=6.6 Hz, 2H), 3.28 (t, J=6.6 Hz, 2H).

Sodium Salt:

TLC: Rf 0.57 (chloroform:methanol=10:1).

EXAMPLE 10(179)(2E)-N-(3,4-difluorophenylsulfonyl)-3-(4-(pyrazol-1-ylmethyl)-3-(2-(naphthalen-2-yl)ethoxy)thiophen-2-yl)-2-propenamide

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.94-7.66 (m, 7H), 7.54-7.23 (m, 5H), 7.11 (m,1H), 7.05 (s, 1H), 6.17 (t, J=2.1 Hz, 1H), 5.86 (d, J=15.3 Hz, 1H), 4.96(s, 2H), 4.16 (t, J=6.6 Hz, 2H), 3.18 (t, J=6.6 Hz, 2H).

EXAMPLE 10(180)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(4-phenylpiperazin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

[Salt-Free]

TLC: Rf 0.58 (ethyl acetate:methanol=5:1).

Sodium Salt:

TLC: Rf 0.40 (chloroform:methanol=10:1).

EXAMPLE 10(181)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(4-phenyl-1,2,3,6-tetrahydropyridin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

[Salt-Free]

TLC: Rf 0.66 (ethyl acetate:methanol=5:1).

Sodium Salt:

TLC: Rf 0.37 (chloroform:methanol=10:1).

EXAMPLE 10(182)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(4-phenylpiperidin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.67 (ethyl acetate:methanol=5:1).

EXAMPLE 10(183)N-(3,4-difluorophenylsulfonyl)-4-(2-(2-phenylethoxy)-4-(3-cyanophenoxymethyl)phenyl)butanamide

TLC: Rf 0.70 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.96-7.80 (m, 2H), 7.42-7.14 (m, 10H), 7.03 (d,J=7.2 Hz, 1H), 6.94-6.85 (m, 2H), 5.01 (s, 2H), 4.23 (t, J=6.5 Hz, 2H),3.10 (t, J=6.5 Hz, 2H), 2.55 (t, J=7.0 Hz, 2H), 1.97 (t, J=7.0 Hz, 2H),1.80-1.64 (m, 2H).

EXAMPLE 10(184)N-(3,4-difluorophenylsulfonyl)-4-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)butanamide

[Salt-Free]

TLC: Rf 0.84 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.92-7.70 (m, 4H), 7.55-7.14 (m, 10H), 7.01 (d,J=7.5 Hz, 1H), 6.94-6.84 (m, 2H), 5.00 (s, 2H), 4.31 (t, J=6.3 Hz, 2H),3.26 (t, J=6.3 Hz, 2H), 2.49 (t, J=7.2 Hz, 2H), 1.81 (t, J=7.2 Hz, 2H),1.74-1.50 (m, 2H).

Sodium Salt:

TLC: Rf 0.74 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 7.90-7.78 (m, 5H), 7.68 (m, 1H), 7.62-7.30 (m,8H), 7.05 (s, 1H), 7.02 (d, J=7.5 Hz, 1H), 6.91 (d, J=7.5 Hz, 1H), 5.09(s, 2H), 4.25 (m, 2H), 3.20 (m, 2H), 2.40 (m, 2H), 2.02 (m, 2H), 1.59(m, 2H).

EXAMPLE 10(185)N-(3,4-difluorophenylsulfonyl)-3-(2-(5-phenylpentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.63 (chloroform:methanol=10:1).

EXAMPLE 10(186)N-(3,4-difluorophenylsulfonyl)-3-(2-(6-phenylhexyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.61 (chloroform:methanol=10:1).

EXAMPLE 10(187)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-hydroxymethylphenyl)propanamide

TLC: Rf 0.52 (chloroform:methanol 10:1).

EXAMPLE 10(188)N-(3,4-difluorophenylsulfonyl)-2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenoxy)acetamide

[Salt-Free]

TLC: Rf 0.40 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.93-7.71 (m, 6H), 7.57-7.36 (m, 5H), 7.25 (m,1H), 6.89-6.74 (m, 3H), 6.29 (t, J=2.3 Hz, 1H), 5.24 (s, 2H), 4.46 (s,2H), 4.35 (t, J=7.2 Hz, 2H), 3.35 (t, J=7.2 Hz, 2H).

Sodium Salt:

TLC: Rf 0.45 (chloroform:methanol=10:1).

EXAMPLE 10(189)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(pyrazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.40 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.90-7.80 (m, 2H), 7.56 (d, J=2.1 Hz, 1H), 7.53(d, J=2.1 Hz, 1H), 7.48 (d, J=2.1 Hz, 1H), 7.38 (d, J=2.1 Hz, 1H),7.33-7.24 (m, 1H), 6.99 (d, J=7.5 Hz, 1H), 6.69 (d, J=7.5 Hz, 1H), 6.56(s, 1H), 6.35 (t, J=2.1 Hz, 1H), 6.27 (t, J=2.1 Hz, 1H), 5.24 (s, 2H),4.59 (t, J=4.2 Hz, 2H), 4.23 (t, J=4.2 Hz, 2H), 2.83-2.77 (m, 2H),2.43-2.38 (m, 2H).

EXAMPLE 10(190)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(2-methylimidazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.30 (chloroform:methanol=4:1);

NMR (300 MHz, CDCl₃): δ 7.97-7.84 (m, 2H), 7.53 (d, J=2.1 Hz, 1H), 7.38(d, J=2.1 Hz, 1H), 7.28-7.19 (m, 1H), 7.06-6.97 (m, 3H), 6.73 (d, J=7.8Hz, 1H), 6.58 (s, 1H), 6.28 (t, J=2.1 Hz, 1H), 5.23 (s, 2H), 4.32 (t,J=5.1 Hz, 2H), 4.14 (t, J=5.1 Hz, 2H), 2.64 (t, J=8.4 Hz, 2H), 2.52 (s,3H), 1.86 (t, J=8.4 Hz, 2H).

EXAMPLE 10(191)N-(3,4-difluorophenylsulfonyl)-2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzoylamino)acetamide

TLC: Rf 0.30 (chloroform:methanol=4:1);

NMR (300 MHz, DMSO-d₆): δ 8.38-8.35 (m, 1H), 7.92-7.71 (m, 8H),7.52-7.43 (m, 5H), 7.05 (s, 1H), 6.74 (d, J=8.1 Hz, 1H), 6.26 (t, J=2.1Hz, 1H), 5.33 (s, 2H), 4.37 (t, J=6.6 Hz, 2H), 3.76 (d, J=4.5 Hz, 2H),3.33-3.29 (m, 2H).

EXAMPLE 10(192)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(N-ethyl-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.32 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.82-7.70 (m, 2H), 7.54 (d, J=1.8 Hz, 1H), 7.38(d, J=2.1 Hz, 1H), 7.32-7.20 (m, 3H), 6.92 (d, J=7.5 Hz, 1H), 6.78-6.63(m, 5H), 6.28 (dd, J=2.1, 1.8 Hz, 1H), 5.24 (s, 2H), 4.10 (t, J=5.7 Hz,2H), 3.71 (t, J=5.7 Hz, 2H), 3.42 (q, J=6.9 Hz, 2H), 2.77 (t, J=7.5 Hz,2H), 2.35 (t, J=7.5 Hz, 2H), 1.16 (t, J=6.9 Hz, 3H).

EXAMPLE 10(193)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(N-(2-hydroxyethyl)-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.41 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.86-7.74 (m, 2H), 7.53 (d, J=2.1 Hz, 1H), 7.37(d, J=2.4 Hz, 1H), 7.32-7.24 (m, 3H), 6.96 (d, J=7.8 Hz, 1H), 6.87-6.80(m, 3H), 6.71-6.64 (m, 2H), 6.27 (dd, J=2.4, 2.1 Hz, H), 5.22 (s, 2H),4.18 (t, J=4.5 Hz, 2H), 3.95 (t, J=4.8 Hz, 2H), 3.80 (t, J=4.5 Hz, 2H),3.64 (t, J=4.8 Hz, 2H), 2.83 (t, J=7.5 Hz, 2H), 2.36 (t, J=7.5 Hz, 2H).

EXAMPLE 10(194)N-(3,4-difluorophenylsulfonyl)-3-(2-(3-(N-methyl-N-phenylamino)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.30 (chloroform:methanol=19:1);

NMR (300 MHz, CDCl₃): δ 7.82-7.68 (m, 2H), 7.54 (d, J=1.8 Hz, 1H), 7.40(d, J=1.8 Hz, 1H), 7.30-7.16 (m, 3H), 6.93 (d, J=8.1 Hz, 1H), 6.74-6.60(m, 5H), 6.29 (dd, J=1.8, 1.8 Hz, 1H), 5.25 (s, 2H), 3.97 (t, J=6.0 Hz,2H), 3.48 (t, J=6.9 Hz, 2H), 2.92 (s, 3H), 2.87 (t, J=7.2 Hz, 2H), 2.51(t, J=7.2 Hz, 2H), 2.05 (m, 2H).

EXAMPLE 10(195)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(1-hydroxy-1-methylethyl)phenyl)propanamide

TLC: Rf 0.58 (chloroform:methanol=10:1).

EXAMPLE 10(196)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propynamide

[Salt-Free]

TLC: Rf 0.78 (chloroform:methanol:acetic acid=18:1:1).

Sodium Salt:

TLC: Rf 0.17 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 7.94-7.76 (m, 5H), 7.69 (m, 1H), 7.63-7.38 (m,6H), 7.31(d, J=8.1 Hz, 1H), 6.91 (s, 1H), 6.66 (d, J=7.5 Hz, 1H), 6.27(t, J=2.1 Hz, 1H), 5.31 (s, 2H), 4.21 (m, 2H), 3.19 (m, 2H).

EXAMPLE 10(197)N-phenylsulfonyl-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanamide

TLC: Rf 0.55 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.88 (dd, J=7.8, 1.8 Hz, 2H), 7.55 (m, 1H),7.45-7.30 (m, 1H), 7.13 (d, J=7.8 Hz, 1H), 7.03-6.96 (m, 3H), 6.26 (d,J=8.4 Hz, 1H), 5.27 (dt, J=8.4, 8.4 Hz, 1H), 5.02 (s, 2H), 2.96-2.75 (m,2H), 2.50 (dt, J=1.8, 8.1 Hz, 2H), 1.90-1.55 (m, 3H), 1.02 (d, J=6.6 Hz,3H), 1.01 (d, J=6.6 Hz, 3H).

EXAMPLE 10(198)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-hydroxy-2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide

TLC: Rf 0.41 (hexane:ethyl acetate=1:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 7.98-7.86 (m, 4H), 7.82-7.72 (m, 2H), 7.60-7.52(m, 3H), 7.36 (m, 1H), 7.30-7.14 (m, 4H), 7.06 (d, J=8.1 Hz, 1H),6.90-6.84 (m, 2H), 5.46 (dd, J=8.7, 3.0 Hz, 1H), 4.98 (s, 2H), 4.30 (dd,J=9.9, 3.0 Hz, 1H), 4.19 (dd, J=9.9, 8.7 Hz, 1H), 3.05-2.80 (m, 2H),2.70-2.45 (m, 2H).

EXAMPLE 10(199)N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-(morpholin-4-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.40 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.75-7.69 (m, 2H), 7.55 (d, J=2.1 Hz, 1H), 7.40(d, J=2.1 Hz, 1H), 7.30-7.23 (m, 2H), 6.94-6.80 (m, 4H), 6.67-6.62 (m,2H), 6.29 (t, J=2.1 Hz, 1H), 5.26 (s, 2H), 4.21 (t, J=6.0 Hz, 2H),3.89-3.86 (m, 4H), 3.21-3.18 (m, 4H), 3.05 (t, J=6.0 Hz, 2H), 2.69 (t,J=7.5 Hz, 2H), 2.20 (t, J=7.5 Hz, 2H).

EXAMPLE 10(200)N-(3,4-difluorophenylsulfonyl)-3-(2-(5-phenylpentyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.60 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 9.12 (brs, 1H), 7.88-7.78 (m, 2H), 7.53 (d,J=2.1 Hz, 1H), 7.43 (d, J=2.1 Hz, 1H), 7.33-7.25 (m, 3H), 7.20-7.15 (m,3H), 6.96 (s, 1H), 6.82 (s, 2H), 6.30 (t, J=2.1 Hz, 1H), 5.26 (s, 2H),2.80 (t, J=7.8 Hz, 2H), 2.59 (t, J=7.8 Hz, 2H), 2.43 (t, J=7.8 Hz, 2H),2.33 (t, J=7.8 Hz, 2H), 1.65-1.56 (m, 2H), 1.54-1.44 (m, 2H), 1.39-1.31(m, 2H).

EXAMPLE 10(201)N-(3,4-difluorophenylsulfonyl)-3-(2-(5-phenyl-1-pentenyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.60 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 8.82 (brs, 1H), 7.85-7.75 (m, 2H), 7.54 (d,J=2.1 Hz, 1H), 7.43 (d, J=2.1 Hz, 1H), 7.32-7.18 (m, 7H), 6.85 (s, 2H),6.42 (d, J=15.6 Hz, 1H), 6.30 (t, J=2.1 Hz, 1H), 6.05 (dt, J=15.6, 6.9Hz, 1H), 5.27 (s, 2H), 2.86 (t, J=7.8 Hz, 2H), 2.65 (t, J=7.8 Hz, 2H),2.36 (t, J=7.8 Hz, 2H), 2.25-2.18 (m, 2H), 1.83-1.72 (m, 2H).

EXAMPLE 10(202)N-(3,4-difluorophenylsulfonyl)-3-(2-(5-phenyl-1-pentynyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.60 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 8.41 (brs, 1H), 7.84-7.71 (m, 2H), 7.55 (d,J=2.1 Hz, 1H), 7.41 (d, J=2.1 Hz, 1H), 7.33-7.18 (m, 7H), 6.96-6.95 (m,2H), 6.30 (t, J=2.1 Hz, 1H), 5.24 (s, 2H), 3.01 (t, J=7.2 Hz, 2H), 2.74(t, J=7.2 Hz, 2H), 2.56 (t, J=7.2 Hz, 2H), 2.42 (t, J=7.2 Hz, 2H),1.95-1.85 (m, 2H).

EXAMPLE 10(203)N-(3,4-difluorophenylsulfonyl)-3-(2-(N-benzoylpiperazin-1-yl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.60 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 7.69-7.61 (m, 2H), 7.54 (d, J=2.1 Hz, 1H), 7.42(s, 6H), 7.25-7.16 (m, 1H), 7.02 (d, J=8.1 Hz, 1H), 6.91 (s, 1H), 6.83(d, J=8.1 Hz, 1H), 6.30 (t, J=2.1 Hz, 1H), 5.27 (s, 2H), 3.87 (m, 2H),3.56 (m, 2H), 2.92-2.84 (m, 6H), 2.59 (t, J=7.2 Hz, 2H).

EXAMPLE 10(204)N-(3,4-difluorophenylsulfonyl)-2-(1-(1-(naphthalen-1-yl)ethylcarbonyl)indol-3-yl)acetamide

TLC: Rf 0.71 (ethyl acetate:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.62 (d, J=8.1 Hz, 1H), 8.19 (d, J=8.7 Hz, 1H),7.95 (d, J=8.1 Hz, 1H), 7.80 (m, 1H), 7.72-7.58 (m, 4H), 7.46-7.35 (m,3H), 7.21 (d, J=7.5 Hz, 1H), 7.19 (d, J=7.2 Hz, 1H), 7.11 (d, J=7.5 Hz,1H), 7.05 (s, 1H), 5.16 (q, J=6.6 Hz, 1H), 3.40 (s, 2H), 1.75 (d, J=6.6Hz, 3H).

EXAMPLE 10(205)N-(3,4-difluorophenylsulfonyl)-2-(2-methyl-1-(1-(naphthalen-1-yl)ethylcarbonyl)indol-3-yl)acetamide

TLC: Rf 0.77 (ethyl acetate:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.01 (d, J=7.5 Hz, 1H), 7.92 (d, J=8.1 Hz, 1H),7.82-7.77 (m, 2H), 7.74-7.52 (m, 4H), 7.47 (d, J=6.0 Hz, 1H), 7.40 (dd,J=7.8, 7.8 Hz, 1H), 7.24-7.06 (m, 4H), 5.38 (q, J=6.9 Hz, 1H), 3.57 (s,2H), 2.41 (s, 3H), 1.81 (d, J=6.9 Hz, 3H).

EXAMPLE 10(206)N-(3,4-difluorophenylsulfonyl)-3-(1-(1-(naphthalen-1-yl)ethylcarbonyl)indol-3-yl)propanamide

TLC: Rf 0.87 (ethyl acetate:methanol=8:1);

NMR (300 MHz, CDCl₃): δ 8.58 (d, J=8.4 Hz, 1H), 8.21 (d, J=7.8 Hz, 1H),7.94 (d, J=9.0 Hz, 1H), 7.84-7.64 (m, 4H), 7.59 (dd, J=7.5, 7.5 Hz, 1H),7.42-7.17 (m, 6H), 6.89 (s, 1H), 5.11 (q, J=6.6 Hz, 1H), 2.72 (m, 2H),2.30 (m, 2H), 1.73 (d, J=6.6 Hz, 3H).

EXAMPLE 10(207)N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methoxymethylphenyl)propanamide

TLC: Rf 0.45 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.68-7.60 (m, 2H), 7.44-7.08 (m, 9H), 6.30 (d,J=9.3 Hz, 1H), 5.27 (m, 1H), 4.42 (s, 2H), 3.44 (s, 3H), 3.00-2.76 (m,2H), 2.64-2.48 (m, 2H), 1.92-1.70 (m, 3H), 1.02 (d, J=6.6 Hz, 3H), 1.01(d, J=6.6 Hz, 3H).

EXAMPLE 10(208)N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methylsulfonylaminophenyl)propanamide

TLC: Rf 0.30 (n-hexane:ethyl acetate=1:2).

EXAMPLE 10(209)N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(N-methyl-N-methylsulfonylamino)phenyl)propanamide

TLC: Rf 0.30 (n-hexane:ethyl acetate=1:2).

EXAMPLE 10(210)N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methoxycarbonylaminophenyl)propanamide

TLC: Rf 0.60 (n-hexane:ethyl acetate=1:2).

EXAMPLE 10(211) N-(3,4-difluorophenylsulfonyl)-3-(4-cyano-2-((3-methyl-1-phenylbutyl)carbamoyl)phenyl)propanamide

TLC: Rf 0.54 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.84-7.70 (m, 2H), 7.64 (d, J=1.8 Hz, 1H), 7.59(dd, J=7.8, 1.8 Hz, 1H), 7.46-7.20 (m, 7H), 6.34 (d, J=7.8 Hz, 1H), 5.23(m, 1H), 3.02-2.80 (m, 2H), 2.51 (t, J=7.4 Hz, 2H), 1.92-1.46 (m, 3H),1.03 (d, J=5.9 Hz, 3H), 1.01 (d, J=5.9 Hz, 3H).

EXAMPLE 10(212)N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-isopropylsulfonyloxyphenyl)propanamide

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 12.30 (brs, 1H), 8.88 (d, J=8.4 Hz, 1H), 7.94(m, 1H), 7.80-7.68 (m, 2H), 7.33-7.19 (m, 7H), 7.08 (d, J=2.1 Hz, 1H),4.98 (m, 1H), 3.75 (quint, J=6.9 Hz, 1H), 2.76-2.71 (m, 2H), 2.54-2.49(m, 2H), 1.75-1.38 (m, 3H), 1.41 (d, J=6.9 Hz, 6H), 0.87-0.83 (m, 6H).

EXAMPLE 10(213)N-(3-fluorophenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.43 (chloroform:methanol 10:1);

NMR (300 MHz, DMSO-d₆): δ 8.62 (t, J=5.4 Hz, 1H), 7.77 (d, J=2.1 Hz,1H), 7.72-7.53 (m, 4H), 7.45-7.30 (m, 4H), 7.07 (m, 1H), 6.86 (d, J=8.1Hz, 1H), 6.85 (s, 1H), 6.56 (d, J=8.1 Hz, 1H), 6.24 (t, J=2.1 Hz, 1H),5.22 (s, 2H), 4.06-3.97 (m, 2H), 3.78 (s, 3H), 3.65-3.56 (m, 2H), 2.66(t, J=7.2 Hz, 2H), 2.46 (t, J=7.2 Hz, 2H).

EXAMPLE 10(214)N-(4-fluorophenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.44 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.62 (t, J=5.4 Hz, 1H), 7.96-7.87 (m, 2H),7.77 (d, J=2.1 Hz, 1H), 7.47-7.30 (m, 6H), 7.07 (m, 1H), 6.86 (d, J=7.8Hz, 1H), 6.84 (s, 1H), 6.56 (d, J=7.8 Hz, 1H), 6.24 (t, J=2.1 Hz, 1H),5.23 (s, 2H), 4.02 (t, J=5.7 Hz, 2H), 3.78 (s, 3H), 3.65-3.56 (m, 2H),2.65 (t, J=7.2 Hz, 2H), 2.44 (t, J=7.2 Hz, 2H).

EXAMPLE 10(215)N-(4-methylphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.44 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.62 (t, J=5.7 Hz, 1H), 7.77 (d, J=2.1 Hz,1H), 7.72 (d, J=8.1 Hz, 2H), 7.47-7.31 (m, 6H), 7.07 (m, 1H), 6.86 (s,1H), 6.84 (d, J=7.2 Hz, 1H), 6.55 (d, J=7.2 Hz, 1H), 6.24 (t, J=2.1 Hz,1H), 5.23 (s, 2H), 4.01 (t, J=5.4 Hz, 2H), 3.78 (s, 3H), 3.64-3.55 (m,2H), 2.64 (t, J=7.5 Hz, 2H), 2.44 (t, J=7.5 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 10(216)N-(3-nitrophenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.61 (t, J=5.4 Hz, 1H), 8.57 (s, 1H), 8.52 (d,J=7.8 Hz, 1H), 8.25 (d, J=7.8 Hz, 1H), 7.89 (t, J=7.8 Hz, 1H), 7.76 (d,J=2.1 Hz, 1H), 7.45-7.28 (m, 4H), 7.07 (m, 1H), 6.85 (d, J=8.4 Hz, 1H),6.84 (s, 1H), 6.53 (d, J=8.4 Hz, 1H), 6.23 (t, J=2.1 Hz, 1H), 5.21 (s,2H), 4.01 (t, J=5.7 Hz, 2H), 3.77 (s, 3H), 3.64-3.54 (m, 2H), 2.65 (t,J=7.2 Hz, 2H), 2.46 (t, J=7.2 Hz, 2H).

EXAMPLE 10(217)N-(3-cyanophenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.62 (t, J=5.4 Hz, 1H), 8.25 (s, 1H), 8.17 (d,J=8.1 Hz, 1H), 8.13 (d, J=8.1 Hz, 1H), 7.80 (t, J=8.1 Hz, 1H), 7.76 (d,J=2.1 Hz, 1H), 7.77 (d, J=2.1 Hz, 1H), 7.46-7.30 (m, 4H), 7.07 (m, 1H),6.85 (d, J=7.8 Hz, 1H), 6.84 (s, 1H), 6.56 (d, J=7.8 Hz, 1H), 6.24 (t,J=2.1 Hz, 1H), 5.23 (s, 2H), 4.02 (t, J=5.4 Hz, 2H), 3.78 (s, 3H),3.66-3.56 (m, 2H), 2.65 (t, J=6.9 Hz, 2H), 2.45 (t, J=7.2 Hz, 2H).

EXAMPLE 10(218)N-(3-methylphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.62 (t, J=5.4 Hz, 1H), 7.77 (d, J=2.1 Hz,1H), 7.69-7.60 (m, 2H), 7.52-7.30 (m, 6H), 7.07 (m, 1H), 6.86 (d, J=7.8Hz, 1H), 6.85 (s, 1H), 6.56 (d, J=7.8 Hz, 1H), 6.24 (t, J=2.1 Hz, 1H),5.22 (s, 2H), 4.02 (t, J=5.7 Hz, 2H), 3.78 (s, 3H), 3.65-3.55 (m, 2H),2.65 (t, J=7.2 Hz, 2H), 2.43 (t, J=7.2 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 10(219)N-(3-methoxyphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.44 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.63 (t, J=5.4 Hz, 1H), 7.77 (d, J=2.1 Hz,1H), 7.53-7.23 (m, 9H), 7.07 (m, 1H), 6.86 (d, J=7.8 Hz, 1H), 6.85 (s,1H), 6.56 (d, J=7.8 Hz, 1H), 6.24 (t, J=2.1 Hz, 1H), 5.23 (s, 2H), 4.02(t, J=5.7 Hz, 2H), 3.80 (s, 3H), 3.78 (s, 3H), 3.65-3.56 (m, 2H), 2.66(t, J=7.2 Hz, 2H), 2.44 (t, J=7.2 Hz, 2H).

EXAMPLE 10(220)N-(3-trifluoromethylphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.43 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.62 (t, J=5.4 Hz, 1H), 8.16-8.07 (m, 3H),7.85 (t, J=8.1 Hz, 1H), 7.76 (d, J=2.1 Hz, 1H), 7.46-7.28 (m, 4H), 7.08(m, 1H), 6.85 (s, 1H), 6.83 (d, J=7.8 Hz, 1H), 6.53 (d, J=7.8 Hz, 1H),6.24 (t, J=2.1 Hz, 1H), 5.23 (s, 2H), 4.01(t, J=5.7 Hz, 2H), 3.77 (s,3H), 3.65-3.55 (m, 2H), 2.65 (t, J=6.9 Hz, 2H), 2.46 (t, J=6.9 Hz, 2H).

EXAMPLE 10(221)N-(3-methoxycarbonylphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.44 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.61 (t, J=5.4 Hz, 1H), 8.40 (s, 1H), 8.23 (d,J=7.8 Hz, 1H), 8.09 (d, J=7.8 Hz, 1H), 7.78-7.69 (m, 2H), 7.44-7.29 (m,4H), 7.06(m, 1H), 6.84 (s, 1H), 6.83 (d, J=7.5 Hz, 1H), 6.53 (d, J=7.5Hz, 1H), 6.24 (t, J=2.1 Hz, 1H), 5.21 (s, 2H), 4.01(t, J=5.7 Hz, 2H),3.90 (s, 3H), 3.77 (s, 3H), 3.64-3.55 (m, 2H), 2.64 (t, J=7.2 Hz, 2H),2.44 (t, J=7.2 Hz, 2H).

EXAMPLE 10(222)N-(3-carboxyphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide

TLC: Rf 0.21 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 8.62 (t, J=5.4 Hz, 1H), 8.40 (s, 1H), 8.22 (d,J=7.8 Hz, 1H), 8.06 (d, J=7.8 Hz, 1H), 7.79-7.69 (m, 2H), 7.46-7.30 (m,4H), 7.06(m, 1H), 6.84 (s, 1H), 6.83 (d, J=7.5 Hz, 1H), 6.53 (d, J=7.5Hz, 1H), 6.24 (t, J=2.1 Hz, 1H), 5.21 (s, 2H), 4.01(t, J=5.7 Hz, 2H),3.77 (s, 3H), 3.64-3.55 (m, 2H), 2.64 (t, J=7.2 Hz, 2H), 2.44 (t, J=7.2Hz, 2H).

EXAMPLE 10(223)N-(3,4-difluorophenylsulfonyl)-3-(6-cyano-1-(1-(naphthalen-1-yl)ethylcarbonyl)indol-3-yl)propanamide

TLC: Rf 0.46 (n-hexane:ethyl acetate:acetic acid=100:100:1);

NMR (300 MHz, DMSO-d₆): δ 12.25 (brs, 1H), 8.70 (s, 1H), 8.24 (d, J=8.7Hz, 1H), 7.98 (m, 1H), 7.89-7.82 (m, 2H), 7.84-7.72 (m, 3H), 7.68-7.55(m, 4H), 7.44 (t, J=7.5 Hz, 1H), 7.38 (m, 1H), 5.50 (q, J=6.9 Hz, 1H),2.80-2.60 (m, 2H), 2.57-2.43 (m, 2H), 1.63 (d, J=6.9 Hz, 3H).

EXAMPLE 10(224)N-(3,4-difluorophenylsulfonyl)-2-(5-(pyrazol-1-ylmethyl)-2-(naphthalen-1-ylmethyl)isoindolin-3-one-1-yl)acetamide

TLC: Rf 0.40 (ethyl acetate:methanol=8:1);

NMR (300 MHz, CDCl₃): δ 7.91 (d, J=9.0 Hz, 1H), 7.75 (d, J=7.5 Hz, 1H),7.67 (m, 2H), 7.50-7.00 (m, 10H), 6.87 (brs, 1H), 6.15 (s, 1H), 5.68 (d,J=15.1 Hz, 1H), 5.15 (s, 2H), 4.52 (d, J=15.1 Hz, 1H), 4.31 (s, 1H),2.80-2.60 (m, 2H).

EXAMPLE 10(225)N-(3,4-difluorophenylsulfonyl)-2-(5-phenoxymethyl-2-(3-methyl-1-phenylbutyl)isoindolin-3-one-1-yl)acetamide

TLC: Rf 0.64 (ethyl acetate:methanol=50:1);

NMR (300 MHz, CDCl₃): δ 7.90-6.92 (m, 16H), 5.70-4.70 (m, 2H), 5.08 (m,2H), 3.00-2.00 (m, 2H), 1.95-1.45 (m, 3H), 0.94 (m, 6H).

REFERENCE EXAMPLE 20 methyl3-(2-formyl-4-methoxymethoxymethylphenyl)propanoate

Using methyl 3-(2-carboxy-4-methoxymethoxymethylphenyl)propanoate, thetitle compounds having the following physical data were obtained by thesame procedures as a series of reactions of Reference Example12→Reference Example 19.

TLC: Rf 0.58 (hexane:ethyl acetate=1:1).

REFERENCE EXAMPLE 21 methyl3-(2-(5-methyl-3-phenylhexanoyl)-4-methoxymethoxymethylphenyl)propanoate

To a solution of the compound prepared in Reference Example 20 intetrahydrofuran (5 ml) was added dropwise a Grignard reagent prepared byknown method (4-methyl-2-phenylpentylmagnesium bromide; 2.33 ml, 0.55Msolution in tetrahydrofuran) under an atmosphere of argon. The mixturewas stirred at the same temperature for 1 hour. To the mixture was added0.5 ml of Grignard reagent and then the mixture was stirred for 1 hour.To the reaction mixture was added a saturated aqueous solution ofammonium chloride and the mixture was extracted with ethyl acetate. Theorganic layer was washed with water and a saturated aqueous solution ofsodium chloride subsequently, dried over anhydrous magnesium sulfate andconcentrated to give alcohol. The alcohol was mixed with triethylamine(0.71 ml) and dimethylsulfoxide (5 ml). To the mixture was added sulfurtrioxide pyridine complex (407 mg) and the mixture was stirred at roomtemperature for 3 hours. The reaction mixture was poured into crash-ice,and then extracted with ethyl acetate. The organic layer was washed with1N hydrochloric acid, water and a saturated aqueous solution of sodiumchloride subsequently, dried over anhydrous magnesium sulfate andconcentrated to give the title compound (225 mg) having the followingphysical data.

TLC: Rf 0.56 (hexane:ethyl acetate=2:1).

EXAMPLE 1113-(2-(5-methyl-3-phenylhexanoyl)-4-hydroxymethylphenyl)propanoic acidmethyl ester

To a solution of the compound prepared in Reference Example 21 (220 mg)in methanol (3 ml) was added 10% hydrogen chloride in methanol (0.5 ml)and the mixture was stirred at room temperature overnight. To themixture was added 10% hydrogen chloride in methanol (0.5 ml) and themixture was stirred at 45° C. for 1 hour and then concentrated. Theresidue was purified by column chromatography on silica gel to give thetitle compound (200 mg) having the following physical data.

TLC: Rf 0.32 (hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 7.42 (d, J=1.5 Hz, 1H), 7.35-7.13 (m, 7H), 4.66(d, J=4.5 Hz, 2H), 3.64 (s, 3H), 3.38 (m, 1H), 3.20 (dd, J=16.2, 7.8 Hz,1H), 3.11 (dd, J=16.2, 6.6 Hz, 1H), 2.88 (m, 2H), 2.49 (m, 2H),1.70-1.30 (m, 4H), 0.90 (d, J=6.6 Hz, 3H), 0.84 (d, J=6.6 Hz, 3H).

EXAMPLE 123-(2-(5-methyl-3-phenylhexanoyl)-4-phenoxymethylphenyl)propanoic acid

Using the compound prepared in Example 11 or corresponding compounds,the title compounds having the following physical data were obtained bythe same procedures as a series of reactions of Reference Example2→Example 3.

TLC: Rf 0.28 (hexane:ethyl acetate=3:1, 0.5% acetic acid);

NMR (300 MHz, CDCl₃): δ 7.52 (d, J=1.5 Hz, 1H), 7.43 (dd, J=7.8, 1.5 Hz,1H), 7.36-7.21 (m, 5H), 7.19-7.12 (m, 3H), 7.03-6.94 (m, 3H), 5.03 (s,2H), 3.38 (m, 1H), 3.20 (dd, J=16.2, 7.8 Hz, 1H), 3.11 (dd, J=16.2, 6.6Hz, 1H), 2.88 (m, 2H), 2.54 (m, 2H), 1.64 (ddd, J=13.2, 9.9, 4.5 Hz,1H), 1.52-1.30 (m, 2H), 0.89 (d, J=6.6 Hz, 3H), 0.83 (d, J=6.6 Hz, 3H).

EXAMPLE 133-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanol

To a solution of the compound prepared in Example 6(40) (2.00 g) intetrahydrofuran (5 ml) was added dropwise diborane (1M solution intetrahydrofuran, 8.6 ml) at 0° C. under an atmosphere of argon. Themixture was stirred at room temperature for 30 minutes. To the reactionmixture was added water and the mixture was extracted with ethylacetate. The organic layer was washed with water and a saturated aqueoussolution of sodium chloride subsequently, dried over anhydrous magnesiumsulfate and concentrated. The residue was washed with hexane-ethylacetate to give the title compound (1.67 g) having the followingphysical data.

TLC: Rf 0.40 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.43 (dd, J=8.1, 2.1 Hz, 1H), 7.34-7.27 (m, 6H),7.07-6.95 (m, 5H), 6.13 (d, J=8.1 Hz, 1H), 5.21 (q, J=8.1 Hz, 1H), 5.02(s, 2H), 3.44 (t, J=5.4 Hz, 2H), 2.87-2.71 (m, 2H), 1.91-1.52 (m, 5H),0.98 (d, J=6.6 Hz, 6H).

EXAMPLE 13(1)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanol

Using the compound prepared in Example 6(33), the title compound havingthe following physical data was obtained by the same procedure ofExample 13.

TLC: Rf 0.61 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.46-7.25 (m, 10H), 7.02-6.94 (m, 3H), 6.13 (d,J=9.0 Hz, 1H), 5.24 (dt, J=9.0, 9.0 Hz, 1H), 5.02 (s, 2H), 3.50 (brs,1H), 3.43 (brs, 2H), 2.86-2.72 (m, 2H), 1.85-1.50 (m, 5H), 0.98 (d,J=6.3 Hz, 6H).

REFERENCE EXAMPLE 223-[4-phenoxymethyl-2-[1-(4-fluorophenyl)-3-methylbutylaminocarbonyl]phenyl]propylazide

The compound prepared in Example 13(1) (1.46 g) was dissolved inmethylene chloride (5 ml). To the solution were added mesyl chloride(0.30 ml) and pyridine (1 ml) and the mixture was stirred at 50° C. for2 days. To the mixture was added water and the mixture was extractedwith ethyl acetate. The organic layer was washed with water and asaturated aqueous solution of sodium chloride subsequently, dried overanhydrous magnesium sulfate and concentrated. The residue was dissolvedin N,N-dimethylformamide. The mixture was added sodium azide (354 mg)and then stirred at 80° C. overnight. To the reaction mixture was addedwater and the mixture was extracted with ethyl acetate. The residue waspurified by column chromatography on silica gel to give the titlecompound (1.16 g) having the following physical data.

Mass(APCI, pos.20V); 475 (M+H)⁺.

REFERENCE EXAMPLE 233-[4-phenoxymethyl-2-[1-(4-fluorophenyl)-3-methylbutylaminocarbonyl]phenyl]propanamine

To a solution of the compound prepared in Reference Example 22 (600 mg)in tetrahydrofuran (3 ml) were added triphenylphosphine (500 mg) andwater (0.3 ml). The mixture was stirred at room temperature for 2 days.The reaction mixture was concentrated. The residue was purified bycolumn chromatography on silica gel to give the title compound (290 mg)having the following physical data.

NMR (300 MHz, CDCl₃): δ 7.42-7.23 (m, 7H), 7.07-6.87 (m, 6H), 5.22 (q,J=8.1 Hz, 1H), 5.02 (s, 2H), 2.80-2.74 (m, 2H), 2.62 (t, J=6.6 Hz, 2H),1.83-1.55 (m, 5H), 1.00-0.97 (m, 6H).

EXAMPLE 14N-(3-methyl-1-(4-fluorophenyl)butyl)-2-(3-mesylaminopropyl)-5-phenoxymethylbenzamide

To a solution of the compound prepared in Reference Example 23 (154 mg)in methylene chloride (1 ml) were added mesyl chloride (0.030 ml) andpyridine (0.2 ml). The mixture was stirred at room temperatureovernight. To the mixture was added water and the mixture was extractedwith ethyl acetate. The organic layer was washed with water and asaturated aqueous solution of sodium chloride subsequently, dried overanhydrous magnesium sulfate and concentrated. The residue was washedwith hexane-ethyl acetate to give the title compound (126 mg) having thefollowing physical data.

TLC: Rf 0.20 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.44 (dd, J=7.8, 1.8 Hz, 1H), 7.36-7.29 (m, 6H),7.08-6.95 (m, 5H), 6.03 (d, J=8.1 Hz, 1H), 5.70 (t, J=6.3 Hz, 1H), 5.20(q, J=8.1 Hz, 1H), 5.03 (s, 2H), 3.03-2.96 (m, 2H), 2.84 (s, 3H),2.81-2.64 (m, 2H), 1.95-1.65 (m, 5H), 0.99 (d, J=6.3 Hz, 6H).

EXAMPLE 14(1)˜EXAMPLE 14(5)

Using corresponding compounds, the following compounds were obtained bythe same procedure of Example 14.

EXAMPLE 14(1)N-(3-methyl-1-(4-fluorophenyl)butyl)-2-(3-phenylsulfonylaminopropyl)-5-phenoxymethylbenzamide

TLC: Rf 0.50 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.80-7.77 (m, 2H), 7.49-7.29 (m, 9H), 7.18 (d,J=8.1 Hz, 1H), 7.09-6.94 (m, 5H), 6.10 (t, J=6.0 Hz, 1H), 6.02 (d, J=8.1Hz, 1H), 5.23 (q, J=8.1 Hz, 1H), 5.01 (s, 2H), 2.86-2.58 (m, 4H),1.83-1.61 (m, 5H), 1.00 (d, J=6.3 Hz, 6H).

EXAMPLE 14(2)N-(3-methyl-1-(4-fluorophenyl)butyl)-2-(3-benzoylaminopropyl)-5-phenoxymethylbenzamide

TLC: Rf 0.50 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.91-7.88 (m, 2H), 7.72-7.68 (m, 1H), 7.48-7.38(m, 4H), 7.34-7.23 (m, 6H), 7.02-6.95 (m, 5H), 6.10 (d, J=8.1 Hz, 1H),5.16 (q, J=8.1 Hz, 1H), 5.00 (s, 2H), 3.38-3.31 (m, 2H), 2.88-2.67 (m,2H), 1.99-1.90 (m, 2H), 1.82-1.61 (m, 3H), 0.97-0.93 (m, 6H).

EXAMPLE 14(3)N-(3-methyl-1-(4-fluorophenyl)butyl)-2-(3-formylaminopropyl)-5-phenoxymethylbenzamide

TLC: Rf 0.65 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 8.06 (d, J=1.5 Hz, 1H), 7.45-7.42 (m, 1H),7.35-7.29 (m, 6H), 7.08-6.95 (m, 5H), 6.75 (br s, 1H), 6.08 (d, J=8.1Hz, 1H), 5.18 (q, J=8.1 Hz, 1H), 5.03 (s, 2H), 3.20-3.09 (m, 2H),2.81-2.60 (m, 2H), 1.86-1.61 (m, 5H), 0.99 (d, J=6.3 Hz, 6H).

EXAMPLE 14(4)N-phenylsulfonyl-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)aminocarboxamide

TLC: Rf 0.50 (chloroform:methanol=10:1).

EXAMPLE 14(5)N-(3,4-difluorophenylsulfonyl)-N′-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)urea

TLC: Rf 0.49 (chloroform:methanol=10:1).

EXAMPLE 153-[4-phenoxymethyl-2-[1-(4-fluorophenyl)-3-methylbutylcarbamoyl]phenyl]propanamide

To a solution of the compound prepared in Example 6(40) (150 mg) intetrahydrofuran (2 ml) were added triethylamine (0.068 ml) and ethylchloroformate (0.037 ml). The mixture was stirred at room temperaturefor 30 minutes under an atmosphere of argon. To the reaction mixture wasadded ammonia water and the mixture was stirred for 10 minutes. To thereaction mixture was added water and then the mixture was extracted withethyl acetate. The organic layer was washed with 1N hydrochloric acid,water and a saturated aqueous solution of sodium chloride subsequently,dried over anhydrous magnesium sulfate and concentrated. The residue waswashed with n-hexane-ethyl acetate to give the title compound (119 mg)having the following physical data.

NMR (300 MHz, CDCl₃):7.44-7.28 (m, 7H), 7.07-6.95 (m, 5H), 6.88 (d,J=8.4 Hz, 1H), 6.04 (br s, 1H), 5.23-5.16 (m, 2H), 5.03 (s, 2H),3.06-2.89 (m, 2H), 2.61 (t, J=7.2 Hz, 2H), 1.84-1.62 (m, 3H), 0.98 (d,J=6.3 Hz, 6H).

REFERENCE EXAMPLE 24N-(3-methyl-1-(4-fluorophenyl)butyl)-2-(2-cyanoethyl)-5-phenoxymethylbenzamide

To a suspension of the compound prepared in Example 15 (119 mg) indioxane (2 ml) were added pyridine (0.1 ml) and trifluoromethanesulfonicacid anhydride (54 μl) at 0° C. under an atmosphere of argon. Themixture was stirred at room temperature for 10 minutes. To the reactionmixture was added water and the mixture was extracted with ethylacetate. The organic layer was washed with water and a saturated aqueoussolution of sodium chloride subsequently, dried over anhydrous magnesiumsulfate and concentrated. The residue was washed with n-hexane:ethylacetate to give the title compound (94 mg) having the following physicaldata.

NMR (300 MHz, CDCl₃): δ 7.50-7.29 (m, 7H), 7.08-6.96 (m, 5H), 6.07 (d,J=8.4 Hz, 1H), 5.17 (q, J=8.4 Hz, 1H), 5.06 (s, 2H), 3.08-2.91 (m, 2H),2.76-2.62 (m, 2H), 1.82-1.68 (m, 3H), 1.00-0.97 (m, 6H).

EXAMPLE 16N-(3-methyl-1-(4-fluorophenyl)butyl)-2-(2-(tetrazol-5-yl)ethyl)-5-phenoxymethylbenzamide

To a solution of the compound prepared in Reference Example 24 (94 mg)in toluene (2 ml) was added trimethyltin azide (65 mg). The mixture wasstirred at 120° C. for 3 days. The reaction mixture was concentrated. Tothe residue were added methanol (3 ml) and 1N hydrochloric acid (2 ml).The mixture was stirred at room temperature for 1 hour. To the reactionmixture was added water and the mixture was extracted with ethylacetate. The organic layer was washed with water and a saturated aqueoussolution of sodium chloride subsequently, dried over anhydrous magnesiumsulfate and concentrated. The residue was washed with n-hexane-ethylacetate to give the title compound (94 mg) having the following physicaldata.

TLC: Rf 0.30 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 8.90 (d, J=8.4 Hz, 1H), 7.43-7.36 (m, 4H),7.32-7.24 (m, 3H), 7.11-6.91 (m, 5H), 5.08 (s, 2H), 5.05-5.00 (m, 1H),3.15-3.04 (m, 4H), 1.62-1.53 (m, 1H), 1.48-1.39 (m, 1H), 0.87 (d, J=6.3Hz, 6H).

EXAMPLE 16(1)1-(2-(tetrazol-5-yl)ethyl)-2-(4-methyl-2-phenylpentyloxy)-4-phenoxymethylbenzene

Using corresponding compounds, the compound having the followingphysical data was obtained by the same procedure of Example 16.

TLC: Rf 0.40 (hexane:ethyl acetate=1:1).

REFERENCE EXAMPLE 25 N-t-butylmethanesulfonamide

To a solution of tert-butylamine (6.8 ml) and pyridine (7.8 ml) inmethylene chloride (50 ml) was added dropwise mesyl chloride (5.0 ml) at0° C. The mixture was stirred for 30 munutes. The reaction mixture waspoured into water and then extracted with methylene chloride. Theorganic layer was concentrated. The residue was purified by columnchromatography to give the title compound (5.2 g) having the followingphysical data.

TLC: Rf 0.26 (n-hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 4.22 (brs, 1H), 3.02 (s, 3H), 1.39 (s, 9H).

REFERENCE EXAMPLE 264-(1-pyrazolylmethyl)-2-[2-(naphthalen-2-yl)ethyloxy]benzamide

Using methyl 2-hydroxy-4-hydroxymethylbenzoate, the title compoundshaving the following physical data were obtained by the same proceduresas a series of reactions of Reference Reference Example 13→ReferenceExample 3→Example 7→Example 2→Example 3→Example 13→Reference Example 19.

TLC: Rf 0.49 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 10.41 (s, 1H), 7.86-7.69 (m, 5H), 7.57 (m, 1H),7.52-7.35 (m, 4H), 6.79 (d, J=7.8 Hz, 1H), 6.73 (brs, 1H), 6.31 (t,J=2.1 Hz, 1H), 5.32 (s, 2H), 4.30 (t, J=6.6 Hz, 2H), 3.28 (t, J=6.6 Hz,2H).

REFERENCE EXAMPLE 27N-(t-butyl)-2-hydroxy-2-[2-[2-(naphthalen-2-yl)ethyloxy]-4-(1-pyrazolylmethyl)phenyl]ethylsulfonamide

To a solution of the compound prepared in Reference Example 26 (64 mg)in tetrahydrofuran (1.5 ml) was added n-butyl lithium (1.59M solution inhexane, 0.55 ml) at −78° C. The mixture was stirred at 0° C. for 1 hour.The solution was cooled to −78° C. again. To the solution was added asolution of the compound prepared in Reference Example 25 (100 mg) intetrahydrofuran (1.0 ml), and then the mixture was stirred for 20minutes. To the reaction mixture was added an aqueous solution ofammonium chloride. The mixture was poured into water and the mixture wasextracted with ethyl acetate. The organic layer was washed with waterand a saturated aqueous solution of sodium chloride, dried overanhydrous magnesium sulfate and concentrated. The residue was purifiedby column chromatography on silica gel (n-hexane:ethyl acetate=1:1) togive the title compound (141 mg) having the following physical data.

TLC: Rf 0.28 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.87-7.78 (m, 3H), 7.74 (s, 1H), 7.54 (d, J=2.1Hz, 1H), 7.42-7.35 (m, 5H), 6.84 (d, J=7.5 Hz, 1H), 6.73 (d, J=1.2 Hz,1H), 6.28 (t, J=2.1 Hz, 1H), 5.44 (m, 1H), 5.28 (s, 2H), 4.36-4.18 (m,2H), 3.95 (s, 1H), 3.59 (d, J=3.9 Hz, 1H), 3.37-3.14 (m, 4H), 1.19 (s,9H).

EXAMPLE 17(E)-N-(t-butyl)-2-[2-[2-(naphthalen-2-yl)ethyloxy]-4-(1-pyrazolylmethyl)phenyl]ethenylsulfonamide

To a solution of the compound prepared in Reference Example 27 (90 mg)in 1,2-dichloroethane (1.8 ml) were added triethylamine (0.12 ml) andmesyl chloride (0.02 ml) at 0° C. The mixture was stirred at 60° C. for40 minutes. To the reaction mixture was added ice-water and then themixture was extracted with methylene chloride. The organic layer waswashed with a saturated aqueous solution of sodium chloride, dried overanhydrous magnesium sulfate and concentrated. The residue was purifiedby column chromatography on silica gel (chloroform:acetone=50:1) to givethe title compound (77 mg) having the following physical data.

TLC: Rf 0.48 (chloroform:acetone=10:1);

NMR (300 MHz, CDCl₃): δ 7.91-7.76 (m, 4H), 7.58-7.38 (m, 5H), 7.30 (d,J=7.8 Hz, 1H), 7.26 (s, 1H), 6.88 (d, J=15.9 Hz, 1H), 6.80-6.71 (m, 2H),6.30 (t, J=1.8 Hz, 1H), 5.29 (s, 2H), 4.30 (t, J=6.6 Hz, 2H), 3.96 (s,1H), 3.28 (t, J=6.6 Hz, 2H), 1.14 (s, 9H).

EXAMPLE 18N-(t-butyl)-2-[2-[2-(naphthalen-2-yl)ethyloxy]-4-(1-pyrazolylmethyl)phenyl]ethylsulfonamide

To a solution of the compound prepared in Example 17 (77 mg) in ethanol(2.0 ml) was added platinum dioxide (15 mg) at room temperature. Themixture was stirred at 70° C. for 2 hours under an atmosphere ofhydrogen. The atmosphere was substituted with argon. The mixture wasfiltered. The filtrate was concentrated to give the title compoundhaving the following physical data. The compound was used to the nextstep without further purification.

TLC: Rf 0.52 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.87-7.68 (m, 4H), 7.58-7.32 (m, 5H), 7.11 (d,J=7.8 Hz, 1H), 6.78-6.65 (m, 2H), 6.26 (t, J=2.1 Hz, 1H), 5.23 (s, 2H),4.23 (t, J=6.6 Hz, 2H), 3.75 (s, 1H), 3.23 (t, J=6.6 Hz, 2H), 3.18-2.95(m, 4H), 1.14 (s, 9H).

EXAMPLE 192-[2-[2-(naphthalen-2-yl)ethyloxy]-4-(1-pyrazolylmethyl)phenyl]ethylsulfonamide

To the compound prepared in Example 18 were added anisole (0.05 ml) andtrifluoroacetic acid (0.5 ml). The mixture was stirred at roomtemperature for 5 hours. The reaction mixture was azeotroped withtoluene, added a saturated aqueous solution of sodium bicarbonate andthe mixture was extracted with ethyl acetate. The organic layer wasdried over anhydrous magnesium sulfate and concentrated. The residue waspurified by column chromatography on silica gel (n-hexane:ethylacetate=1:1) to give the title compound (30 mg) having the followingphysical data.

TLC: Rf 0.22 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.87-7.78 (m, 3H), 7.74 (s, 1H), 7.58-7.36 (m,5H), 7.08 (d, J=7.5 Hz, 1H), 6.76-6.68 (m, 2H), 6.28 (brs, 1H), 5.27 (s,2H), 4.28 (t, J=6.0 Hz, 2H), 3.93 (s, 2H), 3.25 (t, J=6.6 Hz, 2H), 2.99(s, 4H).

EXAMPLE 20N-(2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)ethylsulfonyl)benzamide

To a solution of the compound prepared in Example 19 (35 mg) and benzoicacid (15 mg) in N,N-dimethylformamide (1.0 ml) were added1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (31 mg)and dimethylaminopyridine (30 mg) at 0° C. The mixture was stirred atroom temperature overnight. To the reaction mixture was added water andthe mixture was extracted with ethyl acetate. The organic layer wasdried over anhydrous magnesium sulfate and concentrated. The residue waspurified by column chromatography on silica gel (n-hexane:ethylacetate=2:3→chloroform:methanol=10:1) to give the title compound (25 mg)having the following physical data.

TLC: Rf 0.31 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 7.98-7.91 (m, 2H), 7.89-7.77 (m, 4H), 7.76 (d,J=2.4 Hz, 1H), 7.62 (m, 1H), 7.56-7.40 (m, 6H), 7.13 (d, J=8.1 Hz, 1H),6.87 (s, 1H), 6.65 (d, J=8.1 Hz, 1H), 6.24 (t, J=2.1 Hz, 1H), 5.23 (s,2H), 4.17 (t, J=6.6 Hz, 2H), 3.74-3.61 (m, 2H), 3.15 (t, J=6.6 Hz, 2H),3.01-2.91 (m, 2H).

EXAMPLE 213-[2-[2-(naphthalen-2-yl)ethyloxy]-4-(1-pyrazolylmethyl)phenyl]propanamide

To a solution of the compound prepared in Example 3(12) (700 mg) inmethylene chloride (15 ml) were added oxalyl chloride (305 μl) andN,N-dimethylformamide (catalytic amount) at room temperature under anatmosphere of argon. The mixture was stirred for 30 minutes. To thereaction mixture was added 28% ammonia water (5 ml) with vigorouslystirring, the mixture was stirred at room temperature for 30 minutes. Tothe reaction mixture was added 1N hydrochloric acid, and the mixture wasextracted with ethyl acetate-tetrahydrofuran. The organic layer waswashed with water and a saturated aqueous solution of sodium chloridesubsequently, dried over anhydrous sodium sulfate and concentrated togive the title compound (708 mg) having the following physical data.

TLC: Rf 0.35 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.76 (m, 3H), 7.72 (s, 1H), 7.54 (d, J=1.5Hz, 1H), 7.49-7.36 (m, 4H), 7.08 (d, J=7.5 Hz, 1H), 6.71 (d, J=7.5 Hz,1H), 6.69 (s, 1H), 6.27 (dd, J=2.4, 1.5 Hz, 1H), 5.25 (s, 2H), 4.93(brs, 1H), 4.72 (brs, 1H), 4.26 (t, J=6.6 Hz, 2H), 3.25 (t, J=6.6 Hz,2H), 2.80 (t, J=7.5 Hz, 2H), 2.14 (t, J=7.5 Hz, 2H).

REFERENCE EXAMPLE 283-[4-(1-pyrazolylmethyl)-2-[2-(naphthalen-2-yl)ethyloxy]phenyl]propanenitrile

Using the compounds prepared in Example 21, the title compound (1.56 g)having the following physical data was obtained by the same procedure ofReference Example 24.

TLC: Rf 0.50 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.85-7.78 (m, 3H), 7.70 (s, 1H), 7.54 (d, J=1.8Hz, 1H), 7.51-7.36 (m, 4H), 7.08 (d, J=7.5 Hz, 1H), 6.73 (dd, J=7.5, 1.2Hz, 1H), 6.69 (d, J=1.2 Hz, 1H), 6.27 (dd, J=2.1, 1.8 Hz, 1H), 5.26 (s,2H), 4.23 (t, J=6.6 Hz, 2H), 3.23 (t, J=6.6 Hz, 2H), 2.82 (t, J=7.5 Hz,2H), 2.31 (t, J=7.5 Hz, 2H).

REFERENCE EXAMPLE 293-[4-(1-pyrazolylmethyl)-2-[2-(naphthalen-2-yl)ethyloxy]phenyl]-1-hydroxyiminopropylamine

To a solution of the compound prepared in Reference Example 28 inethanol (30 ml) were added triethylamine (1.06 ml) and hydroxylaminehydrochloride (530 mg). The mixture was refluxed for 2 days. Thereaction mixture was standing to cool, and then the mixture wasextracted with ethyl acetate. The organic layer was washed with waterand a saturated aqueous solution of sodium chloride subsequently, driedover anhydrous sodium sulfate and concentrated. The residue was purifiedby column chromatography on silica gel (n-hexane:ethylacetate=1:1→chloroform:methanol=10:1) to give the title compound (920mg) having the following physical data.

TLC: Rf 0.33 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.82-7.76 (m, 3H), 7.71 (s, 1H), 7.54 (m, 1H),7.48-7.35 (m, 4H), 7.06 (d, J=7.5 Hz, 1H), 6.70 (dd, J=7.5, 0.9 Hz, 1H),6.69 (d, J=0.9 Hz, 1H), 6.26 (dd, J=2.4, 2.1 Hz, 1H), 5.25 (s, 2H), 4.24(t, J=6.6 Hz, 2H), 4.20 (brs, 2H), 3.24 (t, J=6.6 Hz, 2H), 2.77-2.72 (m,2H), 2.24-2.18 (m, 2H).

EXAMPLE 223-(2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)ethyl-1,2,4-oxadiazole-5-thione

To a solution of the compound prepared in Reference Example 29 (180 mg)in acetonitorile (4.0 ml) were added 1,8-diazabicyclo[5.4.0]undec-7-ene(260 μl) and N,N′-thiocarbonyldiimidazole (116 mg) at room temperature.The mixture was stirred for 1 hour. To the reaction mixture was added 1Nhydrochloric acid and the mixture was extracted with ethyl acetate. Theorganic layer was washed with water and a saturated aqueous solution ofsodium chloride subsequently, dried over anhydrous sodium sulfate andconcentrated. The residue was purified by column chromatography onsilica gel (n-hexane:ethyl acetate=1:1→1:3) to give the title compound(150 mg) having the following physical data.

TLC: Rf 0.41 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.82-7.73 (m, 3H), 7.69 (s, 1H), 7.58 (d, J=1.8Hz, 1H), 7.50-7.35 (m, 4H), 6.64 (d, J=7.5 Hz, 1H), 6.58 (d, J=0.9 Hz,1H), 6.40 (dd, J=7.5, 0.9 Hz, 1H), 6.32 (dd, J=2.1, 1.8 Hz, 1H), 5.19(s, 2H), 4.19 (t, J=6.6 Hz, 2H), 3.20 (t, J=6.6 Hz, 2H), 2.67 (t, J=7.5Hz, 2H), 2.32 (t, J=7.5 Hz, 2H).

EXAMPLE 22(1)˜EXAMPLE 22(5)

The compounds having the following physical data were obtained by thesame procedure of Example 22.

EXAMPLE 22(1)3-(2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)ethyl1-1,2,4-oxadiazole-5-one

TLC: Rf 0.46 (hexane:ethyl acetate=1:3);

NMR (300 MHz, CDCl₃): δ 7.82-7.74 (m, 3H), 7.70 (s, 1H), 7.54 (dd,J=2.4, 0.9 Hz, 1H), 7.51-7.36 (m, 4H), 6.92 (d, J=7.8 Hz, 1H), 6.66 (s,1H), 6.62 (d, J=7.8 Hz, 1H), 6.29 (dd, J=2.4, 2.1 Hz, 1H), 5.23 (s, 2H),4.25 (t, J=6.6 Hz, 2H), 3.23 (t, J=6.6 Hz, 2H), 2.75 (t, J=7.5 Hz, 2H),2.36 (t, J=7.5 Hz, 2H).

EXAMPLE 22(2)3-(2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)ethyl-1,2,4-thiadiazole-5-one

TLC: Rf 0.38 (hexane:ethyl acetate=2:3);

NMR (300 MHz, CDCl₃): δ 9.08 (brs, 1H), 7.83-7.73 (m, 3H), 7.70 (s, 1H),7.54 (d, J=1.8 Hz, 1H), 7.50-7.37 (m, 4H), 7.01 (d, J=8.1 Hz, 1H), 6.70(s, 1H), 6.69 (d, J=8.1 Hz, 1H), 6.28 (dd, J=2.1, 1.8 Hz, 1H), 5.25 (s,2H), 4.27 (t, J=6.6 Hz, 2H), 3.25 (t, J=6.6 Hz, 2H), 2.84 (t, J=7.5 Hz,2H), 2.40 (t, J=7.5 Hz, 2H).

EXAMPLE 22(3)4-(2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)ethyl-1,2,3,5-oxathiadiazole-2-one

TLC: Rf 0.44 (hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.84-7.78 (m, 3H), 7.72 (s, 1H), 7.55 (d, J=1.5Hz, 1H), 7.52-7.39 (m, 4H), 6.89 (d, J=7.8 Hz, 1H), 6.67 (s, 1H), 6.62(d, J=7.8 Hz, 1H), 6.30 (dd, J=2.1, 1.5 Hz, 1H), 5.25 (s, 2H), 4.25 (t,J=6.6 Hz, 2H), 3.22 (t, J=6.6 Hz, 2H), 2.72 (t, J=7.5 Hz, 2H), 2.34 (t,J=7.5 Hz, 2H).

EXAMPLE 22(4)3-(2-(2-(3-methyl-1-phenylbutylcarbamoyl)-4-phenoxymethyl)phenyl)ethyl-1,2,4-oxadiazole-5-one

TLC: Rf 0.66 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, DMSO-d₆): δ 8.88 (d, J=8.4 Hz, 1H), 7.47-7.16 (m, 1H),7.05-6.90 (m, 3H), 5.09 (s, 2H), 5.04 (m, 1H), 2.98-2.87 (m, 2H),2.79-2.67 (m, 2H), 1.75 (m, 1H), 1.61 (m, 1H), 1.45 (m, 1H), 0.91(d,J=6.3 Hz, 3H), 0.90 (d, J=6.3 Hz, 3H).

EXAMPLE 22(5)3-(2-(2-(3-methyl-1-phenylbutylcarbamoyl)-4-phenoxymethyl)phenyl)ethyl-1,2,4-oxadiazole-5-thione

TLC: Rf 0.48 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 7.52-7.22 (m, 10H), 7.04-6.93 (m, 3H), 6.31(d, J=8.4 Hz, 1H), 5.24 (m, 1H), 5.05 (s, 2H), 3.17-2.88 (m, 4H),1.89-1.51 (m, 3H), 1.01 (d, J=6.6 Hz, 3H), 1.00 (d, J=6.6 Hz, 3H).

REFERENCE EXAMPLE 304-phenoxymethyl-2-(2-nitrophenylsulfonylamino)phenyl iodide

To a solution of 2-iodo-4-phenoxymethylaniline (600 mg) in methylenechloride (4.0 ml) were added pyridine (0.45 ml) and2-nitrophenylsulfonylchloride (429 mg) at 0° C. The mixture was stirredovernight. The reaction mixture was poured into water and then extractedwith ethyl acetate. The organic layer was washed with a saturatedaqueous solution of sodium chloride, dried over anhydrous magnesiumsulfate and concentrated. The residue was purified by columnchromatography on silica gel (n-hexane:ethyl acetate=2:1) to give thetitle compound having the following physical data.

TLC: Rf 0.38 (n-hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 7.90 (m, 1H), 7.80 (m, 1H), 7.77-7.65 (m, 3H),7.56 (m, 1H), 7.36-7.23 (m, 3H), 7.05-6.91 (m, 4H), 5.06 (s, 2H).

REFERENCE EXAMPLE 314-phenoxymethyl-2-[N-[2-(naphthalen-2-yl)ethyl]-N-2-nitrophenylsulfonylamino]phenyliodide

To a solution of the compound prepared in Reference Example 30 (788 mg)and 2-(naphthalen-2-yl)ethanol (385 mg) in tetrahydrofuran (5.0 ml) wereadded diethylazodicarboxylate (0.97 ml) and triphenylphosphine (585 mg)at room temperature. The mixture was stirred overnight. The reactionmixture was concentrated and the residue was purified by columnchromatography on silica gel (n-hexane:ethyl acetate=3:1) to give thetitle compound having the following physical data.

TLC: Rf 0.47 (n-hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 7.88-7.11 (m, 16H), 7.04-6.85 (m, 3H), 6.87 (d,J=12.3 Hz, 1H), 4.80 (d, J=12.3 Hz, 1H), 4.40 (m, 1H), 3.89 (m, 1H),3.18-3.00 (m, 2H).

REFERENCE EXAMPLE 324-phenoxymethyl-2-[2-(naphthalen-2-yl)ethylamino]phenyl iodide

To a solution of the compound prepared in Reference Example 31 (750 mg)in acetonitorile (3.8 ml) were added potassium carbonate (160 mg) andthiophenol (0.14 ml). The mixture was stirred overnight. To the reactionmixture was added water, and the mixture was extracted with ethylacetate. The organic layer was washed with 2N aqueous solution of sodiumhydroxide and a saturated aqueous solution of sodium chloridesubsequently, dried over anhydrous magnesium sulfate and concentrated.The residue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=20:1) to give the title compound having thefollowing physical data.

TLC: Rf 0.84 (n-hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 7.86-7.76 (m, 3H), 7.68 (s, 1H), 7.62 (d, J=7.8Hz, 1H), 7.52-7.41 (m, 2H), 7.39-7.24 (m, 3H), 7.01-6.92 (m, 3H), 6.69(m, 1H), 6.52 (m, 1H), 4.98 (s, 2H), 4.32 (m, 1H), 3.57-3.45 (m, 2H),3.10 (t, J=6.9 Hz, 2H).

REFERENCE EXAMPLE 334-phenoxymethyl-2-[N-[2-(naphthalen-2-yl)ethyl]-N-methylamino]phenyliodide

To a solution of the compound prepared in Reference Example 32 (170 mg)in N,N-dimethylformamide (1.2 ml) were added cesium carbonate (570 mg)and methyl iodide (0.07 ml) at room temperature. The mixture was stirredat 60° C. for 1.5 hours. The reaction mixture was cooled to roomtemperature, poured into water and then extracted with ethyl acetate.The organic layer was washed with a saturated aqueous solution of sodiumchloride, dried over anhydrous magnesium sulfate and concentrated togive the title compound having the following physical data.

TLC: Rf 0.47 (n-hexane:ethyl acetate=10:1);

NMR (300 MHz, CDCl₃): δ 7.86 (d, J=8.1 Hz, 1H), 7.83-7.71 (m, 3H), 7.63(s, 1H), 7.48-7.24 (m, 5H), 7.18 (d, J=1.8 Hz, 1H), 7.71-6.92 (m, 3H),6.86 (dd, J=7.8, 1.8 Hz, 1H), 4.98 (s, 2H), 3.32-3.24 (m, 2H), 3.06-2.97(m, 2H), 2.84 (s, 3H).

EXAMPLE 234-phenoxymethyl-2-[N-[2-(naphthalen-2-yl)ethyl]-N-methylamino]cinnamicacid ethyl ester

Using the compounds prepared in Reference Example 33, the titlecompounds having the following physical data were obtained by the sameprocedure of Example 1.

TLC: Rf 0.26 (n-hexane:ethyl acetate=10:1);

NMR (300 MHz, CDCl₃): δ 8.07 (d, J=16.2 Hz, 1H), 7.82-7.69 (m, 3H),7.60-7.50 (m, 2H), 7.48-7.36 (m, 2H), 7.35-7.22 (m, 3H), 7.15 (s, 1H),7.08 (m, 1H), 7.03-6.90 (m, 3H), 6.40 (d, J=16.2 Hz, 1H), 5.02 (s, 2H),4.27 (q, J=7.2 Hz, 2H), 3.32-3.22 (m, 2H), 3.19-2.99 (m, 2H), 2.87 (s,3H), 1.33 (t, J=7.2 Hz, 3H).

EXAMPLE 243-[4-phenoxymethyl-2-[N-[2-(naphthalen-2-yl)ethyl]-N-methylamino]phenyl]propanoicacid ethyl ester

To a solution of the compound prepared in Example 23 (135 mg) intetrahydrofuran (1.2 ml)-ethanol (0.3 ml) were added portionwise nickelchloride hexahydrate (70 mg) and sodium borohydride (45 mg) at 0° C. Themixture was stirred for 15 minutes. The reaction mixture was extractedwith diethyl ether. The organic layer was filtered. The filtrate wasextracted with diethyl ether. The organic layer was washed with asaturated aqueous solution of sodium chloride, dried over anhydrousmagnesium sulfate and concentrated to give the title compound having thefollowing physical data.

TLC: Rf 0.59 (toluene:ethyl acetate=10:1);

NMR (300 MHz, CDCl₃): δ 7.82-7.70 (m, 3H), 7.59 (m, 1H), 7.48-7.06 (m,8H), 7.02-6.91 (m, 3H), 5.00 (s, 2H), 4.09 (q, J=7.2 Hz, 2H), 3.26-3.16(m, 2H), 3.01-2.88 (m, 4H), 2.76 (s, 3H), 2.60-2.50 (m, 2H), 1.22 (t,J=7.2 Hz, 3H).

EXAMPLE 253-(2-(N-methyl-N-(2-(naphthalen-2-yl)ethyl)amino)-4-phenoxymethylphenyl)propanoicacid

Using the compound prepared in Example 24, the title compound having thefollowing physical data was obtained by the same procedure of Example 3.

TLC: Rf 0.58 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.82-7.71 (m, 3H), 7.60 (s, 1H), 7.48-7.36 (m,2H), 7.35-7.12 (m, 6H), 7.02-6.92 (m, 3H), 5.02 (s, 2H), 3.28-3.18 (m,2H), 3.03-2.88 (m, 4H), 2.80 (s, 3H), 2.62 (t, J=7.2 Hz, 2H).

REFERENCE EXAMPLE 344-phenoxymethyl-2-[N-[2-(naphthalen-2-yl)ethyl]-N-acetylamino]phenyliodide

To a solution of the compound prepared in Reference Example 32 (125 mg)in methylene chloride (1.3 ml) were added dimethylaminopyridine (65 mg)and acetylchloride (0.03 ml), and the mixture was stirred for 1 hour. Tothe reaction mixture was added 1N hydrochloric acid (0.5 ml) and themixture was extracted with ethyl acetate. The organic layer was washedwith a saturated aqueous solution of sodium chloride, dried overanhydrous magnesium sulfate and concentrated to give the title compoundhaving the following physical data.

TLC: Rf 0.30 (n-hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ7.89 (d, J=8.4 Hz, 1H), 7.79-7.70 (m, 3H), 7.62(s, 1H), 7.48-7.36 (m, 2H), 7.34-7.22 (m, 3H), 7.09 (m, 1H), 6.98 (m,1H), 6.87-6.79 (m, 2H), 6.64 (m, 1H), 4.65 (s, 2H), 4.53 (m, 1H), 3.28(m, 1H), 3.20-3.01 (m, 2H), 1.76 (s, 3H).

EXAMPLE 263-(2-(N-acetyl-N-(2-(naphthalen-2-yl)ethyl)amino)-4-phenoxymethylpheny)propanoicacid

Using the compound prepared in Reference Example 34, the title compoundhaving the following physical data was obtained by the same proceduresas a series of reactions of Reference Example 1→Example 24→Example 3.

TLC: Rf 0.49 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.80-7.68 (m, 3H), 7.61 (s, 1H), 7.48-7.22 (m,7H), 6.97 (t, J=7.4 Hz, 1H), 6.93-6.83 (m, 2H), 6.70 (s, 1H), 4.77 (s,2H), 4.55 (m, 1H), 3.25 (m, 1H), 3.10 (t, J=7.7 Hz, 2H), 2.93-2.81 (m,2H), 2.72-2.61 (m, 2H), 1.76 (s, 3H).

REFERENCE EXAMPLE 35 2-(naphthalen-2-yl)ethanethiol

To a solution of 2-vinylnaphthalene (3.0 g) in benzene (20 ml) wereadded triphenylsilylthiol (6.5 g) and 2,2′-azobis(2-methylpropionitorile(950 mg) at room temperature. The mixture was refluxed for 30 minutes.The reaction mixture was cooled to room temperature, addedtrifluoroacetic acid (7.5 ml) and stirred for additional 30 minutes. Thereaction mixture was concentrated. The residue was purified by columnchromatography on silica gel to give the title compound (2.5 g) havingthe following physical data.

TLC: Rf 0.63 (n-hexane:ethyl acetate=10:1);

NMR (300 MHz, CDCl₃): δ 7.86-7.75 (m, 2H), 7.68-7.60 (m, 1H), 7.53-7.10(m, 4H), 3.09 (t, J=7.4 Hz, 2H), 2.88 (dt, J=7.8, 7.4 Hz, 2H), 1.41 (t,J=7.8 Hz, 1H).

REFERENCE EXAMPLE 364-bromo-2-[2-(naphthalen-2-yl)ethylthio]benzaldehyde

To a solution of the compound prepared in Reference Example 35 (2.8 g)in N,N-dimethylformamide (20 ml) was added sodium hydride (450 mg, 62.7%in oil). The reaction mixture was stirred for 1 hour. To a solution of4-bromo-2-fluorobenzaldehyde (2.0 g) in N,N-dimethylformamide (10 ml)was added above-mentioned reaction mixture at 0° C. The mixture wasstirred for 30 minutes. To the mixture was added ice and an aqueoussolution of ammonium chloride and the mixture was extracted with diethylether. The organic layer was washed with water and a saturated aqueoussolution of sodium chloride subsequently, dried and concentrated. Theresidue was purified by column chromatography on silica gel(n-hexane:ethyl acetate=20:1) to give the title compound (2.6 g) havingthe following physical data.

TLC: Rf 0.44 (n-hexane:ethyl acetate=10:1);

NMR (300 MHz, CDCl₃): δ 10.28 (s, 1H), 7.89-7.76 (m, 3H), 7.70-7.63 (m,2H), 7.57-7.32 (m, 5H), 3.36-3.26 (m, 2H), 3.22-3.12 (m, 2H).

REFERENCE EXAMPLE 374-bromo-2-[2-(naphthalen-2-yl)ethylthio]benzylalcohol

To a solution of the compound prepared in Reference Example 36 (2.5 g)in tetrahydrofuran (15 ml)-ethanol (20 ml) was added sodium borohydride(226 mg). The mixture was stirred at 0° C. for 10 minutes. To thereaction solution were added acetone and ethyl acetate. The mixture wasconcentrated. The residue was extracted with ethyl acetate. The organiclayer was washed, dried over anhydrous magnesium sulfate and thenconcentrated to give the title crude compound having the followingphysical data. The compound was used to the next step without furtherpurification.

TLC: Rf 0.13 (n-hexane:ethyl acetate 10:1);

NMR (300 MHz, CDCl₃): δ 7.86-7.76 (m, 3H), 7.66-7.61 (m, 1H), 7.52-7.40(m, 3H), 7.36-7.24 (m, 3H), 4.68 (s, 2H), 3.33-3.24 (m, 2H), 3.16-3.07(m, 2H).

REFERENCE EXAMPLE 38[4-bromo-2-[2-(naphthalen-2-yl)ethylthio]benzyl]-(t-butyldimethylsilyl)ether

Using the compounds prepared in Reference Example 37, the title compound(2.7 g) having the following physical data was obtained by the sameprocedure of Reference Example 13.

TLC: Rf 0.89 (n-hexane:ethyl acetate=5:1);

NMR (300 MHz, CDCl₃): δ 7.86-7.76 (m, 3H), 7.64 (brs, 1H), 7.52-7.30 (m,6H), 4.69 (s, 2H), 3.29-3.20 (m, 2H), 3.14-3.05 (m, 2H), 0.94 (s, 9H),0.10 (s, 6H).

REFERENCE EXAMPLE 39 ethyl4-(t-butyldimethylsilyloxymethyl)-3-[2-(naphthalen-2-yl)ethylthio]benzoate

To a solution of the compound prepared in Reference Example 38 (1.5 g),ethanol (12 ml), triethylamine (9 ml) in N,N-dimethylformamide (9 ml)was added palladium bis(triphenylphosphine)dichloride (110 mg). Themixture was stirred at 80° C. for 3 days under an atmosphere of carbonmonoxide. To the reaction mixture was added diethyl ether and themixture was filtered. The filtrate was extracted with diethyl ether. Theorganic layer was washed, dried and purified by column chromatography onsilica gel (n-hexane:ethyl acetate=30:1) to give the title compound (1.6g) having the following physical data.

TLC: Rf 0.34 (n-hexane:ethyl acetate=20:1);

NMR (300 MHz, CDCl₃): δ 8.04 (d, J=1.8 Hz, 1H), 7.90 (dd, J=7.8, 1.8 Hz,1H), 7.85-7.74 (m, 3H), 7.68-7.60 (m, 2H), 7.51-7.40 (m, 2H), 7.34 (dd,J=8.4, 1.8 Hz, 1H), 4.79 (s, 2H), 4.39 (q, J=7.1 Hz, 2H), 3.35-3.26 (m,2H), 3.16-3.06 (m, 2H), 1.41 (t, J=7.1 Hz, 3H), 0.95 (s, 9H), 0.11 (s,6H).

REFERENCE EXAMPLE 404-(pyrazol-1-ylmethyl)-2-[2-(naphthalen-2-yl)ethylthio]benzaldehyde

Using the compound prepared in Reference Example 39, the title compoundhaving the following physical data was obtained by the same proceduresas a series of reactions of Reference Example 4→Example 2→Example7→Reference Example 1.

TLC: Rf 0.33 (n-hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 10.33 (s, 1H), 8.65-8.58 (m, 1H), 7.86-7.25 (m,1H), 6.32 (t, J=2.1 Hz, 1H), 5.33 (s, 2H), 3.27-3.05 (m, 4H).

EXAMPLE 273-(2-(2-(naphthalen-2-yl)ethylthio)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid ethyl ester

To a solution of diethyl ethoxycarbonylmethylphosphonate (0.56 ml, 2.82mmol) in tetrahydrofuran (6 ml) was added sodium hydride (98 mg, 63.1%in oil) at 0° C. and the mixture was stirred for 10 minutes. To thesolution was added a solution of the compound prepared in ReferenceExample 40 (2.35 mmol) in tetrahydrofuran (6 ml) and the mixture wasstirred for 15 minutes. To the reaction mixture was added a saturatedaqueous solution of ammonium chloride. The mixture was extracted withethyl acetate. The organic layer was washed, dried over anhydrousmagnesium sulfate and concentrated to give the title compound having thefollowing physical data. The compound was used to the next step withoutfurther purification.

TLC: Rf 0.45 (n-hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 8.20 (d, J=15.9 Hz, 1H), 7.84-7.73 (m, 3H),7.62-7.36 (m, 6H), 7.30-7.24 (m, 1H), 7.22-7.17 (m, 1H), 7.05-6.69 (m,1H), 6.35 (d, J=15.9 Hz, 1H), 6.30 (t, J=2.3 Hz, 1H), 5.27 (s, 2H), 4.26(q, J=6.9 Hz, 2H), 3.21-3.13 (m, 2H), 3.07-3.00 (m, 2H), 1.35 (t, J=6.9Hz, 3H).

EXAMPLE 283-(2-(2-(naphthalen-2-yl)ethylthio)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

Using the compound prepared in Example 27, the title compound having thefollowing physical data was obtained by the same procedures as a seriesof reactions of Reference Example 24→Example 3.

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.74 (m, 3H), 7.61 (brs, 1H), 7.58-7.54 (m,1H), 7.50-7.39 (m, 2H), 7.38-7.35 (m, 1H), 7.32-7.26 (m, 1H), 7.21-7.11(m, 2H), 6.98-6.92 (m, 1H), 6.27 (t, J=1.9 Hz, 1H), 5.26 (s, 2H),3.23-3.14 (m, 2H), 3.09-2.99 (m, 4H), 2.70-2.60 (m, 2H).

EXAMPLE 293-(2-(2-(naphthalen-2-yl)ethylthio)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid ethyl ester

Using the compound prepared in Example 27, the title compound having thefollowing physical data was obtained by the same procedure of Example24.

TLC: Rf 0.47 (hexane:ethyl acetate=2:1).

EXAMPLE 303-[4-(pyrazol-1-ylmethyl)-2-[2-(naphthalen-2-yl)ethylsulfonyl]phenyl]propanoicacid ethyl ester

To a solution of the compound prepared in Example 29 (100 mg) inmethylene chloride (2.5 ml) were added disodium hydrogenphosphate (97mg) and 3-chloroperbenzoic acid (105 mg) at −30° C. The mixture wasstirred for 1 hour. To the mixture was added 3-chloroperbenzoic acid (30ml) and the mixture was stirred at room temperature for additional 1hour. To the reaction solution was added a saturated aqueous solution ofsodium bicarbonate and the mixture was extracted with methylenechloride. The organic layer was washed, dried and purified by columnchromatography on silica gel (n-hexane:ethyl acetate=3:2) to give thetitle compound (90 mg) having the following physical data.

TLC: Rf 0.41 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.86-7.69 (m, 5H), 7.60-7.53 (m, 2H), 7.50-7.38(m, 3H), 7.36-7.19 (m, 2H), 6.31 (t, J=2.1 Hz, 1H), 5.21 (s, 2H), 4.12(q, J=7.2 Hz, 2H), 3.59-3.50 (m, 2H), 3.36-3.16 (m, 4H), 2.78-2.69 (m,2H), 1.22 (t, J=7.2 Hz, 3H).

EXAMPLE 313-(2-(2-(naphthalen-2-yl)ethylsulfonyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

Using the compound prepared in Example 30, the title compound having thefollowing physical data was obtained by the same procedure of Example 3.

TLC: Rf 0.39 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.68 (m, 4H), 7.58-7.54 (m, 2H), 7.48-7.39(m, 3H), 7.35-7.25 (m, 2H), 7.20 (dd, J=8.7, 1.8 Hz, 1H), 6.31 (t, J=2.1Hz, 1H), 5.26 (s, 2H), 3.58-3.49 (m, 2H), 3.35-3.16 (m, 4H), 2.82-2.72(m, 2H).

REFERENCE EXAMPLE 41 7-methoxymethoxycoumarin

To a solution of 7-hydroxycoumarin (100 g) and isopropylethylamine (161ml) in anhydrous dimethylformamide (DMF; 500 ml) was added dropwisemethoxymethylchloride (70.3 ml) at 0° C. under an atmosphere of argon.The mixture was stirred at room temperature for 4 hours. To the reactionmixture were added hexane/ethyl acetate (2/1, 1000 ml) and a saturatedaqueous solution of sodium bicarbonate (1000 ml) and the mixture wasextracted twice with ethyl acetate. The organic layer was washewd withwater (twice) and a saturated aqueous solution of sodium chloride, driedover anhydrous magnesium sulfate and concentrated to give the titlecompound (74.1 g) having the following physical data. The obtained crudeproduct was used to the next step without further purification.

TLC: Rf 0.50 (hexane:ethyl acetate=3:2);

NMR (300 MHz, CDCl₃): δ 7.64 (d, J=9.6 Hz, 1H), 7.39 (d, J=8.7 Hz, 1H),7.01 (d, J=2.4 Hz, 1H), 6.96 (dd, J=8.7, 2.4 Hz, 1H), 6.28 (d, J=9.6 Hz,1H), 5.24 (s, 2H), 3.49 (s, 3H).

REFERENCE EXAMPLE 42 3-(4-methoxymethoxy-2-hydroxyphenyl)propenoic acidmethyl ester

To a suspension of sodium hydride (46.9 g; 63.1%, in oil) in anhydroustetrahydrofuran (THF; 300 ml) was added anhydrous methanol (60 ml) underice-cooling under an atmosphere of argon. The mixture was stirred atroom temperature for 20 minutes. To the reaction solution was addeddropwise a solution of the compound prepared in Reference Example 41 inanhydrous THF (1000 ml)/anhydrous methanol (100 ml) and the mixture wasstirred at 60° C. for 40 minutes. To the reaction mixutre were added asaturated aqueous solution of ammonium chloride and water and then theorganic layer was separated. The aqueous layer was neutralized with 2Nhydrochloric acid and then extracted with ethyl acetate. The combinedorganic layer was washed with water and a saturated aqueous solution ofsodium chloride, dried over anhydrous magnesium sulfate andconcentrated. To the residue were added ethyl acetate and hexane. Theobtained solid was filtered to give the title compound (100.2 g) havingthe following physical data.

TLC: Rf 0.38 (hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 7.92 (d, J=16 Hz, 1H), 7.39 (d, J=8.5 Hz, 1H),6.62 (dd, J=8.5, 2.2 Hz, 1H), 6.54 (d, J=2.2 Hz, 1H), 6.51 (d, J=16 Hz,1H), 6.01 (s, 1H), 5.17 (s, 2H), 3.81 (s, 3H), 3.47 (s, 3H).

REFERENCE EXAMPLE 43 3-(4-methoxymethoxy-2-hydroxyphenyl)propanoic acidmethyl ester

A solution of the compound prepared in Reference Example 42 (45.0 g) and10% palladium carbon (4.2 g, wet) in methanol (500 ml) was stirred atroom temperature for 7 hours under an atmosphere of hydrogen. Thereaction was carried out twice and the two reaction mixture werecombined and then filtered. The filtrate was concentrated to give thetitle compound (92.1 g) having the following physical data.

TLC: Rf 0.47 (hexane:ethyl acetate=3:2);

NMR (300 MHz, CDCl₃): δ 7.24 (s, 1H), 6.97 (d, J=8.2 Hz, 1H), 6.61 (d,J=2.5 Hz, 1H), 6.57 (dd, J=8.2, 2.5 Hz, 1H), 5.13 (s, 2H), 3.69 (s, 3H),3.46 (s, 3H), 2.84 (t, J=6.1 Hz, 2H), 2.69 (t, J=6.1 Hz, 2H).

REFERENCE EXAMPLE 443-(4-methoxymethoxy-2-trifluoromethanesulfoxyphenyl)propanoic acidmethyl ester

To a solution of the compound prepared in Reference Example 43 (82.8 g)and pyridine (33.5 ml) in methylene chloride (300 ml) was added dropwisetrifluoromethanesulfonic acid (63.8 ml) under ice-cooling under anatmosphere of argon and the mixture was stirred for 10 minutes. To thereaction mixture were added ethyl acetate and water, and the organiclayer was separated. The organic layer was washed with water and asaturated aqueous solution of sodium chloride, dried over anhydrousmagnesium sulfate and concentrated to give the title compound (121.8 g)having the following physical data. The obtained crude product was usedto the next step without further purification.

TLC: Rf 0.65 (hexane:ethyl acetate=2:1);

NMR (300 MHz, CDCl₃): δ 7.24 (d, J=8.4 Hz, 1H), 7.04-6.96 (m, 2H), 5.16(s, 2H), 3.68 (s, 3H), 3.47 (s, 3H), 2.98 (t, J=7.5 Hz, 2H), 2.63 (t,J=7.5 Hz, 2H).

REFERENCE EXAMPLE 45 3-(4-methoxymethoxy-2-carboxyphenyl)propanoic acidmethyl ester

A solution of the compound prepared in Reference Example 44,1,1′-bis(diphenylphosphino)ferrocene (7.65 g), potassium acetate (169.0g) and palladium(II) acetate (21.55 g) in anhydrous DMF (400 ml) wasstirred at 90° C. for 2 days under an atmosphere of carbon monoxide. Thereaction mixture was filtered through celite (trade mark) and theresidue was washed with a mixture of t-butylmethyl ether/ethyl acetate(1/1). To the filtrate was added water and the mixture was extractedwith ethyl acetate (4 times). The organic layer was washed with waterand a saturated aqueous solution of sodium chloride, dried overanhydrous magnesium sulfate and concentrated. The residue was purifiedby column chromatography (hexane:ethyl acetate=1:1) and thenrecrystallized from etnyl acetate/hexane to give the title compound(51.4 g) having the following physical data.

TLC: Rf 0.34 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.71 (d, J=2.7 Hz, 1H), 7.24 (d, J=8.7 Hz, 1H),7.17 (dd, J=8.7, 2.7 Hz, 1H), 5.20 (s, 2H), 3.67 (s, 3H), 3.49 (s, 3H),3.27 (t, J=7.6 Hz, 2H), 2.68 (t, J=7.6 Hz, 2H).

REFERENCE EXAMPLE 46 1-aza-1-benzyloxy-4-methylpent-1-ene

A solution of 3-methylbutanal (60.8 g) and benzyloxyamine hydrochloride(112.7 g) in pyridine (500 ml) was stirred at 80° C. for 2 hours. Thereaction solution was concentrated and azeotroped with toluene. Theresidue was dissolved in ethyl acetate, washed with 1N hydrochloricacid, water and a saturated aqueous solution of sodium chloride, driedover anhydrous sodium sulfate, and concentrated to give the titlecompound (134 g) having the following physical data.

TLC: Rf 0.85 (n-hexane:ethyl acetate=9:1).

REFERENCE EXAMPLE 47N-benzyloxy-N-(3-methyl-1-(3,5-dimethylphenyl)butyl)amine

To a solution of 5-bromo-m-xylene (75 g) in THF (575 ml) was addedn-butyllithium (235 ml) at −78° C. under an atmosphere of argon. Themixture was stirred for 1 hour. To the mixture were added a solution ofthe compound prepared in Reference Example 46 (29.8 g) in toluene (338ml) and boron trifluoride diethyl ether complex (51 ml) subsequently,and the mixture was stirred for 3 hours. To the reaction solution wasadded water and the mixture was extracted with ethyl acetate. Theorganic layer was washed with a saturated aqueous solution of sodiumchloride, dried over anhydrous sodium sulfate and then concentrated. Tothe residue was added 4N hydrogen chloride in ethyl acetate (50 ml). Theobtained hydrochloride was washed with ethyl acetate/hexane and thendissolved in ethyl acetate. The solution was neutralized with asaturated aqueous solution of sodium bicarbonate, and washed with waterand a saturated aqueous solution of sodium chloride to give the titlecompound (23 g) having the following physical data.

TLC: Rf 0.72 (n-hexane:ethyl acetate=9:1);

NMR (300 MHz, CDCl₃): δ 7.20-7.00 (m, 5H), 6.96 (s, 2H), 6.91 (s, 1H),4.67(m, 1H), 4.61 (d, J=15.3 Hz, 1H), 4.53 (d, J=15.3 Hz, 1H), 2.32 (s,6H), 1.80-1.57(m, 3H), 0.95 (d, J=6.6 Hz, 6H).

REFERENCE EXAMPLE 48 3-methyl-1-(3,5-dimethylphenyl)butylaminehydrochloride

To a solution of the compound prepared in Reference Example 47 (12 g) inmethanol (120 ml) was added 10% palladium carbon (1.2 g) and the mixturewas stirred overnight under an atmosphere of hydrogen. The reactionmixture was filtered through celite (trade mark) and the filtrate wasconcentrated. To the residue was added 4N hydrogen chloride in ethylacetate. The obtained hydrochloride was washed with ethyl acetate/hexaneto give the title compound (7.5 g) having the following physical data.

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 8.32 (br, 3H), 7.11 (s, 2H), 6.98 (s, 1H),4.07 (m, 1H), 2.23(s, 6H), 1.74-1.66 (m, 2H), 1.31 (m, 1H), 0.88 (d,J=6.6 Hz, 3H), 0.86 (d, J=6.6 Hz, 3H).

REFERENCE EXAMPLE 49(2R)-3-aza-2-phenyl-4-(3,5-dimethylphenyl)but-3-en-1-ol

A solution of 3,5-dimethylbenzaldehyde (30.0 g) and (R)-phenylglycinol(30.7 g) in toluene (200 ml) was refluxed for 3 hours with removingwater. The reaction solution was concentrated to give the title compound(59.7 g) having the following physical data.

TLC: Rf 0.69 (n-hexane:ethyl acetate=4:1).

REFERENCE EXAMPLE 50(2R,4R)-3-aza-2-phenyl-6-methyl-4-(3,5-dimethylphenyl)hept-6-en-1-olhydrochloride

To a solution of magunesium (40.8 g) in anhydrous THF (800 ml) was addeddropwise a solution of 3-chloro-2-methyl-1-propene (60.8 g) in anhydrousTHF (450 ml) under sodium chloride-ice cooling under an atmosphere ofargon. The mixture was stirred for 1.5 hour under ice-cooling. Themixture was stirred for additional 1 hour at room temperature to giveGrignard reagent.

To a mixture of the compound prepared in Reference Example 49 inanhydrous toluene (300 ml) was added dropwise Grignard reagent (0.5M;1120 ml) during 3 hours under an atmosphere of argon and the mixture wasstirred for 30 minutes. To the reaction mixture were added a saturatedaqueous solution of ammonium chloride and water and the organic layerwas separated. The aqueous layer was extracted with ethyl acetate. Theseorganic layer were combined, washed with a saturated aqueous solution ofsodium chloride, dried over anhydrous magnesium sulfate andconcentrated. To a solution of the residue in ethyl acetate (500 ml) wasadded 4N hydrochloric acid in dioxane (100 ml) under ice-cooling. Thesolution was concentrated and recrystallized from iso propanol-hexane togive the title compound (60.9 g) having the following physical data.

TLC: Rf 0.80 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 9.52 (brs, 2H), 7.39-7.20 (m, 5H), 6.94 (s, 2H),6.81 (s, 1H), 5.44 (brs, 1H), 4.70 (s, 1H), 4.63 (s, 1H), 4.40-4.20 (m,2H), 4.14 (m, 1H), 3.83 (m, 1H), 3.11 (dd, J=14, 4.4 Hz, 1H), 2.94 (dd,J=14, 11 Hz, 1H), 2.17 (s, 6H), 1.49 (s, 3H).

REFERENCE EXAMPLE 51 (1R)-3-methyl-1-(3,5-dimethylphenyl)butylaminehydrochloride

A solution of the compound prepared in Reference Example 50 (33.0 g) andplatinum (IV) dioxide (4.60 g) in ethanol (330 ml) was stirred at 60° C.for 40 hours under an atmosphere of hydrogen. The reaction mixture wasfiltered through celite (trade mark) and the filtrate was concentrated.The residue was recrystallized from ethanol-ethyl acetate to give thetitle compound (7.30 g) having the following physical data.

TLC: Rf 0.30 (chloroform:methanol=9:1);

NMR (300 MHz, DMSO-d₆): δ 8.41 (brs, 3H), 7.11 (s, 2H), 7.01 (s, 1H),4.10 (m, 1H), 2.27 (s, 6H), 1.82-1.66 (m, 2H), 1.31 (m, 1H), 0.86 (d,J=6.6 Hz, 3H), 0.82 (d, J=6.6 Hz, 3H).

REFERENCE EXAMPLE 52 4-hydroxy-4-(3,5-dimethylphenyl)tetrahydropyran

To a solution of 5-bromo-m-xylene (5.55 g) in THF (60 ml) was addedn-butyl lithium (17.8 ml) at −78° C. under an atmosphere of argon. Themixture was stirred for 1 hour. To the reaction solution was addedtetrahydropyran-4-one (2.0 g) and the mixture was stirred for additional3 hours. To the reaction solution was added water and the mixture wasextracted with ethyl acetate. The organic layer was washed with waterand a saturated aqueous solution of sodium chloride, dried overanhydrous sodium sulfate and concentrated. The residue was purified bycolumn chromatography on silica gel (ethyl acetate:n-hexane=1:3) to givethe title compound (2.6 g) having the following physical data.

TLC: Rf 0.51 (ethyl acetate:n-hexane=1:1);

NMR (300 MHz, CDCl₃): δ 7.10 (s, 2H), 6.93 (s, 1H), 3.99-3.82 (m, 5H),2.34 (s, 6H), 2.23-2.11 (m, 2H), 1.72-1.63 (m, 2H).

REFERENCE EXAMPLE 53N-(4-(3,5-dimethylphenyl)perhydropyran-4-yl)-chloroacetamide

To a solution of the compound prepared in Reference Example 52 (1.51 g)in chloroacetonitorile (5 ml) and acetic acid (10 ml) was added dropwisesulfuric acid (3 drops) slowly under ice-cooling. The mixture wasstirred overnight. The reaction solution was poured into ice-water,alkalized with 5N aqueous solution of sodium hydroxide and extractedwith t-butylmethyl ether. The organic layer was washed with water and asaturated aqueous solution of sodium chloride, dried over anhydroussodium sulfate and concentrated. The residue was purified by columnchromatography on silica gel (ethyl acetate:n-hexane=1:3) to give thetitle compound (288 mg) having the following physical data.

TLC: Rf 0.54 (ethyl acetate:n-hexane=1:1);

NMR (300 MHz, CDCl₃): δ 6.98 (s, 2H), 6.90 (s, 1H), 6.76 (bs, 1H), 4.02(s, 2H), 3.89 (dt, J=12.0, 3.3 Hz, 2H), 3.72 (dt, J=12.0, 2.1 Hz, 2H),2.42-2.34 (m, 2H), 2.32 (s, 6H), 2.29-2.13 (m, 2H).

REFERENCE EXAMPLE 54 N-(4-(3,5-dimethylphenyl)perhydropyran-4-yl)amine

To a solution of the compound prepared in Reference Example 53 (250 mg)in ethanol (2 ml)-acetic acid (0.4 ml) was added thiourea (81.2 mg) andthe mixture was stirred at 70° C. overnight. The reaction solution wasdiluted with t-butylmethyl ether, alkalized with 2N aqueous solution ofsodium hydroxide, and then the organic layer was separated. The organiclayer was washed with water and a saturated aqueous solution of sodiumchloride, dried over anhydrous sodium sulfate and concentrated to givethe title compound (160 mg) having the following physical data.

TLC: Rf 0.54 (methanol:chloroform=1:5);

NMR (300 MHz, CDCl₃): δ 7.07 (s, 2H), 6.90 (s, 1H), 3.92 (dt, J=11.4,2.4 Hz, 2H), 3.79 (dt, J=11.4, 4.2 Hz, 2H), 2.34 (s, 6H), 2.24-2.13 (m,2H), 1.68-1.60 (m, 2H).

EXAMPLE 323-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-methoxymethoxyphenyl)propanoicacid methyl ester

A solution of the compound prepared in Reference Example 45 (1.00 g),the compound prepared in Reference Example 48 (930 mg),1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (1.36 g),1-hydroxybenzotriazole (958 mg) and N-methylmorpholine (1.6 ml) in DMF(14 ml) was stirred at room temperature for 3 hours. To the reactionmixture were added water and ethyl acetate, and the organic layer wasseparated. The organic layer was washed with water and a saturatedaqueous solution of sodium chloride, dried over anhydrous sodium sulfateand concentrated. The obtained crude crystal was recrystallized fromethyl acetate/hexane to give the title compound (1.29 g) having thefollowing physical data.

TLC: Rf 0.84 (hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.16-7.12 (m, 1H), 7.04-6.98 (m, 2H), 6.96 (s,2H), 6.89 (s, 1H), 6.40 (d, J=9.0 Hz, 1H), 5.20-5.10 (m, 3H), 3.62 (s,3H), 3.46 (s, 3H), 3.00-2.90 (m, 2H), 2.65-2.55 (m, 2H), 2.31 (s, 6H),1.80-1.60 (m, 3H), 0.98 (d, J=6.3 Hz, 3H), 0.97 (d, J=6.3 Hz, 3H).

EXAMPLE 333-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methylbenzyloxy)phenyl)propanoicacid methyl ester

Using the compound prepared in Example 32, the title compounds havingthe following physical data were obtained by the same procedures as aseries of reactions of Example 11→Example 5.

TLC: Rf 0.61 (n-hexane:acetone=2:1).

EXAMPLE 33(1)˜33(21)

Using corresponding compounds, the following compounds were obtained bythe same procedure of Example 33.

EXAMPLE 33(1)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxyphenyl)propanoicacid ethyl ester

TLC: Rf 0.26 (n-hexane:ethyl acetate=4:1).

EXAMPLE 33(2)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanobenzyloxy)phenyl)propanoicacid ethyl ester

TLC: Rf 0.41 (n-hexane:ethyl acetate=3:1).

EXAMPLE 33(3)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-phenoxyphenyl)butanoicacid methyl ester

TLC: Rf 0.69 (n-hexane:ethyl acetate=1:1).

EXAMPLE 33(4)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxybenzyloxy)phenyl)propanoicacid methyl ester

TLC: Rf 0.53 (n-hexane:ethyl acetate=2:1).

EXAMPLE 33(5)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chlorobenzyloxy)phenyl)propanoicacid methyl ester

TLC: Rf 0.53 (n-hexane:ethyl acetate=2:1).

EXAMPLE 33(6)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-cyanophenoxy)phenyl)butanoicacid methyl ester

TLC: Rf 0.47 (n-hexane:ethyl acetate 1:1).

EXAMPLE 33(7)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-aminophenoxy)phenyl)butanoicacid methyl ester

TLC: Rf 0.43 (n-hexane:ethyl acetate=1:1).

EXAMPLE 33(8)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(3-fluorophenoxy)phenyl)butanoicacid methyl ester

TLC: Rf 0.85 (n-hexane:ethyl acetate=1:1).

EXAMPLE 33(9)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(3-methoxyphenoxy)phenyl)butanoicacid methyl ester

TLC: Rf 0.64 (n-hexane:ethyl acetate=1:1).

EXAMPLE 33(10)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-fluorophenoxy)phenyl)butanoicacid methyl ester

TLC: Rf 0.67 (n-hexane:ethyl acetate=2:1).

EXAMPLE 33(11)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(pyridin-2-yl)oxyphenyl)butanoicacid methyl ester

TLC: Rf 0.34 (n-hexane:ethyl acetate=1:1).

EXAMPLE 33(12)3-(2-((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxyphenyl)propanoicacid methyl ester

TLC: Rf 0.86 (n-hexane:ethyl acetate=1:1).

EXAMPLE 33(13)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)propanoicacid methyl ester

TLC: Rf 0.36 (n-hexane:ethyl acetate=2:1).

EXAMPLE 33(14)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chloro-6-fluorobenzyloxy)phenyl)propanoicacid methyl ester

TLC: Rf 0.68 (n-hexane:ethyl acetate=1:1).

EXAMPLE 33(15)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,3,6-trifluorobenzyloxy)phenyl)propanoicacid methyl ester

TLC: Rf 0.61 (n-hexane:ethyl acetate=1:1).

EXAMPLE 33(16)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxyphenyl)propanoicacid methyl ester

TLC: Rf 0.38 (n-hexane:ethyl acetate=2:1).

EXAMPLE 33(17)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-6-fluorobenzyloxy)phenyl)propanoicacid methyl ester

TLC: Rf 0.41 (n-hexane:ethyl acetate=2:1).

EXAMPLE 33(18)3-(2-((4-(naphthalen-1-yl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)propanoicacid methyl ester

TLC: Rf 0.51 (n-hexane:ethyl acetate=1:1).

EXAMPLE 33(19)4-(2-((4-(naphthalen-1-yl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)butanoicacid methyl ester

TLC: Rf 0.63 (n-hexane:ethyl acetate=1:1).

EXAMPLE 33(20)4-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)butanoicacid methyl ester

TLC: Rf 0.71 (n-hexane:ethyl acetate 1:1).

EXAMPLE 33(21)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,6-trifluorobenzyloxy)phenyl)propanoicacid methyl ester

TLC: Rf 0.53 (n-hexane:ethyl acetate=2:1).

EXAMPLE 343-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methylbenzyloxy)phenyl)propanoicacid

Using the compounds prepared in Example 33, the title compound havingthe following physical data was obtained by the same procedure ofExample 3.

TLC: Rf 0.69 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.29 (d, J=7.8 Hz, 2H), 7.22-7.18 (m, 3H),6.98-6.88 (m, 5H), 6.21 (d, J=8.4 Hz, 1H), 5.13 (q, J=8.4 Hz, 1H), 4.99(s, 2H), 3.00-2.90 (m, 2H), 2.69 (t, J=7.5 Hz, 2H), 2.36 (s, 3H), 2.30(s, 6H), 1.80-1.50 (m, 3H), 0.97 (d, J=6.3 Hz, 3H), 0.97 (d, J=6.3 Hz,3H).

EXAMPLE 34(1)˜34(191)

Using the compounds prepared in Example 33(1)˜33(21), the compounds wereobtained by the same procedure of Example 34, or using correspondingcompounds and Reference Example 48, Reference Example 51, ReferenceExample 54 or the compounds corresponding to them, the compounds wereobtained by the same procedures as a series of reactions of ReferenceExample 32→Example 33→Example 34.

EXAMPLE 34(1)3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(3-cyanobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.72 (s, 1H), 7.66-7.60 (m, 2H), 7.49 (t, J=7.8Hz, 1H), 7.39-7.23 (m, 5H), 7.17 (d, J=8.1 Hz, 1H), 6.97-6.89 (m, 2H),6.47 (d, J=8.4 Hz, 1H), 5.22 (m, 1H), 5.05 (s, 2H), 2.94 (t, J=6.8 Hz,2H), 2.69 (t, J=6.8 Hz, 2H), 1.88-1.50 (m, 3H), 0.98 (d, J=6.6 Hz, 6H).

EXAMPLE 34(2)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxyphenyl)propanoicacid

TLC: Rf 0.35 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.43-7.33 (m, 5H), 7.17 (m, 1H), 6.98-6.90 (m,5H), 6.24 (d, J=8.4 Hz, 1H), 5.14 (m, 1H), 5.04 (s, 2H), 2.99-2.92 (m,2H), 2.70 (t, J=7.5 Hz, 2H), 2.31 (s, 6H), 1.80-1.53 (m, 3H), 0.97 (d,J=6.6 Hz, 6H).

EXAMPLE 34(3)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.38 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.71 (s, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.61 (s,1H), 7.49 (dd, J=7.8, 7.8 Hz, 1H), 7.17 (d, J=7.8 Hz, 1H), 6.97-6.87 (m,5H), 6.40 (d, J=8.4 Hz, 1H), 5.15 (m, 1H), 5.04 (s, 2H), 2.98-2.91 (m,2H), 2.71-2.64 (m, 2H), 2.30 (s, 6H), 1.82-1.53 (m, 3H), 0.97 (d, J=6.6Hz, 6H).

EXAMPLE 34(4)3-(2-(naphthalen-1-ylmethylcarbamoyl)-4-phenoxyphenyl)propanoic acid

TLC: Rf 0.47 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.08 (d, J=7.8 Hz, 1H), 7.91-7.79 (m, 2H),7.58-7.39 (m, 4H), 7.36-7.06 (m, 5H), 7.02-6.90 (m, 3H), 6.27 (m, 1H),5.06 (d, J=5.4 Hz, 2H), 3.06 (t, J=7.5 Hz, 2H), 2.77 (t, J=7.5 Hz, 2H).

EXAMPLE 34(5)3-(2-(1-(naphthalen-2-yl)ethylcarbamoyl)-4-phenoxyphenyl)propanoic acid

TLC: Rf 0.47 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.88-7.72 (m, 4H), 7.52-6.92 (m, 1H), 6.46 (d,J=7.5 Hz, 1H), 5.46 (m, 1H), 3.03 (t, J=7.5 Hz, 2H), 2.75 (t, J=7.5 Hz,2H). 1.67 (d, J=6.6 Hz, 3H).

EXAMPLE 34(6)3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.48 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.29 (d, J=8.4 Hz, 1H), 7.86 (d, J=7.5 Hz, 1H),7.78 (d, J=7.5 Hz, 1H), 7.62-7.28 (m, 6H), 7.22-7.07 (m, 2H), 7.02-6.90(m, 4H), 6.27 (d, J=8.7 Hz, 1H), 6.10 (m, 1H), 2.99 (t, J=7.5 Hz, 2H),2.71 (t, J=7.5 Hz, 2H), 1.97-1.90 (m, 2H), 1.78 (m, 1H), 1.11 (d, J=6.6Hz, 3H), 0.99 (d, J=6.6 Hz, 3H).

EXAMPLE 34(7)3-(2-(4-methyl-2-phenylpentyl)carbamoyl)-4-phenoxyphenyl)propanoic acid

TLC: Rf 0.47 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.35 (t, J=7.5 Hz, 2H), 7.30-7.10 (m, 7H),7.00-6.90 (m, 3H), 6.73 (d, J=2.7 Hz, 1H), 5.85-5.80 (m, 1H), 3.86-3.76(m, 1H), 3.40-3.28 (m, 1H), 3.02-2.84 (m, 3H), 2.67 (t, J=7.8 Hz, 2H),1.65-1.35 (m, 3H), 0.86 (d, J=6.3 Hz, 3H), 0.84 (d, J=6.3 Hz, 3H).

EXAMPLE 34(8)3-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-cyanophenoxy)phenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.19 (d, J=8.1 Hz, 1H), 7.87 (d, J=8.1 Hz, 1H),7.81 (d, J=8.1 Hz, 1H), 7.68-7.42 (m, 6H), 7.28 (m, 1H), 7.18-6.98 (m,3H), 6.84 (d, J=8.4 Hz, 1H), 6.40 (d, J=7.8 Hz, 1H), 6.12 (m, 1H), 3.08(t, J=7.5 Hz, 2H), 2.77 (t, J=7.5 Hz, 2H), 1.79 (d, J=6.6 Hz, 3H).

EXAMPLE 34(9)3-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-cyanophenoxy)phenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.17 (d, J=8.1 Hz, 1H), 7.87 (m, 1H), 7.81 (d,J=8.1 Hz, 1H), 7.60-7.41 (m, 6H), 7.28 (m, 1H), 7.04-6.90 (m, 4H), 6.35(d, J=8.4 Hz, 1H), 6.11 (m, 1H), 3.13-3.02 (t, J=7.5 Hz, 2H), 2.75 (t,J=7.5 Hz, 2H), 1.79 (d, J=6.6 Hz, 3H).

EXAMPLE 34(10)3-(2-((1R)-1-phenylethylcarbamoyl)-4-phenoxyphenyl)propanoic acid

TLC: Rf 0.47 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.23 (m, 7H), 7.20 (d, J=8.4 Hz, 1H), 7.12(t, J=7.2 Hz, 1H), 7.05 (d, J=2.4 Hz, 1H), 7.02-6.92 (m, 3H), 6.39 (d,J=7.5 Hz, 1H), 5.28 (q, J=7.5 Hz, 1H), 3.01 (t, J=7.5 Hz, 2H), 2.73 (t,J=7.5 Hz, 2H), 1.57 (d, J=6.9 Hz, 3H).

EXAMPLE 34(11)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-phenoxyphenyl)butanoicacid

TLC: Rf 0.64 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.19 (d, J=7.8 Hz, 1H), 7.86 (d, J=7.5 Hz, 1H),7.80 (d, J=8.1 Hz, 1H), 7.58-7.40 (m, 4H), 7.31 (t, J=7.5 Hz, 2H),7.20-7.06 (m, 2H), 6.98-6.88 (m, 4H), 6.15-6.05 (m, 1H), 6.01 (d, J=8.1Hz, 1H), 2.85-2.70 (m, 2H), 2.40-2.20 (m, 2H), 2.00-1.80 (m, 2H), 1.76(d, J=6.3 Hz, 3H).

EXAMPLE 34(12)3-(2-((1R)-1-(4-methylphenyl)ethylcarbamoyl)-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.24 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.37-7.31 (m, 2H), 7.26-7.10 (m, 6H), 7.04 (d,J=2.1 Hz, 1H), 7.00-6.93 (m, 3H), 6.29 (brd, J=5.4 Hz, 1H), 5.25 (m,1H), 3.05-3.00 (m, 2H), 2.77-2.72 (m, 2H), 2.33 (s, 3H), 1.56 (d, J=6.6Hz, 3H).

EXAMPLE 34(13)3-(2-(1-(4-fluorophenyl)ethylcarbamoyl)-4-phenoxyphenyl)propanoic acid

TLC: Rf 0.62 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.38-7.30 (m, 4H), 7.20 (d, J=8.4 Hz, 1H), 7.12(t, J=7.5 Hz, 1H), 7.05-6.93 (m, 6H), 6.40 (d, J=7.5 Hz, 1H), 5.30-5.20(m, 1H), 3.00 (t, J=7.5 Hz, 2H), 2.72 (t, J=7.5 Hz, 2H), 1.55 (d, J=6.9Hz, 3H).

EXAMPLE 34(14)3-(2-((1R)-1-indan-1-yl)carbamoyl-4-phenoxyphenyl)propanoic acid

TLC: Rf 0.59 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.30 (m, 3H), 7.30-7.20 (m, 4H), 7.15-7.05(m, 2H), 7.03-6.94 (m, 3H), 6.27 (d, J=8.7 Hz, 1H), 5.64 (q, J=7.5 Hz,1H), 3.10 (t, J=7.5 Hz, 2H), 3.06-2.84 (m, 2H), 2.80 (t, J=7.5 Hz, 2H),2.76-2.62 (m, 1H), 2.00-1.80 (m, 1H).

EXAMPLE 34(15)3-(2-(1-methyl-3-phenylpropyl)carbamoyl-4-phenoxyphenyl)propanoic acid

TLC: Rf 0.54 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.40-6.94 (m, 13H), 5.92 (d, J=8.4 Hz, 1H), 4.22(m, 1H), 3.05 (t, J=7.5 Hz, 2H), 2.81 (t, J=7.5 Hz, 2H), 2.70 (t, J=7.8Hz, 2H), 1.93-1.78 (m, 2H), 1.27 (d, J=6.6 Hz, 3H).

EXAMPLE 34(16)3-(2-((1R)-1-(4-nitrophenyl)ethylcarbamoyl)-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.19 (d, J=7.8 Hz, 2H), 7.53 (d, J=7.8 Hz, 2H),7.40-6.94 (m, 8H), 6.66 (d, J=7.2 Hz, 1H), 5.33 (m, 1H), 2.99 (t, J=7.2Hz, 2H), 2.73 (t, J=7.2 Hz, 2H), 1.59 (d, J=7.2 Hz, 3H).

EXAMPLE 34(17) 3-(2-diphenylmethylcarbamoyl-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol 10:1);

NMR (300 MHz, CDCl₃): δ 7.44-6.93 (m, 18H), 6.71 (d, J=8.1 Hz, 1H), 6.42(d, J=8.1 Hz, 1H), 3.02 (t, J=7.2 Hz, 2H), 2.72 (t, J=7.2 Hz, 2H).

EXAMPLE 34(18)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.57 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.39-7.09 (m, 5H), 7.05-6.87 (m, 6H), 6.21 (d,J=8.4 Hz, 1H), 5.13 (m, 1H), 3.06-2.92 (m, 2H), 2.72 (t, J=7.8 Hz, 2H),2.29 (s, 6H), 1.81-1.50 (m, 3H), 0.97 (d, J=6.3 Hz, 3H), 0.96 (d, J=6.3Hz, 3H).

EXAMPLE 34(19)3-(2-((1R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.38-6.92 (m, 12H), 6.25 (d, J=8.4 Hz, 1H), 5.35(m, 1H), 3.10 (t, J=7.2 Hz, 2H), 2.90-2.71 (m, 4H), 2.14 (m, 1H),2.01-1.78 (m, 3H).

EXAMPLE 34(20)3-(2-((1R)-1-(1,1′-biphenyl-4-yl)ethylcarbamoyl)-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.65-6.92 (m, 17H), 6.40 (d, J=8.1 Hz, 1H), 5.33(m, 1H), 3.03 (t, J=7.2 Hz, 2H), 2.80-2.70 (m, 2H), 1.61 (d, J=6.9 Hz,3H).

EXAMPLE 34(21)3-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-methylphenoxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.17 (d, J=7.8 Hz, 1H), 7.90-7.77 (m, 2H),7.59-7.41 (m, 4H), 7.21-7.07 (m, 3H), 6.98-6.80 (m, 4H), 6.29 (d, J=8.1Hz, 1H), 6.10 (m, 1H), 3.04 (t, J=7.2 Hz, 2H), 2.75 (t, J=7.2 Hz, 2H),2.33 (s, 3H), 1.78 (d, J=6.9 Hz, 3H).

EXAMPLE 34(22) 3-(2-(cyano-phenylcarbamoyl)-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.62 (methylene chloride:methanol=9:1);

NMR (300 MHz, CD₃OD): δ7.58-7.54 (m, 2H), 7.48-7.28 (m, 6H), 7.13 (t,J=7.5 Hz, 1H), 7.03-6.97 (m, 4H), 6.29 (s, 1H), 2.97 (t, J=7.2 Hz, 2H),2.57 (t, J=7.2 Hz, 2H).

EXAMPLE 34(23)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.61 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.32 (m, 2H), 7.18-7.12 (m, 1H), 7.10-7.02(m, 2H), 6.96-6.88 (m, 5H), 6.27 (d, J=8.4 Hz, 1H), 5.14 (q, J=8.4 Hz,1H), 4.98 (s, 2H), 3.00-2.90 (m, 2H), 2.75-2.65 (m, 2H), 2.30 (s, 6H),1.80-1.50 (m, 3H), 0.97 (d, J=6.3 Hz, 3H), 0.97 (d, J=6.3 Hz, 3H).

EXAMPLE 34(24)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-cyanobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.63 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.70 (d, J=7.5 Hz, 1H), 7.63 (dd, J=4.8, 1.2 Hz,2H), 7.50-7.40 (m, 1H), 7.18 (d, J=8.7 Hz, 1H), 7.02-6.94 (m, 4H), 6.90(s, 1H), 6.36 (d, J=8.4 Hz, 1H), 5.23 (s, 2H), 5.15 (q, J=8.4 Hz, 1H),3.00-2.90 (m, 2H), 2.75-2.65 (m, 2H), 2.30 (s, 6H), 1.85-1.50 (m, 3H),0.98 (d, J=6.6 Hz, 6H).

EXAMPLE 34(25)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.40 (d, J=7.2 Hz, 1H), 7.31 (m, 1H), 7.17 (m,1H), 7.04-6.87 (m, 7H), 6.22 (d, J=8.4 Hz, 1H), 5.14 (m, 1H), 5.08 (s,2H), 3.84 (s, 3H), 3.02-2.90 (m, 2H), 2.71 (t, J=7.5 Hz, 2H), 2.31 (s,6H), 1.83-1.52 (m, 3H), 0.97 (d, J=6.0 Hz, 6H).

EXAMPLE 34(26)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chlorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.51 (m, 1H), 7.40 (m, 1H), 7.33-7.23 (m, 2H),7.18 (m, 1H), 7.00-6.87 (m, 5H), 6.23 (d, J=8.7 Hz, 1H), 5.20-5.10 (m,1H), 5.15 (s, 2H), 3.02-2.89 (m, 2H), 2.70 (t, J=7.5 Hz, 2H), 2.31 (s,6H), 1.83-1.52 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(27)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-phenylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.56 (m, 1H), 7.44-7.30 (m, 8H), 7.11 (d, J=8.1Hz, 1H), 6.95-6.77 (m, 5H), 6.17 (d, J=8.4 Hz, 1H), 5.13 (m, 1H), 4.91(s, 2H), 2.99-2.87 (m, 2H), 2.68 (t, J=7.5 Hz, 2H), 2.30 (s, 6H),1.83-1.50 (m, 3H), 0.97 (d, J=6.3 Hz, 6H).

EXAMPLE 34(28)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.57 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.36 (d, J=7.2 Hz, 1H), 7.30-7.14 (m, 4H),7.01-6.88 (m, 5H), 6.24 (d, J=8.4 Hz, 1H), 5.15 (m, 1H), 5.01 (s, 2H),3.02-2.90 (m, 2H), 2.68 (t, J=7.5 Hz, 2H), 2.36 (s, 3H), 2.30 (s, 6H),1.83-1.53 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(29)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.50-7.42 (m, 1H), 7.38-7.28 (m, 1H), 7.23-7.04(m, 3H), 7.02-6.88 (m, 5H), 6.24 (d, J=8.7 Hz, 1H), 5.20-5.08 (m, 1H),5.11 (s. 2H), 3.02-2.90 (m, 2H), 2.72 (t, J=7.2 Hz, 2H), 2.31 (s, 6H),1.84-1.50 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(30)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-ethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.32 (d, J=7.8 Hz, 2H), 7.25-7.14 (m, 3H),7.00-6.88 (m, 5H), 6.23 (d, J=8.1 Hz, 1H), 5.20-5.10 (m, 1H), 5.00 (s.2H), 3.02-2.90 (m, 2H), 2.75-2.60 (m, 4H), 2.31 (s, 6H), 1.82-1.50 (m,3H), 1.24 (t, J=7.5 Hz, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(31)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(32)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3-dimethoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.17 (d, J=7.8 Hz, 1H), 7.12-6.88 (m, 8H), 6.27(d, J=8.7 Hz, 1H), 5.20-5.08 (m, 1H), 5.09 (s. 2H), 3.88 (s, 3H), 3.86(s, 3H), 3.02-2.90 (m, 2H), 2.71 (t, J=7.2 Hz, 2H), 2.31 (s, 6H),1.84-1.50 (m, 3H), 0.98 (d, J=6.6 Hz, 6H).

EXAMPLE 34(33)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,6-dimethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.54 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.28-7.13 (m, 3H), 7.12-6.95 (m, 3H), 6.94 (s,2H), 6.90 (s, 1H), 6.29 (d, J=8.7 Hz, 1H), 5.15 (m, 1H), 5.01 (s, 2H),3.03-2.92 (m, 2H), 2.72 (t, J=6.9 Hz, 2H), 2.38 (s, 6H), 2.30 (s, 6H),1.82-1.55 (m, 3H), 0.97 (d, J=6.3 Hz, 6H).

EXAMPLE 34(34)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chlorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.42 (s, 1H), 7.34-7.22 (m, 3H), 7.21-7.14 (m,1H), 6.97-6.88 (m, 5H), 6.26 (d, J=8.1 Hz, 1H), 5.20-5.10 (m, 1H), 5.01(s. 2H), 3.00-2.93 (m, 2H), 2.71 (t, J=7.2 Hz, 2H), 2.31 (s, 6H),1.84-1.50 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(35)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.30 (m, 1H), 7.21-7.10 (m, 3H), 7.07-6.98(m, 1H), 6.98-6.89 (m, 5H), 6.26 (d, J=8.7 Hz, 1H), 5.20-5.08 (m, 1H),5.04 (s. 2H), 3.00-2.90 (m, 2H), 2.71 (t, J=7.2 Hz, 2H), 2.31 (s, 6H),1.84-1.50 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(36)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(37)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-trifluoromethyloxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(38)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-isopropylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(39)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(naphthalen-1-yl)methyloxyphenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 8.05-7.98 (m, 1H), 7.94-7.84 (m, 2H), 7.60-7.40(m, 4H), 7.22 (d, J=8.1 Hz, 1H), 7.10-7.00 (m, 2H), 6.96-6.88 (m, 3H),6.26 (d, J=8.1 Hz, 1H), 5.47 (s, 2H), 5.20-5.10 (m, 1H), 3.05-2.90 (m,2H), 2.73 (t, J=7.2 Hz, 2H), 2.30 (s, 6H), 1.84-1.50 (m, 3H), 0.97 (d,J=6.3 Hz, 3H), 0.96 (d, J=6.3 Hz, 3H).

EXAMPLE 34(40)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-butylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(41)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-t-butylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(42)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-phenylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.65-7.55 (m, 4H), 7.55-7.32 (m, 5H), 7.23-7.15(m, 1H), 7.06-6.86 (m, 5H), 6.24 (d, J=8.4 Hz, 1H), 5.20-5.08 (m, 1H),5.08 (s, 2H), 3.03-2.92 (m, 2H), 2.72 (t, J=6.9 Hz, 2H), 2.30 (s, 6H),1.84-1.50 (m, 3H), 0.98 (d, J=5.4 Hz, 6H).

EXAMPLE 34(43)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-benzylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(44)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-6-fluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.36-7.18 (m, 3H), 7.10-6.88 (m, 6H), 6.27 (d,J=8.7 Hz, 1H), 5.20-5.10 (m, 3H), 3.02-2.94 (m, 2H), 2.73 (t, J=6.9 Hz,2H), 2.31 (s, 6H), 1.84-1.50 (m, 3H), 0.98 (d, J=6.0 Hz, 6H).

EXAMPLE 34(45)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.25-7.16 (m, 2H), 7.10-6.90 (m, 7H), 6.28 (d,J=8.1 Hz, 1H), 5.20-5.10 (m, 1H), 5.09 (s, 2H), 3.05-2.90 (m, 2H), 2.72(t, J=7.5 Hz, 2H), 2.31 (s, 6H), 1.84-1.50 (m, 3H), 0.98 (d, J=6.3 Hz,6H).

EXAMPLE 34(46)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chlorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(47)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-5-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(48)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-difluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(49)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,5-dimethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(50)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(1-ethyl-3-methylpyrazol-5-yl)methoxyphenyl)propanoicacid

TLC: Rf 0.33 (n-hexane:ethyl acetate=1:1).

EXAMPLE 34(51)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-6-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.57 (n-hexane:ethyl acetate=1:1).

EXAMPLE 34(52)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3-difluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.57 (n-hexane:ethyl acetate=1:1).

EXAMPLE 34(53)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,6-difluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.57 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃+CD₃OD): δ 7.34 (m, 1H), 7.19 (d, J=8.4 Hz, 1H),7.03-6.85 (m, 7H), 6.28 (d, J=8.4 Hz, 1H), 5.15 (m, 1H), 5.11 (s, 2H),3.11-2.88 (m, 2H), 2.69 (t, J=7.1 Hz, 2H), 2.30 (s, 6H), 1.86-1.52 (m,3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(54)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-4-fluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.60 (n-hexane:ethyl acetate=1:1).

EXAMPLE 34(55)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,5-difluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (n-hexane:ethyl acetate=1:1).

EXAMPLE 34(56)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,5-bis(trifluoromethyl)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.59 (n-hexane:ethyl acetate=1:1).

EXAMPLE 34(57)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,4-difluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.60 (n-hexane:ethyl acetate=1:1).

EXAMPLE 34(58)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-trifluoromethyloxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.57 (n-hexane:ethyl acetate=1:1).

EXAMPLE 34(59)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,4-dimethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (n-hexane:ethyl acetate=1:1).

EXAMPLE 34(60)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxynaphthalen-1-ylmethyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(61)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,6-trifluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.26-7.12 (m, 2H), 7.02-6.84 (m, 6H), 6.29 (d,J=8.7 Hz, 1H), 5.20-5.10 (m, 1H), 5.11 (s. 2H), 3.00-2.92 (m, 2H), 2.70(t, J=7.2 Hz, 2H), 2.31 (s, 6H), 1.84-1.54 (m, 3H), 0.98 (d, J=6.3 Hz,6H).

EXAMPLE 34(62)4-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxyphenyl)butanoicacid

TLC: Rf 0.54 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.45-7.28 (m, 5H), 7.12 (d, J=8.1 Hz, 1H),6.99-6.86 (m, 5H), 5.89 (d, J=8.4 Hz, 1H), 5.14 (m, 1H), 5.04 (s, 2H),2.68 (t, J=7.5 Hz, 2H), 2.31 (s, 6H), 2.26 (t, J=7.2 Hz, 2H), 1.96-1.48(m, 5H), 0.98 (d, J=4.8 Hz, 6H).

EXAMPLE 34(63)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-nitrophenoxy)phenyl)butanoicacid

TLC: Rf 0.46 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.23-8.13 (m, 3H), 7.87 (d, J=8.1 Hz, 1H), 7.82(d, J=8.1 Hz, 1H), 7.59-7.42 (m, 4H), 7.06-6.92 (m, 4H), 6.12 (m, 1H),6.01 (d, J=8.7 Hz, 1H), 2.88-2.76 (m, 2H), 2.37-2.29 (m, 2H), 2.00-1.88(m, 2H), 1.79 (d, J=6.6 Hz, 3H).

EXAMPLE 34(64)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-aminophenoxy)phenyl)butanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1).

EXAMPLE 34(65)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-methylsulfonylphenoxy)phenyl)butanoicacid

TLC: Rf 0.43 (chloroform:methanol=10:1).

EXAMPLE 34(66)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-thienylmethyloxy)phenyl)propanoicacid

TLC: Rf 0.45 (chloroform:methanol=10:1).

EXAMPLE 34(67)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(1,3-dioxyindan-4-yl)methyloxyphenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=10:1).

EXAMPLE 34(68)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-dimethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=10:1).

EXAMPLE 34(69)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1).

EXAMPLE 34(70)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methylthiobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=10:1).

EXAMPLE 34(71)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-dimethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1).

EXAMPLE 34(72)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-4-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(73)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluoro-3-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(74)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluoro-5-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(75)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluoro-3-chlorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(76)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluoro-4-methylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(77)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-5-methoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.19 (m, 1H), 7.04-6.89 (m, 7H), 6.82 (m, 1H),6.26 (d, J=8.7 Hz, 1H), 5.15 (m, 1H), 5.07 (s, 2H), 3.78 (s, 3H),3.00-2.92 (m, 2H), 2.70 (t, J=7.4 Hz, 2H), 2.31 (s, 6H), 1.83-1.50 (m,3H), 0.98 (d, J=6.0 Hz, 6H).

EXAMPLE 34(78)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-isobutylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.31 (d, J=8.1 Hz, 2H), 7.20-7.13 (m, 3H),6.99-6.88 (m, 5H), 6.22 (d, J=8.4 Hz, 1H), 5.14 (m, 1H), 5.00 (s, 2H),3.00-2.91 (m, 2H), 2.70 (t, J=7.5 Hz, 2H), 2.48 (d, J=7.2 Hz, 2H), 2.30(s, 6H), 1.93-1.52 (m, 4H), 0.98 (d, J=6.3 Hz, 3H), 0.97 (d, J=6.3 Hz,3H), 0.91 (d, J=6.6 Hz, 6H).

EXAMPLE 34(79)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4,5-trimethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.60 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.18 (d, J=9.0 Hz, 1H), 7.12 (s, 1H), 7.02-6.88(m, 6H), 6.25 (d, J=8.4 Hz, 1H), 5.14 (m, 1H), 4.93 (s, 2H), 3.03-2.90(m, 2H), 2.70 (t, J=7.5 Hz, 2H), 2.30 (s, 6H), 2.29 (s, 3H), 2.23 (s,6H), 1.83-1.52 (m, 3H), 0.98 (d, J=6.3 Hz, 3H), 0.97 (d, J=6.3 Hz, 3H).

EXAMPLE 34(80%3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-(4-methoxyphenoxy)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.62 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.30 (t, J=7.9 Hz, 1H), 7.16 (d, J=8.0 Hz, 1H),7.07 (d, J=8.0 Hz, 1H), 7.02-6.84 (m, 1H), 6.24 (d, J=8.7 Hz, 1H), 5.14(m, 1H), 4.99 (s, 2H), 3.80 (s, 3H), 3.00-2.89 (m, 2H), 2.69 (t, J=7.5Hz, 2H), 2.30 (s, 6H), 1.83-1.50 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(81)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(82)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,4-trimethoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1).

EXAMPLE 34(83)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-cyanophenoxy)phenyl)butanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1).

EXAMPLE 34(84)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-acetylaminophenoxy)phenyl)butanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1).

EXAMPLE 34(85)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-methylsulfonylaminophenoxy)phenyl)butanoicacid

TLC: Rf 0.42 (chloroform:methanol=10:1).

EXAMPLE 34(86)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluoro-3-methoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.54 (n-hexane:ethyl acetate=1:1);

7.17 (m, 1H), 7.10-7.00 (m, 2H), 6.95-6.90 (m, 6H), 6.30 (brd, J=8.4 Hz,1H), 5.14 (m, 1H), 4.96 (s, 2H), 3.89 (s, 3H), 2.98-2.93 (m, 2H),2.71-2.66 (m, 2H), 2.30 (s, 6H), 1.82-1.50 (m, 3H), 0.97 (d, J=6.3 Hz,3H), 0.96 (d, J=6.3 Hz, 3H).

EXAMPLE 34(87)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methoxynaphthalen1-ylmethyloxy)phenyl)propanoic acid

TLC: Rf 0.54 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.33 (m, 1H), 7.96 (m, 1H), 7.58-7.44 (m, 4H),7.20 (d, J=8.4 Hz, 1H), 7.06-6.89 (m, 4H), 6.77 (d, J=7.8 Hz, 1H), 6.26(brd, J=8.4 Hz, 1H), 5.36 (s, 2H), 5.14 (m, 1H), 4.01 (s, 3H), 3.00-2.95(m, 2H), 2.73-2.69 (m, 2H), 2.29 (s, 6H), 1.80-1.52 (m, 3H), 0.96 (d,J=6.3 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H).

EXAMPLE 34(88)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxy-3,5-di(t-butyl)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.36 (d, J=2.4 Hz, 1H), 7.31 (d, J=2.4 Hz, 1H),7.20 (m, 1H), 7.01-7.00 (m, 2H), 6.95 (brs, 2H), 6.90 (brs, 1H), 6.24(d, J=8.7 Hz, 1H), 5.15 (m, 1H), 5.03 (s, 2H), 3.79 (s, 3H), 3.00-2.95(m, 2H), 2.71 (m, 2H), 2.31 (s, 6H), 1.82-1.56 (m, 3H), 1.41 (s, 9H),1.30 (s, 9H), 0.98 (d, J=6.3 Hz, 3H), 0.97 (d, J=6.3 Hz, 3H).

EXAMPLE 34(89)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-phenoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.54 (n-hexane:ethyl acetate=1:1);

7.38-7.32 (m, 4H), 7.19-6.90 (m, 1H), 6.27 (d, J=8.7 Hz, 1H), 5.14 (m,1H), 4.99 (s, 2H), 2.99-2.93 (m, 2H), 2.71-2.66 (m, 2H), 2.30 (s, 6H),1.81-1.53 (m, 3H), 0.98 (d, J=6.3 Hz, 3H), 0.97 (d, J=6.3 Hz, 3H).

EXAMPLE 34(90)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-acetylphenoxy)phenyl)butanoicacid

TLC: Rf 0.48 (chloroform:methanol 10:1).

EXAMPLE 34(91)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-furylmethyloxy)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=10:1).

EXAMPLE 34(92)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chloro-3-fluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.54 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.40 (m, 1H), 7.24-7.11 (m, 3H), 6.94-6.89 (m,5H), 6.29 (d, J=9.0 Hz, 1H), 5.15 (m, 1H), 5.00 (s, 2H), 2.98-2.93 (m,2H), 2.72-2.67 (m, 2H), 2.31 (s, 6H), 1.82-1.55 (m, 3H), 0.98 (d, J=6.3Hz, 6H).

EXAMPLE 34(93)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-((3,5-dimethyl-4-benzyloxy)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.54 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.51-7.35(m, 5H), 7.18 (m, 1H), 7.09 (brs, 2H),6.98-6.90 (m, 5H), 6.25 (d, J=8.4 Hz, 1H), 5.15 (m, 1H), 4.92 (s, 2H),4.81 (s, 2H), 3.00-2.95 (m, 2H), 2.76-2.70 (m, 2H), 2.32 (s, 6H), 2.31(s, 6H), 1.82-1.56 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(94)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2,3,4,5,6-pentafluorophenoxy)phenyl)butanoicacid

TLC: Rf 0.47 (chloroform:methanol=10:1).

EXAMPLE 34(95)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(benzo[e]1,4-dioxan-6-yl)methyloxy)phenyl)propanoicacid

TLC: Rf 0.54 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 7.15 (m, 1H), 6.94-6.87 (m, 8H), 6.24 (d, J=8.7Hz, 1H), 5.14 (m, 1H), 4.91 (s, 2H), 4.26 (s, 4H), 2.98-2.91 (m, 2H),2.71-2.66 (m, 2H), 2.30 (s, 6H), 1.80-1.56 (m, 3H), 0.98 (d, J=6.0 Hz,6H).

EXAMPLE 34(96)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4,6-trifluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.20 (d, J=8.4 Hz, 1H), 7.00-6.95 (m, 4H), 6.91(brs, 1H), 6.74-6.68 (m, 2H), 6.30 (brd, J=8.7 Hz, 1H), 5.15 (m, 1H),5.04 (s, 2H), 2.99-2.94 (m, 2H), 2.73-2.68 (m, 2H), 2.31 (s, 6H),1.83-1.55 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(97)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-4,5-difluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.39 (dd, J=10.8, 8.7 Hz, 1H), 7.28-7.18 (m,2H), 6.95-6.91 (m, 5H), 6.33 (brd, J=8.7 Hz, 1H), 5.15 (m, 1H), 5.06 (s,2H), 2.99-2.94 (m, 2H), 2.93-2.68 (m, 2H), 2.31 (s, 6H), 1.85-1.54 (m,3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(98)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluoro-4-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.61 (m, 1H), 7.30-7.25 (m, 2H), 7.18 (d, J=8.7Hz, 1H), 6.95-6.89 (m, 5H), 6.35 (d, J=8.7 Hz, 1H), 5.15 (m, 1H), 5.08(s, 2H), 2.98-2.93 (m, 2H), 2.72-2.67 (m, 2H), 2.31 (s, 6H), 1.83-1.55(m, 3H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(99)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.85 (brs, 1H), 7.54-7.53 (m, 2H), 7.21 (m, 1H),7.00-6.91 (m, 5H), 6.36 (brd, J=7.8 Hz, 1H), 5.16 (m, 1H), 5.15 (s, 2H),3.00-2.94 (m, 2H), 2.74-2.68 (m, 2H), 2.31 (s, 6H), 1.84-1.56 (m, 3H),0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(100)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-diethoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (n-hexane:ethyl acetate=1:2).

EXAMPLE 34(101)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyano-4-fluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (n-hexane:ethyl acetate=1:2).

EXAMPLE 34(102)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-ethoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.53 (n-hexane:ethyl acetate=1:2).

EXAMPLE 34(103)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-benzyloxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (n-hexane:ethyl acetate=1:2).

EXAMPLE 34(104)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,4,5,6-pentafluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.58 (n-hexane:ethyl acetate=1:2).

EXAMPLE 34(105)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-bis(trifluoromethyl)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (n-hexane:ethyl acetate=1:2).

EXAMPLE 34(106)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methyl-5-fluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (n-hexane:ethyl acetate=1:2).

EXAMPLE 34(107)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-((4-methylnaphthalen-1-yl)methyloxy)phenyl)propanoicacid

TLC: Rf 0.60 (n-hexane:ethyl acetate=1:2).

EXAMPLE 34(108)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4′-trifluoromethyl-1,1′-biphenyl-2-yl)methyloxy)phenyl)propanoicacid

TLC: Rf 0.55 (n-hexane:ethyl acetate=1:2).

EXAMPLE 34(109)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-phenylethoxy)phenyl)propanoicacid

TLC: Rf 0.71 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.59 Hz, 6H) 1.71 (m, 3H) 2.30 (s,6H) 2.68 (m, 2H) 2.94 (m, 2H) 3.08 (t, J=7.14 Hz, 2H) 4.16 (t, J=7.14Hz, 2H) 5.13 (m, 1H) 6.26 (d, J=7.97 Hz, 1H) 6.90 (m, 5H) 7.15 (m,J=8.79 Hz, 1H) 7.29 (m, 5H).

EXAMPLE 34(110)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-phenylpropoxy)phenyl)propanoicacid

TLC: Rf 0.69 (chloroform:methanol=10:1).

EXAMPLE 34(111)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoicacid

TLC: Rf 0.63 (chloroform:methanol=10:1).

EXAMPLE 34(112)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methyl-3-chlorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.69 (chloroform:methanol=10:1).

EXAMPLE 34(113)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-trifluoromethyloxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1).

EXAMPLE 34(114)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-bis(trifluoromethyl)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.64 (chloroform:methanol=10:1).

EXAMPLE 34(115)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-ethoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.58 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40 (dd, J=7.8, 1.8 Hz, 1H), 7.27 (m, 1H), 7.17(m, 1H), 7.03-6.84 (m, 7H), 6.22 (d, J=8.1 Hz, 1H), 5.14 (m, 1H), 5.10(s, 2H), 4.06 (q, J=6.9 Hz, 2H), 3.02-2.89 (m, 2H), 2.70 (t, J=7.5 Hz,2H), 2.31 (s, 6H), 1.83-1.51 (m, 3H), 1.40 (t, J=6.9 Hz, 3H), 0.98 (d,J=6.3 Hz, 6H).

EXAMPLE 34(116)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methylsulfonylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1).

EXAMPLE 34(117)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,5,6-tetrafluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=10:1).

EXAMPLE 34(118)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-3,6-difluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.59 Hz, 6H) 1.70 (m, 3H) 2.31 (s,6H) 2.72 (t, J=7.14 Hz, 2H) 2.97 (m, 2H) 5.16 (m, 1H) 5.16 (s, 2H) 6.27(d, J=8.52 Hz, 1H) 7.00 (m, 6H) 7.18 (m, 2H).

EXAMPLE 34(119)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-hexylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.32-7.30 (m, 2H), 7.20-7.15 (m, 3H), 6.97-6.90(m, 5H), 6.22 (d, J=8.7 Hz, 1H), 5.14 (m, 1H), 4.99 (s, 2H), 2.98-2.93(m, 2H), 2.71-2.66 (m, 2H), 2.63-2.58 (m, 2H), 2.30 (s, 6H), 1.80-1.56(m, 5H), 1.37-1.28 (m, 6H), 0.98 (d, J=6.3 Hz, 3H), 0.97 (d, J=6.3 Hz,3H), 0.90-0.86 (m, 3H).

EXAMPLE 34(120)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,4-diethoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.17 (m, 1H), 6.97-6.85 (m, 8H), 6.25 (d, J=9.0Hz, 1H), 5.14 (m, 1H), 4.94 (s, 2H), 4.09 (q, J=6.9 Hz, 4H), 2.99-2.93(m, 2H), 2.72-2.68 (m, 2H), 2.31 (s, 6H), 1.82-1.55 (m, 3H), 1.45 (t,J=6.9 Hz, 3H), 1.44 (t, J=6.9 Hz, 3H).

EXAMPLE 34(121)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-trifluoromethylthiobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1).

EXAMPLE 34(122)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(6-chloro-2-fluoro-3-methylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=5.77 Hz, 6H) 1.68 (m, 3H) 2.27 (s,3H) 2.30 (s, 6H) 2.71 (t, J=7.50 Hz, 2H) 2.98 (m, 2H) 5.15 (s, 2H) 5.16(m, 1H) 6.25 (d, J=8.24 Hz, 1H) 6.99 (m, 5H) 7.17 (m, 3H).

EXAMPLE 34(123)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-trifluoromethylthiobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=10:1).

EXAMPLE 34(124)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-6-fluoro-3-methylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=5.49 Hz, 6H) 1.69 (m, 3H) 2.27 (d,J=2.20 Hz, 3H) 2.31 (s, 6H) 2.72 (t, J=7.42 Hz, 2H) 2.98 (m, 2H) 5.14(m, 1H) 5.15 (s, 2H) 6.26 (d, J=8.52 Hz, 1H) 7.00 (m, 5H) 7.17 (m, 3H).

EXAMPLE 34(125)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-(4-chlorophenylthio)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol 10:1);

NMR (300 MHz, CDCl₃): δ 0.99 (d, J=6.60 Hz, 6H) 1.69 (m, 3H) 2.31 (s,6H) 2.70 (t, J=7.50 Hz, 2H) 2.95 (m, 2H) 5.13 (m, 2H) 5.14 (s, 1H) 6.23(d, J=8.52 Hz, 1H) 6.90 (m, 5H) 7.13 (m, 3H) 7.22 (m, 2H) 7.35 (m, 3H)7.56 (d, J=7.69 Hz, 1H).

EXAMPLE 34(126)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-carbamoylphenoxy)phenyl)butanoicacid

TLC: Rf 0.23 (chloroform:methanol=10:1).

EXAMPLE 34(127)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-N-methylcarbamoylphenoxy)phenyl)butanoicacid

TLC: Rf 0.26 (chloroform:methanol=10:1).

EXAMPLE 34(128)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-N,N-dimethylcarbamoylphenoxy)phenyl)butanoicacid

TLC: Rf 0.28 (chloroform:methanol=10:1).

EXAMPLE 34(129)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-pentylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.70 (chloroform:methanol=9:1).

EXAMPLE 34(130)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-(4-methylphenoxy)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.75 (chloroform:methanol=9:1).

EXAMPLE 34(131)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chloro-2-fluoro-6-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.70 (chloroform:methanol=9:1).

EXAMPLE 34(132)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-difluoromethoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.60 (chloroform:methanol=9:1).

EXAMPLE 34(133)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(fluoren-2-ylmethyloxy)phenyl)propanoicacid

TLC: Rf 0.73 (chloroform:methanol=9:1).

EXAMPLE 34(134)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chloro-3-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.74 (chloroform:methanol=9:1).

EXAMPLE 34(135)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluoro-2-methylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.69 (chloroform:methanol=9:1).

EXAMPLE 34(136)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,5-trifluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.77 (chloroform:methanol=9:1).

EXAMPLE 34(137)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-(pyridin-2-yl)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.70 (m, 1H), 7.98-7.96 (m, 2H), 7.81-7.70 (m,2H), 7.49 (d, J=8.4 Hz, 2H), 7.25 (m, 1H), 7.16 (d, J=8.7 Hz, 1H),6.99-6.89 (m, 5H), 6.41 (d, J=8.4 Hz, 1H), 5.14 (m, 1H), 5.10 (s, 2H),2.96-2.93 (m, 2H), 2.72-2.67 (m, 2H), 2.29 (s, 6H), 1.80-1.52 (m, 3H),0.97 (d, J=6.3 Hz, 3H), 0.96 (d, J=6.3 Hz, 3H).

EXAMPLE 34(138)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-(4-t-butylphenoxy)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.36-7.26 (m, 3H), 7.18-7.07 (m, 3H), 6.95-6.90(m, 8H), 6.24 (brd, J=8.3 Hz, 1H), 5.14 (m, 1H), 5.00 (s, 2H), 2.99-2.93(m, 2H), 2.72-2.67 (m, 2H), 2.30 (s, 6H), 1.82-1.55 (m, 3H), 1.32 (s,9H), 0.98 (d, J=6.3 Hz, 6H).

EXAMPLE 34(139)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-ethylthiobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.32 (s, 3H), 7.18-7.15 (m, 2H), 6.95-6.90 (m,5H), 6.25 (brd, J=8.4 Hz, 1H), 5.14 (m, 1H), 4.99 (s, 2H), 2.99-2.92 (m,4H), 2.72-2.67 (m, 2H), 2.31 (s, 6H), 1.82-1.56 (m, 3H), 1.32 (t, J=7.2Hz, 3H), 0.98 (t, J=6.3 Hz, 6H).

EXAMPLE 34(140)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-(4-fluorobenzyloxy)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.42-7.38 (m, 2H), 7.35-7.32 (m, 2H), 7.16 (m,1H), 7.10-7.04 (m, 2H), 6.98-6.90 (m, 7H), 6.25 (d, J=8.5 Hz, 1H), 5.14(m, 1H), 5.03 (s, 2H), 4.96 (s, 2H), 2.98-2.93 (m, 2H), 2.72-2.67 (m,2H), 2.30 (s, 6H), 1.82-1.55 (m, 3H), 0.98 (d, J=6.3 Hz, 3H), 0.97 (d,J=6.3 Hz, 3H).

EXAMPLE 34(141)4-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxyphenyl)butanoicacid

TLC: Rf 0.59 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.38-7.30 (m, 2H), 7.17 (d, J=8.4 Hz, 1H), 7.12(t, J=7.4 Hz, 1H), 7.02-6.88 (m, 7H), 5.91 (d, J=8.7 Hz, 1H), 5.12 (m,1H), 2.73 (t, J=7.7 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 2.29 (s, 6H),1.97-1.49 (m, 5H), 0.97 (d, J=6.6 Hz, 3H), 0.96 (d, J=6.6 Hz, 3H).

EXAMPLE 34(142)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-cyanophenoxy)phenyl)butanoicacid

TLC: Rf 0.48 (chloroform:methanol=10:1).

EXAMPLE 34(143)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-(3-trifluoromethylphenoxy)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.70 (chloroform:methanol=9:1).

EXAMPLE 34(144)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chloro-2-fluoro-5-trifluoromethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.66 (chloroform:methanol=9:1).

EXAMPLE 34(145)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3-dimethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.66 (chloroform:methanol=9:1).

EXAMPLE 34(146)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3-difluoro-4-methylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.36 (methylene chloride:methanol=9:1).

EXAMPLE 34(147)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chloro-2-fluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.33 (methylene chloride:methanol=9:1).

EXAMPLE 34(148)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chloro-2,6-difluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.33 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.04 Hz, 6H) 1.69 (m, 3H) 2.30 (s,6H) 2.69 (t, J=7.14 Hz, 2H) 2.96 (m, 2H) 5.15 (m, 3H) 6.29 (d, J=8.52Hz, 1H) 6.94 (m, 6H) 7.20 (d, J=8.79 Hz, 1H) 7.41 (m, 1H).

EXAMPLE 34(149)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,4,5-trifluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.35 (methylene chloride:methanol=9:1).

EXAMPLE 34(150)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluoro-3-methylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.35 (methylene chloride:methanol=9:1).

EXAMPLE 34(151)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-(4-chlorophenoxy)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.35 (methylene chloride:methanol=9:1).

EXAMPLE 34(152)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-(4-propylphenyl)benzyloxy)phenyl)propanoicacid

TLC: Rf 0.56 (chloroform:methanol=9:1).

EXAMPLE 34(153)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-phenoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.53 (chloroform:methanol=9:1).

EXAMPLE 34(154)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(5-chloro-2-methoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.51 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.32 Hz, 6H) 1.68 (m, 3H) 2.31 (s,6H) 2.71 (m, 2H) 2.97 (m, 2H) 3.82 (s, 3H) 5.03 (s, 2H) 5.15 (m, 1H)6.28 (d, J=8.24 Hz, 1H) 6.82 (d, J=8.79 Hz, 1H) 6.95 (m, 5H) 7.18 (d,J=8.24 Hz, 1H) 7.23 (d, J=2.75 Hz, 1H) 7.42 (d, J=2.47 Hz, 1H).

EXAMPLE 34(155)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-dimethylaminobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.44 (chloroform:methanol=9:1).

EXAMPLE 34(156)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylthiobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.44 (chloroform:methanol=9:1).

EXAMPLE 34(157)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-nitrophenoxy)phenyl)butanoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 1.78 (d, J=6.32 Hz, 3H), 1.93 (m, 2H), 2.30 (m,2H), 2.78 (m, 2H), 6.10 (m, 2H), 6.96 (m, 3H), 7.21 (m, 2H), 7.49 (m,5H), 7.81 (d, J=7.97 Hz, 1H), 7.87 (dd, J=7.20, 1.80 Hz, 1H), 7.93 (dd,J=8.10, 1.51 Hz, 1H), 8.20 (d, J=7.97 Hz, 1H).

EXAMPLE 34(158)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-aminophenoxy)phenyl)butanoicacid

TLC: Rf 0.46 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 1.77 (d, J=6.04 Hz, 3H), 1.91 (m, 2H), 2.27 (m,2H), 2.75 (m, 2H), 6.09 (m, 2H), 6.68 (m, 1H), 6.81 (m, 3H), 6.96 (m,2H), 7.11 (d, J=8.52 Hz, 1H), 7.50 (m, 4H), 7.81 (d, J=7.97 Hz, 1H),7.87 (m, 1H), 8.19 (d, J=7.69 Hz, 1H).

EXAMPLE 34(159)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-acetylaminophenoxy)phenyl)butanoicacid

TLC: Rf 0.40 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 1.55 (d, J=6.87 Hz, 3H), 1.70 (m, 2H), 1.99(s, 3H), 2.09 (m, 2H), 2.62 (m, 2H), 5.87 (m, 1H), 6.91 (m, 3H), 7.10(m, 2H), 7.21 (d, J=8.24 Hz, 1H), 7.52 (m, 4H), 7.82 (d, J=7.97 Hz, 1H),7.93 (m, 2H), 8.20 (d, J=8.24 Hz, 1H), 8.94 (d, J=7.97 Hz, 1H), 9.44 (s,1H), 12.01 (s, 1H).

EXAMPLE 34(160)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-methylsulfonylaminophenoxy)phenyl)butanoicacid

TLC: Rf 0.41 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 1.78 (d, J=6.59 Hz, 3H), 1.90 (m, 2H), 2.27 (m,2H), 2.76 (m, 2H), 2.90 (s, 3H), 6.10 (m, 1H), 6.22 (d, J=8.40 Hz, 1H),6.77 (s, 1H), 6.88 (m, 3H), 7.13 (m, 3H), 7.51 (m, 5H), 7.81 (d, J=8.24Hz, 1H), 7.88 (m, 1H), 8.18 (m, 1H).

EXAMPLE 34(161)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-methoxyphenoxy)phenyl)butanoicacid

TLC: Rf 0.15 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.18 (m, 1H), 7.87 (m, 1H), 7.80 (d, J=8.4 Hz,1H), 7.56-7.42 (m, 4H), 7.11 (d, J=8.4 Hz, 1H), 6.92-6.83 (m, 6H), 6.09(m, 1H), 5.99 (brd, J=8.4 Hz, 1H), 3.80 (s, 3H), 2.83-2.67 (m, 2H),2.32-2.67 (m, 2H), 1.95-1.86 (m, 2H), 1.76 (d, J=6.6 Hz, 3H).

EXAMPLE 34(162)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-fluorophenoxy)phenyl)butanoicacid

TLC: Rf 0.19 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.18 (m, 1H), 7.88 (m, 1H), 7.81 (d, J=8.1 Hz,1H), 7.55-7.42 (m, 4H), 7.14 (m, 1H), 7.02-6.92 (m, 2H), 6.90-6.86 (m,4H), 6.09 (m, 1H), 5.98 (brd, J=7.8 Hz, 1H), 2.85-2.68 (m, 2H),2.39-2.22 (m, 2H), 1.96-1.87 (m, 2H), 1.77 (d, J=6.6 Hz, 3H).

EXAMPLE 34(163) 4-(2-((1R)-1naphthalen-1-yl)ethylcarbamoyl)-4-(3-fluorophenoxy)phenyl)butanoic acid

TLC: Rf 0.22 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.19 (d, J=8.1 Hz, 1H), 7.86 (m, 1H), 7.81 (d,J=7.8 Hz, 1H), 7.55-7.42 (m, 4H), 7.27-7.17 (m, 2H), 6.96-6.94 (m, 2H),6.78 (m, 1H), 6.69 (m, 1H), 6.63 (m, 1H), 6.11 (m, 1H), 6.02 (m, 1H),2.83-2.73 (m, 2H), 2.35-2.28 (m, 2H), 1.98-1.88 (m, 2H), 1.78 (d, J=6.6Hz, 3H).

EXAMPLE 34(164)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(3-methoxyphenoxy)phenyl)butanoicacid

TLC: Rf 0.25 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.19 (d, J=8.1 Hz, 1H), 7.87 (m, 1H), 7.81 (d,J=7.8 Hz, 1H), 7.57-7.42 (m, 4H), 7.22-7.15 (m, 2H), 6.95-6.91 (m, 2H),6.64 (m, 1H), 6.51-6.49 (m, 2H), 6.10 (m, 1H), 6.01 (brd, J=8.4 Hz, 1H),3.75 (s, 3H), 2.85-2.70 (m, 2H), 2.34-2.28 (m, 2H), 1.97-1.88 (m, 2H),1.77 (d, J=6.6 Hz, 3H).

EXAMPLE 34(165)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chloro-2,6-difluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.62 (chloroform:methanol=9:1).

EXAMPLE 34(166)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-ethylbenzyloxy)phenyl)propanoicacid

TLC: Rf 0.62 (chloroform:methanol=9:1).

EXAMPLE 34(167)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chloro-2-methoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.62 (chloroform:methanol=9:1).

EXAMPLE 34(168)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methyl-3-methoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.62 (chloroform:methanol=9:1).

EXAMPLE 34(169)3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methyl-4-methoxybenzyloxy)phenyl)propanoicacid

TLC: Rf 0.62 (chloroform:methanol=9:1).

EXAMPLE 34(170)4-(2-(3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxyphenyl)butanoic acid

TLC: Rf 0.31 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 0.97 (d, J=6.32 Hz, 6H), 1.74 (m, 5H), 2.29 (m,2H), 2.71 (m, 2H), 5.20 (m, 1H), 5.97 (d, J=8.52 Hz, 1H), 6.96 (m, 4H),7.14 (m, 2H), 7.31 (m, 7H).

EXAMPLE 34(171)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-fluorophenoxy)phenyl)butanoicacid

TLC: Rf 0.24 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 8.18 (m, 1H), 7.86 (m, 1H), 7.80 (d, J=8.0 Hz,1H), 7.56-7.41 (m, 4H), 7.18-7.03 (m, 4H), 7.01 (m, 1H), 6.92 (d, J=2.8Hz, 1H), 6.85 (dd, J=8.5, 2.8 Hz, 1H), 6.13-6.04 (m, 2H), 2.83-2.67 (m,2H), 2.38-2.20 (m, 2H), 1.94-1.86 (m, 2H), 1.76 (d, J=6.3 Hz, 3H).

EXAMPLE 34(172) 4-(2-((1R)-1naphthalen-1-yl)ethylcarbamoyl)-4-cyclohexyloxyphenyl)butanoic acid

TLC: Rf 0.15 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 1.36 (m, 6H), 1.84 (m, 9H), 2.28 (m, 2H), 2.72(m, 2H), 4.12 (m, 1H), 6.07 (m, 2H), 6.81 (m, 2H), 7.09 (d, J=8.24 Hz,1H), 7.54 (m, 4H), 7.85 (m, 2H), 8.23 (d, J=8.52 Hz, 1H).

EXAMPLE 34(173)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(pyridin-2-yl)oxyphenyl)butanoicacid

TLC: Rf 0.45 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 1.74 (d, J=6.87 Hz, 3H), 1.86 (m, 2H), 2.19 (m,2H), 2.73 (m, 2H), 6.10 (m, 1H), 6.58 (d, J=8.52 Hz, 1H), 6.91 (d,J=8.24 Hz, 1H), 7.02 (m, 3H), 7.19 (m, 1H), 7.49 (m, 4H), 7.69 (m, 1H),7.77 (d, J=8.24 Hz, 1H), 7.84 (m, 1H), 8.08 (m, 1H), 8.21 (d, J=8.24 Hz,1H).

EXAMPLE 34(174)4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-acetylphenoxy)phenyl)butanoicacid

TLC: Rf 0.45 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 1.77 (d, J=6.04 Hz, 3H), 1.90 (m, 2H), 2.29 (m,2H), 2.55 (s, 3H), 2.76 (m, 2H), 6.12 (m, J=6.04 Hz, 2H), 6.83 (m,J=8.24 Hz, 1H), 6.90 (m, 1H), 6.96 (d, J=2.75 Hz, 1H), 7.15 (m, 2H),7.45 (m, 5H), 7.79 (m, 2H), 7.86 (m, 1H), 8.20 (d, J=7.97 Hz, 1H).

EXAMPLE 34(175)4-(2-(1-(naphthalen-1-yl)propylcarbamoyl)-4-phenoxyphenyl)butanoic acid

TLC: Rf 0.12 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 1.08 (t, J=7.42 Hz, 3H), 1.89 (m, 2H), 2.20 (m,4H), 2.73 (m, 2H), 5.96 (m, 2H), 6.93 (m, 4H), 7.13 (m, 2H), 7.32 (m,2H), 7.51 (m, 4H), 7.80 (m, 1H), 7.87 (m, 1H), 8.26 (d, J=8.24 Hz, 1H).

EXAMPLE 34(176)4-(2-(1-(naphthalen-1-yl)butylcarbamoyl)-4-phenoxyphenyl)butanoic acid

TLC: Rf 0.12 (n-hexane:ethyl acetate=1:1);

NMR (300 MHz, CDCl₃): δ 1.01 (m, 3H), 1.52 (m, 2H), 1.87 (m, 2H), 2.05(m, 2H), 2.25 (m, 2H), 2.72 (t, J=7.69 Hz, 2H), 6.00 (m, 2H), 6.94 (m,4H), 7.12 (m, 2H), 7.32 (m, 2H), 7.50 (m, 4H), 7.80 (m, 1H), 7.86 (m,1H), 8.27 (d, J=8.52 Hz, 1H).

EXAMPLE 34(177)4-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-phenoxyphenyl)butanoicacid

TLC: Rf 0.18 (n-hexane:ethyl acetate=2:1);

NMR (300 MHz, DMSO-d₆): δ 8.99 (d, J=8.1 Hz, 1H), 8.18 (d, J=8.7 Hz,1H), 7.94 (m, 1H), 7.80 (d, J=7.8 Hz, 1H), 7.62-7.38 (m, 6H), 7.24 (d,J=8.7 Hz, 1H), 7.16 (m, 1H), 7.05-7.02 (m, 2H), 6.98 (dd, J=8.1, 2.4 Hz,1H), 6.88 (d, J=2.4 Hz, 1H), 5.85 (m, 1H), 2.68-2.50 (m, 2H), 2.10-2.05(m, 2H), 1.90-1.65 (m, 4H), 1.56 (m, 1H), 1.06 (d, J=6.6 Hz, 3H), 0.89(d, J=6.3 Hz, 1H).

EXAMPLE 34(178)4-(2-((3-methyl-1-(4-fluoro-3-methylphenyl)butyl)carbamoyl)-4-phenoxyphenyl)butanoicacid

TLC: Rf 0.16 (n-hexane:ethyl acetate=2:1);

NMR (300 MHz, DMSO-d₆): δ 8.73 (d, J=8.7 Hz, 1H), 7.43-7.37 (m, 2H),7.24-7.13 (m, 4H), 7.07-6.95 (m, 4H), 6.83 (d, J=2.4 Hz, 1H), 4.95 (m,1H), 2.61-2.54 (m, 2H), 2.18 (brs, 3H), 2.08-2.03 (m, 2H), 1.75-1.53 (m,4H), 1.39 (m, 1H), 0.89 (d, J=6.0 Hz, 3H), 0.87 (d, J=6.3 Hz, 3H).

EXAMPLE 34(179)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methoxyphenoxy)phenyl)butanoicacid

TLC: Rf 0.52 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.96 (d, J=6.32 Hz, 3H), 0.97 (d, J=6.32 Hz,3H), 1.75 (m, 5H), 2.30 (m, 2H), 2.29 (s, 6H), 2.73 (t, J=7.69 Hz, 2H),3.78 (s, 3H), 5.13 (m, 1H), 5.94 (d, J=8.52 Hz, 1H), 6.56 (m, 2H), 6.66(m, 1H), 6.95 (m, 5H), 7.19 (m, 2H).

EXAMPLE 34(180)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.57 (methylene chloride:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 7.40-7.30 (m, 2H), 7.17 (d, J=8.1 Hz, 1H),7.16-7.09 (m, 1H), 7.04-6.82 (m, 7H), 6.19 (d, J=8.4 Hz, 1H), 5.13 (q,J=8.4 Hz, 1H), 3.08-2.92 (m, 2H), 2.71 (t, J=6.9 Hz, 2H), 2.29 (s, 6H),1.80-1.50 (m, 3H), 0.96 (dd, J=6.3, 1.8 Hz, 6H).

EXAMPLE 34(181)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(benzothiazol-2-yl)oxyphenyl)propanoicacid

TLC: Rf 0.55 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.96 (d, J=6.32 Hz, 3H), 0.97 (d, J=6.32 Hz,3H), 1.68 (m, 3H), 2.28 (s, 6H), 2.68 (m, 2H), 3.01 (m, 2H), 5.14 (m,1H), 6.64 (d, J=8.24 Hz, 1H), 6.88 (s, 1H), 6.95 (s, 2H), 7.34 (m, 5H),7.69 (m, 2H).

EXAMPLE 34(182)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.35 (n-hexane:ethyl acetate:acetic acid=100:100:1);

NMR (300 MHz, DMSO-d₆): δ 1.89 (m, 2H), 2.20 (s, 6H), 2.35 (m, 2H), 2.46(m, J=7.48 Hz, 2H), 2.84 (t, J=7.48 Hz, 2H), 3.68 (m, 4H), 6.81 (s, 1H),6.91 (d, J=2.75 Hz, 1H), 7.02 (m, 5H), 7.17 (m, 1H), 7.30 (d, J=8.52 Hz,1H), 7.41 (m, 2H), 8.55 (s, 1H), 12.10 (s, 1H).

EXAMPLE 34(183)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-benzyloxyphenyl)propanoicacid

TLC: Rf 0.47 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 2.22 (m, 2H), 2.32 (s, 6H), 2.44 (m, 2H), 2.67(t, J=7.28 Hz, 2H), 2.95 (t, J=7.28 Hz, 2H), 3.77 (m, 2H), 3.92 (m, 2H),5.07 (s, 2H), 6.35 (s, 1H), 6.90 (s, 1H), 6.98 (dd, J=8.50, 2.75 Hz,1H), 7.04 (d, J=2.75 Hz, 1H), 7.07 (s, 2H), 7.18 (d, J=8.50 Hz, 1H),7.39 (m, 5H).

EXAMPLE 34(184)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chloro-6-fluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.46 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 2.23 (m, 2H), 2.32 (s, 6H), 2.47 (m, 2H), 2.68(t, J=7.28 Hz, 2H), 2.96 (t, J=7.28 Hz, 2H), 3.87 (m, 4H), 5.19 (d,J=1.92 Hz, 2H), 6.41 (s, 1H), 6.90 (s, 1H), 7.06 (m, 5H), 7.22 (d,J=8.50 Hz, 1H), 7.31 (m, 2H).

EXAMPLE 34(185)3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,3,6-trifluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 2.23 (m, 2H), 2.32 (s, 6H), 2.47 (m, 2H), 2.67(t, J=7.28 Hz, 2H) 2.96 (t, J=7.28 Hz, 2H), 3.85 (m, 4H), 5.13 (s, 2H),6.49 (s, 1H), 6.90 (m, 2H), 7.00 (dd, J=8.52, 2.75 Hz, 1H), 7.06 (d,J=2.75 Hz, 1H), 7.08 (s, 2H) 7.20 (m, 1H), 7.20 (d, J=8.52 Hz, 1H).

EXAMPLE 34(186)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxyphenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.98 (d, J=6.32 Hz, 6H), 1.67 (m, 3H), 2.31 (s,6H), 2.69 (m, 2H), 2.95 (m, 2H), 5.04 (s, 2H), 5.14 (m, 1H), 6.24 (d,J=8.52 Hz, 1H), 6.90 (s, 1H), 6.96 (m, 4H), 7.17 (m, 1H), 7.37 (m, 5H).

EXAMPLE 34(187)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-6-fluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.40 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.98 (m, 6H), 1.70 (m, 3H), 2.30 (s, 6H), 2.70(m, 2H), 2.97 (m, 2H), 5.15 (m, 3H), 6.28 (d, J=8.79 Hz, 1H), 6.90 (s,1H), 6.94 (s, 2H), 7.03 (m, 3H), 7.21 (d, J=8.52 Hz, 1H), 7.29 (m, 2H).

EXAMPLE 34(188)3-(2-((4-(naphthalen-1-yl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)propanoicacid

TLC: Rf 0.50 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 2.49 (m, 4H), 2.83 (m, 4H), 3.92 (m, 4H), 6.88(s, 1H), 6.98 (m, 4H), 7.19 (m, 3H), 7.34 (m, 3H), 7.48 (t, J=7.82 Hz,1H), 7.72 (d, J=6.59 Hz, 1H), 7.78 (d, J=8.24 Hz, 1H), 7.86 (dd, J=8.24,1.37 Hz, 1H), 8.33 (d, J=8.52 Hz, 1H).

EXAMPLE 34(189)4-(2-((4-(naphthalen-1-yl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)butanoicacid

TLC: Rf 0.29 (n-hexane:ethyl acetate:acetic acid=50:50:1);

NMR (300 MHz, DMSO-d₆): δ 1.56 (m, 2H), 1.91 (t, J=7.55 Hz, 2H), 2.08(m, 2H), 2.35 (m, 2H), 2.77 (m, 2H), 3.82 (m, 4H), 6.73 (d, J=2.47 Hz,1H), 6.99 (m, 3H), 7.16 (m, 3H), 7.39 (m, 3H), 7.47 (d, J=7.69 Hz, 1H),7.63 (d, J=7.42 Hz, 1H), 7.78 (d, J=8.24 Hz, 1H), 7.89 (d, J=7.14 Hz,1H), 8.61 (d, J=8.79 Hz, 1H), 9.06 (s, 1H).

EXAMPLE 34(190)4-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)butanoicacid

TLC: Rf 0.35 (n-hexane:ethyl acetate:acetic acid=50:50:1);

NMR (300 MHz, DMSO-d₆): δ 1.72 (m, 2H), 1.88 (m, 2H), 2.11 (t, J=7.55Hz, 2H), 2.21 (s, 6H), 2.38 (m, 2H), 2.59 (m, 2H), 3.63 (m, 2H), 3.74(m, 2H), 6.82 (s, 1H), 6.90 (d, J=2.75 Hz, 1H), 7.01 (m, 3H), 7.07 (m,2H), 7.17 (m, 1H), 7.25 (d, J=8.52 Hz, 1H), 7.42 (m, 2H), 8.51 (s, 1H).

EXAMPLE 34(191)3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,6-trifluorobenzyloxy)phenyl)propanoicacid

TLC: Rf 0.49 (chloroform:methanol=9:1);

NMR (300 MHz, CDCl₃): δ 0.97 (m, 6H), 1.68 (m, 3H), 2.30 (s, 6H), 2.69(m, 2H), 2.95 (m, 2H), 5.11 (s, 2H), 5.17 (m, 1H), 6.27 (d, J=8.52 Hz,1H), 6.93 (m, 6H), 7.17 (m, 2H).

REFERENCE EXAMPLE 55 7-bromomethylcoumarin

To a solution of 7-methylcoumarin (50 g) in acetonitorile (1.2 L) wereadded N-bromosuccinimide (56 g) α,α′-azobisisobutyronitrile (510 mg) andthe mixture was stirred at 78° C. for 30 minutes. The reaction solutionwas concentrated and then added water (1 L). The appeared crystal wasfiltrated to give the title compound (76 g) having the followingphysical data.

NMR (300 MHz, CDCl₃): δ 7.69 (d, 9.6 Hz, 1H), 7.46 (d, J=8.1 Hz, 1H),7.34 (d, J=1.8 Hz, 1H), 7.30 (dd, J=8.1, 1.8 Hz, 1H), 6.43 (d, 9.6 Hz,1H), 4.52 (s, 2H).

REFERENCE EXAMPLE 56 7-(2,5-difluorophenoxymethyl)coumarin

A mixture of the compound prepared in Reference Example 55 (40 g),2,5-difluorophenol (21.8 g) and potassium carbonate (46.4 g) in DMF (250ml) was stirred at 60° C. for 50 minutes. The reaction solution wascooled to room temperature and then added water. The appeared solid wasfiltered and dried to give the title compound (43.9 g) having thefollowing physical data.

NMR (300 MHz, DMSO-d₆): δ 8.05 (d, J=9.6 Hz, 1H), 7.74 (d, J=7.8 Hz,1H), 7.46 (brs, 1H), 7.41 (brd, J=7.8 Hz, 1H), 7.32-7.18 (m, 2H), 6.78(m, 1H), 6.49 (d, J=9.6 Hz, 1H), 5.30 (s, 2H).

REFERENCE EXAMPLE 573-(2-hydroxy-4-(2,5-difluorophenoxymethyl)phenyl)propenoic acid methylester

Using the compounds prepared in Reference Example 56 (43.9 g), the titlecompound (46.5 g) having the following physical data was obtained by thesame procedure of Reference Example 42.

NMR (300 MHz, DMSO-d₆): δ 10.4 (s, 1H), 7.84 (d, J=16.2 Hz, 1H), 7.64(d, J=7.8 Hz, 1H), 7.26 (m, 1H), 7.16 (m, 1H), 6.98 (s, 1H), 6.89 (d,J=7.8 Hz, 1H), 6.77 (m, 1H), 6.61 (d, J=16.2 Hz, 1H), 5.15 (s, 2H), 3.70(s, 3H).

REFERENCE EXAMPLE 583-(2-hydroxy-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid methylester

Using the compounds prepared in Reference Reference Example 57 (46.5 g),the title compound (23.6 g) having the following physical data wasobtained by the same procedure of Example 24.

NMR (300 MHz, CDCl₃): δ 7.20 (s, 1H), 7.10 (d, J=7.8 Hz, 1H), 7.01 (ddd,J=10.5, 9.0, 5.4 Hz, 1H), 6.96-6.91 (m, 2H), 6.71 (m, 1H), 6.58 (m, 1H),5.03 (s, 2H), 3.70 (s, 3H), 2.92-2.88 (m, 2H), 2.74-2.70 (m, 2H).

REFERENCE EXAMPLE 593-(2-carboxy-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid methylester

Using the compound prepared in Reference Example 58 (250 mg), the titlecompound (193 mg) having the following physical data was obtained by thesame procedures as a series of reactions of Reference Example44→Reference Example 45.

NMR (300 MHz, CDCl₃): δ 8.11 (d, J=1.8 Hz, 1H), 7.59 (dd, J=8.1, 1.8 Hz,1H), 7.38 (d, J=8.1 Hz, 1H), 7.04 (ddd, J=10.5, 9.0, 5.1 Hz, 1H), 6.74(ddd, J=9.6, 6.6, 3.0 Hz, 1H), 6.62 (m, 1H), 5.11 (s, 2H), 3.67 (s, 3H),3.38-3.33 (m, 2H), 2.74-2.69 (m, 2H).

EXAMPLE 353-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoicacid

Using the compound prepared in Reference Example 59 and the compoundprepared in Reference Example 48, the title compound having thefollowing physical data was obtained by the same procedures as a seriesof reactions of Reference Reference Example 8→Example 3.

TLC: Rf 0.51 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 0.99 (d, J=6.32 Hz, 6H), 1.70 (m, 3H), 2.31 (s,6H), 2.72 (t, J=7.00 Hz, 2H), 3.03 (m, 2H), 5.06 (s, 2H), 5.16 (m, 1H),6.31 (d, J=8.24 Hz, 1H), 6.61 (m, 1H), 6.73 (m, 1H), 6.90 (s, 1H), 6.96(s, 2H), 7.04 (m, 1H), 7.29 (d, J=8.24 Hz, 1H), 7.41 (m, 2H).

REFERENCE EXAMPLE 603-(2-trifluoromethanesulfoxy-4-(pyrazol-1-ylmethyl)phenyl)propanoic acidmethyl ester

Using 3-(2-hydroxy-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid methylester (1.00 g), the title compound (1.48 g) having the followingphysical data was obtained by the same procedure of Reference Example44.

NMR (300 MHz, CDCl₃): δ 7.57 (m, 1H), 7.42 (d, J=2.1 Hz, 1H), 7.32 (d,J=8.1 Hz, 1H), 7.12 (d, J=8.1 Hz, 1H), 7.04 (s, 1H), 6.32 (t, J=2.1 Hz,1H), 3.67 (s, 3H), 3.02 (t, J=7.5 Hz, 2H), 2.64 (t, J=7.5 Hz, 2H).

EXAMPLE 363-(2-(5-phenyl-1-pentynyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acidmethyl ester

To a solution of the compound prepared in Reference Example 60 (300 mg)in DMF (3 ml) were added 5-phenyl-1-pentyne (165 mg),di(triphenylphosphine)palladium dichloride (54 mg), copper iodide (44mg), tetrabutylammonium iodide (848 mg) and triethylamine (0.6 ml) underan atmosphere of argon. The mixture was stirred at room temperatureovernight. To the reaction mixture was added water, the mixture wasextracted with ethyl acetate. The organic layer was washed with waterand a saturated aqueous solution of sodium chloride, dried overanhydrous magnesium sulfate and concentrated. The residue was purifiedby column chromatography on silica gel to give the title compound (128mg) having the following physical data.

NMR (300 MHz, CDCl₃): δ 7.55 (d, J=2.1 Hz, 1H), 7.37 (d, J=2.1 Hz, 1H),7.32-7.16 (m, 7H), 7.05 (dd, J=7.8, 1.8 Hz, 1H), 6.28 (t, J=2.1 Hz, 1H),5.26 (s, 2H), 3.62 (s, 3H), 3.08 (t, J=7.5 Hz, 2H), 2.78 (t, J=7.5 Hz,2H), 2.65 (t, J=7.5 Hz, 2H), 2.44 (t, J=7.5 Hz, 2H), 1.97-1.87 (m, 2H).

EXAMPLE 37 3-(2-(5-phenylpentyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

To a solution of the compound prepared in Example 36 (300 mg) inmethanol (3 ml) was added 10% palladium carbon (30 mg) and the mixturewas stirred at room temperature overnight under an atmosphere ofhydrogen. The reaction mixture was filtered through cellite (trade mark)and then the filtrate was concentrated. To a solution of the residue inTHF were added 1N aqueous solution of sodium hydroxide (2 ml) andmethanol (2 ml) and the mixture was stirred at room temperatureovernight. The reaction solution was neutralized with 1N hydrochloricacid and then extracted with ethyl acetate. The organic layer was washedwith water and a saturated aqueous solution of sodium chloride, driedover anhydrous magnesium sulfate and concentrated. The residue waspurified by column chromatography on silica gel to give the titlecompound (220 mg) having the following physical data.

TLC: Rf 0.50 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.54 (d, J=2.1 Hz, 1H), 7.35 (d, J=2.1 Hz, 1H),7.30-7.25 (m, 2H), 7.19-7.11 (m, 4H), 6.99-6.96 (m, 2H), 6.27 (t, J=2.1Hz, 1H), 5.26 (s, 2H), 2.94 (t, J=7.8 Hz, 2H), 2.63-2.55 (m, 6H),1.70-1.52 (m, 4H), 1.45-1.37 (m, 2H).

EXAMPLE 383-(2-(5-phenyl-1-pentenyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acidmethyl ester

To a solution of the compound prepared in Reference Example 60 (133 mg)in DMF (1 ml) were added boronic acid (129 mg),tetrakis(triphenylphosphine)palladium (39 mg) and potassium phosphate(144 mg) under an atmosphere of argon, the mixture was stirred at 80° C.for 2 hours. To the mixture was added water and the mixture wasextracted with ethyl acetate. The organic layer was washed with waterand a saturated aqueous solution of sodium chloride, dried overanhydrous magnesium sulfate and concentrated. The residue was purifiedby column chromatography on silica gel to give the title compound (131mg) having the following physical data.

NMR (300 MHz, CDCl₃): δ 7.54 (m, 1H), 7.38 (d, J=2.1 Hz, 1H), 7.32-7.16(m, 6H), 7.11 (d, J=7.8 Hz, 1H), 7.01-6.97 (m, 1H), 6.57 (d, J=15.6 Hz,1H), 6.27(t, J=2.1 Hz, 1H), 6.13-6.03 (m, 1H), 5.27 (s, 2H), 3.65 (s,3H), 2.97 (t, J=7.8 Hz, 2H), 2.67 (t, J=7.8 Hz, 2H), 2.54 (t, J=7.8 Hz,2H), 2.30-2.22 (m, 2H), 1.86-1.75 (m, 2H).

EXAMPLE 39(1)˜39(2)

Using the compounds prepared in Example 36 and Example 38, the followingcompounds were obtained by the same procedure of Example 3.

EXAMPLE 39(1)3-(2-(5-phenyl-1-pentynyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.45 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.54 (d, J=2.1 Hz, 1H), 7.38 (d, J=2.1 Hz, 1H),7.32-7.27 (m, 3H), 7.22-7.18 (m, 4H), 7.05 (dd, J=8.1, 2.1 Hz, 1H), 6.28(t, J=2.1 Hz, 1H), 5.25 (s, 2H), 3.09 (t, J=7.8 Hz, 2H), 2.80-2.68 (m,4H), 2.44 (t, J=6.9 Hz, 2H), 1.97-1.87 (m, 2H).

EXAMPLE 39(2)3-(2-(5-phenyl-1-pentenyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid

TLC: Rf 0.50 (n-hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.55 (d, J=2.1 Hz, 1H), 7.38 (d, J=2.1 Hz, 1H),7.31-7.27 (m, 3H), 7.21-7.11 (m, 4H), 6.99 (dd, J=8.1, 2.1 Hz, 1H), 6.57(d, J=15.6 Hz, 1H), 6.27 (t, J=2.1 Hz, 1H), 6.08 (dt, J=15.6, 6.9 Hz,1H), 5.28 (s, 2H), 2.98 (t, J=8.1 Hz, 2H), 2.70-2.56 (m, 4H), 2.30-2.22(m, 2H), 1.86-1.76 (m, 2H).

REFERENCE EXAMPLE 613-(4-(pyrazol-1-ylmethyl)-2-hydroxymethylphenyl)propanoic acid methylester

To a solution of 3-(4-(pyrazol-1-ylmethyl)-2-carboxyphenyl)propanoicacid methyl ester (600 mg) in anhydrous THF (8.0 ml) was added dropwisea solution of borane-tetrahydrofuran complex in THF (3.2 ml) at 0° C.and the mixture was stirred at room temperature for 2.5 hours. To themixture was added a solution of borane-tetrahyrofuran complex in THF(3.5 ml) and the mixture was stirred for 1 hour. To the reactionsolution was added ice and the mixture was extracted with ethyl acetate.The organic layer was washed with water and a saturated aqueous solutionof sodium chloride, dried over anhydrous magnesium sulfate andconcentrated. The residue was purified by column chromatography onsilica gel (hexane:ethyl acetate=1:2) to give the title compound (420mg) having the following physical data.

TLC: Rf 0.59 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.75 (m, 1H), 7.34-7.06 (m, 4H), 6.32 (t, J=2.4Hz, 1H), 5.34 (s, 2H), 4.74 (d, J=4.8 Hz, 2H), 3.67 (s, 3H), 3.02 (t,J=7.5 Hz, 2H), 2.70 (t, J=7.5 Hz, 2H), 2.23 (m, 1H).

REFERENCE EXAMPLE 623-(4-(pyrazol-1-ylmethyl)-2-(1,3-dioneisoindolin-2-ylmethyl)phenyl)propanoicacid methyl ester

To a solution of the compound prepared in Reference Example 61 (420 mg)in THF (4 ml) were added triethylamine (0.35 ml) andmethanesulfonylchloride (0.13 ml) at 0° C., and the mixture was stirredfor 30 minutes. To the reaction solution was added ice, and then themixture was extracted with ethyl acetate. The organic layer was driedover anhydrous magnesium sulfate and concentrated. The residue wasdissolved in DMF. To the solution was added potassium phthalimide (370mg) and the mixture was stirred for 3 hours. To the reaction solutionwas added a saturated aqueous solution of ammonium chloride and themixture was extracted with ethyl acetate. The organic layer was washedwith a saturated aqueous solution of sodium chloride, dried overanhydrous magnesium sulfate and concentrated. The residue was purifiedby column chromatography on silica gel (hexane:ethyl acetate=2:1). Theobtained solid was washed with hexane/ethyl acetate (5:1) to give thetitle compound (320 mg) having the following physical data.

TLC: Rf 0.63 (hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 7.91-7.82 (m, 2H), 7.79-7.70 (m, 2H), 7.44 (m,1H), 7.32 (m, 1H), 7.15 (d, J=7.8 Hz, 1H), 7.08 (m, 1H), 6.99 (m, 1H),6.20 (t, J=2.1 Hz, 1H), 5.23 (s, 2H), 4.89 (s, 2H), 3.69 (s, 3H), 3.17(t, J=7.8 Hz, 2H), 2.67 (t, J=7.8 Hz, 2H).

REFERENCE EXAMPLE 633-(4-(pyrazol-1-ylmethyl)-2-aminomethylphenyl)propanoic acidhydrochloride

To a solution of the compound prepared in Reference Example 62 (300 mg)in 1,2-dichloroethane (1 ml) and methanol (1 ml) was added hydrazinemonohydrate (0.043 ml) and the mixture was stirred at 60° C. overnight.The reaction solution was cooled to room temperature, poured into waterand then extracted with ethyl acetate. The organic layer wasconcentrated to give3-(4-(1-pyrazol-1-ylmethyl)-2-aminomethylphenyl)propanoic acid. Theaqueous layer was concentrated and then added ethyl acetate. Theinsoluble material was removed by filtration and the filtrate wasconcentrated to give the title compound. The obtained compounds werecombined. To the mixture was added concentrated hydrochloric acid (5 ml)and the mixture was stirred at 100° C. for 1 hour. The reaction solutionwas concentrated and azeotropted with toluene to give the title compound(190 mg) having the following physical data.

TLC: Rf 0.09 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.24 (m, 3H), 7.81 (d, J=2.1 Hz, 1H), 7.46 (d,J=2.1 Hz, 1H), 7.38 (m, 1H), 7.27 (d, J=7.8 Hz, 1H), 7.16 (m, 1H), 6.28(t, J=2.1 Hz, 1H), 5.30 (s, 2H), 4.12-4.00 (m, 2H), 2.87 (t, J=4.5 Hz,2H), 2.62-2.40 (m, 2H).

EXAMPLE 403-(4-(pyrazol-1-ylmethyl)-2-(naphthalen-2-ylcarbonylaminomethyl)phenyl)propanoicacid

To a solution of the compound prepared in Reference Example (90 mg) inmethylene chloride (4 ml) were added triethylamine (0.13 ml) and2-naphthalenecarboxylic acid chloride (65 mg) at 0° C. and the mixturewas stirred at 0° C. for 30 minutes. The reaction mixture wasneutralized with 2N hydrochloric acid and then extracted with ethylacetate. The organic layer was dried over anhydrous magnesium sulfateand concentrated. The residue was purified by column chromatography onsilica gel (chloroform:methanol=100:1) to give the title compound (4.5mg) having the following physical data.

TLC: Rf 0.40 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 9.10 (t, J=6.3 Hz, 1H), 8.48 (s, 1H),8.33-7.84 (m, 4H), 7.77 (d, J=2.1 Hz, 1H), 7.68-7.55 (m, 2H), 7.39 (d,J=2.1 Hz, 1H), 7.28-7.12 (m, 2H), 7.04 (d, J=8.4 Hz, 1H), 6.21 (t, J=2.1Hz, 1H), 5.28 (s, 2H), 4.54 (d, J=6.3 Hz, 2H), 2.93 (t, J=7.6 Hz, 2H),2.64-2.40 (m, 2H).

EXAMPLE 413-(4-(pyrazol-1-ylmethyl)-2-(4-benzoylpiperazin-1-yl)phenyl)propenoicacid ethyl ester

To a solution of tris(dibenzylideneacetone)dipalladium(0) (60 mg) and2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl(48 mg) in dioxane(3 ml) and t-butanol (3 ml) were added cesium carbonate (598 mg),3-(2-iodo-4-(pyrazol-1-ylmethyl)phenyl)propenoic acid (500 mg) andpiperazine (226 mg) under an atmosphere of argon and the mixture wasstirred at 100° C. for 5 hours. To the reaction mixture was added waterand the mixture was extracted with ethyl acetate. The organic layer wasextracted with 1N hydrochloric acid. The aqueous layer was neutralizedwith 1N aqueous solution of sodium hydroxide and then extracted withethyl acetate. The organic layer was washed with water and a saturatedaqueous solution of sodium chloride, dried over anhydrous magnesiumsulfate and concentrated. The residue was dissolved in methylenechloride (2 ml) under an atmosphere of argon. To the mixture were addedbenzoylchloride (0.15 ml) and pyridine (0.4 ml) and the mixture wasstirred at room temperature for 2 hours. To the reaction solution wasadded water and the mixture was extracted with ethyl acetate. Theorganic layer was washed with water and a saturated aqueous solution ofsodium chloride, dried over anhydrous magnesium sulfate andconcentrated. The residue was purified by column chromatography onsilica gel to give the title compound (306 mg) having the followingphysical data.

TLC: Rf 0.45 (hexane:ethyl acetate=1:2);

NMR (300 MHz, CDCl₃): δ 8.00 (d, J=16.2 Hz, 1H), 7.58-7.42 (m, 8H), 6.90(d, J=8.4 Hz, 1H), 6.82 (s, 1H), 6.38 (d, J=16.2 Hz, 1H), 6.32-6.30 (m,1H), 5.32 (s, 2H), 4.25 (q, J=7.2 Hz, 2H), 3.95 (m, 2H), 3.61 (m, 2H),2.98-2.85 (m, 4H), 1.33 (t, J=7.2 Hz, 3H).

EXAMPLE 423-(2-(N-benzoylpiperazin-1-yl)-4-(pyrazol-1-ylmethyl)phenyl)propanoicacid

Using the compounds prepared in Example 41 (306 mg), the title compound(210 mg) having the following physical data was obtained by the sameprocedure of Example 37.

TLC: Rf 0.45 (ethyl acetate);

NMR (300 MHz, CDCl₃): δ 7.56 (d, J=2.1 Hz, 1H), 7.43 (s, 5H), 7.39 (d,J=2.1 Hz, 1H), 7.18 (d, J=8.4 Hz, 1H), 6.93-6.91 (m, 2H), 6.29 (t, J=2.1Hz, 1H), 5.28 (s, 2H), 3.92 (m, 2H), 3.57 (m, 2H), 2.99 (t, J=7.8 Hz,2H), 2.91-2.84 (m, 4H), 2.69 (t, J=7.8 Hz, 2H).

EXAMPLE 433-(4-methoxymethoxy-2-(naphthalen-2-ylmethylcarbamoyl)phenyl)propenoicacid methyl ester

Using 3-(2-hydroxy-4-methoxymethoxymethylphenyl)propenoic acid methylester, the title compound having the following physical data wasobtained by the same procedures as a series of reactions of ReferenceExample 44→Reference Example 45→Example 32.

TLC: Rf 0.51 (chloroform:methanol=10:1).

EXAMPLE 442-(5-hydroxymethyl-2-(naphthalen-2-ylmethyl)isoindolin-3-one-1-yl)aceticacid methyl ester

To a solution of the compound prepared in Example 43 (672 mg) inmethanol (7 ml) was added potassium carbonate (478 mg) and the mixturewas stirred for 3 hours. The reaction mixture was diluted with ethylacetate, washed with 1N hydrochloric acid, water and a saturated aqueoussolution of sodium chloride, dried over anhydrous sodium sulfate andconcentrated. The residue was dissolved in methanol. To the solution wasadded trimethylsilyldiazomethane (3 ml) and the mixture was stirred for1 hour and then concentrated. To the residue was added methanol (10 ml)and a 4N solution of hydrogen chloride in dioxane (10 ml). The mixturewas stirred for 2 hours. The reaction solution was concentrated. Theresidue was purified by column chromatography on silica gel (ethylacetate:hexane=1:5→1:3→1:1 ethyl acetate) to give the title compound(300 mg) having the following physical data.

TLC: Rf 0.26 (ethyl acetate:toluene=2:1);

NMR (300 MHz, CDCl₃): δ 7.93 (s, 1H), 7.85-7.74 (m, 3H), 7.71 (s, 1H),7.58-7.34 (m, 5H), 5.35 (d, J=15.3 Hz, 1H), 4.84 (m, 1H), 4.81 (s, 2H),4.59 (d, J=15.3 Hz, 1H), 3.58 (s, 3H), 2.84 (dd, J=15.9, 5.4 Hz, 1H),2.62 (dd, J=15.9, 6.9 Hz, 1H).

EXAMPLE 452-(5-phenoxymethyl-2-(naphthalen-2-ylmethyl)isoindolin-3-one-1-yl)aceticacid

Using the compound prepared in Example 44 (85 mg), the title compound(29 mg) having the following physical data was obtained by the sameprocedures as a series of reactions of Example 5→Example 6.

TLC: Rf 0.46 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 7.90-7.78 (m, 5H), 7.68 (d, J=8.4 Hz, 1H),7.57 (d, J=7.8 Hz, 1H), 7.53-7.44 (m, 2H), 7.40 (d, J=8.4 Hz, 1H),7.34-7.25 (m, 2H), 7.06-7.00 (m, 2H), 6.94 (m, 1H), 5.22 (s, 2H), 5.21(d, J=15.3 Hz, 1H), 4.76 (m, 1H), 4.58 (d, J=15.3 Hz, 1H), 3.02 (dd,J=16.5, 4.2 Hz, 1H), 2.69 (dd, J=16.5, 7.2 Hz, 1H).

EXAMPLE 45(1)2-(5-(4-cyanophenoxymethyl)-2-(naphthalen-2-ylmethyl)isoindolin-3-one-1-yl)aceticacid

Using the compounds prepared in Example 44, the title compound havingthe following physical data was obtained by the same procedure ofExample 45.

TLC: Rf 0.46 (chloroform:methanol=10:1);

NMR (300 MHz, DMSO-d₆): δ 7.91-7.35 (m, 14H), 5.29 (s, 2H), 5.21 (d,J=15.6 Hz, 1H), 4.77 (m, 1H), 4.59 (d, J=15.6 Hz, 1H), 3.02 (dd, J=16.5,4.2 Hz, 1H), 2.69 (dd, J=16.5, 7.2 Hz, 1H).

EXAMPLE 45(2)2-(5-(pyrazol-1-ylmethyl)-2-(naphthalen-2-ylmethyl)isoindolin-3-one-1-yl)aceticacid

Using the compound prepared in Example 44, the title compound having thefollowing physical data was obtained by the same procedures as a seriesof reactions of Example 2→Example 3.

TLC: Rf 0.27 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 7.84-7.62 (m, 5H), 7.57-7.33 (m, 7H), 6.30 (t,J=2.4 Hz, 1H), 5.41 (d, J=15.0 Hz, 1H), 5.40 (s, 2H), 4.78 (m, 1H), 4.52(d, J=15.0 Hz, 1H), 3.02 (dd, J=16.2, 4.5 Hz, 1H), 2.51 (dd, J=16.2, 8.7Hz, 1H).

EXAMPLE 45(3)2-(5-(pyrazol-1-ylmethyl)-2-(naphthalen-1-ylmethyl)isoindolin-3-one-1-yl)aceticacid

Using the compound prepared in Example 44, the title compound having thefollowing physical data was obtained by the same procedures as a seriesof reactions of Example 2→Example 3.

TLC: Rf 0.23 (chloroform:methanol=10:1);

NMR (300 MHz, CDCl₃): δ 8.16-8.08 (m, 1H), 7.88-7.77 (m, 2H), 7.73 (brs,1H), 7.58-7.33 (m, 8H), 6.29 (t, J=2.1 Hz, 1H), 5.86 (d, J=15.3 Hz, 1H),5.39 (s, 2H), 4.66 (d, J=15.3 Hz, 1H), 4.54(dd, J=9.3, 3.3 Hz, 1H), 3.12(dd, J=15.9, 3.3 Hz, 1H), 2.48 (dd, J=15.9, 9.3 Hz, 1H).

EXAMPLE 45(4)2-(5-phenoxymethyl-2-(3-methyl-1-phenylbutyl)isoindolin-3-one-1-yl)aceticacid

Using the compounds prepared in Example 44, the title compound havingthe following physical data was obtained by the same procedure ofExample 45.

TLC: Rf 0.62 (chloroform:methanol=10:1).

FORMULATION EXAMPLE 1

The following components were admixed in conventional method and punchedout to obtain 100 tablets each containing 5 mg of active ingredient.

(2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoicacid . . . 500 mg

Carboxymethylcellulose calcium (disintegrating agent) . . . 200 mg

Magnesium stearate (lubricating agent) . . . 100 mg

Microcrystalline cellulose . . . 9.2 g

1. A carboxylic acid derivative of formula (I):

wherein R¹ is —COOH, —COOR⁴, —CH₂OH, —CONR⁵SO₂R⁶, —CONR⁷R⁸, —CH₂NR⁵SO₂R⁶, —CH₂NR⁹COR¹⁰, —CH₂NR⁹CONR⁵SO₂R⁶, —CH₂SO₂NR⁹COR¹⁰, —CH₂OCONR⁵SO₂R⁶, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, 1,3-thiazolidin-2,4-dione or 1,2,3,5-oxathiadiazol-2-one, R⁴ is C1-6 alkyl or —(C1-4 alkylene)-R¹¹, R¹¹ is hydroxy, C1-4 alkoxy, —COOH, C1-4 alkoxycarbonyl or —CONR⁷R⁸, R⁵ is hydrogen or C1-6 alkyl, R⁶ is (i) C1-6 alkyl, (ii) a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to 15-membered mono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R¹² or unsubstituted, (iii) C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl substituted with a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to 15-membered mono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R¹² or unsubstituted, R⁷ and R⁸ each independently, is (i) hydrogen, (ii) C1-6 alkyl, (iii) hydroxy, (iv) —COR¹⁷, (v) a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to 15-membered mono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R¹² or unsubstituted, or (vi) C1-4 alkyl substituted with a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to 15-membered mono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R¹² or unsubstituted, R⁹ is hydrogen or C1-6 alkyl, R¹⁰ is (i) hydrogen, (ii) C1-6 alkyl, (iii) a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to 15-membered mono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R¹² or unsubstituted, or (iv) C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl substituted with a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to 15-membered mono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R¹² or unsubstituted, R¹² is (a) C1-6 alkyl, (b) C1-6 alkoxy, (c) C1-6 alkylthio, (d) halogen, (e) CF₃, (f) cyano, (g) nitro, (h) hydroxy, (i) —COOR¹³, (j) —NHCOR¹³, (k) —SO₂R¹⁴, (l) —NR¹⁵R¹⁶, (m) a C3-7 mono-carbocyclic ring which is substituted with C1-4 alkyl or oxo or unsubstituted, (n) a 3- to 7-membered mono-heterocyclic ring which is substituted with C1-4 alkyl or oxo or unsubstituted, or (o) C1-4 alkyl substituted with hydroxy, —COOR¹³, —NHCOR³, —SO₂R¹⁴ or —NR¹⁵R¹⁶, R¹³ is hydrogen, C1-4 alkyl, phenyl, or phenyl-(C1-4) alkyl, R¹⁴ is C1-4 alkyl, R¹⁵ and R¹⁶ each independently, is hydrogen, C1-4 alkyl, phenyl, or phenyl-(C1-4) alkyl, R¹⁷ is C1-4 alkyl or phenyl, A is (i) a single bond, (ii) C1-6 alkylene, (iii) C2-6 alkenylene, (iv) C2-6 alkynylene, (v) —O—(C1-3 alkylene), (vi) —S—(C1-3 alkylene), (vii) —NR²⁰—(C1-3 alkylene), (viii) —CONR²¹—(C1-3 alkylene), (ix) —(C1-3 alkylene)-O—(C1-3 alkylene), (x) —(C1-3 alkylene)-S—(C1-3 alkylene), (xi) —(C1-3 alkylene)-NR²⁰—(C1-3 alkylene), (xii) —(C1-3 alkylene)-CONR²¹—(C1-3 alkylene), (xiii) -Cyc1, (xiv) —(C1-4 alkylene)-Cyc1 or (xv) -Cyc1-(C1-4 alkylene), the alkylene, alkenylene and alkynylene in A may be substituted with 1-6 of the following substituents of (a)-(i): (a) C1-6 alkyl, (b) C1-6 alkoxy, (c) halogen, (d) CHF₂, (e) CF₃, (f) OCHF₂, (g) OCF₃, (h) hydroxy, (i) hydroxy-(C1-4) alkyl, R²⁰ is hydrogen, C1-4 alkyl, —SO₂—(C1-4) alkyl or C2-5 acyl, R²¹ is hydrogen or C1-4 alkyl, Cyc1 is a C3-7 mono-carbocyclic ring or a 3- to 7-membered mono-heterocyclic ring which is substituted with 1-4 of C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halogen, CHF₂, CF₃, nitro or cyano, or unsubstituted, B ring is a C3-12 mono- or bi-carbocyclic ring or a 3- to 12-membered mono- or bi-heterocyclic ring, R² is C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halogen, CHF₂, CF₃, nitro, cyano, phenyl or oxo, m is 0, 1 or 2, n is 1 or 2 when -D-R³ binds to B ring at the ortho position based on -A-R¹, n is 0, 1 or 2 when -D-R³ binds to B ring at the non-ortho position based on -A-R¹, Q is (1)(i) —(C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene)-Cyc2, (ii) —(C1-4 alkylene)-Z-Cyc3, (iii) C1-4 alkyl substituted with a substituent(s) selected from —NR²⁴R²⁵, —S(O)_(p)R²⁶, cyano, —NR²³COR²⁷, —NR²³SO₂R²⁸ and —NR²³CONR²⁴R²⁵, (iv) C1-4 alkoxy(C1-4) alkoxy, —NR²³COR²⁷, —COR²⁸, —OSO₂R²⁸, —NR²³SO₂R²⁸ or —NR²³CONR²⁴R²⁵, (v) a C3-7 mono-carbocyclic ring or a 3- to 6-membered mono-heterocyclic ring which is substituted with 1-5 of R³⁰, wherein one R³⁰ of them always binds to the ring at the non 1-position, (vi) a C8-15 mono-, bi- or tri-carbocyclic ring or a 7- to 15-membered mono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R³⁰ or unsubstituted, (vii) -T-Cyc5, (viii) -L-Cyc⁶⁻¹, -L-(C3-6 cycloalkyl), -L-CH₂—(C3-6 cycloalkyl), -L-(C2-4 alkylene)-Cyc⁶⁻² or -L-(C1-4 alkylene)_(q)-Cyc⁶⁻³, wherein the cycloalkyl is substituted with 1-5 of R³⁰ or unsubstituted, (2)(i) phenoxy, (ii) benzyloxy, (iii) hydroxy(C1-4) alkyl, (iv) C1-4 alkoxy(C1-4) alkyl, or (v) —(C1-4 alkylene)-O-benzyl, or (3)(i) C2-6 alkenyl, (ii) C2-6 alkynyl, (iii) C1-6 alkyl substituted with 1-3 halogen(s), (iv) cyano, (v) nitro, (vi) —NR³³R³⁴, (vii) —CONR³³R³⁴, (viii) —S(O)_(p)—(C1-4) alkynyl, (ix) —S(O)_(p)—CHF₂, (x) —S(O)_(p)—NR³³R³⁴, (xi) —O—(C3-6) alkynyl, (xii) —O—CHF₂, or (xiii) C3-7 cycloalkyl, R²² is hydrogen, C1-4 alkyl, —SO₂—(C1-4) alkyl or C2-5 acyl, R²³ is hydrogen, C1-4 alkyl, phenyl or phenyl(C1-4) alkyl, R²⁴ and R²⁵ each independently, is hydrogen, C1-4 alkyl, Cyc4 or (C1-4 alkylene)-Cyc4, R²⁶ is C1-4 alkyl or Cyc4, R²⁷ is hydrogen, C1-4 alkyl, —OR²⁹ or Cyc4, R²⁸ is C1-4 alkyl, Cyc4 or —(C1-4 alkylene)-Cyc4, R²⁹ is hydrogen, C1-4 alkyl, Cyc4 or (C1-4 alkylene)-Cyc4, R³⁰ is C1-8 alkyl, C1-8 alkoxy, C1-8 alkylthio, halogen, CF₃, OCF₃, SCF₃, CHF₂, SCHF₂, hydroxy, cyano, nitro, —NR³¹R³², —CONR³¹R³², formyl, C2-5 acyl, hydroxy(C1-4) alkyl, C1-4 alkoxy(C1-4) alkyl, C1-4 alkylthio(C1-4) alkyl, —(C1-4 alkylene)-CONR³¹R³², —SO₂(C1-4) alkyl, —NR²³CO—(C1-4) alkyl, —NR²³ SO₂—(C1-4) alkyl, benzoyl, oxo, a C3-7 mono-carbocyclic ring, a 3- to 7-membered mono-heterocyclic ring, —(C1-4 alkylene)-NR³¹R³², -M-(C3-7 mono-carbocyclic ring), or -M-(3- to 7-membered mono-heterocyclic ring), the C3-7 mono-carbocyclic ring and 3- to 7-membered mono-heterocyclic ring in R³⁰ may be substituted with 1-5 of the following substituents (a)-(l): (a) C1-6 alkyl, (b) C2-6 alkenyl, (c) C2-6 alkyl, (d) c1-6 alkoxy, (e) C1-6 alkylthio, (f) halogen, (g) CHF₂, (h) CF₃, (I) nitro, (j) cyano, (k) hydroxy, (l) amino; M is —O—, —S—, C1-4 alkylene, —O—(C1-4 alkylene)-, —S—(C1-4 alkylene)-, —(C1-4 alkylene)-O— or —(C1-4 alkylene)-S—, R³¹ and R³² each independently, is hydrogen or C1-4 alkyl, Cyc2 is a C3-15 mono-, bi- tri-carbocyclic ring or a 3- to 15-membered mono-, bi- tri-heterocyclic ring which is substituted with 1-5 of R³⁰ or unsubstituted, Z is —O—, —S(O)_(p)—, —NR²²—, —NR²³CO—, —NR²³SO₂—, —NR²²—(C1-4 alkylene)-, —S(O)_(p)—(C1-4 alkylene)-, —O—(C2-4 alkylene)-, —NR²³CO—(C1-4 alkylene) or —NR²³ SO₂—(C1-4 alkylene), p is 0, 1 or 2, Cyc3 is a C3-15 mono-, bi- tri-carbocyclic ring or a 3- to 15-membered mono-, bi- tri-heterocyclic ring which is substituted with 1-5 of R³⁰ or unsubstituted, Cyc4 is a C3-12 mono-, bi-carbocyclic ring or a 3- to 12-membered mono-, bi-heterocyclic ring which is substituted with 1-5 of R³⁰ or unsubstituted, T is —O—, —NR²²—, —O—(C1-4 alkylene)-, —S(O)_(p)—(C1-4 alkylene)- or —NR²²—(C1-4 alkylene)-, Cyc5 is a 3- to 15-membered mono-, bi- tri-heterocyclic ring which is substituted with 1-5 of R³⁰ or unsubstituted, q is 0 or 1, L is —O— or —NR²³—, Cyc⁶⁻¹ is phenyl or benzyl which is substituted with one or more R³⁰, Cyc⁶⁻² is a C3-6 mono-carbocyclic ring which is substituted with 1-5 of R³⁰ or unsubstituted, Cyc⁶⁻³ is a C7-15 mono-, bi- or tri-carbocyclic ring which is substituted with 1-5 of R³⁰ or unsubstituted, R³³ and R³⁴ each independently, is hydrogen, C1-4 alkyl, phenyl or benzyl, or NR³³R³⁴ is a 3- to 6-membered mono-heterocyclic ring containing one nitrogen and optionally containing one hetero atom selected from nitrogen, oxygen and sulfur, D is (1) a 1- or 2-membered linking chain comprising an atom(s) selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond in the chain and may be substituted with 1-4 of R⁴⁰, (2) a 3- to 6-membered linking chain comprising atoms selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond and may be substituted with 1-12 of R⁴⁰, wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is a substituent of R³, taken together may form —(CH₂)_(y)—, in which y is 1-4, or (3) a 7- to 10-membered linking chain comprising atoms selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond and may be substituted with 1-20 of R⁴⁰, wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is a substituent of R³, taken together may form —(CH₂)_(y)—, R⁴⁰ is (a) C1-8 alkyl, (b) C2-8 alkenyl, (c) C2-8 alkynyl, (d) oxo, (e) halogen, (f) CF₃, (g) hydroxy, (h) C1-6 alkoxy, (i) C2-6 alkenyloxy, (j) C2-6 alkynyloxy, (k) OCF₃, (l) —S(O)_(p)—(C1-6) alkyl, (m) —S(O)_(p)—(C2-6) alkenyl, (n) —S(O)_(p)—(C2-6) alkynyl, (o) C2-5 acyl, (p) Cyc9, (q) C1-4 alkoxy(C1-4) alkoxy, or (r) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted with 1 or 2 of substituents selected from halogen, CF₃, OCF₃, hydroxy, cyano, C1-4 alkoxy, —S(O)_(p)—(C1-6) alkyl, Cyc9 and C1-4 alkoxy(C1-4) alkoxy or two R⁴⁰'s taken together with the atom of a linking chain to which they bind, may form a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to 15-membered mono-, bi- or tri-heterocyclic ring containing 1-2 hetero atom(s) selected from O, S, SO₂ and N, wherein the carbocyclic ring and the heterocyclic ring may be substituted with 1-3 substituent(s) selected from C1-4 alkyl, C1-4 alkoxy, C2-5 acyl, SO₂(C1-4 alkyl), phenyl and phenyl(C1-4) alkyl, Cyc9 is a C3-6 mono-carbocyclic ring or a 3- to 6-membered mono-heterocyclic ring, which is substituted with 1-5 of R⁴¹ or unsubstituted, R⁴¹ is C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkoxy(C1-4) alkyl, halogen, CF₃, OCF₃, SCF₃, hydroxy, cyano, formyl, C2-5 acyl, —SO₂—(C1-4) alkyl, —NR²³CO—(C1-4) alkyl, benzoyl or oxo, R³ is (1) C1-6 alkyl or (2) a C3-15 mono-, bi- or tri-carbocyclic ring or a 3- to 15-membered mono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R⁴² or unsubstituted, R⁴² is (a) C1-6 alkyl, (b) C1-6 alkoxy, (c) C1-6 alkylthio, (d) halogen, (e) cyano, (f) CF₃, (g) CHF₂, (h) OCF₃, (i) OCHF₂, (j) SCF₃, (k) —NR⁴³R⁴⁴, (l) —SO₂R⁴⁵, (m) —NR⁴⁶COR⁴⁷, (n) hydroxy, (o) oxo, (p) C1-4 alkoxy(C1-4) alkyl, (q) Cyc10, (r) C1-6 alkylene-Cyc10, (s) —CO-Cyc10, (t) —W-Cyc10, (u) —(C1-6 alkylene)-W-Cyc10, (v) —W—(C1-6 alkylene)-Cyc10 or (w) —(C1-6 alkylene)-W—(C1-6 alkylene)-Cyc10, R⁴³ and R⁴⁴ each independently, is hydrogen or C1-4 alkyl, R⁴⁵ is C1-4 alkyl, R⁴⁶ is hydrogen or C1-4 alkyl, R⁴⁷ is hydrogen or C1-4 alkyl, Cyc10 is a C3-12 mono- or bi-carbocyclic ring or a 3- to 12-membered mono- or bi-heterocyclic ring which is substituted with 1-5 of substitutes of the following (a)-(j) or unsubstituted, (a) C1-4 alkyl, (b) C2-5 acyl, (c) 1-4 alkoxy, (d) halogen, (e) hydroxy, (f) nitro, (g) cyano, (h) amine, (i) CF₃, (j) OCF₃, W is —O—, —S(O)_(p)— or —NR⁴⁸—, R⁴⁸ is hydrogen or C1-4 alkyl; or a non-toxic salt thereof.
 2. The compound according to claim 1, wherein, in formula (I), n is 1 or 2, Q is (1)(i) —(C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene)-Cyc2, (ii) —(C1-4 alkylene)-Z-Cyc3, (iii) C1-4 alkyl substituted with —NR²⁴R²⁵, —S(O)_(p)R²⁶, cyano, —NR²³COR²⁷, —NR²³SO₂R²⁸ or —NR²³CONR²⁴R²⁵, (iv) C1-4 alkoxy(C1-4) alkoxy, —NR²³COR²⁷, —COR²⁸, —OSO₂R²⁸, —NR²³SO₂R²⁸ or —NR²³CONR²⁴R²⁵, (v) a C3-7 mono-carbocyclic ring or 3- to 6-membered mono-heterocyclic ring which is substituted with 1-5 of R³⁰, wherein one R³⁰ is always substituted on the ring at the non 1-position, (vi) a C8-15 mono-, bi- or tri-carbocyclic ring or 7- to 15-membered mono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R³⁰ or unsubstituted, (vii) -T-Cyc5, (viii) -L-Cyc⁶⁻¹, -L-(C2-4 alkylene)-Cyc⁶⁻² or -L-(C1-4 alkylene)_(q)-Cyc⁶⁻³, and D is (1) a 1- or 2-membered linking chain comprising an atom(s) selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond in the chain and may be substituted with 1-4 of R⁴⁰, (2) a 3- to 6-membered linking chain comprising atoms selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond in the chain and may be substituted with 1-12 of R⁴⁰, wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is a substituent of R³, taken together may form —(CH₂)_(y)—.
 3. The compound according to claim 2, wherein D is (1) a 1- or 2-membered linking chain comprising an atom(s) selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond in the chain and may be substituted with 1-4 of R⁴⁰.
 4. The compound according to claim 2, wherein D is (2) a 3- to 6-membered linking chain comprising atoms selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond in the chain and may be substituted with 1-12 of R⁴⁰, wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is a substituent of R³, taken together may form —(CH₂)_(y)—.
 5. The compound according to claim 1, wherein, in formula (I), n is 1 or 2, Q is (2)(i) phenoxy, (ii) benzyloxy, (iii) hydroxy(C1-4) alkyl, (iv) C1-4 alkoxy(C1-4) alkyl, or (v) —(C1-4 alkylene)-O—(C1-4 alkylene)-Cyc7, and D is (2) a 3- to 6-membered linking chain comprising atoms selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond in the chain and may be substituted with 1-12 of R⁴⁰, wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is a substituent of R³, taken together may form —(CH₂)_(y)—.
 6. The compound according to claim 1, wherein, in formula (I), n is 1 or 2, Q is (3)(i) C2-6 alkenyl, (ii) C2-6 alkynyl, (iii) C1-6 alkyl substituted with 1-3 halogen(s), (iv) cyano, (v) nitro, (vi) —NR³³R³⁴, (vii) —CONR³³R³⁴, (viii) —S(O)_(p)—(C2-4) alkynyl, (ix) —S(O)_(p)—CHF₂, (x) —S(O)_(p)—NR³³R³⁴, (xi) —O—(C3-6) alkynyl, (xii) —O—CHF₂, or (xiii) C3-7 cycloalkyl, and D is (1) a 1- or 2-membered linking chain comprising an atom(s) selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond in the chain and may be substituted with 1-4 of R⁴⁰.
 7. The compound according to claim 1, wherein, in formula (I), n is 0, and D is (1) a 1- or 2-membered linking chain comprising an atom(s) selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond in the chain and may be substituted with 1-4 of R⁴⁰, (2) a 3- to 6-membered linking chain comprising atoms selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond in the chain and may be substituted with 1-12 of R⁴⁰, wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is a substituent of R³, taken together may form —(CH₂)_(y)—.
 8. The compound according to claim 1, wherein, in formula (I), n is 0, 1 or 2, Q is (1)(i) —(C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene)-Cyc2, (ii) —(C1-4 alkylene)-Z-Cyc3, (iii) C1-4 alkyl substituted with —NR²⁴R²⁵, —S(O)_(p)R²⁶, cyano, —NR²³COR²⁷, —NR²³SO₂R²⁸ or —NR²³CONR²⁴R²⁵, (iv) C1-4 alkoxy(C1-4) alkoxy, —NR²³COR²⁷, —COR²⁸, —OSO₂R²⁸, —NR²³SO₂R²⁸ or —NR²³CONR²⁴R²⁵, (v) a C3-7 mono-carbocyclic ring or 3- to 6-membered mono-heterocyclic ring which is substituted with 1-5 of R³⁰, wherein one R³⁰ is always substituted on the rings at the non 1-position, (vi) a C8-15 mono-, bi- or tri-carbocyclic ring or 7- to 15-membered mono-, bi- or tri-heterocyclic ring which is substituted with 1-5 of R³⁰ or unsubstituted, (vii) -T-Cyc5, (viii) -L-Cyc⁶⁻¹, -L-(C2-4 alkylene)-Cyc⁶⁻² or -L-(C1-4 alkylene)_(q)-Cyc⁶⁻³, (2)(i) phenoxy, (ii) benzyloxy, (iii) hydroxy(C1-4) alkyl, (iv) C1-4 alkoxy(C1-4) alkyl, or (v) —(C1-4 alkylene)-O—(C1-4 alkylene)-Cyc7, or (3)(i) C2-6 alkenyl, (ii) C2-6 alkynyl, (iii) C1-6 alkyl substituted with 1-3 halogen(s), (iv) cyano, (v) nitro, (vi) —NR³³R³⁴, (vii) —CONR³³R³⁴, (viii) —S(O)_(p)—(C1-4) alkynyl, (ix) —S(O)_(p)—CHF₂, (x) —S(O)_(p)—NR³³R³⁴, (xi) —O—(C3-6) alkynyl, (xii) —O—CHF₂, or (xiii) C3-7 cycloalkyl, and D is (3) a 7- to 10-membered linking chain comprising atoms selected from carbon, nitrogen, oxygen and sulfur, which may contain a double bond or a triple bond in the chain and may be substituted with 1-20 of R⁴⁰, wherein R⁴⁰ substituted on the atom bound to R³, and R⁴² which is a substituent of R³, taken together may form —(CH₂)_(y)—.
 9. The compound according to the claim 3, which is selected from (1) (2E)-3-(2-(naphthalen-2-ylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (2) 3-(2-phenylsulfonylamino-4-phenoxymethylphenyl)propanoic acid, (3) (2E)-3-(2-(naphthalen-2-ylmethyl)-4-phenoxymethylphenyl)-2-propenoic acid, (4) (2E)-3-(2-(naphthalen-2-ylmethyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (5) (2E)-3-(2-benzyl-4-phenoxymethylphenyl)-2-propenoic acid, (6) 3-(2-(naphthalen-2-ylmethyl)-4-phenoxymethylphenyl)propanoic acid, (7) 3-(2-(naphthalen-2-ylmethyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (8) (2E)-N-phenylsulfonyl-3-(2-(naphthalen-2-ylmethyl)-4-phenoxymethylphenyl)-2-propenamide, (9) (2E)-N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(naphthalen-2-ylmethyl)-4-phenoxymethylphenyl)-2-propenamide, (10) (2E)-N-phenylsulfonyl-3-(2-(naphthalen-2-ylmethyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide, (11) (2E)-N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(naphthalen-2-ylmethyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide, (12) (2E)-N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-benzyl-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide, (13) (2E)-N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-benzyl-4-phenoxymethylphenyl)-2-propenamide, (14) N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(naphthalen-2-ylmethyl)-4-phenoxymethylphenyl)propanamide, (15) N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(naphthalen-2-ylmethyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (16) 2-(5-(pyrazol-1-ylmethyl)-2-(naphthalen-2-ylmethyl)isoindolin-3-one-1-yl)acetic acid, (17) 2-(5-phenoxymethyl-2-(naphthalen-2-ylmethyl)isoindolin-3-one-1-yl)acetic acid, (18) 2-(5-(4-cyanophenoxymethyl)-2-(naphthalen-2-ylmethyl)isoindolin-3-one-1-yl)acetic acid, (19) 2-(5-(pyrazol-1-ylmethyl)-2-(naphthalen-1-ylmethyl)isoindolin-3-one-1-yl)acetic acid, (20) 2-(5-phenoxymethyl-2-(3-methyl-1-phenylbutyl)isoindolin-3-one-1-yl)acetic acid, (21) N-(3,4-difluorophenylsulfonyl)-2-(5-(pyrazol-1-ylmethyl)-2-(naphthalen-1-ylmethyl)isoindolin-3-one-1-yl)acetamide, (22) N-(3,4-difluorophenylsulfonyl)-2-(5-phenoxymethyl-2-(3-methyl-1-phenylbutyl)isoindolin-3-one-1-yl)acetamide, (23) 3-(2-((3-methylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (24) N-phenylsulfonyl-3-(2-((3-methylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, methyl ester thereof, ethyl ester thereof or non-toxic salts thereof.
 10. The compound according to the claim 4, which is selected from (1) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (2) (2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-methoxychroman-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoic acid, (3) (2E)-3-(2-(2-(2,5,7,8-tetramethylchroman-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoic acid, (4) (2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (5) (2E)-3-(2-(3-phenoxypropoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoic acid, (6) (2E)-3-(2-(4-phenoxybutoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoic acid, (7) (2E)-3-(2-(2-(chroman-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoic acid, (8) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoic acid, (9) (2E)-3-(2-(2-(benzofuran-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoic acid, (10) (2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-(2-methylimidazol-1-ylmethyl)phenyl)-2-propenoic acid, (11) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (12) (2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-(2H-1,2,3-triazol-2-ylmethyl)phenyl)-2-propenoic acid, (13) (2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-(1H-1,2,3-triazol-1-ylmethyl)phenyl)-2-propenoic acid, (14) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-benzylphenyl)-2-propenoic acid, (15) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(thiophen-2-ylmethyl)phenyl)-2-propenoic acid, (16) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(thiophen-3-ylmethyl)phenyl)-2-propenoic acid, (17) 4-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)butanoic acid, (18) (2E)-3-(2-(2-(naphthalen-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (19) (2E)-3-(2-(3-(naphthalen-2-yl)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (20) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxymethylphenyl)-2-propenoic acid, (21) 2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)acetic acid, (22) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-oxopyrrolidin-1-yl)phenyl)-2-propenoic acid, (23) 2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenoxy)acetic acid, (24) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-dimethylaminomethylphenyl)-2-propenoic acid, (25) (2E)-3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (26) (2E)-3-(2-(naphthalen-2-ylmethoxymethyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (27) (2E)-3-(2-((3E)-4-phenyl-3-butenyloxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (28) (2E)-3-(2-(2-hydroxy-3-phenoxypropoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (29) (2E)-3-(2-(2-(1,4-benzodioxan-6-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (30) (2E)-3-(2-(2-(1,4-benzodioxan-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (31) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-cyanomethylphenyl)-2-propenoic acid, (32) (2E)-3-(2-(2-(naphthalen-2-yloxy)ethyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (33) (2E)-3-(2-(2-(N-benzoyl-N-methylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (34) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylthiomethylphenyl)-2-propenoic acid, (35) (2E)-3-(2-(2-(benzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (36) (2E)-3-(2-(2-methoxy-3-phenoxypropoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (37) (2E)-3-(2-(2-methoxy-2-(naphthalen-2-yl)ethoxy)-4-(pyrazol 1-ylmethyl)phenyl)-2-propenoic acid, (38) (2E)-3-(2-(pyrazol-1-ylmethyl)-3-(2-(naphthalen-2-yl)ethoxy)thiophen-4-yl)-2-propenoic acid, (39) (2E)-3-(3-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)thiophen-2-yl)-2-propenoic acid, (40) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-mesyl-N-phenylaminomethyl)phenyl)-2-propenoic acid, (41) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-acetyl-N-phenylaminomethyl)phenyl)-2-propenoic acid, (42) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-benzoyl-N-methylaminomethyl)phenyl)-2-propenoic acid, (43) (2E)-3-(2-(2-(naphthalen-2-yl)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (44) 3-(2-((naphthalen-2-yl)carbonylmethoxy)-4-(pyrazole-1-methyl)phenyl)propanoic acid, (45) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrrol-1-ylmethyl)phenyl)propanoic acid, (46) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-methylpyrazol-1-ylmethyl)phenyl)propanoic acid, (47) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3,5-dimethylpyrazol-1-ylmethyl)phenyl)propanoic acid, (48) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylsulfonylmethylphenyl)propanoic acid, (49) 3-(2-(2-(1,1′-biphenyl-4-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (50) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-benzoylaminophenyl)propanoic acid, (51) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-benzoyl-N-methylamino)phenyl)propanoic acid, (52) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-mesyl-N-methylamino)phenyl)propanoic acid, (53) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-mesylaminophenyl)propanoic acid, (54) 3-(2-(2-(1,1′-biphenyl-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (55) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(benzimidazol-1-ylmethyl)phenyl)propanoic acid, (56) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-methyl-2-oxoimidazolidin-1-ylmethyl)phenyl)propanoic acid, (57) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-oxopyridin-1-ylmethyl)phenyl)propanoic acid, (58) 3-(2-(2-(1,1′-biphenyl-3-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (59) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylsulfonylaminophenyl)propanoic acid, (60) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-acetylaminophenyl)propanoic acid, (61) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-methylpyridin-3-yloxymethyl)phenyl)propanoic acid, (62) 3-(2-(4-methyl-2-(naphthalen-1-yl)pentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (63) 3-(2-(2-(benzothiophen-3-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (64) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-3-yloxymethyl)phenyl)propanoic acid, (65) 3-(2-(2-(indol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (66) 3-(2-(2-(1-methylindol-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (67) 3-(2-(2-(benzothiophen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (68) 3-(2-(2-(benzofuran-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (69) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-methylpyridin-5-yloxymethyl)phenyl)propanoic acid, (70) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-2-yloxy)phenyl)propanoic acid, (71) 3-(2-(2-(naphthalen-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (72) 3-(2-(2-(chroman-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (73) 3-(2-(2-(1-methylindol-3-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (74) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-methylimidazol-1-ylmethyl)phenyl)propanoic acid, (75) 3-(2-(4-methyl-2-(naphthalen-2-yl)pentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (76) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-cyanopyridin-3-yloxymethyl)phenyl)propanoic acid, (77) 3-(2-(2-methoxy-2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (78) 3-(2-(4-methyl-2-phenylpentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (79) 3-(2-(4-methyl-2-phenylpentyloxy)-4-phenoxymethylphenyl)propanoic acid, (80) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxymethylphenyl)propanoic acid, (81) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylaminomethylphenyl)propanoic acid, (82) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-phenyl-N-methylaminomethyl)phenyl)propanoic acid, (83) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-ethyl-N-phenylaminomethyl)phenyl)propanoic acid, (84) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-(pyrazol-1-yl)propyl)phenyl)propanoic acid, (85) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoic acid, (86) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (87) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-methoxyphenoxymethyl)phenyl)propanoic acid, (88) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-methylphenoxymethyl)phenyl)propanoic acid, (89) 3-(2-(2-phenylethoxy)-4-phenoxymethylphenyl)propanoic acid, (90) 3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (91) 3-(2-(4-methyl-2-(3,5-dimethylphenyl)pentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (92) 3-(2-(4-methyl-2-(4-fluoro-3-methylphenyl)pentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (93) 2-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)benzyl)benzoic acid, (94) 2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)benzoic acid, (95) 2-(2-(4-methyl-2-phenylpentyloxy)-4-(pyrazol-1-ylmethyl)benzyl)benzoic acid, (96) 2-(2-(4-methyl-2-(3,5-dimethylphenyl)pentyloxy)-4-(pyrazol-1-ylmethyl)benzyl)benzoic acid, (97) 3-(2-(4-methyl-2-(4-methoxy-1,3-dioxaindan-6-yl)pentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (98) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenylaminomethyl)phenyl)propanoic acid, (99) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-methylphenylaminomethyl)phenyl)propanoic acid, (100) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-3-ylaminomethyl)phenyl)propanoic acid, (101) 3-(2-(2-(benzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (102) 3-(2-(2-(phenylsulfonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (103) 3-(2-(2-(N-methyl-N-phenylsulfonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (104) 3-(2-(2-methoxy-3-phenoxypropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (105) 3-(2-(2-ethoxy-3-phenoxypropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (106) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)-5-chlorophenyl)propanoic acid, (107) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)-5-methoxyphenyl)propanoic acid, (108) 3-(2-(2-(benzimidazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (109) 3-(2-(4-methyl-2-(4-fluoro-3-methylphenyl)pentyloxy)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (110) 3-(2-(4-methyl-2-(4-fluoro-3-methylphenyl)pentyloxy)-4-phenoxymethylphenyl)propanoic acid, (111) 3-(2-(2-(2-methylbenzimidazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (112) 3-(2-(2-(1H-indazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (113) 3-(2-(2-(2H-benzotriazol-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (114) 3-(2-(2-(1H-benzotriazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (115) 3-(2-(2-((3-methylbenzoyl)amino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (116) 3-(2-(2-((3-methoxybenzoyl)amino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (117) 3-(2-(2-((naphthalen-2-ylcarbonyl)amino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (118) 3-(2-(2-((4-methoxybenzoyl)amino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (119) 3-(2-(2-((4-chlorobenzoyl)amino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (120) 3-(2-(4-methyl-2-benzoylaminopentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (121) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-acetylpiperazin-1-ylmethyl)phenyl)propanoic acid, (122) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(morpholin-4-ylmethyl)phenyl)propanoic acid, (123) 3-(2-(2-(4-methylbenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (124) 3-(2-(2-(naphthalen-1-ylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (125) 3-(2-(2-(2-benzylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (126) 3-(2-(2-(2-methylbenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (127) 3-(2-(2-(2-chlorobenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (128) 3-(2-(2-(2-methoxybenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (129) 3-(2-phenylcarbamoylmethoxy-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (130) 3-(2-(naphthalen-1-ylcarbamoylmethoxy)-4-(pyrazol 1-ylmethyl)phenyl)propanoic acid, (131) 3-(2-(naphthalen-2-ylcarbamoylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (132) 3-(2-(3-phenylpropoxy)-4-phenoxymethylphenyl)propanoic acid, (133) 3-(2-(4-phenylbutoxy)-4-phenoxymethylphenyl)propanoic acid, (134) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-methylpiperazin 1-ylmethyl)phenyl)propanoic acid, (135) 2-((2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)amino)acetic acid, (136) 2-(N-methyl-N-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)amino)acetic acid, (137) 2-(N-mesyl-N-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)amino)acetic acid, (138) 2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzoic acid, (139) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-2-ylaminomethyl)phenyl)propanoic acid, (140) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(thiazol-2-ylaminomethyl)phenyl)propanoic acid, (141) 3-(2-(2-cyclohexyloxyethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (142) 3-(2-(benzylcarbamoylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (143) 3-(2-((1-phenylethyl)carbamoylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (144) 3-(2-(2-(3-chlorobenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (145) 2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyloxy)acetic acid, (146) 3-(2-(2-(1-oxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (147) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-(pyrazol-1-yl)ethyl)phenyl)propanoic acid, (148) 3-(2-(2-(thiophen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (149) 3-(2-(2-(thiophen-3-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (150) 3-(2-(3-cyclohexylpropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (151) 3-(2-(2-phenoxyethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (152) 3-(2-(2-(N-methyl-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (153) 3-(2-(2-phenylethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (154) 3-(2-(2-phenylethoxy)-4-(2-chloro-4-methylphenoxymethyl)phenyl)propanoic acid, (155) 3-(2-(3-phenylpropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (156) 3-(2-(4-phenylbutoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (157) (2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoic acid, (158) 3-(2-(3,3-diphenylpropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (159) 3-(2-(2-(N,N-diphenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (160) 3-(2-(2-(4-phenylpiperazin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (161) 3-(2-(2-(4-phenyl-1,2,3,6-tetrahydropyridin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (162) 3-(2-(2-(4-phenylpiperidin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (163) 3-(2-(2-(phenoxazin-10-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (164) 4-(2-(2-phenylethoxy)-4-(3-cyanophenoxymethyl)phenyl)butanoic acid, (165) 4-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)butanoic acid, (166) 2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzoylamino)acetic acid, (167) 3-(2-(2-(2-methylimidazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (168) 3-(2-(5-phenylpentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (169) 3-(2-(3-(N-methyl-N-phenylamino)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (170) 3-(2-(2-(N-ethyl-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (171) 3-(2-(2-(N-(2-hydroxyethyl)-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (172) 3-(2-(2-(3-(piperidin-1-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (173) 3-(2-(2-(3-(morpholin-4-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (174) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propynoic acid, (175) 3-(2-(2-hydroxy-2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (176) 3-(2-(2-(1,2,3,4-tetrahydroisoquinolin-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (177) 3-(2-(2-(9-methylcarbazol-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (178) 3-(2-(2-(3-(4-methylpiperazin-1-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (179) 3-(2-(2-(3-(4-acetylpiperazin-1-yl)phenyl)ethoxy)-4-(pyrazol 1-ylmethyl)phenyl)propanoic acid, (180) 3-(2-(2-phenylaminoethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (181) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-acetyl-N-methylaminomethyl)phenyl)propanoic acid, (182) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-ethoxycarbonyl-N-methylaminomethyl)phenyl)propanoic acid, (183) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoic acid, (184) (2E)-3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (185) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (186) (2E)-3-(2-((naphthalen-2-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (187) (2E)-3-(2-(N-(naphthalen-2-ylmethyl)-N-methylcarbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (188) (2E)-3-(2-((naphthalen-2-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)-2-propenoic acid, (189) (2E)-3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)-2-propenoic acid, (190) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (191) (2E)-3-(2-(1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)-2-propenoic acid, (192) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoic acid, (193) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2,5-dichlorophenoxymethyl)phenyl)propanoic acid, (194) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoic acid, (195) 3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (196) 3-(2-((1-methyl-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (197) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2,6-dimethylphenoxymethyl)phenyl)propanoic acid, (198) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-chloro-6-methylphenoxymethyl)phenyl)propanoic acid, (199) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (200) 3-(2-(((1R)-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (201) 3-(2-((1-(naphthalen-1-yl)propyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (202) 3-(2-(((1S)-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (203) 3-(2-((1-(naphthalen-2-yl)ethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (204) 3-(2-((4-methoxynaphthalen-1-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (205) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-methylthiophenoxymethyl)phenyl)propanoic acid, (206) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-mesylphenoxymethyl)phenyl)propanoic acid, (207) 4-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)butanoic acid, (208) 3-(2-((4-fluoronaphthalen-1-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (209) 3-(2-((quinolin-4-ylmethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (210) 3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (211) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-cyanophenoxymethyl)phenyl)propanoic acid, (212) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoic acid, (213) 3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(pyridin-3-yloxymethyl)phenyl)propanoic acid, (214) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-formylphenoxymethyl)phenyl)propanoic acid, (215) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-hydroxymethylphenoxymethyl)phenyl)propanoic acid, (216) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (217) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-acetylaminophenoxymethyl)phenyl)propanoic acid, (218) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenyl)propanoic acid, (219) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-methoxymethylphenoxymethyl)phenyl)propanoic acid, (220) 3-(2-((3-methyl-1-(4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (221) 3-(2-(((1R)-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-(pyridin-2-yloxy)phenyl)propanoic acid, (222) 3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (223) 3-(2-((3-methyl-1-(4-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (224) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyridin-3-yloxymethyl)phenyl)propanoic acid, (225) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyridin-4-yloxymethyl)phenyl)propanoic acid, (226) 3-(2-((1-phenylethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (227) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyridin-2-yloxymethyl)phenyl)propanoic acid, (228) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenylaminomethylphenyl)propanoic acid, (229) 2-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenoxy)acetic acid, (230) 3-(2-((1-phenylpropyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (231) 3-(2-((1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (232) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyrimidin-2-yloxymethyl)phenyl)propanoic acid, (233) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyrazin-2-yloxymethyl)phenyl)propanoic acid, (234) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methylpyridin-3-yloxymethyl)phenyl)propanoic acid, (235) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenylthiomethylphenyl)propanoic acid, (236) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(thiazol-2-ylthiomethyl)phenyl)propanoic acid, (237) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(1-methylimidazol-2-ylthiomethyl)phenyl)propanoic acid, (238) 3-(2-((2-cyclopropyl-1-phenylethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (239) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoic acid, (240) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenyl)propanoic acid, (241) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-hydroxyphenoxymethyl)phenyl)propanoic acid, (242) 3-(2-((2-phenylethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (243) 3-(2-benzylcarbamoyl-4-phenoxymethylphenyl)propanoic acid, (244) 3-(2-((3-methyl-1-phenyl-3-butenyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (245) 3-(2-phenylcarbamoyl-4-phenoxymethylphenyl)propanoic acid, (246) 3-(2-((3-methyl-1-(4-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (247) 3-(2-((3-methyl-1-(4-ethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (248) 3-(2-((3-methyl-1-(3-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (249) 3-(2-((3-methyl-1-(3-chlorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (250) 3-(2-((3-methyl-1-(4-chlorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (251) 3-(2-((3-methyl-1-(3-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (252) 3-(2-((3-methyl-1-(3-chloro-4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (253) 3-(2-((3-methyl-1-(3-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (254) 3-(2-((3-methyl-1-(3,4,5-trifluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (255) 3-(2-((3-methyl-1-(3,5-ditrifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (256) 3-(2-((3-methyl-1-(3-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (257) 3-(2-((3-methyl-1-(4-ethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (258) 3-(2-((3-methyl-1-(4-butylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (259) 3-(2-((3-methyl-1-(4-fluoro-3-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (260) 3-(2-((3-methyl-1-(3-fluoro-4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (261) 3-(2-((3-methyl-1-(3-fluoro-4-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (262) 3-(2-((3-methyl-1-(4-chloro-3-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (263) 3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoic acid, (264) 3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoic acid, (265) 3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenyl)propanoic acid, (266) 3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (267) 3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoic acid, (268) 3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(pyridin-3-yloxymethyl)phenyl)propanoic acid, (269) 3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (270) 3-(2-((3-methyl-1-(4-t-butylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (271) 3-(2-((3-methyl-1-(2-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (272) 3-(2-((3-methyl-1-(4-fluoro-2-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (273) 3-(2-((3-methyl-1-(3-ethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (274) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (275) 3-(2-((3-methyl-1-(3,5-dimethyl-4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (276) 3-(2-((3-methyl-1-(5-methyl-2-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (277) 3-(2-((3-methyl-1-(4-propylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (278) 3-(2-((3-methyl-1-(3-trifluoromethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (279) 3-(2-((3-methyl-1-(3-isopropylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (280) 3-(2-((3-methyl-1-(3-isopropyloxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (281) 3-(2-((3-methyl-1-(1,3-dioxaindan-5-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (282) 3-(2-((3-methyl-1-(4-propoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (283) 3-(2-((3-methyl-1-(2-fluoro-4-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (284) 3-(2-((3-methyl-1-(4-trifluoromethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (285) 3-(2-((3-methyl-1-(2,5-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (286) 3-(2-((3-methyl-1-(1,4-benzodioxan-6-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (287) 3-(2-((3-methyl-1-(4-difluoromethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (288) 3-(2-((3-methyl-1-(3,4,5-trimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (289) 3-(2-((3-methyl-1-(2-chloro-3,4-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (290) 3-(2-((3-methyl-1-(4-isobutylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (291) 3-(2-((3-methyl-1-(2-fluoro-5-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (292) 3-(2-((3-methyl-1-(2-chloro-6-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (293) 3-(2-((3-methyl-1-(2-chloro-5-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (294) 3-(2-((3-methyl-1-(2-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (295) 2-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methylphenoxymethyl)phenoxy)acetic acid, (296) 2-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenoxy)acetic acid, (297) 3-(2-((3-methyl-1-(4-acetylaminophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (298) 3-(2-((3-methyl-1-(3-fluoro-4-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (299) 3-(2-((3-methyl-1-(4,5-dimethoxy-2-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (300) 3-(2-((3-methyl-1-(2-fluoro-4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (301) 3-(2-((3-methyl-1-(3,4-difluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (302) 3-(2-((3-methyl-1-(4-methoxy-1,3-dioxaindan-6-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (303) 3-(2-((3-methyl-1-(3-ethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (304) 3-(2-((3-methyl-1-(4-trifluoromethylthiophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (305) 3-(2-((3-methyl-1-(2-difluoromethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (306) 3-(2-((3-methyl-1-(2,3,5,6-tetrafluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (307) 3-(2-((3-methyl-1-(2-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (308) 3-(2-((3-methyl-1-(2,5-difluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (309) 3-(2-((3-methyl-1-(2-fluoro-5-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (310) 3-(2-((3-methyl-1-(3,4-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (311) 3-(2-((3-methyl-1-(2,4-difluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (312) 3-(2-((3-methyl-1-(2,3,6-trifluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (313) 3-(2-((3-methyl-1-(4-chloro-2-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (314) 3-(2-((3-methyl-1-(2,4,5-trifluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (315) 3-(2-((3-methyl-1-(2,3-difluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (316) 3-(2-((3-methyl-1-(2-chloro-4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (317) 3-(2-((3-methyl-1-(2,4,6-trifluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (318) 3-(2-((3-methyl-1-(2,3-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (319) 3-(2-((3-methyl-1-(4-diethylaminophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (320) 3-(2-((3-methyl-1-(2,3,4,5,6-pentafluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (321) (2E)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)-2-propenoic acid, (322) 3-(2-((3-methyl-1-(4-mesylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (323) 3-(2-((3-methyl-1-(3-fluoro-2-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (324) 3-(2-((3-methyl-1-(2,3,4-trifluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (325) 3-(2-((3-methyl-1-(4-(pyrrolidin-1-yl)phenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (326) 3-(2-((3-methyl-1-(4-dimethylaminophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (327) 3-(2-((3-methyl-1-(4-dimethylamino-2-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (328) 3-(2-((3-methyl-1-(2,4-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (329) 3-(2-((3-methyl-1-(4-butoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (330) 3-(2-((3-methyl-1-(4-ethoxy-3-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (331) 3-(2-((3-methyl-1-(4-isopropyloxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (332) 3-(2-((3-methyl-1-(3,4-diethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (333) 3-(2-((3-methyl-1-(2,3,4-trimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (334) 3-(2-((3-methyl-1-(2,4-dimethoxy-3-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (335) 3-(2-((3-methyl-1-(thiophen-2-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (336) 3-(2-((3-methyl-1-(2,4,5-trimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (337) 3-(2-((3-methyl-1-(3-methylthiophen-2-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (338) 3-(2-((3-methyl-1-(2,3-dimethyl-4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (339) 3-(2-((3-methyl-1-(2,5-dimethyl-4-methoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (340) 3-(2-((3-methyl-1-(4-methoxy-3-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (341) 3-(2-((3-methyl-1-(5-methylfuran-2-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (342) 3-(2-((3-methyl-1-(2,4-diethoxy-3-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (343) 3-(2-((3-methyl-1-(1-methylpyrrol-2-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (344) 3-(2-((3-methyl-1-(4-ethylthiophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (345) 3-(2-((3-methyl-1-(3-trifluoromethylthiophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (346) 3-(2-((3-methyl-1-(4-methylthiophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (347) 3-(2-((3-methyl-1-(4-cyanophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (348) 3-(2-((3-methyl-1-(thiophen-3-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (349) 3-(2-((3-methyl-1-(2,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (350) 3-(2-((3-methyl-1-(3,4-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (351) 3-(2-((3-methyl-1-(1,3-dioxaindan-4-yl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (352) 3-(2-(N-benzyl-N-methylcarbamoyl)-4-phenoxymethylphenyl)propanoic acid, (353) 3-(2-(N-benzyl-N-propylcarbamoyl)-4-phenoxymethylphenyl)propanoic acid, (354) 3-(2-((3-methyl-1-(3-fluoro-5-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (355) 3-(2-((3-methyl-1-(4-fluoro-2-trifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (356) 3-(2-((3-methyl-1-(2,4-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (357) 3-(2-((3-methyl-1-(2,4-ditrifluoromethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (358) 3-(2-((3-methyl-1-(2-methylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (359) 3-(2-((3-methyl-1-(2,3-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (360) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(furan-2-ylcarbonylaminomethyl)phenyl)propanoic acid, (361) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (362) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-phenylethyl)phenyl)propanoic acid, (363) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (364) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoic acid, (365) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoic acid, (366) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(pyridin-3-yloxymethyl)phenyl)propanoic acid, (367) 3-(2-((3-methyl-1-(4-methoxy-1,3-dioxaindan-6-yl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoic acid, (368) 3-(2-((3-methyl-1-(4-methoxy-1,3-dioxaindan-6-yl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (369) 3-(2-((3-methyl-1-(4-methoxy-1,3-dioxaindan-6-yl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoic acid, (370) 3-(2-((3-methyl-1-(3,5-dichlorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (371) 3-(2-((3-methyl-1-(3-chloro-5-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (372) 3-(2-((3-methyl-1-(4-fluoro-3-methylphenyl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoic acid, (373) 3-(2-((3-methyl-1-(4-fluoro-3-methylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoic acid, (374) 3-(2-((3-methyl-1-(3,5-difluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (375) 3-(2-((3-methyl-1-(3,5-dimethoxyphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (376) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(1-phenoxyethyl)phenyl)propanoic acid, (377) 3-(2-((2-methoxy-2-phenylethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (378) 3-(2-((2-phenylpropyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (379) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-phenoxyethyl)phenyl)propanoic acid, (380) 3-(2-(3-phenylmorpholin-4-ylcarbonyl)-4-phenoxymethylphenyl)propanoic acid, (381) 3-(2-(4-phenoxypiperidin-1-ylcarbonyl)-4-phenoxymethylphenyl)propanoic acid, (382) 3-(2-((2-methoxy-1-(3,5-dimethylphenyl)ethyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoic acid, (383) 3-(2-((4-methyl-2-phenylpentyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (384) 3-(2-diphenylmethylcarbamoyl-4-phenoxymethylphenyl)propanoic acid, (385) 3-(2-((2-cyclopropyl-1-(3,5-dimethylphenyl)ethyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoic acid, (386) 3-(2-((1-(3,5-dimethylphenyl)ethyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoic acid, (387) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethyl-5-methoxyphenyl)propanoic acid, (388) 3-(2-((1-methyl-2-phenylethyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (389) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(benzothiazol-2-yl)phenyl)propanoic acid, (390) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(1,3-dioxaindan-2-yl)phenyl)propanoic acid, (391) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(indol-1-ylmethyl)phenyl)propanoic acid, (392) 3-(2-((4-methyl-1-phenylpentan-2-yl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (393) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethyl-5-methylphenyl)propanoic acid, (394) 3-(2-((naphthalen-2-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (395) 3-(2-((3-methyl-1-phenylbutyl)sulfamoyl)-4-phenoxymethylphenyl)propanoic acid, (396) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (397) 3-(2-((3-methyl-1-(3,5-dimethoxyphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (398) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-3-methyl-4-phenoxymethylphenyl)propanoic acid, (399) 2-(2-(3-methyl-1-phenylbutyl)carbamoyl-4-phenoxymethylbenzyloxy)acetic acid, (400) 3-(2-((3-hydroxy-3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (401) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-ethoxyphenoxymethyl)phenyl)butanoic acid, (402) (2E)-3-(2-((2-(naphthalen-2-yl)acetyl)amino)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (403) 2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-mesyloxybenzyl)benzoic acid, (404) 2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-acetylaminobenzyl)benzoic acid, (405) 2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-mesylaminobenzyl)benzoic acid, (406) 2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-(N-mesyl-N-methylamino)benzyl)benzoic acid, (407) 2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-(pyrazol-1-ylmethyl)benzyl)benzoic acid, (408) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenoxymethylphenyl)butanoic acid, (409) 2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-mesylmethylbenzyl)benzoic acid, (410) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-methylthiomethylphenyl)butanoic acid, (411) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-methylsulfinylmethylphenyl)butanoic acid, (412) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-mesylmethylphenyl)butanoic acid, (413) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-aminomethylphenyl)butanoic acid, (414) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-acetylaminomethylphenyl)butanoic acid, (415) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-mesylaminomethylphenyl)butanoic acid, (416) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(N-mesyl-N-methylaminomethyl)phenyl)butanoic acid, (417) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzoylaminophenyl)butanoic acid, (418) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylsulfonylaminophenyl)butanoic acid, (419) 4-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-phenoxymethylphenyl)butanoic acid, (420) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-oxopyridin-1-ylmethyl)phenyl)butanoic acid, (421) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(pyridin-3-yloxymethyl)phenyl)butanoic acid, (422) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylthiomethylphenyl)butanoic acid, (423) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylaminomethylphenyl)butanoic acid, (424) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylsulfinylmethylphenyl)butanoic acid, (425) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylsulfonylmethylphenyl)butanoic acid, (426) 3-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-phenoxymethylphenyl)propanoic acid, (427) 4-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-(pyrazol-1-ylmethyl)phenyl)butanoic acid, (428) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzoylaminomethylphenyl)butanoic acid, (429) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(pyridin-4-yloxymethyl)phenyl)butanoic acid, (430) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-phenoxyethyl)phenyl)butanoic acid, (431) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(pyridin-2-yloxymethyl)phenyl)butanoic acid, (432) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(N-methyl-N-phenylaminomethyl)phenyl)butanoic acid, (433) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(N-benzoyl-N-methylamino)phenyl)butanoic acid, (434) 4-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-phenoxymethylphenyl)butanoic acid, (435) 4-(2-((2-phenylpropanoyl)amino)-4-phenoxymethylphenyl)butanoic acid, (436) 3-(2-((4-methyl-2-phenylpentanoyl)amino)-4-phenoxymethylphenyl)propanoic acid, (437) 3-(2-((2-phenylpentanoyl)amino)-4-phenoxymethylphenyl)propanoic acid, (438) 3-(2-((2-phenylpropanoyl)amino)-4-phenoxymethylphenyl)propanoic acid, (439) 3-(2-((2-phenylbutanoyl)amino)-4-phenoxymethylphenyl)propanoic acid, (440) 4-(2-((2-phenylpropanoyl)amino)-4-phenylaminomethylphenyl)butanoic acid, (441) 4-(2-((2-phenylpropanoyl)amino)-4-benzoylaminomethylphenyl)butanoic acid, (442) 4-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-benzoylaminomethylphenyl)butanoic acid, (443) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylsulfonylaminomethylphenyl)butanoic acid, (444) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzylaminomethylphenyl)butanoic acid, (445) 4-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-phenylaminomethylphenyl)butanoic acid, (446) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-cyanophenoxymethyl)phenyl)butanoic acid, (447) 4-(2-((2-(benzothiophen-3-yl)propanoyl)amino)-4-phenylaminomethylphenyl)butanoic acid, (448) 2-(2-((2-phenylpropanoyl)amino)-4-phenoxymethylbenzyl)benzoic acid, (449) 2-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenoxymethylbenzyl)benzoic acid, (450) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-ethoxycarbonylaminomethylphenyl)butanoic acid, (451) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(furan-2-ylcarbonylaminomethyl)phenyl)butanoic acid, (452) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-fluorobenzoylaminomethyl)phenyl)butanoic acid, (453) 3-(2-(N-benzylsulfonyl-N-methylamino)-4-phenoxymethylphenyl)propanoic acid, (454) (2E)-3-(2-(N-benzylsulfonyl-N-methylamino)-4-phenoxymethylphenyl)-2-propenoic acid, (455) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-methoxybenzoylaminomethyl)phenyl)butanoic acid, (456) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-cyclopropylcarbonylaminomethylphenyl)butanoic acid, (457) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(thiophen-2-ylcarbonylaminomethyl)phenyl)butanoic acid, (458) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-methylbenzoylaminomethyl)phenyl)butanoic acid, (459) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-chlorobenzoylaminomethyl)phenyl)butanoic acid, (460) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-cyanobenzoylaminomethyl)phenyl)butanoic acid, (461) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-fluorobenzoylaminomethyl)phenyl)butanoic acid, (462) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-fluorobenzoylaminomethyl)phenyl)butanoic acid, (463) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-chloro-4-fluorobenzoylaminomethyl)phenyl)butanoic acid, (464) 4-(2-((2-(2-chlorophenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoic acid, (465) 4-(2-((2-(3-chlorophenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoic acid, (466) 4-(2-((2-(4-chlorophenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoic acid, (467) 4-(2-((2-(4-fluorophenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoic acid, (468) 4-(2-((2-(4-methoxyphenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoic acid, (469) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-ethoxybenzoylaminomethyl)phenyl)butanoic acid, (470) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3,5-difluorobenzoylaminomethyl)phenyl)butanoic acid, (471) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-fluorophenoxymethyl)phenyl)butanoic acid, (472) 4-(2-((2-(4-methylphenyl)propanoyl)amino)-4-phenoxymethylphenyl)butanoic acid, (473) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-cyano-2-methoxyphenoxymethyl)phenyl)butanoic acid, (474) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-acetylphenoxymethyl)phenyl)butanoic acid, (475) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-isopropyl-5-methylphenoxymethyl)phenyl)butanoic acid, (476) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2,4,6-trifluorophenoxymethyl)phenyl)butanoic acid, (477) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-trifluoromethylthiophenoxymethyl)phenyl)butanoic acid, (478) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-bromophenoxymethyl)phenyl)butanoic acid, (479) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-methoxyphenoxymethyl)phenyl)butanoic acid, (480) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-methoxyphenoxymethyl)phenyl)butanoic acid, (481) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-methylbenzothiazol-5-yloxymethyl)phenyl)butanoic acid, (482) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-(1,2,4-triazol-1-yl)phenoxymethyl)phenyl)butanoic acid, (483) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-ethoxyphenoxymethyl)phenyl)butanoic acid, (484) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-methoxy-5-methylphenoxymethyl)phenyl)butanoic acid, (485) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3,5-dimethoxyphenoxymethyl)phenyl)butanoic acid, (486) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-fluoro-6-methoxyphenoxymethyl)phenyl)butanoic acid, (487) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-isopropyloxyphenoxymethyl)phenyl)butanoic acid, (488) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-acetyl-5-methoxyphenoxymethyl)phenyl)butanoic acid, (489) 2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-phenoxymethylbenzyl)benzoic acid, (490) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-chloro-4,5-dimethylphenoxymethyl)phenyl)butanoic acid, (491) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(1-oxo-1,2,3,4-tetrahydronaphthalen-6-yloxymethyl)phenyl)butanoic acid, (492) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-cyanophenoxymethyl)phenyl)butanoic acid, (493) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-chloro-5-methoxyphenoxymethyl)phenyl)butanoic acid, (494) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-ethyl-2-methoxyphenoxymethyl)phenyl)butanoic acid, (495) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-acetylamino-2-chlorophenoxymethyl)phenyl)butanoic acid, (496) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-methylthiophenoxymethyl)phenyl)butanoic acid, (497) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(4-butanoylphenoxymethyl)phenyl)butanoic acid, (498) (2E)-3-(2-((4-methyl-2-phenylpentanoyl)amino)-4-phenoxymethylphenyl)-2-propenoic acid, (499) 4-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-(pyrazol-1-ylmethyl)phenyl)butanoic acid, (500) 3-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-phenoxymethylphenyl)propanoic acid, (501) 3-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-phenylaminomethylphenyl)propanoic acid, (502) 3-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (503) 2-(2-((2-(4-fluoronaphthalen-1-yl)acetyl)amino)-4-phenoxymethylbenzyl)benzoic acid, (504) 2-(2-((2-(4-fluoronaphthalen-1-yl)propanoyl)amino)-4-phenoxymethylbenzyl)benzoic acid, (505) 2-(2-((4-methyl-2-phenylpentanoyl)amino)-4-phenoxymethylbenzyl)benzoic acid, (506) 2-(2-((4-methyl-2-(3,5-dimethylphenyl)pentanoyl)amino)-4-phenoxymethylbenzyl)benzoic acid, (507) 2-(2-((2-(naphthalen-1-yl)acetyl)amino)-4-phenoxymethylbenzyl)benzoic acid, (508) 3-(2-((4-methyl-2-(4-fluoro-3-methylphenyl)pentanoyl)amino)-4-phenoxymethylphenyl)propanoic acid, (509) 3-(2-((4-methyl-2-(3,5-dimethylphenyl)pentanoyl)amino)-4-phenoxymethylphenyl)propanoic acid, (510) 3-(2-((4-methyl-2-(4-methoxy-1,3-dioxaindan-6-yl)pentanoyl)amino)-4-phenoxymethylphenyl)propanoic acid, (511) 2-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-methylphenoxymethyl)benzyl)benzoic acid, (512) 2-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(2-chloro-5-methylphenoxymethyl)benzyl)benzoic acid, (513) 2-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(3-cyanophenoxymethyl)benzyl)benzoic acid, (514) 2-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-(pyridin-3-yloxymethyl)benzyl)benzoic acid, (515) (2E)-3-(2-(3-phenylpropyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenoic acid, (516) 2-(2-(3-(naphthalen-2-yl)propyl)-4-(pyrazol-1-ylmethyl)phenoxy)acetic acid, (517) N-mesyl-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (518) N-phenylsulfonyl-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (519) N-phenylsulfonyl-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (520) N-methyl-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (521) N-(pyridin-2-yl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (522) N-(4-trifluoromethylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (523) N-(naphthalen-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (524) N-(3-chloro-4-methylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (525) N-(4-ethylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (526) N-isopropylsulfonyl-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (527) N-(4-mesylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (528) N-((1,1′-biphenyl-4-yl)sulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (529) N-((1,1′-biphenyl-2-yl)sulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (530) N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (531) N-(2,6-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (532) N-(2,5-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (533) N-(2,5-dimethoxyphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (534) N-((E)-2-phenylethenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (535) N-(furan-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (536) N-(thiophen-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (537) N-(7-chlorobenzofurazan-4-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (538) N-(3,4-dichlorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (539) N-(4-methoxyphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (540) N-(3-methylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (541) N-(2-fluorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (542) N-(4-cyanophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (543) N-(3-cyanophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (544) N-(2-chloro-4-cyanophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (545) N-(3-methoxyphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (546) N-(4-butoxyphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (547) N-(4-fluorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (548) N-(2-chloro-6-methylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (549) N-(2-trifluoromethylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (550) N-(3-trifluoromethylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (551) N-(4-propylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (552) N-(4-isopropylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (553) N-(naphthalen-1-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (554) N-(4-butylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (555) N-(5-benzoylaminomethylthiophen-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (556) N-phenylsulfonyl-2-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenoxy)acetamide, (557) N-phenylsulfonyl-2-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methylphenoxymethyl)phenoxy)acetamide, (558) N-phenylsulfonyl-2-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenoxy)acetamide, (559) N-(5-methylfuran-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (560) N-(thiophen-3-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (561) N-(furan-3-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (562) N-(1-methylpyrrol-2-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (563) N-(3,5-dimethylisoxazol-4-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (564) N-benzylsulfonyl-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (565) N-(5-dimethylaminonaphthalen-1-ylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (566) N-(4-acetylaminophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (567) N-(4-chlorophenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (568) N-(2-methoxycarbonylphenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (569) N-(3-(3-methyl-5-oxopyrazol-1-yl)phenylsulfonyl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (570) N-(tetrazol-5-yl)-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (571) (2E)-N-phenylsulfonyl-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)-2-propenamide, (572) N-(pyridin-2-yl)-3-(2-(4-methyl-2-phenylpentyloxy)-4-phenoxymethylphenyl)propanamide, (573) N-(tetrazol-5-yl)-3-(2-(4-methyl-2-phenylpentyloxy)-4-phenoxymethylphenyl)propanamide, (574) N-phenylsulfonyl-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxymethylphenyl)propanamide, (575) N-phenylsulfonyl-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (576) N-(tetrazol-5-yl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (577) N-(tetrazol-5-yl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxymethylphenyl)propanamide, (578) N-phenylsulfonyl-3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (579) N-(tetrazol-5-yl)-3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (580) N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (581) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (582) N-(7-chlorobenzofurazan-4-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (583) N-(3,4-dichlorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (584) N-(3-cyanophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (585) N-(3-chloro-4-methylphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (586) N-(3-chloro-4-fluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (587) N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (588) N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (589) N-phenylsulfonyl-3-(2-(2-phenylethoxy)-4-phenoxymethylphenyl)propanamide, (590) N-(3-chloro-4-fluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide, (591) N-(3-cyanophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide, (592) N-(3,4-dichlorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide, (593) N-(3-chloro-4-methylphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide, (594) N-(7-chlorobenzofurazan-4-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide, (595) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide, (596) N-(5-bromo-2-methoxyphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide, (597) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-phenylethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (598) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(benzimidazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (599) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(benzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (600) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(2H-benzotriazol-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (601) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(1H-benzotriazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (602) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(2-methylbenzimidazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (603) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(1H-indazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (604) (2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide, (605) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-methylpiperazin-1-ylmethyl)phenyl)propanamide, (606) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-acetylpiperazin-1-ylmethyl)phenyl)propanamide, (607) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(morpholin-4-ylmethyl)phenyl)propanamide, (608) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-3-yloxymethyl)phenyl)propanamide, (609) N-phenylsulfonyl-2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)acetamide, (610) N-phenylsulfonyl-4-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)butanamide, (611) N-(3,4-difluorophenylsulfonyl)-4-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)butanamide, (612) N-(pyridin-3-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol 1-ylmethyl)phenyl)propanamide, (613) N-(1-methylpyrrol-2-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (614) N-(4-methylthiazol-2-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (615) N-(3,5-dimethylisoxazol-4-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (616) N-(pyridin-2-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol 1-ylmethyl)phenyl)propanamide, (617) N-hydroxy-3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (618) N-(1-methyl imidazol-2-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (619) N-phenylsulfonyl-2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzamide, (620) N-(5-methylfuran-2-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (621) N-(furan-3-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol 1-ylmethyl)phenyl)propanamide, (622) N-(thiophen-3-ylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (623) N-(2,5-dimethoxyphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (624) N-(4-methoxyphenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (625) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-cyclohexyloxyethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (626) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(piperidin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (627) N-phenylsulfonyl-3-(2-(2-(3-methoxybenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (628) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-methoxybenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (629) N-(3,4-difluorophenylsulfonyl)-3-(3-(3-phenylpropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (630) N-(3,4-difluorophenylsulfonyl)-3-(3-(3-(naphthalen-1-yl)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (631) N-phenylsulfonyl-3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (632) N-(3,4-difluorophenylsulfonyl)-3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (633) N-phenylsulfonyl-3-(2-((naphthalen-2-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (634) N-(3,4-difluorophenylsulfonyl)-3-(2-((naphthalen-2-ylmethyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (635) N-phenylsulfonyl-3-(2-(benzylcarbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (636) N-(3,4-difluorophenylsulfonyl)-3-(2-(benzylcarbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (637) N-(3,4-difluorophenylsulfonyl)-3-(3-(3-(naphthalen-2-yl)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (638) N-phenylsulfonyl-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (639) N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (640) N-phenylsulfonyl-3-(2-((3-methyl-1-(3,5-dimethoxyphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (641) N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(3,5-dimethoxyphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (642) (2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(4-acetylpiperazin-1-ylmethyl)phenyl)-2-propenamide, (643) (2E)-N-phenylsulfonyl-3-(2-(N-benzylsulfonyl-N-methylamino)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide, (644) (2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(N-benzylsulfonyl-N-methylamino)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide, (645) N-(3,4-difluorophenylsulfonyl)-3-(2-((2-(naphthalen-1-yl)acetyl)amino)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (646) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(thiophen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (647) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(thiophen-3-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (648) N-(tetrazol-5-yl)-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanamide, (649) N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanamide, (650) N-(3,4-difluorophenylsulfonyl)-2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyloxy)acetamide, (651) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-dimethylaminomethylphenyl)propanamide, (652) N-(3,4-difluorophenylsulfonyl)-3-(2-(3-cyclohexylpropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (653) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-phenoxyethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (654) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-methyl-2-oxoimidazolidin-1-ylmethyl)phenyl)propanamide, (655) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-benzoylaminophenyl)propanamide, (656) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylsulfonylaminophenyl)propanamide, (657) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-mesylaminophenyl)propanamide, (658) N-(3,4-difluorophenylsulfonyl)-3-(2-(naphthalen-1-ylcarbamoylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (659) N-(3,4-difluorophenylsulfonyl)-3-(2-(benzylcarbamoylmethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (660) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-methylbenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (661) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-chlorobenzoylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (662) N-(3,4-difluorophenylsulfonyl)-3-(2-(3-phenylpropoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (663) N-(3,4-difluorophenylsulfonyl)-3-(2-(4-phenylbutoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (664) (2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(2-oxopyrrolidin-1-ylmethyl)phenyl)-2-propenamide, (665) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-(piperidin-1-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (666) (2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-cyanomethylphenyl)-2-propenamide, (667) N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(morpholin-4-ylmethyl)phenyl)propanamide, (668) N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanamide, (669) N-(3,4-difluorophenylsulfonyl)-2-(2-(3-(naphthalen-2-yl)propyl)-4-(pyrazol-1-ylmethyl)phenoxy)acetamide, (670) (2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(thiophen-3-ylmethyl)phenyl)-2-propenamide, (671) (2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-benzylphenyl)-2-propenamide, (672) (2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-benzoyl-N-methylaminomethyl)phenyl)-2-propenamide, (673) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-phenylethoxy)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanamide, (674) N-(3,4-difluorophenylsulfonyl)-2-(N′-methyl-N′-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)amino)acetamide, (675) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N′-acetyl-N′-methylaminomethyl)phenyl)propanamide, (676) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N′-ethoxycarbonyl-N′-methylaminomethyl)phenyl)propanamide, (677) N-(3,4-difluorophenylsulfonyl)-3-(2-((2E)-3-phenyl-2-propenyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (678) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(N′-methyl-N′-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (679) (2E)-N-(3,4-difluorophenylsulfonyl)-3-(2-(3-phenylpropyl)-4-(pyrazol-1-ylmethyl)phenyl)-2-propenamide, (680) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-phenylethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide, (681) N-benzyl-N-hydroxy-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (682) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(thiazol-2-ylaminomethyl)phenyl)propanamide, (683) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyridin-2-yloxy)phenyl)propanamide, (684) N-(3,4-difluorophenylsulfonyl)-5-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)pentanamide, (685) (2E-N-(3,4-difluorophenylsulfonyl)-3-(2-(pyrazol-1-ylmethyl)-3-(2-(naphthalen-2-yl)ethoxy)thiophen-4-yl)-2-propenamide, (686) (2E)-N-(3,4-difluorophenylsulfonyl)-3-(4-(pyrazol-1-ylmethyl)-3-(2-(naphthalen-2-yl)ethoxy)thiophen-2-yl)-2-propenamide, (687) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(4-phenylpiperazin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (688) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(4-phenyl-1,2,3,6-tetrahydropyridin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (689) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(4-phenylpiperidin-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (690) N-(3,4-difluorophenylsulfonyl)-4-(2-(2-phenylethoxy)-4-(3-cyanophenoxymethyl)phenyl)butanamide, (691) N-(3,4-difluorophenylsulfonyl)-4-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)butanamide, (692) N-(3,4-difluorophenylsulfonyl)-3-(2-(5-phenylpentyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (693) N-(3,4-difluorophenylsulfonyl)-2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenoxy)acetamide, (694) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(pyrazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (695) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(2-methylimidazol-1-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (696) N-(3,4-difluorophenylsulfonyl)-2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzoylamino)acetamide, (697) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(N-ethyl-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (698) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(N-(2-hydroxyethyl)-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (699) N-(3,4-difluorophenylsulfonyl)-3-(2-(3-(N-methyl-N-phenylamino)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (700) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propynamide, (701) N-phenylsulfonyl-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanamide, (702) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-hydroxy-2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide, (703) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-(morpholin-4-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (704) 3-(2-(5-methyl-3-phenylhexanoyl)-4-phenoxymethylphenyl)propanoic acid, (705) 3-(2-((3-methyl-1-(4-fluorophenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanol (706) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxymethylphenyl)propanol (707) N-(3-methyl-1-(4-fluorophenyl)butyl)-2-(3-mesylaminopropyl)-5-phenoxymethylbenzamide, (708) N-(3-methyl-1-(4-fluorophenyl)butyl)-2-(3-phenylsulfonylaminopropyl)-5-phenoxymethylbenzamide, (709) N-(3-methyl-1-(4-fluorophenyl)butyl)-2-(3-benzoylaminopropyl)-5-phenoxymethylbenzamide, (710) N-(3-methyl-1-(4-fluorophenyl)butyl)-2-(3-formylaminopropyl)-5-phenoxymethylbenzamide, (711) N-phenylsulfonyl-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)aminocarboxamide (712) N-(3,4-difluorophenylsulfonyl)-N′-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)benzyl)urea (713) 3-[4-phenoxymethyl-2-[1-(4-fluorophenyl)-3-methylbutylaminocarbonyl]phenyl]propanamide, (714) N-(3-methyl-1-(4-fluorophenyl)butyl)-2-(2-(tetrazol-5-yl)ethyl)-5-phenoxymethylbenzamide, (715) 1-(2-(tetrazol-5-yl)ethyl)-2-(4-methyl-2-phenylpentyloxy)-4-phenoxymethylbenzene (716) N-(2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)ethylsulfonyl)benzamide, (717) 3-[2-[2-(naphthalen-2-yl)ethyloxy]-4-(1-pyrazolylmethyl)phenyl]propanamide, (718) 3-(2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)ethyl-1,2,4-oxadiazole-5-thione (719) 3-(2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)ethyl-1,2,4-oxadiazole-5-one (720) 3-(2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)ethyl-1,2,4-thiadiazole-5-one (721) 4-(2-(2-(2-(naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)ethyl-1,2,3,5-oxathiadiazole-2-one (722) 3-(2-(N-methyl-N-(2-(naphthalen-2-yl)ethyl)amino)-4-phenoxymethylphenyl)propanoic acid, (723) 3-(2-(N-acetyl-N-(2-(naphthalen-2-yl)ethyl)amino)-4-phenoxymethylphenyl)propanoic acid, (724) 3-(2-(2-(naphthalen-2-yl)ethylthio)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (725) 3-(2-(2-(naphthalen-2-yl)ethylsulfonyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (726) 3-(2-(2-(N-benzyl-N-methylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (727) 3-(2-(2-(N-benzyl-N-ethylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (728) 3-(2-(2-(N-phenyl-N-propylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (729) 3-(2-(2-(6-methoxy-naphthalen-2-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (730) 3-(2-(2-(carbazol-9-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (731) 3-(2-(2-(9,10-dihydroacridin-9-one-10-yl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (732) 3-(2-(5-phenylpentyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (733) 3-(2-(5-phenyl-1-pentenyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (734) 3-(2-(5-phenyl-1-pentynyl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (735) 3-(4-(pyrazol-1-ylmethyl)-2-(naphthalen-2-ylcarbonylaminomethyl)phenyl)propanoic acid, (736) 3-(2-(2-(N-phenyl-N-methylsulfonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (737) 3-(2-(2-(N-acetyl-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (738) 3-(2-(2-(N-benzyl-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (739) 3-(2-(2-(N-(2-cyanoethyl)-N-phenylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (740) 3-(2-(3-(phenoxazin-10-yl)propoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (741) N-(3,4-difluorophenylsulfonyl)-3-(2-(5-phenylpentyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (742) N-(3,4-difluorophenylsulfonyl)-3-(2-(5-phenyl-1-pentenyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (743) N-(3,4-difluorophenylsulfonyl)-3-(2-(5-phenyl-1-pentynyl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (744) 3-(2-(N-benzoylpiperazin-1-yl)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (745) N-(3,4-difluorophenylsulfonyl)-3-(2-(N-benzoylpiperazin-1-yl)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (746) 3-(2-(2-(3-methyl-1-phenylbutylcarbamoyl)-4-phenoxymethyl)phenyl)ethyl-1,2,4-oxadiazole-5-one (747) 2-(1-benzyl-3-(3-methyl-1-phenylbutylcarbamoyl)indol-4-yl)acetic acid, (748) 3-(1-benzyl-3-(3-methyl-1-phenylbutylcarbamoyl)indol-4-yl)propanoic acid, (749) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(3-cyanobenzyloxy)phenyl)propanoic acid, (750) 1-benzyl-3-(3-methyl-1-phenylbutylcarbamoyl)-5-indolecarboxylic acid, (751) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanobenzyloxy)phenyl)propanoic acid, (752) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methylsulfonylaminophenyl)propanoic acid, (753) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(N-methyl-N-methylsulfonylamino)phenyl)propanoic acid, (754) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methoxycarbonylaminophenyl)propanoic acid, (755) N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methylsulfonylaminophenyl)propanamide, (756) N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-(N-methyl-N-methylsulfonylamino)phenyl)propanamide, (757) N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methoxycarbonylaminophenyl)propanamide, (758) 3-(2-(2-(3-methyl-1-phenylbutylcarbamoyl)-4-phenoxymethyl)phenyl)ethyl-1,2,4-oxadiazole-5-thione (759) 3-(2-((3-methyl-1-(3-methylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (760) 3-(2-((3-methyl-1-(3-methoxyphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (761) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-phenylsulfonyloxyphenyl)propanoic acid, (762) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-isopropylsulfonyloxyphenyl)propanoic acid, (763) N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-isopropylsulfonyloxyphenyl)propanamide, (764) 3-(1-benzyl-3-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)indol-4-yl)propanoic acid, (765) 3-(1-(3-cyanobenzyl)-3-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)indol-4-yl)propanoic acid, (766) 3-(2-((3-methyl-1-(3,4-dimethoxyphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (767) 3-(3-benzyl-1-(3-methyl-1-phenylbutylcarbamoylmethyl)indol-7-yl)propanoic acid, (768) 3-(2-((3-methyl-1-(3-methyl-4-fluorophenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (769) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methylsulfonyloxyphenyl)propanoic acid, (770) 3-(2-((3-methyl-1-(3,5-dimethoxyphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (771) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxycarbonylaminophenyl)propanoic acid, (772) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(isoindolin-2-yl)phenyl)propanoic acid, (773) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxycarbonylaminophenyl)propanoic acid, (774) 3-(2-((3-methyl-1-(3,5-difluorophenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (775) N-(3-fluorophenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (776) N-(4-fluorophenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (777) N-(4-methylphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (778) N-(3-nitrophenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (779) N-(3-cyanophenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (780) N-(3-methylphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (781) N-(3-methoxyphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (782) N-(3-trifluoromethylphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (783) N-(3-methoxycarbonylphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (784) N-(3-carboxyphenylsulfonyl)-3-(2-(2-(3-methoxyphenylcarbonylamino)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, (785) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzoylaminophenyl)propanoic acid, (786) 2-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenoxy)acetic acid, (787) 2-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenoxy)acetic acid, (788) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(N-acetyl-N-benzylamino)phenyl)propanoic acid, (789) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-((N-phenylamino)carbonylamino)phenyl)propanoic acid, (790) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenylsulfonylaminophenyl)propanoic acid, (791) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(N-benzyl-N-methylsulfonylamino)phenyl)propanoic acid, (792) 3-(3-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-5-(3-cyanophenoxymethyl)phenyl)propanoic acid, (793) 3-(3-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-5-(3-cyanophenoxymethyl)phenyl)propenoic acid, (794) 4-(3-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-5-(3-cyanophenoxymethyl)phenyl)butanoic acid, (795) 3-(2-(1-(3,5-dimethylphenyl)butylcarbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (796) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(pyrazol-1-ylmethylcarbonyl)phenyl)propanoic acid, (797) 3-(2-((1-(3,5-dimethylphenyl)propyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (798) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-phenylvinyl)phenyl)propanoic acid, (799) 3-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-cyanophenoxy)phenyl)propanoic acid, (800) 3-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-cyanophenoxy)phenyl)propanoic acid, (801) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-(pyrazol-1-yl)ethyl)phenyl)propanoic acid, (802) 3-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-methylphenoxy)phenyl)propanoic acid, (803) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methylbenzyloxy)phenyl)propanoic acid, (804) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluorobenzyloxy)phenyl)propanoic acid, (805) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-cyanobenzyloxy)phenyl)propanoic acid, (806) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxybenzyloxy)phenyl)propanoic acid, (807) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chlorobenzyloxy)phenyl)propanoic acid, (808) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-phenylbenzyloxy)phenyl)propanoic acid, (809) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methylbenzyloxy)phenyl)propanoic acid, (810) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluorobenzyloxy)phenyl)propanoic acid, (811) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-ethylbenzyloxy)phenyl)propanoic acid, (812) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-trifluoromethylbenzyloxy)phenyl)propanoic acid, (813) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3-dimethoxybenzyloxy)phenyl)propanoic acid, (814) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluorophenoxymethyl)phenyl)propanoic acid, (815) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoic acid, (816) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-difluorophenoxymethyl)phenyl)propanoic acid, (817) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluorophenoxymethyl)phenyl)propanoic acid, (818) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (819) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-fluorophenoxymethyl)phenyl)propanoic acid, (820) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,6-dimethylbenzyloxy)phenyl)propanoic acid, (821) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-cyanophenoxymethyl)phenyl)propanoic acid, (822) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-cyanophenoxymethyl)phenyl)propanoic acid, (823) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methoxyphenoxymethyl)phenyl)propanoic acid, (824) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methoxyphenoxymethyl)phenyl)propanoic acid, (825) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methylphenoxymethyl)phenyl)propanoic acid, (826) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxy-5-cyanophenoxymethyl)phenyl)propanoic acid, (827) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chlorobenzyloxy)phenyl)propanoic acid, (828) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluorobenzyloxy)phenyl)propanoic acid, (829) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-trifluoromethylbenzyloxy)phenyl)propanoic acid, (830) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-trifluoromethyloxybenzyloxy)phenyl)propanoic acid, (831) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-isopropylbenzyloxy)phenyl)propanoic acid, (832) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(naphthalen-1-yl)methyloxyphenyl)propanoic acid, (833) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-butylbenzyloxy)phenyl)propanoic acid, (834) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenyl)propanoic acid, (835) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-acetylphenoxymethyl)phenyl)propanoic acid, (836) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-t-butylbenzyloxy)phenyl)propanoic acid, (837) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-phenylbenzyloxy)phenyl)propanoic acid, (838) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-benzylbenzyloxy)phenyl)propanoic acid, (839) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-4-fluorophenoxymethyl)phenyl)propanoic acid, (840) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methyl-4-fluorophenoxymethyl)phenyl)propanoic acid, (841) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoic acid, (842) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-carbamoylmethylphenoxymethyl)phenyl)propanoic acid, (843) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxy-5-methylphenoxymethyl)phenyl)propanoic acid, (844) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methylphenoxymethyl)phenyl)propanoic acid, (845) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluorophenoxymethyl)phenyl)propanoic acid, (846) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-6-fluorobenzyloxy)phenyl)propanoic acid, (847) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorobenzyloxy)phenyl)propanoic acid, (848) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chlorobenzyloxy)phenyl)propanoic acid, (849) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-5-trifluoromethylbenzyloxy)phenyl)propanoic acid, (850) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-difluorobenzyloxy)phenyl)propanoic acid, (851) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,5-dimethylbenzyloxy)phenyl)propanoic acid, (852) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(1-ethyl-3-methylpyrazol-5-yl)methoxyphenyl)propanoic acid, (853) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-6-trifluoromethylbenzyloxy)phenyl)propanoic acid, (854) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3-difluorobenzyloxy)phenyl)propanoic acid, (855) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,6-difluorobenzyloxy)phenyl)propanoic acid, (856) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-4-fluorobenzyloxy)phenyl)propanoic acid, (857) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,5-difluorobenzyloxy)phenyl)propanoic acid, (858) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-bis(trifluoromethyl)benzyloxy)phenyl)propanoic acid, (859) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,4-difluorobenzyloxy)phenyl)propanoic acid, (860) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-trifluoromethyloxybenzyloxy)phenyl)propanoic acid, (861) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,4-dimethylbenzyloxy)phenyl)propanoic acid, (862) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxynaphthalen-1-ylmethyloxy)phenyl)propanoic acid, (863) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,6-trifluorobenzyloxy)phenyl)propanoic acid, (864) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-nitrophenoxy)phenyl)butanoic acid, (865) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-aminophenoxy)phenyl)butanoic acid, (866) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-methylsulfonylphenoxy)phenyl)butanoic acid, (867) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-thienylmethyloxy)phenyl)propanoic acid, (868) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(1,3-dioxyindan-4-yl)methyloxyphenyl)propanoic acid, (869) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-dimethylbenzyloxy)phenyl)propanoic acid, (870) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methylbenzyloxy)phenyl)propanoic acid, (871) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methylthiobenzyloxy)phenyl)propanoic acid, (872) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-dimethylbenzyloxy)phenyl)propanoic acid, (873) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-4-trifluoromethylbenzyloxy)phenyl)propanoic acid, (874) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluoro-3-trifluoromethylbenzyloxy)phenyl)propanoic acid, (875) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluoro-5-trifluoromethylbenzyloxy)phenyl)propanoic acid, (876) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluoro-3-chlorobenzyloxy)phenyl)propanoic acid, (877) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluoro-4-methylbenzyloxy)phenyl)propanoic acid, (878) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-5-methoxybenzyloxy)phenyl)propanoic acid, (879) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-isobutylbenzyloxy)phenyl)propanoic acid, (880) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4,5-trimethylbenzyloxy)phenyl)propanoic acid, (881) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-(4-methoxyphenoxy)benzyloxy)phenyl)propanoic acid, (882) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methoxybenzyloxy)phenyl)propanoic acid, (883) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,4-trimethoxybenzyloxy)phenyl)propanoic acid, (884) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-cyanophenoxy)phenyl)butanoic acid, (885) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-acetylaminophenoxy)phenyl)butanoic acid, (886) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-methylsulfonylaminophenoxy)phenyl)butanoic acid, (887) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methoxy-5-cyanophenoxymethyl)phenyl)propanoic acid, (888) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluoro-3-methoxybenzyloxy)phenyl)propanoic acid, (889) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methoxynaphthalen-1-ylmethyloxy)phenyl)propanoic acid, (890) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxy-3,5-di(t-butyl)benzyloxy)phenyl)propanoic acid, (891) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-phenoxybenzyloxy)phenyl)propanoic acid, (892) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-acetylphenoxy)phenyl)butanoic acid, (893) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-furylmethyloxy)phenyl)propanoic acid, (894) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chloro-3-fluorobenzyloxy)phenyl)propanoic acid, (895) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-((3,5-dimethyl-4-benzyloxy)benzyloxy)phenyl)propanoic acid, (896) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2,3,4,5,6-pentafluorophenoxy)phenyl)butanoic acid, (897) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(benzo[e]1,4-dioxan-6-yl)methyloxy)phenyl)propanoic acid, (898) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4,6-trifluorobenzyloxy)phenyl)propanoic acid, (899) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-4,5-difluorobenzyloxy)phenyl)propanoic acid, (900) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluoro-4-trifluoromethylbenzyloxy)phenyl)propanoic acid, (901) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-trifluoromethylbenzyloxy)phenyl)propanoic acid, (902) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-diethoxybenzyloxy)phenyl)propanoic acid, (903) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyano-4-fluorobenzyloxy)phenyl)propanoic acid, (904) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-ethoxybenzyloxy)phenyl)propanoic acid, (905) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-benzyloxybenzyloxy)phenyl)propanoic acid, (906) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,4,5,6-pentafluorobenzyloxy)phenyl)propanoic acid, (907) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-bis(trifluoromethyl)benzyloxy)phenyl)propanoic acid, (908) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methyl-5-fluorobenzyloxy)phenyl)propanoic acid, (909) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-((4-methylnaphthalen-1-yl)methyloxy)phenyl)propanoic acid, (910) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4′-trifluoromethyl-1,1′-biphenyl-2-yl)methyloxy)phenyl)propanoic acid, (911) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-phenylethoxy)phenyl)propanoic acid, (912) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-phenylpropoxy)phenyl)propanoic acid, (913) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid, (914) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methyl-3-chlorobenzyloxy)phenyl)propanoic acid, (915) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-trifluoromethyloxybenzyloxy)phenyl)propanoic acid, (916) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-bis(trifluoromethyl)benzyloxy)phenyl)propanoic acid, (917) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-ethoxybenzyloxy)phenyl)propanoic acid, (918) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chlorophenoxymethyl)phenyl)propanoic acid, (919) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-5-methylphenoxymethyl)phenyl)propanoic acid, (920) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,4,5,6-pentafluorophenoxymethyl)phenyl)propanoic acid, (921) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,6-difluorophenoxymethyl)phenyl)propanoic acid, (922) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methylsulfonylbenzyloxy)phenyl)propanoic acid, (923) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chlorophenoxymethyl)phenyl)propanoic acid, (924) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,5,6-tetrafluorobenzyloxy)phenyl)propanoic acid, (925) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-3,6-difluorobenzyloxy)phenyl)propanoic acid, (926) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-hexylbenzyloxy)phenyl)propanoic acid, (927) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,4-diethoxybenzyloxy)phenyl)propanoic acid, (928) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-trifluoromethylthiobenzyloxy)phenyl)propanoic acid, (929) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(6-chloro-2-fluoro-3-methylbenzyloxy)phenyl)propanoic acid, (930) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-trifluoromethylthiobenzyloxy)phenyl)propanoic acid, (931) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-6-fluoro-3-methylbenzyloxy)phenyl)propanoic acid, (932) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-(4-chlorophenylthio)benzyloxy)phenyl)propanoic acid, (933) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-carbamoylphenoxy)phenyl)butanoic acid, (934) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-N-methylcarbamoylphenoxy)phenyl)butanoic acid, (935) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-N,N-dimethylcarbamoylphenoxy)phenyl)butanoic acid, (936) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-pentylbenzyloxy)phenyl)propanoic acid, (937) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-(4-methylphenoxy)benzyloxy)phenyl)propanoic acid, (938) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chloro-2-fluoro-6-trifluorobenzyloxy)phenyl)propanoic acid, (939) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-difluoromethoxybenzyloxy)phenyl)propanoic acid, (940) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(fluoren-2-ylmethyloxy)phenyl)propanoic acid, (941) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chloro-3-trifluoromethylbenzyloxy)phenyl)propanoic acid, (942) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluoro-2-methylbenzyloxy)phenyl)propanoic acid, (943) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,5-trifluorobenzyloxy)phenyl)propanoic acid, (944) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-(pyridin-2-yl)benzyloxy)phenyl)propanoic acid, (945) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-(4-t-butylphenoxy)benzyloxy)phenyl)propanoic acid, (946) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-ethylthiobenzyloxy)phenyl)propanoic acid, (947) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-(4-fluorobenzyloxy)benzyloxy)phenyl)propanoic acid, (948) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3-difluorophenoxymethyl)phenyl)propanoic acid, (949) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,5-difluorophenoxymethyl)phenyl)propanoic acid, (950) 3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(4-fluorophenoxymethyl)phenyl)propanoic acid, (951) 3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (952) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-cyanophenoxy)phenyl)butanoic acid, (953) 3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (954) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,4-difluorophenoxymethyl)phenyl)propanoic acid, (955) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methyl-4-fluorophenoxymethyl)phenyl)propanoic acid, (956) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluoro-6-methoxyphenoxymethyl)phenyl)propanoic acid, (957) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-(3-trifluoromethylphenoxy)benzyloxy)phenyl)propanoic acid, (958) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chloro-2-fluoro-5-trifluoromethylbenzyloxy)phenyl)propanoic acid, (959) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3-dimethylbenzyloxy)phenyl)propanoic acid, (960) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3-difluoro-4-methylbenzyloxy)phenyl)propanoic acid, (961) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chloro-2-fluorobenzyloxy)phenyl)propanoic acid, (962) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chloro-2,6-difluorobenzyloxy)phenyl)propanoic acid, (963) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3,4,5-trifluorobenzyloxy)phenyl)propanoic acid, (964) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluoro-3-methylbenzyloxy)phenyl)propanoic acid, (965) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-(4-chlorophenoxy)benzyloxy)phenyl)propanoic acid, (966) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,6-trifluorophenoxymethyl)phenyl)propanoic acid, (967) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,5,6-tetrafluorophenoxymethyl)phenyl)propanoic acid, (968) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluoro-4-cyanophenoxymethyl)phenyl)propanoic acid, (969) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-(4-propylphenyl)benzyloxy)phenyl)propanoic acid, (970) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-phenoxybenzyloxy)phenyl)propanoic acid, (971) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(5-chloro-2-methoxybenzyloxy)phenyl)propanoic acid, (972) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-dimethylaminobenzyloxy)phenyl)propanoic acid, (973) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-5-methylthiobenzyloxy)phenyl)propanoic acid, (974) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-carbamoylphenoxymethyl)phenyl)propanoic acid, (975) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methylcarbamoylphenoxymethyl)phenyl)propanoic acid, (976) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-dimethylcarbamoylphenoxymethyl)phenyl)propanoic acid, (977) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-hydroxymethylphenoxymethyl)phenyl)propanoic acid, (978) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-nitrophenoxy)phenyl)butanoic acid, (979) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-aminophenoxy)phenyl)butanoic acid, (980) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-acetylaminophenoxy)phenyl)butanoic acid, (981) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-methylsulfonylaminophenoxy)phenyl)butanoic acid, (982) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-methoxyphenoxy)phenyl)butanoic acid, (983) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(4-fluorophenoxy)phenyl)butanoic acid, (984) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(3-fluorophenoxy)phenyl)butanoic acid, (985) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(3-methoxyphenoxy)phenyl)butanoic acid, (986) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chloro-2,6-difluorobenzyloxy)phenyl)propanoic acid, (987) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-ethylbenzyloxy)phenyl)propanoic acid, (988) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-chloro-2-methoxybenzyloxy)phenyl)propanoic acid, (989) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-methyl-3-methoxybenzyloxy)phenyl)propanoic acid, (990) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methyl-4-methoxybenzyloxy)phenyl)propanoic acid, (991) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methoxymethylphenoxymethyl)phenyl)propanoic acid, (992) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-fluorophenoxy)phenyl)butanoic acid, (993) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (994) 3-(2-(((1S)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (995) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-cyclohexyloxyphenyl)butanoic acid, (996) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(pyridin-2-yl)oxyphenyl)butanoic acid, (997) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-(2-acetylphenoxy)phenyl)butanoic acid, (998) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-methoxyphenoxy)phenyl)butanoic acid, (999) 2-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-phenylethyl)phenoxy)acetic acid, (1000) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-fluorophenoxymethyl)phenyl)propanoic acid, (1001) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(4-fluorophenoxymethyl)phenyl)propanoic acid, (1002) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methoxyphenoxymethyl)phenyl)propanoic acid, (1003) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoic acid, (1004) 3-(2-diphenylmethylcarbamoyl-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1005) 3-(2-((1-(3,5-dimethylphenyl)cyclohexyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1006) 3-(2-((1-(3,5-dimethylphenyl)cyclopentyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1007) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-fluorophenoxymethyl)phenyl)propanoic acid, (1008) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-ethoxyphenoxymethyl)phenyl)propanoic acid, (1009) 3-(2-((N-(2-methylpropyl)-N-(3,5-dimethylphenyl)amino)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1010) 3-(2-(1-ethyl-1-(3,5-dimethylphenyl)propyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1011) 3-(2-(4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1012) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (1013) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,4-difluorophenoxymethyl)phenyl)propanoic acid, (1014) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoic acid, (1015) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoic acid, (1016) 3-(2-(1-methyl-1-(3,5-dimethylphenyl)ethyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1017) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (1018) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(benzothiazol-2-yl)oxyphenyl)propanoic acid, (1019) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chloro-6-fluorobenzyloxy)phenyl)propanoic acid, (1020) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-ethylphenoxymethyl)phenyl)propanoic acid, (1021) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(3-chlorophenoxymethyl)phenyl)propanoic acid, (1022) 3-(2-(4-(3,5-dimethylphenyl)perhydrothiopyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1023) 3-(2-(1-benzyl-4-(3,5-dimethylphenyl)piperidin-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1024) 3-(2-(1,1-dione-4-(3,5-dimethylphenyl)perhydrothiopyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1025) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid, (1026) 3-(2-((2,6-dimethyl-4-(3,5-dimethylphenyl)-4-heptyl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1027) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,3,6-trifluorobenzyloxy)phenyl)propanoic acid, (1028) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-6-fluorobenzyloxy)phenyl)propanoic acid, (1029) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chloro-5-fluorophenoxymethyl)phenyl)propanoic acid, (1030) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chloro-5-methylphenoxymethyl)phenyl)propanoic acid, (1031) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-dichlorophenoxymethyl)phenyl)propanoic acid, (1032) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-phenoxymethylphenyl)propanoic acid, (1033) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(3-chlorophenoxymethyl)phenyl)propanoic acid, (1034) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(3-fluorophenoxymethyl)phenyl)propanoic acid, (1035) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoic acid, (1036) 3-(2-((1-methylsulfonyl-4-(3,5-dimethylphenyl)piperidin-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1037) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-fluorophenoxymethyl)phenyl)propanoic acid, (1038) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2-chlorophenoxymethyl)phenyl)propanoic acid, (1039) 3-(2-((4-(3-methylphenyl)perhydropyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1040) 3-(2-((4-(naphthalen-1-yl)perhydropyran-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1041) 3-(2-((1-methyl-4-(3,5-dimethylphenyl)piperidin-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1042) 3-(2-((1-ethyl-4-(3,5-dimethylphenyl)piperidin-4-yl)carbamoyl)-4-(2,5-difluorophenoxymethyl)phenyl)propanoic acid, (1043) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,3,6-trifluorobenzyloxy)phenyl)propanoic acid, (1044) 2-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2-chloro-6-fluorobenzyloxy)phenoxy)acetic acid, methyl ester thereof, ethyl ester thereof or non-toxic salts thereof.
 11. The compound according to the claim 5, which is selected from (1) (2E)-3-(2-(2-(2,5,7,8-tetramethyl-6-hydroxychroman-2-yl)ethoxy)-4-hydroxymethylphenyl)-2-propenoic acid, (2) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-benzyloxyphenyl)-2-propenoic acid, (3) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxyphenyl)propanoic acid, (4) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-hydroxymethylphenyl)propanoic acid, (5) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(1-hydroxy-1-methylethyl)phenyl)propanoic acid, (6) 3-(2-(((1R)-1-(naphthalen-1-yl)ethyl)carbamoyl)-4-phenoxyphenyl)propanoic acid, (7) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-benzyloxyphenyl)propanoic acid, (8) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-benzyloxymethylphenyl)propanoic acid, (9) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-cyclopropylmethoxymethylphenyl)propanoic acid, (10) 2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-hydroxymethylbenzyl)benzoic acid, (11) 2-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-methoxymethylbenzyl)benzoic acid, (12) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-hydroxymethylphenyl)butanoic acid, (13) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-methoxymethylphenyl)butanoic acid, (14) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzyloxyphenyl)butanoic acid, (15) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenoxyphenyl)butanoic acid, (16) 3-(2-((4-methyl-2-phenylpentanoyl)amino)-4-phenoxyphenyl)propanoic acid, (17) 4-(2-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-4-phenoxyphenyl)butanoic acid, (18) 4-(2-((4-methyl-2-phenylpentanoyl)amino)-4-phenoxyphenyl)butanoic acid, (19) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzyloxymethylphenyl)butanoic acid, (20) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenoxyphenyl)propanamide, (21) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-hydroxymethylphenyl)propanamide, (22) N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(1-hydroxy-1-methylethyl)phenyl)propanamide, (23) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methoxymethylphenyl)propanoic acid, (24) N-(3,4-difluorophenylsulfonyl)-3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-methoxymethylphenyl)propanamide, (25) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxyphenyl)propanoic acid, (26) 3-(2-(naphthalen-1-ylmethylcarbamoyl)-4-phenoxyphenyl)propanoic acid, (27) 3-(2-(1-(naphthalen-2-yl)ethylcarbamoyl)-4-phenoxyphenyl)propanoic acid, (28) 3-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-phenoxyphenyl)propanoic acid, (29) 3-(2-(4-methyl-2-phenylpentyl)carbamoyl)-4-phenoxyphenyl)propanoic acid, (30) 3-(2-((1R)-1-phenylethylcarbamoyl)-4-phenoxyphenyl)propanoic acid, (31) 4-(2-((1R)-1-(naphthalen-1-yl)ethylcarbamoyl)-4-phenoxyphenyl)butanoic acid, (32) 3-(2-((1R)-1-(4-methylphenyl)ethylcarbamoyl)-4-phenoxyphenyl)propanoic acid, (33) 3-(2-(1-(4-fluorophenyl)ethylcarbamoyl)-4-phenoxyphenyl)propanoic acid, (34) 3-(2-((1R)-1-indan-1-yl)carbamoyl-4-phenoxyphenyl)propanoic acid, (35) 3-(2-(1-methyl-3-phenylpropyl)carbamoyl-4-phenoxyphenyl)propanoic acid, (36) 3-(2-((1R)-1-(4-nitrophenyl)ethylcarbamoyl)-4-phenoxyphenyl)propanoic acid, (37) 3-(2-diphenylmethylcarbamoyl-4-phenoxyphenyl)propanoic acid, (38) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxyphenyl)propanoic acid, (39) 3-(2-((1R)-1-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl-4-phenoxyphenyl)propanoic acid, (40) 3-(2-((1R)-1-(1,1′-biphenyl-4-yl)ethylcarbamoyl)-4-phenoxyphenyl)propanoic acid, (41) 3-(2-(cyano-phenylcarbamoyl)-4-phenoxyphenyl)propanoic acid, (42) 4-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxyphenyl)butanoic acid, (43) 4-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxyphenyl)butanoic acid, (44) 4-(2-(3-methyl-1-phenylbutyl)carbamoyl)-4-phenoxyphenyl)butanoic acid, (45) 4-(2-(1-(naphthalen-1-yl)propylcarbamoyl)-4-phenoxyphenyl)butanoic acid, (46) 4-(2-(1-(naphthalen-1-yl)butylcarbamoyl)-4-phenoxyphenyl)butanoic acid, (47) 4-(2-((3-methyl-1-(naphthalen-1-yl)butyl)carbamoyl)-4-phenoxyphenyl)butanoic acid, (48) 4-(2-((3-methyl-1-(4-fluoro-3-methylphenyl)butyl)carbamoyl)-4-phenoxyphenyl)butanoic acid, (49) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenoxyphenyl)propanoic acid, (50) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)propanoic acid, (51) 3-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-benzyloxyphenyl)propanoic acid, (52) 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxyphenyl)propanoic acid, (53) 3-(2-((4-(naphthalen-1-yl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)propanoic acid, (54) 4-(2-((4-(naphthalen-1-yl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)butanoic acid, (55) 4-(2-((4-(3,5-dimethylphenyl)perhydropyran-4-yl)carbamoyl)-4-phenoxyphenyl)butanoic acid, (56) 2-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzyloxyphenoxy)acetic acid, methyl ester thereof, ethyl ester thereof or non-toxic salts thereof.
 12. The compound according to the claim 6, which is selected from (1) 4-(2-(naphthalen-1-yl)carbonylamino-4-cyanophenyl)butanoic acid, (2) 3-(6-cyano-1-(2-(naphthalen-1-yl)propionyl)indol-3-yl)propanoic acid, (3) N-(3,4-difluorophenylsulfonyl)-3-(6-cyano-1-(1-(naphthalen-1-yl)ethylcarbonyl)indol-3-yl)propanamide, methyl ester thereof, ethyl ester thereof or non-toxic salts thereof.
 13. The compound according to the claim 7, which is selected from (1) 4-(3-methyl-1-phenylbutylcarbamoyl)-2-benzofurancarboxylic acid, (2) 7-(3-methyl-1-phenylbutylcarbamoyl)-2-benzofurancarboxylic acid, (3) 2-(7-(3-methyl-1-phenylbutylcarbamoyl)indol-1-yl)acetic acid, (4) 2-(7-(3-methyl-1-phenylbutylcarbamoyl)indol-3-yl)acetic acid, (5) 7-(3-methyl-1-phenylbutylcarbamoyl)naphthalenecarboxylic acid, (6) 2-(7-(3-methyl-1-phenylbutylcarbamoyl)indolin-1-yl)acetic acid, (7) 3-(7-(3-methyl-1-phenylbutylcarbamoyl)indolin-1-yl)propanoic acid, (8) 3-(8-(3-methyl-1-phenylbutylcarbamoyl)-1,2,3,4-tetrahydroquinolin-1-yl)propanoic acid, (9) 2-(8-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)-1,2,3,4-tetrahydroquinolin-1-yl)acetic acid, (10) 2-(7-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)indolin-1-yl)acetic acid, (11) 8-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)-2-naphthalenecarboxylic acid, (12) 7-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)-2-benzofurancarboxylic acid, (13) 2-(7-(3-methyl-1-(3,5-dimethylphenyl)butylcarbamoyl)benzofuran-2-yl)acetic acid, (14) 7-((2-(naphthalen-1-yl)acetyl)amino)-2-benzofurancarboxylic acid, (15) 7-((2-(naphthalen-1-yl)propanoyl)amino)-2-benzofurancarboxylic acid, (16) 7-((4-methyl-2-(naphthalen-1-yl)pentanoyl)amino)-2-benzofurancarboxylic acid, (17) 2-(1-(2-(naphthalen-1-yl)propionyl)indol-3-yl)acetic acid, (18) 2-(2-methyl-1-(2-(naphthalen-1-yl)propionyl)indol-3-yl)acetic acid, (19) 3-(1-(2-(naphthalen-1-yl)propionyl)indol-3-yl)propanoic acid, (20) 3-(2-methyl-1-(2-(naphthalen-1-yl)propionyl)indol-3-yl)propanoic acid, (21) N-(3,4-difluorophenylsulfonyl)-2-(1-(1-(naphthalen-1-yl)ethylcarbonyl)indol-3-yl)acetamide, (22) N-(3,4-difluorophenylsulfonyl)-2-(2-methyl-1-(1-(naphthalen-1-yl)ethylcarbonyl)indol-3-yl)acetamide, (23) N-(3,4-difluorophenylsulfonyl)-3-(1-(1-(naphthalen-1-yl)ethylcarbonyl)indol-3-yl)propanamide, methyl ester thereof, ethyl ester thereof or non-toxic salts thereof.
 14. The compound according to the claim 8, which is selected from (1) (2E)-3-(2-(6-phenoxyhexyloxy)-4-(imidazol-1-ylmethyl)phenyl)-2-propenoic acid, (2) 3-(2-(6-phenylhexyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid, (3) N-(3,4-difluorophenylsulfonyl)-3-(2-(6-phenylhexyloxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide, methyl ester thereof, ethyl ester thereof or non-toxic salts thereof.
 15. A compound according to the claim 1 selected from (1) (2E)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-phenylcarbamoylphenyl)-2-propenoic acid, (2) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylphenyl)butanoic acid, (3) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-benzylcarbamoylphenyl)butanoic acid, (4) 4-(2-((2-(naphthalen-1-yl)propanoyl)amino)-4-phenylcarbamoylphenyl)butanoic acid, (5) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-cyanophenyl)propanoic acid, (6) N-(3,4-difluorophenylsulfonyl)-3-(4-cyano-2-((3-methyl-1-phenylbutyl)carbamoyl)phenyl)propanamide, (7) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-dibenzylaminophenyl)propanoic acid, (8) 3-(2-((3-methyl-1-phenylbutyl)carbamoyl)-4-benzylaminophenyl)propanoic acid, (9) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-benzylaminophenyl)propanoic acid, (10) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(N-benzyl-N-methylamino)phenyl)propanoic acid, (11) 3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(N-phenylcarbamoyl)phenyl)propanoic acid, (12) 3-(2-((3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-phenylcarbamoylphenyl)propanoic acid, methyl ester thereof, ethyl ester thereof or non-toxic salts thereof.
 16. A pharmaceutical composition, which comprises the compound of formula (I) according to claim 1, or a non-toxic salt thereof.
 17. A therapeutic and/or preventive agent for diseases induced by activation of EP₃ and/or EP₄ acceptor, which comprises the compound of formula (I) according to claim 1, or a non-toxic salt thereof.
 18. The therapeutic and/or preventive agent according to claim 1, wherein the disease is pain, allodynia, hyperalgesia, itch, urticaria, atopic dermatitis, contact dermatitis, poison ivy dermatitis, allergic conjunctivitis, various symptoms in dialysis, asthma, rhinitis, allergic rhinitis, nasal obstruction, sneeze, psoriasis, urinary frequency, urinary disturbance, dysspermia, fever, systemic inflammatory response syndrome, learning disability, Alzheimer's disease, angiogenesis, canceration, cancer proliferation, cancer metastasis into organ, cancer metastasis into bone, hypercalcemia accompanying cancer metastasis into bone, retinosis, red spot, erythema, leukoma, skin spot, burn, ambustion, steroid burn, renal insufficiency, nephropathy, acute nephritis, chronic nephritis, blood electrolyte imbalance, threatened premature delivery, threatened abortion, epimenorrhagia, dysmenorrhea, endometriosis, premenstrual syndrome, adenomyosis uteri, reproductive disturbance, stress, anxiety, depression, psychosomatic disorder, mental diseases, thrombosis, embolism, transient ischemic attack, brain infraction, atheroma, organ transplantation, myocardial infarction, heart failure, hypertension, arteriosclerosis, circulatory disturbance and ulcer accompanying the same, nerve disorder, vascular dementia, edema, diarrhea, constipation, biliary discharge disorder, ulcerative colitis, Crohn's disease, irritable colitis, relieving rebound phenomena after using steroids, accelerating reduction and elimination of steroids, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung injury, liver injury, acute hepatitis, myocardial ischemia, Kawasaki's disease, multiple organ failure, chronic headache, angiitis, venous insufficiency, varicose vein, anal fistula, diabetes insipidus, newborn patent ductus arteriosus, cholelithiasis, sleep disturbance or platelet aggregation.
 19. A method for treating and/or preventing diseases induced by activation of EP₃ and/or EP₄ acceptor, which comprises administering the compound of formula (I) according to claim 1 or a non-toxic salt thereof.
 20. The method according to claim 19, wherein the disease is pain, allodynia, hyperalgesia, itch, urticaria, atopic dermatitis, contact dermatitis, poison ivy dermatitis, allergic conjunctivitis, various symptoms in dialysis, asthma, rhinitis, allergic rhinitis, nasal obstruction, sneeze, psoriasis, urinary frequency, urinary disturbance, dysspermia, fever, systemic inflammatory response syndrome, learning disability, Alzheimer's disease, angiogenesis, canceration, cancer proliferation, cancer metastasis into organ, cancer metastasis into bone, hypercalcemia accompanying cancer metastasis into bone, retinosis, red spot, erythema, leukoma, skin spot, burn, ambustion, steroid burn, renal insufficiency, nephropathy, acute nephritis, chronic nephritis, blood electrolyte imbalance, threatened premature delivery, threatened abortion, epimenorrhagia, dysmenorrhea, endometriosis, premenstrual syndrome, adenomyosis uteri, reproductive disturbance, stress, anxiety, depression, psychosomatic disorder, mental diseases, thrombosis, embolism, transient ischemic attack, brain infraction, atheroma, organ transplantation, myocardial infarction, heart failure, hypertension, arteriosclerosis, circulatory disturbance and ulcer accompanying the same, nerve disorder, vascular dementia, edema, diarrhea, constipation, biliary discharge disorder, ulcerative colitis, Crohn's disease, irritable colitis, relieving rebound phenomena after using steroids, accelerating reduction and elimination of steroids, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung injury, liver injury, acute hepatitis, myocardial ischemia, Kawasaki's disease, multiple organ failure, chronic headache, angiitis, venous insufficiency, varicose vein, anal fistula, diabetes insipidus, newborn patent ductus arteriosus, cholelithiasis, sleep disturbance or platelet aggregation. 